(in-package :sparser)


(DEFPARAMETER *JSON-SEXP-STATEMENTS*
  '(((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "18ecf7c2-8d5c-4616-b69c-0562a85c96ec")
     (:SUPPORTED--BY "af3032f5-b52b-4d7e-9ba5-f57e04eb3d31"
      "94483683-5d38-4a80-b6bb-6e8da95f4b7b"
      "36577525-08fc-463e-9e82-43fa01cd2737"
      "e1bbf22f-ba99-45cf-ab93-6ed0a6671233"
      "3f55042a-38d9-47d2-80ef-aa910f472fc8")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0410a2d93e47710532d69d790b09274b")
       (:PMID . "11781242") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_990e205711f46aa8317f10dfe3a7f20e")
       (:PMID . "15339792") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_990e205711f46aa8317f10dfe3a7f20e")
       (:PMID . "18046313") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_990e205711f46aa8317f10dfe3a7f20e")
       (:PMID . "15048073") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_990e205711f46aa8317f10dfe3a7f20e")
       (:PMID . "9094314") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_990e205711f46aa8317f10dfe3a7f20e")
       (:PMID . "12538620") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_990e205711f46aa8317f10dfe3a7f20e")
       (:PMID . "16894566") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_990e205711f46aa8317f10dfe3a7f20e")
       (:PMID . "15843522") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_990e205711f46aa8317f10dfe3a7f20e")
       (:PMID . "18033240") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_6817c3b2ac9b1c8d4e837a07bf44fcd9")
       (:PMID . "15047866") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_6817c3b2ac9b1c8d4e837a07bf44fcd9")
       (:PMID . "11809791") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_1f4599e6c90313fb3e139094069e7455")
       (:PMID . "11312610") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_1f4599e6c90313fb3e139094069e7455")
       (:PMID . "11546794") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_1f4599e6c90313fb3e139094069e7455")
       (:PMID . "11027222") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_1f4599e6c90313fb3e139094069e7455")
       (:PMID . "10383446") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_1f4599e6c90313fb3e139094069e7455")
       (:PMID . "15608670") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_1f4599e6c90313fb3e139094069e7455")
       (:PMID . "12376533") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "bd1cb34c-a9b0-48c9-b67a-3a9ba9e73b09")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_af98d8ae931ac85ff6c55d71338ebc95")
       (:PMID . "16527273") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_af98d8ae931ac85ff6c55d71338ebc95")
       (:PMID . "14657000") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31751") (:+HGNC+ . "392")) (:NAME . "AKT2"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "1a3ad8f3-6cc5-49bc-abf8-99c7ac64a185")
     (:SUPPORTED--BY "cb76a5df-b7c9-40e1-ac65-54487ac3dfc0"
      "68e07b2e-18ae-45cc-8b31-c20531a333dd"
      "3202e851-0d6b-4918-95e2-825570814a00")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_a2312a7d599bbc25d08eb79ea80f435b")
       (:PMID . "8524413") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_a2312a7d599bbc25d08eb79ea80f435b")
       (:PMID . "12147684") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_a2312a7d599bbc25d08eb79ea80f435b")
       (:PMID . "9109420") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_a2312a7d599bbc25d08eb79ea80f435b")
       (:PMID . "8978681") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_a2312a7d599bbc25d08eb79ea80f435b")
       (:PMID . "9065430") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE) (:TYPE . "ActiveForm")
     (:ID . "ab26ec0c-6a9d-4267-9ccc-db15cbc8476c")
     (:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31751") (:+HGNC+ . "392")) (:NAME . "AKT2"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_d390fd9a5416d16a7cd14460a065399b")
       (:PMID . "16982699") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_d390fd9a5416d16a7cd14460a065399b")
       (:PMID . "11231573") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q9Y243") (:+HGNC+ . "393")) (:NAME . "AKT3"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "2ba17615-539b-4b96-aacd-ce0d541a8156")
     (:SUPPORTED--BY "5c3b05eb-c4b6-40ae-a188-375589cd82e0")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_AKT3_pmod_P_T_305_DirectlyIncreases_kin_p_HGNC_AKT3")
       (:TEXT
        . "After PIP3 binding, Akt1 is activated by phosphorylation on two critical residues, namely threonine %308 (T308) and serine 473 (S473); similar activation residues (S472 and S474, %respectively) are highly conserved in Akt2 and Akt3 Phosphoinositol-3-phosphate (PIP3) is a product of phosphoinositol 3-kinase enzymatic activity and has been shown to be a prerequisite lipid modulator of Akt activity Akt activity can be regulated by the PTEN tumour suppressor gene, which negatively regulates PIP3 levels PIP3 has been described as a downstream component of a wide range of receptors, including the c-Met receptor [5], the epidermal growth factor receptor family [6], fibroblast growth factor receptor [7], insulin growth factor receptor [8] and platelet-derived growth factor receptor")
       (:PMID . "15987444") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_AKT3_pmod_P_T_305_DirectlyIncreases_kin_p_HGNC_AKT3")
       (:TEXT
        . "After PIP3 binding, Akt1 is activated by phosphorylation on two critical residues, namely threonine %308 (T308) and serine 473 (S473); similar activation residues (S472 and S474, %respectively) are highly conserved in Akt2 and Akt3 Phosphoinositol-3-phosphate (PIP3) is a product of phosphoinositol 3-kinase enzymatic activity and has been shown to be a prerequisite lipid modulator of Akt activity Akt activity can be regulated by the PTEN tumour suppressor gene, which negatively regulates PIP3 levels PIP3 has been described as a downstream component of a wide range of receptors, including the c-Met receptor [5], the epidermal growth factor receptor family [6], fibroblast growth factor receptor [7], insulin growth factor receptor [8] and platelet-derived growth factor receptor")
       (:PMID . "15987444") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_AKT3_pmod_P_T_305_DirectlyIncreases_kin_p_HGNC_AKT3")
       (:TEXT
        . "Relative kinase activities of both splice variants were reflected in the phosphorylation status of Thr-305, the lower level of phosphorylation of HA-PKB?1 correlating with lesser activation (Fig.5  C). Finally, by monitoring the phosphorylation status of Ser-472 of HA-PKB? under the different conditions we found that okadaic acid treatment led to phosphorylation at Ser-472 but not Thr-305 and to low levels of kinase activation (Fig.5  D). ")
       (:PMID . "11387345") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_AKT3_pmod_P_T_305_DirectlyIncreases_kin_p_HGNC_AKT3")
       (:TEXT
        . "When Thr-305 of HA-PKB?1 was mutated to an alanine that cannot be phosphorylated (HA-PKB?1T305A), the activation was abolished (Fig. 4  A). ")
       (:PMID . "11387345") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_AKT3_pmod_P_T_305_DirectlyIncreases_kin_p_HGNC_AKT3")
       (:TEXT
        . "Upon stimulation with insulin, AKT is recruited to cellular membranes by binding of its amino terminal pleckstrin (PH) domain to membrane bound phosphatidylinositol 3,4,5, trisphosphate (PIP3) [3]. The membrane bound form of AKT then becomes phosphorylated on two regulatory residues, a threonine within the activation loop (Thr308 in AKT1,Thr309 in AKT2, Thr305 in AKT3) and a serine in the C-terminus of the enzyme (Ser473 in AKT1,Ser474 in AKT2, Ser472 in AKT3), and both phosphorylations are considered to be required for AKT to reach maximum kinase activity [1]. The kinase responsible for phosphorylation of Thr308/309/305 has been identified as phosphoinositide-dependent kinase 1 (PDK1) [3].")
       (:PMID . "15890450") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_AKT3_pmod_P_T_305_DirectlyIncreases_kin_p_HGNC_AKT3")
       (:TEXT
        . "Activation of PKB gamma 1 requires phosphorylation phosphorylation on the activation loop site by phosphoinositide-dependent protein kinase-1.")
       (:PMID . "11387345") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_AKT3_pmod_P_T_305_DirectlyIncreases_kin_p_HGNC_AKT3")
       (:TEXT
        . "three isoforms, AKT1 (PKBalpha), AKT2 (PKBbeta) and AKT3 (PKBgamma) they all contain a central kinase domain with an activation-loop phosphorylation site, Thr308, and a conserved, regulatory C-terminal phosphorylation site, Ser473")
       (:PMID . "12044776") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_AKT3_pmod_P_T_305_DirectlyIncreases_kin_p_HGNC_AKT3")
       (:TEXT
        . "All three isoforms (PKBalpha, PKBbeta and PKBgamma) were phosphorylated at similar rates and activated to similar extents by 3-phosphoinositide-dependent protein kinase-1 (PDK1)")
       (:PMID . "9512493") (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "b8788870-30f5-4269-bf16-99fb92612d56")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "1981") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13315") (:+HGNC+ . "795")) (:NAME . "ATM"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ATM_pmod_P_S_1981_DirectlyIncreases_kin_p_HGNC_ATM")
       (:TEXT
        . "In the cells exposed to CS, there is strong and rather uniform IF revealing the presence of activated ATM throughout the nucleus (Fig. 7C).")
       (:PMID . "17594478") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ATM_pmod_P_S_1981_DirectlyIncreases_kin_p_HGNC_ATM")
       (:TEXT
        . "Figure 3 Nbs1 modulates ATMactivation after low doses of IR. Human NBS-Tert cells expressing different Nbs1 mutant forms and the cells infected with empty vector were irradiated with 2Gy and lysed at the indicated times (5 min to 8 h) after irradiation. Phosphorylation of S1981 of ATMand S966 of SMC1 and the total level of SMC1 were examined by immunoblotting as described in Figure 1")
       (:PMID . "15048089") (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "adb62f34-3340-4e01-8d02-8497bdfad178")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "389") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P51451") (:+HGNC+ . "1057")) (:NAME . "BLK"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9425276") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "1696179") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "14967142") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7730365") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9742401") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7477410") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18193084") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "2415973") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "16537894") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "10779329") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11489946") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11074000") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18799748") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE) (:TYPE . "ActiveForm")
     (:ID . "c874100d-1dbc-4aff-85e4-cf55a9325ae0")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "750") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "401") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "753") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "151") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_363667104482be5cbfc425beff948f91")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "35ab62cf-0b7e-40ed-87b0-0d17acc38c3d")
     (:SUPPORTED--BY "70a242cd-bbbe-4f10-b1ad-33d753188866")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "b8367f40-fece-46b1-9255-a2167138e33d")
     (:SUPPORTED--BY "70a242cd-bbbe-4f10-b1ad-33d753188866")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_97b1acd419a5d88ac0520d0f557edb67")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_97b1acd419a5d88ac0520d0f557edb67")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_97b1acd419a5d88ac0520d0f557edb67")
       (:PMID . "8073291") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_97b1acd419a5d88ac0520d0f557edb67")
       (:PMID . "14970219") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_97b1acd419a5d88ac0520d0f557edb67")
       (:PMID . "18567582") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "17123127-914e-4818-8502-2cebe5092fbc")
     (:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_ae8f86e37cb7451815681d5b8275d278")
       (:PMID . "16157584") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_ae8f86e37cb7451815681d5b8275d278")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_ae8f86e37cb7451815681d5b8275d278")
       (:PMID . "11278445") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_ae8f86e37cb7451815681d5b8275d278")
       (:PMID . "12917261") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_ae8f86e37cb7451815681d5b8275d278")
       (:PMID . "15632082") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_ae8f86e37cb7451815681d5b8275d278")
       (:PMID . "9560161") (:SOURCE--API . "biopax"))))
    ((:AGENT (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "588828ce-3af4-4adf-922c-92ae0633bda1")
     (:SUPPORTED--BY "cfabfd3b-681a-41ab-bbb9-cf3b4a718a1b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "15191558")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "15009714")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "12819038")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "14734469")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "17145850")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "16170021")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "15467732")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "16001072")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "15588860")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "14961576")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "15294323")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "12794760")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "12778069")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "14668801")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "15782137")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "12670889")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "15688405")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "12068308")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_BRAF_sub_V_600_E_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "From mutations file") (:PMID . "14602780")
       (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "7a16862b-4861-4fdc-8629-cdafe8a70dda")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "14") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q03135") (:+HGNC+ . "1527")) (:NAME . "CAV1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_6ebf276bb4d83cc13ca3d95f851073da")
       (:PMID . "16388599") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_6ebf276bb4d83cc13ca3d95f851073da")
       (:PMID . "12036959") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "371") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "774") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "700") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P22681") (:+HGNC+ . "1541")) (:NAME . "CBL"))
     (:ACTIVITY . "catalytic") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "4b08f62c-7314-49c6-b2ed-bdb6d9a8d6c5")
     (:SUPPORTED--BY "716c89f9-58a5-45ac-8ab7-84765563e195"
      "e5706f88-b722-4add-bd60-1c681e4562ec"
      "7b765769-a1e6-43a0-b45c-d8f9685f44d4")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_9b20057c8114e03612a08e563377e7d0")
       (:PMID . "14690593") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_9b20057c8114e03612a08e563377e7d0")
       (:PMID . "11997497") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_9b20057c8114e03612a08e563377e7d0")
       (:PMID . "9447983") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_9b20057c8114e03612a08e563377e7d0")
       (:PMID . "11001060") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE) (:TYPE . "ActiveForm")
     (:ID . "33bb382e-2837-410b-98ea-aa39a8dd5669")
     (:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "14") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P24941") (:+HGNC+ . "1771")) (:NAME . "CDK2"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_CDK2_pmod_P_T_14_DirectlyDecreases_kin_p_HGNC_CDK2")
       (:TEXT
        . "Cdc25A dual specificity phosphatase controls entry into and progression through S phase by dephosphorylating sites of inhibitory phosphorylation on cyclin E-cdk2 (Thr14 and Tyr15). Immunoblotting reveals that a 3 hour treatment of U937 cells with 5 muM sodium arsenite results in a dramatic decrease in cdc25A protein levels. ")
       (:PMID . "17545210") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_CDK2_pmod_P_T_14_DirectlyDecreases_kin_p_HGNC_CDK2")
       (:TEXT
        . "Replacement of T160 with alanine abolishes the kinase activity of CDK2, indicating that phosphorylation at this site (as in CDC2) is required for kinase activity. Mutation of Y15 and T14 stimulates kinase activity, demonstrating that phosphorylation at these sites (as in CDC2) is inhibitory. Similarly, CDK2 is activated in vitro by dephosphorylation of Y15 and T14 by the phosphatase CDC25.")
       (:PMID . "1396589") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1172") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1092") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1016") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1069") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1197") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1110") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "a04f4ef0-d93b-4aa5-8b0a-a93d97cf70f5")
     (:SUPPORTED--BY "6d793a01-9798-4894-906a-fbc93526ea55")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_325162876268720d78856e45bb7871ec")
       (:PMID . "12024020") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_325162876268720d78856e45bb7871ec")
       (:PMID . "15574420") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "389") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "383") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P19419") (:+HGNC+ . "3321")) (:NAME . "ELK1"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "e383a93f-469f-40a9-90ea-7fd3d0f2734e")
     (:SUPPORTED--BY "1f5f8c97-94ab-40c3-aa2f-f66a6eb6ef07")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3bf9878387ccce7efa57ed39555f7b72")
       (:PMID . "8386592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3bf9878387ccce7efa57ed39555f7b72")
       (:PMID . "9927426") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3bf9878387ccce7efa57ed39555f7b72")
       (:PMID . "8262053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3bf9878387ccce7efa57ed39555f7b72")
       (:PMID . "7889942") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1112") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "6f3744ad-c51e-41d4-a2d7-91edf3927df2")
     (:SUPPORTED--BY "fcdc5aa0-fcde-4a6b-b6ed-0d8f5aeeba3d"
      "dc784012-960b-41eb-8367-d20fe7cf5077")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "877") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "1d412d2f-4248-411c-abf4-0a62b5d35260")
     (:SUPPORTED--BY "51d5b184-637f-427a-b91f-f25341378f62"
      "dc784012-960b-41eb-8367-d20fe7cf5077"
      "fcdc5aa0-fcde-4a6b-b6ed-0d8f5aeeba3d")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "118") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P03372") (:+HGNC+ . "3467")) (:NAME . "ESR1"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "ea7bda73-bafb-4cd1-85f5-4e843f71953a")
     (:SUPPORTED--BY "f93bec76-471d-4013-aafa-03e6a09bc988")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ESR1_pmod_P_S_118_DirectlyIncreases_tscript_p_HGNC_ESR1")
       (:TEXT
        . "Coexpression of wild-type ER-alpha and the dominant negative Akt mutant in COS-1 cells also blocked the growth factor-stimulated activation of ER-alpha, but coexpression of the wild-type receptor with the constitutively active Akt mutant increased ER-alpha activity. Receptor activation was blocked by an antiestrogen. Studies using mutants of ER-alpha demonstrated that Akt increased estrogen receptor activity through the amino-terminal activation function-1 (AF-1). Serines S104 S106, S118, and S167 appear to play a role in the activation of ER-alpha by Akt.")
       (:PMID . "11108261") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ESR1_pmod_P_S_118_DirectlyIncreases_tscript_p_HGNC_ESR1")
       (:TEXT
        . "The phosphorylation of the human estrogen receptor (ER) serine residue at position 118 is required for full activity of the ER activation function 1 (AF-1). This Ser118 is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro and in cells treated with epidermal growth factor (EGF) and insulin-like growth factor (IGF) in vivo. Overexpression of MAPK kinase (MAPKK) or of the guanine nucleotide binding protein Ras, both of which activate MAPK, enhanced estrogen-induced and antiestrogen (tamoxifen)-induced transcriptional activity of wild-type ER, but not that of a mutant ER with an alanine in place of Ser118.")
       (:PMID . "7491495") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ESR1_pmod_P_S_118_DirectlyIncreases_tscript_p_HGNC_ESR1")
       (:TEXT
        . "Certain growth factors can mimic estrogen responses by activating the estrogen receptor via its phosphorylation by mitogen-activated protein (MAP) kinase.")
       (:PMID . "9632141") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ESR1_pmod_P_S_118_DirectlyIncreases_tscript_p_HGNC_ESR1")
       (:TEXT
        . "For instance, activation of epidermal growth factor receptor (EGFR) by EGF leads to phosphorylation of the Ser118 residue in the ERalpha AF-1 domain by p44/42 mitogen-activated protein kinase (MAPK), which in turn recruits the coactivator p68/p72 and activates target gene transcription in a ligand-independent manner [80,81].")
       (:PMID . "14680484") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ESR1_pmod_P_S_118_DirectlyIncreases_tscript_p_HGNC_ESR1")
       (:TEXT
        . "In searching for a possible linkage between HA-CD44-mediated IQGAP1 signaling and ERK and ER{alpha} function, we demonstrated that IQGAP1-linked ERK2 isolated from SK-OV-3.ipl cells treated with HA was capable of phosphorylating ER{alpha} in vitro (Fig. 5A, bar b). EGF stimulation of MAPKs such as ERK1 and ERK2 has been shown to phosphorylate ER{alpha} at Ser118 in the N-terminal domain and to enhance transcriptional activity. ER{alpha} phosphorylation in vivo (as detected by anti-phospho-ER{alpha} antibody (Ser118)) was also greatly enhanced in SK-OV-3.ipl cells treated with HA.The level of ERE gene activity was low in untreated cells (bar a) or in cells pretreated with anti-CD44 antibody, followed by HA treatment (bar c). ERE gene activity was greatly enhanced in SK-OV-3.ipl cells treated with intact HA")
       (:PMID . "15655247") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "167") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P03372") (:+HGNC+ . "3467")) (:NAME . "ESR1"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "f97c52d2-8011-47d2-988f-74b2100e5d6c")
     (:SUPPORTED--BY "f93bec76-471d-4013-aafa-03e6a09bc988")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ESR1_pmod_P_S_167_DirectlyIncreases_tscript_p_HGNC_ESR1")
       (:TEXT
        . "Coexpression of wild-type ER-alpha and the dominant negative Akt mutant in COS-1 cells also blocked the growth factor-stimulated activation of ER-alpha, but coexpression of the wild-type receptor with the constitutively active Akt mutant increased ER-alpha activity. Receptor activation was blocked by an antiestrogen. Studies using mutants of ER-alpha demonstrated that Akt increased estrogen receptor activity through the amino-terminal activation function-1 (AF-1). Serines S104 S106, S118, and S167 appear to play a role in the activation of ER-alpha by Akt.")
       (:PMID . "11108261") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ESR1_pmod_P_S_167_DirectlyIncreases_tscript_p_HGNC_ESR1")
       (:TEXT
        . "docking of p90 ribosomal S6 kinase 2 (Rsk2) to the hormone-binding domain (HBD) of estrogen receptor alpha (ERalpha) induces a conformational change that enhances the transcriptional activation function contained in the HBD A constitutively active mutant of Rsk2 specifically enhances ERalpha-mediated transcription by phosphorylation of Ser167 in ERalpha")
       (:PMID . "11432835") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "38") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P14921") (:+HGNC+ . "3488")) (:NAME . "ETS1"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "882b92fe-71be-4a2d-84f9-6a1bd1372572")
     (:SUPPORTED--BY "4c99ee98-e6d1-47fc-8c90-327ab5d784e0")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_872292fd9d748d718900fa4e2ac3b8b8")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "a0118d61-8649-458c-bcc2-6c494768824c")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15036") (:+HGNC+ . "3489")) (:NAME . "ETS2"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ETS2_pmod_P_S_DirectlyIncreases_tscript_p_HGNC_ETS2")
       (:TEXT
        . "overexpression of wild-type PTEN in the MCF-7 breast cancer line results in phosphatase activity-dependent decreases in the phosphorylation of ETS-2 PTEN blocks insulin-stimulated ETS-2 phosphorylation Our observations, therefore, suggest that PTEN blocks insulin-stimulated ETS-2 phosphorylation through inhibition of the ERK members of the MAP kinase family")
       (:PMID . "12095911") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ETS2_pmod_P_S_DirectlyIncreases_tscript_p_HGNC_ETS2")
       (:TEXT
        . "In the current study, we demonstrate that overexpression of wild-type PTEN in the MCF-7 breast cancer line results in phosphatase activity-dependent decreases in the phosphorylation of ETS-2, which is a transcription factor whose DNA-binding ability is controlled by phosphorylation.")
       (:PMID . "12095911") (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "ba806d34-d85f-44cd-bf87-3cb130a1428f")
     (:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "72") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15036") (:+HGNC+ . "3489")) (:NAME . "ETS2"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ETS2_pmod_P_T_72_DirectlyIncreases_tscript_p_HGNC_ETS2")
       (:TEXT
        . "We investigated the possibility that the induction of CD13/APN is mediated by phosphorylation of Ets-2 via RAS/MAPK. A phosphorylation-defective Ets-2 mutant, T72A, failed to transactivate CD13/APN, suggesting that Ets-2 phosphorylation is obligatory for CD13/APN induction.")
       (:PMID . "14507917") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_ETS2_pmod_P_T_72_DirectlyIncreases_tscript_p_HGNC_ETS2")
       (:TEXT
        . "phosphorylation-defective ETS2 mutant T72A, failed to transactivate CD13, suggesting that ETS2 phosphorylation is obligatory for CD13 induction")
       (:PMID . "14507917") (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "6726db19-2642-4352-99c8-dd0c30b8a806")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P09769") (:+HGNC+ . "3697")) (:NAME . "FGR"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9425276") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "1696179") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "14967142") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7730365") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9742401") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7477410") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18193084") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "2415973") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "16537894") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "10779329") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11489946") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11074000") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18799748") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "2dc2f23b-d24d-44b9-a912-dfc7355c44c5")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "420") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06241") (:+HGNC+ . "4037")) (:NAME . "FYN"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9425276") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "1696179") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "14967142") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7730365") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9742401") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7477410") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18193084") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "2415973") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "16537894") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "10779329") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11489946") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11074000") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18799748") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0baf00ef6e8cef4ce1a08adb845d8f79")
       (:PMID . "15494733") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0baf00ef6e8cef4ce1a08adb845d8f79")
       (:PMID . "15494732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0baf00ef6e8cef4ce1a08adb845d8f79")
       (:PMID . "15494734") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_bd99661145c5301b1fa62b4f838cf37e")
       (:PMID . "18065418") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_bd99661145c5301b1fa62b4f838cf37e")
       (:PMID . "11777936") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "9") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE) (:TYPE . "ActiveForm")
     (:ID . "1c53f532-af93-4ef8-b285-987fada1d9d7")
     (:SUPPORTED--BY "3aef091c-2c90-459b-a21a-54726f3906e5")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "The phosphorylation of serine 9 results in autoinhibition of GSK3B")
       (:PMID . "12167628") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "GSK-3 activity is inhibited through phosphorylation of serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta. These serine residues of GSK-3 have been previously identified as targets of protein kinase B (PKB/Akt), a serine/threonine kinase located downstream of phosphatidylinositol 3-kinase.      ")
       (:PMID . "11035810") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "In various cell types, AKT phosphorylates and inhibits glycogen synthase kinase-3 (GSK-3). Upon serum stimulation of EC, GSK-3beta was phosphorylated at Ser-9.")
       (:PMID . "11779850") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "We then investigated the convergence point of PTH/cAMP signaling and the canonical Wnt pathway. Western blotting demonstrated that GSK-3beta was rapidly phosphorylated at Ser(9) on treatment with PTH or forskolin, leading to its inactivation. Moreover, overexpression of a constitutively active mutant of GSK-3beta abolished the TCF-dependent transactivation induced by forskolin. ")
       (:PMID . "17990294") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . ", whereas no significant changes were observed in the total amount of this protein (Fig. 5, D and E). Therefore, the phosphorylation of p90rsk may be the link between ERK activation and GSK3{beta} phosphorylation. The stimulation of glycogen synthesis by insulin is triggered by the phosphorylation of GSK3{beta} at serine 9 and its concomitant inactivation.")
       (:PMID . "12925525") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "glycogen synthase kinase GSK3 which itself is a target of protein kinase B (PKB) and the serum and glucocorticoid inducible kinase SGK1. Phosphorylation of GSK3 by PKB or SGK1 inhibits GSK3 activity an the present study explored whether mineralocorticoid excess had any effect on the phosphorylation status of the a and beta isoforms of GSK3. Western blotting using an antibody specific for the PKB/SGK1 consensus phosphorylation site in GSK3a/beta (serine 21 and 9 respectively) revealed an increase in GSK3a/beta phosphorylation in human embryonic kidney 293 (HEK293) cells overexpressing wild type SGK1, constitutively active SGK1, but not catalytically inactive SGK1. The effect of SGK1 was mimicked by PKB and SGK3.")
       (:PMID . "16543730") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . ". A major mechanism of cell necrosis is the opening of the mitochondrial permeability transition pore (mPTP), which consists of multiple protein subunits, including adenine nucleotide translocase (ANT). The threshold for mPTP opening is elevated by phosphorylation of GSK-3beta at Ser9, which reduces activity of this kinase. {FROM FULL TEST: The mPTP is a non-selective large conductance channel in the mitochondrial inner membrane, which is physiologically closed. Opening of mPTPs is involved in cell death induced by a variety of causes (for example, ischemia/reperfusion, alcohol, endotoxin, anti-cancer agents), therefore 'opening' is modeled as tportof(mitochondrial permeability transition pore) and increased threshold for opening is modeled as decrease in tportof -SE}")
       (:PMID . "19506320") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "In mammals GSK3 is present in two isoforms, alpha and beta regulated by phosphorylation: phosphorylation of Ser9 in GSK3beta or Ser21 in GSK3alpha leads to inactivation while phosphorylation of Tyr216 in GSK3beta or Tyr279 in GSK3alpha leads to activation.")
       (:PMID . "15265592") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "E2 and PLD induce phosphorylation of GSK-3b at the negative regulatory site Ser9")
       (:PMID . "16996503") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "In unstimulated cells, GSK3 is active and contributes significantly towards the phosphorylation and inhibition of glycogen synthase [12]. Insulin stimulates glycogen synthesis both by inactivating GSK3 and also by promoting the dephosphorylation of glycogen synthase. The inactivation of GSK3 and GSK3 is achieved through phosphorylation of Ser21 and Ser9, respectively [12], and this is mediated by PKB in a PI3K-dependent fashion. Thus PI3K, PDK, PKB and GSK3 constitute one important arm of the insulin signalling cascade regulating glycogen synthesis. In addition to inducing an increase in glucose transport, over-expression of PKB elicited an inhibition of GSK3 and a concomitant increase in glycogen and protein synthesis a decrease in insulin-stimulated GLUT4 translocation, glucose transport and membrane ruffling, which coincided with reduced phosphorylation of PKB and p70S6K but normal phosphorylation of p42/44 MAPK observed an inhibition of PKB phosphorylation and downstream p70S6K activation, which was attributable to a PP2A-type phosphatase activity Akt phosphorylates and inactivates GSK-3, decreasing the rate of phosphorylation of glycogen synthase")
       (:PMID . "11257494") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "GSK3b phosphorylation of Bcl3 has previously been shown to result in its degradation (Viatour et al., 2004), whereas GSK3b activity can be repressed by Akt (PKB) induced phosphorylation on serine 9 (Emamian et al., 2004).")
       (:PMID . "20513428") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "Moreover, we show that the repression of AR activity by LY294002 is mediated through phosphorylation and inactivation of GSK3beta, a downstream substrate of PI3K/Akt, which results in the nuclear accumulation of beta-catenin The activation of Akt results in the phosphorylation of a number of downstream substrates such as glycogen synthase kinase (GSK3) It has been shown that GSK3 plays an important role in the Wnt pathway by regulating the degradation of -catenin Recently, a specific protein-protein interaction between -catenin and AR was identified by us and others (22, 23). Through this interaction, -catenin augments the ligand-dependent activity of AR in prostate cancer cells.")
       (:PMID . "12063252") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . ". A major mechanism of cell necrosis is the opening of the mitochondrial permeability transition pore (mPTP), which consists of multiple protein subunits, including adenine nucleotide translocase (ANT). The threshold for mPTP opening is elevated by phosphorylation of GSK-3beta at Ser9, which reduces activity of this kinase. {FROM FULL TEST: The mPTP is a non-selective large conductance channel in the mitochondrial inner membrane, which is physiologically closed. Opening of mPTPs is involved in cell death induced by a variety of causes (for example, ischemia/reperfusion, alcohol, endotoxin, anti-cancer agents), therefore 'opening' is modeled as tportof(mitochondrial permeability transition pore) and increased threshold for opening is modeled as decrease in tportof -SE}")
       (:PMID . "19506320") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_GSK3B_pmod_P_S_9_DirectlyDecreases_kin_p_HGNC_GSK3B")
       (:TEXT
        . "##from text## p70S6Ks down-regulates the activity of GSK3beta by phosphorylating Ser9 residue [33].")
       (:PMID . "19575820") (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "3e405662-bb74-4dd6-8b48-c5903c6377af")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "411") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08631") (:+HGNC+ . "4840")) (:NAME . "HCK"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9425276") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "1696179") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "14967142") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7730365") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9742401") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7477410") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18193084") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "2415973") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "16537894") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "10779329") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11489946") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11074000") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18799748") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "a601cd76-006a-40fe-84cf-153a574e3e28")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "15") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "82") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "78") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04792") (:+HGNC+ . "5246")) (:NAME . "HSPB1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_b894d1dba0ff51e1e1f673c747628bcf")
       (:PMID . "1332886") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_b894d1dba0ff51e1e1f673c747628bcf")
       (:PMID . "7750577") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_b894d1dba0ff51e1e1f673c747628bcf")
       (:PMID . "9628874") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_b894d1dba0ff51e1e1f673c747628bcf")
       (:PMID . "8626550") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE) (:TYPE . "ActiveForm")
     (:ID . "470833df-aa6b-4999-ab5f-fd3381e9c0f7")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06213") (:+HGNC+ . "6091")) (:NAME . "INSR"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_INSR_pmod_P_S_DirectlyDecreases_kin_p_HGNC_INSR")
       (:TEXT
        . "Thus, we postulate that the decreased tyrosine kinase activity of the insulin receptor may be caused by serine/threonine phosphorylation by PKC.")
       (:PMID . "10923637") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_INSR_pmod_P_S_DirectlyDecreases_kin_p_HGNC_INSR")
       (:TEXT
        . "the tyrosine kinase activity of the receptor decreases as a consequence of serine/threonine phosphorylation.")
       (:PMID . "11849969") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06213") (:+HGNC+ . "6091")) (:NAME . "INSR"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "2c0f2d0e-7710-434d-8765-190a31d5b2d3")
     (:SUPPORTED--BY "a47dda04-99eb-4ccc-91f6-c4b212942819")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_INSR_pmod_P_Y_960_DirectlyIncreases_kin_p_HGNC_INSR")
       (:TEXT
        . "Phosphotyrosine at site 960 of the b subunit just inside the membrane creates an NPXpY-recognition motif for the PTB domain of the IRS proteins. Modification of this tyrosine completely inhibits subsequent phosphorylation of IRS-1 and other insulin receptor substrates and leads to loss of most insulin-dependent biological actions")
       (:PMID . "10194465") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_INSR_pmod_P_Y_960_DirectlyIncreases_kin_p_HGNC_INSR")
       (:TEXT
        . "Phosphotyrosine at site 960 of the b subunit just inside the membrane creates an NPXpY-recognition motif for the PTB domain of the IRS proteins. Modification of this tyrosine completely inhibits subsequent phosphorylation of IRS-1 and other insulin receptor substrates and leads to loss of most insulin-dependent biological actions")
       (:PMID . "10194465") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_INSR_pmod_P_Y_960_DirectlyIncreases_kin_p_HGNC_INSR")
       (:TEXT
        . "Phosphotyrosine at site 960 of the b subunit just inside the membrane creates an NPXpY-recognition motif for the PTB domain of the IRS proteins. Modification of this tyrosine completely inhibits subsequent phosphorylation of IRS-1 and other insulin receptor substrates and leads to loss of most insulin-dependent biological actions")
       (:PMID . "10194465") (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "catalytic") (:IS--ACTIVE) (:TYPE . "ActiveForm")
     (:ID . "d17a5405-b1a0-4298-a3a1-880f06263fef")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_IRS1_pmod_P_S_DirectlyDecreases_cat_p_HGNC_IRS1")
       (:TEXT
        . "Here, we demonstrate that nutrients suppress phosphatidylinositol 3 (PI3)-kinase/Akt signaling via Raptor-dependent mTOR (mammalian target of rapamycin)-mediated phosphorylation of insulin receptor substrate 1 (IRS-1). Raptor directly binds to and serves as a scaffold for mTOR-mediated phosphorylation of IRS-1 on Ser636/639")
       (:PMID . "16354680") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_IRS1_pmod_P_S_DirectlyDecreases_cat_p_HGNC_IRS1")
       (:TEXT
        . "Here we report that glycogen synthase kinase 3 (GSK-3) is capable of phosphorylating IRS-1 and that this modification converts IRS-1 into an inhibitor of IR tyrosine kinase activity in vitro.")
       (:PMID . "9275179") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_IRS1_pmod_P_S_DirectlyDecreases_cat_p_HGNC_IRS1")
       (:TEXT
        . "S6K was shown to directly phosphorylate IRS-1 to inhibit phosphatidylinositol-3-kinase (PI3K) and Akt activation (Harrington ete al, 2004).")
       (:PMID . "16404421") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_IRS1_pmod_P_S_DirectlyDecreases_cat_p_HGNC_IRS1")
       (:TEXT
        . "The 3 members of the JNK group of serine/threonine kinases, JNK-1, -2, and -3, JNK has recently emerged as a central metabolic regulator, playing an important role in the development of insulin resistance in obesity In response to stimuli such as ER stress, cytokines, and fatty acids, JNK is activated, whereupon it associates with and phosphorylates IRS-1 on Ser307, impairing insulin action")
       (:PMID . "15864338") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_IRS1_pmod_P_S_DirectlyDecreases_cat_p_HGNC_IRS1")
       (:TEXT
        . "Insulin affects cells through binding to its receptor on the surface of insulin-responsive cells. The stimulated insulin receptor phosphorylates itself and several substrates, including members of the insulin receptor substrate (IRS) family, thus initiating downstream signaling events (32, 33). The inhibition of signaling downstream of the insulin receptor is a primary mechanism through which inflammatory signaling leads to insulin resistance. Exposure of cells to TNF-a or elevated levels of free fatty acids stimulates inhibitory phosphorylation of serine residues of IRS-1")
       (:PMID . "15864338") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:ACTIVITY . "catalytic") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "6fb26128-93bc-48a6-b70b-7d10e9cb168f")
     (:SUPPORTED--BY "a70344e2-4a68-4ecb-b80f-f4669396974f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_IRS1_pmod_P_Y_DirectlyIncreases_cat_p_HGNC_IRS1")
       (:TEXT
        . "Accordingly, under the cellular context of the elevated expression of IL- 6Ra on myeloma cells, it is assumed that IL-6Ra molecules are located close to IGF-I receptors at lipid rafts, and IL-6 stimulation triggers the complex formation of IL-6Ra not only with gp130 but also with IGF-I receptors, leading to autophosphorylation of IGF-I receptor b and subsequent acti- vation of PI-3 kinase-Akt pathways (Fig. 4) 79 .")
       (:PMID . "17142955") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_IRS1_pmod_P_Y_DirectlyIncreases_cat_p_HGNC_IRS1")
       (:TEXT
        . "TNF-{alpha} reduces insulin-stimulated receptor tyrosine kinase activity at low concentrations and can also decrease the expression of the insulin receptor, IRS-1 and GLUT-4 at higher concentrations (22) as well as increase the phosphorylation of serine 307 of IRS-1, thus impairing its ability to bind to the insulin receptor and initiate downstream signaling.")
       (:PMID . "12952969") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1007") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O60674") (:+HGNC+ . "6192")) (:NAME . "JAK2"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "1c8ac13f-65d7-48f6-a631-6361b610cecb")
     (:SUPPORTED--BY "c4b4bdcd-0adc-421c-a9c4-a7d490562af1")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c1acda77bad5d3383bf73c9a3463a1ab")
       (:PMID . "11773439") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c1acda77bad5d3383bf73c9a3463a1ab")
       (:PMID . "17158356") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1008") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O60674") (:+HGNC+ . "6192")) (:NAME . "JAK2"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "2753ad41-c9e4-4327-b3f4-cc51598719c0")
     (:SUPPORTED--BY "10b6b05e-76f0-4f75-912c-8736e664463b"
      "c4b4bdcd-0adc-421c-a9c4-a7d490562af1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_JAK2_pmod_P_Y_1008_DirectlyIncreases_kin_p_HGNC_JAK2")
       (:TEXT
        . "We found that AngII, through the AT(1) receptor, rapidly stimulated JAK2 phosphorylation at Tyr(1007/1008), the critical sites for the kinase activation.")
       (:PMID . "11818507") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_JAK2_pmod_P_Y_1008_DirectlyIncreases_kin_p_HGNC_JAK2")
       (:TEXT
        . "Two tyrosine residues at the corresponding positions of Jak2 (tyrosine-1007 and tyrosine-1008) were found to be phosphorylated, and a single mutation of tyrosine-1007 eliminated essentially all tyrosine kinase activity [59].")
       (:PMID . "9716487") (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "e160b0b1-895a-400f-b9d2-27ed20d876e5")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "980") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "981") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P52333") (:+HGNC+ . "6193")) (:NAME . "JAK3"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "1940342") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "2047859") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7665592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7973659") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "1618313") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7973658") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7973657") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "3095922") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "9822600") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "8552611") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "2106566") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "10214954") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "9391116") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "2303462") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "9202126") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "1545122") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "1631559") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7988557") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "10373548") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "8262551") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "8702919") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "2590941") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "9382798") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "10514520") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "63") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "73") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P05412") (:+HGNC+ . "6204")) (:NAME . "JUN"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "c4c91182-a56c-40c9-b79d-2ee7614fe3e1")
     (:SUPPORTED--BY "14ed747c-72bf-411b-905f-d1c568872df2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_95407a42e10418faf03fc99161e928a2")
       (:PMID . "18362184") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_95407a42e10418faf03fc99161e928a2")
       (:PMID . "11562357") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_95407a42e10418faf03fc99161e928a2")
       (:PMID . "10385525") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "10493750") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "9315636") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "17055484") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "17143273") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "7600582") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "9184210") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "9891069") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "9487126") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "15068801") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "9305638") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "12881422") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "10713700") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "12087092") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "9407028") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "10882101") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_99a3a01c8ea867dd44411bbd38fab6eb")
       (:PMID . "11801649") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P10721") (:+HGNC+ . "6342")) (:NAME . "KIT"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "62a0b90c-eb8f-44ba-b38e-ce736d988750")
     (:SUPPORTED--BY "7fdc1e88-ada9-486d-b9df-d8c1cdd5ddfc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_KIT_pmod_P_Y_DirectlyIncreases_kin_p_HGNC_KIT")
       (:TEXT
        . "Binding of dimerized KitL induces the dimerization of Kit [32]. This leads to the autophosphorylation of Kit on tyrosine and its association with substrates of various kinds. The phophatidylinositol-3-kinase (PI3K)/Akt system is one of the major pathways [33] (fig. 1). PI3K is composed of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit. The 85-kDa regulatory subunit is associated with activated Kit through an SH2 domain, and then is phosphorylated on tyrosine. The 110-kDa catalytic subunit of the activated PI3K produces phosphatidylinositol-3,4-bisphosphate, which in turn is used for phosphorylation of Akt, a serine-threonine kinase. The activated Akt is involved in the inhibition of apoptosis of cells whose survival depends on Kit signaling. A tyrosine kinase inhibitor, imatinib mesylate blocks not only autophosphorylation of Kit but also phosphorylation of Akt [34]. Induction of apoptosis in Kit signaling-dependent cells by imatinib mesylate may be mediated through the inhibition of Akt activity.")
       (:PMID . "15583854") (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "671adb52-c2f6-412f-8cd9-2443c15a0b1c")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "394") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06239") (:+HGNC+ . "6524")) (:NAME . "LCK"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_6109c96270fd9c62d3df78bb6bdf8b22")
       (:PMID . "7553885") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_6109c96270fd9c62d3df78bb6bdf8b22")
       (:PMID . "12036857") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "1940342") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "2047859") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7665592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7973659") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "1618313") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7973658") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7973657") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "3095922") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "9822600") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "8552611") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "2106566") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "10214954") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "9391116") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "2303462") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "9202126") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "1545122") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "1631559") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "7988557") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "10373548") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "8262551") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "8702919") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "2590941") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "9382798") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_febd24622b72e5baea730c62ad694c80")
       (:PMID . "10514520") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9425276") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "1696179") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "14967142") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7730365") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9742401") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7477410") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18193084") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "2415973") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "16537894") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "10779329") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11489946") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11074000") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18799748") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P07948") (:+HGNC+ . "6735")) (:NAME . "LYN"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "99f5cd1e-0715-4d02-9969-a6ced9e2c284")
     (:SUPPORTED--BY "586780de-4044-46f1-b42e-94ba2c9d9889"
      "38db384a-f42c-49b8-a693-d9eacfe1a7d1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9425276") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "1696179") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "14967142") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7730365") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "9742401") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "7477410") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18193084") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "2415973") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "16537894") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "10779329") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11489946") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "11074000") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5c8209316c7b5c90e0691d76fbeebe7d")
       (:PMID . "18799748") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "508") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P07948") (:+HGNC+ . "6735")) (:NAME . "LYN"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE) (:TYPE . "ActiveForm")
     (:ID . "094fc2dd-574c-41f3-9670-23dae9ccfe74")
     (:SUPPORTED--BY "c2988034-e886-4a08-9636-2d7a46c5b1e0")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_LYN_pmod_P_Y_508_DirectlyDecreases_kin_p_HGNC_LYN")
       (:TEXT
        . "Lyn phosphorylates Cbp on multiple tyrosine residues, including two that can bind Lyn's SH2 domain with high affinity. Lyn also phosphorylates Y314, which recruits Csk/Ctk to phosphorylate Lyn at its Y508 negative site, allowing an inactive conformation to form. ")
       (:PMID . "17905674") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_LYN_pmod_P_Y_507_DirectlyDecreases_kin_p_HGNC_LYN")
       (:TEXT
        . "Additionally, IL-6-induced Lyn kinase activity in CD45+ U266 cells was increased by the cross-linking of CD45, and this increase was due to the dephosphorylation of Tyr507 at Lyn")
       (:PMID . "14979481") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "12d19950-25d2-4c30-837a-0d4c2269fe53")
     (:SUPPORTED--BY "8fce62b8-4d25-4da0-b18b-d6a996397094"
      "4218048f-eb06-4891-a787-bbbc06858968"
      "c81916e0-546d-473e-bdd1-6a1ea7a92431"
      "bb8bb38e-c015-401d-bc6d-41680427557e")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "226") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842")) (:NAME . "MAP2K2"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "9b1de505-1f35-4ee2-9d9d-458223251060")
     (:SUPPORTED--BY "67ad2211-7d54-42fb-be52-35c11cf83188")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8b21f47776c16fbbe738728af9861d1e")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8b21f47776c16fbbe738728af9861d1e")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5304f8e7195b52d93cd9b3a512323e82")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5ccf21ab6879eb53d5fcf6e9892d3e4c")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5ccf21ab6879eb53d5fcf6e9892d3e4c")
       (:PMID . "16508002") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5ccf21ab6879eb53d5fcf6e9892d3e4c")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_49f53f69e846939e9051974045eeaba1")
       (:PMID . "8933152") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_49f53f69e846939e9051974045eeaba1")
       (:PMID . "10969079") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876")) (:NAME . "MAPK14"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "14d474a7-ec67-416d-bda4-5ee059f2ceae")
     (:SUPPORTED--BY "045cb804-e691-4759-8fe9-4ec4a02a092f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "7693711") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "9528766") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "14970210") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "14585994") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "15728454") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "7914033") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "16282370") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "8940174") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "9854026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "15632082") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "11304531") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "16157584") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "16407200") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "7997261") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "21402774") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "11309380") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "7592586") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "10734320") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "9790884") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "8622669") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "9582275") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "18586681") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2ce561b71d0510c1b7e7578e4a1caebf")
       (:PMID . "7839144") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "9169478") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "10318845") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "8636072") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "11727828") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "9362518") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "10066828") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "18375741") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "17143273") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "8798750") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "14661019") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "18291705") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "14634666") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "12133933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "12038794") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "12354380") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "16467404") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "7592586") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_5e3c99a6bd2c3c13a4b55d7522b0655c")
       (:PMID . "16260598") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "f4e0dce9-d657-41e0-938a-c8bbbd8cd590")
     (:SUPPORTED--BY "48da586a-21de-4775-80a1-f3270fe453ca"
      "6d8ee3cf-305e-4ceb-9061-616f8fc4fcb0"
      "c45b5587-e216-4c71-9ab1-14c3f3679a42")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16452216") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "22569333") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15210957") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12048245") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11432864") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16049136") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10327068") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10995751") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11319218") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16418218") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16076871") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12865341") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12716924") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12810709") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15509650") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "18319301") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9703991") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15843522") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12750158") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9160888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16820412") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10329710") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10617617") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17363898") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16195423") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10693928") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9854026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "14657000") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12110689") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16691505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "21493899") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12598525") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12890486") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11278665") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11532940") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9988698") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "8903320") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12824293") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12925710") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12668516") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17267519") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9490736") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10734053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12175535") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17540773") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9560161") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9beeffe6ae3050bc79b0ce841a02553b")
       (:PMID . "10871282") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9beeffe6ae3050bc79b0ce841a02553b")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9beeffe6ae3050bc79b0ce841a02553b")
       (:PMID . "11118451") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9beeffe6ae3050bc79b0ce841a02553b")
       (:PMID . "11046147") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_a90f58d797b7cfaec799c37ea533e72f")
       (:PMID . "12876277") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2797bdd3d82770a2c9707a397ec20d89")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_917305744b651a50a2dd1d1a595148cf")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_917305744b651a50a2dd1d1a595148cf")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c3d19dbb951873970faeec263f4042aa")
       (:PMID . "10206983") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c3d19dbb951873970faeec263f4042aa")
       (:PMID . "16210616") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c3d19dbb951873970faeec263f4042aa")
       (:PMID . "1381507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c3d19dbb951873970faeec263f4042aa")
       (:PMID . "8376945") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3fe03cdf8209058bd5028115322afd5d")
       (:PMID . "10777511") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3fe03cdf8209058bd5028115322afd5d")
       (:PMID . "12952943") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3fe03cdf8209058bd5028115322afd5d")
       (:PMID . "9032297") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3fe03cdf8209058bd5028115322afd5d")
       (:PMID . "10998418") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3fe03cdf8209058bd5028115322afd5d")
       (:PMID . "9148935") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3fe03cdf8209058bd5028115322afd5d")
       (:PMID . "14743221") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_6cd907d666d65e69765fd3dac9e80efe")
       (:PMID . "9765155") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "4680b890-bf6a-4130-a537-3e313d2f9139")
     (:SUPPORTED--BY "48da586a-21de-4775-80a1-f3270fe453ca"
      "3b90f5c0-27ec-4145-8023-3e8a9f5c5e63"
      "a21c9613-1051-4bfd-9444-7780129f93d8")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16452216") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "22569333") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15210957") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12048245") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11432864") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16049136") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10327068") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10995751") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11319218") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16418218") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16076871") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12865341") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12716924") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12810709") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15509650") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "18319301") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9703991") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15843522") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12750158") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9160888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16820412") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10329710") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10617617") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17363898") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16195423") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10693928") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9854026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "14657000") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12110689") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16691505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "21493899") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12598525") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12890486") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11278665") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11532940") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9988698") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "8903320") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12824293") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12925710") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12668516") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17267519") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9490736") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "10734053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "12175535") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "17540773") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_08e5b4ec1110fcfa3fc7cebd54febf81")
       (:PMID . "9560161") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9beeffe6ae3050bc79b0ce841a02553b")
       (:PMID . "10871282") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9beeffe6ae3050bc79b0ce841a02553b")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9beeffe6ae3050bc79b0ce841a02553b")
       (:PMID . "11118451") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9beeffe6ae3050bc79b0ce841a02553b")
       (:PMID . "11046147") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_2797bdd3d82770a2c9707a397ec20d89")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c3d19dbb951873970faeec263f4042aa")
       (:PMID . "10206983") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c3d19dbb951873970faeec263f4042aa")
       (:PMID . "16210616") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c3d19dbb951873970faeec263f4042aa")
       (:PMID . "1381507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c3d19dbb951873970faeec263f4042aa")
       (:PMID . "8376945") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_917305744b651a50a2dd1d1a595148cf")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_917305744b651a50a2dd1d1a595148cf")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P45984") (:+HGNC+ . "6886")) (:NAME . "MAPK9"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "f7f517b7-cc9c-431e-a3fb-cd154e5a0a90")
     (:SUPPORTED--BY "b8473e57-00ca-4442-96be-2f9dc4920de8")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_22d0a3f64305f0226054cad53a836aa9")
       (:PMID . "18667433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_22d0a3f64305f0226054cad53a836aa9")
       (:PMID . "17646398") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "10318845") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "9362518") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "17143273") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "15548667") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "11756426") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "11279271") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "11389443") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "14960584") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "12376548") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "8878481") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "15668238") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "11847100") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "11777929") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "10748139") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "16076903") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "18426980") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "14523011") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "12133933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "15538382") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "11756498") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "11487608") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "11489946") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "12354380") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "17878362") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_3c6ebdba0b3904f99f58d96b322d36e9")
       (:PMID . "16260598") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_81c5e1678bcaf9bca14092fb6f4533d5")
       (:PMID . "18423204") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "catalytic") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "85db9754-c5b8-4c79-923f-bea6203f24aa")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "166") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q00987") (:+HGNC+ . "6973")) (:NAME . "MDM2"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MDM2_pmod_P_S_166_DirectlyIncreases_cat_p_HGNC_MDM2")
       (:TEXT
        . "Phosphorylation of MDM2 enhances its nuclear localization and its interaction with p300, and inhibits its interaction with p19ARF, thus increasing p53 degradation")
       (:PMID . "11715018") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MDM2_pmod_P_S_166_DirectlyIncreases_cat_p_HGNC_MDM2")
       (:TEXT
        . "Phosphorylation of MDM2 by the protein kinase AKT is thought to regulate MDM2 function in response to survival signals PMID: 11715018")
       (:PMID . "15527798") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1234") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "8e45bf46-d59a-4945-bd0d-f30846c58833")
     (:SUPPORTED--BY "16dddfc0-4036-4ea1-90e4-0ff3f2487a0d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MET_pmod_P_Y_1234_DirectlyIncreases_kin_p_HGNC_MET")
       (:TEXT
        . "Substitution of either Tyr1235 or Tyr1234 with phenylalanine severely reduced the in vitro kinase activity toward exogenous substrates.")
       (:PMID . "8302603") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MET_pmod_P_Y_1234_DirectlyIncreases_kin_p_HGNC_MET")
       (:TEXT
        . "After ligand activation, the Met receptor becomes inducibly phosphorylated at multiple sites, including the major autophosphorylation sites Tyr1230/1234/1235 (homologous to Tyr361/365/366 in TPR-MET). Phosphorylation at these sites correlates with activation of the Met kinase. Using phospho-specific antibodies to Tyr1230/1234/1235, we found that SU11274 completely blocked the increase in phosphorylation (Fig. 4A, bottom).")
       (:PMID . "14500382") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MET_pmod_P_Y_1234_DirectlyIncreases_kin_p_HGNC_MET")
       (:TEXT
        . "Using the appropriate 'kinase inactive' mutant receptors, we show that ligand-induced activation of Met results in transphosphorylation of Ron, and vice versa. Transphosphorylation is direct, as it occurs in Met or Ron receptors lacking the docking sites for signal transducers. Phosphate groups are transferred to the tyrosine phosphorylation sites responsible both for kinase up-regulation (Met: Y1234/Y1235 and Ron: Y1238/Y1239) and for generation of signal transducer docking sites (Met: Y1349/Y1356 and Ron Y1353/Y1360). ")
       (:PMID . "10871856") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MET_pmod_P_Y_1234_DirectlyIncreases_kin_p_HGNC_MET")
       (:TEXT
        . "Here we investigate the molecular mechanisms underlying met oncogenic conversion by generating antibodies specific for the differently phosphorylated forms of the Met protein. Using these antibodies, we show that activation of wild-type Met is achieved through sequential phosphorylation of Tyr1235 and Tyr1234 in the activation loop and that mutagenesis of either tyrosine dramatically impairs kinase function. ")
       (:PMID . "12746450") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1235") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "331a11c8-d5ef-45d7-a0db-de74350c72e5")
     (:SUPPORTED--BY "16dddfc0-4036-4ea1-90e4-0ff3f2487a0d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MET_pmod_P_Y_1235_DirectlyIncreases_kin_p_HGNC_MET")
       (:TEXT
        . "Here we investigate the molecular mechanisms underlying met oncogenic conversion by generating antibodies specific for the differently phosphorylated forms of the Met protein. Using these antibodies, we show that activation of wild-type Met is achieved through sequential phosphorylation of Tyr1235 and Tyr1234 in the activation loop and that mutagenesis of either tyrosine dramatically impairs kinase function. ")
       (:PMID . "12746450") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MET_pmod_P_Y_1235_DirectlyIncreases_kin_p_HGNC_MET")
       (:TEXT
        . "Using the appropriate 'kinase inactive' mutant receptors, we show that ligand-induced activation of Met results in transphosphorylation of Ron, and vice versa. Transphosphorylation is direct, as it occurs in Met or Ron receptors lacking the docking sites for signal transducers. Phosphate groups are transferred to the tyrosine phosphorylation sites responsible both for kinase up-regulation (Met: Y1234/Y1235 and Ron: Y1238/Y1239) and for generation of signal transducer docking sites (Met: Y1349/Y1356 and Ron Y1353/Y1360). ")
       (:PMID . "10871856") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MET_pmod_P_Y_1235_DirectlyIncreases_kin_p_HGNC_MET")
       (:TEXT
        . "Substitution of either Tyr1235 or Tyr1234 with phenylalanine severely reduced the in vitro kinase activity toward exogenous substrates.")
       (:PMID . "8302603") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MET_pmod_P_Y_1235_DirectlyIncreases_kin_p_HGNC_MET")
       (:TEXT
        . "After ligand activation, the Met receptor becomes inducibly phosphorylated at multiple sites, including the major autophosphorylation sites Tyr1230/1234/1235 (homologous to Tyr361/365/366 in TPR-MET). Phosphorylation at these sites correlates with activation of the Met kinase. Using phospho-specific antibodies to Tyr1230/1234/1235, we found that SU11274 completely blocked the increase in phosphorylation (Fig. 4A, bottom).")
       (:PMID . "14500382") (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "c6dbe3ff-985c-48e3-b6fc-ea221b881792")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "2448") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P42345") (:+HGNC+ . "3942")) (:NAME . "MTOR"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_7a181c7aeaab79e589709151752c33c1")
       (:PMID . "10499523") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_7a181c7aeaab79e589709151752c33c1")
       (:PMID . "1614535") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_7a181c7aeaab79e589709151752c33c1")
       (:PMID . "15051500") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "62") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P01106") (:+HGNC+ . "7553")) (:NAME . "MYC"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "4e7d4aa4-9914-4044-8de6-2cf044542589")
     (:SUPPORTED--BY "20b1fcfe-1417-49c7-84a5-cd5a8d860351")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MYC_pmod_P_S_62_DirectlyIncreases_tscript_p_HGNC_MYC")
       (:TEXT
        . "Exposure to H2O2 enhances c-Myc recruitment to gamma-GCS regulatory regions through ERK-dependent phosphorylation. Phosphorylation at Ser-62 is required for c-Myc recruitment to gamma-GCS promoters and determines the cellular response to oxidative stress induced by different stimuli.")
       (:PMID . "16483932") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_MYC_pmod_P_S_62_DirectlyIncreases_tscript_p_HGNC_MYC")
       (:TEXT
        . "In agreement with the role of S62 phosphorylation on reporter gene expression, the hTERT and Bmi-1 genes were repressed by IFN-? + TPA and by the Cdk2 inhibitor CVT-313 (Fig. 6D), whereas the p21 and p16Ink4A genes were strongly induced (Fig. 6E). The changes in gene expression are consistent with the ChIP results and indicate that cyclin E/Cdk2 enhances, whereas IFN-?, through the activation of p27, represses Myc-activated transcription (and vice versa for Myc-repressed transcription) of genes involved in cellular senescence. ")
       (:PMID . "19966300") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "144") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13153") (:+HGNC+ . "8590")) (:NAME . "PAK1"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "f9f0d707-e87e-46a9-ae0c-bb885d541afc")
     (:SUPPORTED--BY "c6ff6dd9-fb40-4201-9c13-6910e86118cc")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "199") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13153") (:+HGNC+ . "8590")) (:NAME . "PAK1"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "d7050df2-8083-4250-9c52-392f3f4d132c")
     (:SUPPORTED--BY "c6ff6dd9-fb40-4201-9c13-6910e86118cc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c6425266393d35ff1d59453adb544872")
       (:PMID . "10793146") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c6425266393d35ff1d59453adb544872")
       (:PMID . "19628037") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_83ad2b360e96708ddf3862a290f25cb0")
       (:PMID . "15788770") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "423") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13153") (:+HGNC+ . "8590")) (:NAME . "PAK1"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "0c790d66-7258-429f-b5a1-7d12a1417561")
     (:SUPPORTED--BY "bf7d43f9-b4cd-48e8-a053-fb5b56b0eb13"
      "c6ff6dd9-fb40-4201-9c13-6910e86118cc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_42bd881d44013faf52a9ab6535744729")
       (:PMID . "16049136") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_42bd881d44013faf52a9ab6535744729")
       (:PMID . "11689432") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/ComplexAssembly_42bd881d44013faf52a9ab6535744729")
       (:PMID . "9764820") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "6a5524f9-038b-460c-8691-a4646502026a")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13177") (:+HGNC+ . "8591")) (:NAME . "PAK2"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_e844bb3fe73cf00eef7f2de56ce35701")
       (:PMID . "9535855") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_e844bb3fe73cf00eef7f2de56ce35701")
       (:PMID . "18319301") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_e844bb3fe73cf00eef7f2de56ce35701")
       (:PMID . "7744004") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "f5545daf-6568-47d8-946d-8c66b1371425")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9ac48bc34b5aa334465447f6c452585c")
       (:PMID . "10856237") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_9ac48bc34b5aa334465447f6c452585c")
       (:PMID . "10480933") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "4df4a55a-6f0c-411b-89d8-43fe63d20605")
     (:AGENT
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_PRKCA_pmod_P_T_DirectlyIncreases_kin_p_HGNC_PRKCA")
       (:SOURCE--API . "bel"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "ef96a183-dc73-499d-8962-b46237cfb224")
     (:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "507") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_c2a47d51e49e3f9143bcc05b67840ef7")
       (:PMID . "12817007") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "078ffc23-a6b0-4160-baf5-382b5087bfd1")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_ba4f60c0c2ec744e8307b981f98227f5")
       (:PMID . "11884618") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "90") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "538") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "676") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "695") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q04759") (:+HGNC+ . "9410")) (:NAME . "PRKCQ"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "d9ca5451-38b4-4f7f-b025-8bf7d76e2e88")
     (:SUPPORTED--BY "2f1fff98-2a7b-4d33-b2ee-8c3920d30eb3")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "410") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05513") (:+HGNC+ . "9412")) (:NAME . "PRKCZ"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "128e8a60-5417-47e2-9581-fbe2634a5397")
     (:SUPPORTED--BY "a6e5fb9e-2d11-45da-9291-37a84f7c8edc"
      "ac09e45f-7c62-4b5b-814e-29d67478a446"
      "b02c2182-5eb4-4997-9b26-058b14ef93ee")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_PRKCZ_pmod_P_T_410_DirectlyIncreases_kin_p_HGNC_PRKCZ")
       (:TEXT
        . "PDK-1 is a downstream molecule of PI3K, which activates among many others, PKC-z (37). This protein kinase is a member of the atypical PKCs. Unlike conventional or novel PKCs, it does not require diacylglycerol or phorbol esters for its activation and its function is Ca2+ independent (38). To achieve catalytic potential, PKC-z needs to be phosphorylated on threonine 410 (T410) through PDK-1 (37, 39).")
       (:PMID . "14604996") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_PRKCZ_pmod_P_T_410_DirectlyIncreases_kin_p_HGNC_PRKCZ")
       (:TEXT
        . "Our findings suggest that insulin, via PIP(3), provokes increases in PKC-zeta enzyme activity through (a) PDK-1-dependent T410 loop phosphorylation, (b) T560 autophosphorylation")
       (:PMID . "11141077") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "c0293690-c58e-49df-a639-26c8034f8bc7")
     (:SUPPORTED--BY "38eeac8b-33ac-4755-b25d-4685e3c21edc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_d5f922119ac9dcf95cf1f5469a2d80d9")
       (:PMID . "9182576") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_d5f922119ac9dcf95cf1f5469a2d80d9")
       (:PMID . "16760434") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "201c8421-d6f8-40ee-b523-5a8af3775e83")
     (:SUPPORTED--BY "fc1e2efd-027e-4bca-9616-c9b6af636ee6"
      "38eeac8b-33ac-4755-b25d-4685e3c21edc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_381f1c76fc94d21536979d1d89a66a63")
       (:PMID . "15247219") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "576") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "577") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "925") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "b13a51ff-57cf-4195-a318-582c61efa742")
     (:SUPPORTED--BY "97c6f6ec-71e0-40b4-a752-2362ff35208a"
      "876dc856-b662-4acb-bea7-7ba3bc8b4619"
      "df56578c-b6d9-4e7d-bac7-47178e0f06ae"
      "38eeac8b-33ac-4755-b25d-4685e3c21edc"
      "6ca6b07f-91e6-4347-8e30-bf4373fcd9a0"
      "fc1e2efd-027e-4bca-9616-c9b6af636ee6"
      "cb704528-58ca-49d6-806c-7d779b8dd275"
      "9829d6f1-3c52-46a4-9930-df0303da9b7b"
      "92f08dd4-3b22-4d1b-91d5-915ae3f8ea16")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_668bf91905a842567b9429dd2d1a19f9")
       (:PMID . "10583594") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "fae03191-517a-4657-9f91-d10e40b58119")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q06124") (:+HGNC+ . "9644")) (:NAME . "PTPN11"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_5496016119ad702a54843ebb179fee19")
       (:PMID . "12270932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0b56c5137c108b091cc4f5a769e8430b")
       (:PMID . "12754506") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0b56c5137c108b091cc4f5a769e8430b")
       (:PMID . "7642582") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0b56c5137c108b091cc4f5a769e8430b")
       (:PMID . "9794795") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0b56c5137c108b091cc4f5a769e8430b")
       (:PMID . "8505282") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0b56c5137c108b091cc4f5a769e8430b")
       (:PMID . "8662827") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0b56c5137c108b091cc4f5a769e8430b")
       (:PMID . "7513703") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_7d00ad817d31ecd780f7b9971bacb79f")
       (:PMID . "10531446") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "259") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE) (:TYPE . "ActiveForm")
     (:ID . "52a8a95b-f203-4e69-b2ec-f2e2c165360e")
     (:SUPPORTED--BY "3a621afc-183f-4b58-b393-74db01fbe0b7")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RAF1_pmod_P_S_259_DirectlyDecreases_kin_p_HGNC_RAF1")
       (:TEXT
        . "This zinc-induced protein kinase A activation inhibited Raf-1 activity by phosphorylation at serine 259, preventing activation of Raf-1 by phosphorylation of serine 338. ")
       (:PMID . "17785857") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RAF1_pmod_P_S_259_DirectlyDecreases_kin_p_HGNC_RAF1")
       (:TEXT
        . "Raf itself is negatively regulated by phosphorylation at Ser259 through Akt, an important effector of phosphoinositide 3-kinase (PI3K) signaling (30, 44).")
       (:PMID . "19223555") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RAF1_pmod_P_S_259_DirectlyDecreases_kin_p_HGNC_RAF1")
       (:TEXT
        . "The cyclic AMP (cAMP)-dependent protein kinase (PKA) can inhibit Raf-1 by direct phosphorylation.  We have mapped all cAMP-induced phosphorylation sites in Raf-1, showing that serines 43, 259, and 621 are phosphorylated by PKA in vitro and induced by cAMP in vivo. ")
       (:PMID . "11971957") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RAF1_pmod_P_S_259_DirectlyDecreases_kin_p_HGNC_RAF1")
       (:TEXT
        . "Phosphorylation. Raf is principally activated by phosphorylation of specific amino acid residues as shown for each isoform in Figure 4. From an evolutionary standpoint, the Raf activation sites are highly conserved from yeast to humans. Several amino acids in Raf, particularly serine (S) 259 and S621, which bind 14-3-3 and maintain C-Raf in a closed auto-inhibited conformation, are phosphorylated in the basal state.")
       (:PMID . "16170185") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RAF1_pmod_P_S_259_DirectlyDecreases_kin_p_HGNC_RAF1")
       (:TEXT
        . "This inhibitory phosphorylation on Raf reduces the activity of MAPK pathway (Zimmermann and Moelling, 1999).")
       (:PMID . "18794886") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RAF1_pmod_P_S_259_DirectlyDecreases_kin_p_HGNC_RAF1")
       (:TEXT
        . "the phosphorylation of Raf-1 on Ser-259 induced by paclitaxel he region surrounding Ser-259 in Raf-1 conforms to a consensus sequence for phosphorylation by Akt")
       (:PMID . "12087097") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "6a7edb01-be59-46db-8acd-e94af97a33a5")
     (:SUPPORTED--BY "462fca5a-6918-4f9a-882a-e0d1d2008eef"
      "499a148e-05db-4899-9b4d-65fee2dd96e0"
      "ddf96310-8d53-480a-84a5-4123acd0451b"
      "270cbd98-7b58-44dc-8304-99015d2adf62")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_510797f5b694751b166b87a2dd88781b")
       (:PMID . "9665134") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_510797f5b694751b166b87a2dd88781b")
       (:PMID . "8180183") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_510797f5b694751b166b87a2dd88781b")
       (:PMID . "19595761") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_510797f5b694751b166b87a2dd88781b")
       (:PMID . "11134016") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_510797f5b694751b166b87a2dd88781b")
       (:PMID . "16093354") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_510797f5b694751b166b87a2dd88781b")
       (:PMID . "1990291") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_510797f5b694751b166b87a2dd88781b")
       (:PMID . "8332195") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_510797f5b694751b166b87a2dd88781b")
       (:PMID . "8503013") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_510797f5b694751b166b87a2dd88781b")
       (:PMID . "18775988") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "ad399241-572a-465c-b781-be5053be2b2b")
     (:SUPPORTED--BY "25056019-d645-41a9-bb4c-5a431d8362d5")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_749ba1ca7f707c61d5e5ba9e022565d9")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_749ba1ca7f707c61d5e5ba9e022565d9")
       (:PMID . "12917261") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_749ba1ca7f707c61d5e5ba9e022565d9")
       (:PMID . "11032808") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_90d500dc6e7db39b1da61bf2ff3893f4")
       (:PMID . "1996324") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_90d500dc6e7db39b1da61bf2ff3893f4")
       (:PMID . "8805624") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_90d500dc6e7db39b1da61bf2ff3893f4")
       (:PMID . "1639773") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_90d500dc6e7db39b1da61bf2ff3893f4")
       (:PMID . "1708096") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "da34d763-4e21-49ef-978e-9d5d99550675")
     (:SUPPORTED--BY "499a148e-05db-4899-9b4d-65fee2dd96e0"
      "25056019-d645-41a9-bb4c-5a431d8362d5")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_85b822371d7e90869b29598c3831282f")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_85b822371d7e90869b29598c3831282f")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "858e197e-045e-43fe-8fc9-2a976f33e772")
     (:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "184") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O95267") (:+HGNC+ . "9878")) (:NAME . "RASGRP1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_a52270e89fdffcae7b3a39537a1b9c53")
       (:PMID . "9819387") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_a52270e89fdffcae7b3a39537a1b9c53")
       (:PMID . "15899849") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "780") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06400") (:+HGNC+ . "9884")) (:NAME . "RB1"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE) (:TYPE . "ActiveForm")
     (:ID . "fc3e0cb3-9c09-4d14-a6bd-00e3b1c1b944")
     (:SUPPORTED--BY "f7666aff-eed7-47f4-840d-ea8a8d213061")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RB1_pmod_P_S_780_DirectlyDecreases_tscript_p_HGNC_RB1")
       (:TEXT
        . "PD 0183812 blocks phosphorylation on pRb in tumor cells PD 0183812 inhibits phosphorylation of pRb at serine 780")
       (:PMID . "11278443") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RB1_pmod_P_S_780_DirectlyDecreases_tscript_p_HGNC_RB1")
       (:TEXT
        . "TGF-beta1 increased retinoblastoma protein phosphorylation at both Ser807/811 and Ser780. Silencing Nox4 prevented TGF-beta1-mediated retinoblastoma protein phosphorylation, proliferation, and cell hypertrophy. TGF-beta1 also increased phosphorylation of eukaryotic translation initiation factor 4E binding protein-1 at Thr37/46, and this was likewise blocked by silencing Nox4")
       (:PMID . "17369289") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "380") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "359") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "573") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "363") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430")) (:NAME . "RPS6KA1"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "96ae0aaf-2341-4a5b-a1ee-007ada04bfee")
     (:SUPPORTED--BY "49d9545d-5893-4e86-b5e7-93f78ef8d8df"
      "efb4b1c4-eae7-49c6-996f-36957768c52c"
      "ed773c6e-ff92-4c41-b097-35e5482d8773")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_d4642dbe6c1239ffe2c2280f49800952")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0db6043052a5626f54fea94fc323b642")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0db6043052a5626f54fea94fc323b642")
       (:PMID . "11544482") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "e37c51a2-f837-47f9-81c9-8db6b1d5f838")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "360") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "377") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "570") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q15349") (:+HGNC+ . "10431")) (:NAME . "RPS6KA2"))
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "75d54be4-55ab-4241-93e2-a996ee2f8efe")
     (:SUPPORTED--BY "1a0c32eb-1091-44de-842f-5927205add64")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_58175fd0a920e802a937acb15954b7d5")
       (:PMID . "10330191") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0166d5c5868c70bc355562dae9d50072")
       (:PMID . "16061664") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "0bd81d59-5728-4031-b344-653b2744e046")
     (:SUPPORTED--BY "1a0c32eb-1091-44de-842f-5927205add64")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RPS6KB1_pmod_P_T_412_DirectlyIncreases_kin_p_HGNC_RPS6KB1")
       (:TEXT
        . "the treatment of SV40-immortalized human corneal epithelial cells (HCE-T cells) with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), widely used as an AMPK  activator, inhibits p70 S6 kinase a (p70a) activities. AICAR treatment also inhibits phosphorylation of Thr-412 in p70a, which is indispensable for its activity.")
       (:PMID . "14684182") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RPS6KB1_pmod_P_T_412_DirectlyIncreases_kin_p_HGNC_RPS6KB1")
       (:TEXT
        . "We report here that a mammalian recombinant p70alpha polypeptide, extracted in an inactive form from rapamycin-treated cells, can be directly phosphorylated by the mTOR kinase in vitro predominantly at the rapamycin-sensitive site Thr-412. ")
       (:PMID . "10567431") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RPS6KB1_pmod_P_T_412_DirectlyIncreases_kin_p_HGNC_RPS6KB1")
       (:TEXT
        . "Although the p70s6kE389 construct has high basal activity, its overexpression in the absence of mitogen stimulation does not induce the translational up-regulation of eEF-1a transcripts, indicating that p70s6k activation is not sufficent to induce this response.")
       (:PMID . "9218810") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_RPS6KB1_pmod_P_T_412_DirectlyIncreases_kin_p_HGNC_RPS6KB1")
       (:TEXT
        . "altered glucose availability, which regulates AMPK activity, also modulates the activity of p70 S6k. AICAR treatment also inhibits phosphorylation of Thr-412 in the p70 S6 kinase (p70 S6k), which is indispensable for the activity. In addition to the mTOR signal acting as a priming switch that modulates p70 S6k activation, AMPK appears to provide an overriding switch linking p70 S6k regulation to cellular energy metabolism.")
       (:PMID . "12558800") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "349") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "350") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "427") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P29353") (:+HGNC+ . "10840")) (:NAME . "SHC1"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "caaf306b-5cfe-4fa9-8f77-257327feb572")
     (:SUPPORTED--BY "7dc3f69c-4de9-4b75-b901-13fc8615c446"
      "823bdc48-c685-41b4-98bd-6a4af2c88706"
      "47afe00e-d99a-4abf-bf00-0682cf90aa78")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_483412a03b9226cdc29ad3dcb174575e")
       (:PMID . "9710204") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_ed8a9b6c919861237e4e43f7316b6299")
       (:PMID . "9710204") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "423") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "425") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P84022") (:+HGNC+ . "6769")) (:NAME . "SMAD3"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "9a27e261-5f93-4dcd-ae7d-3d7a848eea1f")
     (:SUPPORTED--BY "54f6ecc3-09b8-463c-81e3-97c1d31836cf")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:ACTIVITY . "catalytic") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "377bcc5e-f907-426d-8537-84d0c8f29009")
     (:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q07889") (:+HGNC+ . "11187")) (:NAME . "SOS1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_a86c8c9c1c02a9a0ee2af27596dbebd2")
       (:PMID . "10499589") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_a86c8c9c1c02a9a0ee2af27596dbebd2")
       (:PMID . "15039778") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_a86c8c9c1c02a9a0ee2af27596dbebd2")
       (:PMID . "11777939") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_a86c8c9c1c02a9a0ee2af27596dbebd2")
       (:PMID . "12515821") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:ACTIVITY . "kinase") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "b9186da3-b1a1-48ec-b38b-3e81296c9c5f")
     (:SUPPORTED--BY "f51f6bde-d58c-4b3c-97b4-3fb7b76593d8"
      "5201530b-5f80-4090-a987-1d3bcb23ae85"
      "92cea195-1d85-46dd-88bc-08f25d8f98df")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_SRC_pmod_P_Y_416_DirectlyIncreases_kin_p_HGNC_SRC")
       (:TEXT
        . "In parallel to activation, autophosphorylation at Tyr-416 of Src kinase increased Aldosterone led to increased association of Src with HSP84")
       (:PMID . "15251441") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_SRC_pmod_P_Y_416_DirectlyIncreases_kin_p_HGNC_SRC")
       (:TEXT
        . "In cells expressing RPTPkappa RNAi, phosphorylation of Src at Tyr527 was increased and (activating) phosphorylation of Src at Tyr416 was reduced.")
       (:PMID . "15899872") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_SRC_pmod_P_Y_416_DirectlyIncreases_kin_p_HGNC_SRC")
       (:TEXT
        . "The chief phosphorylation sites of Src include tyrosine 416 that results in activation from autophosphorylation and tyrosine 527 that results in inhibition from phosphorylation by C-terminal Src kinase")
       (:PMID . "15504335") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_SRC_pmod_P_Y_419_DirectlyIncreases_kin_p_HGNC_SRC")
       (:TEXT
        . "The autophosphorylation and dephosphorylation of Y419 are directly correlated with the level of src TK activity.")
       (:PMID . "8755732") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "705") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "727") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364")) (:NAME . "STAT3"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "eb5361fd-6752-4ec9-8aaa-4732c73ebcbf")
     (:SUPPORTED--BY "608ad35a-5b74-4ee3-9742-fe6e81551061"
      "c4015b88-398d-4564-a38a-ddf3ddd71260"
      "d76b68c8-ea07-487c-9165-f2b5c2efa4a6"
      "7fd6deb6-07a5-4dc4-a0c8-664b09727b10")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "7537214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "12361954") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "9880505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "8164674") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "8662591") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "8272872") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "7678052") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "8626374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "12754506") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "12754505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "12754507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "8140422") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "15677447") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "11335711") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_4b48a49fad4c7b50d8a9ce74718cccbb")
       (:PMID . "10446219") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "694") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P42229") (:+HGNC+ . "11366")) (:NAME . "STAT5A"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "c83905c2-9229-4722-9dce-66527841e452")
     (:SUPPORTED--BY "608ad35a-5b74-4ee3-9742-fe6e81551061")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8e17d1a6bf904b2e139666fffa17bd2e")
       (:PMID . "15504549") (:SOURCE--API . "biopax"))
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8897027117b4e9042bade32c916e403f")
       (:PMID . "11238105") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8897027117b4e9042bade32c916e403f")
       (:PMID . "12032860") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8897027117b4e9042bade32c916e403f")
       (:PMID . "8977232") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8897027117b4e9042bade32c916e403f")
       (:PMID . "7537213") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8897027117b4e9042bade32c916e403f")
       (:PMID . "9389692") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8897027117b4e9042bade32c916e403f")
       (:PMID . "18692472") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8897027117b4e9042bade32c916e403f")
       (:PMID . "7720707") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_8897027117b4e9042bade32c916e403f")
       (:PMID . "8671609") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_673e70561772cebee1d5a22421a6be65")
       (:PMID . "10642538") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_673e70561772cebee1d5a22421a6be65")
       (:PMID . "8703030") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_673e70561772cebee1d5a22421a6be65")
       (:PMID . "9484840") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "699") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P51692") (:+HGNC+ . "11367")) (:NAME . "STAT5B"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "c6ff2cc5-52f9-43ec-a0a6-f14fe0e6e8a6")
     (:SUPPORTED--BY "d1195c93-e93f-425d-bb47-84ab9a955d69"
      "41219be7-ae04-4b97-9ea9-262afef44b12"
      "608ad35a-5b74-4ee3-9742-fe6e81551061"
      "33b14c3f-aaf0-48bc-abe3-518d1ac2ce5c")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_STAT5B_pmod_P_Y_699_DirectlyIncreases_tscript_p_HGNC_STAT5B")
       (:TEXT
        . "the stable overexpression of a kinase-defective c-Src in the context of EGFR overexpression results in a decrease in the tyrosine phosphorylation of STAT5b in response to EGF and a more dramatic decrease in EGF-induced transcriptional activation of STAT5b,")
       (:PMID . "12429742") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_STAT5B_pmod_P_Y_699_DirectlyIncreases_tscript_p_HGNC_STAT5B")
       (:TEXT
        . "Moreover, we demonstrated that human Stat5 activation is also dependent on Tyr-694 in Stat5A and Tyr-699 in Stat5B, indicating that these tyrosines are required for dimerization.")
       (:PMID . "8631883") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "641") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P42226") (:+HGNC+ . "11368")) (:NAME . "STAT6"))
     (:ACTIVITY . "activity") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "3f0c4b0e-8dfb-40c2-b4d0-fb7aa73f5302")
     (:SUPPORTED--BY "608ad35a-5b74-4ee3-9742-fe6e81551061")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0f70c2f02e404983e128465535ea5696")
       (:PMID . "7760829") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0f70c2f02e404983e128465535ea5696")
       (:PMID . "7544011") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0f70c2f02e404983e128465535ea5696")
       (:PMID . "8609418") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0f70c2f02e404983e128465535ea5696")
       (:PMID . "8602264") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0f70c2f02e404983e128465535ea5696")
       (:PMID . "9852037") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0f70c2f02e404983e128465535ea5696")
       (:PMID . "8085155") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0f70c2f02e404983e128465535ea5696")
       (:PMID . "12459556") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0f70c2f02e404983e128465535ea5696")
       (:PMID . "11714803") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_0f70c2f02e404983e128465535ea5696")
       (:PMID . "15153491") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "20") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "15") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "9e3e75fb-769c-450a-96be-58a0ecc8c201")
     (:SUPPORTED--BY "71159157-618a-4115-b904-6601a69ff78e"
      "a064fc2a-5602-4123-941f-aac047c0102b")
     (:EVIDENCE
      ((:TEXT . "structural-behavioral inference") (:SOURCE--API . "r3"))))
    ((:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "4ac388c2-ea88-40a9-b6d5-99d01421dbc3")
     (:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "392") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_6c2df917793a70574a3715f0a06fb250")
       (:PMID . "10747897") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/BiochemicalReaction_6c2df917793a70574a3715f0a06fb250")
       (:PMID . "10212189") (:SOURCE--API . "biopax"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "46") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "a5112a29-fd67-414d-91b5-297f56b993ae")
     (:SUPPORTED--BY "0a25a2e8-7ccc-4f70-8ce7-949dc61db12f"
      "58916619-e891-4e92-b503-4839670011f6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_TP53_pmod_P_S_46_DirectlyIncreases_tscript_p_HGNC_TP53")
       (:TEXT
        . "Mutation of p53 Ser(58) (equivalent to human p53 Ser(46)) abrogates transcription of these genes")
       (:PMID . "19118006") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_TP53_pmod_P_S_46_DirectlyIncreases_tscript_p_HGNC_TP53")
       (:TEXT
        . "Co-exposure to C75 and Taxol induced a remarkable nuclear accumulation of activated p38 mitogen-activated protein kinase (p38 MAPK), which was accompanied by a synergistic nuclear accumulation of the p53 tumor-suppressor protein that was phosphorylated at Ser46, a p38 MAPK-regulated pro-apoptotic modification of p53")
       (:PMID . "15657900") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_TP53_pmod_P_S_46_DirectlyIncreases_tscript_p_HGNC_TP53")
       (:TEXT
        . "Through direct cloning of p53 binding sequences from human genomic DNA, we have isolated a novel gene, designated p53AIP1 (p53-regulated Apoptosis-Inducing Protein 1), whose expression is inducible by wild-type p53. Ectopically expressed p53AIP1, which is localized within mitochondria, leads to apoptotic cell death through dissipation of mitochondrial A(psi)m. We have found that upon severe DNA damage, Ser-46 on p53 is phosphorylated and apoptosis is induced. In addition, substitution of Ser-46 inhibits the ability of p53 to induce apoptosis and selectively blocks expression of p53AIP1. Our results suggest that p53AIP1 is likely to play an important role in mediating p53-dependent apoptosis, and phosphorylation of Ser-46 regulates the transcriptional activation of this apoptosis-inducing gene.")
       (:PMID . "11030628") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_TP53_pmod_P_S_46_DirectlyIncreases_tscript_p_HGNC_TP53")
       (:TEXT
        . "TP53INP1 mediates phosphorylation of p53 on serine 46 (S46). ASPP-1 and ASPP-2 modulate the cellular apoptotic threshold by direct interaction with p53, thereby enhancing the DNA binding and trans-activation function of p53 on the promoters of pro-apoptotic genes in vivo")
       (:PMID . "16530485") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_TP53_pmod_P_S_46_DirectlyIncreases_tscript_p_HGNC_TP53")
       (:TEXT
        . "HIPK2 is activated by ultraviolet (UV) radiation and selectively phosphorylates p53 at Ser 46 ... Accordingly, the kinase function of HIPK2 mediates the increased expression of p53 target genes")
       (:PMID . "11740489") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_TP53_pmod_P_S_46_DirectlyIncreases_tscript_p_HGNC_TP53")
       (:TEXT
        . "Recent studies revealed that phosphorylation of p53 on Ser(46) was associated with induction of p53AIP1 expression, resulting in the commitment of the cell fate into apoptotic cell death.")
       (:PMID . "16377624") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_TP53_pmod_P_S_46_DirectlyIncreases_tscript_p_HGNC_TP53")
       (:TEXT
        . "Here we demonstrate that homeodomain-interacting protein kinase-2 (HIPK2), a member of a novel family of nuclear serine/threonine kinases, binds to and activates p53 by directly phosphorylating it at Ser 46")
       (:PMID . "11780126") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "18") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:ACTIVITY . "transcription") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "e7fc048b-ce21-4fe5-8263-d94e3dad0dfc")
     (:SUPPORTED--BY "58916619-e891-4e92-b503-4839670011f6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_TP53_pmod_P_T_18_DirectlyIncreases_tscript_p_HGNC_TP53")
       (:TEXT
        . "Endogenous p53 is also phosphorylated in Thr18 by VRK2B, promoting its stabilization and transcriptional activation in A549 cells")
       (:PMID . "16704422") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/p_HGNC_TP53_pmod_P_T_18_DirectlyIncreases_tscript_p_HGNC_TP53")
       (:TEXT
        . "Thr18 residue phosphorylation, in the transactivation domain of p53, has been implicated in both disruption of p53-Mdm2 interaction and p300 coactivator recruitment, which acetylates the p53 carboxy terminus. This leads to a decrease in p53 degradation and its subsequent stabilization and to an increase in p53-dependent transactivation activity. ")
       (:PMID . "15542844") (:SOURCE--API . "bel"))))
    ((:AGENT
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "174") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "160") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "142") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15498") (:+HGNC+ . "12657")) (:NAME . "VAV1"))
     (:ACTIVITY . "catalytic") (:IS--ACTIVE . T) (:TYPE . "ActiveForm")
     (:ID . "6888495e-3720-423b-8183-a03ca1c0c597")
     (:SUPPORTED--BY "e479bf8e-637e-4893-8318-914897a4f415"
      "6ba6be9c-16dd-416b-8cf6-f61c4454f2ab")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_edc993cffd53a313cfc9920d648cc3d9")
       (:PMID . "9438848") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_edc993cffd53a313cfc9920d648cc3d9")
       (:PMID . "15933714") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_edc993cffd53a313cfc9920d648cc3d9")
       (:PMID . "16169499") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_edc993cffd53a313cfc9920d648cc3d9")
       (:PMID . "9822663") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/TransportWithBiochemicalReaction_edc993cffd53a313cfc9920d648cc3d9")
       (:PMID . "8627172") (:SOURCE--API . "biopax"))))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "CHK-1") (:+NCIT+ . "C25919") (:+UP+ . "O14757")
       (:+HGNC+ . "1925"))
      (:NAME . "CHEK1"))
     (:TYPE . "Activation") (:OBJ--ACTIVITY . "activity")
     (:SUPPORTED--BY "9278e0e4-e2fb-49b5-9198-cbb06749b90e")
     (:EVIDENCE
      ((:TEXT
        . "In response to DNA replication perturbation, ATR activates Chk1 by phosphorylation on Ser317 and Ser345 in an absolute Claspin dependent manner leading to cell cycle arrest and recovery.")
       (:PMID . "17274954") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "For instance, AKT1 destabilizes p53 via the phosphorylation of Mdm2 [XREF_BIBR]; AKT1 controls the basal expression of XRCC1 [XREF_BIBR]; the activation of AKT1 leads to the sequestration of CHK1 to the cytoplasm [XREF_BIBR - XREF_BIBR], and AKT1 phosphorylates and prevents the activation of CHK1 by ATR and ATM [XREF_BIBR]; finally, AKT1 reduces the abundance of gamma-gH2AX foci [XREF_BIBR, XREF_BIBR] in asynchronous cells, and inhibits the activation of CHK1 and the repair of DSBs at the end of G2 [XREF_BIBR].")
       (:PMID . "21321378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Chk1 and Chk2 are proteins that are activated following DNA damage; Chk1 is activated by ATR  (ataxia-telangiectasia and Rad3 related) primarily in response to the detection of single strand breaks bulky lesions, while Chk2 is activated by ATM  (ataxia-telangiectasia mutated) following the detection of double strand breaks in DNA [XREF_BIBR].")
       (:PMID . "23518201") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The ATR complex assembles at stalled replication fork and activates checkpoint kinase 1 (CHK1).")
       (:PMID . "26810087") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "On the other hand, depletion of MTA1 compromises the ATR mediated Chk1 activation following UV treatment, accompanied by a marked down-regulation of Chk1 and its interacting partner Claspin, an adaptor protein that is required for the phosphorylation and activation of Chk1 by ATR.")
       (:PMID . "20427275") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These genes include CHEK1, which participates in the G2/M checkpoint and is activated by ATR in response to unresolved DNA damage, and BRCA1, which is in a surveillance complex that activates double-strand break repair.")
       (:PMID . "19748357") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Chk1 activation by ATR also requires 9-1-1 complex loading by the Rad17 and RFC complex as well as several essential \" mediators \".")
       (:PMID . "20068082") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This could be due to the fact that activation of CHEK1 by ATR leads to its proteolyic degradation.")
       (:PMID . "18346918") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The data presented herein suggest that during S phase low levels and low activity of Plk1 contribute to the accumulation of Claspin, which mediates the activation of Chk1 by ATR.")
       (:PMID . "16885022") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Generally, ATM activates Chk2, while ATR primarily activates Chk1, although considerable cross-talk between ATM and ATR occurs.")
       (:PMID . "20068082") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Similarly, in response to UV induced DNA damage, ATR activates Chk1 and p38 SAPK activates MAPKAP kinase-2, leading to phosphorylation of the same core motif on Cdc25 family members.")
       (:PMID . "15629715") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "ATR activates Chk1 by phosphorylating this protein on at least two residues (Ser 317 and Ser 345) located in a Ser and Thr-Gln-rich domain ().")
       (:PMID . "16137618") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "It is well accepted that the ATR dependent activation of Chk1 in response to incompletely replicated and damaged DNA leads to inhibition of origin firing at chromosomal regions that are not already engaged in replication  (XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "25557548") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "ATR") (:+HGNC+ . "882") (:+UP+ . "Q13535")
       (:+NCIT+ . "C21430"))
      (:NAME . "ATR"))
     (:ID . "98fca3b7-8b0d-4aae-a77b-ec8e14eb6e00"))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "BID") (:+HGNC+ . "1050") (:+UP+ . "P55957")
       (:+NCIT+ . "C21199"))
      (:NAME . "BID"))
     (:TYPE . "Activation") (:OBJ--ACTIVITY . "activity")
     (:SUPPORTED--BY "49424784-ac72-448c-a3b3-ee4cf6d18032")
     (:EVIDENCE
      ((:TEXT
        . "Although in most cases engagement of the mitochondrial pathway is caspase independent (as noted above), Bid is activated by caspases and therefore can link other routes of caspase activation (e.g., death receptor signaling) to mitochondrial outer membrane permeabilization (XREF_BIBR).")
       (:PMID . "12515825") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here we showed that, besides the specific cleavage and activation of Bid by caspase-8 and caspase-3, TRAIL induced apoptosis in Jurkat T cells required the specific cleavage of Mcl-1 at Asp 127 and Asp 157 by caspase-3, while other prototypic antiapoptotic factors such as Bcl-2 or Bcl-X (L) seemed not to be affected.")
       (:PMID . "15637055") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The activation of Bid by caspase-8 in this pathway promotes further cytochrome c release, thereby completing a positive feedback loop of caspase activation.")
       (:PMID . "12232792") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "BID, a pro apoptotic member of the BCL-2 family, is activated by caspase 8, and translocates to OM followed by catalysis of MMP (XREF_BIBR - XREF_BIBR).")
       (:PMID . "22130162") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "CASP8") (:+UP+ . "Q14790") (:+HGNC+ . "1509"))
      (:NAME . "CASP8"))
     (:ID . "ed7fde67-9f93-44f6-868c-f7629486b4ee"))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE) (:ACTIVITY--TYPE . "kinase"))
      (:DB--REFS (:+TEXT+ . "B-RAF") (:+HGNC+ . "1097") (:+UP+ . "P15056")
       (:+NCIT+ . "C17476"))
      (:NAME . "BRAF"))
     (:TYPE . "Activation") (:OBJ--ACTIVITY . "kinase")
     (:SUPPORTED--BY "f30b060b-3ae5-4af6-8562-e422a44c8002")
     (:EVIDENCE
      ((:TEXT
        . "This paper finds that, although unfarnesylated Ras can bind B-Raf, only farnesylated Ras can activate B-Raf in an in vitro activation system.")
       (:PMID . "9069260") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The RAS activated BRAF kinase plays a central role in the regulation of mitogen activated protein kinase (MAPK) signaling pathway, which regulates cell division, proliferation and differentiation in melanoma, and thus is considered a promising target for anti-melanoma therapies [XREF_BIBR, XREF_BIBR].")
       (:PMID . "23153455") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "HRAS") (:+UP+ . "P01112") (:+HGNC+ . "5173"))
      (:NAME . "HRAS"))
     (:ID . "c18e6351-9933-4e5e-80b5-11cf1c78ff94"))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE) (:ACTIVITY--TYPE . "kinase"))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Activation") (:OBJ--ACTIVITY . "kinase")
     (:SUPPORTED--BY "b4795e06-2e77-4a8c-9dc4-e7d2bfac4395")
     (:EVIDENCE
      ((:TEXT
        . "The RAS activated BRAF kinase plays a central role in the regulation of mitogen activated protein kinase (MAPK) signaling pathway, which regulates cell division, proliferation and differentiation in melanoma, and thus is considered a promising target for anti-melanoma therapies [XREF_BIBR, XREF_BIBR].")
       (:PMID . "23153455") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This paper finds that, although unfarnesylated Ras can bind B-Raf, only farnesylated Ras can activate B-Raf in an in vitro activation system.")
       (:PMID . "9069260") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "KRAS") (:+UP+ . "P01116") (:+HGNC+ . "6407"))
      (:NAME . "KRAS"))
     (:ID . "984760e5-2dad-48e1-bed9-4112d6f41bc5"))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE) (:ACTIVITY--TYPE . "kinase"))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Activation") (:OBJ--ACTIVITY . "kinase")
     (:SUPPORTED--BY "dbcd371d-6dcd-4888-bb88-fe1f473740ff")
     (:EVIDENCE
      ((:TEXT
        . "The RAS activated BRAF kinase plays a central role in the regulation of mitogen activated protein kinase (MAPK) signaling pathway, which regulates cell division, proliferation and differentiation in melanoma, and thus is considered a promising target for anti-melanoma therapies [XREF_BIBR, XREF_BIBR].")
       (:PMID . "23153455") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This paper finds that, although unfarnesylated Ras can bind B-Raf, only farnesylated Ras can activate B-Raf in an in vitro activation system.")
       (:PMID . "9069260") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "NRAS") (:+UP+ . "P01111") (:+HGNC+ . "7989"))
      (:NAME . "NRAS"))
     (:ID . "984760e5-2dad-48e1-bed9-4112d6f41bc5"))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "MTOR") (:+HGNC+ . "3942") (:+UP+ . "P42345")
       (:+NCIT+ . "C38929"))
      (:NAME . "MTOR"))
     (:TYPE . "Activation") (:OBJ--ACTIVITY . "activity")
     (:SUPPORTED--BY "516bac86-6125-414a-805e-153348f9179c")
     (:EVIDENCE
      ((:TEXT
        . "In summary, we have found that inhibition of Rce1- and Icmt catalyzed modifications does not prevent Rheb activation of mTOR, and that FTS inhibits mTOR through a mechanism that does not involve Rheb inhibition.")
       (:PMID . "19838215") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In the abundance of growth factors activation of the PI3K (phosphatidylinositol 3-kinase) activates and phosphorylates AKT, that in turn leads to the downstream phosphorylation of TSC2 and inhibits its GAP activity towards RHEB, allowing RHEB to activate mTOR [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26255626") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Full-length TSC2 protein interacts with TSC1 to inhibit the activation of mTOR by Rheb.")
       (:PMID . "24318044") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition to Rheb 's activation of mTOR, Rheb also inhibits the activity of B-Raf and C-Raf kinase (,).")
       (:PMID . "17914450") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT phosphorylation of TSC2 inhibits activity of TSC1 and TSC2 complex, which allows GTP bound Rheb to accumulate and activate the mTOR of mTORC1.")
       (:PMID . "23348097") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In mammalian cells, in response to AAs, the Rag GTPase complex recruits mTORC1 to lysosomes, where mTOR is activated by Rheb (XREF_BIBR, XREF_BIBR).")
       (:PMID . "21512002") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "GTP bound RHEB is known to activate mTOR, whereas GDP bound RHEB loses its ability to activate mTOR, suggesting that the TSC1 and TSC2 complex can downregulate the mTOR pathway through suppressing RHEB function.Upregulation of the TSC and mTOR signaling pathway has been implicated in the development of cancers.")
       (:PMID . "17693255") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "RHEB") (:+HGNC+ . "10011") (:+UP+ . "Q15382")
       (:+NCIT+ . "C115284"))
      (:NAME . "RHEB"))
     (:ID . "b56b0f77-8f12-4ae2-9a8e-861b91fddc18"))
    ((:ENZ (:DB--REFS (:+TEXT+ . "ATR") (:+UP+ . "Q13535") (:+HGNC+ . "882"))
      (:NAME . "ATR"))
     (:TYPE . "Autophosphorylation")
     (:ID . "80a208c5-f690-45d4-8344-a140015f21e5")
     (:EVIDENCE
      ((:TEXT
        . "We further found that SIRT2 deacetylation of ATRIP at K32 drives ATR autophosphorylation and signaling and facilitates DNA replication fork progression and recovery of stalled replication forks following replication stress, demonstrating that SIRT2 functions as an important regulator of ATR activity and helping to explain why Sirt2 deficiency results in genomic instability and cancer development.")
       (:PMID . "26854234") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "ATRIP Acetylation at Lysine 32 Impairs ATR Autophosphorylation and Signaling.")
       (:PMID . "26854234") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "SIRT2 depletion significantly reduced ATR autophosphorylation, but not total ATR levels, in response to HU treatment (XREF_FIG), suggesting that SIRT2 promotes ATR activation in response to replication stress.")
       (:PMID . "26854234") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "SIRT2 deacetylation of ATRIP at K32 drives ATR autophosphorylation and signaling and facilitates DNA replication fork progression and recovery of stalled replication forks.")
       (:PMID . "26854234") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Finally, expression of HA-ATRIP WT but not K32Q alleviated the impairment in HU induced ATR autophosphorylation and CHK1 Ser317 phosphorylation following SIRT2 depletion (XREF_FIG), strongly suggesting that the effects of SIRT2 depletion on ATR activation are mediated through K32 deacetylation.")
       (:PMID . "26854234") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))))
    ((:ENZ
      (:DB--REFS (:+TEXT+ . "CHK-2") (:+HGNC+ . "16627") (:+UP+ . "O96017")
       (:+NCIT+ . "C40966"))
      (:NAME . "CHEK2"))
     (:TYPE . "Autophosphorylation")
     (:ID . "b79f377e-b8c7-4a2b-ae25-95469b44767e")
     (:EVIDENCE
      ((:TEXT
        . "First, ATM dependent phosphorylation of CHK2 promotes not only CHK2 autophosphorylation, but also phosphorylation of the phosphatase CDC25A, which targets it to the proteasome.")
       (:PMID . "25247188") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "PML and RARalpha in APL suppresses Chk2 by dominantly inhibiting the auto-phosphorylation step, but inactivation of PML and RARalpha with alltrans retinoic acid (ATRA) restores Chk2 autophosphorylation and activity.")
       (:PMID . "16835227") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))))
    ((:ENZ
      (:DB--REFS (:+TEXT+ . "MTOR") (:+HGNC+ . "3942") (:+UP+ . "P42345")
       (:+NCIT+ . "C38929"))
      (:NAME . "MTOR"))
     (:TYPE . "Autophosphorylation")
     (:ID . "0699759b-fdd7-4e93-8212-93eec7e174ab")
     (:EVIDENCE
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Interestingly, ULK1 overexpression also increases phosphorylation of Raptor Ser863 and the mTOR autophosphorylation site, Ser2481 in a mTORC1 dependent manner.")
       (:PMID . "21460630") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "SIRT6") (:+UP+ . "Q8N6T7") (:+HGNC+ . "14934"))
      (:NAME . "SIRT6"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "5810ef35-7fbf-4fe7-a8ae-5bbb2fbc8926")
     (:EVIDENCE
      ((:TEXT
        . "Utilizing prostate cancer and bladder cancer cell lines, our data support our hypothesis that E2F1 suppresses SIRT6 transcription and facilities cancer cell glycolysis.")
       (:PMID . "25816777") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our finding on the repression of SIRT6 transcription by E2F1 will broaden the therapeutic opportunities to enhance SIRT6 tumor suppressor activities with compounds like CDK4/6 inhibitor, which retains E2F1 in the RB and E2F1 complex by diminishing the phosphorylation of RB by CDK4/6.")
       (:PMID . "25816777") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Based on the published study on the metabolic phenotype of E2F1 -/- mice and SIRT6 -/- mice, we hypothesize that E2F1 enhances glycolysis and inhibits the expression of Sirt6.")
       (:PMID . "25816777") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here we tested our hypothesis in bladder and prostate cancer cell lines and found that E2F1 could indeed suppress SIRT6 transcription and promote cancer cell glycolysis.")
       (:PMID . "25816777") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "E2F1") (:+UP+ . "Q01094") (:+HGNC+ . "3113"))
      (:NAME . "E2F1"))
     (:ID . "ea6d70e2-b8e5-4f1e-9e0d-3b92584b3132"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "Plk1") (:+UP+ . "P53350") (:+HGNC+ . "9077"))
      (:NAME . "PLK1"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "53293de2-dc83-4ab7-b402-7f0b19f38608")
     (:EVIDENCE
      ((:TEXT
        . "Restoring p53 by depletion of E6 also reduced the level of active Plk1 on chromatin (T210P level; XREF_FIG).")
       (:PMID . "24152729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, activation of p53 has been shown to suppress the transcription of Plk1 directly or via the p21 dependent mechanism.")
       (:PMID . "21726628") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Downregulation of PLK1 expression by p53 is relieved by the histone deacetylase inhibitor, trichostatin A, and involves recruitment of histone deacetylase to the vicinity of p53RE2, further supporting a transcriptional repression mechanism.")
       (:PMID . "20962589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our finding that p21 mediates the DNA damage induced p53 dependent suppression of PLK1 does not exclude the possibility of direct suppression of PLK1 transcription by p53.")
       (:PMID . "24407240") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We have previously shown in H1299 cells stably transfected with a temperature sensitive p53 mutant (tsp53) that the induction of functional p53 decreases PLK1 protein levels in a p21 dependent manner.")
       (:PMID . "24407240") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these data indicate that p53 negatively regulates PLK1 expression, while E2F1 positively regulates PLK1 expression.E2F1 is implicated in activating the PLK1 gene, but yet the mechanism is unknown.")
       (:PMID . "24076372") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Recent evidence from a knockout mouse model suggests that p21 is required for p53 dependent repression of Plk1 expression [XREF_BIBR].")
       (:PMID . "26595675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistically, this is mediated by p53 which represses PLK1 expression through chromatin remodelling.")
       (:PMID . "22405092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PLK1 is down-regulated by p53 as part of the G2/M cell cycle checkpoint [XREF_BIBR - XREF_BIBR] and we recently established that this occurs mainly through p53 dependent repression of PLK1 expression [XREF_BIBR].")
       (:PMID . "22405092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild type, but not mutant, p53 represses expression of the PLK1 promoter when fused upstream of a reporter gene.")
       (:PMID . "20962589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "20") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "15") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:ID . "cd64c2ba-2df9-4ab0-b429-b77c0bde46d9"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "Plk1") (:+UP+ . "P53350") (:+HGNC+ . "9077"))
      (:NAME . "PLK1"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "53293de2-dc83-4ab7-b402-7f0b19f38608")
     (:EVIDENCE
      ((:TEXT
        . "Restoring p53 by depletion of E6 also reduced the level of active Plk1 on chromatin (T210P level; XREF_FIG).")
       (:PMID . "24152729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, activation of p53 has been shown to suppress the transcription of Plk1 directly or via the p21 dependent mechanism.")
       (:PMID . "21726628") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Downregulation of PLK1 expression by p53 is relieved by the histone deacetylase inhibitor, trichostatin A, and involves recruitment of histone deacetylase to the vicinity of p53RE2, further supporting a transcriptional repression mechanism.")
       (:PMID . "20962589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our finding that p21 mediates the DNA damage induced p53 dependent suppression of PLK1 does not exclude the possibility of direct suppression of PLK1 transcription by p53.")
       (:PMID . "24407240") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We have previously shown in H1299 cells stably transfected with a temperature sensitive p53 mutant (tsp53) that the induction of functional p53 decreases PLK1 protein levels in a p21 dependent manner.")
       (:PMID . "24407240") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these data indicate that p53 negatively regulates PLK1 expression, while E2F1 positively regulates PLK1 expression.E2F1 is implicated in activating the PLK1 gene, but yet the mechanism is unknown.")
       (:PMID . "24076372") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Recent evidence from a knockout mouse model suggests that p21 is required for p53 dependent repression of Plk1 expression [XREF_BIBR].")
       (:PMID . "26595675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistically, this is mediated by p53 which represses PLK1 expression through chromatin remodelling.")
       (:PMID . "22405092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PLK1 is down-regulated by p53 as part of the G2/M cell cycle checkpoint [XREF_BIBR - XREF_BIBR] and we recently established that this occurs mainly through p53 dependent repression of PLK1 expression [XREF_BIBR].")
       (:PMID . "22405092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild type, but not mutant, p53 represses expression of the PLK1 promoter when fused upstream of a reporter gene.")
       (:PMID . "20962589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "392") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:ID . "eb567c8e-dcb1-4500-8c27-42b9949a5c7a"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "Plk1") (:+UP+ . "P53350") (:+HGNC+ . "9077"))
      (:NAME . "PLK1"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "53293de2-dc83-4ab7-b402-7f0b19f38608")
     (:EVIDENCE
      ((:TEXT
        . "Restoring p53 by depletion of E6 also reduced the level of active Plk1 on chromatin (T210P level; XREF_FIG).")
       (:PMID . "24152729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, activation of p53 has been shown to suppress the transcription of Plk1 directly or via the p21 dependent mechanism.")
       (:PMID . "21726628") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Downregulation of PLK1 expression by p53 is relieved by the histone deacetylase inhibitor, trichostatin A, and involves recruitment of histone deacetylase to the vicinity of p53RE2, further supporting a transcriptional repression mechanism.")
       (:PMID . "20962589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our finding that p21 mediates the DNA damage induced p53 dependent suppression of PLK1 does not exclude the possibility of direct suppression of PLK1 transcription by p53.")
       (:PMID . "24407240") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We have previously shown in H1299 cells stably transfected with a temperature sensitive p53 mutant (tsp53) that the induction of functional p53 decreases PLK1 protein levels in a p21 dependent manner.")
       (:PMID . "24407240") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these data indicate that p53 negatively regulates PLK1 expression, while E2F1 positively regulates PLK1 expression.E2F1 is implicated in activating the PLK1 gene, but yet the mechanism is unknown.")
       (:PMID . "24076372") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Recent evidence from a knockout mouse model suggests that p21 is required for p53 dependent repression of Plk1 expression [XREF_BIBR].")
       (:PMID . "26595675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistically, this is mediated by p53 which represses PLK1 expression through chromatin remodelling.")
       (:PMID . "22405092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PLK1 is down-regulated by p53 as part of the G2/M cell cycle checkpoint [XREF_BIBR - XREF_BIBR] and we recently established that this occurs mainly through p53 dependent repression of PLK1 expression [XREF_BIBR].")
       (:PMID . "22405092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild type, but not mutant, p53 represses expression of the PLK1 promoter when fused upstream of a reporter gene.")
       (:PMID . "20962589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "46") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:ID . "9d4f6d95-0b52-4122-8f1b-7ced69c32675"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "Plk1") (:+UP+ . "P53350") (:+HGNC+ . "9077"))
      (:NAME . "PLK1"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "53293de2-dc83-4ab7-b402-7f0b19f38608")
     (:EVIDENCE
      ((:TEXT
        . "Restoring p53 by depletion of E6 also reduced the level of active Plk1 on chromatin (T210P level; XREF_FIG).")
       (:PMID . "24152729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, activation of p53 has been shown to suppress the transcription of Plk1 directly or via the p21 dependent mechanism.")
       (:PMID . "21726628") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Downregulation of PLK1 expression by p53 is relieved by the histone deacetylase inhibitor, trichostatin A, and involves recruitment of histone deacetylase to the vicinity of p53RE2, further supporting a transcriptional repression mechanism.")
       (:PMID . "20962589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our finding that p21 mediates the DNA damage induced p53 dependent suppression of PLK1 does not exclude the possibility of direct suppression of PLK1 transcription by p53.")
       (:PMID . "24407240") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We have previously shown in H1299 cells stably transfected with a temperature sensitive p53 mutant (tsp53) that the induction of functional p53 decreases PLK1 protein levels in a p21 dependent manner.")
       (:PMID . "24407240") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these data indicate that p53 negatively regulates PLK1 expression, while E2F1 positively regulates PLK1 expression.E2F1 is implicated in activating the PLK1 gene, but yet the mechanism is unknown.")
       (:PMID . "24076372") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Recent evidence from a knockout mouse model suggests that p21 is required for p53 dependent repression of Plk1 expression [XREF_BIBR].")
       (:PMID . "26595675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistically, this is mediated by p53 which represses PLK1 expression through chromatin remodelling.")
       (:PMID . "22405092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PLK1 is down-regulated by p53 as part of the G2/M cell cycle checkpoint [XREF_BIBR - XREF_BIBR] and we recently established that this occurs mainly through p53 dependent repression of PLK1 expression [XREF_BIBR].")
       (:PMID . "22405092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild type, but not mutant, p53 represses expression of the PLK1 promoter when fused upstream of a reporter gene.")
       (:PMID . "20962589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "18") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:ID . "e69f12d7-48ef-4b84-9a51-2b606e9a7ea3"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "CCNA1") (:+UP+ . "P78396") (:+HGNC+ . "1577"))
      (:NAME . "CCNA1"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "3b60bb83-7b9e-4bdc-b0d3-63c63be6273d")
     (:EVIDENCE
      ((:TEXT
        . "In agreement with a direct involvement of YB-1 in regulating cyclin D1 expression, YB-1 knockdown led to increased cyclin D1 levels (B).")
       (:PMID . "19411069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of cyclin D1 and cyclin A were also decreased by si-YB-1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these results show that altered cyclin A expression following YB-1 knockdown in OS cells is secondary to reduction of cyclin D1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Taken together, these results suggest that the primary reason for the G1/S phase growth arrest in YB-1 knockdown human OS cells was decreased expression of cyclin D1, followed by downregulation of cyclin A. Knockdown of YB-1 inhibited the growth of OS graft tumours in vivo.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As cyclin D1 is well defined target genes of E2F1 (XREF_BIBR), reduction of cyclin D1 expression by si-YB-1 in OS cells could be the reflection of si-YB-1-induced reduction of E2F1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "At molecular level, YB-1 shRNA plasmids were successfully delivered into tumor cells and downregulated the expression of YB-1 and Cyclin D1 (XREF_FIG).")
       (:PMID . "25993060") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:ID . "a946b1d7-0810-49d7-8a9a-d6e81c7bfcc9"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "CCNA2") (:+UP+ . "P20248") (:+HGNC+ . "1578"))
      (:NAME . "CCNA2"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "3b60bb83-7b9e-4bdc-b0d3-63c63be6273d")
     (:EVIDENCE
      ((:TEXT
        . "Taken together, these results suggest that the primary reason for the G1/S phase growth arrest in YB-1 knockdown human OS cells was decreased expression of cyclin D1, followed by downregulation of cyclin A. Knockdown of YB-1 inhibited the growth of OS graft tumours in vivo.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "At molecular level, YB-1 shRNA plasmids were successfully delivered into tumor cells and downregulated the expression of YB-1 and Cyclin D1 (XREF_FIG).")
       (:PMID . "25993060") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In agreement with a direct involvement of YB-1 in regulating cyclin D1 expression, YB-1 knockdown led to increased cyclin D1 levels (B).")
       (:PMID . "19411069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these results show that altered cyclin A expression following YB-1 knockdown in OS cells is secondary to reduction of cyclin D1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As cyclin D1 is well defined target genes of E2F1 (XREF_BIBR), reduction of cyclin D1 expression by si-YB-1 in OS cells could be the reflection of si-YB-1-induced reduction of E2F1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The expression of cyclin D1 and cyclin A were also decreased by si-YB-1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:ID . "67ce6778-3f0a-4bf5-82b9-52749142dfd6"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "CCNB1") (:+UP+ . "P14635") (:+HGNC+ . "1579"))
      (:NAME . "CCNB1"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "0665f8a8-8e04-422d-b70d-06cb5333aa6b")
     (:EVIDENCE
      ((:TEXT
        . "Taken together, these results suggest that the primary reason for the G1/S phase growth arrest in YB-1 knockdown human OS cells was decreased expression of cyclin D1, followed by downregulation of cyclin A. Knockdown of YB-1 inhibited the growth of OS graft tumours in vivo.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The knock-down of YBX1 reduced CCNB1 expression, confirming the role of YBX1 as a CCNB1 regulator in these cells (XREF_FIG).")
       (:PMID . "21170361") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these results show that altered cyclin A expression following YB-1 knockdown in OS cells is secondary to reduction of cyclin D1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of cyclin D1 and cyclin A were also decreased by si-YB-1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In agreement with a direct involvement of YB-1 in regulating cyclin D1 expression, YB-1 knockdown led to increased cyclin D1 levels (B).")
       (:PMID . "19411069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "At molecular level, YB-1 shRNA plasmids were successfully delivered into tumor cells and downregulated the expression of YB-1 and Cyclin D1 (XREF_FIG).")
       (:PMID . "25993060") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As cyclin D1 is well defined target genes of E2F1 (XREF_BIBR), reduction of cyclin D1 expression by si-YB-1 in OS cells could be the reflection of si-YB-1-induced reduction of E2F1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:ID . "59774fee-42d1-4152-bc6a-57dfaf61b855"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "CCND1") (:+UP+ . "P24385") (:+HGNC+ . "1582"))
      (:NAME . "CCND1"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "f7ea077b-f5ab-47f7-98df-324b97045840")
     (:EVIDENCE
      ((:TEXT
        . "At molecular level, YB-1 shRNA plasmids were successfully delivered into tumor cells and downregulated the expression of YB-1 and Cyclin D1 (XREF_FIG).")
       (:PMID . "25993060") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In agreement with a direct involvement of YB-1 in regulating cyclin D1 expression, YB-1 knockdown led to increased cyclin D1 levels (B).")
       (:PMID . "19411069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these results show that altered cyclin A expression following YB-1 knockdown in OS cells is secondary to reduction of cyclin D1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Taken together, these results suggest that the primary reason for the G1/S phase growth arrest in YB-1 knockdown human OS cells was decreased expression of cyclin D1, followed by downregulation of cyclin A. Knockdown of YB-1 inhibited the growth of OS graft tumours in vivo.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As cyclin D1 is well defined target genes of E2F1 (XREF_BIBR), reduction of cyclin D1 expression by si-YB-1 in OS cells could be the reflection of si-YB-1-induced reduction of E2F1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The expression of cyclin D1 and cyclin A were also decreased by si-YB-1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:ID . "9cd839da-a2d7-4027-a079-4baf90192d05"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "CCND2") (:+UP+ . "P30279") (:+HGNC+ . "1583"))
      (:NAME . "CCND2"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "f1d1d8fe-825b-41fd-99bd-ee3cd9cbb731")
     (:EVIDENCE
      ((:TEXT
        . "Together, these results show that altered cyclin A expression following YB-1 knockdown in OS cells is secondary to reduction of cyclin D1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In agreement with a direct involvement of YB-1 in regulating cyclin D1 expression, YB-1 knockdown led to increased cyclin D1 levels (B).")
       (:PMID . "19411069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Taken together, these results suggest that the primary reason for the G1/S phase growth arrest in YB-1 knockdown human OS cells was decreased expression of cyclin D1, followed by downregulation of cyclin A. Knockdown of YB-1 inhibited the growth of OS graft tumours in vivo.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of cyclin D1 and cyclin A were also decreased by si-YB-1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As cyclin D1 is well defined target genes of E2F1 (XREF_BIBR), reduction of cyclin D1 expression by si-YB-1 in OS cells could be the reflection of si-YB-1-induced reduction of E2F1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "At molecular level, YB-1 shRNA plasmids were successfully delivered into tumor cells and downregulated the expression of YB-1 and Cyclin D1 (XREF_FIG).")
       (:PMID . "25993060") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:ID . "2ec0b194-f083-4d5f-95a5-46990b07eb93"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "CCND3") (:+UP+ . "P30281") (:+HGNC+ . "1585"))
      (:NAME . "CCND3"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "3de51e3c-b75d-4d5f-b93e-3c06ff42727a")
     (:EVIDENCE
      ((:TEXT
        . "In agreement with a direct involvement of YB-1 in regulating cyclin D1 expression, YB-1 knockdown led to increased cyclin D1 levels (B).")
       (:PMID . "19411069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Taken together, these results suggest that the primary reason for the G1/S phase growth arrest in YB-1 knockdown human OS cells was decreased expression of cyclin D1, followed by downregulation of cyclin A. Knockdown of YB-1 inhibited the growth of OS graft tumours in vivo.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of cyclin D1 and cyclin A were also decreased by si-YB-1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "At molecular level, YB-1 shRNA plasmids were successfully delivered into tumor cells and downregulated the expression of YB-1 and Cyclin D1 (XREF_FIG).")
       (:PMID . "25993060") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As cyclin D1 is well defined target genes of E2F1 (XREF_BIBR), reduction of cyclin D1 expression by si-YB-1 in OS cells could be the reflection of si-YB-1-induced reduction of E2F1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Together, these results show that altered cyclin A expression following YB-1 knockdown in OS cells is secondary to reduction of cyclin D1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:ID . "0444a077-7a7a-475f-946d-f17c68fa6c92"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "CCNE1") (:+UP+ . "P24864") (:+HGNC+ . "1589"))
      (:NAME . "CCNE1"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "f5018dd9-80a4-4684-9cf3-16281a6977ed")
     (:EVIDENCE
      ((:TEXT
        . "In agreement with a direct involvement of YB-1 in regulating cyclin D1 expression, YB-1 knockdown led to increased cyclin D1 levels (B).")
       (:PMID . "19411069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As cyclin D1 is well defined target genes of E2F1 (XREF_BIBR), reduction of cyclin D1 expression by si-YB-1 in OS cells could be the reflection of si-YB-1-induced reduction of E2F1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Taken together, these results suggest that the primary reason for the G1/S phase growth arrest in YB-1 knockdown human OS cells was decreased expression of cyclin D1, followed by downregulation of cyclin A. Knockdown of YB-1 inhibited the growth of OS graft tumours in vivo.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of cyclin D1 and cyclin A were also decreased by si-YB-1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "At molecular level, YB-1 shRNA plasmids were successfully delivered into tumor cells and downregulated the expression of YB-1 and Cyclin D1 (XREF_FIG).")
       (:PMID . "25993060") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these results show that altered cyclin A expression following YB-1 knockdown in OS cells is secondary to reduction of cyclin D1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:ID . "f69b93b6-1de7-438c-b8c6-18e5345fc38e"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "CCNE2") (:+UP+ . "O96020") (:+HGNC+ . "1590"))
      (:NAME . "CCNE2"))
     (:TYPE . "DecreaseAmount")
     (:SUPPORTED--BY "f7ea077b-f5ab-47f7-98df-324b97045840")
     (:EVIDENCE
      ((:TEXT
        . "At molecular level, YB-1 shRNA plasmids were successfully delivered into tumor cells and downregulated the expression of YB-1 and Cyclin D1 (XREF_FIG).")
       (:PMID . "25993060") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In agreement with a direct involvement of YB-1 in regulating cyclin D1 expression, YB-1 knockdown led to increased cyclin D1 levels (B).")
       (:PMID . "19411069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Taken together, these results suggest that the primary reason for the G1/S phase growth arrest in YB-1 knockdown human OS cells was decreased expression of cyclin D1, followed by downregulation of cyclin A. Knockdown of YB-1 inhibited the growth of OS graft tumours in vivo.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Together, these results show that altered cyclin A expression following YB-1 knockdown in OS cells is secondary to reduction of cyclin D1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As cyclin D1 is well defined target genes of E2F1 (XREF_BIBR), reduction of cyclin D1 expression by si-YB-1 in OS cells could be the reflection of si-YB-1-induced reduction of E2F1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The expression of cyclin D1 and cyclin A were also decreased by si-YB-1.")
       (:PMID . "23462806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:ID . "e66f2808-ea80-4970-a5e4-ea1fc4fd7d76"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "6af1c623-706f-4c50-8611-8ae6060cb572")
     (:EVIDENCE
      ((:TEXT
        . "Lack-of-function siRNA screening revealed that DUSP1 preferentially dephosphorylates p38 protein and is involved in Ang-1-induced cell migration and differentiation.")
       (:PMID . "24308939") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Lack-of-function siRNA screening revealed that DUSP1 preferentially dephosphorylates p38 protein and is involved in Ang-1-induced cell migration and differentiation.")
       (:PMID . "24308939") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This study also demonstrated for the first time that MKP-1 dephosphorylation of p38MAPK and JNK may participate in TSA 's protective actions in HUVECs exposed to LPS, an inflammatory stimulus.Stress kinases, p38MAPK and JNK, play critical roles in COX-2 expression under the influence of inflammatory stimuli in macrophages and lung epithelial cells.")
       (:PMID . "21911040") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Anti-inflammatory effects of glucocorticoids (GCs) are partly mediated by up-regulation of DUSP1 (dual specificity phosphatase 1), which dephosphorylates and inactivates mitogen activated protein kinases.")
       (:PMID . "19940143") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "DUSP1 dephosphorylates mitogen-activated protein kinases, which are evolutionary conserved enzymes that play an important role in orchestrating various cellular processes, including proliferation, differentiation, and apoptosis.")
       (:PMID . "24339725") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Mitogen activated protein kinase (MAPK) phosphatase-1 (MKP-1) dephosphorylates mitogen activated protein kinase [extracellular signal regulated kinase (ERK), c-Jun NH (2)-terminal kinase (JNK), and p38], mediates breast cancer chemoresistance, and is repressible by doxorubicin in breast cancer cells.")
       (:PMID . "19417026") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These results show that DUSP1 catalyzed the dephosphorylation of p38 MAPK and thereby inactivated p38 MAPK in A549 and J774 cells.")
       (:PMID . "21547253") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Using phospho specific antibodies and Western blotting, we determined that although DUSP1 could effectively dephosphorylate ERK, JNK and p38, wt DUSP26 does not exhibit DUSP activity towards these MAPKs in vitro (b).")
       (:PMID . "20347885") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This study also demonstrated for the first time that MKP-1 dephosphorylation of p38MAPK and JNK may participate in TSA 's protective actions in HUVECs exposed to LPS, an inflammatory stimulus.Stress kinases, p38MAPK and JNK, play critical roles in COX-2 expression under the influence of inflammatory stimuli in macrophages and lung epithelial cells.")
       (:PMID . "21911040") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "DUSP1 dephosphorylates mitogen activated protein kinases, which are evolutionary conserved enzymes that play an important role in orchestrating various cellular processes, including proliferation, differentiation, and apoptosis.")
       (:PMID . "24339725") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that in HMC CTGF induces the rapid transcriptional activation and synthesis of MKP-1 (MAPK phosphatase-1), a dual specificity phosphatase that dephosphorylates p38 MAPK.")
       (:PMID . "17489738") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Using phospho specific antibodies and Western blotting, we determined that although DUSP1 could effectively dephosphorylate ERK, JNK and p38, wt DUSP26 does not exhibit DUSP activity towards these MAPKs in vitro (b).")
       (:PMID . "20347885") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We next tested two other dual-specificity MAPK phosphatases : MKP1 and MKP5, which both de-phosphorylate Erk and p38 MAPK 30.")
       (:PMID . "22447027") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/phos_p_HGNC_DUSP1_DirectlyDecreases_p_HGNC_MAPK14_pmod_P")
       (:TEXT
        . "MAP kinase phosphatase-1 (MKP-1) is an immediate-early gene with a dual-specificity phosphatase properties that dephosphorylates ERK1/2 [19-22], as well as SAPK and p38 MAP kinase")
       (:PMID . "15107593") (:SOURCE--API . "bel"))
      ((:TEXT
        . "DUSP1 preferentially dephosphorylates activated p38 and JNK relative to ERK1/2 [XREF_BIBR].")
       (:PMID . "26158762") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The results are consistent with findings by Chen et al. [XREF_BIBR], supporting the idea that MKP-1 plays a major role in dephosphorylation of activated JNK and p38 MAPK, but it only has minor effects on activated ERK.")
       (:PMID . "21733716") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our previous report also revealed that MKP-1 only selectively de-phosphorylated gamma-radiation-mediated activation of JNK, but not ERK or p38.")
       (:PMID . "22014408") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "DUSP1") (:+UP+ . "P28562") (:+HGNC+ . "3064"))
      (:NAME . "DUSP1"))
     (:TYPE . "Dephosphorylation")
     (:ID . "b378c495-71a2-451e-95bf-fb0984e9a901"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "2001a3ee-36c4-4134-8194-4621dfb90e0a"
      "cef92e20-e6bc-45a4-96a8-493fb29871a1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "7939666") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "7761091") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "8221888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "9430728") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75e274d63637e14d2661b0c0b5e85d9e")
       (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ (:DB--REFS (:+UP+ . "P28562") (:+HGNC+ . "3064")) (:NAME . "DUSP1"))
     (:TYPE . "Dephosphorylation")
     (:ID . "c0d124ca-511c-4dc3-94aa-578076bd2551"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "2001a3ee-36c4-4134-8194-4621dfb90e0a"
      "cef92e20-e6bc-45a4-96a8-493fb29871a1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75e274d63637e14d2661b0c0b5e85d9e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "7939666") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "7761091") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "8221888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "9430728") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ (:DB--REFS (:+UP+ . "P28562") (:+HGNC+ . "3064")) (:NAME . "DUSP1"))
     (:TYPE . "Dephosphorylation")
     (:ID . "289e8c61-771d-47bd-b51f-efe83d3a43e9"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0a1d9e33-0bef-4a9b-ba04-aef1ce85f50a"
      "3dab88d5-4bfc-4777-b3c1-b6027f9a7311")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "7939666") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "7761091") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "8221888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "9430728") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75e274d63637e14d2661b0c0b5e85d9e")
       (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ (:DB--REFS (:+UP+ . "P28562") (:+HGNC+ . "3064")) (:NAME . "DUSP1"))
     (:TYPE . "Dephosphorylation")
     (:ID . "45c5272b-fb78-4ce4-9ec4-458b2cf33323"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "3dab88d5-4bfc-4777-b3c1-b6027f9a7311"
      "0a1d9e33-0bef-4a9b-ba04-aef1ce85f50a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75e274d63637e14d2661b0c0b5e85d9e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "7939666") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "7761091") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "8221888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28dd49543efbae08cb0d0d9d88edc62a")
       (:PMID . "9430728") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ (:DB--REFS (:+UP+ . "P28562") (:+HGNC+ . "3064")) (:NAME . "DUSP1"))
     (:TYPE . "Dephosphorylation")
     (:ID . "746ad2a1-15ae-4692-8349-a39a89319d9b"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "2001a3ee-36c4-4134-8194-4621dfb90e0a")
     (:EVIDENCE
      ((:TEXT
        . "For example, DUSP2 and DUSP9, which are known to dephosphorylate ERK, are at the bottom of the ranked list while other dual specificity phosphatase, DUSP13, which is not specific for ERK1/2, is towards the top indicating the possibility that ERK1/2 plays a dominant role in transmitting signals from IL-4R.")
       (:PMID . "22712053") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "DUSP2") (:+UP+ . "Q05923") (:+HGNC+ . "3068"))
      (:NAME . "DUSP2"))
     (:TYPE . "Dephosphorylation")
     (:ID . "84da21b1-2906-4367-9e6f-4ea3a773fe99"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "3dab88d5-4bfc-4777-b3c1-b6027f9a7311")
     (:EVIDENCE
      ((:TEXT
        . "For example, DUSP2 and DUSP9, which are known to dephosphorylate ERK, are at the bottom of the ranked list while other dual specificity phosphatase, DUSP13, which is not specific for ERK1/2, is towards the top indicating the possibility that ERK1/2 plays a dominant role in transmitting signals from IL-4R.")
       (:PMID . "22712053") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "DUSP2") (:+UP+ . "Q05923") (:+HGNC+ . "3068"))
      (:NAME . "DUSP2"))
     (:TYPE . "Dephosphorylation")
     (:ID . "3a00f998-ab12-4e4b-b6fb-b8e5ac42b8aa"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "2001a3ee-36c4-4134-8194-4621dfb90e0a")
     (:EVIDENCE
      ((:TEXT
        . "Immunodepletion of endogenous VHR eliminated the dephosphorylation of cellular ERK.")
       (:PMID . "10224087") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Subsequent kinetic analyses and transfection studies demonstrated that VHR specifically dephosphorylates and inactivates ERK1 and ERK2 in vitro and in vivo.")
       (:PMID . "10224087") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "VHR") (:+UP+ . "P51452") (:+HGNC+ . "3069"))
      (:NAME . "DUSP3"))
     (:TYPE . "Dephosphorylation")
     (:ID . "e3690aea-90ac-4786-9764-1df720f976eb"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ERK1") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "3dab88d5-4bfc-4777-b3c1-b6027f9a7311")
     (:EVIDENCE
      ((:TEXT
        . "Subsequent kinetic analyses and transfection studies demonstrated that VHR specifically dephosphorylates and inactivates ERK1 and ERK2 in vitro and in vivo.")
       (:PMID . "10224087") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Immunodepletion of endogenous VHR eliminated the dephosphorylation of cellular ERK.")
       (:PMID . "10224087") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ (:DB--REFS (:+TEXT+ . "VHR") (:+UP+ . "P51452") (:+HGNC+ . "3069"))
      (:NAME . "DUSP3"))
     (:TYPE . "Dephosphorylation")
     (:ID . "2e0422f2-9b7c-4ee8-b36b-48c1e0831735"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "2001a3ee-36c4-4134-8194-4621dfb90e0a"
      "69667f1d-259a-400a-b21b-faec93a7a6d9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75e274d63637e14d2661b0c0b5e85d9e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/phos_p_HGNC_DUSP4_DirectlyDecreases_p_HGNC_MAPK1_pmod_P_T_185")
       (:TEXT
        . "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2")
       (:PMID . "7535768") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b1095a3199efe976e390422ddbc1094e")
       (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ (:DB--REFS (:+UP+ . "Q13115") (:+HGNC+ . "3070")) (:NAME . "DUSP4"))
     (:TYPE . "Dephosphorylation")
     (:ID . "49e2254e-affd-4b84-bb82-93482c6b3767"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "69667f1d-259a-400a-b21b-faec93a7a6d9"
      "2001a3ee-36c4-4134-8194-4621dfb90e0a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b1095a3199efe976e390422ddbc1094e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75e274d63637e14d2661b0c0b5e85d9e")
       (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ (:DB--REFS (:+UP+ . "Q13115") (:+HGNC+ . "3070")) (:NAME . "DUSP4"))
     (:TYPE . "Dephosphorylation")
     (:ID . "45abb943-b0ab-428c-9dc4-308eb36c9dad"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "69667f1d-259a-400a-b21b-faec93a7a6d9"
      "3dab88d5-4bfc-4777-b3c1-b6027f9a7311")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b1095a3199efe976e390422ddbc1094e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/phos_p_HGNC_DUSP4_DirectlyDecreases_p_HGNC_MAPK3_pmod_P_T_202")
       (:TEXT
        . "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2")
       (:PMID . "7535768") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75e274d63637e14d2661b0c0b5e85d9e")
       (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ (:DB--REFS (:+UP+ . "Q13115") (:+HGNC+ . "3070")) (:NAME . "DUSP4"))
     (:TYPE . "Dephosphorylation")
     (:ID . "b63315cd-75a4-4802-91f4-2d98405112cd"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "3dab88d5-4bfc-4777-b3c1-b6027f9a7311"
      "69667f1d-259a-400a-b21b-faec93a7a6d9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b1095a3199efe976e390422ddbc1094e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75e274d63637e14d2661b0c0b5e85d9e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/phos_p_HGNC_DUSP4_DirectlyDecreases_p_HGNC_MAPK3_pmod_P_Y_204")
       (:TEXT
        . "Recombinant HVH2 phosphatase exhibited a high substrate specificity toward activated ERK and dephosphorylated both threonine and tyrosine residues of activated ERK1 and ERK2")
       (:PMID . "7535768") (:SOURCE--API . "bel")))
     (:POSITION . "204")
     (:ENZ (:DB--REFS (:+UP+ . "Q13115") (:+HGNC+ . "3070")) (:NAME . "DUSP4"))
     (:TYPE . "Dephosphorylation")
     (:ID . "b04a9db3-de4c-4e5c-b30f-35dabb44dad2"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "ERK-2") (:+HGNC+ . "6871") (:+NCIT+ . "C52872")
       (:+UP+ . "P28482"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "2001a3ee-36c4-4134-8194-4621dfb90e0a")
     (:EVIDENCE
      ((:TEXT
        . "DUSP5 preferentially dephosphorylates ERK1/2 proteins and is involved in cell survival and inhibition of permeability.")
       (:PMID . "24308939") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "DUSP5 preferentially dephosphorylates ERK1/2 proteins and is involved in cell survival and inhibition of permeability.")
       (:PMID . "24308939") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "ERK1/2 can be dephosphorylated by the inducible DUSP1, DUSP4, and DUSP5, which are found primarily in the nucleus, and by the cytosolic isoforms DUSP6, DUSP7, and DUSP9 (XREF_BIBR).")
       (:PMID . "21610072") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "DUSP-5") (:+NCIT+ . "C111864") (:+UP+ . "Q16690")
       (:+HGNC+ . "3071"))
      (:NAME . "DUSP5"))
     (:TYPE . "Dephosphorylation")
     (:ID . "8eac8bbc-93f1-4b63-8ba3-6662663b26fc"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "3dab88d5-4bfc-4777-b3c1-b6027f9a7311")
     (:EVIDENCE
      ((:TEXT
        . "DUSP5 preferentially dephosphorylates ERK1/2 proteins and is involved in cell survival and inhibition of permeability.")
       (:PMID . "24308939") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "DUSP5 preferentially dephosphorylates ERK1/2 proteins and is involved in cell survival and inhibition of permeability.")
       (:PMID . "24308939") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "ERK1/2 can be dephosphorylated by the inducible DUSP1, DUSP4, and DUSP5, which are found primarily in the nucleus, and by the cytosolic isoforms DUSP6, DUSP7, and DUSP9 (XREF_BIBR).")
       (:PMID . "21610072") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "DUSP5") (:+UP+ . "Q16690") (:+HGNC+ . "3071"))
      (:NAME . "DUSP5"))
     (:TYPE . "Dephosphorylation")
     (:ID . "f488d1eb-d0d6-41de-8551-eb036bafa4e3"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "2001a3ee-36c4-4134-8194-4621dfb90e0a"
      "a0d51cc2-e788-4fa9-906e-cfeb2d0736e9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fe2604c152e311ae1ee6f6f78ad2f93f")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b1095a3199efe976e390422ddbc1094e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "14690430") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "9596579") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "8910287") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "17322878") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "8626780") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ (:DB--REFS (:+UP+ . "Q16828") (:+HGNC+ . "3072")) (:NAME . "DUSP6"))
     (:TYPE . "Dephosphorylation")
     (:ID . "01e219f8-1440-4507-830f-f891d0c8744b"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a0d51cc2-e788-4fa9-906e-cfeb2d0736e9"
      "2001a3ee-36c4-4134-8194-4621dfb90e0a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fe2604c152e311ae1ee6f6f78ad2f93f")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "14690430") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "9596579") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "8910287") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "17322878") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "8626780") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b1095a3199efe976e390422ddbc1094e")
       (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ (:DB--REFS (:+UP+ . "Q16828") (:+HGNC+ . "3072")) (:NAME . "DUSP6"))
     (:TYPE . "Dephosphorylation")
     (:ID . "3138d829-ff03-4198-85be-57bbd896ba90"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "03ee18b6-1998-4c8f-ba49-e12203476706"
      "3dab88d5-4bfc-4777-b3c1-b6027f9a7311")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b1095a3199efe976e390422ddbc1094e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "14690430") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "9596579") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "8910287") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "17322878") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "8626780") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fe2604c152e311ae1ee6f6f78ad2f93f")
       (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ (:DB--REFS (:+UP+ . "Q16828") (:+HGNC+ . "3072")) (:NAME . "DUSP6"))
     (:TYPE . "Dephosphorylation")
     (:ID . "020251c3-6134-48bd-bac6-e0a40c44eecb"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "3dab88d5-4bfc-4777-b3c1-b6027f9a7311"
      "03ee18b6-1998-4c8f-ba49-e12203476706")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fe2604c152e311ae1ee6f6f78ad2f93f")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "14690430") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "9596579") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "8910287") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "17322878") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9a401e2b3a06a2780bd8576e70bb3afa")
       (:PMID . "8626780") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b1095a3199efe976e390422ddbc1094e")
       (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ (:DB--REFS (:+UP+ . "Q16828") (:+HGNC+ . "3072")) (:NAME . "DUSP6"))
     (:TYPE . "Dephosphorylation")
     (:ID . "4a9e9b73-89b0-47e3-81b4-509df00af3e9"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "2672fd50-8426-45b0-8a30-1423df3fd806"
      "1dc46f7d-8415-4efd-880e-2535d4589b0d"
      "d90c0cb1-5015-4fc7-be48-31e7d2581dff")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b96a7fcef1fd9b4743552016729b19aa")
       (:PMID . "10205168") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b96a7fcef1fd9b4743552016729b19aa")
       (:PMID . "8340422") (:SOURCE--API . "biopax")))
     (:POSITION . "621")
     (:ENZ (:DB--REFS (:+UP+ . "P01112") (:+HGNC+ . "5173")) (:NAME . "HRAS")
      (:BOUND--CONDITIONS
       ((:IS--BOUND . T)
        (:AGENT (:DB--REFS (:+CHEBI+ . "15996")) (:NAME . "GTP")))))
     (:TYPE . "Dephosphorylation")
     (:ID . "7fe3a0d3-3391-4425-a9f1-f40c3e45e9a6"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "d90c0cb1-5015-4fc7-be48-31e7d2581dff"
      "1dc46f7d-8415-4efd-880e-2535d4589b0d"
      "2672fd50-8426-45b0-8a30-1423df3fd806")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b96a7fcef1fd9b4743552016729b19aa")
       (:PMID . "10205168") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b96a7fcef1fd9b4743552016729b19aa")
       (:PMID . "8340422") (:SOURCE--API . "biopax")))
     (:POSITION . "621")
     (:ENZ (:DB--REFS (:+UP+ . "P01116") (:+HGNC+ . "6407")) (:NAME . "KRAS")
      (:BOUND--CONDITIONS
       ((:IS--BOUND . T)
        (:AGENT (:DB--REFS (:+CHEBI+ . "15996")) (:NAME . "GTP")))))
     (:TYPE . "Dephosphorylation")
     (:ID . "5c9d51b6-0df7-4e06-94f2-1746a08d7e95"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "1dc46f7d-8415-4efd-880e-2535d4589b0d"
      "d90c0cb1-5015-4fc7-be48-31e7d2581dff"
      "2672fd50-8426-45b0-8a30-1423df3fd806")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b96a7fcef1fd9b4743552016729b19aa")
       (:PMID . "10205168") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b96a7fcef1fd9b4743552016729b19aa")
       (:PMID . "8340422") (:SOURCE--API . "biopax")))
     (:POSITION . "621")
     (:ENZ (:DB--REFS (:+UP+ . "P01111") (:+HGNC+ . "7989")) (:NAME . "NRAS")
      (:BOUND--CONDITIONS
       ((:IS--BOUND . T)
        (:AGENT (:DB--REFS (:+CHEBI+ . "15996")) (:NAME . "GTP")))))
     (:TYPE . "Dephosphorylation")
     (:ID . "a287c1ec-8571-458d-b13b-75c2a04f2eaa"))
    ((:SUB (:DB--REFS (:+TEXT+ . "CFL1") (:+UP+ . "P23528") (:+HGNC+ . "1874"))
      (:NAME . "CFL1"))
     (:SUPPORTED--BY "fdf3c394-c1e7-435f-b23e-c72ba8a7b709")
     (:EVIDENCE
      ((:TEXT
        . "These effects were associated with robust dephosphorylation of the actin depolymerizing factor cofilin by PP1 and PP2A serine/threonine protein phosphatases but not the cofilin specific phosphatases slingshot and chronophin.")
       (:PMID . "20729910") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In fact, the PP1 and PP2A inhibitor calyculin prevented cofilin dephosphorylation and restored motility.")
       (:PMID . "20729910") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Cofilin is dephosphorylated by PP1 and PP2A in response to FDH.")
       (:PMID . "20729910") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "ALDH1L1 Inhibits Cell Motility Via Dephosphorylation of Cofilin by PP1 and PP2A.")
       (:PMID . "20729910") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PPP1CA") (:+UP+ . "P62136") (:+HGNC+ . "9281"))
      (:NAME . "PPP1CA"))
     (:TYPE . "Dephosphorylation")
     (:ID . "378a1300-92aa-4740-9679-3a44abbfaf05"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Chk1") (:+UP+ . "O14757") (:+HGNC+ . "1925"))
      (:NAME . "CHEK1"))
     (:SUPPORTED--BY "354a6ca9-b3b5-4018-9215-aa6e9a30bd9a")
     (:EVIDENCE
      ((:TEXT
        . "Similarly, Chk1 itself is a component of the checkpoint termination machinery, in that dephosphorylation of the activated Chk1 mediated by PP1, PP2A, or PPM1D and Wip1 phosphatases promotes recovery from cell-cycle arrest (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "19716789") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Recent studies suggest that at least three mechanisms inactivate Chk1 in vertebrate cells : (1) SCF beta-Trcp1 -mediated degradation of Claspin, an essential mediator during the ATR induced Chk1 phosphorylation (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR); (2) dephosphorylation of activated Chk1 by PP1, PP2A, or PP2C type phosphatases (XREF_BIBR; XREF_BIBR; XREF_BIBR); and (3) Cul1 or Cul4A dependent degradation of Chk1, as described in this paper and elsewhere (XREF_BIBR; XREF_BIBR).")
       (:PMID . "19716789") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Previous studies have shown that the protein phosphatases PP1, PP2A, and PPM1D and Wip1 dephosphorylate activated Chk1 and promote termination of the checkpoint response [XREF_BIBR - XREF_BIBR].")
       (:PMID . "21440578") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PPP1CA") (:+UP+ . "P62136") (:+HGNC+ . "9281"))
      (:NAME . "PPP1CA"))
     (:TYPE . "Dephosphorylation")
     (:ID . "a9f5bc95-a197-4e58-a068-1e453ad25b74"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Rb") (:+UP+ . "P06400") (:+HGNC+ . "9884"))
      (:NAME . "RB1"))
     (:SUPPORTED--BY "34d15c81-23c4-49c3-8ef6-184e9aa01ad1")
     (:EVIDENCE
      ((:TEXT
        . "During mitosis, Rb is dephosphorylated and thus activated by PP1.")
       (:PMID . "16764854") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rb remains hyper-phosphorylated in M phase and is dephosphorylated by activation of the PP1 phosphatase as cells exit mitosis into the next early G 1 phase (XREF_BIBR).")
       (:PMID . "24876129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In proliferating cells, Rb phosphorylation status is controlled by the Cyclin Dependent Kinases (cdks) which phosphorylate Rb in response to growth stimulatory signals and Protein Phosphatase 1 (PP1) which dephosphorylates Rb at the end of each M phase (XREF_BIBR, XREF_BIBR).")
       (:PMID . "20372802") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The enzyme protein phosphatase 1 (PP1), which is required for mitotic exit and is responsible for reversing the phosphorylation of many Cdk substrates, dephosphorylates Rb beginning in anaphase XREF_BIBR - XREF_BIBR.")
       (:PMID . "20694007") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, in our study of the effect Rb phosphorylation on apoptosis, we utilized a siRNA method that activates PP1 phosphatase activity that causes dephosphorylation of Rb.")
       (:PMID . "25483096") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Since this is the time during mitosis when pRB is normally dephosphorylated [XREF_BIBR, XREF_BIBR], it is tempting to speculate that prevention of pRB dephosphorylation by inhibiting PP1 activity impedes an orderly progression through mitosis, perhaps contributing towards a transformed phenotype.")
       (:PMID . "12914669") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Within cells, cyclin dependent kinases (cdks) phosphorylate Rb in response to growth stimulatory signals, whereas protein phosphatase 1 (PP1) dephosphorylates Rb when cells stop proliferating or undergo apoptosis in response to anti-proliferative or stress signals.")
       (:PMID . "20372802") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PPP1CA") (:+UP+ . "P62136") (:+HGNC+ . "9281"))
      (:NAME . "PPP1CA"))
     (:TYPE . "Dephosphorylation")
     (:ID . "a1a07046-d289-494f-8251-4a901074fc8e"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "β-catenin") (:+UP+ . "P35222") (:+HGNC+ . "2514"))
      (:NAME . "CTNNB1"))
     (:SUPPORTED--BY "47e54a0d-f786-40fd-957c-ee382fd72dbf")
     (:EVIDENCE
      ((:TEXT
        . "SHP2 dephosphorylates VE-cadherin–associated β-catenin in response to thrombin.")
       (:PMID . "22956765") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "SHP2 dephosphorylates VE-cadherin-associated beta-catenin in response to thrombin.")
       (:PMID . "22956765") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "SHP2 dephosphorylates VE-cadherin-associated beta-catenin in response to thrombin.")
       (:PMID . "22956765") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, given that adherens junction composition is not altered upon thrombin stimulation, how does beta-catenin dephosphorylation by SHP2 then affect VE-cadherin function?")
       (:PMID . "22956765") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, given that adherens junction composition is not altered upon thrombin stimulation, how does beta-catenin dephosphorylation by SHP2 then affect VE-cadherin function?")
       (:PMID . "22956765") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Tyrosine phosphorylation of beta-catenin is induced by PYK2 (proline rich kinase 2) [XREF_BIBR] and dephosphorylated by SHP2 [XREF_BIBR].")
       (:PMID . "24965120") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Reconstitution of the endothelial barrier involves SHP2 mediated dephosphorylation of VE-cadherin-associated beta-catenin, leading to reassembly of adherens junctions and thereby closing the gaps between endothelial cells.")
       (:PMID . "22956765") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "SHP2 dephosphorylates VE-cadherin-associated beta-catenin in response to thrombin")
       (:PMID . "22956765") (:SOURCE--API . "sparser")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "SHP2") (:+UP+ . "Q06124") (:+HGNC+ . "9644"))
      (:NAME . "PTPN11"))
     (:TYPE . "Dephosphorylation")
     (:ID . "cd575726-1267-4059-a92c-934d1226784d"))
    ((:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "095376ed-30d3-4cbe-855f-efc42754d6cd")
     (:EVIDENCE
      ((:TEXT
        . "To further validate that SHP2 directly dephosphorylates FAK, we incubated MEF cell lysates expressing FLAG tagged FAK with purified GST-WT-PTP lacking the regulatory SH2 domains.")
       (:PMID . "23512980") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Manes et al. reported that SHP-2 dephosphorylates FAK and increases cell migration by promoting turnover of focal adhesions in insulin like growth factor  (IGF)-1-stimulated MCF-7 cells.")
       (:PMID . "19275884") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Abrogation of SHP-2 catalytic activity with a dominant negative mutant (SHP2-C> S) abolishes IGF-I-induced FAK dephosphorylation, and cells expressing SHP2-C> S show reduced IGF-I-stimulated chemotaxis compared with either mock- or SHP-2 wild-type-transfected cells.")
       (:PMID . "10082579") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To further validate that SHP2 directly dephosphorylates FAK, we incubated MEF cell lysates expressing FLAG tagged FAK with purified GST-WT-PTP lacking the regulatory SH2 domains.")
       (:PMID . "23512980") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Manes et al. reported that SHP-2 dephosphorylates FAK and increases cell migration by promoting turnover of focal adhesions in insulin like growth factor (IGF)-1-stimulated MCF-7 cells.")
       (:PMID . "19275884") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While some studies have indicated SHP-2 promotes dephosphorylation of FAK, possibly to regenerate active FAK through a recycling mechanism (XREF_BIBR, XREF_BIBR), others have shown that SHP-2 enhances phosphorylation and activation of FAK by inhibiting phosphorylation of the inhibitory tyrosine residue of Src family kinases by C-terminal Src family kinase (CSK) (XREF_BIBR, XREF_BIBR).")
       (:PMID . "23335101") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "SHP2") (:+UP+ . "Q06124") (:+HGNC+ . "9644"))
      (:NAME . "PTPN11"))
     (:TYPE . "Dephosphorylation")
     (:ID . "72dbf19a-4f88-48b1-a768-77159acb42c6"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:SUPPORTED--BY "187efcef-ee2e-43fd-96d8-1d2259054e36"
      "77b7c851-cd52-49c6-93fb-9f3473c82e02"
      "30b88274-2576-4ac4-8dae-73931727d547")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad7cb9131d29f9d9ef2e4e2f1dac0170")
       (:PMID . "11748077") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad7cb9131d29f9d9ef2e4e2f1dac0170")
       (:PMID . "15884057") (:SOURCE--API . "biopax")))
     (:POSITION . "473")
     (:ENZ (:DB--REFS (:+UP+ . "P61586") (:+HGNC+ . "667")) (:NAME . "RHOA")
      (:BOUND--CONDITIONS
       ((:IS--BOUND . T)
        (:AGENT (:DB--REFS (:+CHEBI+ . "15996")) (:NAME . "GTP")))))
     (:TYPE . "Dephosphorylation")
     (:ID . "adb6b0e3-2328-40a7-bb51-d0e0f673f788"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "STAT3") (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "8c6299a4-9ec7-4155-a3a3-bd314014414a")
     (:EVIDENCE
      ((:TEXT
        . "Another mechanism is an inhibition of STAT3 dephosphorylation by STAT3 RA in the nucleus.")
       (:PMID . "16140268") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Dephosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "705") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "727") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "STAT3") (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:TYPE . "Dephosphorylation")
     (:ID . "552cf19b-bb1b-4e28-b099-039965bee571"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "7e8509b5-7a72-4b71-b152-dd8382447856")
     (:EVIDENCE
      ((:TEXT
        . "Thus, A/R induced up-regulation of Akt mRNA level (as detected by Q-PCR) by approximately 1.5-fold (A).")
       (:PMID . "16405925") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In low passage LNCaP cells, activation of AKT represses AR transcription in reporter assays whereas the opposite is observed in high passage LNCaP cells.")
       (:PMID . "21820033") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUBJ (:DB--REFS (:+TEXT+ . "A/R") (:+UP+ . "P10275") (:+HGNC+ . "644"))
      (:NAME . "AR"))
     (:ID . "5dc0c2ae-e98e-4ab3-9b45-fe8552096710"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "565e219f-a93b-4d19-91fe-57a394c4a054")
     (:EVIDENCE
      ((:TEXT
        . "In low passage LNCaP cells, activation of AKT represses AR transcription in reporter assays whereas the opposite is observed in high passage LNCaP cells.")
       (:PMID . "21820033") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, A/R induced up-regulation of Akt mRNA level (as detected by Q-PCR) by approximately 1.5-fold (A).")
       (:PMID . "16405925") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ (:DB--REFS (:+TEXT+ . "AR") (:+UP+ . "P10275") (:+HGNC+ . "644"))
      (:NAME . "AR"))
     (:ID . "fa0b3de2-e0fe-42ef-b2fa-9521ac60511e"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "AR") (:+UP+ . "P10275") (:+HGNC+ . "644"))
      (:NAME . "AR"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "450c02e1-57b7-40d1-b436-393a3b0c2b3a")
     (:EVIDENCE
      ((:TEXT
        . "Most frequently, deregulation of AR is observed, as can be achieved through amplification of the AR gene locus, alternative mechanisms that induce high level AR gene expression, and/or mechanisms that induce AR protein stabilization.")
       (:PMID . "21782001") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the former study, in which PIM-1S had no effect on AR transcriptional activity in a reporter assay, the experiments were performed under low androgen conditions (XREF_BIBR), whereas in the later study using a high concentration (10 nm) of synthetic androgen R1881, PIM-1S-mediated AR S213 phosphorylation repressed AR dependent transcription (XREF_BIBR).")
       (:PMID . "24424504") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "SIRT1 binds to, and deacetylates, the AR at a conserved lysine motif, down-regulating its levels in the cell and repressing androgen induced AR transcription (XREF_BIBR; XREF_BIBR).")
       (:PMID . "23169992") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "SIRT1 binds to, and deacetylates, the AR at a conserved lysine motif, down-regulating its levels in the cell and repressing androgen induced AR transcription (XREF_BIBR; XREF_BIBR).")
       (:PMID . "23169992") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Further, inhibition of AR also prevented the expression of AR protein in xenograft tissues (XREF_FIG).")
       (:PMID . "20354121") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AR mediated resistance was associated with a failure to block ER transcriptional activity and enhanced up-regulation of AR and ER responsive gene expression.")
       (:PMID . "25178514") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Functionally, these AR isoforms are constitutively active and promote the expression of endogenous AR dependent genes, as well as the proliferation of 22Rv1 cells in a ligand independent manner.")
       (:PMID . "18593950") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "A recent study showed expression of AR variants driven by AR gene rearrangements can mediate resistance to therapies targeting full-length AR, including enzalutamide (XREF_BIBR).")
       (:PMID . "24307657") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "CRPC usually possess a transcriptionally active AR that modulates the expression of AR regulated messenger RNAs XREF_BIBR, XREF_BIBR.")
       (:PMID . "22114732") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Recently, Sharma et al. have suggested that the progression to castration resistant prostate cancer is dependent on disruption of Rb which produces increased expression of the androgen receptor (AR) through the direct action of E2F1 (XREF_BIBR).")
       (:PMID . "22349817") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_3"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Silencing of AR using shRNA reduced AR mRNA expression, and sensitized txr cells to taxol induced apoptosis and cell death.")
       (:PMID . "26318424") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We also showed that factors in the HS-5 bone marrow stromal cell (BMSC) conditioned medium can upregulate p62 in AR + PCa cell lines, leading us to investigate AR expression under those growth conditions.")
       (:PMID . "25103771") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AR mutations, which can broaden AR ligand specificity, and AR amplification, which can lead to AR protein overexpression, are two genomic mechanisms that can support the CRPCa phenotype (XREF_BIBR - XREF_BIBR).")
       (:PMID . "21248069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AR is known to auto-regulate its transcription [XREF_BIBR], and a decline of AR protein would be expected to cause an increase in AR transcription.")
       (:PMID . "26196320") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in XREF_FIG, co-expression of WT AR and PIM1 repressed AR mediated transcription in a dose dependent manner.")
       (:PMID . "22986532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "For example, when cancer cell lines are cultured under hypoxic conditions, beta-catenin forms a complex with HIF-1 leading to hypoxia adaptation (XREF_BIBR), and in prostate cancer cells, a beta-catenin-androgen receptor (AR) complex increases the transcription of AR (XREF_BIBR).")
       (:PMID . "23245941") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Further investigation of the mechanisms underlying Raf/MEK/ERK mediated AR downregulation may lead to the development of a novel means to control AR levels in PCa cells.")
       (:PMID . "21871886") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Therefore, one can expect that nutlin induced elevated MDM2 could also facilitate AR degradation and further reduce AR levels when combined with androgen ablation.")
       (:PMID . "21539745") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ (:DB--REFS (:+TEXT+ . "AR") (:+UP+ . "P10275") (:+HGNC+ . "644"))
      (:NAME . "AR"))
     (:ID . "c1591463-356d-4248-a47a-7e4aff2a34e4"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "Ebp1") (:+UP+ . "P19838") (:+HGNC+ . "7794"))
      (:NAME . "NFKB1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "02ef689b-8517-4d3e-9efb-55b62f305ce1")
     (:EVIDENCE
      ((:TEXT
        . "Ebp1 inhibited AR regulated transcription in these androgen independent cells.")
       (:PMID . "15583694") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We have previously established that Ebp1, a protein cloned in our laboratory via its interactions with the ErbB3 receptor, inhibits AR mediated transcription and growth of the AR positive LNCaP cell line (Zhang et al, 2002).")
       (:PMID . "15583694") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUBJ (:DB--REFS (:+TEXT+ . "AR") (:+UP+ . "P10275") (:+HGNC+ . "644"))
      (:NAME . "AR"))
     (:ID . "913aed50-fa5b-4102-b1aa-806a20d5f4e1"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "BRCA1") (:+UP+ . "P38398") (:+HGNC+ . "1100"))
      (:NAME . "BRCA1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "16326715-2e90-44b7-9153-c8da770622ee")
     (:EVIDENCE
      ((:TEXT
        . "In contrast, Gadd45alpha transcription was downregulated by ~ 20% (in the presence of exogenous BRCA1 and SUMO1 proteins or in the cells without either exogenous expression) to 35% (in the presence of exogenously expressed BRCA1 alone), when the level of BRCA1 was reduced by deletion of endogenous BRCA1 (XREF_FIG A).")
       (:PMID . "18025037") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here we demonstrate that BRCA1 plays an essential role in mediating vinorelbine induced apoptosis, as evidenced by (1) the strong correlation between vinorelbine sensitivity and BRCA1 expression level; (2) induction of resistance to vinorelbine by BRCA1 using siRNA oligonucleotides; (3) dramatic down-regulation of BRCA1 following selection for vinorelbine resistance; and (4) the re-activation of vinorelbine induced apoptosis following re-expression of BRCA1 in resistant cells.")
       (:PMID . "22190288") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_3"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Over-expression of either CtBP or BRCA1 caused bidirectional repression of transcription, suggesting that promoter and direction specific repression of BRCA1 transcription by CtBP and BRCA1 requires a structural chromatin context at the endogenous BRCA1 promoter that is not recapitulated by transiently transfected DNA constructs (XREF_FIG).")
       (:PMID . "21102443") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This complex is disrupted by genotoxic stress resulting in the displacement of BRCA1 protein from the BRCA1 promoter and subsequent up-regulation of BRCA1 transcription.")
       (:PMID . "20068145") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This shows that BRCA1 negatively modulates Pol III gene transcription and the overexpression of BRCA1 decreases the induction of Pol III genes by alcohol.")
       (:PMID . "25447904") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Significantly, BRCA1 promoter and terminator interactions vary in different breast cancer cell lines, indicating that defects in BRCA1 chromatin structure may contribute to dysregulated expression of BRCA1 seen in breast tumors.")
       (:PMID . "18375767") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRCA1 siRNA enabled us to study the effect of BRCA1 expression in the same background.")
       (:PMID . "25841766") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Breast cancer MCF-7 and T-47D cell were transfected with a vector containing the coding sequence of BRCA1 (pFlag-CMV2-BRCA1 wt) to induce BRCA1 overexpression or with the empty vector (control).")
       (:PMID . "22931600") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Under these conditions, BRCA1 would be released from its promoter and recruited to sites of DNA repair allowing the now de-repressed BRCA1 promoter to increase BRCA1 transcription so that BRCA1 protein, consumed in the repair process, can be replaced.")
       (:PMID . "20068145") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "BRCA1") (:+UP+ . "P38398") (:+HGNC+ . "1100"))
      (:NAME . "BRCA1"))
     (:ID . "401055c5-4cd9-43c5-9887-3c700327923b"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "ER") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "143ede02-d4bd-4762-951b-f11d155375b9")
     (:EVIDENCE
      ((:TEXT
        . "Recent molecular evidence suggests that functional BRCA1 protein is necessary to induce expression of ER in breast cell progenitors (XREF_BIBR, XREF_BIBR).")
       (:PMID . "20823142") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This model explains how BRCA1 can both activate and repress ER-alpha transcription in hormone responsive tissues like breast and ovaries.")
       (:PMID . "21344391") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Preclinical models suggest that BRCA1 can transcriptionally induce ER gene expression and that loss of BRCA1 function is accompanied by loss of ER expression [XREF_BIBR - XREF_BIBR].")
       (:PMID . "21080930") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results indicate that proper regulation of ER-alpha expression by pVHL or BRCA1 is important for MTOC regulation and prevention of chromosomal instability.HEK293, MCF-7, and MDA-MB-468 (DMEM) were purchased from ATCC (Manassas, VA).")
       (:PMID . "25499220") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "BRCA1") (:+UP+ . "P38398") (:+HGNC+ . "1100"))
      (:NAME . "BRCA1"))
     (:ID . "3fec101d-c18b-46bb-a508-b552bf9a97e0"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "RB") (:+UP+ . "P06400") (:+HGNC+ . "9884"))
      (:NAME . "RB1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "92eff3b0-faaa-4eb5-ab03-c0378b45f5bd")
     (:EVIDENCE
      ((:TEXT
        . "Contrary to previous reports, our study showed that E2F-1 activates RB expression in asynchronously growing cells.")
       (:PMID . "20224733") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Second, O-GlcNAc modification has been shown to be involved in repressing transcription in some systems (XREF_BIBR) and pRB represses E2F-1 mediated transcription (XREF_BIBR).")
       (:PMID . "20680651") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Collectively, these data demonstrate that RB represses Pax8 mediated E2F1 transcription in thyroid cancer cells.")
       (:PMID . "21602887") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "E2F-1") (:+UP+ . "Q01094") (:+HGNC+ . "3113"))
      (:NAME . "E2F1"))
     (:ID . "6dddc42f-2c21-4b7c-ace3-a95ae602326a"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "p21") (:+UP+ . "P38936") (:+HGNC+ . "1784"))
      (:NAME . "CDKN1A"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "2bf1c1e9-ae7f-4cdc-a5e4-ea974b0d95f2")
     (:EVIDENCE
      ((:TEXT
        . "p21 positively regulates ERalpha dependent transcription via an interaction with CBP.")
       (:PMID . "23211592") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "More importantly, we provide new evidence that ERalpha mediates proliferation of MCF-7 cells by up-regulating miR-17 to silence the expression of p21.")
       (:PMID . "24283290") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, in cell types exhibiting normal MEK and ERK status, mortalin overexpression suppressed B-Raf (V600E) - or DeltaRaf-1 : ER induced MEK and ERK activation, p21 (CIP1) expression, and cell cycle arrest.")
       (:PMID . "23959801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_2"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "118") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "ERalpha") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:ID . "af2146bb-bd85-474b-9b4c-4944a55fa78f"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "p21") (:+UP+ . "P38936") (:+HGNC+ . "1784"))
      (:NAME . "CDKN1A"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "2bf1c1e9-ae7f-4cdc-a5e4-ea974b0d95f2")
     (:EVIDENCE
      ((:TEXT
        . "p21 positively regulates ERalpha dependent transcription via an interaction with CBP.")
       (:PMID . "23211592") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "More importantly, we provide new evidence that ERalpha mediates proliferation of MCF-7 cells by up-regulating miR-17 to silence the expression of p21.")
       (:PMID . "24283290") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, in cell types exhibiting normal MEK and ERK status, mortalin overexpression suppressed B-Raf (V600E) - or DeltaRaf-1 : ER induced MEK and ERK activation, p21 (CIP1) expression, and cell cycle arrest.")
       (:PMID . "23959801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_2"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "167") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "ERalpha") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:ID . "c838d2b0-fb71-4aef-9d01-9169f4df60d6"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "beta-catenin") (:+UP+ . "P35222")
       (:+HGNC+ . "2514"))
      (:NAME . "CTNNB1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "864c4b3a-de8f-4000-b3c9-1b0e557f3c8c")
     (:EVIDENCE
      ((:TEXT
        . "beta-catenin expression and cells invasiveness ability were up-regulated by 17beta-estradiol (E 2) in an estrogen receptor (ESR)-dependent manner, whereas beta-catenin siRNA abrogated this phenomenon.")
       (:PMID . "26432349") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Other studies have shown that the ERalpha transcription complex includes beta-catenin and that beta-catenin coactivates ERalpha mediated transcription ().")
       (:PMID . "16427018") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "118") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "estrogen receptor") (:+UP+ . "P03372")
       (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:ID . "8db818f8-5861-4afb-a7fa-f7fe30d00843"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "beta-catenin") (:+UP+ . "P35222")
       (:+HGNC+ . "2514"))
      (:NAME . "CTNNB1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "864c4b3a-de8f-4000-b3c9-1b0e557f3c8c")
     (:EVIDENCE
      ((:TEXT
        . "beta-catenin expression and cells invasiveness ability were up-regulated by 17beta-estradiol (E 2) in an estrogen receptor (ESR)-dependent manner, whereas beta-catenin siRNA abrogated this phenomenon.")
       (:PMID . "26432349") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Other studies have shown that the ERalpha transcription complex includes beta-catenin and that beta-catenin coactivates ERalpha mediated transcription ().")
       (:PMID . "16427018") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "167") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "estrogen receptor") (:+UP+ . "P03372")
       (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:ID . "078db2cf-8918-4a84-a95c-6fa97abe815c"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "ER") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "76d2bb62-4492-49ff-896f-b40e87aeb915")
     (:EVIDENCE
      ((:TEXT
        . "Our data implicated HOXB7 as a key ER cofactor that promotes ER target gene expression; which also could serve as yet another target in endocrine therapy.")
       (:PMID . "26180042") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Interestingly, insulin and ER stress inhibition (Tudca) were able to significantly reduce ER stress marker expression in MRAs from STZ mice (XREF_FIG).")
       (:PMID . "22665120") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Treatment of the ERalpha negative breast cancer cell line MDA-MB-231 with 5-aza-2 '-deoxycytidine (AZA) was reported to reactivate ERalpha expression, and a synergistic induction of ERalpha expression was possible with the combination of AZA and trichostatin A (TSA; XREF_BIBR, XREF_BIBR).")
       (:PMID . "19458056") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Over-expression of SnoN enhanced the transcriptional activity of ERalpha in estrogen response element (ERE)-reporter assays, augmented the expression of several ERalpha target genes and increased the proliferation of MCF7 breast carcinoma cells in an estrogen dependent manner.")
       (:PMID . "22227247") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In T47D cells, overexpression of wild-type ESR1 gene and protein increased growth in low-estradiol conditions, supporting the notion that by driving ESR1 overexpression, ESR1 gene amplification promotes adaptive resistance to estrogen deprivation (XREF_FIG).")
       (:PMID . "24055055") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We showed that overexpression of wild-type ESR1 potently (about 3.6 times control vector) stimulated ESR1 mediated transcription in a concentration dependent fashion, while overexpression of Delta7 ESR1 failed to elicit a transcriptional response at any dose.")
       (:PMID . "18424448") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Overexpression of ERalpha can be caused by estrogen receptor 1 (ESR1) gene amplification and was originally reported to be a frequent event associated with a significantly longer survival for ER positive women treated with adjuvant tamoxifen monotherapy, which was however questioned by subsequent studies.")
       (:PMID . "20966540") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "And studies have suggested a potential role of ER in leukomogenesis because ER CpG island methylation at very high frequency caused inactivation of ER expression in human leukaemias.")
       (:PMID . "25307539") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Western blot showed that ERalpha expression levels in RAW264.7 cells were overexpressed by ERalpha plasmid transfection or suppressed by specific siRNA (A).")
       (:PMID . "26186972") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Chronic ER stress in tumor cells increases the expression of the ER chaperones which provides a survival advantage to tumor cells in an adverse microenvironment.")
       (:PMID . "24453000") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "6 Consistent with the conclusion that HDAC5 and -9 negatively regulate the expression of ERalpha in vivo, ERalpha expression was significantly upregulated in cardiac samples of both HDAC5 and -9 KO animals, whereas ERbeta expression levels were unchanged (XREF_FIG and data not shown).")
       (:PMID . "19893013") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.")
       (:PMID . "24495356") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Briefly, by directly inhibiting proteosome activities, celastrol induced ER stress, activated CHOP and XBP1s, increased transcription of ER stress target genes such as BIM, induced Bax translocation into mitochondria and finally activated mitochondrial apoptosis.")
       (:PMID . "23846217") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "118") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "ER") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:ID . "b4a2ae4e-adf8-41ff-817c-0fab7993fa69"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "ER") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "34b7127b-1d5c-4203-ba43-1772f9b1fbc9")
     (:EVIDENCE
      ((:TEXT
        . "Our data implicated HOXB7 as a key ER cofactor that promotes ER target gene expression; which also could serve as yet another target in endocrine therapy.")
       (:PMID . "26180042") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Interestingly, insulin and ER stress inhibition (Tudca) were able to significantly reduce ER stress marker expression in MRAs from STZ mice (XREF_FIG).")
       (:PMID . "22665120") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Treatment of the ERalpha negative breast cancer cell line MDA-MB-231 with 5-aza-2 '-deoxycytidine (AZA) was reported to reactivate ERalpha expression, and a synergistic induction of ERalpha expression was possible with the combination of AZA and trichostatin A (TSA; XREF_BIBR, XREF_BIBR).")
       (:PMID . "19458056") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Over-expression of SnoN enhanced the transcriptional activity of ERalpha in estrogen response element (ERE)-reporter assays, augmented the expression of several ERalpha target genes and increased the proliferation of MCF7 breast carcinoma cells in an estrogen dependent manner.")
       (:PMID . "22227247") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In T47D cells, overexpression of wild-type ESR1 gene and protein increased growth in low-estradiol conditions, supporting the notion that by driving ESR1 overexpression, ESR1 gene amplification promotes adaptive resistance to estrogen deprivation (XREF_FIG).")
       (:PMID . "24055055") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We showed that overexpression of wild-type ESR1 potently (about 3.6 times control vector) stimulated ESR1 mediated transcription in a concentration dependent fashion, while overexpression of Delta7 ESR1 failed to elicit a transcriptional response at any dose.")
       (:PMID . "18424448") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Overexpression of ERalpha can be caused by estrogen receptor 1 (ESR1) gene amplification and was originally reported to be a frequent event associated with a significantly longer survival for ER positive women treated with adjuvant tamoxifen monotherapy, which was however questioned by subsequent studies.")
       (:PMID . "20966540") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "And studies have suggested a potential role of ER in leukomogenesis because ER CpG island methylation at very high frequency caused inactivation of ER expression in human leukaemias.")
       (:PMID . "25307539") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Western blot showed that ERalpha expression levels in RAW264.7 cells were overexpressed by ERalpha plasmid transfection or suppressed by specific siRNA (A).")
       (:PMID . "26186972") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Chronic ER stress in tumor cells increases the expression of the ER chaperones which provides a survival advantage to tumor cells in an adverse microenvironment.")
       (:PMID . "24453000") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "6 Consistent with the conclusion that HDAC5 and -9 negatively regulate the expression of ERalpha in vivo, ERalpha expression was significantly upregulated in cardiac samples of both HDAC5 and -9 KO animals, whereas ERbeta expression levels were unchanged (XREF_FIG and data not shown).")
       (:PMID . "19893013") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.")
       (:PMID . "24495356") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Briefly, by directly inhibiting proteosome activities, celastrol induced ER stress, activated CHOP and XBP1s, increased transcription of ER stress target genes such as BIM, induced Bax translocation into mitochondria and finally activated mitochondrial apoptosis.")
       (:PMID . "23846217") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "167") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "ER") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:ID . "5ff6f089-1380-49d1-8770-d670d488534f"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "PI3Kalpha") (:+UP+ . "P42336") (:+HGNC+ . "8975"))
      (:NAME . "PIK3CA"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "60f39dc5-1d40-436d-9fba-9a5fd995a6c8")
     (:EVIDENCE
      ((:TEXT
        . "Combined Suppression of PI3Kalpha and PDK1 Activates FOXO Dependent Transcription.")
       (:PMID . "27451907") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In that study, FoxO3a promoted cytosolic localization of FoxO1 by transcriptionally elevating expression of the PI3-kinase catalytic subunit in human embryonic kidney cells and mouse embryonic fibroblast cells XREF_BIBR; hence FoxO3a acted as a positive regulator of autophagy in those cell types.")
       (:PMID . "25546383") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "FOXO3") (:+UP+ . "O43524") (:+HGNC+ . "3821"))
      (:NAME . "FOXO3"))
     (:ID . "9a302b9f-aef4-4d58-a3e2-239f0fc19f66"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "Sirt1") (:+UP+ . "Q96EB6") (:+HGNC+ . "14929"))
      (:NAME . "SIRT1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "015d19ac-0b4e-480b-91c6-fe83b88be74c")
     (:EVIDENCE
      ((:TEXT
        . "Moreover, starvation induced increase in Sirt1 expression requires Foxo3a, and stimulation of Sirt1 expression by Foxo3a was mediated through physical interaction between Foxo3a and p53, which binds to two p53 binding sites present in the mouse Sirt1 promoter [XREF_BIBR].")
       (:PMID . "19267881") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Consistent with FoxO3 up-regulation of Sirt1 expression, FoxO3 expression antagonizes NF-kappaB signaling [XREF_BIBR].")
       (:PMID . "23262029") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, expression of the Class III histone deacetylase Sirt1 is induced by E2F1 phosphorylated by the stress responsive kinase ataxia telangiectasia mutated (ATM), by p53 and FOXO3a (activated in nutrient deprived mammalian cells), by c-Myc and by the redox sensor carboxy terminal of E1A binding protein (CtBP) (reviewed in XREF_BIBR).")
       (:PMID . "24416372") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, SIRT1 can deacetylate P53 and FOXO and thereby inhibit P53 and/or FOXO dependent transcription or apoptosis.")
       (:PMID . "21414717") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Accordingly, hSir2 (SIRT1)-mediated deacetylation precludes FOXO inhibition through acetylation and thereby prolongs FOXO dependent transcription of stress regulating genes.")
       (:PMID . "15126506") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Furthermore, they found that stimulation of Sirt1 transcription by Foxo3a was mediated via a p53 binding site (two half sites) in the mouse Sirt1 promoter, and there was a nutrient sensitive physical interaction between Foxo3a and p53.")
       (:PMID . "19267881") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Stimulation of SIRT1 transcription by Foxo3a was mediated through two p53 binding sites present in the SIRT1 promoter, and a nutrient sensitive physical interaction was observed between Foxo3a and p53.")
       (:PMID . "15604409") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, under nutritional stress, p53 and Foxo proteins promote SIRT1 expression, which serves as a protective mechanism against excessive apoptosis.")
       (:PMID . "19267881") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "Foxo3a") (:+UP+ . "O43524") (:+HGNC+ . "3821"))
      (:NAME . "FOXO3"))
     (:ID . "49fd8935-f874-4f2e-af87-1c4d044bd2d2"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "BRCA1") (:+UP+ . "P38398") (:+HGNC+ . "1100"))
      (:NAME . "BRCA1"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "16326715-2e90-44b7-9153-c8da770622ee")
     (:EVIDENCE
      ((:TEXT
        . "BRCA1 expression activated by c-Myc could be the final outcome of the interplay within multi-component transcriptional networks containing factors important for breast tumorigenesis.")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells.")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These data suggest that c-Myc activates BRCA1 expression through the E boxes in the distal BRCA1 promoter region.")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our studies revealed that BRCA1 represses Myc mediated transcription while having no effect on some other transcriptional activities.")
       (:PMID . "9788437") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Taken together, these data indicated that c-Myc activates BRCA1 expression through the region of the BRCA1 promoter (-1714 to +42), which could contain c-Myc-mediated DNA regulatory elements.")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Intriguingly, MYC induces expression of BRCA1 [XREF_BIBR] and also of astrocyte elevated gene-1 (AEG-1) [XREF_BIBR].")
       (:PMID . "21951562") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In this report we show that c-Myc can activate BRCA1 expression in breast cancer cells, and depletion of c-Myc reduced BRCA1 dependent DNA repair.")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These data suggest that reduced c-Myc might decrease BRCA1 expression in these two breast cancer cell lines through the BRCA1 promoter.")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Whether c-Myc can directly regulate BRCA1 expression at the transcriptional level is not clear.")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To establish that BRCA1 expression was directly modulated by c-Myc through DNA regulatory elements in the BRCA1 promoter region, we constructed a BRCA1 promoter and luciferase reporter vector containing the BRCA1 promoter region -1714 to +42.")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It has been shown that HIF-1alpha transcriptional machinery activated by hypoxia signaling pathway abrogates c-Myc activation of BRCA1 expression in colon cancer cells [XREF_BIBR].")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "62") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "c-Myc") (:+UP+ . "P01106") (:+HGNC+ . "7553"))
      (:NAME . "MYC"))
     (:ID . "57448d1d-f28e-4dfd-9222-b0570db4f002"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "CDKN1A") (:+UP+ . "P38936") (:+HGNC+ . "1784"))
      (:NAME . "CDKN1A"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "2bf1c1e9-ae7f-4cdc-a5e4-ea974b0d95f2")
     (:EVIDENCE
      ((:TEXT
        . "Both c-Myc RNAi and AR RNAi reduced expression of the c-Myc-activated gene E2F1; conversely, c-Myc and AR RNAi both increased expression of the c-Myc-repressed gene CDKN1A (XREF_FIG).")
       (:PMID . "23704919") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Since c-Myc is a potent transcriptional repressor of p21, these findings suggest that c-Myc may negatively modulate p21 expression through an additional pathway except transcriptional suppression.")
       (:PMID . "20878079") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Secondly, DLX4 induced c-myc expression might lead to down-regulated expression of p15 Ink4B and p21 WAF1 and Cip1, since transcription of these genes is repressed by c-myc (XREF_BIBR; XREF_BIBR).")
       (:PMID . "21297662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Similarly, p21 represses MYC dependent transcription and in turn, MYC disrupts the PCNA-p21 interaction, thus alleviating p21 dependent inhibition of PCNA and DNA synthesis 14.")
       (:PMID . "22634755") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Either c-myc release from the complexes or interaction others with Miz-1 may activate p21 transcription.")
       (:PMID . "15474507") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As expected, c-Myc knockdown by siRNA decreased the expression of cyclin D1, cyclin E, and E2F1, and increased the expression of p21 Cip1 (XREF_FIG), leading to impaired CAFs proliferation (XREF_FIG).")
       (:PMID . "25970706") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Secondly, DLX4 induced c-myc expression might lead to down-regulated expression of p15 Ink4B and p21 WAF1 and Cip1, since transcription of these genes is repressed by c-myc (XREF_BIBR; XREF_BIBR).")
       (:PMID . "21297662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "62") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "c-Myc") (:+UP+ . "P01106") (:+HGNC+ . "7553"))
      (:NAME . "MYC"))
     (:ID . "0c55aea8-faa0-41b2-85b9-88427f28e669"))
    ((:OBJ
      (:DB--REFS (:+TEXT+ . "hTERT") (:+UP+ . "O14746") (:+HGNC+ . "11730"))
      (:NAME . "TERT"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "f64492d3-e90e-4f0c-96f3-965a6c6c1369")
     (:EVIDENCE
      ((:TEXT
        . "c-Myc binds to these E-boxes through heterodimer formation with Max proteins and directly activates the hTERT transcription.")
       (:PMID . "14611815") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the absence of TGF-beta, c-Myc associated with E-box sequences of hTERT promoter to activate hTERT expression in immortalized cells in this study (D, left panel).")
       (:PMID . "26235880") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Many repeats of hTERT-VNTR2-1 st include the canonical CACGTG binding site of the MYC family of oncogenic transcription factors, that is also present in the promoter region; overexpression of c-MYC activates hTERT transcription through this promoter element [XREF_BIBR, XREF_BIBR].")
       (:PMID . "20659312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Hence, c-Myc upregulates telomerase by enhancing hTERT expression [XREF_BIBR, XREF_BIBR].")
       (:PMID . "21614210") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We previously showed that MYC recruits the STAGA complex to activate transcription of the endogenous TERT gene in HeLa cervical cancer cells and that the activation mechanisms are distinct from a simple stimulation of histone acetylation (XREF_BIBR).")
       (:PMID . "24705139") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous studies showed that MYC activated hTERT transcription through binding to the E-boxes at the hTERT promoter in some cancer cells (XREF_BIBR; XREF_BIBR).")
       (:PMID . "19672873") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because c-Myc can activate transcription of the human telomerase reverse transcriptase gene (hTERT), we addressed the role of BRCA1 and Nmi in modulating c-Myc-induced hTERT promoter activity.")
       (:PMID . "11916966") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT . "Direct activation of TERT transcription by c-MYC.")
       (:PMID . "9988278") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Therefore, these results indicate that the increase of telomere length observed in previous studies may not just depend on the activation of telomerase transcription by c-Myc.")
       (:PMID . "17765874") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT . "Direct activation of TERT transcription by c-Myc.")
       (:PMID . "16036112") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Further, MAD1 is also a transcription repressor of hTERT that binds to its 5 '-CACGTG-3 ' sequence (E-box), while c-MYC binds to the same promoter sites to activate hTERT expression (XREF_BIBR, XREF_BIBR, XREF_BIBR).")
       (:PMID . "21411498") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "c-Myc overexpression activated the wildtype, but not the mutant, hTERT promoter, despite of the presence of numerous potential c-Myc binding sites downstream of the promoter in the mutant BACs (XREF_BIBR), indicating that activation of hTERT transcription by c-Myc was mediated only by the E-box sites at core promoter.")
       (:PMID . "25170084") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While hTERT activation by c-Myc overexpression has been previously reported, it was a surprise to discover that c-Myc and Max KD also activated hTERT transcription in a chromosomal context in fibroblasts.")
       (:PMID . "25170084") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Finally, Myc activates the transcription of human telomerase (), which may contribute to sustain the proliferation of tumor cells along the cell cycle.")
       (:PMID . "24704206") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, some cases of intestinal metaplasia may carry short telomeres and due to this telomere dysfunction, MYC stimulates hTERT expression.")
       (:PMID . "22768805") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, earlier reported studies have found that MMP-9 silencing could induce down-regulation of hTERT expression mediated by beta1 integrin and FAK intracellular signaling deregulation of c-Myc and MAD expression in glioma xenograft cells.")
       (:PMID . "23993966") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "62") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "c-Myc") (:+UP+ . "P01106") (:+HGNC+ . "7553"))
      (:NAME . "MYC"))
     (:ID . "dcd96598-8bb7-467d-bf8f-a3846bdc282a"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "5ada391a-44dd-46a8-9e3a-6c5783fef44e")
     (:EVIDENCE
      ((:TEXT
        . "Mutant p53 expression in U251 cells was dependent upon endogenous MYC, because knockdown of MYC suppressed p53 expression (XREF_FIG).")
       (:PMID . "24272483") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This effect was preceded and mediated by down-regulation of MYC, which enhances p53 protein levels via the ARF-HDM2 pathway.")
       (:PMID . "24727092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On the other hand, p53 represses c-Myc transcription by binding to the c-Myc promoter and recruiting the general repressor mSin3a; this repression is required for cell cycle arrest and differentiation but not apoptosis [XREF_BIBR].")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These data suggest that p53 represses c-myc transcription through a mechanism that involves histone deacetylation.")
       (:PMID . "16107691") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Blocking c-Myc induction in HuH-7 cells prevented the LCA mediated increase in p53 and cyclin D1 expression and reduced apoptosis.")
       (:PMID . "19086036") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression level of another pro apoptotic protein, p53, was also up-regulated in AU565 and SKBR3 cells treated with CDK1 inhibitors and MYC knockdown prevented increase of p53 expression by CDK1 inhibitors (Additional file XREF_SUPPLEMENTARY : Figure S5B), whereas MYC overexpression in MCF-7 cells and MDA-MB-175 cells (Additional file XREF_SUPPLEMENTARY : Figure S5B) induced p53 expression upon treatment with CDK1 inhibitors.")
       (:PMID . "24444383") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "c-Myc activates the expression of p53 through an E box within the p53 promoter [XREF_BIBR].")
       (:PMID . "21668996") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "62") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MYC") (:+UP+ . "P01106") (:+HGNC+ . "7553"))
      (:NAME . "MYC"))
     (:ID . "d3123b71-0c0b-4808-9570-6fef950b4149"))
    ((:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "20") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "15") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "TP53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:OBJ (:DB--REFS (:+TEXT+ . "MGMT") (:+UP+ . "P16455") (:+HGNC+ . "7059"))
      (:NAME . "MGMT"))
     (:TYPE . "IncreaseAmount") (:ID . "32327aed-4fc3-452f-99f3-cf674840327a")
     (:EVIDENCE
      ((:TEXT
        . "In addition, mutant TP53 knockdown induced a dramatic decrease of MGMT expression (P = 0.0000034).")
       (:PMID . "23224642") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:FOUND--BY . "expression_1")
        (:TISSUE) (:LOCATION) (:CELL--LINE "cellosaurus:CVCL_0020")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The tumor suppressor p53 is reported to suppress MGMT expression either by directly binding to MGMT or by sequestering specificity protein 1 (SP1), a transcription factor which binds to the MGMT promoter.")
       (:PMID . "25240597") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, ionizing radiation induced MGMT expression in normal rodent fibroblasts and hepatoma cells is greater in wild-type p53 cells than in p53 mutated cells, suggesting that p53 positively regulate MGMT transcription in cells treated with a DNA damaging agent.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, a recent report showed that p53 knockout or RNA interference of p53 reduces MGMT expression in murine astrocytes.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although several glioma studies have demonstrated correlations between inactivation of the p53 pathway and lower levels and/or activity of MGMT [XREF_BIBR - XREF_BIBR], the introduction of wild type p53 failed to restore MGMT protein levels in transformed NHA cells.")
       (:PMID . "17547775") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild-type p53, rather than mutant p53, promotes MGMT expression by modulating MGMT methylation by reducing DNMT1 expression in lung cancer cell lines [XREF_BIBR], while transduction of IMR90 fibroblasts (human fetal lung cells) with a wild-type p53-adenoviral vector reduced MGMT expression [XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In order to investigate if abnormal p53 protein is capable to induce MGMT expression, we transfected plasmids encoding for GFP (pEGFP-N1), wild type p53 (pP53wt) or a dominant negative mutant p53 (pP53mut) into MeWo cells.")
       (:PMID . "19056673") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Surprisingly, knockdown of p53 dramatically suppressed MGMT mRNA expression in A549 cells, whereas overexpression of WT-p53 in H1299 cells significantly increased MGMT mRNA levels (a).")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results clearly indicate that WT-p53 promotes MGMT transcription by modulating MGMT promoter methylation.DNMT1 and HDAC1 play a crucial role in gene silencing via promoter methylation.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It appears that in astrocytes, p53 positively modulate MGMT expression directly by binding to its promoter.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This negative regulation of MGMT expression by WT-p53 has been confirmed with two other human cell lines, namely, the GM47.23 glioblastoma cell line, which contains a dexamethasone inducible p53, and the H460 lung cancer cell line, in which WT-p53 is inactivated by the human papillomavirus 16 E6 protein.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Interestingly, p53 appears to stimulate MGMT expression, and p53 inhibition sensitizes human glioma cells to TMZ [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On the contrary, some reports suggest that p53 may positively regulate MGMT expression, and that p53 inhibition sensitizes human glioma cells to TMZ [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild-type p53 rather than mutant p53 promoted MGMT expression by modulating MGMT methylation, presumably by reducing DNMT1 (DNA-methyltransferase 1) expression in lung cancer cell lines [XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))))
    ((:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "392") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "TP53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:OBJ (:DB--REFS (:+TEXT+ . "MGMT") (:+UP+ . "P16455") (:+HGNC+ . "7059"))
      (:NAME . "MGMT"))
     (:TYPE . "IncreaseAmount") (:ID . "b851aed6-9998-4a42-ba34-035bc0bead03")
     (:EVIDENCE
      ((:TEXT
        . "In addition, mutant TP53 knockdown induced a dramatic decrease of MGMT expression (P = 0.0000034).")
       (:PMID . "23224642") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:FOUND--BY . "expression_1")
        (:TISSUE) (:LOCATION) (:CELL--LINE "cellosaurus:CVCL_0020")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The tumor suppressor p53 is reported to suppress MGMT expression either by directly binding to MGMT or by sequestering specificity protein 1 (SP1), a transcription factor which binds to the MGMT promoter.")
       (:PMID . "25240597") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, ionizing radiation induced MGMT expression in normal rodent fibroblasts and hepatoma cells is greater in wild-type p53 cells than in p53 mutated cells, suggesting that p53 positively regulate MGMT transcription in cells treated with a DNA damaging agent.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, a recent report showed that p53 knockout or RNA interference of p53 reduces MGMT expression in murine astrocytes.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although several glioma studies have demonstrated correlations between inactivation of the p53 pathway and lower levels and/or activity of MGMT [XREF_BIBR - XREF_BIBR], the introduction of wild type p53 failed to restore MGMT protein levels in transformed NHA cells.")
       (:PMID . "17547775") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild-type p53, rather than mutant p53, promotes MGMT expression by modulating MGMT methylation by reducing DNMT1 expression in lung cancer cell lines [XREF_BIBR], while transduction of IMR90 fibroblasts (human fetal lung cells) with a wild-type p53-adenoviral vector reduced MGMT expression [XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In order to investigate if abnormal p53 protein is capable to induce MGMT expression, we transfected plasmids encoding for GFP (pEGFP-N1), wild type p53 (pP53wt) or a dominant negative mutant p53 (pP53mut) into MeWo cells.")
       (:PMID . "19056673") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Surprisingly, knockdown of p53 dramatically suppressed MGMT mRNA expression in A549 cells, whereas overexpression of WT-p53 in H1299 cells significantly increased MGMT mRNA levels (a).")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results clearly indicate that WT-p53 promotes MGMT transcription by modulating MGMT promoter methylation.DNMT1 and HDAC1 play a crucial role in gene silencing via promoter methylation.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It appears that in astrocytes, p53 positively modulate MGMT expression directly by binding to its promoter.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This negative regulation of MGMT expression by WT-p53 has been confirmed with two other human cell lines, namely, the GM47.23 glioblastoma cell line, which contains a dexamethasone inducible p53, and the H460 lung cancer cell line, in which WT-p53 is inactivated by the human papillomavirus 16 E6 protein.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Interestingly, p53 appears to stimulate MGMT expression, and p53 inhibition sensitizes human glioma cells to TMZ [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On the contrary, some reports suggest that p53 may positively regulate MGMT expression, and that p53 inhibition sensitizes human glioma cells to TMZ [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild-type p53 rather than mutant p53 promoted MGMT expression by modulating MGMT methylation, presumably by reducing DNMT1 (DNA-methyltransferase 1) expression in lung cancer cell lines [XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))))
    ((:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "46") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "TP53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:OBJ (:DB--REFS (:+TEXT+ . "MGMT") (:+UP+ . "P16455") (:+HGNC+ . "7059"))
      (:NAME . "MGMT"))
     (:TYPE . "IncreaseAmount") (:ID . "7bb17f20-1d8e-4108-8ce9-0a38384f8ed4")
     (:EVIDENCE
      ((:TEXT
        . "In addition, mutant TP53 knockdown induced a dramatic decrease of MGMT expression (P = 0.0000034).")
       (:PMID . "23224642") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:FOUND--BY . "expression_1")
        (:TISSUE) (:LOCATION) (:CELL--LINE "cellosaurus:CVCL_0020")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The tumor suppressor p53 is reported to suppress MGMT expression either by directly binding to MGMT or by sequestering specificity protein 1 (SP1), a transcription factor which binds to the MGMT promoter.")
       (:PMID . "25240597") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, ionizing radiation induced MGMT expression in normal rodent fibroblasts and hepatoma cells is greater in wild-type p53 cells than in p53 mutated cells, suggesting that p53 positively regulate MGMT transcription in cells treated with a DNA damaging agent.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, a recent report showed that p53 knockout or RNA interference of p53 reduces MGMT expression in murine astrocytes.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although several glioma studies have demonstrated correlations between inactivation of the p53 pathway and lower levels and/or activity of MGMT [XREF_BIBR - XREF_BIBR], the introduction of wild type p53 failed to restore MGMT protein levels in transformed NHA cells.")
       (:PMID . "17547775") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild-type p53, rather than mutant p53, promotes MGMT expression by modulating MGMT methylation by reducing DNMT1 expression in lung cancer cell lines [XREF_BIBR], while transduction of IMR90 fibroblasts (human fetal lung cells) with a wild-type p53-adenoviral vector reduced MGMT expression [XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In order to investigate if abnormal p53 protein is capable to induce MGMT expression, we transfected plasmids encoding for GFP (pEGFP-N1), wild type p53 (pP53wt) or a dominant negative mutant p53 (pP53mut) into MeWo cells.")
       (:PMID . "19056673") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Surprisingly, knockdown of p53 dramatically suppressed MGMT mRNA expression in A549 cells, whereas overexpression of WT-p53 in H1299 cells significantly increased MGMT mRNA levels (a).")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results clearly indicate that WT-p53 promotes MGMT transcription by modulating MGMT promoter methylation.DNMT1 and HDAC1 play a crucial role in gene silencing via promoter methylation.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It appears that in astrocytes, p53 positively modulate MGMT expression directly by binding to its promoter.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This negative regulation of MGMT expression by WT-p53 has been confirmed with two other human cell lines, namely, the GM47.23 glioblastoma cell line, which contains a dexamethasone inducible p53, and the H460 lung cancer cell line, in which WT-p53 is inactivated by the human papillomavirus 16 E6 protein.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Interestingly, p53 appears to stimulate MGMT expression, and p53 inhibition sensitizes human glioma cells to TMZ [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On the contrary, some reports suggest that p53 may positively regulate MGMT expression, and that p53 inhibition sensitizes human glioma cells to TMZ [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild-type p53 rather than mutant p53 promoted MGMT expression by modulating MGMT methylation, presumably by reducing DNMT1 (DNA-methyltransferase 1) expression in lung cancer cell lines [XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))))
    ((:SUBJ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "18") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "TP53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:OBJ (:DB--REFS (:+TEXT+ . "MGMT") (:+UP+ . "P16455") (:+HGNC+ . "7059"))
      (:NAME . "MGMT"))
     (:TYPE . "IncreaseAmount") (:ID . "0c3fcf79-0b34-4c88-a927-c3e9b5f93b26")
     (:EVIDENCE
      ((:TEXT
        . "In addition, mutant TP53 knockdown induced a dramatic decrease of MGMT expression (P = 0.0000034).")
       (:PMID . "23224642") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:FOUND--BY . "expression_1")
        (:TISSUE) (:LOCATION) (:CELL--LINE "cellosaurus:CVCL_0020")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The tumor suppressor p53 is reported to suppress MGMT expression either by directly binding to MGMT or by sequestering specificity protein 1 (SP1), a transcription factor which binds to the MGMT promoter.")
       (:PMID . "25240597") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, ionizing radiation induced MGMT expression in normal rodent fibroblasts and hepatoma cells is greater in wild-type p53 cells than in p53 mutated cells, suggesting that p53 positively regulate MGMT transcription in cells treated with a DNA damaging agent.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, a recent report showed that p53 knockout or RNA interference of p53 reduces MGMT expression in murine astrocytes.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although several glioma studies have demonstrated correlations between inactivation of the p53 pathway and lower levels and/or activity of MGMT [XREF_BIBR - XREF_BIBR], the introduction of wild type p53 failed to restore MGMT protein levels in transformed NHA cells.")
       (:PMID . "17547775") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild-type p53, rather than mutant p53, promotes MGMT expression by modulating MGMT methylation by reducing DNMT1 expression in lung cancer cell lines [XREF_BIBR], while transduction of IMR90 fibroblasts (human fetal lung cells) with a wild-type p53-adenoviral vector reduced MGMT expression [XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In order to investigate if abnormal p53 protein is capable to induce MGMT expression, we transfected plasmids encoding for GFP (pEGFP-N1), wild type p53 (pP53wt) or a dominant negative mutant p53 (pP53mut) into MeWo cells.")
       (:PMID . "19056673") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Surprisingly, knockdown of p53 dramatically suppressed MGMT mRNA expression in A549 cells, whereas overexpression of WT-p53 in H1299 cells significantly increased MGMT mRNA levels (a).")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results clearly indicate that WT-p53 promotes MGMT transcription by modulating MGMT promoter methylation.DNMT1 and HDAC1 play a crucial role in gene silencing via promoter methylation.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It appears that in astrocytes, p53 positively modulate MGMT expression directly by binding to its promoter.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This negative regulation of MGMT expression by WT-p53 has been confirmed with two other human cell lines, namely, the GM47.23 glioblastoma cell line, which contains a dexamethasone inducible p53, and the H460 lung cancer cell line, in which WT-p53 is inactivated by the human papillomavirus 16 E6 protein.")
       (:PMID . "18555750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Interestingly, p53 appears to stimulate MGMT expression, and p53 inhibition sensitizes human glioma cells to TMZ [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On the contrary, some reports suggest that p53 may positively regulate MGMT expression, and that p53 inhibition sensitizes human glioma cells to TMZ [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, wild-type p53 rather than mutant p53 promoted MGMT expression by modulating MGMT methylation, presumably by reducing DNMT1 (DNA-methyltransferase 1) expression in lung cancer cell lines [XREF_BIBR].")
       (:PMID . "26400193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))))
    ((:OBJ (:DB--REFS (:+TEXT+ . "p73") (:+UP+ . "O15350") (:+HGNC+ . "12003"))
      (:NAME . "TP73"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "1a28cb1f-f340-4c22-8a2c-2c2a67371993")
     (:EVIDENCE
      ((:TEXT
        . "Because dimer formation between mutant and wild type p53 increases p53 stability and inactivates wtp53 XREF_BIBR, increased p73 levels in these cells suggest that p53 inactivation by point mutation may also induce p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To further demonstrate the specific role of E2F-1 in p53 inactivation regulated p73 transcription, we tested whether mutation of E2F binding sites abolishes p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that inactivation of p53 in MCF-7 and HCT-116 cells resulted in increased expression of TAp73, but not DNp73, which suggests that p53 inactivation-mediated-upregulation of p73 may contribute to the p73 overexpression detected in human cancers.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition to p53 knockdown and knockout, we found that inactivation of p53 by overexpression of mtp53 (G135A) led to p73 upregulation, indicating that p53 inactivation by means other than deletion and knockdown also induce p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These data suggest that p53 inactivation upregulated p73 transcription, which was independent of p53 binding.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Based on our evidence showing that p53 inactivation upregulates p73 transcription, one would expect a decrease of p73 expression in the cells transfected with wtp53.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Hence, our results not only address how p53 inactivation upregulates p73 transcription in a DNA binding independent manner but also underscores the role of pRb and E2F -1 pathway in the regulation of p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Particularly, p53 binds to a palindromic site in the TAp73 promoter, activates the promoter of TAp73, and selectively induces TAp73 transcription.")
       (:PMID . "17693405") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It was also reported that overexpression of p53 or p73 induced p73 transcription in certain cell lines XREF_BIBR.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because E2F-1 is a major transcription factor that regulates TAp73 transcription and there are multiple E2F binding sites in the proximal promoter region XREF_BIBR, XREF_BIBR, XREF_BIBR, we reasoned that modulation of E2F-1 activity might play a role in p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These include dimers between certain p53 mutants and p73 that downregulates p73 activity XREF_BIBR, XREF_BIBR; a potential interaction between p53 and the p73 promoter at the distal region XREF_BIBR; p53 mediated induction of oncogenic DNp73; and our finding that p53 inactivation upregulates p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p53 inactivation upregulates p73 transcription through E2F-1.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Taken together, our results reveal that p53 inactivation may upregulate TAp73 expression through E2F-1 mediated transcriptional regulation, which involves modulated p21 activity.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p53 Inactivation Upregulates p73 Expression through E2F-1 Mediated Transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results demonstrate that modulation of E2F activity plays a critical role in p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, p63 and p73 have overlapping functions to p53 and can regulate p53 gene transcription.")
       (:PMID . "18215742") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Using several p53 inactivation models we demonstrated that inactivation of p53 upregulated TAp73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although less p53 induction was observed in TP53 mutant Daoy cells, increased TP73 levels including DeltaN ' p73 were detected.")
       (:PMID . "17626635") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "20") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "15") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:ID . "b0f51ab9-041c-4d31-8f1d-927d02eb8411"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "p73") (:+UP+ . "O15350") (:+HGNC+ . "12003"))
      (:NAME . "TP73"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "1a28cb1f-f340-4c22-8a2c-2c2a67371993")
     (:EVIDENCE
      ((:TEXT
        . "Because dimer formation between mutant and wild type p53 increases p53 stability and inactivates wtp53 XREF_BIBR, increased p73 levels in these cells suggest that p53 inactivation by point mutation may also induce p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To further demonstrate the specific role of E2F-1 in p53 inactivation regulated p73 transcription, we tested whether mutation of E2F binding sites abolishes p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that inactivation of p53 in MCF-7 and HCT-116 cells resulted in increased expression of TAp73, but not DNp73, which suggests that p53 inactivation-mediated-upregulation of p73 may contribute to the p73 overexpression detected in human cancers.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition to p53 knockdown and knockout, we found that inactivation of p53 by overexpression of mtp53 (G135A) led to p73 upregulation, indicating that p53 inactivation by means other than deletion and knockdown also induce p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These data suggest that p53 inactivation upregulated p73 transcription, which was independent of p53 binding.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Based on our evidence showing that p53 inactivation upregulates p73 transcription, one would expect a decrease of p73 expression in the cells transfected with wtp53.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Hence, our results not only address how p53 inactivation upregulates p73 transcription in a DNA binding independent manner but also underscores the role of pRb and E2F -1 pathway in the regulation of p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Particularly, p53 binds to a palindromic site in the TAp73 promoter, activates the promoter of TAp73, and selectively induces TAp73 transcription.")
       (:PMID . "17693405") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It was also reported that overexpression of p53 or p73 induced p73 transcription in certain cell lines XREF_BIBR.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because E2F-1 is a major transcription factor that regulates TAp73 transcription and there are multiple E2F binding sites in the proximal promoter region XREF_BIBR, XREF_BIBR, XREF_BIBR, we reasoned that modulation of E2F-1 activity might play a role in p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These include dimers between certain p53 mutants and p73 that downregulates p73 activity XREF_BIBR, XREF_BIBR; a potential interaction between p53 and the p73 promoter at the distal region XREF_BIBR; p53 mediated induction of oncogenic DNp73; and our finding that p53 inactivation upregulates p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p53 inactivation upregulates p73 transcription through E2F-1.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Taken together, our results reveal that p53 inactivation may upregulate TAp73 expression through E2F-1 mediated transcriptional regulation, which involves modulated p21 activity.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p53 Inactivation Upregulates p73 Expression through E2F-1 Mediated Transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results demonstrate that modulation of E2F activity plays a critical role in p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, p63 and p73 have overlapping functions to p53 and can regulate p53 gene transcription.")
       (:PMID . "18215742") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Using several p53 inactivation models we demonstrated that inactivation of p53 upregulated TAp73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although less p53 induction was observed in TP53 mutant Daoy cells, increased TP73 levels including DeltaN ' p73 were detected.")
       (:PMID . "17626635") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "392") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:ID . "baa86589-6609-4fb7-a494-9babcf0fcca1"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "p73") (:+UP+ . "O15350") (:+HGNC+ . "12003"))
      (:NAME . "TP73"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "1a28cb1f-f340-4c22-8a2c-2c2a67371993")
     (:EVIDENCE
      ((:TEXT
        . "Because dimer formation between mutant and wild type p53 increases p53 stability and inactivates wtp53 XREF_BIBR, increased p73 levels in these cells suggest that p53 inactivation by point mutation may also induce p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To further demonstrate the specific role of E2F-1 in p53 inactivation regulated p73 transcription, we tested whether mutation of E2F binding sites abolishes p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that inactivation of p53 in MCF-7 and HCT-116 cells resulted in increased expression of TAp73, but not DNp73, which suggests that p53 inactivation-mediated-upregulation of p73 may contribute to the p73 overexpression detected in human cancers.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition to p53 knockdown and knockout, we found that inactivation of p53 by overexpression of mtp53 (G135A) led to p73 upregulation, indicating that p53 inactivation by means other than deletion and knockdown also induce p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These data suggest that p53 inactivation upregulated p73 transcription, which was independent of p53 binding.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Based on our evidence showing that p53 inactivation upregulates p73 transcription, one would expect a decrease of p73 expression in the cells transfected with wtp53.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Hence, our results not only address how p53 inactivation upregulates p73 transcription in a DNA binding independent manner but also underscores the role of pRb and E2F -1 pathway in the regulation of p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Particularly, p53 binds to a palindromic site in the TAp73 promoter, activates the promoter of TAp73, and selectively induces TAp73 transcription.")
       (:PMID . "17693405") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It was also reported that overexpression of p53 or p73 induced p73 transcription in certain cell lines XREF_BIBR.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because E2F-1 is a major transcription factor that regulates TAp73 transcription and there are multiple E2F binding sites in the proximal promoter region XREF_BIBR, XREF_BIBR, XREF_BIBR, we reasoned that modulation of E2F-1 activity might play a role in p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These include dimers between certain p53 mutants and p73 that downregulates p73 activity XREF_BIBR, XREF_BIBR; a potential interaction between p53 and the p73 promoter at the distal region XREF_BIBR; p53 mediated induction of oncogenic DNp73; and our finding that p53 inactivation upregulates p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p53 inactivation upregulates p73 transcription through E2F-1.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Taken together, our results reveal that p53 inactivation may upregulate TAp73 expression through E2F-1 mediated transcriptional regulation, which involves modulated p21 activity.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p53 Inactivation Upregulates p73 Expression through E2F-1 Mediated Transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results demonstrate that modulation of E2F activity plays a critical role in p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, p63 and p73 have overlapping functions to p53 and can regulate p53 gene transcription.")
       (:PMID . "18215742") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Using several p53 inactivation models we demonstrated that inactivation of p53 upregulated TAp73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although less p53 induction was observed in TP53 mutant Daoy cells, increased TP73 levels including DeltaN ' p73 were detected.")
       (:PMID . "17626635") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "46") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:ID . "8fe0e7c5-a2cc-4816-8239-678e7aa72b9d"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "p73") (:+UP+ . "O15350") (:+HGNC+ . "12003"))
      (:NAME . "TP73"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "1a28cb1f-f340-4c22-8a2c-2c2a67371993")
     (:EVIDENCE
      ((:TEXT
        . "Because dimer formation between mutant and wild type p53 increases p53 stability and inactivates wtp53 XREF_BIBR, increased p73 levels in these cells suggest that p53 inactivation by point mutation may also induce p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To further demonstrate the specific role of E2F-1 in p53 inactivation regulated p73 transcription, we tested whether mutation of E2F binding sites abolishes p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that inactivation of p53 in MCF-7 and HCT-116 cells resulted in increased expression of TAp73, but not DNp73, which suggests that p53 inactivation-mediated-upregulation of p73 may contribute to the p73 overexpression detected in human cancers.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition to p53 knockdown and knockout, we found that inactivation of p53 by overexpression of mtp53 (G135A) led to p73 upregulation, indicating that p53 inactivation by means other than deletion and knockdown also induce p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These data suggest that p53 inactivation upregulated p73 transcription, which was independent of p53 binding.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Based on our evidence showing that p53 inactivation upregulates p73 transcription, one would expect a decrease of p73 expression in the cells transfected with wtp53.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Hence, our results not only address how p53 inactivation upregulates p73 transcription in a DNA binding independent manner but also underscores the role of pRb and E2F -1 pathway in the regulation of p73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Particularly, p53 binds to a palindromic site in the TAp73 promoter, activates the promoter of TAp73, and selectively induces TAp73 transcription.")
       (:PMID . "17693405") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It was also reported that overexpression of p53 or p73 induced p73 transcription in certain cell lines XREF_BIBR.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because E2F-1 is a major transcription factor that regulates TAp73 transcription and there are multiple E2F binding sites in the proximal promoter region XREF_BIBR, XREF_BIBR, XREF_BIBR, we reasoned that modulation of E2F-1 activity might play a role in p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These include dimers between certain p53 mutants and p73 that downregulates p73 activity XREF_BIBR, XREF_BIBR; a potential interaction between p53 and the p73 promoter at the distal region XREF_BIBR; p53 mediated induction of oncogenic DNp73; and our finding that p53 inactivation upregulates p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p53 inactivation upregulates p73 transcription through E2F-1.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Taken together, our results reveal that p53 inactivation may upregulate TAp73 expression through E2F-1 mediated transcriptional regulation, which involves modulated p21 activity.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p53 Inactivation Upregulates p73 Expression through E2F-1 Mediated Transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results demonstrate that modulation of E2F activity plays a critical role in p53 inactivation mediated upregulation of p73 transcription.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, p63 and p73 have overlapping functions to p53 and can regulate p53 gene transcription.")
       (:PMID . "18215742") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Using several p53 inactivation models we demonstrated that inactivation of p53 upregulated TAp73 expression.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "expression_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although less p53 induction was observed in TP53 mutant Daoy cells, increased TP73 levels including DeltaN ' p73 were detected.")
       (:PMID . "17626635") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "amount_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "18") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:ID . "0108de77-54c6-4b91-953e-b63b16dd2488"))
    ((:OBJ (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:TYPE . "IncreaseAmount")
     (:SUPPORTED--BY "b04b646f-cb89-45ab-9c8e-c39ca93fb4ef")
     (:EVIDENCE
      ((:TEXT
        . "Functionally, p73, a family member of p53, activates transcription of p21- and p53 responsive genes, which participate in cell cycle control, DNA repair, and apoptosis and inhibits cell growth in a p53 like manner by inducing apoptosis or G1 cell cycle arrest XREF_BIBR, XREF_BIBR.")
       (:PMID . "19585505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "When activated, p73 signals transcription of p53 responsive genes, thereby acting as a tumor suppressor.")
       (:PMID . "22052649") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p73 activates transcription of p21- and p53 responsive genes, which participate in cell cycle control, DNA repair, apoptosis and inhibits cell growth in a p53 like manner by inducing apoptosis or G1 cell cycle arrest XREF_BIBR, XREF_BIBR.")
       (:PMID . "24820515") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Particularly, p53 binds to a palindromic site in the TAp73 promoter, activates the promoter of TAp73, and selectively induces TAp73 transcription.")
       (:PMID . "17693405") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The full length transcriptionally active form of p73 (TAp73) is normally found in the nucleus and can induce the transcription of downstream p53 target genes.")
       (:PMID . "20540768") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On the other hand p73 can activate the transcription of p53 responsive genes [XREF_BIBR].")
       (:PMID . "25954972") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1b"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Since the p53 related transcription factors p63 and p73 can modulate p53 functions and activate the transcription of some p53 target genes XREF_BIBR, XREF_BIBR, we examined the impact at the FLT1 promoter alleles using gene reporter assays and ectopic expression of p53 or of selected p63 and p73 isoforms.")
       (:PMID . "20422012") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_1"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It was also reported that overexpression of p53 or p73 induced p73 transcription in certain cell lines XREF_BIBR.")
       (:PMID . "22952705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "transcription_0"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "p73") (:+UP+ . "O15350") (:+HGNC+ . "12003"))
      (:NAME . "TP73"))
     (:ID . "9ce8456c-b31b-4ec1-b05e-7fd43fd7ca07"))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "FOXO-3-A") (:+HGNC+ . "3821") (:+NCIT+ . "C52907")
       (:+UP+ . "O43524"))
      (:NAME . "FOXO3"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "activity")
     (:SUPPORTED--BY "7140e963-741b-4cfe-b53d-7c90665ceaf0")
     (:EVIDENCE
      ((:TEXT
        . "Inactivation of FOXO3a by AKT was essential for neuroblastoma cell survival.")
       (:PMID . "23378341") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt inactivates FoxO3a which in turn influences ER expression.")
       (:PMID . "23305873") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, given that FoxO3a is inactivated by AKT in proliferating cells, it was puzzling that SOD2 expression was maintained in proliferating cells (A-S2C, 1, 6 and 9).")
       (:PMID . "24703840") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The mechanism for this resistance involves inactivation of FoxO3a by Akt which down-regulates cav-1 expression (XREF_FIG).")
       (:PMID . "23580232") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:ID . "60fc18b7-4c70-4c78-bcea-9879d43bb6c2"))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "FOXO-3-A") (:+HGNC+ . "3821") (:+NCIT+ . "C52907")
       (:+UP+ . "O43524"))
      (:NAME . "FOXO3"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "activity")
     (:SUPPORTED--BY "b663e4b5-7543-4230-8c9f-ec86b975a93c")
     (:EVIDENCE
      ((:TEXT
        . "Inactivation of FOXO3a by AKT was essential for neuroblastoma cell survival.")
       (:PMID . "23378341") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt inactivates FoxO3a which in turn influences ER expression.")
       (:PMID . "23305873") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, given that FoxO3a is inactivated by AKT in proliferating cells, it was puzzling that SOD2 expression was maintained in proliferating cells (A-S2C, 1, 6 and 9).")
       (:PMID . "24703840") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The mechanism for this resistance involves inactivation of FoxO3a by Akt which down-regulates cav-1 expression (XREF_FIG).")
       (:PMID . "23580232") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:ID . "60fc18b7-4c70-4c78-bcea-9879d43bb6c2"))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "FOXO-3-A") (:+HGNC+ . "3821") (:+NCIT+ . "C52907")
       (:+UP+ . "O43524"))
      (:NAME . "FOXO3"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "activity")
     (:SUPPORTED--BY "467ef84f-6d50-4c56-8386-cd60d366aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Inactivation of FOXO3a by AKT was essential for neuroblastoma cell survival.")
       (:PMID . "23378341") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, given that FoxO3a is inactivated by AKT in proliferating cells, it was puzzling that SOD2 expression was maintained in proliferating cells (A-S2C, 1, 6 and 9).")
       (:PMID . "24703840") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt inactivates FoxO3a which in turn influences ER expression.")
       (:PMID . "23305873") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The mechanism for this resistance involves inactivation of FoxO3a by Akt which down-regulates cav-1 expression (XREF_FIG).")
       (:PMID . "23580232") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:ID . "60fc18b7-4c70-4c78-bcea-9879d43bb6c2"))
    ((:OBJ (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "FOXO-3-A") (:+HGNC+ . "3821") (:+NCIT+ . "C52907")
       (:+UP+ . "O43524"))
      (:NAME . "FOXO3"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "activity")
     (:SUPPORTED--BY "22c549bc-b159-4919-85e7-d369385f7a5e")
     (:EVIDENCE
      ((:TEXT
        . "Inactivation of FOXO3a by AKT was essential for neuroblastoma cell survival.")
       (:PMID . "23378341") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt inactivates FoxO3a which in turn influences ER expression.")
       (:PMID . "23305873") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, given that FoxO3a is inactivated by AKT in proliferating cells, it was puzzling that SOD2 expression was maintained in proliferating cells (A-S2C, 1, 6 and 9).")
       (:PMID . "24703840") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The mechanism for this resistance involves inactivation of FoxO3a by Akt which down-regulates cav-1 expression (XREF_FIG).")
       (:PMID . "23580232") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:ID . "60fc18b7-4c70-4c78-bcea-9879d43bb6c2"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PRKCA") (:+UP+ . "P17252") (:+HGNC+ . "9393"))
      (:NAME . "PRKCA"))
     (:ID . "240e63d8-054d-485d-83fb-9b00f96eefa6"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "PRKCB") (:+UP+ . "P05771") (:+HGNC+ . "9395"))
      (:NAME . "PRKCB"))
     (:ID . "8fce4b57-a318-42d2-9990-a4c1db839812"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "507") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PRKCD") (:+UP+ . "Q05655") (:+HGNC+ . "9399"))
      (:NAME . "PRKCD"))
     (:ID . "b2d7b96b-5f62-45e6-b7c0-3fad76ac7e63"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PRKCD") (:+UP+ . "Q05655") (:+HGNC+ . "9399"))
      (:NAME . "PRKCD"))
     (:ID . "86305a6a-8221-4bfb-88c3-4211d446b89f"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "PRKCE") (:+UP+ . "Q02156") (:+HGNC+ . "9401"))
      (:NAME . "PRKCE"))
     (:ID . "a453a6ff-5dd4-4586-8e4f-09f033fc5a65"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "PRKCG") (:+UP+ . "P05129") (:+HGNC+ . "9402"))
      (:NAME . "PRKCG"))
     (:ID . "bf4087d1-e478-4205-9428-a66eff5ed62a"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "PRKCH") (:+UP+ . "P24723") (:+HGNC+ . "9403"))
      (:NAME . "PRKCH"))
     (:ID . "d4468bb3-4dc6-405a-9829-c75476f2afcd"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "PRKCI") (:+UP+ . "P41743") (:+HGNC+ . "9404"))
      (:NAME . "PRKCI"))
     (:ID . "2c69523e-c519-4947-a2e2-437e61096f3a"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "90") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "538") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "676") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "695") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PRKCQ") (:+UP+ . "Q04759") (:+HGNC+ . "9410"))
      (:NAME . "PRKCQ"))
     (:ID . "381000b1-ac4a-42f3-ae7c-750f2024a2cd"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "410") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PRKCZ") (:+UP+ . "Q05513") (:+HGNC+ . "9412"))
      (:NAME . "PRKCZ"))
     (:ID . "aeb85cb3-5eaa-4048-8733-387dcadbdcd3"))
    ((:OBJ (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:TYPE . "Inhibition") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT
        . "Taken from CST pathway map, G-protein Coupled Receptor Signaling to MAPK/ERK  www.cellsignal.com.")
       (:PMID . "11431032") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyDecreases_cat_p_HGNC_RASA1")
       (:TEXT . "From CST pathway map for GPCR Signaling to ERK. ")
       (:PMID . "16890451") (:SOURCE--API . "bel")))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "PRKD3") (:+UP+ . "O94806") (:+HGNC+ . "9408"))
      (:NAME . "PRKD3"))
     (:ID . "3de43763-1d97-4506-ad10-77808f2a7183"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "O43524") (:+HGNC+ . "3821")) (:NAME . "FOXO3"))
     (:SUPPORTED--BY "b7752bf2-bf69-46d3-8f1a-a8dc623a8814"
      "7be85629-1dbb-48d5-aaee-d26e1a58f33c"
      "722bfd65-b8e1-4981-84ff-5b38b6392d86"
      "8fd9b89e-b547-4ef1-b391-5309a80b4f78"
      "6fde9737-2e38-4d7b-82eb-33b4112f2b1b"
      "c72805ce-5398-4ce7-bfc1-560f39139191"
      "652e2a73-9691-4b6e-987f-4db46bd17da7"
      "ff94ebce-6c96-4564-bac0-ff4697a4b6c5"
      "bfd8642f-2d41-485b-a345-aec96180a7fa")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_22e3a52fda0cf8e1faff255eec6d8e1f")
       (:PMID . "11953455") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_22e3a52fda0cf8e1faff255eec6d8e1f")
       (:PMID . "10102273") (:SOURCE--API . "biopax")))
     (:POSITION . "315")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "74035551-68b0-40d0-9957-58057dd8a106"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "O43524") (:+HGNC+ . "3821")) (:NAME . "FOXO3"))
     (:SUPPORTED--BY "b7752bf2-bf69-46d3-8f1a-a8dc623a8814"
      "b80c0596-344e-4063-a2b9-aa475198f727"
      "bb115bad-67ad-4118-a2a3-4f7a5755f607"
      "b6acb268-32f8-4fe4-98f1-c3bf472dd379"
      "92d9c202-7e99-4994-8ac0-3c32ebd440d6"
      "c72805ce-5398-4ce7-bfc1-560f39139191"
      "393d27e8-6be0-42ee-b92f-b59529610bb6"
      "ff94ebce-6c96-4564-bac0-ff4697a4b6c5"
      "bfd8642f-2d41-485b-a345-aec96180a7fa")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_22e3a52fda0cf8e1faff255eec6d8e1f")
       (:PMID . "11953455") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_22e3a52fda0cf8e1faff255eec6d8e1f")
       (:PMID . "10102273") (:SOURCE--API . "biopax")))
     (:POSITION . "315")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "e530f3cd-f44f-4c12-83ce-a05ae28a085a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "344f37d1-c2fc-4bb5-ace9-83fc6b7b9b11"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "5a85624b-b67d-4eca-8a00-886a64928214"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "12a6b05d-8f69-458f-9031-b5c4955c6fb3"
      "b41e32ef-0573-4385-9157-515bac1512ed"
      "f38a4cfc-102e-450b-86ff-b86deb88878c"
      "bc3d101f-ca1c-4da2-a580-00dea05f4363"
      "73c8e338-85c5-40c2-a014-4a1153b3d0ae"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70b00a451f650f77bdaaea7ff0a29c70")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_be61a3a8ad3428052aeeef78ff800ed1")
       (:PMID . "15207235") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_be61a3a8ad3428052aeeef78ff800ed1")
       (:PMID . "10729337") (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "e8749d64-19f1-45ae-9333-0566cbcdbd7b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "a133659e-7b45-44ee-8255-f30129171963"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "98e42a67-205f-441a-a86b-22235840c5d2"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "63d9fd9a-d103-4344-adbe-9c230032a0ff"
      "32cfd9cb-da80-42de-840e-f0960cce9699"
      "3e558635-4913-4e41-b922-db880b819964"
      "7e7ca0c9-c449-418e-81d0-4fcaff14aaea"
      "60adc9f5-d250-4305-95ef-9c03c6f0df43"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70b00a451f650f77bdaaea7ff0a29c70")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_be61a3a8ad3428052aeeef78ff800ed1")
       (:PMID . "15207235") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_be61a3a8ad3428052aeeef78ff800ed1")
       (:PMID . "10729337") (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "3d1064c9-040a-4168-9098-7129d9c31105"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "0c3defb4-0500-48a8-b740-25905eef5cc0"
      "41fe8b1a-38c0-4215-8408-8de26c9e6028"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "e5725e26-8af7-4e04-9781-b4b2f8c9b410"
      "7f4f6749-0550-4a36-ab89-4f4b0e2c39cc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_de15d3c0f8220b6da90db12acbe7d72a")
       (:PMID . "12048182") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_de15d3c0f8220b6da90db12acbe7d72a")
       (:PMID . "10576742") (:SOURCE--API . "biopax")))
     (:POSITION . "259")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "bc3df85f-be14-487b-9e0a-b4a6549104c3"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "0c3defb4-0500-48a8-b740-25905eef5cc0"
      "aa42cd39-c4d9-48b1-b7b7-4d7d85de9df2"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "b1627065-3847-4ff3-8735-99641096f881"
      "5878c993-969e-4bcb-9108-d528589626f3")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_de15d3c0f8220b6da90db12acbe7d72a")
       (:PMID . "12048182") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_de15d3c0f8220b6da90db12acbe7d72a")
       (:PMID . "10576742") (:SOURCE--API . "biopax")))
     (:POSITION . "259")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "2d8d1e20-7b57-4672-aefa-a34628269baa"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "599b4647-35a0-4220-aede-c76b6befb7d3"
      "b28b8904-16f2-4735-94cd-b0a0175d31dc"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "a950ec98-3882-4735-8a62-508ddba18532"
      "23d25a35-f836-4e09-ae1b-9a10bd1e0d7a"
      "137494ac-fc40-4499-8bc7-4e942ab34d01"
      "169c9bfe-f613-40f7-9ee5-bf28e94ecee3"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_476f89b63f406beae0b2e1b5a99c1945")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffeec5e6d73298dda8cbbb5ed81b9d3b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "21")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "80d0e0a2-e8fe-4362-b32c-dcf8064700f8"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "f9204a1d-1520-4e1e-96d8-178c5e2307a6"
      "bfbdee47-39d0-477e-9fcd-c11b3b8e1648"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "a950ec98-3882-4735-8a62-508ddba18532"
      "ece48199-d9ba-4694-b654-f2373ad37f82"
      "5912428c-60df-4c6c-8c51-8b12b3d61bc5"
      "b1435c36-3749-422b-994b-c4143c6232d8"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_476f89b63f406beae0b2e1b5a99c1945")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffeec5e6d73298dda8cbbb5ed81b9d3b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "21")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "6370bf3a-4e21-4cbf-9491-6b98eaa4216c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q00987") (:+HGNC+ . "6973")) (:NAME . "MDM2"))
     (:SUPPORTED--BY "b514bde9-b0ed-44e0-af91-bcc5f9cce69b"
      "7959e20d-649a-4bd6-93d0-b63bbc6b94a4"
      "5a6bc0ac-1d27-432e-b526-5ef352871f0d"
      "099f75e1-c863-467b-9430-b840e7cf96b8"
      "174e2a12-386f-4ec1-b626-e4193aea8dec"
      "335652e2-3a42-4580-b6c0-5ba29778fa9e"
      "3e52e3cd-ff68-411b-955b-829b597b529e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7e43af9ae371206777faed12dc1f4eb1")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f546e4153f23af95fbb03284ba39c29d")
       (:SOURCE--API . "biopax")))
     (:POSITION . "166")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "8fde4d1b-8323-480c-ae57-5cbc22d46a8d"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q00987") (:+HGNC+ . "6973")) (:NAME . "MDM2"))
     (:SUPPORTED--BY "99703ebe-1035-44f4-ac9f-16ae30c2be9b"
      "7959e20d-649a-4bd6-93d0-b63bbc6b94a4"
      "3b53de5b-0e33-437c-b73e-45da178fe572"
      "9d522042-0f65-41d1-81a2-97a7edfcd00d"
      "174e2a12-386f-4ec1-b626-e4193aea8dec"
      "a9fe7587-5e29-4ba8-9de1-7afa912a2948"
      "b6bf662e-0c97-4375-8d5e-e762e800d296")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7e43af9ae371206777faed12dc1f4eb1")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f546e4153f23af95fbb03284ba39c29d")
       (:SOURCE--API . "biopax")))
     (:POSITION . "166")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "ef2c53cd-c5a3-4f8c-8c44-49db21a1fadf"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P42345") (:+HGNC+ . "3942")) (:NAME . "MTOR"))
     (:SUPPORTED--BY "732d0157-1176-4a5c-ac21-b340d3cb72ce"
      "3f164d35-7b34-4585-bbd6-884b979e4395"
      "04751282-f4e6-4d44-8bd7-6629f1923ef7"
      "c3fd1005-b622-4721-8f84-11a8568461ca"
      "e010a957-e1c4-4e3c-bbcc-d299ba03f7a5"
      "e20ea4ea-43a4-4fed-b58d-5517f73f2874"
      "5ce75012-303c-4ea2-bd38-3257f0f7c4be"
      "6e81ae92-9a86-4952-82c9-fa353626e87a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_48eaea031594db43a49e41b2591e7693")
       (:PMID . "15051500") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_39dc0c6bd648157018567abb15a4ef21")
       (:PMID . "1614535") (:SOURCE--API . "biopax")))
     (:POSITION . "2448")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "796fcc98-f9d5-4a6c-9c1c-f02551beb69c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P42345") (:+HGNC+ . "3942")) (:NAME . "MTOR"))
     (:SUPPORTED--BY "af7a90ea-278b-44e6-bc44-d54b0a37055d"
      "3f164d35-7b34-4585-bbd6-884b979e4395"
      "04751282-f4e6-4d44-8bd7-6629f1923ef7"
      "c3fd1005-b622-4721-8f84-11a8568461ca"
      "6d2ec662-6dc2-4985-8012-3e83e53f54d8"
      "e20ea4ea-43a4-4fed-b58d-5517f73f2874"
      "814db087-f950-440c-a5b3-f49f4a815335"
      "4c56cf74-4b79-4fee-93e6-c7cf9f14ddf0")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_48eaea031594db43a49e41b2591e7693")
       (:PMID . "15051500") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_39dc0c6bd648157018567abb15a4ef21")
       (:PMID . "1614535") (:SOURCE--API . "biopax")))
     (:POSITION . "2448")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "b365b7d4-8f75-493b-93a2-a7449ffa48c3"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P49815") (:+HGNC+ . "12363")) (:NAME . "TSC2"))
     (:SUPPORTED--BY "db804c3c-b9df-4531-9f26-e988764cfe9d"
      "711a1526-8822-42a0-a8e0-75f26d13897e"
      "1f93095d-57a0-4f05-94f7-d223813f1f05"
      "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef"
      "96b59dd8-76ff-4174-a5a2-824e7268f057"
      "8ef31dbb-5c8a-4a9e-b05d-8de64b02ac1e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ccdea689425c21534b91c18153be663f")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ac9ba66b92f1c74c88d4bc96b81fbc36")
       (:SOURCE--API . "biopax")))
     (:POSITION . "1462")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "77de5a73-61dd-4ecb-87c6-9d638cce6dd2"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P49815") (:+HGNC+ . "12363")) (:NAME . "TSC2"))
     (:SUPPORTED--BY "fba26c7f-81d6-47e4-959e-3fb9f41c693b"
      "711a1526-8822-42a0-a8e0-75f26d13897e"
      "1f93095d-57a0-4f05-94f7-d223813f1f05"
      "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef"
      "81e1637b-b04d-4210-9ce6-6542b49f4f8a"
      "8ef31dbb-5c8a-4a9e-b05d-8de64b02ac1e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ccdea689425c21534b91c18153be663f")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ac9ba66b92f1c74c88d4bc96b81fbc36")
       (:SOURCE--API . "biopax")))
     (:POSITION . "1462")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "28597571-adef-40f9-b305-ed015a1bceec"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "b4bcefa8-5825-404c-9e20-1f9a11bcb142"
      "5757b142-0a4a-4a74-be36-db6f3c483dac"
      "f4a7bddf-18f8-4dcb-9a07-3c49f93739b0"
      "93479685-470d-4066-be3b-df902d8c2ae9")
     (:EVIDENCE
      ((:TEXT
        . "Also, coimmunoprecipitation experiments showed that PDK1 did not associate with any of the three TCL1 family members, suggesting that there is no direct TCL1 induced Akt, TCL1, and PDK1 complex formation in vivo.Our data show that TCL1 induces Akt kinase activity dependent phosphorylation of Akt on both Ser 473 and Thr 308.")
       (:PMID . "10983986") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "IR is known to mediate a rapid activation of Akt [XREF_BIBR] and recent studies showed that ATM can function as an activating Akt kinase that phosphorylates rapidly Akt-S473 [XREF_BIBR].")
       (:PMID . "22607554") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Whereas mTORC2 directly phosphorylates AKT, activated p70S6K phosphorylates and negatively regulates insulin receptor substrate 1.13 As insulin receptor substrate 1 is an important upstream activator of PI3K-AKT, phosphorylation of p70S6K, thus, evokes a physiological negative feedback loop toward AKT.5 Phosphorylation of AKT at Ser 473 was slightly attenuated in 3T3 cells expressing active mTOR mutants compared with that in those expressing the wild-type protein, consistent with a previous observation.8 Transforming activity of mTOR mutants is rapamycin sensitive.")
       (:PMID . "26432419") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, src family tyrosine kinases are important regulators of Akt signalling in infection.-induced EGFR activation mediates Akt Ser473 phosphorylation in several cell lines ().")
       (:PMID . "25194338") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "According to our current findings, this model has to be extended by the Akt pathway.Phosphorylation of Akt at serine 473 results in the activation of Akt ().")
       (:PMID . "22280833") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PDK1 XREF_BIBR phosphorylates AKT at T308, and mTORC2 XREF_BIBR as well as other potential PDK2s phosphorylates AKT at S473.")
       (:PMID . "20361045") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in XREF_FIG, overexpressing miR-519a significantly increased, but silencing miR-519a decreased, the Akt activity and the expression of phosphorylated Akt (Ser473) in HCC cells (P < 0.05).")
       (:PMID . "26708293") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "473")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "35de4f66-bf2f-4524-9e06-e1888244f58f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "b4bcefa8-5825-404c-9e20-1f9a11bcb142"
      "5757b142-0a4a-4a74-be36-db6f3c483dac"
      "198d7586-dd52-46d1-93c7-1e468518c8db"
      "93479685-470d-4066-be3b-df902d8c2ae9")
     (:EVIDENCE
      ((:TEXT
        . "Also, coimmunoprecipitation experiments showed that PDK1 did not associate with any of the three TCL1 family members, suggesting that there is no direct TCL1 induced Akt, TCL1, and PDK1 complex formation in vivo.Our data show that TCL1 induces Akt kinase activity dependent phosphorylation of Akt on both Ser 473 and Thr 308.")
       (:PMID . "10983986") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "IR is known to mediate a rapid activation of Akt [XREF_BIBR] and recent studies showed that ATM can function as an activating Akt kinase that phosphorylates rapidly Akt-S473 [XREF_BIBR].")
       (:PMID . "22607554") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Whereas mTORC2 directly phosphorylates AKT, activated p70S6K phosphorylates and negatively regulates insulin receptor substrate 1.13 As insulin receptor substrate 1 is an important upstream activator of PI3K-AKT, phosphorylation of p70S6K, thus, evokes a physiological negative feedback loop toward AKT.5 Phosphorylation of AKT at Ser 473 was slightly attenuated in 3T3 cells expressing active mTOR mutants compared with that in those expressing the wild-type protein, consistent with a previous observation.8 Transforming activity of mTOR mutants is rapamycin sensitive.")
       (:PMID . "26432419") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, src family tyrosine kinases are important regulators of Akt signalling in infection.-induced EGFR activation mediates Akt Ser473 phosphorylation in several cell lines ().")
       (:PMID . "25194338") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "According to our current findings, this model has to be extended by the Akt pathway.Phosphorylation of Akt at serine 473 results in the activation of Akt ().")
       (:PMID . "22280833") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PDK1 XREF_BIBR phosphorylates AKT at T308, and mTORC2 XREF_BIBR as well as other potential PDK2s phosphorylates AKT at S473.")
       (:PMID . "20361045") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in XREF_FIG, overexpressing miR-519a significantly increased, but silencing miR-519a decreased, the Akt activity and the expression of phosphorylated Akt (Ser473) in HCC cells (P < 0.05).")
       (:PMID . "26708293") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "473")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "49f83fa6-ee07-46ae-92e3-3eb4acc495b7"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "b0cbde8b-46e3-4757-819f-18c35f74fbb4"
      "2d0c1b00-41a3-41a5-b9c5-41366e2ba7ec"
      "93479685-470d-4066-be3b-df902d8c2ae9"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "PDK1 XREF_BIBR phosphorylates AKT at T308, and mTORC2 XREF_BIBR as well as other potential PDK2s phosphorylates AKT at S473.")
       (:PMID . "20361045") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In the case of AKT, the interaction of the pleckstrin homology (PH) domain of AKT with membrane bound PIP 3 confers a conformational change in AKT which allows PDK1 to phosphorylate AKT at residue threonine 308 (XREF_BIBR - XREF_BIBR).")
       (:PMID . "19602588") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "308")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "9427e502-eae4-4a48-aaa7-a6f7066f1d2e"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "b0cbde8b-46e3-4757-819f-18c35f74fbb4"
      "2d0c1b00-41a3-41a5-b9c5-41366e2ba7ec"
      "93479685-470d-4066-be3b-df902d8c2ae9"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "PDK1 XREF_BIBR phosphorylates AKT at T308, and mTORC2 XREF_BIBR as well as other potential PDK2s phosphorylates AKT at S473.")
       (:PMID . "20361045") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In the case of AKT, the interaction of the pleckstrin homology (PH) domain of AKT with membrane bound PIP 3 confers a conformational change in AKT which allows PDK1 to phosphorylate AKT at residue threonine 308 (XREF_BIBR - XREF_BIBR).")
       (:PMID . "19602588") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "308")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "cc2fe5be-c553-4591-92ca-12e39546b761"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "4832d2c8-cdfd-42a1-a711-d6a23bbb59b6"
      "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_EIF4EBP1_pmod_P_S")
       (:TEXT
        . "At least two Akt substrates, Bad  and the translation inhibitor 4E-BP1, are also phosphorylated by Pim-2")
       (:PMID . "12897050") (:SOURCE--API . "bel")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "7aaff534-3d23-4ea3-b760-5de38af8ac8e"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "7e749fe3-a74d-490f-a574-0519dba2f39f"
      "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_EIF4EBP1_pmod_P_S")
       (:TEXT
        . "At least two Akt substrates, Bad  and the translation inhibitor 4E-BP1, are also phosphorylated by Pim-2")
       (:PMID . "12897050") (:SOURCE--API . "bel")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "67b9a466-a628-4663-82e9-c4a769cf69b5"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "ELK-1") (:+HGNC+ . "3321") (:+NCIT+ . "C18288")
       (:+UP+ . "P19419"))
      (:NAME . "ELK1"))
     (:SUPPORTED--BY "71e84804-8b59-4792-85c9-69e7caa8f847")
     (:EVIDENCE
      ((:TEXT
        . "The PI3K and Akt pathway did not directly phosphorylate the Elk-1 but it played a major role in the nuclear localization of phosphorylated ERK1/2 and Elk-1.")
       (:PMID . "22085529") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, Elk-1 has been implicated in protecting cells from apoptosis (), and downregulating apoptosis associated genes (), thereby mediating cell survival, and Akt dependent phosphorylation of Elk-1 has been shown to be important for proliferation of glioblastoma cells (; Mut and Kurnaz, unpublished data).")
       (:PMID . "19013529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The PI3K and Akt pathway did not directly phosphorylate the Elk-1 but it played a major role in the nuclear localization of phosphorylated ERK1/2 and Elk-1.")
       (:PMID . "22085529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "e84243f8-4b3d-4240-b292-804bccdae0d9"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "ELK-1") (:+HGNC+ . "3321") (:+NCIT+ . "C18288")
       (:+UP+ . "P19419"))
      (:NAME . "ELK1"))
     (:SUPPORTED--BY "71e84804-8b59-4792-85c9-69e7caa8f847")
     (:EVIDENCE
      ((:TEXT
        . "The PI3K and Akt pathway did not directly phosphorylate the Elk-1 but it played a major role in the nuclear localization of phosphorylated ERK1/2 and Elk-1.")
       (:PMID . "22085529") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, Elk-1 has been implicated in protecting cells from apoptosis (), and downregulating apoptosis associated genes (), thereby mediating cell survival, and Akt dependent phosphorylation of Elk-1 has been shown to be important for proliferation of glioblastoma cells (; Mut and Kurnaz, unpublished data).")
       (:PMID . "19013529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The PI3K and Akt pathway did not directly phosphorylate the Elk-1 but it played a major role in the nuclear localization of phosphorylated ERK1/2 and Elk-1.")
       (:PMID . "22085529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "e84243f8-4b3d-4240-b292-804bccdae0d9"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P03372") (:+HGNC+ . "3467")) (:NAME . "ESR1"))
     (:SUPPORTED--BY "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d"
      "3260772b-9084-446c-bf3c-299d15c29a67")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "AKT overexpression increased ERalpha S167 phosphorylation and reduced tamoxifen sensitivity, whereas inhibition of AKT using RNAi directed toward AKT decreased ERalpha S167 phosphorylation and restored tamoxifen sensitivity.")
       (:PMID . "25597633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1de6c272b2bb09c816068d3e533c56c6")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT . "7838153;9528769;11432835;11139588") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT
        . "Coexpression of wild-type ER-alpha and the dominant negative Akt mutant in COS-1 cells also blocked the growth factor-stimulated activation of ER-alpha, but coexpression of the wild-type receptor with the constitutively active Akt mutant increased ER-alpha activity. Receptor activation was blocked by an antiestrogen. Studies using mutants of ER-alpha demonstrated that Akt increased estrogen receptor activity through the amino-terminal activation function-1 (AF-1). Serines S104 S106, S118, and S167 appear to play a role in the activation of ER-alpha by Akt.")
       (:PMID . "11108261") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT
        . "Cyclooxygenase-2 (COX-2) antagonists, by blocking prostaglandin production, might inhibit this pathway 149.")
       (:PMID . "12635173") (:SOURCE--API . "bel"))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Indeed, it has been shown that AKT phosphorylates the Ser167 residue of ER and increases its transcriptional activity, resulting in the preferential growth of ER positive cells in the presence of PIK3CA mutations.")
       (:PMID . "22640628") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a4fd052f-18a0-4e2a-8945-754e39426339"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P03372") (:+HGNC+ . "3467")) (:NAME . "ESR1"))
     (:SUPPORTED--BY "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d"
      "52e118cf-431d-4eb7-a345-6ea1ab114c32")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "AKT overexpression increased ERalpha S167 phosphorylation and reduced tamoxifen sensitivity, whereas inhibition of AKT using RNAi directed toward AKT decreased ERalpha S167 phosphorylation and restored tamoxifen sensitivity.")
       (:PMID . "25597633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1de6c272b2bb09c816068d3e533c56c6")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT . "7838153;9528769;11432835;11139588") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT
        . "Coexpression of wild-type ER-alpha and the dominant negative Akt mutant in COS-1 cells also blocked the growth factor-stimulated activation of ER-alpha, but coexpression of the wild-type receptor with the constitutively active Akt mutant increased ER-alpha activity. Receptor activation was blocked by an antiestrogen. Studies using mutants of ER-alpha demonstrated that Akt increased estrogen receptor activity through the amino-terminal activation function-1 (AF-1). Serines S104 S106, S118, and S167 appear to play a role in the activation of ER-alpha by Akt.")
       (:PMID . "11108261") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT
        . "Cyclooxygenase-2 (COX-2) antagonists, by blocking prostaglandin production, might inhibit this pathway 149.")
       (:PMID . "12635173") (:SOURCE--API . "bel"))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Indeed, it has been shown that AKT phosphorylates the Ser167 residue of ER and increases its transcriptional activity, resulting in the preferential growth of ER positive cells in the presence of PIK3CA mutations.")
       (:PMID . "22640628") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a4fd052f-18a0-4e2a-8945-754e39426339"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04792") (:+HGNC+ . "5246")) (:NAME . "HSPB1"))
     (:SUPPORTED--BY "f33453d8-5ec9-44ba-8064-e14fbeddd738"
      "ebf6ddf8-0747-4810-8f6b-63ab0edf7a4a"
      "5393ddd5-b889-4c51-af2a-abd7746fc71b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_HSPB1_pmod_P_S_82")
       (:TEXT . "93076920;15302935;16097034;15728188;1332886;1730670;17081983")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75cd2af0b92fb0699413f99c6e27fbdc")
       (:SOURCE--API . "biopax")))
     (:POSITION . "82")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "536c2875-9886-4186-b03b-b065fda246c5"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04792") (:+HGNC+ . "5246")) (:NAME . "HSPB1"))
     (:SUPPORTED--BY "f33453d8-5ec9-44ba-8064-e14fbeddd738"
      "ebf6ddf8-0747-4810-8f6b-63ab0edf7a4a"
      "5393ddd5-b889-4c51-af2a-abd7746fc71b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_HSPB1_pmod_P_S_82")
       (:TEXT . "93076920;15302935;16097034;15728188;1332886;1730670;17081983")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_75cd2af0b92fb0699413f99c6e27fbdc")
       (:SOURCE--API . "biopax")))
     (:POSITION . "82")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "08340727-268d-4425-925f-224f0b79b34a"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "18 As expected, CP724714 inhibited phosphorylation of ERK and pERK and AKT and pAKT (XREF_FIG).")
       (:PMID . "24763051") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT inhibition increases phosphorylation of EGFR at Tyr 1068 and phosphorylation of ERK in MCF10A cells.")
       (:PMID . "23757022") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Of interest, we found that overexpression of RhoU correlates with an increased phosphorylation of JNK and ERK (XREF_FIG) but not PLCgamma or AKT on EGF stimulation (Supplemental Figure S3F).")
       (:PMID . "21508312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the latter evodiamine caused increased ERK phosphorylation and reduced insulin stimulated phosphorylation of Akt, which were prevented by the MEK inhibitor PD98059.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Immunoblotting lysates of H441 cells treated with cediranib, MK2206 (AKT inhibitor) or AZD6244 (MEK inhibitor) for 24 h showed that MK2206 significantly reduced AKT phosphorylation and AZD6244 reduced p42/44 MAPK phosphorylation and, to a lesser extent, AKT phosphorylation (XREF_FIG).")
       (:PMID . "26179332") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, Akt1 mutant cells do not show any appreciable increase in phosphorylation of Erk1 and Erk2 compared to PIK3CA knock in clones (XREF_FIG).")
       (:PMID . "20101210") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:FOUND--BY . "Phosphorylation_syntax_1a_noun") (:TISSUE) (:LOCATION)
        (:CELL--LINE "cellosaurus:CVCL_0598") (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Effect of Akt knock-down by siRNA on H. pylori induced phosphorylation of GSK3, PDK1 and mitogen activated protein kinase.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, constitutively active Akt1 has been reported to suppress ERK activity downstream of Raf and MEK and independent of ERK phosphorylation (XREF_BIBR).")
       (:PMID . "16365168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 phosphorylation was reduced not only by MAPK pathway inhibitors but also by PI3K and mTOR inhibitors; when PI3K was inhibited, ERK phosphorylation could be induced by microinjected activated Akt, indicating important cross-talk between the PI3K and ERK1/2 pathways.")
       (:PMID . "15242975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "48ca910f-e82f-4c1e-b16f-f8f966d982aa"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "18 As expected, CP724714 inhibited phosphorylation of ERK and pERK and AKT and pAKT (XREF_FIG).")
       (:PMID . "24763051") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT inhibition increases phosphorylation of EGFR at Tyr 1068 and phosphorylation of ERK in MCF10A cells.")
       (:PMID . "23757022") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Of interest, we found that overexpression of RhoU correlates with an increased phosphorylation of JNK and ERK (XREF_FIG) but not PLCgamma or AKT on EGF stimulation (Supplemental Figure S3F).")
       (:PMID . "21508312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the latter evodiamine caused increased ERK phosphorylation and reduced insulin stimulated phosphorylation of Akt, which were prevented by the MEK inhibitor PD98059.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Immunoblotting lysates of H441 cells treated with cediranib, MK2206 (AKT inhibitor) or AZD6244 (MEK inhibitor) for 24 h showed that MK2206 significantly reduced AKT phosphorylation and AZD6244 reduced p42/44 MAPK phosphorylation and, to a lesser extent, AKT phosphorylation (XREF_FIG).")
       (:PMID . "26179332") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, Akt1 mutant cells do not show any appreciable increase in phosphorylation of Erk1 and Erk2 compared to PIK3CA knock in clones (XREF_FIG).")
       (:PMID . "20101210") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:FOUND--BY . "Phosphorylation_syntax_1a_noun") (:TISSUE) (:LOCATION)
        (:CELL--LINE "cellosaurus:CVCL_0598") (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Effect of Akt knock-down by siRNA on H. pylori induced phosphorylation of GSK3, PDK1 and mitogen activated protein kinase.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, constitutively active Akt1 has been reported to suppress ERK activity downstream of Raf and MEK and independent of ERK phosphorylation (XREF_BIBR).")
       (:PMID . "16365168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 phosphorylation was reduced not only by MAPK pathway inhibitors but also by PI3K and mTOR inhibitors; when PI3K was inhibited, ERK phosphorylation could be induced by microinjected activated Akt, indicating important cross-talk between the PI3K and ERK1/2 pathways.")
       (:PMID . "15242975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "ab786613-31e5-470d-9e48-85371548fded"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "18 As expected, CP724714 inhibited phosphorylation of ERK and pERK and AKT and pAKT (XREF_FIG).")
       (:PMID . "24763051") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT inhibition increases phosphorylation of EGFR at Tyr 1068 and phosphorylation of ERK in MCF10A cells.")
       (:PMID . "23757022") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the latter evodiamine caused increased ERK phosphorylation and reduced insulin stimulated phosphorylation of Akt, which were prevented by the MEK inhibitor PD98059.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, constitutively active Akt1 has been reported to suppress ERK activity downstream of Raf and MEK and independent of ERK phosphorylation (XREF_BIBR).")
       (:PMID . "16365168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Effect of Akt knock-down by siRNA on H. pylori induced phosphorylation of GSK3, PDK1 and mitogen activated protein kinase.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Of interest, we found that overexpression of RhoU correlates with an increased phosphorylation of JNK and ERK (XREF_FIG) but not PLCgamma or AKT on EGF stimulation (Supplemental Figure S3F).")
       (:PMID . "21508312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Immunoblotting lysates of H441 cells treated with cediranib, MK2206 (AKT inhibitor) or AZD6244 (MEK inhibitor) for 24 h showed that MK2206 significantly reduced AKT phosphorylation and AZD6244 reduced p42/44 MAPK phosphorylation and, to a lesser extent, AKT phosphorylation (XREF_FIG).")
       (:PMID . "26179332") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, Akt1 mutant cells do not show any appreciable increase in phosphorylation of Erk1 and Erk2 compared to PIK3CA knock in clones (XREF_FIG).")
       (:PMID . "20101210") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:FOUND--BY . "Phosphorylation_syntax_1a_noun") (:TISSUE) (:LOCATION)
        (:CELL--LINE "cellosaurus:CVCL_0598") (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 phosphorylation was reduced not only by MAPK pathway inhibitors but also by PI3K and mTOR inhibitors; when PI3K was inhibited, ERK phosphorylation could be induced by microinjected activated Akt, indicating important cross-talk between the PI3K and ERK1/2 pathways.")
       (:PMID . "15242975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "92e64f11-aa7f-4e09-b26f-541d08780965"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "18 As expected, CP724714 inhibited phosphorylation of ERK and pERK and AKT and pAKT (XREF_FIG).")
       (:PMID . "24763051") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT inhibition increases phosphorylation of EGFR at Tyr 1068 and phosphorylation of ERK in MCF10A cells.")
       (:PMID . "23757022") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the latter evodiamine caused increased ERK phosphorylation and reduced insulin stimulated phosphorylation of Akt, which were prevented by the MEK inhibitor PD98059.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, constitutively active Akt1 has been reported to suppress ERK activity downstream of Raf and MEK and independent of ERK phosphorylation (XREF_BIBR).")
       (:PMID . "16365168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Effect of Akt knock-down by siRNA on H. pylori induced phosphorylation of GSK3, PDK1 and mitogen activated protein kinase.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Of interest, we found that overexpression of RhoU correlates with an increased phosphorylation of JNK and ERK (XREF_FIG) but not PLCgamma or AKT on EGF stimulation (Supplemental Figure S3F).")
       (:PMID . "21508312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Immunoblotting lysates of H441 cells treated with cediranib, MK2206 (AKT inhibitor) or AZD6244 (MEK inhibitor) for 24 h showed that MK2206 significantly reduced AKT phosphorylation and AZD6244 reduced p42/44 MAPK phosphorylation and, to a lesser extent, AKT phosphorylation (XREF_FIG).")
       (:PMID . "26179332") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, Akt1 mutant cells do not show any appreciable increase in phosphorylation of Erk1 and Erk2 compared to PIK3CA knock in clones (XREF_FIG).")
       (:PMID . "20101210") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:FOUND--BY . "Phosphorylation_syntax_1a_noun") (:TISSUE) (:LOCATION)
        (:CELL--LINE "cellosaurus:CVCL_0598") (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 phosphorylation was reduced not only by MAPK pathway inhibitors but also by PI3K and mTOR inhibitors; when PI3K was inhibited, ERK phosphorylation could be induced by microinjected activated Akt, indicating important cross-talk between the PI3K and ERK1/2 pathways.")
       (:PMID . "15242975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "09854122-d299-441e-bea1-f8e67b6b24d8"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Myc") (:+UP+ . "P01106") (:+HGNC+ . "7553"))
      (:NAME . "MYC"))
     (:SUPPORTED--BY "2a130ba1-188a-4615-9842-6c35b12675c5")
     (:EVIDENCE
      ((:TEXT
        . "Consistently, recombinant Akt1 strongly phosphorylated immunoprecipitated Myc tagged DLC1, S298A, and S329A but not S567A ().")
       (:PMID . "20600027") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Akt1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "625d2fb1-501d-465d-8dcf-3b238bbf8134"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Myc") (:+UP+ . "P01106") (:+HGNC+ . "7553"))
      (:NAME . "MYC"))
     (:SUPPORTED--BY "2a130ba1-188a-4615-9842-6c35b12675c5")
     (:EVIDENCE
      ((:TEXT
        . "Consistently, recombinant Akt1 strongly phosphorylated immunoprecipitated Myc tagged DLC1, S298A, and S329A but not S567A ().")
       (:PMID . "20600027") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Akt1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "985190fd-a699-427e-a945-3710245bf89b"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "p70S6K") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "3bbd8931-e8cc-433e-becb-c02560ae6954")
     (:EVIDENCE
      ((:TEXT
        . "Unlike the parental HCT116, inhibition of AKT alone in HKh-2 and HKe-3 (wild-type RAS) cells was sufficient to inhibit phosphorylation of p70S6K, S6 and 4E-BP1, induce binding of 4E-BP1 to the eIF4E mRNA complex and inhibit cap dependent translation (XREF_FIG and XREF_SUPPLEMENTARY).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of phosphorylated mTOR (p-mTOR), phosphorylated AKT (p-AKT), p85alpha and p110gamma subunits of PI3K, phosphorylated p70S6K (p-p70S6K), phosphatase and tensin homolog (PTEN) and phosphorylated 4E-BP1 (p-4E-BP1) was examined by immunohistochemistry in 102NSCLC specimens.")
       (:PMID . "23728071") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The data presented here show that c48/80 : i) at low doses (up to 10mug/ml) augments serum induced phosphorylation of PKB and p70 in a manner sensitive to both PI 3-kinase and PKC inhibitors, ii) at higher doses induces the phosphorylation of p70 and the translocation of PKCalpha in a PI 3-kinase dependent fashion, but inhibits the phosphorylation of PKB.")
       (:PMID . "16942862") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, upstream overexpression or knockdown of Akt2 or Akt2 phosphorylation inhibition, rather than Akt1 or Akt3, resulted in striking hyperphosphorylation or dephosphorylation of mTOR, p70S6K and rpS6 (all P < 0.05), without any change in total proteins expressions.")
       (:PMID . "26490682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To investigate whether HCA 2 -induced p70S6K1 phosphorylation is mediated by ERK1/2 activation or Akt activation, U0126, a highly selective inhibitor of both MEK1 and MEK2, and Wortmannin, a highly selective inhibitor of PI3K, were analyzed for their effect on the activation of p70S6K1.")
       (:PMID . "25375133") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "While SIRT2 overexpression in 3T3-L1 preadipocytes and HeLa cells enhanced insulin induced Akt activation and phosphorylation of its downstream targets GSK3beta and p70S6 kinase, pharmacological or genetic SIRT2 inhibition causes the opposite effect.")
       (:PMID . "26538315") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, in tumor cells with coexistent KRAS and PIK3CA mutations (HCT116), inhibition of neither AKT nor MEK was sufficient to rapidly inhibit phosphorylation of p70S6K, S6, or 4E-BP1 at any of its four phosphorylation sites, although modest inhibition was observed after exposure to the MEK inhibitor for 24 h. However, combined inhibition of MEK and AKT synergistically inhibited phosphorylation of all these sites 6 h after drug exposure and profoundly by 12 h (XREF_FIG).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "79f0cab5-be7c-4029-b080-2b554b6de822"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "p70S6K") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "8ed647f4-3473-4b56-a125-d3403c1cafc7")
     (:EVIDENCE
      ((:TEXT
        . "Unlike the parental HCT116, inhibition of AKT alone in HKh-2 and HKe-3 (wild-type RAS) cells was sufficient to inhibit phosphorylation of p70S6K, S6 and 4E-BP1, induce binding of 4E-BP1 to the eIF4E mRNA complex and inhibit cap dependent translation (XREF_FIG and XREF_SUPPLEMENTARY).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of phosphorylated mTOR (p-mTOR), phosphorylated AKT (p-AKT), p85alpha and p110gamma subunits of PI3K, phosphorylated p70S6K (p-p70S6K), phosphatase and tensin homolog (PTEN) and phosphorylated 4E-BP1 (p-4E-BP1) was examined by immunohistochemistry in 102NSCLC specimens.")
       (:PMID . "23728071") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The data presented here show that c48/80 : i) at low doses (up to 10mug/ml) augments serum induced phosphorylation of PKB and p70 in a manner sensitive to both PI 3-kinase and PKC inhibitors, ii) at higher doses induces the phosphorylation of p70 and the translocation of PKCalpha in a PI 3-kinase dependent fashion, but inhibits the phosphorylation of PKB.")
       (:PMID . "16942862") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, upstream overexpression or knockdown of Akt2 or Akt2 phosphorylation inhibition, rather than Akt1 or Akt3, resulted in striking hyperphosphorylation or dephosphorylation of mTOR, p70S6K and rpS6 (all P < 0.05), without any change in total proteins expressions.")
       (:PMID . "26490682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To investigate whether HCA 2 -induced p70S6K1 phosphorylation is mediated by ERK1/2 activation or Akt activation, U0126, a highly selective inhibitor of both MEK1 and MEK2, and Wortmannin, a highly selective inhibitor of PI3K, were analyzed for their effect on the activation of p70S6K1.")
       (:PMID . "25375133") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "While SIRT2 overexpression in 3T3-L1 preadipocytes and HeLa cells enhanced insulin induced Akt activation and phosphorylation of its downstream targets GSK3beta and p70S6 kinase, pharmacological or genetic SIRT2 inhibition causes the opposite effect.")
       (:PMID . "26538315") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, in tumor cells with coexistent KRAS and PIK3CA mutations (HCT116), inhibition of neither AKT nor MEK was sufficient to rapidly inhibit phosphorylation of p70S6K, S6, or 4E-BP1 at any of its four phosphorylation sites, although modest inhibition was observed after exposure to the MEK inhibitor for 24 h. However, combined inhibition of MEK and AKT synergistically inhibited phosphorylation of all these sites 6 h after drug exposure and profoundly by 12 h (XREF_FIG).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "d19d45ef-feee-4b5b-af5b-1ca472615b8a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P84022") (:+HGNC+ . "6769")) (:NAME . "SMAD3"))
     (:SUPPORTED--BY "ec699d53-2669-4c6a-b9ba-7c3f373c1114")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "423")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "3ffc30c2-1040-4344-89cd-a04fccf28c91"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P84022") (:+HGNC+ . "6769")) (:NAME . "SMAD3"))
     (:SUPPORTED--BY "ec699d53-2669-4c6a-b9ba-7c3f373c1114")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "423")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "3ffc30c2-1040-4344-89cd-a04fccf28c91"))
    ((:SUB (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "TUBERIN") (:+HGNC+ . "12363") (:+UP+ . "P49815")
       (:+NCIT+ . "C17913"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "069699a7-541e-4f56-9f74-03612f007581"
      "cc8c1c6c-7aac-4da7-8eac-186039d9321b"
      "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef")
     (:EVIDENCE
      ((:TEXT
        . "ERK, Rsk1, and Akt all directly phosphorylate and inactivate tuberin, thereby leading to mTOR activation (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "19234517") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "TSC2 links TOR to the mitogen sensing phosphoinositide 3-kinase (PI3K) signaling pathway, as Akt (which is activated by PI3K) phosphorylates and inactivates TSC2.")
       (:PMID . "15341740") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt, Erk and other mitogen activated kinases directly phosphorylate and inactivate TSC2, leading to mTORC1 activation.")
       (:PMID . "23712032") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt directly phosphorylates and inactivates TSC2 (known as tuberin), which results in increased Rheb (ras homolog enriched in brain) activity.")
       (:PMID . "23597702") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt phosphorylated by PI-3K at Ser 473 phosphorylates and inactivates TSC2 and leads to the activation of mTOR [XREF_BIBR].")
       (:PMID . "24797175") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Activated Akt, ERK, and RSK1 kinases phosphorylate and inactivate the tumor suppressor TSC2, thus relieving its inhibitory role on mTORC1.")
       (:PMID . "19276265") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4fb60bcd-946b-4027-a73d-147251e41be8"))
    ((:SUB (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "TUBERIN") (:+HGNC+ . "12363") (:+UP+ . "P49815")
       (:+NCIT+ . "C17913"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "069699a7-541e-4f56-9f74-03612f007581"
      "6e6c8855-e541-460e-9b82-0eaca4532b6f"
      "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef")
     (:EVIDENCE
      ((:TEXT
        . "ERK, Rsk1, and Akt all directly phosphorylate and inactivate tuberin, thereby leading to mTOR activation (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "19234517") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "TSC2 links TOR to the mitogen sensing phosphoinositide 3-kinase (PI3K) signaling pathway, as Akt (which is activated by PI3K) phosphorylates and inactivates TSC2.")
       (:PMID . "15341740") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt, Erk and other mitogen activated kinases directly phosphorylate and inactivate TSC2, leading to mTORC1 activation.")
       (:PMID . "23712032") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt directly phosphorylates and inactivates TSC2 (known as tuberin), which results in increased Rheb (ras homolog enriched in brain) activity.")
       (:PMID . "23597702") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt phosphorylated by PI-3K at Ser 473 phosphorylates and inactivates TSC2 and leads to the activation of mTOR [XREF_BIBR].")
       (:PMID . "24797175") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Activated Akt, ERK, and RSK1 kinases phosphorylate and inactivate the tumor suppressor TSC2, thus relieving its inhibitory role on mTORC1.")
       (:PMID . "19276265") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4fb60bcd-946b-4027-a73d-147251e41be8"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "YB-1") (:+HGNC+ . "8014") (:+NCIT+ . "C93120")
       (:+UP+ . "P67809"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "12992216-69c2-418c-a486-1732896693c6"
      "6219f4ef-1d02-4915-a6b6-5d3e00f51eb5")
     (:EVIDENCE
      ((:TEXT
        . "While we have previously established that AKT can interact and phosphorylate YB-1 S102 [XREF_BIBR], it is unclear whether other kinases are also able to perform this function.")
       (:PMID . "19036157") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells")
       (:PMID . "15806160") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Herein, we illustrate that activated Akt binds to and phosphorylates the YB-1 cold shock domain at Ser102.")
       (:PMID . "15806160") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells.")
       (:PMID . "15806160") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Previous work in our lab showed that the serine/threonine kinase AKT phosphorylates, and thereby activates, YB-1 at S102 and that inhibiting this site disrupts nuclear trafficking XREF_BIBR, DNA binding XREF_BIBR and tumour cell growth XREF_BIBR.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "It has been demonstrated that Akt phosphorylates YB-1 at S102 and affects the anchorage independent growth of breast cancer cells [XREF_BIBR].")
       (:PMID . "21392397") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Several pathways have been shown to influence YB-1 location, including the PI3K-AKT pathway (XREF_BIBR), which phosphorylated YB-1 at Ser102.")
       (:PMID . "24335958") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells.")
       (:PMID . "15806160") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "It has been demonstrated that Akt phosphorylates YB-1 at S102 and affects the anchorage independent growth of breast cancer cells [XREF_BIBR].")
       (:PMID . "21392397") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_81d32f69f9aeb2ebe1552014cf525f73")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, the translational block of pro growth genes in a human cell model and the resistance of chicken fibroblasts to cellular transformation after YB-1 overexpression could be overcome by Akt dependent phosphorylation of YB-1 at S102.")
       (:PMID . "24461929") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This can be mediated by Akt dependent phosphorylation of YB-1 at S102, as described above.")
       (:PMID . "24461929") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "102")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "473") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "308") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a7c21331-0a0f-40cd-a39b-a43de516e187"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "YB-1") (:+HGNC+ . "8014") (:+NCIT+ . "C93120")
       (:+UP+ . "P67809"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "12992216-69c2-418c-a486-1732896693c6"
      "c4406a38-d69f-4512-b2c4-d04f2fe08747")
     (:EVIDENCE
      ((:TEXT
        . "While we have previously established that AKT can interact and phosphorylate YB-1 S102 [XREF_BIBR], it is unclear whether other kinases are also able to perform this function.")
       (:PMID . "19036157") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells")
       (:PMID . "15806160") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Herein, we illustrate that activated Akt binds to and phosphorylates the YB-1 cold shock domain at Ser102.")
       (:PMID . "15806160") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells.")
       (:PMID . "15806160") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Previous work in our lab showed that the serine/threonine kinase AKT phosphorylates, and thereby activates, YB-1 at S102 and that inhibiting this site disrupts nuclear trafficking XREF_BIBR, DNA binding XREF_BIBR and tumour cell growth XREF_BIBR.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "It has been demonstrated that Akt phosphorylates YB-1 at S102 and affects the anchorage independent growth of breast cancer cells [XREF_BIBR].")
       (:PMID . "21392397") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Several pathways have been shown to influence YB-1 location, including the PI3K-AKT pathway (XREF_BIBR), which phosphorylated YB-1 at Ser102.")
       (:PMID . "24335958") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells.")
       (:PMID . "15806160") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "It has been demonstrated that Akt phosphorylates YB-1 at S102 and affects the anchorage independent growth of breast cancer cells [XREF_BIBR].")
       (:PMID . "21392397") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_81d32f69f9aeb2ebe1552014cf525f73")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, the translational block of pro growth genes in a human cell model and the resistance of chicken fibroblasts to cellular transformation after YB-1 overexpression could be overcome by Akt dependent phosphorylation of YB-1 at S102.")
       (:PMID . "24461929") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This can be mediated by Akt dependent phosphorylation of YB-1 at S102, as described above.")
       (:PMID . "24461929") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "102")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "475") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a7c21331-0a0f-40cd-a39b-a43de516e187"))
    ((:SUB (:DB--REFS (:+UP+ . "O43524") (:+HGNC+ . "3821")) (:NAME . "FOXO3"))
     (:SUPPORTED--BY "c72805ce-5398-4ce7-bfc1-560f39139191"
      "5344b195-e9a5-4b63-9937-bf20c8597fed")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1f64411ffa48af0273b69431fa950733")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31751") (:+HGNC+ . "392")) (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "38f4b75f-02f2-45e6-8cd0-47eeaa0ea46f"))
    ((:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "3f66b4c4-3725-4180-8619-3805af661ba5"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1d7f494f39b82000c5595b09b8839623")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31751") (:+HGNC+ . "392")) (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "981ad7d9-bd4c-41a0-8618-f2ad13e59e42"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "994a0fe3-cff7-475a-b47a-e6e93219ffa2"
      "0a42b47d-c9d6-49c6-ae41-1a8116303210"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "3d4b5028-1396-4122-bc58-de71d748741e"
      "1f68cc70-fd07-4c9c-9ee1-eccc99e03a94"
      "35a4d075-3b46-4dc9-b916-dbc73f2bf7da"
      "48d45a6a-b8c2-4f0a-b38f-c4be562533ca"
      "595c27db-1d32-425d-8876-a51951f4500e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffeec5e6d73298dda8cbbb5ed81b9d3b")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_419753a4dbf61e61d04cc800f0dbf871")
       (:PMID . "9712142") (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31751") (:+HGNC+ . "392")) (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "8277bbe9-08c9-4372-bc71-96c73d575b3f"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P49815") (:+HGNC+ . "12363")) (:NAME . "TSC2"))
     (:SUPPORTED--BY "711a1526-8822-42a0-a8e0-75f26d13897e"
      "90a032ce-7cf2-4204-aec4-594cca72da1e"
      "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef"
      "47233074-73a0-45f6-b378-c1d7649d3810"
      "1f93095d-57a0-4f05-94f7-d223813f1f05"
      "455b1cf3-20f3-4065-b5c4-14ac165e1f84")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ac9ba66b92f1c74c88d4bc96b81fbc36")
       (:SOURCE--API . "biopax")))
     (:POSITION . "1462")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P31751") (:+HGNC+ . "392")) (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "1075458c-ceb1-4d0e-8c62-a9389bf6745e"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "b4bcefa8-5825-404c-9e20-1f9a11bcb142"
      "5757b142-0a4a-4a74-be36-db6f3c483dac"
      "93479685-470d-4066-be3b-df902d8c2ae9"
      "ef6af6fd-a27b-4b47-a0ea-5e127e83364e")
     (:EVIDENCE
      ((:TEXT
        . "Also, coimmunoprecipitation experiments showed that PDK1 did not associate with any of the three TCL1 family members, suggesting that there is no direct TCL1 induced Akt, TCL1, and PDK1 complex formation in vivo.Our data show that TCL1 induces Akt kinase activity dependent phosphorylation of Akt on both Ser 473 and Thr 308.")
       (:PMID . "10983986") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PDK1 XREF_BIBR phosphorylates AKT at T308, and mTORC2 XREF_BIBR as well as other potential PDK2s phosphorylates AKT at S473.")
       (:PMID . "20361045") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, src family tyrosine kinases are important regulators of Akt signalling in infection.-induced EGFR activation mediates Akt Ser473 phosphorylation in several cell lines ().")
       (:PMID . "25194338") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "IR is known to mediate a rapid activation of Akt [XREF_BIBR] and recent studies showed that ATM can function as an activating Akt kinase that phosphorylates rapidly Akt-S473 [XREF_BIBR].")
       (:PMID . "22607554") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Whereas mTORC2 directly phosphorylates AKT, activated p70S6K phosphorylates and negatively regulates insulin receptor substrate 1.13 As insulin receptor substrate 1 is an important upstream activator of PI3K-AKT, phosphorylation of p70S6K, thus, evokes a physiological negative feedback loop toward AKT.5 Phosphorylation of AKT at Ser 473 was slightly attenuated in 3T3 cells expressing active mTOR mutants compared with that in those expressing the wild-type protein, consistent with a previous observation.8 Transforming activity of mTOR mutants is rapamycin sensitive.")
       (:PMID . "26432419") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "According to our current findings, this model has to be extended by the Akt pathway.Phosphorylation of Akt at serine 473 results in the activation of Akt ().")
       (:PMID . "22280833") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in XREF_FIG, overexpressing miR-519a significantly increased, but silencing miR-519a decreased, the Akt activity and the expression of phosphorylated Akt (Ser473) in HCC cells (P < 0.05).")
       (:PMID . "26708293") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "473")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "bedadbed-4da5-41f0-abe2-c786c839698a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "9ad2bd78-0716-4811-8e24-8ee062139f2c"
      "9a413ed1-6a76-4762-88d8-cccdb104afd8"
      "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "Antibodies against Hsp90, beta-Actin, by Santa Cruz Biotechnology (Santa Cruz, CA, USA), total MAPK, phosphorylated p42/44 MAPK (Thr and Tyr), total Akt, phosphorylated Akt (Ser), total HER2 and phosphorylated HER2 (Tyr) from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "23228483") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Indeed, phosphorylation of the N-terminal serine 9 residue, a negative regulation site, of GSK3beta by Akt and PKB, is important for the inhibition of GSK3beta during insulin dependent glycogen synthesis and neuronal survival mediated through Akt.")
       (:PMID . "14636889") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt decreased ASK1 kinase activity stimulated by both oxidative stress and overexpression in 293 cells by phosphorylating a consensus Akt site at serine 83 of ASK1.")
       (:PMID . "11154276") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "2008c4cf-7b89-4ae2-9652-bf9055b0aa38"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "On membrane docking, AKT undergoes a conformational change and is phosphorylated by PDK1, thereby stimulating AKT and subsequent signaling via its downstream effectors ().")
       (:PMID . "11875759") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "On the other hand, phosphorylation of PGC-1alpha by AKT and protein kinase B (PKB), downstream of insulin signaling in the liver, is known to decrease its stability and transcriptional activity (XREF_BIBR).")
       (:PMID . "26831453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Because HST has been described to block EGF and EGFR- induced Akt and PKB phosphorylation and proliferation in vitro [20], the previously mentioned findings could be interpreted as an attempt by the HST positive cancer cells to block Akt and PKB phosphorylation.")
       (:PMID . "18592003") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Several targets of p-AKT, such as BAD, MDM2 and FOXO1, contain the RXXS motif and are phosphorylated by p-AKT [XREF_BIBR - XREF_BIBR] (XREF_TABLE).")
       (:PMID . "23315288") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The OGA inhibitors might also have additional functions that activate the upstream kinase activity of AKT, which in turn might lead to AKT phosphorylation in neuronal cells.")
       (:PMID . "22687243") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The Akt Inhibitor X selectively inhibits the phosphorylation of Akt with minimal effects on PI3K, PDK1, or SGK1 signaling.")
       (:PMID . "18159252") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These compounds inhibited Akt activation and phosphorylation of several downstream substrates of Akt in tumor cells without affecting the activities of upstream kinases (such as PI3-K and 3-phosphoinositide-dependent protein kinase 1 (PDK1, also known as PDPK1), or members of other signaling pathways such as ERK2.")
       (:PMID . "21110830") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT inhibitors either compete for the catalytic ATP binding site of AKT or block phosphorylation of AKT in allosteric fashion [XREF_BIBR].")
       (:PMID . "25186604") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "A specific inhibitor of AKT kinase, GSK690693, inhibited AKT phosphorylation (XREF_FIG) and attenuated CXCL12 induced migration by 56% (XREF_FIG).")
       (:PMID . "25897806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We first show that this dominant negative Akt (DN-Akt) eliminates Akt phosphorylation in response to Insulin Growth Factor in cells transfected with DN-Akt compared to empty vector (XREF_FIG).")
       (:PMID . "23409128") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Third, Akt phosphorylates Osterix and Akt activation prolonged the half-life of the Osterix protein.")
       (:PMID . "21777568") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Insulin stimulates phosphorylation of Akt and activated Akt exerts various biological effects such as cell growth and survival, angiogenesis, and metabolism by regulating downstream effectors [XREF_BIBR].")
       (:PMID . "26491696") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the addition of trastuzumab did not inhibit the already low level of HER2 phosphorylation or further diminish the minimally detectable HER3 phosphorylation in these cells, nor did it further decrease PI3K-Akt signaling through Akt or S6 phosphorylation.")
       (:PMID . "24451154") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt inhibition with LY294002 strongly diminished the phosphorylation of Akt and its downstream target 4E-BP1 in all five mesothelioma cell lines and control LP9 cells (XREF_FIG).")
       (:PMID . "19603014") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The data presented here show that c48/80 : i) at low doses (up to 10mug/ml) augments serum induced phosphorylation of PKB and p70 in a manner sensitive to both PI 3-kinase and PKC inhibitors, ii) at higher doses induces the phosphorylation of p70 and the translocation of PKCalpha in a PI 3-kinase dependent fashion, but inhibits the phosphorylation of PKB.")
       (:PMID . "16942862") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These observations establish that TCL1 functions as an Akt kinase coactivator, which enhances the phosphorylation and activation of Akt in vivo.We next studied the biological effects of the TCL1 and Akt interaction in vivo.Transient transfection of TCL1 into the 293 cell line resulted in a 10-fold increase of proliferative responses (, lane 2).")
       (:PMID . "10983986") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, coimmunoprecipitation experiments showed that PDK1 did not associate with any of the three TCL1 family members, suggesting that there is no direct TCL1 induced Akt, TCL1, and PDK1 complex formation in vivo.Our data show that TCL1 induces Akt kinase activity dependent phosphorylation of Akt on both Ser 473 and Thr 308.")
       (:PMID . "10983986") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Acetylation blocked binding of Akt and PDK1 to PIP (3), thereby preventing membrane localization and phosphorylation of Akt.")
       (:PMID . "21775285") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The receptor activation elicits phosphorylation of IRS-1 and AKT and PKB in CHO cells.")
       (:PMID . "23220417") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The reduced AKT activation in MCF-7PIK3CAWT cells in turn caused greatly reduced phosphorylation of known AKT target proteins, including PRAS40, FOXO 1/3, and AS160.")
       (:PMID . "23888070") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In accordance with the RPMI 8226 cell data, CXCL12 induced AKT phosphorylation and LPS suppressed CXCL12 mediated AKT phosphorylation in plasmablasts (Fig XREF_FIG and XREF_FIG).")
       (:PMID . "25897806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt was rapidly phosphorylated by glimepiride treatment (A) and antisense Akt completely inhibited glimepiride induced NO production (= 5, < 0.05; B).")
       (:PMID . "16216590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "High degrees of Akt phosphorylation and hyperactivation of the Akt signaling pathway are hallmarks of tumors in which PTEN function is impaired.")
       (:PMID . "20388916") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT phosphorylation is blocked by the inhibitors of AKT, PI3K and FGFR ().")
       (:PMID . "24662006") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Additionally, both PI3K and Akt activators, pervanadate and insulin, partly reversed the inhibition of TGF-beta1-induced Akt phosphorylation by anti-miR33a, whereas Akt specific inhibitor MK2206 did not show this reversed inhibition effect.")
       (:PMID . "24100264") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Analyses of AKT kinase inhibitors have shown that acute AKT inhibition causes a paradoxical increase of AKT phosphorylation, probably through a negative feedback loop.")
       (:PMID . "19394761") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This notion was supported by the evidence that overexpression of the PH domain of Akt inhibited endogenous Akt phosphorylation, whereas the Akt PH domain mutant retaining the PI (3,4,5) P3 binding did not.")
       (:PMID . "20081374") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, MDA-MB-231 cells expressing either helical domain or kinase domain p110alpha mutants showed elevated basal levels of Akt phosphorylation as well as enhanced EGF stimulated Akt phosphorylation.")
       (:PMID . "19903845") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, inhibiting Akt activation using the PI3K inhibitor LY294002 completely prevented EPO+IGFI-I-induced Akt phosphorylation and GSK-3beta phosphorylation compared to control (see XREF_FIG), confirming the involvement of the PI3K/Akt/GSK-3beta pathway.")
       (:PMID . "20818790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Blocking of PI3K-Akt signaling by LY294002 has been shown to reduce Akt phosphorylation at both S473 and T308 sites (XREF_BIBR).")
       (:PMID . "25304263") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, inhibition of AKT by the overexpression of kinase-dead AKT decreased the AKT phosphorylation levels, and resulted in decreased sensitivity to perifosine (XREF_FIG).")
       (:PMID . "25519148") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Active recombinant Akt readily phosphorylated Bmi1, but not a Bmi1 S316A mutant protein (XREF_FIG), and expression of a constitutively active form of Akt (myristoylated Akt) in human embryonic kidney (HEK) 293T cells resulted in phosphorylation of Bmi1 (XREF_SUPPLEMENTARY) (XREF_BIBR).")
       (:PMID . "23092893") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "XREF_BIBR) (Akt inhibitors that suppress Akt activation processes including Akt-Ser473 phosphorylation), wortmannin or LY294002 (the inhibitors of PI3K upstream of Akt) reduced both Plk1-Ser99 phosphorylation and the interaction between Plk1 and 14-3-3gamma (XREF_SUPPLEMENTARY).")
       (:PMID . "23695676") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, expression of dominant negative Akt abrogated endogenous Akt activity, Rab3D phosphorylation and GAG synthesis, whereas expression of constitutively activated Akt stimulated Rab3D phosphorylation and GAG synthesis in the absence of PDGF-BB.")
       (:PMID . "11903042") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT overexpression completely prevented PEITC induced suppression of AKT phosphorylation.")
       (:PMID . "22952709") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous studies have shown that AKT kinase inhibition increases AKT phosphorylation through negative feedback mechanisms.")
       (:PMID . "19394761") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results suggest that GRP induces c-Src dependent Akt phosphorylation but EGF stimulates Akt phosphorylation directly, without involvement of c-Src.")
       (:PMID . "17349623") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, the inhibition of Akt phosphorylation by the application of wortmannin or by a specific reduction of Akt kinase activity reduced the hEAG mRNA levels.")
       (:PMID . "17520698") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Both trastuzumab and an allosteric AKT and PKB inhibitor could decrease PKB phosphorylation.")
       (:PMID . "24952873") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It was observed that Akt substantially increased the level of 5-HT-induced Akt phosphorylation in Du145 cells and, to lesser extent in, PC-3 cells, but not in LNCaP cells.")
       (:PMID . "19926313") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of Akt phosphorylation by a PI3K inhibitor or dominant negative Akt mutant has been shown to suppress UVB induced COX-2 transcription in human keratinocytes [XREF_BIBR].")
       (:PMID . "25710724") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Increased AKT phosphorylation can also be caused by defined AKT mutations.")
       (:PMID . "22363598") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN "uberon:UBERON:0000479")
        (:FOUND--BY . "Phosphorylation_syntax_4_noun") (:TISSUE)
        (:LOCATION "go:GO:0005886") (:CELL--LINE "cellosaurus:CVCL_2585")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, we sought to analyze other biologically relevant, cancer related proteins, including downstream targets of PI3K signaling, such as phosphorylated Akt (p-Akt), mTOR (p-mTOR), and S6 ribosomal protein (p-S6).")
       (:PMID . "22674438") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in XREF_FIG, Akt siRNA, as expected, completely abolished the phosphorylation of Akt and caused a 1.4-folds increase in cleaved caspase-3 protein level.")
       (:PMID . "24699278") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylated PI3K generates the second messenger PIP3 that recruits Akt to the inner cell membrane, enabling phosphorylation of the Akt by its activating kinases, at the threonine 308 residue (by PDK1) and at the serine 473 residue [by rictor and mTOR complex in response to growth factor stimulation (XREF_BIBR) or by DNA-PK in response to DNA damage (XREF_BIBR)].")
       (:PMID . "22842582") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Next, a specific inhibitor of PI3K and Akt pathway, LY294002, was used to inhibit Akt phosphorylation in wound healing assay to test whether inhibition of Akt phosphorylation has effect on VEGF 165 -induced migration.")
       (:PMID . "24987682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Under conditions of growth factor deprivation, the PI3K and Akt pathway is inactivated, FKHRL1 is unphosphorylated at its Akt sites, and FKHRL1 accumulates in the nucleus where it may activate death genes, including the Fas ligand gene, and thereby participate actively in the process of apoptosis.When fibroblasts are exposed to IGF1 or serum, Akt is activated and catalyzes the phosphorylation of FKHRL1.")
       (:PMID . "10102273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pharmacological inhibition of Akt efficiently abrogated both basal and TGF-beta-stimulated Akt phosphorylation ().")
       (:PMID . "18323784") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "3d649cf0-f877-4489-82d3-94dcc833f487"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "4E-BP1") (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:TEXT
        . "An inhibitor of Akt diminished IGF-I-mediated phosphorylation of 4E-BP1, whereas inhibiting MAPK signalling had no such effect.")
       (:PMID . "19603014") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The functional consequences of Akt phosphorylation show activating and inactivating phosphorylations of S6 kinase and 4EBP-1, respectively, thus demonstrating activation of TORC1.")
       (:PMID . "21426932") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, blockade of Akt inhibited phosphorylation of 4E-BP1 and S6, confirming that the mTOR pathway is downstream of Akt in monocytes (C and).")
       (:PMID . "18848473") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Erlotinib pre-treatment prevented Akt phosphorylation and subsequent hyperphosphorylation of 4E-BP1 in each of the cell lines after 20 minutes of EGF stimulation.")
       (:PMID . "23883783") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As expected, the inhibition of PI3K and Akt through LY294002 (20muM) and Akti1/2 (2muM), respectively, and Akt depletion using specific siRNA abrogated the -induced phosphorylation of 4E-BP1 and prevented de-phosphorylation of eEF2 (C, D; Supplementary Fig. 1).")
       (:PMID . "25194338") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Combined Inhibition of AKT and ERK Are Required to Suppress 4E-BP1 Phosphorylation and Tumor Growth in Vivo.")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, both RAS and MAPK and PI3K and AKT signaling mediate phosphorylation of 4E-BP1, thereby disengaging the protein from the mRNA cap and disinhibiting translation (XREF_BIBR, XREF_BIBR).")
       (:PMID . "19336517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Both the PI3K and AKT and RAS and MAPK signal transduction pathways mediate 4E-BP1 phosphorylation, releasing 4E-BP1 from the mRNA cap and permitting translation initiation.")
       (:PMID . "19336517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylation decreases the ability of TSC2 to inhibit the phosphorylation of ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E binding protein-1 (4EBP1), which are mTOR substrates.")
       (:PMID . "14651849") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Given the convergence of RAS and MAPK and PI3K and AKT signaling that mediates phosphorylation of 4E-BP1, dephosphorylation of 4E-BP1 may prove to be an effective strategy to improve treatment outcome in patients with metastatic melanoma.")
       (:PMID . "19336517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Expression of constitutively active Akt stimulates 4E-BP1 phosphorylation and VEGF expression in the absence of alpha6beta4 signaling.")
       (:PMID . "12105188") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, in tumor cells with coexistent KRAS and PIK3CA mutations (HCT116), inhibition of neither AKT nor MEK was sufficient to rapidly inhibit phosphorylation of p70S6K, S6, or 4E-BP1 at any of its four phosphorylation sites, although modest inhibition was observed after exposure to the MEK inhibitor for 24 h. However, combined inhibition of MEK and AKT synergistically inhibited phosphorylation of all these sites 6 h after drug exposure and profoundly by 12 h (XREF_FIG).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Selective knockdown of AKT1, but not AKT2 or AKT3, was sufficient to induce significant G1 arrest, loss of cells in S phase and downregulation of cyclin D3 expression and S6- and 4EBP1 phosphorylation (XREF_FIG and XREF_SUPPLEMENTARY).")
       (:PMID . "22328975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Unlike the parental HCT116, inhibition of AKT alone in HKh-2 and HKe-3 (wild-type RAS) cells was sufficient to inhibit phosphorylation of p70S6K, S6 and 4E-BP1, induce binding of 4E-BP1 to the eIF4E mRNA complex and inhibit cap dependent translation (XREF_FIG and XREF_SUPPLEMENTARY).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Combined inhibition of ERK and AKT both effectively inhibits 4E-BP1 phosphorylation and prevents reactivation of ERK and AKT and thus may have a therapeutic advantage.")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "0868c11a-19b7-46f9-b10c-77a7114605a9"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "ELK-1") (:+HGNC+ . "3321") (:+NCIT+ . "C18288")
       (:+UP+ . "P19419"))
      (:NAME . "ELK1"))
     (:SUPPORTED--BY "71e84804-8b59-4792-85c9-69e7caa8f847")
     (:EVIDENCE
      ((:TEXT
        . "The PI3K and Akt pathway did not directly phosphorylate the Elk-1 but it played a major role in the nuclear localization of phosphorylated ERK1/2 and Elk-1.")
       (:PMID . "22085529") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, Elk-1 has been implicated in protecting cells from apoptosis (), and downregulating apoptosis associated genes (), thereby mediating cell survival, and Akt dependent phosphorylation of Elk-1 has been shown to be important for proliferation of glioblastoma cells (; Mut and Kurnaz, unpublished data).")
       (:PMID . "19013529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The PI3K and Akt pathway did not directly phosphorylate the Elk-1 but it played a major role in the nuclear localization of phosphorylated ERK1/2 and Elk-1.")
       (:PMID . "22085529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "e84243f8-4b3d-4240-b292-804bccdae0d9"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERalpha") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "9e54e64a-5f00-4b75-b522-d49c51279e55"
      "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf")
     (:EVIDENCE
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a906350e8206b87128ccc2b713d5e61d")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "AKT overexpression increased ERalpha S167 phosphorylation and reduced tamoxifen sensitivity, whereas inhibition of AKT using RNAi directed toward AKT decreased ERalpha S167 phosphorylation and restored tamoxifen sensitivity.")
       (:PMID . "25597633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Indeed, it has been shown that AKT phosphorylates the Ser167 residue of ER and increases its transcriptional activity, resulting in the preferential growth of ER positive cells in the presence of PIK3CA mutations.")
       (:PMID . "22640628") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT . "7838153;9528769;11432835;11139588") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT
        . "Coexpression of wild-type ER-alpha and the dominant negative Akt mutant in COS-1 cells also blocked the growth factor-stimulated activation of ER-alpha, but coexpression of the wild-type receptor with the constitutively active Akt mutant increased ER-alpha activity. Receptor activation was blocked by an antiestrogen. Studies using mutants of ER-alpha demonstrated that Akt increased estrogen receptor activity through the amino-terminal activation function-1 (AF-1). Serines S104 S106, S118, and S167 appear to play a role in the activation of ER-alpha by Akt.")
       (:PMID . "11108261") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT
        . "Cyclooxygenase-2 (COX-2) antagonists, by blocking prostaglandin production, might inhibit this pathway 149.")
       (:PMID . "12635173") (:SOURCE--API . "bel")))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "711c37e7-3bf9-48c3-b5d6-ae18d8a91922"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "FOXO-3-A") (:+NCIT+ . "C52907") (:+HGNC+ . "3821")
       (:+UP+ . "O43524"))
      (:NAME . "FOXO3"))
     (:SUPPORTED--BY "bfd8642f-2d41-485b-a345-aec96180a7fa"
      "ff94ebce-6c96-4564-bac0-ff4697a4b6c5"
      "38993886-61be-4c48-a9e9-21a6071749c3"
      "b7752bf2-bf69-46d3-8f1a-a8dc623a8814"
      "c72805ce-5398-4ce7-bfc1-560f39139191")
     (:EVIDENCE
      ((:TEXT
        . "AKT and SGK also phosphorylate FOXO1 and FOXO3A at Thr32, Ser253, and Ser315 (FOXO3A numbering) (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Consistent with this notion, one of the first and potentially most important control mechanisms characterized for FOXO3a is its regulation by Akt, where the phosphorylation of FOXO3a at Ser32, Ser253 and Ser315 by Akt results in the cytoplasmic accumulation and subsequent degradation of this transcription factor XREF_BIBR.")
       (:PMID . "23691078") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT and SGK also phosphorylate FOXO1 and FOXO3A at Thr32, Ser253, and Ser315 (FOXO3A numbering) (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT phosphorylation of FoxO3 at sites T32, S253, and S315 results in nuclear exclusion of FoxO3 [XREF_BIBR].")
       (:PMID . "23262029") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Previous studies have shown that IKBKE directly activates Akt and that Akt inhibits FOXO3a by phosphorylation of Ser32, Ser253 and Ser315.")
       (:PMID . "23691078") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "FOXO activities are negatively regulated by Akt, which phosphorylates FOXO at T-32, S253 and S315.")
       (:PMID . "20966391") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of constitutively active Akt induces the phosphorylation of FKHRL1 at S315 in cells, but Akt does not effectively catalyze the phosphorylation of FKHRL1 at S315 in vitro.")
       (:PMID . "10102273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylates FoxO3a at Thr32, Ser253 and Ser315, leading to its cytoplasmic sequestration by 14-3-3 proteins, thus preventing its nuclear translocation [XREF_BIBR].")
       (:PMID . "26405162") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylates FoxO3a at Thr32, Ser253 and Ser315, leading to its cytoplasmic sequestration by 14-3-3 proteins, thus preventing its nuclear translocation [XREF_BIBR].")
       (:PMID . "26405162") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Consistent with this notion, one of the first and potentially most important control mechanisms characterized for FOXO3a is its regulation by Akt, where the phosphorylation of FOXO3a at Ser32, Ser253 and Ser315 by Akt results in the cytoplasmic accumulation and subsequent degradation of this transcription factor XREF_BIBR.")
       (:PMID . "23691078") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These studies demonstrated that AKT phosphorylates FoxO proteins on three residues, Threonine 32, Serine 253 and Serine 315 (for human FoxO3).")
       (:PMID . "21621563") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "FOXO3a are phosphorylated and inactivated by AKT through phosphorylation at Thr32, Ser253, and Ser315 which results in nuclear export and inhibition of its transcription activity XREF_BIBR, XREF_BIBR.")
       (:PMID . "20885957") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "315")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "ab9c41bd-6af3-42f3-8824-4c7cbbf2656a"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "IRS-1") (:+UP+ . "P35568") (:+HGNC+ . "6125"))
      (:NAME . "IRS1"))
     (:SUPPORTED--BY "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE
      ((:TEXT
        . "Finally, to understand if the observed differences in serine phosphorylation are associated with downstream abnormalities in the insulin signaling cascade, we additionally investigated phosphorylation of the IRS-1 target Akt.")
       (:PMID . "25107476") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function.")
       (:PMID . "10497255") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, Ser (629) of IRS-1 is directly phosphorylated by Akt in vitro.")
       (:PMID . "17640984") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, phosphorylation of IRS1 (insulin receptor substrate 1) by PKC, Erk, and Akt results in reduced complex formation with PI-3 kinase.")
       (:PMID . "12419216") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "9f7fb2bf-08dd-4e07-8609-c7a8203cef79"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the latter evodiamine caused increased ERK phosphorylation and reduced insulin stimulated phosphorylation of Akt, which were prevented by the MEK inhibitor PD98059.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Effect of Akt knock-down by siRNA on H. pylori induced phosphorylation of GSK3, PDK1 and mitogen activated protein kinase.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT inhibition increases phosphorylation of EGFR at Tyr 1068 and phosphorylation of ERK in MCF10A cells.")
       (:PMID . "23757022") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "18 As expected, CP724714 inhibited phosphorylation of ERK and pERK and AKT and pAKT (XREF_FIG).")
       (:PMID . "24763051") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "ERK1/2 phosphorylation was reduced not only by MAPK pathway inhibitors but also by PI3K and mTOR inhibitors; when PI3K was inhibited, ERK phosphorylation could be induced by microinjected activated Akt, indicating important cross-talk between the PI3K and ERK1/2 pathways.")
       (:PMID . "15242975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Of interest, we found that overexpression of RhoU correlates with an increased phosphorylation of JNK and ERK (XREF_FIG) but not PLCgamma or AKT on EGF stimulation (Supplemental Figure S3F).")
       (:PMID . "21508312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Immunoblotting lysates of H441 cells treated with cediranib, MK2206 (AKT inhibitor) or AZD6244 (MEK inhibitor) for 24 h showed that MK2206 significantly reduced AKT phosphorylation and AZD6244 reduced p42/44 MAPK phosphorylation and, to a lesser extent, AKT phosphorylation (XREF_FIG).")
       (:PMID . "26179332") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "affe070c-91e3-415a-a365-e4d4e779ebd7"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "18 As expected, CP724714 inhibited phosphorylation of ERK and pERK and AKT and pAKT (XREF_FIG).")
       (:PMID . "24763051") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Immunoblotting lysates of H441 cells treated with cediranib, MK2206 (AKT inhibitor) or AZD6244 (MEK inhibitor) for 24 h showed that MK2206 significantly reduced AKT phosphorylation and AZD6244 reduced p42/44 MAPK phosphorylation and, to a lesser extent, AKT phosphorylation (XREF_FIG).")
       (:PMID . "26179332") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT inhibition increases phosphorylation of EGFR at Tyr 1068 and phosphorylation of ERK in MCF10A cells.")
       (:PMID . "23757022") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Of interest, we found that overexpression of RhoU correlates with an increased phosphorylation of JNK and ERK (XREF_FIG) but not PLCgamma or AKT on EGF stimulation (Supplemental Figure S3F).")
       (:PMID . "21508312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the latter evodiamine caused increased ERK phosphorylation and reduced insulin stimulated phosphorylation of Akt, which were prevented by the MEK inhibitor PD98059.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 phosphorylation was reduced not only by MAPK pathway inhibitors but also by PI3K and mTOR inhibitors; when PI3K was inhibited, ERK phosphorylation could be induced by microinjected activated Akt, indicating important cross-talk between the PI3K and ERK1/2 pathways.")
       (:PMID . "15242975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Effect of Akt knock-down by siRNA on H. pylori induced phosphorylation of GSK3, PDK1 and mitogen activated protein kinase.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "aee41da4-a9d3-48b9-878f-756de93519ad"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "MDM-2") (:+HGNC+ . "6973") (:+UP+ . "Q00987")
       (:+NCIT+ . "C17515"))
      (:NAME . "MDM2"))
     (:SUPPORTED--BY "b55ec329-b7ce-42b5-88ba-cff619d96410"
      "c3d89461-de3b-4572-9117-cd2c4ceb43ab"
      "174e2a12-386f-4ec1-b626-e4193aea8dec"
      "7959e20d-649a-4bd6-93d0-b63bbc6b94a4"
      "ffc25168-3f5a-4895-9c7f-2f3ad6f00461")
     (:EVIDENCE
      ((:TEXT
        . "Following growth factor stimulation, Akt phosphorylates Mdm2 at Ser166 and Ser186 [XREF_BIBR], which increases Mdm2 half-life and stimulates Mdm2 dependent p53 degradation.")
       (:PMID . "20172729") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of HDM2 (S166) by AKT is known to enhance HDM2 mediated P53 ubiquitination and degradation (XREF_BIBR).")
       (:PMID . "24240108") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "To regulate IRF1, Mdm2 must gain nuclear entry, a process which requires phosphorylation of Mdm2 at Ser166 by PKB ().")
       (:PMID . "24721577") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT inhibition by GDC0941 abolished MDM2 phosphorylation at Ser166 and induced p53 and p21 expression (XREF_FIG).")
       (:PMID . "24762959") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt and ERK activate MDM2 phosphorylation at Ser166 resulting in diminishing cellular levels and transcriptional activity of p53 [XREF_BIBR - XREF_BIBR].")
       (:PMID . "25431954") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The serine/threonine kinase Akt phosphorylates Mdm2 at serine 166 and 186 and causes Mdm2 shift to the nucleus where it is considered to play a role in p53 degradation.")
       (:PMID . "19124015") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To regulate IRF1, Mdm2 must gain nuclear entry, a process which requires phosphorylation of Mdm2 at Ser166 by PKB ().")
       (:PMID . "24721577") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This finding is in keeping with studies showing that AKT physically associates with MDM2 and phosphorylates MDM2 at Ser166 and Ser186, leading to nuclear translocation and degradation of the tumour-suppressor p53 (XREF_BIBR; XREF_BIBR), and that activation of MDM2 by AKT in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis (XREF_BIBR).")
       (:PMID . "24762959") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Following growth factor stimulation, Akt phosphorylates Mdm2 at Ser166 and Ser186 [XREF_BIBR], which increases Mdm2 half-life and stimulates Mdm2 dependent p53 degradation.")
       (:PMID . "20172729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "166")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "2d10d739-22d7-4aec-8c16-e15fa1e68391"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "mTOR") (:+UP+ . "P42345") (:+HGNC+ . "3942"))
      (:NAME . "MTOR"))
     (:SUPPORTED--BY "e20ea4ea-43a4-4fed-b58d-5517f73f2874"
      "0e370c8f-710b-4456-a9f5-33e22d347659"
      "c3fd1005-b622-4721-8f84-11a8568461ca"
      "3f164d35-7b34-4585-bbd6-884b979e4395"
      "801755d9-710e-4fb6-8c0e-64c391796e4c")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of mTOR by Akt at serine 2448 might not correlate with mTOR activation, therefore, pmTOR 2448 may not necessary be involved with the development of HRPC, and a more appropriate marker of mTOR activation could be S6Kinase (Ruggero and Sonenberg, 2005)")
       (:PMID . "18349820") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Akt then phosphorylates mTOR at Serine 2448 and activates mTORC1 (XREF_BIBR), which inhibits autophagy by targeting autophagy related protein (ATG) 13 (XREF_BIBR).")
       (:PMID . "24606695") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of mTOR by Akt at serine 2448 might not correlate with mTOR activation, therefore, pmTOR 2448 may not necessary be involved with the development of HRPC, and a more appropriate marker of mTOR activation could be S6Kinase (Ruggero and Sonenberg, 2005).")
       (:PMID . "18349820") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt then phosphorylates mTOR at Serine 2448 and activates mTORC1 (XREF_BIBR), which inhibits autophagy by targeting autophagy related protein (ATG) 13 (XREF_BIBR)")
       (:PMID . "24606695") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Akt can phosphorylate mTOR directly at threonine 2446 and serine 2448, but can also activate mTOR indirectly via phosphorylation of TSC2 (Majumder and Sellers, 2005).")
       (:PMID . "18349820") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt then phosphorylates mTOR at Serine 2448 and activates mTORC1 (XREF_BIBR), which inhibits autophagy by targeting autophagy related protein (ATG) 13 (XREF_BIBR).")
       (:PMID . "24606695") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of mTOR by Akt at serine 2448 might not correlate with mTOR activation, therefore, pmTOR 2448 may not necessary be involved with the development of HRPC, and a more appropriate marker of mTOR activation could be S6Kinase (Ruggero and Sonenberg, 2005).")
       (:PMID . "18349820") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Our results showed that the expressions of EGFR and mTOR dropped off with the ageing of the rats, and Ser473 phosphorylation of Akt and Ser2448 phosphorylation of mTOR were highly expressed in foetal and newborn rats but decreased obviously in adult rats.")
       (:PMID . "23681769") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of mTOR by Akt at serine 2448 might not correlate with mTOR activation, therefore, pmTOR 2448 may not necessary be involved with the development of HRPC, and a more appropriate marker of mTOR activation could be S6Kinase ( xref ).")
       (:PMID . "18349820") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Although AKT phosphorylated mTOR at two COOH-terminal sites (Thr2446 and Ser2448) in vitro, Ser2448 was the major phosphorylation site in insulin stimulated or -activated AKT expressing human embryonic kidney cells.")
       (:PMID . "10910062") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt can phosphorylate mTOR directly at threonine 2446 and serine 2448, but can also activate mTOR indirectly via phosphorylation of TSC2 (Majumder and Sellers, 2005).")
       (:PMID . "18349820") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "2448")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "9ed2a92e-8a37-4b75-9deb-a32463a7533a"))
    ((:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:TEXT
        . "In addition, our results demonstrated that Akt phosphorylated FAK at three novel serine phosphorylation sites, which were also not required for FAK-Akt binding.")
       (:PMID . "21209368") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "01917090-02e4-467e-bef6-6a1ca9bc00b2"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "RAF1") (:+UP+ . "P04049") (:+HGNC+ . "9829"))
      (:NAME . "RAF1"))
     (:SUPPORTED--BY "facd8761-a678-4310-bfb0-47029d1e274b"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "0c3defb4-0500-48a8-b740-25905eef5cc0"
      "e08dcdee-5e38-4e65-b179-2502cd6247f5")
     (:EVIDENCE
      ((:TEXT
        . "Active AKT (pAKT) phosphorylates RAF at serine residue Ser 259 and inhibits the activation of the RAF-MEK-ERK signaling pathway [XREF_BIBR].")
       (:PMID . "26930065") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "At high doses of insulin growth factor, active AKT phosphorylates RAF at serine residue Ser 259 and thus suppresses the activity of RAF-MEK-ERK signaling pathway [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26930065") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Note that increased Akt mediated phosphorylation of Raf-1 at Ser 259 by TGFbeta did not have any inhibitory effect on MEK and Erk phosphorylation (XREF_FIG and XREF_FIG)")
       (:PMID . "23359369") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "According to previous studies, Akt phosphorylates Raf at Ser259, leading to inhibition of the Raf/MEK/ERK pathway")
       (:PMID . "26797279") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "According to previous studies, Akt phosphorylates Raf at Ser259, leading to inhibition of the Raf/MEK/ERK pathway.")
       (:PMID . "26797279") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "At high doses of insulin growth factor, active AKT phosphorylates RAF at serine residue Ser 259 and thus suppresses the activity of RAF-MEK-ERK signaling pathway [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26930065") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Previous studies have shown that c-Raf could be phosphorylated on its inhibitory site S259 by two kinases Protein Kinase A (PKA) or AKT and protein kinase B (PKB) [XREF_BIBR - XREF_BIBR].")
       (:PMID . "21745501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In this report, we demonstrate that Akt1, but not Akt2, down-regulated the Raf/MEK/ERK pathway by phosphorylating c-Raf on Ser259.")
       (:PMID . "20688159") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt is the downstream effector of PI3K, and interestingly, Akt is able to phosphorylate c-Raf at S259 [XREF_BIBR].")
       (:PMID . "25817574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "259")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "a3d53ea5-042d-4ea0-84f0-975655d0f745"))
    ((:SUB (:DB--REFS (:+TEXT+ . "p70") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "7260669a-4292-4fbc-ae58-3affb2004d7a")
     (:EVIDENCE
      ((:TEXT
        . "The data presented here show that c48/80 : i) at low doses (up to 10mug/ml) augments serum induced phosphorylation of PKB and p70 in a manner sensitive to both PI 3-kinase and PKC inhibitors, ii) at higher doses induces the phosphorylation of p70 and the translocation of PKCalpha in a PI 3-kinase dependent fashion, but inhibits the phosphorylation of PKB.")
       (:PMID . "16942862") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of phosphorylated mTOR (p-mTOR), phosphorylated AKT (p-AKT), p85alpha and p110gamma subunits of PI3K, phosphorylated p70S6K (p-p70S6K), phosphatase and tensin homolog (PTEN) and phosphorylated 4E-BP1 (p-4E-BP1) was examined by immunohistochemistry in 102NSCLC specimens.")
       (:PMID . "23728071") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To investigate whether HCA 2 -induced p70S6K1 phosphorylation is mediated by ERK1/2 activation or Akt activation, U0126, a highly selective inhibitor of both MEK1 and MEK2, and Wortmannin, a highly selective inhibitor of PI3K, were analyzed for their effect on the activation of p70S6K1.")
       (:PMID . "25375133") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "While SIRT2 overexpression in 3T3-L1 preadipocytes and HeLa cells enhanced insulin induced Akt activation and phosphorylation of its downstream targets GSK3beta and p70S6 kinase, pharmacological or genetic SIRT2 inhibition causes the opposite effect.")
       (:PMID . "26538315") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, in tumor cells with coexistent KRAS and PIK3CA mutations (HCT116), inhibition of neither AKT nor MEK was sufficient to rapidly inhibit phosphorylation of p70S6K, S6, or 4E-BP1 at any of its four phosphorylation sites, although modest inhibition was observed after exposure to the MEK inhibitor for 24 h. However, combined inhibition of MEK and AKT synergistically inhibited phosphorylation of all these sites 6 h after drug exposure and profoundly by 12 h (XREF_FIG).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Unlike the parental HCT116, inhibition of AKT alone in HKh-2 and HKe-3 (wild-type RAS) cells was sufficient to inhibit phosphorylation of p70S6K, S6 and 4E-BP1, induce binding of 4E-BP1 to the eIF4E mRNA complex and inhibit cap dependent translation (XREF_FIG and XREF_SUPPLEMENTARY).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "0bfb9250-09b2-4de7-8312-1356ffa9af62"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "S6") (:+UP+ . "P62753") (:+HGNC+ . "10429")
       (:+IP+ . "IPR000529"))
      (:NAME . "RPS6"))
     (:SUPPORTED--BY "5e762d2f-73f3-4952-9222-6a3e13eb8666")
     (:EVIDENCE
      ((:TEXT
        . "Activation of mTOR in response to nutrients and growth factors results in the phosphorylation of numerous substrates, including the phosphorylations of S6 kinase by mTORC1 and Akt by mTORC2.")
       (:PMID . "22354785") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Parallel plates of TAg-WT and TAg-PACS-2 -/- MEFs were treated with TRAIL in the presence or absence of the class I PI3K and mTOR inhibitor PI-103, which blocked Akt activation and phosphorylation of ribosomal protein S6 (XREF_FIG).")
       (:PMID . "19481529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Unlike the parental HCT116, inhibition of AKT alone in HKh-2 and HKe-3 (wild-type RAS) cells was sufficient to inhibit phosphorylation of p70S6K, S6 and 4E-BP1, induce binding of 4E-BP1 to the eIF4E mRNA complex and inhibit cap dependent translation (XREF_FIG and XREF_SUPPLEMENTARY).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylation decreases the ability of TSC2 to inhibit the phosphorylation of ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E binding protein-1 (4EBP1), which are mTOR substrates.")
       (:PMID . "14651849") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The functional consequences of Akt phosphorylation show activating and inactivating phosphorylations of S6 kinase and 4EBP-1, respectively, thus demonstrating activation of TORC1.")
       (:PMID . "21426932") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the addition of trastuzumab did not inhibit the already low level of HER2 phosphorylation or further diminish the minimally detectable HER3 phosphorylation in these cells, nor did it further decrease PI3K-Akt signaling through Akt or S6 phosphorylation.")
       (:PMID . "24451154") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The depletion of Akt diminished the phosphorylation of mTOR and S6 in the infected cells (A).")
       (:PMID . "25194338") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of Akt by treatment with Akt inhibitor VIII attenuated phosphorylation of both Foxo3a and the mTORC1 target S6 kinase, as well as prevented inhibition of autophagy by IGF1 (XREF_FIG).")
       (:PMID . "20627085") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activation of Akt in RPE-hTERT cells or insulin treatment of immortalised MEFs only slightly increased the levels of S6 phosphorylation.")
       (:PMID . "21093473") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mounting evidence has established the classical way of Akt1 (Ser473) in rpS6 activation [XREF_BIBR, XREF_BIBR], but nevertheless the Akt independent phosphorylation of rpS6 was also reported [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26490682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Several studies have found that rpS6 is phosphorylated by Akt1 (Ser473) approach in colorectal and bladder cancer cells [XREF_BIBR, XREF_BIBR], but there are also reports revealing the Akt independent phosphorylation of rpS6 [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26490682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, blockade of Akt inhibited phosphorylation of 4E-BP1 and S6, confirming that the mTOR pathway is downstream of Akt in monocytes (C and).")
       (:PMID . "18848473") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Hence, although AKT may modestly contribute to rpS6 phosphorylation, its contribution is substantially less than what is observed following inhibition of BRAF V600E --> MEK1/2 --> ERK1/2 or PI3 '-kinase signaling.")
       (:PMID . "24425783") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, in tumor cells with coexistent KRAS and PIK3CA mutations (HCT116), inhibition of neither AKT nor MEK was sufficient to rapidly inhibit phosphorylation of p70S6K, S6, or 4E-BP1 at any of its four phosphorylation sites, although modest inhibition was observed after exposure to the MEK inhibitor for 24 h. However, combined inhibition of MEK and AKT synergistically inhibited phosphorylation of all these sites 6 h after drug exposure and profoundly by 12 h (XREF_FIG).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "c977e063-6900-4721-846e-636d34c503f9"))
    ((:SUB (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "TUBERIN") (:+HGNC+ . "12363") (:+UP+ . "P49815")
       (:+NCIT+ . "C17913"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "d448dbc6-34f3-4d35-8801-3dc8e97833be"
      "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef"
      "069699a7-541e-4f56-9f74-03612f007581")
     (:EVIDENCE
      ((:TEXT
        . "ERK, Rsk1, and Akt all directly phosphorylate and inactivate tuberin, thereby leading to mTOR activation (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "19234517") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt phosphorylated by PI-3K at Ser 473 phosphorylates and inactivates TSC2 and leads to the activation of mTOR [XREF_BIBR].")
       (:PMID . "24797175") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt directly phosphorylates and inactivates TSC2 (known as tuberin), which results in increased Rheb (ras homolog enriched in brain) activity.")
       (:PMID . "23597702") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "TSC2 links TOR to the mitogen sensing phosphoinositide 3-kinase (PI3K) signaling pathway, as Akt (which is activated by PI3K) phosphorylates and inactivates TSC2.")
       (:PMID . "15341740") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Activated Akt, ERK, and RSK1 kinases phosphorylate and inactivate the tumor suppressor TSC2, thus relieving its inhibitory role on mTORC1.")
       (:PMID . "19276265") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt, Erk and other mitogen activated kinases directly phosphorylate and inactivate TSC2, leading to mTORC1 activation.")
       (:PMID . "23712032") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "4fb60bcd-946b-4027-a73d-147251e41be8"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "Y-box binding protein 1") (:+UP+ . "P67809")
       (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "12992216-69c2-418c-a486-1732896693c6"
      "5c02afe8-77d3-4027-ac03-b4015755ca42")
     (:EVIDENCE
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells.")
       (:PMID . "15806160") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Herein, we illustrate that activated Akt binds to and phosphorylates the YB-1 cold shock domain at Ser102.")
       (:PMID . "15806160") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "It has been demonstrated that Akt phosphorylates YB-1 at S102 and affects the anchorage independent growth of breast cancer cells [XREF_BIBR].")
       (:PMID . "21392397") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "It has been demonstrated that Akt phosphorylates YB-1 at S102 and affects the anchorage independent growth of breast cancer cells [XREF_BIBR].")
       (:PMID . "21392397") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells")
       (:PMID . "15806160") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells.")
       (:PMID . "15806160") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Previous work in our lab showed that the serine/threonine kinase AKT phosphorylates, and thereby activates, YB-1 at S102 and that inhibiting this site disrupts nuclear trafficking XREF_BIBR, DNA binding XREF_BIBR and tumour cell growth XREF_BIBR.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This can be mediated by Akt dependent phosphorylation of YB-1 at S102, as described above.")
       (:PMID . "24461929") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Several pathways have been shown to influence YB-1 location, including the PI3K-AKT pathway (XREF_BIBR), which phosphorylated YB-1 at Ser102.")
       (:PMID . "24335958") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "While we have previously established that AKT can interact and phosphorylate YB-1 S102 [XREF_BIBR], it is unclear whether other kinases are also able to perform this function.")
       (:PMID . "19036157") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, the translational block of pro growth genes in a human cell model and the resistance of chicken fibroblasts to cellular transformation after YB-1 overexpression could be overcome by Akt dependent phosphorylation of YB-1 at S102.")
       (:PMID . "24461929") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "102")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "309") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "474") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:TYPE . "Phosphorylation")
     (:ID . "69fe571a-0526-4d3b-ae0a-8ea5f9164ba2"))
    ((:SUB (:DB--REFS (:+UP+ . "O43524") (:+HGNC+ . "3821")) (:NAME . "FOXO3"))
     (:SUPPORTED--BY "605bd634-ce4e-4848-801c-eb015b898f0f"
      "c72805ce-5398-4ce7-bfc1-560f39139191")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1f64411ffa48af0273b69431fa950733")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q9Y243") (:+HGNC+ . "393")) (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "0b504935-5c5f-4abb-b90f-06dee8f3f9d8"))
    ((:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "73bc4d41-1b78-435c-a492-210fa541da92"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_306e7e42e299430514aaa720bd786dd1")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q9Y243") (:+HGNC+ . "393")) (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "3073e14c-d097-4f95-bc45-e2212eadd3d5"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "b4bcefa8-5825-404c-9e20-1f9a11bcb142"
      "5757b142-0a4a-4a74-be36-db6f3c483dac"
      "07dbbc16-65b1-4468-83a0-8f7ff7967dd5"
      "0b481832-b2fd-417b-a78b-e7692036e3b5"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "IR is known to mediate a rapid activation of Akt [XREF_BIBR] and recent studies showed that ATM can function as an activating Akt kinase that phosphorylates rapidly Akt-S473 [XREF_BIBR].")
       (:PMID . "22607554") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Also, coimmunoprecipitation experiments showed that PDK1 did not associate with any of the three TCL1 family members, suggesting that there is no direct TCL1 induced Akt, TCL1, and PDK1 complex formation in vivo.Our data show that TCL1 induces Akt kinase activity dependent phosphorylation of Akt on both Ser 473 and Thr 308.")
       (:PMID . "10983986") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PDK1 XREF_BIBR phosphorylates AKT at T308, and mTORC2 XREF_BIBR as well as other potential PDK2s phosphorylates AKT at S473.")
       (:PMID . "20361045") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Whereas mTORC2 directly phosphorylates AKT, activated p70S6K phosphorylates and negatively regulates insulin receptor substrate 1.13 As insulin receptor substrate 1 is an important upstream activator of PI3K-AKT, phosphorylation of p70S6K, thus, evokes a physiological negative feedback loop toward AKT.5 Phosphorylation of AKT at Ser 473 was slightly attenuated in 3T3 cells expressing active mTOR mutants compared with that in those expressing the wild-type protein, consistent with a previous observation.8 Transforming activity of mTOR mutants is rapamycin sensitive.")
       (:PMID . "26432419") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, src family tyrosine kinases are important regulators of Akt signalling in infection.-induced EGFR activation mediates Akt Ser473 phosphorylation in several cell lines ().")
       (:PMID . "25194338") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "According to our current findings, this model has to be extended by the Akt pathway.Phosphorylation of Akt at serine 473 results in the activation of Akt ().")
       (:PMID . "22280833") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in XREF_FIG, overexpressing miR-519a significantly increased, but silencing miR-519a decreased, the Akt activity and the expression of phosphorylated Akt (Ser473) in HCC cells (P < 0.05).")
       (:PMID . "26708293") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "473")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "5e295920-9cad-4229-9039-902f1feadb8e"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "b0cbde8b-46e3-4757-819f-18c35f74fbb4"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "86ca3b6b-f1a2-4286-b70f-ba878d5c6633"
      "2d0c1b00-41a3-41a5-b9c5-41366e2ba7ec")
     (:EVIDENCE
      ((:TEXT
        . "PDK1 XREF_BIBR phosphorylates AKT at T308, and mTORC2 XREF_BIBR as well as other potential PDK2s phosphorylates AKT at S473.")
       (:PMID . "20361045") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In the case of AKT, the interaction of the pleckstrin homology (PH) domain of AKT with membrane bound PIP 3 confers a conformational change in AKT which allows PDK1 to phosphorylate AKT at residue threonine 308 (XREF_BIBR - XREF_BIBR).")
       (:PMID . "19602588") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "308")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "6607c36f-a93a-4467-bf42-e9cd097b414d"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "On the other hand, phosphorylation of PGC-1alpha by AKT and protein kinase B (PKB), downstream of insulin signaling in the liver, is known to decrease its stability and transcriptional activity (XREF_BIBR).")
       (:PMID . "26831453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The Akt Inhibitor X selectively inhibits the phosphorylation of Akt with minimal effects on PI3K, PDK1, or SGK1 signaling.")
       (:PMID . "18159252") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The OGA inhibitors might also have additional functions that activate the upstream kinase activity of AKT, which in turn might lead to AKT phosphorylation in neuronal cells.")
       (:PMID . "22687243") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, inhibition of AKT by the overexpression of kinase-dead AKT decreased the AKT phosphorylation levels, and resulted in decreased sensitivity to perifosine (XREF_FIG).")
       (:PMID . "25519148") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because HST has been described to block EGF and EGFR- induced Akt and PKB phosphorylation and proliferation in vitro [20], the previously mentioned findings could be interpreted as an attempt by the HST positive cancer cells to block Akt and PKB phosphorylation.")
       (:PMID . "18592003") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These compounds inhibited Akt activation and phosphorylation of several downstream substrates of Akt in tumor cells without affecting the activities of upstream kinases (such as PI3-K and 3-phosphoinositide-dependent protein kinase 1 (PDK1, also known as PDPK1), or members of other signaling pathways such as ERK2.")
       (:PMID . "21110830") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT overexpression completely prevented PEITC induced suppression of AKT phosphorylation.")
       (:PMID . "22952709") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, both PI3K and Akt activators, pervanadate and insulin, partly reversed the inhibition of TGF-beta1-induced Akt phosphorylation by anti-miR33a, whereas Akt specific inhibitor MK2206 did not show this reversed inhibition effect.")
       (:PMID . "24100264") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT inhibitors either compete for the catalytic ATP binding site of AKT or block phosphorylation of AKT in allosteric fashion [XREF_BIBR].")
       (:PMID . "25186604") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In contrast, MDA-MB-231 cells expressing either helical domain or kinase domain p110alpha mutants showed elevated basal levels of Akt phosphorylation as well as enhanced EGF stimulated Akt phosphorylation.")
       (:PMID . "19903845") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, expression of dominant negative Akt abrogated endogenous Akt activity, Rab3D phosphorylation and GAG synthesis, whereas expression of constitutively activated Akt stimulated Rab3D phosphorylation and GAG synthesis in the absence of PDGF-BB.")
       (:PMID . "11903042") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These observations establish that TCL1 functions as an Akt kinase coactivator, which enhances the phosphorylation and activation of Akt in vivo.We next studied the biological effects of the TCL1 and Akt interaction in vivo.Transient transfection of TCL1 into the 293 cell line resulted in a 10-fold increase of proliferative responses (, lane 2).")
       (:PMID . "10983986") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "A specific inhibitor of AKT kinase, GSK690693, inhibited AKT phosphorylation (XREF_FIG) and attenuated CXCL12 induced migration by 56% (XREF_FIG).")
       (:PMID . "25897806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt was rapidly phosphorylated by glimepiride treatment (A) and antisense Akt completely inhibited glimepiride induced NO production (= 5, < 0.05; B).")
       (:PMID . "16216590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Third, Akt phosphorylates Osterix and Akt activation prolonged the half-life of the Osterix protein.")
       (:PMID . "21777568") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Analyses of AKT kinase inhibitors have shown that acute AKT inhibition causes a paradoxical increase of AKT phosphorylation, probably through a negative feedback loop.")
       (:PMID . "19394761") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results suggest that GRP induces c-Src dependent Akt phosphorylation but EGF stimulates Akt phosphorylation directly, without involvement of c-Src.")
       (:PMID . "17349623") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Insulin stimulates phosphorylation of Akt and activated Akt exerts various biological effects such as cell growth and survival, angiogenesis, and metabolism by regulating downstream effectors [XREF_BIBR].")
       (:PMID . "26491696") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, we sought to analyze other biologically relevant, cancer related proteins, including downstream targets of PI3K signaling, such as phosphorylated Akt (p-Akt), mTOR (p-mTOR), and S6 ribosomal protein (p-S6).")
       (:PMID . "22674438") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We found that the addition of trastuzumab did not inhibit the already low level of HER2 phosphorylation or further diminish the minimally detectable HER3 phosphorylation in these cells, nor did it further decrease PI3K-Akt signaling through Akt or S6 phosphorylation.")
       (:PMID . "24451154") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The data presented here show that c48/80 : i) at low doses (up to 10mug/ml) augments serum induced phosphorylation of PKB and p70 in a manner sensitive to both PI 3-kinase and PKC inhibitors, ii) at higher doses induces the phosphorylation of p70 and the translocation of PKCalpha in a PI 3-kinase dependent fashion, but inhibits the phosphorylation of PKB.")
       (:PMID . "16942862") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We first show that this dominant negative Akt (DN-Akt) eliminates Akt phosphorylation in response to Insulin Growth Factor in cells transfected with DN-Akt compared to empty vector (XREF_FIG).")
       (:PMID . "23409128") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The reduced AKT activation in MCF-7PIK3CAWT cells in turn caused greatly reduced phosphorylation of known AKT target proteins, including PRAS40, FOXO 1/3, and AS160.")
       (:PMID . "23888070") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The receptor activation elicits phosphorylation of IRS-1 and AKT and PKB in CHO cells.")
       (:PMID . "23220417") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt inhibition with LY294002 strongly diminished the phosphorylation of Akt and its downstream target 4E-BP1 in all five mesothelioma cell lines and control LP9 cells (XREF_FIG).")
       (:PMID . "19603014") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Several targets of p-AKT, such as BAD, MDM2 and FOXO1, contain the RXXS motif and are phosphorylated by p-AKT [XREF_BIBR - XREF_BIBR] (XREF_TABLE).")
       (:PMID . "23315288") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in XREF_FIG, Akt siRNA, as expected, completely abolished the phosphorylation of Akt and caused a 1.4-folds increase in cleaved caspase-3 protein level.")
       (:PMID . "24699278") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "High degrees of Akt phosphorylation and hyperactivation of the Akt signaling pathway are hallmarks of tumors in which PTEN function is impaired.")
       (:PMID . "20388916") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Furthermore, inhibiting Akt activation using the PI3K inhibitor LY294002 completely prevented EPO+IGFI-I-induced Akt phosphorylation and GSK-3beta phosphorylation compared to control (see XREF_FIG), confirming the involvement of the PI3K/Akt/GSK-3beta pathway.")
       (:PMID . "20818790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, coimmunoprecipitation experiments showed that PDK1 did not associate with any of the three TCL1 family members, suggesting that there is no direct TCL1 induced Akt, TCL1, and PDK1 complex formation in vivo.Our data show that TCL1 induces Akt kinase activity dependent phosphorylation of Akt on both Ser 473 and Thr 308.")
       (:PMID . "10983986") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In accordance with the RPMI 8226 cell data, CXCL12 induced AKT phosphorylation and LPS suppressed CXCL12 mediated AKT phosphorylation in plasmablasts (Fig XREF_FIG and XREF_FIG).")
       (:PMID . "25897806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Next, a specific inhibitor of PI3K and Akt pathway, LY294002, was used to inhibit Akt phosphorylation in wound healing assay to test whether inhibition of Akt phosphorylation has effect on VEGF 165 -induced migration.")
       (:PMID . "24987682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Elevation of AKT3 protein increases protein abundance of B-Raf and phosphorylation of AKT while decreases expression of TSC1 and TSC2 proteins.")
       (:PMID . "26318033") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Active recombinant Akt readily phosphorylated Bmi1, but not a Bmi1 S316A mutant protein (XREF_FIG), and expression of a constitutively active form of Akt (myristoylated Akt) in human embryonic kidney (HEK) 293T cells resulted in phosphorylation of Bmi1 (XREF_SUPPLEMENTARY) (XREF_BIBR).")
       (:PMID . "23092893") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "XREF_BIBR) (Akt inhibitors that suppress Akt activation processes including Akt-Ser473 phosphorylation), wortmannin or LY294002 (the inhibitors of PI3K upstream of Akt) reduced both Plk1-Ser99 phosphorylation and the interaction between Plk1 and 14-3-3gamma (XREF_SUPPLEMENTARY).")
       (:PMID . "23695676") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous studies have shown that AKT kinase inhibition increases AKT phosphorylation through negative feedback mechanisms.")
       (:PMID . "19394761") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Increased AKT phosphorylation can also be caused by defined AKT mutations.")
       (:PMID . "22363598") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN "uberon:UBERON:0000479")
        (:FOUND--BY . "Phosphorylation_syntax_4_noun") (:TISSUE)
        (:LOCATION "go:GO:0005886") (:CELL--LINE "cellosaurus:CVCL_2585")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, the inhibition of Akt phosphorylation by the application of wortmannin or by a specific reduction of Akt kinase activity reduced the hEAG mRNA levels.")
       (:PMID . "17520698") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Both trastuzumab and an allosteric AKT and PKB inhibitor could decrease PKB phosphorylation.")
       (:PMID . "24952873") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, upstream overexpression or knockdown of Akt2 or Akt2 phosphorylation inhibition, rather than Akt1 or Akt3, resulted in striking hyperphosphorylation or dephosphorylation of mTOR, p70S6K and rpS6 (all P < 0.05), without any change in total proteins expressions.")
       (:PMID . "26490682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It was observed that Akt substantially increased the level of 5-HT-induced Akt phosphorylation in Du145 cells and, to lesser extent in, PC-3 cells, but not in LNCaP cells.")
       (:PMID . "19926313") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of Akt phosphorylation by a PI3K inhibitor or dominant negative Akt mutant has been shown to suppress UVB induced COX-2 transcription in human keratinocytes [XREF_BIBR].")
       (:PMID . "25710724") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Acetylation blocked binding of Akt and PDK1 to PIP (3), thereby preventing membrane localization and phosphorylation of Akt.")
       (:PMID . "21775285") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylated PI3K generates the second messenger PIP3 that recruits Akt to the inner cell membrane, enabling phosphorylation of the Akt by its activating kinases, at the threonine 308 residue (by PDK1) and at the serine 473 residue [by rictor and mTOR complex in response to growth factor stimulation (XREF_BIBR) or by DNA-PK in response to DNA damage (XREF_BIBR)].")
       (:PMID . "22842582") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Under conditions of growth factor deprivation, the PI3K and Akt pathway is inactivated, FKHRL1 is unphosphorylated at its Akt sites, and FKHRL1 accumulates in the nucleus where it may activate death genes, including the Fas ligand gene, and thereby participate actively in the process of apoptosis.When fibroblasts are exposed to IGF1 or serum, Akt is activated and catalyzes the phosphorylation of FKHRL1.")
       (:PMID . "10102273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT phosphorylation is blocked by the inhibitors of AKT, PI3K and FGFR ().")
       (:PMID . "24662006") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Blocking of PI3K-Akt signaling by LY294002 has been shown to reduce Akt phosphorylation at both S473 and T308 sites (XREF_BIBR).")
       (:PMID . "25304263") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pharmacological inhibition of Akt efficiently abrogated both basal and TGF-beta-stimulated Akt phosphorylation ().")
       (:PMID . "18323784") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This notion was supported by the evidence that overexpression of the PH domain of Akt inhibited endogenous Akt phosphorylation, whereas the Akt PH domain mutant retaining the PI (3,4,5) P3 binding did not.")
       (:PMID . "20081374") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On membrane docking, AKT undergoes a conformational change and is phosphorylated by PDK1, thereby stimulating AKT and subsequent signaling via its downstream effectors ().")
       (:PMID . "11875759") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "dc543b7c-d94f-464d-9eea-a0caa1ae5177"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "On the other hand, phosphorylation of PGC-1alpha by AKT and protein kinase B (PKB), downstream of insulin signaling in the liver, is known to decrease its stability and transcriptional activity (XREF_BIBR).")
       (:PMID . "26831453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Because HST has been described to block EGF and EGFR- induced Akt and PKB phosphorylation and proliferation in vitro [20], the previously mentioned findings could be interpreted as an attempt by the HST positive cancer cells to block Akt and PKB phosphorylation.")
       (:PMID . "18592003") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt inhibition with LY294002 strongly diminished the phosphorylation of Akt and its downstream target 4E-BP1 in all five mesothelioma cell lines and control LP9 cells (XREF_FIG).")
       (:PMID . "19603014") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT inhibitors either compete for the catalytic ATP binding site of AKT or block phosphorylation of AKT in allosteric fashion [XREF_BIBR].")
       (:PMID . "25186604") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The OGA inhibitors might also have additional functions that activate the upstream kinase activity of AKT, which in turn might lead to AKT phosphorylation in neuronal cells.")
       (:PMID . "22687243") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, inhibition of AKT by the overexpression of kinase-dead AKT decreased the AKT phosphorylation levels, and resulted in decreased sensitivity to perifosine (XREF_FIG).")
       (:PMID . "25519148") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Several targets of p-AKT, such as BAD, MDM2 and FOXO1, contain the RXXS motif and are phosphorylated by p-AKT [XREF_BIBR - XREF_BIBR] (XREF_TABLE).")
       (:PMID . "23315288") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT overexpression completely prevented PEITC induced suppression of AKT phosphorylation.")
       (:PMID . "22952709") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It was observed that Akt substantially increased the level of 5-HT-induced Akt phosphorylation in Du145 cells and, to lesser extent in, PC-3 cells, but not in LNCaP cells.")
       (:PMID . "19926313") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, expression of dominant negative Akt abrogated endogenous Akt activity, Rab3D phosphorylation and GAG synthesis, whereas expression of constitutively activated Akt stimulated Rab3D phosphorylation and GAG synthesis in the absence of PDGF-BB.")
       (:PMID . "11903042") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR) (Akt inhibitors that suppress Akt activation processes including Akt-Ser473 phosphorylation), wortmannin or LY294002 (the inhibitors of PI3K upstream of Akt) reduced both Plk1-Ser99 phosphorylation and the interaction between Plk1 and 14-3-3gamma (XREF_SUPPLEMENTARY).")
       (:PMID . "23695676") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Analyses of AKT kinase inhibitors have shown that acute AKT inhibition causes a paradoxical increase of AKT phosphorylation, probably through a negative feedback loop.")
       (:PMID . "19394761") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, MDA-MB-231 cells expressing either helical domain or kinase domain p110alpha mutants showed elevated basal levels of Akt phosphorylation as well as enhanced EGF stimulated Akt phosphorylation.")
       (:PMID . "19903845") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Insulin stimulates phosphorylation of Akt and activated Akt exerts various biological effects such as cell growth and survival, angiogenesis, and metabolism by regulating downstream effectors [XREF_BIBR].")
       (:PMID . "26491696") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the addition of trastuzumab did not inhibit the already low level of HER2 phosphorylation or further diminish the minimally detectable HER3 phosphorylation in these cells, nor did it further decrease PI3K-Akt signaling through Akt or S6 phosphorylation.")
       (:PMID . "24451154") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, both PI3K and Akt activators, pervanadate and insulin, partly reversed the inhibition of TGF-beta1-induced Akt phosphorylation by anti-miR33a, whereas Akt specific inhibitor MK2206 did not show this reversed inhibition effect.")
       (:PMID . "24100264") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The data presented here show that c48/80 : i) at low doses (up to 10mug/ml) augments serum induced phosphorylation of PKB and p70 in a manner sensitive to both PI 3-kinase and PKC inhibitors, ii) at higher doses induces the phosphorylation of p70 and the translocation of PKCalpha in a PI 3-kinase dependent fashion, but inhibits the phosphorylation of PKB.")
       (:PMID . "16942862") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We first show that this dominant negative Akt (DN-Akt) eliminates Akt phosphorylation in response to Insulin Growth Factor in cells transfected with DN-Akt compared to empty vector (XREF_FIG).")
       (:PMID . "23409128") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Acetylation blocked binding of Akt and PDK1 to PIP (3), thereby preventing membrane localization and phosphorylation of Akt.")
       (:PMID . "21775285") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, we sought to analyze other biologically relevant, cancer related proteins, including downstream targets of PI3K signaling, such as phosphorylated Akt (p-Akt), mTOR (p-mTOR), and S6 ribosomal protein (p-S6).")
       (:PMID . "22674438") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These observations establish that TCL1 functions as an Akt kinase coactivator, which enhances the phosphorylation and activation of Akt in vivo.We next studied the biological effects of the TCL1 and Akt interaction in vivo.Transient transfection of TCL1 into the 293 cell line resulted in a 10-fold increase of proliferative responses (, lane 2).")
       (:PMID . "10983986") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Increased AKT phosphorylation can also be caused by defined AKT mutations.")
       (:PMID . "22363598") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN "uberon:UBERON:0000479")
        (:FOUND--BY . "Phosphorylation_syntax_4_noun") (:TISSUE)
        (:LOCATION "go:GO:0005886") (:CELL--LINE "cellosaurus:CVCL_2585")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "A specific inhibitor of AKT kinase, GSK690693, inhibited AKT phosphorylation (XREF_FIG) and attenuated CXCL12 induced migration by 56% (XREF_FIG).")
       (:PMID . "25897806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In accordance with the RPMI 8226 cell data, CXCL12 induced AKT phosphorylation and LPS suppressed CXCL12 mediated AKT phosphorylation in plasmablasts (Fig XREF_FIG and XREF_FIG).")
       (:PMID . "25897806") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in XREF_FIG, Akt siRNA, as expected, completely abolished the phosphorylation of Akt and caused a 1.4-folds increase in cleaved caspase-3 protein level.")
       (:PMID . "24699278") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Third, Akt phosphorylates Osterix and Akt activation prolonged the half-life of the Osterix protein.")
       (:PMID . "21777568") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "High degrees of Akt phosphorylation and hyperactivation of the Akt signaling pathway are hallmarks of tumors in which PTEN function is impaired.")
       (:PMID . "20388916") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT phosphorylation is blocked by the inhibitors of AKT, PI3K and FGFR ().")
       (:PMID . "24662006") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The reduced AKT activation in MCF-7PIK3CAWT cells in turn caused greatly reduced phosphorylation of known AKT target proteins, including PRAS40, FOXO 1/3, and AS160.")
       (:PMID . "23888070") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This notion was supported by the evidence that overexpression of the PH domain of Akt inhibited endogenous Akt phosphorylation, whereas the Akt PH domain mutant retaining the PI (3,4,5) P3 binding did not.")
       (:PMID . "20081374") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results suggest that GRP induces c-Src dependent Akt phosphorylation but EGF stimulates Akt phosphorylation directly, without involvement of c-Src.")
       (:PMID . "17349623") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Under conditions of growth factor deprivation, the PI3K and Akt pathway is inactivated, FKHRL1 is unphosphorylated at its Akt sites, and FKHRL1 accumulates in the nucleus where it may activate death genes, including the Fas ligand gene, and thereby participate actively in the process of apoptosis.When fibroblasts are exposed to IGF1 or serum, Akt is activated and catalyzes the phosphorylation of FKHRL1.")
       (:PMID . "10102273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, inhibiting Akt activation using the PI3K inhibitor LY294002 completely prevented EPO+IGFI-I-induced Akt phosphorylation and GSK-3beta phosphorylation compared to control (see XREF_FIG), confirming the involvement of the PI3K/Akt/GSK-3beta pathway.")
       (:PMID . "20818790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Active recombinant Akt readily phosphorylated Bmi1, but not a Bmi1 S316A mutant protein (XREF_FIG), and expression of a constitutively active form of Akt (myristoylated Akt) in human embryonic kidney (HEK) 293T cells resulted in phosphorylation of Bmi1 (XREF_SUPPLEMENTARY) (XREF_BIBR).")
       (:PMID . "23092893") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These compounds inhibited Akt activation and phosphorylation of several downstream substrates of Akt in tumor cells without affecting the activities of upstream kinases (such as PI3-K and 3-phosphoinositide-dependent protein kinase 1 (PDK1, also known as PDPK1), or members of other signaling pathways such as ERK2.")
       (:PMID . "21110830") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On membrane docking, AKT undergoes a conformational change and is phosphorylated by PDK1, thereby stimulating AKT and subsequent signaling via its downstream effectors ().")
       (:PMID . "11875759") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The receptor activation elicits phosphorylation of IRS-1 and AKT and PKB in CHO cells.")
       (:PMID . "23220417") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Previous studies have shown that AKT kinase inhibition increases AKT phosphorylation through negative feedback mechanisms.")
       (:PMID . "19394761") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, the inhibition of Akt phosphorylation by the application of wortmannin or by a specific reduction of Akt kinase activity reduced the hEAG mRNA levels.")
       (:PMID . "17520698") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Both trastuzumab and an allosteric AKT and PKB inhibitor could decrease PKB phosphorylation.")
       (:PMID . "24952873") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, coimmunoprecipitation experiments showed that PDK1 did not associate with any of the three TCL1 family members, suggesting that there is no direct TCL1 induced Akt, TCL1, and PDK1 complex formation in vivo.Our data show that TCL1 induces Akt kinase activity dependent phosphorylation of Akt on both Ser 473 and Thr 308.")
       (:PMID . "10983986") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Elevation of AKT3 protein increases protein abundance of B-Raf and phosphorylation of AKT while decreases expression of TSC1 and TSC2 proteins.")
       (:PMID . "26318033") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The Akt Inhibitor X selectively inhibits the phosphorylation of Akt with minimal effects on PI3K, PDK1, or SGK1 signaling.")
       (:PMID . "18159252") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pharmacological inhibition of Akt efficiently abrogated both basal and TGF-beta-stimulated Akt phosphorylation ().")
       (:PMID . "18323784") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt was rapidly phosphorylated by glimepiride treatment (A) and antisense Akt completely inhibited glimepiride induced NO production (= 5, < 0.05; B).")
       (:PMID . "16216590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylated PI3K generates the second messenger PIP3 that recruits Akt to the inner cell membrane, enabling phosphorylation of the Akt by its activating kinases, at the threonine 308 residue (by PDK1) and at the serine 473 residue [by rictor and mTOR complex in response to growth factor stimulation (XREF_BIBR) or by DNA-PK in response to DNA damage (XREF_BIBR)].")
       (:PMID . "22842582") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Blocking of PI3K-Akt signaling by LY294002 has been shown to reduce Akt phosphorylation at both S473 and T308 sites (XREF_BIBR).")
       (:PMID . "25304263") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of Akt phosphorylation by a PI3K inhibitor or dominant negative Akt mutant has been shown to suppress UVB induced COX-2 transcription in human keratinocytes [XREF_BIBR].")
       (:PMID . "25710724") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Next, a specific inhibitor of PI3K and Akt pathway, LY294002, was used to inhibit Akt phosphorylation in wound healing assay to test whether inhibition of Akt phosphorylation has effect on VEGF 165 -induced migration.")
       (:PMID . "24987682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "5b26ed00-4e9c-4a44-8e5c-60bd15309e12"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "4E-BP1") (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:TEXT
        . "Unlike the parental HCT116, inhibition of AKT alone in HKh-2 and HKe-3 (wild-type RAS) cells was sufficient to inhibit phosphorylation of p70S6K, S6 and 4E-BP1, induce binding of 4E-BP1 to the eIF4E mRNA complex and inhibit cap dependent translation (XREF_FIG and XREF_SUPPLEMENTARY).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Combined Inhibition of AKT and ERK Are Required to Suppress 4E-BP1 Phosphorylation and Tumor Growth in Vivo.")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Combined inhibition of ERK and AKT both effectively inhibits 4E-BP1 phosphorylation and prevents reactivation of ERK and AKT and thus may have a therapeutic advantage.")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "An inhibitor of Akt diminished IGF-I-mediated phosphorylation of 4E-BP1, whereas inhibiting MAPK signalling had no such effect.")
       (:PMID . "19603014") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Expression of constitutively active Akt stimulates 4E-BP1 phosphorylation and VEGF expression in the absence of alpha6beta4 signaling.")
       (:PMID . "12105188") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, blockade of Akt inhibited phosphorylation of 4E-BP1 and S6, confirming that the mTOR pathway is downstream of Akt in monocytes (C and).")
       (:PMID . "18848473") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The functional consequences of Akt phosphorylation show activating and inactivating phosphorylations of S6 kinase and 4EBP-1, respectively, thus demonstrating activation of TORC1.")
       (:PMID . "21426932") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Erlotinib pre-treatment prevented Akt phosphorylation and subsequent hyperphosphorylation of 4E-BP1 in each of the cell lines after 20 minutes of EGF stimulation.")
       (:PMID . "23883783") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Selective knockdown of AKT1, but not AKT2 or AKT3, was sufficient to induce significant G1 arrest, loss of cells in S phase and downregulation of cyclin D3 expression and S6- and 4EBP1 phosphorylation (XREF_FIG and XREF_SUPPLEMENTARY).")
       (:PMID . "22328975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Both the PI3K and AKT and RAS and MAPK signal transduction pathways mediate 4E-BP1 phosphorylation, releasing 4E-BP1 from the mRNA cap and permitting translation initiation.")
       (:PMID . "19336517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, both RAS and MAPK and PI3K and AKT signaling mediate phosphorylation of 4E-BP1, thereby disengaging the protein from the mRNA cap and disinhibiting translation (XREF_BIBR, XREF_BIBR).")
       (:PMID . "19336517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylation decreases the ability of TSC2 to inhibit the phosphorylation of ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E binding protein-1 (4EBP1), which are mTOR substrates.")
       (:PMID . "14651849") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As expected, the inhibition of PI3K and Akt through LY294002 (20muM) and Akti1/2 (2muM), respectively, and Akt depletion using specific siRNA abrogated the -induced phosphorylation of 4E-BP1 and prevented de-phosphorylation of eEF2 (C, D; Supplementary Fig. 1).")
       (:PMID . "25194338") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Given the convergence of RAS and MAPK and PI3K and AKT signaling that mediates phosphorylation of 4E-BP1, dephosphorylation of 4E-BP1 may prove to be an effective strategy to improve treatment outcome in patients with metastatic melanoma.")
       (:PMID . "19336517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, in tumor cells with coexistent KRAS and PIK3CA mutations (HCT116), inhibition of neither AKT nor MEK was sufficient to rapidly inhibit phosphorylation of p70S6K, S6, or 4E-BP1 at any of its four phosphorylation sites, although modest inhibition was observed after exposure to the MEK inhibitor for 24 h. However, combined inhibition of MEK and AKT synergistically inhibited phosphorylation of all these sites 6 h after drug exposure and profoundly by 12 h (XREF_FIG).")
       (:PMID . "20609351") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "0829abd3-fe90-4d0d-9aba-ad2f61d6984d"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "Elk-1") (:+UP+ . "P19419") (:+HGNC+ . "3321"))
      (:NAME . "ELK1"))
     (:SUPPORTED--BY "71e84804-8b59-4792-85c9-69e7caa8f847")
     (:EVIDENCE
      ((:TEXT
        . "The PI3K and Akt pathway did not directly phosphorylate the Elk-1 but it played a major role in the nuclear localization of phosphorylated ERK1/2 and Elk-1.")
       (:PMID . "22085529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The PI3K and Akt pathway did not directly phosphorylate the Elk-1 but it played a major role in the nuclear localization of phosphorylated ERK1/2 and Elk-1.")
       (:PMID . "22085529") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, Elk-1 has been implicated in protecting cells from apoptosis (), and downregulating apoptosis associated genes (), thereby mediating cell survival, and Akt dependent phosphorylation of Elk-1 has been shown to be important for proliferation of glioblastoma cells (; Mut and Kurnaz, unpublished data).")
       (:PMID . "19013529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "ac0da557-ab17-4669-aac0-87e6984fbd17"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERALPHA") (:+NCIT+ . "C38361") (:+UP+ . "P03372")
       (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d"
      "0cec3a16-7a67-46ec-a8b4-c922fb1a9c90"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf")
     (:EVIDENCE
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT overexpression increased ERalpha S167 phosphorylation and reduced tamoxifen sensitivity, whereas inhibition of AKT using RNAi directed toward AKT decreased ERalpha S167 phosphorylation and restored tamoxifen sensitivity.")
       (:PMID . "25597633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT . "7838153;9528769;11432835;11139588") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT
        . "Coexpression of wild-type ER-alpha and the dominant negative Akt mutant in COS-1 cells also blocked the growth factor-stimulated activation of ER-alpha, but coexpression of the wild-type receptor with the constitutively active Akt mutant increased ER-alpha activity. Receptor activation was blocked by an antiestrogen. Studies using mutants of ER-alpha demonstrated that Akt increased estrogen receptor activity through the amino-terminal activation function-1 (AF-1). Serines S104 S106, S118, and S167 appear to play a role in the activation of ER-alpha by Akt.")
       (:PMID . "11108261") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_167")
       (:TEXT
        . "Cyclooxygenase-2 (COX-2) antagonists, by blocking prostaglandin production, might inhibit this pathway 149.")
       (:PMID . "12635173") (:SOURCE--API . "bel"))
      ((:TEXT
        . "Indeed, it has been shown that AKT phosphorylates the Ser167 residue of ER and increases its transcriptional activity, resulting in the preferential growth of ER positive cells in the presence of PIK3CA mutations.")
       (:PMID . "22640628") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "641ff626-ad1a-4e13-9f78-f442c5270d8b"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "FOXO-3-A") (:+NCIT+ . "C52907") (:+HGNC+ . "3821")
       (:+UP+ . "O43524"))
      (:NAME . "FOXO3"))
     (:SUPPORTED--BY "b7752bf2-bf69-46d3-8f1a-a8dc623a8814"
      "ff94ebce-6c96-4564-bac0-ff4697a4b6c5"
      "623116f2-59fc-4d0e-8d38-6f8233415db0"
      "c72805ce-5398-4ce7-bfc1-560f39139191"
      "bfd8642f-2d41-485b-a345-aec96180a7fa")
     (:EVIDENCE
      ((:TEXT
        . "Akt phosphorylates FoxO3a at Thr32, Ser253 and Ser315, leading to its cytoplasmic sequestration by 14-3-3 proteins, thus preventing its nuclear translocation [XREF_BIBR].")
       (:PMID . "26405162") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT phosphorylation of FoxO3 at sites T32, S253, and S315 results in nuclear exclusion of FoxO3 [XREF_BIBR].")
       (:PMID . "23262029") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Consistent with this notion, one of the first and potentially most important control mechanisms characterized for FOXO3a is its regulation by Akt, where the phosphorylation of FOXO3a at Ser32, Ser253 and Ser315 by Akt results in the cytoplasmic accumulation and subsequent degradation of this transcription factor XREF_BIBR.")
       (:PMID . "23691078") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Previous studies have shown that IKBKE directly activates Akt and that Akt inhibits FOXO3a by phosphorylation of Ser32, Ser253 and Ser315.")
       (:PMID . "23691078") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT and SGK also phosphorylate FOXO1 and FOXO3A at Thr32, Ser253, and Ser315 (FOXO3A numbering) (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT and SGK also phosphorylate FOXO1 and FOXO3A at Thr32, Ser253, and Ser315 (FOXO3A numbering) (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "FOXO activities are negatively regulated by Akt, which phosphorylates FOXO at T-32, S253 and S315.")
       (:PMID . "20966391") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Consistent with this notion, one of the first and potentially most important control mechanisms characterized for FOXO3a is its regulation by Akt, where the phosphorylation of FOXO3a at Ser32, Ser253 and Ser315 by Akt results in the cytoplasmic accumulation and subsequent degradation of this transcription factor XREF_BIBR.")
       (:PMID . "23691078") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylates FoxO3a at Thr32, Ser253 and Ser315, leading to its cytoplasmic sequestration by 14-3-3 proteins, thus preventing its nuclear translocation [XREF_BIBR].")
       (:PMID . "26405162") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These studies demonstrated that AKT phosphorylates FoxO proteins on three residues, Threonine 32, Serine 253 and Serine 315 (for human FoxO3).")
       (:PMID . "21621563") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The expression of constitutively active Akt induces the phosphorylation of FKHRL1 at S315 in cells, but Akt does not effectively catalyze the phosphorylation of FKHRL1 at S315 in vitro.")
       (:PMID . "10102273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "FOXO3a are phosphorylated and inactivated by AKT through phosphorylation at Thr32, Ser253, and Ser315 which results in nuclear export and inhibition of its transcription activity XREF_BIBR, XREF_BIBR.")
       (:PMID . "20885957") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "315")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "38b5e67b-5fec-445f-aa7f-bb0a6a4922ef"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:SUPPORTED--BY "5a811a3f-68fe-4e92-a094-b1cfa8bb0f95"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "e7745740-7cac-4af4-b69c-28072023d560"
      "b2906128-c303-48b3-b49c-11714f5a6702"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE
      ((:TEXT
        . "Akt phosphorylates GSK3beta on Ser9, thereby creating a competitive pseudosubstrate that blocks substrate phosphorylation (XREF_BIBR).")
       (:PMID . "21665151") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Since inhibiting the PI3K and Akt cascade resulted in decreased phosphorylation of GSK3beta Ser9 and increased MN differentiation from hNSCs, we then asked if the increase in HB9 expression was due to the increase in GSK3beta activity.")
       (:PMID . "21887250") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation of GSK3beta at ser9 is exclusively mediated by the action of Akt.")
       (:PMID . "25172557") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results indicate that activation of GSK-3 rather than Erk1/2 and p38 may play a pivotal role in the AGE induced tau hyperphosphorylation.It is well known that Akt can phosphorylate GSK-3beta at Ser9 and thus inhibit the kinase ().")
       (:PMID . "21450369") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We postulated that inhibitory phosphorylation of GSK-3beta at Ser9 by Akt might cause the increase in Snail, Zeb2, and Twist mRNA.")
       (:PMID . "24571487") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Activated Akt phosphorylates GSK-3beta at Ser 9 and inactivates its kinase activity.")
       (:PMID . "15652488") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "It has been demonstrated that in response to certain growth stimuli XREF_BIBR, XREF_BIBR - XREF_BIBR, PI3K activated AKT can phosphorylate GSK-3beta at Ser9, leading to inactivation of GSK-3beta and augmentation of beta-catenin-TCF4 transcriptional activity XREF_BIBR.")
       (:PMID . "19190323") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Activated Akt phosphorylates GSK-3beta at Ser 9 and inactivates its kinase activity.")
       (:PMID . "15652488") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In turn, activated Akt phosphorylates GSK3beta, a constitutively active kinase, on the Ser 9 residue and renders it inactive ().")
       (:PMID . "18191226") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AKT phosphorylates GSK3 on serine 9 for GSK3beta or 21 for GSK3alpha, thereby inactivating GSK3 XREF_BIBR.")
       (:PMID . "23077590") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "It has been demonstrated that in response to certain growth stimuli XREF_BIBR, XREF_BIBR - XREF_BIBR, PI3K activated AKT can phosphorylate GSK-3beta at Ser9, leading to inactivation of GSK-3beta and augmentation of beta-catenin-TCF4 transcriptional activity XREF_BIBR.")
       (:PMID . "19190323") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Ser 9 of GSK-3beta is phosphorylated by Akt and Thr 390 is phosphorylated by p38 MAPK, respectively.")
       (:PMID . "26121043") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Suppression of GS phosphorylation normally occurs when GSK3beta is phosphorylated at Ser9 by AKT as a part of the insulin and IGF -1 signaling pathway XREF_BIBR.")
       (:PMID . "19107203") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Active Akt phosphorylates, among other targets, GSK3beta on Ser 9.")
       (:PMID . "18262492") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To prevent interference by Akt, which is also able to phosphorylate GSK-3beta at Ser9, the above 12 tumor tissues were preselected to be negative for phosphorylated Akt by IHC ().")
       (:PMID . "16039586") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Both Akt and Erks can phosphorylate GSK-3beta at the crucial Ser9 residue.")
       (:PMID . "25172662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Growth factors such as insulin activate AKT, which in turn phosphorylates GSK3beta at Ser9, an inhibitory phosphorylation site (XREF_BIBR).")
       (:PMID . "19303846") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylates GSK3beta on Ser9, thereby creating a competitive pseudosubstrate that blocks substrate phosphorylation (XREF_BIBR).")
       (:PMID . "21665151") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As expected, Akt knock-down by Akt specific siRNA led to undetectable levels of GSK3beta (Ser 9) phosphorylation after H. pylori infection, but had no effect on H. pylori induced phosphorylation of PDK1 Ser 241.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_8a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the PI3K pathway Akt phosphorylates GSK3beta at Ser9 and blocks GS3Kbeta driven degradation of beta catenin.")
       (:PMID . "18675921") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Suppression of GS phosphorylation normally occurs when GSK3beta is phosphorylated at Ser9 by AKT as a part of the insulin and IGF -1 signaling pathway XREF_BIBR.")
       (:PMID . "19107203") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Since S9 of GSK-3beta is phosphorylated by Akt, we also examined the phosphorylation of Akt at S473, a hallmark of Akt activity.")
       (:PMID . "25979842") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Insulin was reported to inhibit GSK3 beta through the activation of Akt, which stimulates the phosphorylation and inhibition of GSK3 beta at ser 9 (XREF_BIBR, XREF_BIBR).")
       (:PMID . "23302227") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On the other hand, within the first minutes of LPS exposure, TLR4 activates phosphatidylinositol 3-kinase (PI3K) and its mediator AKT which induces phosphorylation of GSK3beta on Ser9 ().")
       (:PMID . "21334395") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We show that apo (a) increases phosphorylation of both sites for a full activation of Akt (XREF_FIG), which can then phosphorylate GSK-3beta at Ser 9 (XREF_FIG).")
       (:PMID . "23243000") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_GSK3B_pmod_P_S_9")
       (:TEXT
        . "In various cell types, AKT phosphorylates and inhibits glycogen synthase kinase-3 (GSK-3). Upon serum stimulation of EC, GSK-3beta was phosphorylated at Ser-9.")
       (:PMID . "11779850") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_GSK3B_pmod_P_S_9")
       (:TEXT
        . "GSK-3 activity is inhibited through phosphorylation of serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta. These serine residues of GSK-3 have been previously identified as targets of protein kinase B (PKB/Akt), a serine/threonine kinase located downstream of phosphatidylinositol 3-kinase.      ")
       (:PMID . "11035810") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_GSK3B_pmod_P_S_9")
       (:TEXT
        . "in the presence of Dvl, Akt increased the amount of phosphorylated GSK3beta in the Axin complex (Fig. 4B, IP).")
       (:PMID . "11278246") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_GSK3B_pmod_P_S_9")
       (:TEXT
        . "phosphorylation of GSK3beta  at Ser9, which results in its inactivation (10), was higher in [wnt3a overexpressing] than in control cells (Fig. 1, A and B).")
       (:PMID . "11278246") (:SOURCE--API . "bel")))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "0a42b47d-c9d6-49c6-ae41-1a8116303210"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "IRS-1") (:+UP+ . "P35568") (:+HGNC+ . "6125"))
      (:NAME . "IRS1"))
     (:SUPPORTED--BY "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE
      ((:TEXT
        . "Finally, to understand if the observed differences in serine phosphorylation are associated with downstream abnormalities in the insulin signaling cascade, we additionally investigated phosphorylation of the IRS-1 target Akt.")
       (:PMID . "25107476") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function.")
       (:PMID . "10497255") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, Ser (629) of IRS-1 is directly phosphorylated by Akt in vitro.")
       (:PMID . "17640984") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, phosphorylation of IRS1 (insulin receptor substrate 1) by PKC, Erk, and Akt results in reduced complex formation with PI-3 kinase.")
       (:PMID . "12419216") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "a4d943d8-0383-496b-a58c-bc00a276b29b"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "18 As expected, CP724714 inhibited phosphorylation of ERK and pERK and AKT and pAKT (XREF_FIG).")
       (:PMID . "24763051") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT inhibition increases phosphorylation of EGFR at Tyr 1068 and phosphorylation of ERK in MCF10A cells.")
       (:PMID . "23757022") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Of interest, we found that overexpression of RhoU correlates with an increased phosphorylation of JNK and ERK (XREF_FIG) but not PLCgamma or AKT on EGF stimulation (Supplemental Figure S3F).")
       (:PMID . "21508312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In the latter evodiamine caused increased ERK phosphorylation and reduced insulin stimulated phosphorylation of Akt, which were prevented by the MEK inhibitor PD98059.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Immunoblotting lysates of H441 cells treated with cediranib, MK2206 (AKT inhibitor) or AZD6244 (MEK inhibitor) for 24 h showed that MK2206 significantly reduced AKT phosphorylation and AZD6244 reduced p42/44 MAPK phosphorylation and, to a lesser extent, AKT phosphorylation (XREF_FIG).")
       (:PMID . "26179332") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 phosphorylation was reduced not only by MAPK pathway inhibitors but also by PI3K and mTOR inhibitors; when PI3K was inhibited, ERK phosphorylation could be induced by microinjected activated Akt, indicating important cross-talk between the PI3K and ERK1/2 pathways.")
       (:PMID . "15242975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Effect of Akt knock-down by siRNA on H. pylori induced phosphorylation of GSK3, PDK1 and mitogen activated protein kinase.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "765e57c9-eb47-41dd-9c23-004b0fd96bb8"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Furthermore, we observed that the inhibition of AKT (with the inhibitor LY294002) decreased the phosphorylation of ERK and p38 (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "18 As expected, CP724714 inhibited phosphorylation of ERK and pERK and AKT and pAKT (XREF_FIG).")
       (:PMID . "24763051") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In the latter evodiamine caused increased ERK phosphorylation and reduced insulin stimulated phosphorylation of Akt, which were prevented by the MEK inhibitor PD98059.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Of interest, we found that overexpression of RhoU correlates with an increased phosphorylation of JNK and ERK (XREF_FIG) but not PLCgamma or AKT on EGF stimulation (Supplemental Figure S3F).")
       (:PMID . "21508312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT inhibition increases phosphorylation of EGFR at Tyr 1068 and phosphorylation of ERK in MCF10A cells.")
       (:PMID . "23757022") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR also observed that Akt phosphorylates stress activated protein kinase and extracellular signal regulated kinase (SEK) 1 on Ser 78 residue, resulting in the inhibition of SEK1 enzyme activity.")
       (:PMID . "15998799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Immunoblotting lysates of H441 cells treated with cediranib, MK2206 (AKT inhibitor) or AZD6244 (MEK inhibitor) for 24 h showed that MK2206 significantly reduced AKT phosphorylation and AZD6244 reduced p42/44 MAPK phosphorylation and, to a lesser extent, AKT phosphorylation (XREF_FIG).")
       (:PMID . "26179332") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 phosphorylation was reduced not only by MAPK pathway inhibitors but also by PI3K and mTOR inhibitors; when PI3K was inhibited, ERK phosphorylation could be induced by microinjected activated Akt, indicating important cross-talk between the PI3K and ERK1/2 pathways.")
       (:PMID . "15242975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Effect of Akt knock-down by siRNA on H. pylori induced phosphorylation of GSK3, PDK1 and mitogen activated protein kinase.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "52443b67-c541-4e30-8b0a-234bdb8aa3b5"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "MDM2") (:+UP+ . "Q00987") (:+HGNC+ . "6973"))
      (:NAME . "MDM2"))
     (:SUPPORTED--BY "3c907759-cd94-415c-bc57-49a13d88672b"
      "75c2cb7e-efe5-4562-83e6-ce0db1804555"
      "7959e20d-649a-4bd6-93d0-b63bbc6b94a4"
      "92020234-287c-49df-98bc-045bb87cefd0"
      "174e2a12-386f-4ec1-b626-e4193aea8dec")
     (:EVIDENCE
      ((:TEXT
        . "This finding is in keeping with studies showing that AKT physically associates with MDM2 and phosphorylates MDM2 at Ser166 and Ser186, leading to nuclear translocation and degradation of the tumour-suppressor p53 (XREF_BIBR; XREF_BIBR), and that activation of MDM2 by AKT in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis (XREF_BIBR).")
       (:PMID . "24762959") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT inhibition by GDC0941 abolished MDM2 phosphorylation at Ser166 and induced p53 and p21 expression (XREF_FIG).")
       (:PMID . "24762959") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To regulate IRF1, Mdm2 must gain nuclear entry, a process which requires phosphorylation of Mdm2 at Ser166 by PKB ().")
       (:PMID . "24721577") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The serine/threonine kinase Akt phosphorylates Mdm2 at serine 166 and 186 and causes Mdm2 shift to the nucleus where it is considered to play a role in p53 degradation.")
       (:PMID . "19124015") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Following growth factor stimulation, Akt phosphorylates Mdm2 at Ser166 and Ser186 [XREF_BIBR], which increases Mdm2 half-life and stimulates Mdm2 dependent p53 degradation.")
       (:PMID . "20172729") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "To regulate IRF1, Mdm2 must gain nuclear entry, a process which requires phosphorylation of Mdm2 at Ser166 by PKB ().")
       (:PMID . "24721577") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt and ERK activate MDM2 phosphorylation at Ser166 resulting in diminishing cellular levels and transcriptional activity of p53 [XREF_BIBR - XREF_BIBR].")
       (:PMID . "25431954") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation of HDM2 (S166) by AKT is known to enhance HDM2 mediated P53 ubiquitination and degradation (XREF_BIBR).")
       (:PMID . "24240108") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Following growth factor stimulation, Akt phosphorylates Mdm2 at Ser166 and Ser186 [XREF_BIBR], which increases Mdm2 half-life and stimulates Mdm2 dependent p53 degradation.")
       (:PMID . "20172729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "166")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "28472734-4d6f-4c48-9619-7c3cfcb12589"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "MTOR") (:+NCIT+ . "C38929") (:+UP+ . "P42345")
       (:+HGNC+ . "3942"))
      (:NAME . "MTOR"))
     (:SUPPORTED--BY "3f164d35-7b34-4585-bbd6-884b979e4395"
      "c697f765-6c74-43aa-a0ff-dae0f8edd37c"
      "c3fd1005-b622-4721-8f84-11a8568461ca"
      "e20ea4ea-43a4-4fed-b58d-5517f73f2874"
      "a2809255-b705-499e-b575-86ffaea8ab6a")
     (:EVIDENCE
      ((:TEXT
        . "Akt then phosphorylates mTOR at Serine 2448 and activates mTORC1 (XREF_BIBR), which inhibits autophagy by targeting autophagy related protein (ATG) 13 (XREF_BIBR).")
       (:PMID . "24606695") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of mTOR by Akt at serine 2448 might not correlate with mTOR activation, therefore, pmTOR 2448 may not necessary be involved with the development of HRPC, and a more appropriate marker of mTOR activation could be S6Kinase (Ruggero and Sonenberg, 2005)")
       (:PMID . "18349820") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Akt then phosphorylates mTOR at Serine 2448 and activates mTORC1 (XREF_BIBR), which inhibits autophagy by targeting autophagy related protein (ATG) 13 (XREF_BIBR).")
       (:PMID . "24606695") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt can phosphorylate mTOR directly at threonine 2446 and serine 2448, but can also activate mTOR indirectly via phosphorylation of TSC2 (Majumder and Sellers, 2005).")
       (:PMID . "18349820") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt then phosphorylates mTOR at Serine 2448 and activates mTORC1 (XREF_BIBR), which inhibits autophagy by targeting autophagy related protein (ATG) 13 (XREF_BIBR)")
       (:PMID . "24606695") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Phosphorylation of mTOR by Akt at serine 2448 might not correlate with mTOR activation, therefore, pmTOR 2448 may not necessary be involved with the development of HRPC, and a more appropriate marker of mTOR activation could be S6Kinase (Ruggero and Sonenberg, 2005).")
       (:PMID . "18349820") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of mTOR by Akt at serine 2448 might not correlate with mTOR activation, therefore, pmTOR 2448 may not necessary be involved with the development of HRPC, and a more appropriate marker of mTOR activation could be S6Kinase ( xref ).")
       (:PMID . "18349820") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Akt can phosphorylate mTOR directly at threonine 2446 and serine 2448, but can also activate mTOR indirectly via phosphorylation of TSC2 (Majumder and Sellers, 2005).")
       (:PMID . "18349820") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Our results showed that the expressions of EGFR and mTOR dropped off with the ageing of the rats, and Ser473 phosphorylation of Akt and Ser2448 phosphorylation of mTOR were highly expressed in foetal and newborn rats but decreased obviously in adult rats.")
       (:PMID . "23681769") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Although AKT phosphorylated mTOR at two COOH-terminal sites (Thr2446 and Ser2448) in vitro, Ser2448 was the major phosphorylation site in insulin stimulated or -activated AKT expressing human embryonic kidney cells.")
       (:PMID . "10910062") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of mTOR by Akt at serine 2448 might not correlate with mTOR activation, therefore, pmTOR 2448 may not necessary be involved with the development of HRPC, and a more appropriate marker of mTOR activation could be S6Kinase (Ruggero and Sonenberg, 2005).")
       (:PMID . "18349820") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "2448")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "b9f10f92-d5b3-4d48-82c9-20e82a386248"))
    ((:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:TEXT
        . "In addition, our results demonstrated that Akt phosphorylated FAK at three novel serine phosphorylation sites, which were also not required for FAK-Akt binding.")
       (:PMID . "21209368") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "01917090-02e4-467e-bef6-6a1ca9bc00b2"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "c-Raf") (:+UP+ . "P04049") (:+HGNC+ . "9829"))
      (:NAME . "RAF1"))
     (:SUPPORTED--BY "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "e08dcdee-5e38-4e65-b179-2502cd6247f5"
      "d7246dff-a20f-4f44-bb04-75c3afeb4cd4"
      "0c3defb4-0500-48a8-b740-25905eef5cc0")
     (:EVIDENCE
      ((:TEXT
        . "Akt is the downstream effector of PI3K, and interestingly, Akt is able to phosphorylate c-Raf at S259 [XREF_BIBR].")
       (:PMID . "25817574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "According to previous studies, Akt phosphorylates Raf at Ser259, leading to inhibition of the Raf/MEK/ERK pathway.")
       (:PMID . "26797279") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Active AKT (pAKT) phosphorylates RAF at serine residue Ser 259 and inhibits the activation of the RAF-MEK-ERK signaling pathway [XREF_BIBR].")
       (:PMID . "26930065") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "At high doses of insulin growth factor, active AKT phosphorylates RAF at serine residue Ser 259 and thus suppresses the activity of RAF-MEK-ERK signaling pathway [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26930065") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "According to previous studies, Akt phosphorylates Raf at Ser259, leading to inhibition of the Raf/MEK/ERK pathway")
       (:PMID . "26797279") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Previous studies have shown that c-Raf could be phosphorylated on its inhibitory site S259 by two kinases Protein Kinase A (PKA) or AKT and protein kinase B (PKB) [XREF_BIBR - XREF_BIBR].")
       (:PMID . "21745501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "At high doses of insulin growth factor, active AKT phosphorylates RAF at serine residue Ser 259 and thus suppresses the activity of RAF-MEK-ERK signaling pathway [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26930065") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Note that increased Akt mediated phosphorylation of Raf-1 at Ser 259 by TGFbeta did not have any inhibitory effect on MEK and Erk phosphorylation (XREF_FIG and XREF_FIG)")
       (:PMID . "23359369") (:SOURCE--API . "sparser")))
     (:POSITION . "259")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "3e72e47d-bbed-439b-98d3-a6c62d9bb44c"))
    ((:SUB (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "activity"))
      (:DB--REFS (:+TEXT+ . "TSC-2") (:+NCIT+ . "C17913") (:+UP+ . "P49815")
       (:+HGNC+ . "12363"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef"
      "2242a168-2680-46d9-b25a-99d5f190dff7"
      "069699a7-541e-4f56-9f74-03612f007581")
     (:EVIDENCE
      ((:TEXT
        . "Akt phosphorylated by PI-3K at Ser 473 phosphorylates and inactivates TSC2 and leads to the activation of mTOR [XREF_BIBR].")
       (:PMID . "24797175") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Activated Akt, ERK, and RSK1 kinases phosphorylate and inactivate the tumor suppressor TSC2, thus relieving its inhibitory role on mTORC1.")
       (:PMID . "19276265") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "ERK, Rsk1, and Akt all directly phosphorylate and inactivate tuberin, thereby leading to mTOR activation (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "19234517") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt, Erk and other mitogen activated kinases directly phosphorylate and inactivate TSC2, leading to mTORC1 activation.")
       (:PMID . "23712032") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt directly phosphorylates and inactivates TSC2 (known as tuberin), which results in increased Rheb (ras homolog enriched in brain) activity.")
       (:PMID . "23597702") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "TSC2 links TOR to the mitogen sensing phosphoinositide 3-kinase (PI3K) signaling pathway, as Akt (which is activated by PI3K) phosphorylates and inactivates TSC2.")
       (:PMID . "15341740") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "f5d41766-f8e2-41d2-b903-b6169d4276fd"))
    ((:RESIDUE . "T")
     (:SUB
      (:DB--REFS (:+TEXT+ . "tuberin") (:+UP+ . "P49815") (:+HGNC+ . "12363"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef"
      "aa402584-a488-41f8-afd3-eb65d347181e"
      "267be973-91ab-4d3b-98d3-d940eec63e81"
      "1f93095d-57a0-4f05-94f7-d223813f1f05"
      "711a1526-8822-42a0-a8e0-75f26d13897e")
     (:EVIDENCE
      ((:TEXT
        . "Thus Akt phosphorylates tuberin at Thr 1462 to inactivate its suppressive action on Rheb, resulting in TORC1 activation XREF_BIBR, XREF_BIBR")
       (:PMID . "22685542") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "In response to PI3K activation, tuberin is directly phosphorylated by Akt at Thr1462 and Ser939, and a tuberin lacking PI3K dependent phosphorylation sites can block the activation of S6K1.")
       (:PMID . "16192644") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus Akt phosphorylates tuberin at Thr-1462 to inactivate its suppressive action on Rheb, resulting in TORC1 activation xref , xref .")
       (:PMID . "22685542") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Thus Akt phosphorylates tuberin at Thr 1462 to inactivate its suppressive action on Rheb, resulting in TORC1 activation XREF_BIBR, XREF_BIBR.")
       (:PMID . "22685542") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In response to growth factors, Akt phosphorylates TSC2 on T1462 and inhibits the function of TSC1/2, thereby activating mTOR.")
       (:PMID . "20491627") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus Akt phosphorylates tuberin at Thr 1462 to inactivate its suppressive action on Rheb, resulting in TORC1 activation XREF_BIBR, XREF_BIBR.")
       (:PMID . "22685542") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylates TSC2 at the residues S939, S1130, and T1462, thus inhibiting the GAP activity of the TSC complex and enhancing the charge of Rheb with GTP (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "18521078") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In other cell types, it is well characterized that growth factor mediated activation of PI3 kinase and subsequent phosphorylation of Akt leads to phosphorylation of TSC on Ser939 and Thr1462, reducing its GAP activity on Rheb and ultimately resulting in the activation of mTORC1 and phosphorylation of its downstream substrates XREF_BIBR.")
       (:PMID . "24612393") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In response to growth factors, Akt phosphorylates TSC2 on T1462 and inhibits the function of TSC1/2, thereby activating mTOR.")
       (:PMID . "20491627") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Activated Akt phosphorylates the tumor suppressor protein tuberin at Thr-1462 leading to its inactivation, and Rheb-mediated activation of TORC1 xref , xref , xref .")
       (:PMID . "22685542") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Conversely, doxycycline induced REDD1 expression in HEK293 Tet-on HA-REDD1 cells led to decreased phosphorylation of TSC2 (XREF_FIG) These finding are consistent with a model in which REDD1 acts to repress the inhibitory phosphorylation of TSC2 in response to insulin, and because Akt mediates phosphorylation of TSC2 on Thr 1462 and Ser 939 (XREF_BIBR), the results suggest that REDD1 may act to repress the kinase activity of Akt toward the GAP.")
       (:PMID . "25056877") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt directly phosphorylates TSC2 at Thr1462, resulting in activation of mTORC1 ( xref ).")
       (:PMID . "24662921") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Akt directly phosphorylates TSC2 at Thr1462, resulting in activation of mTORC1 (XREF_BIBR).")
       (:PMID . "24662921") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In response to PI3K activation, tuberin is directly phosphorylated by Akt at Thr1462 and Ser939, and a tuberin lacking PI3K dependent phosphorylation sites can block the activation of S6K1.")
       (:PMID . "16192644") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Akt phosphorylates TSC2 at the residues S939, S1130, and T1462, thus inhibiting the GAP activity of the TSC complex and enhancing the charge of Rheb with GTP (XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "18521078") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activated Akt phosphorylates tuberin at Thr1462 residues resulted in its dissociation from hamartin and its degradation [XREF_BIBR].")
       (:PMID . "24797175") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "TSC2 (in a complex with TSC1) is phosphorylated by Akt on S939 and T1462 and this phosphorylation inhibits its ability to act as a GTPase activating protein against Rheb, which in turn regulates mTORC1 's potential to activate p70S6K (XREF_BIBR - XREF_BIBR).")
       (:PMID . "19505958") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt directly phosphorylates and inactivates TSC2 on Ser 924, Thr 1462 and Thr 1518.")
       (:PMID . "19265534") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_TSC2_pmod_P_T_1462")
       (:TEXT
        . "Akt/PKB serves as a branch point in the PI3K-mTOR signalling pathway and has been reported to phosphorylate glycogen synthase kinase (GSK) 3b at Ser9 (Ser23 on GSK-3a; for review, see Coffer et al. 1998), mTOR at Ser2448 (Nave et al. 1999) and tuberous sclerosis complex (TSC) 2 on multiple residues including Ser939, Ser1130 and Thr1462 (for review, see Manning & Cantley, 2003).")
       (:PMID . "15294054") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_TSC2_pmod_P_T_1462")
       (:TEXT
        . "Akt then phosphorylates tuberin on three residues (S939, S1130 and T1462 of full length human tuberin), and this inhibits the tuberin-hamartin complex through an as-yet-undefined mechanism (reviewed in [8]).")
       (:PMID . "14607085") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_AKT_Family_DirectlyIncreases_p_HGNC_TSC2_pmod_P_T_1462")
       (:TEXT . "PhosphoElm data from PMID 15212693") (:PMID . "12150915")
       (:SOURCE--API . "bel"))
      ((:TEXT
        . "Akt activation downstream of PI3 kinase leads to TSC2 phosphorylation on Ser939 and Thr1462, which suppresses the inhibitory effect of TSC2-GAP on Rheb, leading to increased mTORC1 activation XREF_BIBR, XREF_BIBR.")
       (:PMID . "24612393") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "1462")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "974d5254-1dc0-4cd1-8f3a-3bad84be3b90"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "12992216-69c2-418c-a486-1732896693c6"
      "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "8806cc94-ca2c-44a9-af8e-7a72ef95c2e3")
     (:EVIDENCE
      ((:TEXT
        . "Herein, we illustrate that activated Akt binds to and phosphorylates the YB-1 cold shock domain at Ser102.")
       (:PMID . "15806160") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells.")
       (:PMID . "15806160") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells")
       (:PMID . "15806160") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells.")
       (:PMID . "15806160") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "It has been demonstrated that Akt phosphorylates YB-1 at S102 and affects the anchorage independent growth of breast cancer cells [XREF_BIBR].")
       (:PMID . "21392397") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Previous work in our lab showed that the serine/threonine kinase AKT phosphorylates, and thereby activates, YB-1 at S102 and that inhibiting this site disrupts nuclear trafficking XREF_BIBR, DNA binding XREF_BIBR and tumour cell growth XREF_BIBR.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Several pathways have been shown to influence YB-1 location, including the PI3K-AKT pathway (XREF_BIBR), which phosphorylated YB-1 at Ser102.")
       (:PMID . "24335958") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the translational block of pro growth genes in a human cell model and the resistance of chicken fibroblasts to cellular transformation after YB-1 overexpression could be overcome by Akt dependent phosphorylation of YB-1 at S102.")
       (:PMID . "24461929") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This can be mediated by Akt dependent phosphorylation of YB-1 at S102, as described above.")
       (:PMID . "24461929") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "It has been demonstrated that Akt phosphorylates YB-1 at S102 and affects the anchorage independent growth of breast cancer cells [XREF_BIBR].")
       (:PMID . "21392397") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While we have previously established that AKT can interact and phosphorylate YB-1 S102 [XREF_BIBR], it is unclear whether other kinases are also able to perform this function.")
       (:PMID . "19036157") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:POSITION . "102")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "305") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:TYPE . "Phosphorylation")
     (:ID . "143e7620-19b6-41ae-a73c-48b0583db6c8"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "Depletion of NPM and ALK by small interfering RNA (siRNA) or its inhibition by WHI-154 abrogates the MEK1/2 and ERK1/2 phosphorylation.")
       (:PMID . "16909118") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Indeed, when ALK antagonist mAb30 antibody or tyrosine kinase inhibitor crizotinib were administered prior to mAb46 or pervanadate exposure, activation of ALK was completely prevented, whereas downregulation of ALK dependent phosphorylation of ERK was observed only in mAb46 treated cells (XREF_FIG).")
       (:PMID . "26147305") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The suppression of activated ALK in NB-39-nu amplified cells by RNA interference significantly reduced the phosphorylation of, mitogen activated protein kinases, and, inducing rapid apoptosis of the cells.")
       (:PMID . "18165268") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Agonist monoclonal ALK antibodies mediate efficient ERK1/2 phosphorylation and differentiation of PC12 cells; however, this could not be reproduced with PTN which failed to induce phosphorylation of ALK [XREF_BIBR].")
       (:PMID . "19459784") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ (:DB--REFS (:+TEXT+ . "ALK") (:+UP+ . "Q9UM73") (:+HGNC+ . "427"))
      (:NAME . "ALK"))
     (:TYPE . "Phosphorylation")
     (:ID . "db8bed9f-8434-4120-a14e-bb99e861aa1c"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Depletion of NPM and ALK by small interfering RNA (siRNA) or its inhibition by WHI-154 abrogates the MEK1/2 and ERK1/2 phosphorylation.")
       (:PMID . "16909118") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Indeed, when ALK antagonist mAb30 antibody or tyrosine kinase inhibitor crizotinib were administered prior to mAb46 or pervanadate exposure, activation of ALK was completely prevented, whereas downregulation of ALK dependent phosphorylation of ERK was observed only in mAb46 treated cells (XREF_FIG).")
       (:PMID . "26147305") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The suppression of activated ALK in NB-39-nu amplified cells by RNA interference significantly reduced the phosphorylation of, mitogen activated protein kinases, and, inducing rapid apoptosis of the cells.")
       (:PMID . "18165268") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Agonist monoclonal ALK antibodies mediate efficient ERK1/2 phosphorylation and differentiation of PC12 cells; however, this could not be reproduced with PTN which failed to induce phosphorylation of ALK [XREF_BIBR].")
       (:PMID . "19459784") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ (:DB--REFS (:+TEXT+ . "ALK") (:+UP+ . "Q9UM73") (:+HGNC+ . "427"))
      (:NAME . "ALK"))
     (:TYPE . "Phosphorylation")
     (:ID . "b6e33d36-4d21-4a44-acc0-a2c93fbb9a65"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "1f9e903b-b337-4022-b907-fc559bac1720"
      "ca91b967-b4f5-46a0-b7c2-5b08b2eb43c3"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4ed40ed351bc38540f467584657bdf6a")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ALK_DirectlyIncreases_p_HGNC_STAT3_pmod_P_Y_705")
       (:TEXT
        . "9083098;11429593;9582023;15592455;12244095;14551213;11850821;9305919")
       (:PMID . "15212693") (:SOURCE--API . "bel")))
     (:POSITION . "705")
     (:ENZ (:DB--REFS (:+UP+ . "Q9UM73") (:+HGNC+ . "427")) (:NAME . "ALK"))
     (:TYPE . "Phosphorylation")
     (:ID . "f3e8eb9d-8d12-4fd3-9d83-83776bcd2511"))
    ((:SUB (:DB--REFS (:+TEXT+ . "BAD") (:+UP+ . "Q92934") (:+HGNC+ . "936"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "ARAF") (:+UP+ . "P10398") (:+HGNC+ . "646"))
      (:NAME . "ARAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "2c3b4a83-e38d-4987-816d-926ebc090794"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "MAP2K1") (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "e070888c-4fb7-4111-92c5-36e490475675"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE
      ((:TEXT
        . "Specifically, trametinib, which attenuates phosphorylation of MEK by RAF at Serine 217, had greater antitumor effects than PD0325901.")
       (:PMID . "24576830") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7400698b954806ee2dddb1f9bdd20e0a")
       (:PMID . "8621729") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0752704d6dc8e1a484fc4d7e85647dd6")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "218")
     (:ENZ (:DB--REFS (:+TEXT+ . "ARAF") (:+UP+ . "P10398") (:+HGNC+ . "646"))
      (:NAME . "ARAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "f93307a3-1cd7-4cbe-9837-4c3822f667bd"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "e070888c-4fb7-4111-92c5-36e490475675"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_285983c44ac0369728d73cf5d9c72037")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7400698b954806ee2dddb1f9bdd20e0a")
       (:PMID . "8621729") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ (:DB--REFS (:+UP+ . "P10398") (:+HGNC+ . "646")) (:NAME . "ARAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "d9dcf1be-b6ed-43d9-b79c-31a6de5bddd4"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAP2K2") (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:TEXT
        . "503 ed Raf kinase directly phosphorylates and activates MEK (formerly known as MAP kinase) (Kyriakis et al., 1992), which in turn phosphorylates and activates MAP kinase (Ahn et al., 1992).")
       (:PMID . "8697095") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Since it has been proved that under certain conditions MEK2 could not be activated by A-Raf, it is also plausible that A-Raf does not phosphorylate MEK2 so that it could form a stable complex with MEK2 and be detected in our experiments.The Raf family contains three members : A-Raf, B-Raf and c-Raf.")
       (:PMID . "11909642") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This class of MEK inhibitor preventsRAF from phosphorylating MEK at S218 and S222 and therefore not only blocks MEK kinase activity but also RAF dependent phosphorylation of MEK.")
       (:PMID . "25155755") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "MEK is phosphorylated by Raf following the recruitment of Raf to the plasma membrane by GTP-bound Ras.")
       (:PMID . "20230813") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "RAF phosphorylates mitogen activated protein kinase kinase (MEK), which then activates extracellular signal regulated kinase (ERK), which can promote cancer progression or induce cell senescence (XREF_BIBR).")
       (:PMID . "22649091") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Raf kinases are the entry point to the ERK and MAPK pathway, a three tiered kinase cascade where Raf phosphorylates and activates MEK which in turn phosphorylates and activates ERK.")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Active Raf phosphorylates MEK (for MAPK and extracellular signal regulated kinase [ERK] kinase), which subsequently phosphorylates ERK.")
       (:PMID . "19917255") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The Raf family of protein kinases, which is one class of Ras effectors, phosphorylates the dual specific MAP kinases MEK1 and MEK2, which in turn phosphorylate and activate the effector MAP kinases ERK1 and ERK2 [XREF_BIBR].")
       (:PMID . "22376079") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Since it has been proved that under certain conditions MEK2 could not be activated by A-Raf, it is also plausible that A-Raf does not phosphorylate MEK2 so that it could form a stable complex with MEK2 and be detected in our experiments.The Raf family contains three members : A-Raf, B-Raf and c-Raf.")
       (:PMID . "11909642") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The MAPKKKs of the Raf and Mos families phosphorylate and activate MEK1/2, whereas other MAPKKKs such as MEKK1/2/3, MTK1 (MEKK4), TAK1, ASK1 (MAPKKK5), TAO, and mixed lineage kinases (MLKs) preferentially activate some or all of the stress activated MAPKKs, namely MKK3, 4, 6, and 7.")
       (:PMID . "15866172") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here we integrate structural and biochemical studies to understand how KSR promotes stimulatory Raf phosphorylation of MEK (refs 6, 7).")
       (:PMID . "21441910") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Raf then phosphorylates and activates MEK1 and/or MEK2 (MAPK kinase).")
       (:PMID . "18060073") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Since it has been proved that under certain conditions MEK2 could not be activated by A-Raf, it is also plausible that A-Raf does not phosphorylate MEK2 so that it could form a stable complex with MEK2 and be detected in our experiments")
       (:PMID . "11909642") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Active RAF then phosphorylates MEK (for MAPK and extracellular signal-regulated kinase [ERK] kinase), which subsequently phosphorylates ERK to relay extracellular stimuli to the nucleus.")
       (:PMID . "22194995") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Interestingly, the phospho-MEK antibody, which recognises the MEK activation loop phosphorylated by Raf kinases, also detected the phosphorylation of PKCtheta (B), but not of other PKC isoforms (data not shown).")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Unfortunately, after generating a MEK-1 265-301 deletion as well as MEK-1 DVD mutants (W374D, L375E and WL374/375DE), which were previously shown to eliminate MEK phosphorylation by active Raf and mitogens and examining their binding to C-Raf, we found that these mutants bound and activated C-Raf as potently as wildtype MEK-1 (XREF_FIG and data not showed).")
       (:PMID . "23360980") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Once activated, Raf phosphorylates and activates MEK1/2, which are dual-specificity kinases capable of phosphorylating and activating the MAPKs ERK1/2.")
       (:PMID . "22797077") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In contrast, immunoprecipitated Raf1 and A-Raf scarcely phosphorylated MEK regardless of the differentiation stage (XREF_FIG and not depicted).")
       (:PMID . "17535970") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Finally, we found that addition of IGFBP7 to SK-MEL-28 cells resulted in upregulation of RAF inhibitory protein (RKIP) (A and S8C), which has been shown to interact with several RAF proteins, including BRAF, and inhibit RAF mediated phosphorylation of MEK (see, for example,).")
       (:PMID . "18267069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Raf in turn phosphorylates and activates MEK, which in turn phosphorylates and activates MAP kinases including ERK1 and ERK2.")
       (:PMID . "16478641") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We propose that KSR interacts with a regulatory Raf molecule in cis to induce a conformational switch of MEK, facilitating MEK 's phosphorylation by a separate catalytic Raf molecule in trans.")
       (:PMID . "21441910") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Activated Raf phosphorylates and activates MEK1/2, which then activates Erk.")
       (:PMID . "24342356") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We believe that this is the likely mechanism by which it prevents the phosphorylation of MEK by RAF.")
       (:PMID . "24746704") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "MEK is phosphorylated and activated by Raf.")
       (:PMID . "21738705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Similar to ERK and MEK phosphorylation, Raf-1 Ser 338 phosphorylation was lower in cells lacking TSC2 and its activity was not reduced by acidic extracellular pH. Raf is inactive when cytosolic and recruitment to the plasma membrane is required for activation XREF_BIBR, XREF_BIBR.")
       (:PMID . "21738705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Upon stimulation, Raf phosphorylates and activates MEK1/2, which phosphorylates ERK1/2 on Thr183 and Tyr185 in the activation loop, resulting in full activation of ERK1/2.")
       (:PMID . "12049732") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This showed that there might still exist unrecognized isoforms in the MAP kinase pathway.Our results showed that MEK2 could be a new partner of A-Raf, but it remains to be determined whether A-Raf could phosphorylate MEK2 and whether A-Raf activated MEK2 had a specific effector other than ERK1.")
       (:PMID . "11909642") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_159a2cb48901041bae9c1b4d653f6435")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "This finding is in line with previous reports that attribute this effect to a feedback loop from ERK to RAF, which induces RAF activity and MEK phosphorylation when cells are treated with a MEK inhibitor [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26799289") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Upon activation, Raf phosphorylates and activates MEK, which then phosphorylates and activates ERK.")
       (:PMID . "16630891") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Upon activation, RAF phosphorylates and activates MEK, which then phosphorylates and activates ERK.")
       (:PMID . "24211266") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "RAF then phosphorylates MEK, which in turn phosphorylates and activates ERK, leading to cancer progression or senescence depending on the degree of ERK activation and crosstalk with other signaling pathways [ xref ].")
       (:PMID . "26623721") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "In sum, the data imply that MEK inhibitors that block the phosphorylation of MEK by RAF may have greater clinical activity in tumors with activated RAS, including those with loss of NF1 function.")
       (:PMID . "24576830") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The activated Raf phosphorylates MEK (mitogen extracellular regulated kinase) at serine and threonine residues, which subsequently phosphorylates ERK1/2.")
       (:PMID . "22820249") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "RAF phosphorylates and activates MEK, which phosphorylates and activates ERK.")
       (:PMID . "20141835") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "A similar lack of potency was also noted in NF1-null melanoma cells with AZD6244 (XREF_SUPPLEMENTARY), a second non-ATP-competitive MEK inhibitor incapable of abrogating RAF phosphorylation of MEK.")
       (:PMID . "24576830") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "RAS recruits proteins to the membrane to cause activation of RAF, which in turn phosphorylates MEK.")
       (:PMID . "24673746") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "Raf then phosphorylates and activates MEK1 and MEK2.")
       (:PMID . "15979847") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Membrane bound Raf phosphorylates and activates the dual-specificity kinase MEK, which in turn phosphorylates ERK, which then translocates to the nucleus where it regulates gene expression.")
       (:PMID . "24209692") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "Raf then phosphorylates and activates MEK1 and MEK2.")
       (:PMID . "15979847") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "MEK is phosphorylated by Raf following the recruitment of Raf to the plasma membrane by GTP bound Ras.")
       (:PMID . "20230813") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inhibitors that prevent RAF mediated phosphorylation of MEK abrogate this adaptive resistance to MEK inhibition and have greater anti-tumor activity in NF1-null cells.")
       (:PMID . "24576830") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Concomitant conformational changes and recruitment to the cell membrane promote changes in RAF phosphorylation that combine to stimulate its serine/threonine kinase activity, triggering sequential phosphorylation and activation of MEK and ERK.")
       (:PMID . "15035987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Raf then phosphorylates and activates MEK1 and/or MEK2 (MAPK kinase), which in turn phosphorylates and activates ERK1 and/or ERK2 (MAPK).")
       (:PMID . "18413255") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "RAF proteins phosphorylate MEK1/2, which in turn phosphorylate ERK1/2.")
       (:PMID . "15935100") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "KSR proteins are scaffolds for the RAF-MEK-ERK signaling cascade and facilitate the phosphorylation and activation of MEK by RAF.")
       (:PMID . "24095280") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This initiates a signaling cascade in which RAF phosphorylates and activates MEK, which, in turn phosphorylates and activates ERK (reviewed in XREF_BIBR; XREF_BIBR).")
       (:PMID . "24746704") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Active RAF then phosphorylates MEK (for MAPK and extracellular signal regulated kinase [ERK] kinase), which subsequently phosphorylates ERK to relay extracellular stimuli to the nucleus.")
       (:PMID . "22194995") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "A375 cells were treated with selective inhibitors of MEK, ERK, mTOR kinase, AKT or PI3K for 48 hrs, followed by treatment with vemurafenib to assess inhibition of MEK phosphorylation by RAF.")
       (:PMID . "23153539") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Following activation, RAF phosphorylates MEK, which on activation subsequently phosphorylates and activates MAPK, which has multiple targets and leads to changes in gene transcription, resisting apoptosis, and enhancing metastasis [ xref ].")
       (:PMID . "26649302") (:SOURCE--API . "sparser"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_46991066d1cba6e4423f2f242467114b")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "In contrast, immunoprecipitated Raf1 and A-Raf scarcely phosphorylated MEK regardless of the differentiation stage (XREF_FIG and not depicted).")
       (:PMID . "17535970") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "ARAF") (:+UP+ . "P10398") (:+HGNC+ . "646"))
      (:NAME . "ARAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "9abcf93c-59eb-4989-ace6-69f33889f0b7"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "In this pathway, Ras (H-, N- or K-) activation by GTP loading elicits the plasma membrane recruitment of Raf (A-, B- or C-) that phosphorylates and activates to the dual specificity kinases MEK1/2, which then subsequently phosphorylates and activates ERK1/2.")
       (:PMID . "25514808") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activated Raf phosphorylates and activates the mitogen activated ERK kinases, MEK1 and MEK2, which in turn phosphorylate and activate the extracellular signal activated kinases, ERK1 and ERK2.")
       (:PMID . "20230813") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "RAF or MEK inhibitors inhibit ERK phosphorylation (P-ERK) and induce BIM levels in BRAF-mutant melanoma cell lines.")
       (:PMID . "26639561") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Levels of ERK1/2 (p42/44) phosphorylation, induced specifically by activation of the Raf and MEK pathway, were detected by Western analysis using the phospho-ERK1/2-specific antibody.")
       (:PMID . "16005186") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Ectopic expression of RKIP inhibited IGF-I-induced phosphorylation of MEK and ERK but not Raf because it is upstream of RKIP (and).")
       (:PMID . "17030190") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Similar to ERK and MEK phosphorylation, Raf-1 Ser 338 phosphorylation was lower in cells lacking TSC2 and its activity was not reduced by acidic extracellular pH. Raf is inactive when cytosolic and recruitment to the plasma membrane is required for activation XREF_BIBR, XREF_BIBR.")
       (:PMID . "21738705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "RAF kinase becomes active upon binding to RAS-GTP and initiates the MEK and ERK phosphorylation cascade, leading to increases in gene transcription of cell-cycle regulators such as cyclin D1 to promote cell growth and survival.")
       (:PMID . "22573716") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "3CH134 blocks phosphorylation and activation of p42MAPK mediated by serum, oncogenic Ras, or activated Raf, whereas the catalytically inactive mutant of the phosphatase, Cys-258-Ser, augments MAP kinase phosphorylation under similar conditions.")
       (:PMID . "8221888") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "RAF phosphorylates mitogen activated protein kinase kinase (MEK), which then activates extracellular signal regulated kinase (ERK), which can promote cancer progression or induce cell senescence (XREF_BIBR).")
       (:PMID . "22649091") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activated RAF kinases phosphorylate MAPK and ERK kinase (MEK), whichinturnphosphorylate andactivatesERK.")
       (:PMID . "19881948") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inhibition of Raf was observed to partially abrogate ERK phosphorylation, whereas MEK inhibition resulted in complete attenuation of EGF mediated ERK phosphorylation.")
       (:PMID . "26262587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Concomitant conformational changes and recruitment to the cell membrane promote changes in RAF phosphorylation that combine to stimulate its serine/threonine kinase activity, triggering sequential phosphorylation and activation of MEK and ERK.")
       (:PMID . "15035987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This in turn triggers G-protein-mediated activation of the RAS kinase, which phosphorylates the RAF effector, which phosphorylates ERK-2 (MAPK1).")
       (:PMID . "20638106") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "ARAF") (:+UP+ . "P10398") (:+HGNC+ . "646"))
      (:NAME . "ARAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "1d87032f-cd77-4c0f-a190-659cb22e3211"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Activated Raf phosphorylates and activates the mitogen activated ERK kinases, MEK1 and MEK2, which in turn phosphorylate and activate the extracellular signal activated kinases, ERK1 and ERK2.")
       (:PMID . "20230813") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "RAF or MEK inhibitors inhibit ERK phosphorylation (P-ERK) and induce BIM levels in BRAF-mutant melanoma cell lines.")
       (:PMID . "26639561") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Levels of ERK1/2 (p42/44) phosphorylation, induced specifically by activation of the Raf and MEK pathway, were detected by Western analysis using the phospho-ERK1/2-specific antibody.")
       (:PMID . "16005186") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of Raf was observed to partially abrogate ERK phosphorylation, whereas MEK inhibition resulted in complete attenuation of EGF mediated ERK phosphorylation.")
       (:PMID . "26262587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Ectopic expression of RKIP inhibited IGF-I-induced phosphorylation of MEK and ERK but not Raf because it is upstream of RKIP (and).")
       (:PMID . "17030190") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Similar to ERK and MEK phosphorylation, Raf-1 Ser 338 phosphorylation was lower in cells lacking TSC2 and its activity was not reduced by acidic extracellular pH. Raf is inactive when cytosolic and recruitment to the plasma membrane is required for activation XREF_BIBR, XREF_BIBR.")
       (:PMID . "21738705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "RAF phosphorylates mitogen activated protein kinase kinase (MEK), which then activates extracellular signal regulated kinase (ERK), which can promote cancer progression or induce cell senescence (XREF_BIBR).")
       (:PMID . "22649091") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Concomitant conformational changes and recruitment to the cell membrane promote changes in RAF phosphorylation that combine to stimulate its serine/threonine kinase activity, triggering sequential phosphorylation and activation of MEK and ERK.")
       (:PMID . "15035987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "RAF kinase becomes active upon binding to RAS-GTP and initiates the MEK and ERK phosphorylation cascade, leading to increases in gene transcription of cell-cycle regulators such as cyclin D1 to promote cell growth and survival.")
       (:PMID . "22573716") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activated RAF kinases phosphorylate MAPK and ERK kinase (MEK), whichinturnphosphorylate andactivatesERK.")
       (:PMID . "19881948") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In this pathway, Ras (H-, N- or K-) activation by GTP loading elicits the plasma membrane recruitment of Raf (A-, B- or C-) that phosphorylates and activates to the dual specificity kinases MEK1/2, which then subsequently phosphorylates and activates ERK1/2.")
       (:PMID . "25514808") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "ARAF") (:+UP+ . "P10398") (:+HGNC+ . "646"))
      (:NAME . "ARAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "48c21be0-248f-4116-9229-a3a7c9496d96"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "5377520e-d1c5-494f-ad7e-4cdea1263c43"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "12590707") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "11369622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "15728464") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "10753828") (:SOURCE--API . "biopax")))
     (:POSITION . "397")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "389") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P51451") (:+HGNC+ . "1057")) (:NAME . "BLK"))
     (:TYPE . "Phosphorylation")
     (:ID . "4b18d579-5cda-4eec-9a93-d77f186e68a3"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "1f9e903b-b337-4022-b907-fc559bac1720")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9344858") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "10815799") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9484840") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "11404481") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "389") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P51451") (:+HGNC+ . "1057")) (:NAME . "BLK"))
     (:TYPE . "Phosphorylation")
     (:ID . "f0fea00d-1a9b-4423-a3d5-325a2b611358"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "f9004a71-db86-40e0-b666-1ff594c707d3"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "13f2184e-a061-407d-af16-a9bfbc91a9bd"
      "931a9ea0-6ac7-492b-902c-802b6f4afc4c"
      "d5757990-951d-4645-b8fe-aa2a29bccd42"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6e53645153b514858d32a9127049d986")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "14970219") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "18567582") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "ae3feddf-97e8-4133-b423-0216dabf1fd1"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "db740909-70a9-4c98-b40c-373253a8657f"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "179ad610-ca1f-42c1-8eb2-e7298ccf2fff"
      "09459042-83bc-4fe5-b19a-63244f7e7b11"
      "423f748f-609d-4b16-92ea-dda20a230839"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6e53645153b514858d32a9127049d986")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "14970219") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "18567582") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "6366393f-6a69-487b-9215-a403cc79ee34"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "4b8dee34-a27b-4875-843a-0fcabce38582"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "a25a56a4-8f38-42dc-8616-e9472fdfe136"
      "b643d94e-d586-40ff-894b-95ff186f55b6"
      "f17f6ab8-d46a-4314-a651-efa1e6276c0e"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6e53645153b514858d32a9127049d986")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "14970219") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "18567582") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "9b10fa9c-0073-49e2-a76b-ba295f6b110b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "61dad387-8285-4c49-854d-f812eb8f1fa9"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "79debe95-6964-48e9-809e-54049f85a692"
      "213046af-c5f6-4041-a363-0da72f97d910"
      "2c399840-7254-4586-b6f9-122f308a9b8e"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6e53645153b514858d32a9127049d986")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "14970219") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "18567582") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "50e6c6fd-2f14-4b1e-a41f-b5b2399c657c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "e46322f1-5023-4642-94de-7841da13d25a"
      "e70c7de1-420c-43b9-bc1c-30e9baba9c8f"
      "077d82bd-09e5-4264-aaf0-9e2ea04b3d82"
      "a55c1494-f156-4a3e-8996-494bc0076059"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "14970219") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "18567582") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6e53645153b514858d32a9127049d986")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "1a5c9c01-3019-4bbb-8b18-6d906ee6839d"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "8ca11ed6-fb4a-4903-a066-f56711f9044d"
      "f9a38889-73ea-4375-85ac-eb21cbe6ba17"
      "0de309ca-96ea-43ba-a216-442828faa9cc"
      "8c999067-d676-44a1-9c52-b0d37fb11c83"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "14970219") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "18567582") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6e53645153b514858d32a9127049d986")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "01060cb4-bf34-44b6-984f-61b38b19b230"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "f3dc028d-193d-493d-a3a5-78068e238b58"
      "ee824365-cfde-49a8-a2eb-cafdffde8c99"
      "35957bf4-0ae4-4a0f-b127-4c48aef37769"
      "51a95ffe-ec00-4dc3-841a-f8ebaa832639"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "14970219") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "18567582") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6e53645153b514858d32a9127049d986")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "ee282dbf-4ac4-4954-ad6e-3184a8284803"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "20ca2f73-5c0a-414f-92a8-01adc378c639"
      "92bf7d95-03fc-4ea2-9f33-b2b0e8858b92"
      "4ecd284f-a793-4475-8236-5c6134c03722"
      "5eb521c6-68b2-429c-86d6-7d2f604cfcaf"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "14970219") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b8dc61506e7943528137efcdd12bf0e5")
       (:PMID . "18567582") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6e53645153b514858d32a9127049d986")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "cfb3a717-2161-46d9-ba8b-5e0980176359"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "bc3106aa-06ec-4d7b-a7ee-8a6fdca8f3f4"
      "a513e52a-29e9-4677-b4d0-0ad7967977a5"
      "8f202b42-1a9f-494d-8232-d8f3b8c1e61c"
      "4b77db29-41ea-4c65-8c2f-e51bf99d725e"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d28176beb4d58e63a6da575c557148fd")
       (:PMID . "7935374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e88d6a6c0d9890a6cee9a9cabe58b947")
       (:PMID . "9560161") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "8d070e55-d564-445a-80de-005d15285aa1"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "f8026c06-0aa2-43fc-8191-4325fc9ff69b"
      "d852d451-76fb-433e-a4fa-6cbf1e5ac6d6"
      "344ef124-cfec-4fad-bdb0-fc1d92048cf6"
      "2f7db8f9-0f56-408f-aca1-1c71116864f0"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d28176beb4d58e63a6da575c557148fd")
       (:PMID . "7935374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e88d6a6c0d9890a6cee9a9cabe58b947")
       (:PMID . "9560161") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "881d6260-e218-4986-b1ea-48765d10993c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "1b2588e3-1c84-4b6a-9a97-f017d56db71c"
      "c716f7d2-8be5-40fc-be38-ee5ca6e93b9b"
      "486e3fc2-0edb-4186-b6ca-46cea38cbdb8"
      "27f75735-1e0d-4e4a-a211-fb2465cb60f7"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d28176beb4d58e63a6da575c557148fd")
       (:PMID . "7935374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e88d6a6c0d9890a6cee9a9cabe58b947")
       (:PMID . "9560161") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "a2d2f447-d488-4f17-9049-670359f341bb"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "2e02cafe-798c-4c43-a19a-210410c7c1fd"
      "a126edc4-729a-44ab-a48f-f0a85589748d"
      "1e4ea7b9-2f34-491f-94fd-f0baa20b8929"
      "d515d2d0-f420-4de2-824d-1bda711b64af"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d28176beb4d58e63a6da575c557148fd")
       (:PMID . "7935374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e88d6a6c0d9890a6cee9a9cabe58b947")
       (:PMID . "9560161") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "3cc4fdf2-7daf-4194-b3a2-09f58c11fa1f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "fb5f4526-cb98-4a3b-8e3f-0f53271c05d8"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "6848090c-28f1-4ded-a2e9-654c175d8e6b"
      "33ce39e9-3f92-455a-8aeb-86047588b33b"
      "bd35c10c-e7bd-4465-8bc7-5ca36fbc03c1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d28176beb4d58e63a6da575c557148fd")
       (:PMID . "7935374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e88d6a6c0d9890a6cee9a9cabe58b947")
       (:PMID . "9560161") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "e2a60270-7589-4718-a14a-323c30fa5c8f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "fc12227f-e58d-40f2-bf6b-1ddaa1475188"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "aa54ad37-aae0-4e88-9f72-7bd4401fa570"
      "56a19c70-ff81-4f04-b1d0-7c7f2e35301a"
      "10d1d425-34d5-4a4b-901b-dd140f30138c")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d28176beb4d58e63a6da575c557148fd")
       (:PMID . "7935374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e88d6a6c0d9890a6cee9a9cabe58b947")
       (:PMID . "9560161") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "9999e91e-bdd9-48de-992d-aab6cfdd8340"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "adc7b383-26a3-4ba6-855a-9afd95301b46"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "afd832ee-a74c-44f3-8e5a-b05608bb5d5c"
      "3ba445ec-9a1e-4ec6-aba5-5e77218c78c9"
      "19a2ce4c-64de-4fe0-bd7a-e564dd19c52b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d28176beb4d58e63a6da575c557148fd")
       (:PMID . "7935374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e88d6a6c0d9890a6cee9a9cabe58b947")
       (:PMID . "9560161") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "509730d1-cf1f-4f1d-a36e-7f46db8db0af"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "12c4aaaa-9039-483d-b92a-c08821288bbe"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "7c681fba-306f-41a5-85d6-caaff23eaa50"
      "041152a2-2b8c-4b25-8033-3d7641dfc247"
      "9cb7c0c7-09fa-40bf-91f8-cdcdbbd03e7e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d28176beb4d58e63a6da575c557148fd")
       (:PMID . "7935374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e88d6a6c0d9890a6cee9a9cabe58b947")
       (:PMID . "9560161") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "a0c29e6c-1b71-4eac-87a5-455cbd7d775c"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "3348ae6f-25a0-417b-8035-f1ce3b934590"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "d61dcd82-be6c-4c94-b94a-9df42aa8d427"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "109e5251-63c3-46d6-8932-ef346fb97016"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "a78453e0-ab3d-49e1-aeb3-71fd7c933af2"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "fe710462-bc35-4c4c-acaa-aa602298f082"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "611b8fdb-aac9-45c4-8d13-02020fe83cff"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "eb137fff-b557-44ff-a5e7-ef060a40d3e2"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "589003c1-4532-4459-9164-7a9832551e45"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "32983826-373e-4266-84e0-a6c2beb2d895"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "aec90654-dc5b-4792-9580-0f3e3a373def"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "e661deb1-fad0-457e-8559-490ce3a988fa"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "It should be noted that even in the absence of Nf1, RAF partially inhibited AKT phosphorylation, consistent with the known involvement of several redundant negative feedback signals (XREF_BIBR).")
       (:PMID . "23171796") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Combined knock-down of BRAF and rictor did not result in elevation of AKT phosphorylation, suggesting that the BRAFV600E effect on AKT pathway is rictor dependent.")
       (:PMID . "22880048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "aa7dcd98-d4fd-471c-9704-75ac7ddc6499"))
    ((:SUB (:DB--REFS (:+TEXT+ . "BAD") (:+UP+ . "Q92934") (:+HGNC+ . "936"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This is consistent with our results showing that PKCtheta, but not Raf-1 or B-Raf, can phosphorylate BAD directly (A).")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "2c3b4a83-e38d-4987-816d-926ebc090794"))
    ((:SUB (:DB--REFS (:+TEXT+ . "BAD") (:+UP+ . "Q92934") (:+HGNC+ . "936"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This is consistent with our results showing that PKCtheta, but not Raf-1 or B-Raf, can phosphorylate BAD directly (A).")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "2c3b4a83-e38d-4987-816d-926ebc090794"))
    ((:SUB (:DB--REFS (:+TEXT+ . "BAD") (:+UP+ . "Q92934") (:+HGNC+ . "936"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This is consistent with our results showing that PKCtheta, but not Raf-1 or B-Raf, can phosphorylate BAD directly (A).")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "2c3b4a83-e38d-4987-816d-926ebc090794"))
    ((:SUB (:DB--REFS (:+TEXT+ . "BAD") (:+UP+ . "Q92934") (:+HGNC+ . "936"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This is consistent with our results showing that PKCtheta, but not Raf-1 or B-Raf, can phosphorylate BAD directly (A).")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of BAD by active RAF promotes 14-3-3 protein association, in which the phosphoserine 99 represented the major binding site.")
       (:PMID . "19667065") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "2c3b4a83-e38d-4987-816d-926ebc090794"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "4f72f724-a1fe-4c5f-a9e3-334a3807f1bd"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "d2ace147-c392-4c80-9f5f-a67814d919a3"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7706312") (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7773e6cbacad9001ab14740c4780060")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_946d63c7f1af0b5e870b894d0a4e235e")
       (:PMID . "15342917") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "a9d1f14e-568d-4e18-a041-5a34250299d8"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "95f68e38-cf82-4bed-a446-e02c09be314e"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "78297a1e-dc74-45fc-949f-2fd29cb095d3"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7706312") (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7773e6cbacad9001ab14740c4780060")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_946d63c7f1af0b5e870b894d0a4e235e")
       (:PMID . "15342917") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "2d5e152b-0eba-4aca-aba6-f395f6337482"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "307ac691-b126-4f04-b632-0c6bf5df7e11"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "f187465a-8d32-488f-87c9-478843037aa7"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7706312") (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7773e6cbacad9001ab14740c4780060")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_946d63c7f1af0b5e870b894d0a4e235e")
       (:PMID . "15342917") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "fde4a308-3ec7-4e9c-be6e-8364ea5e5d8a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "d50845f7-e892-4929-9771-ab08940145fc"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "7ba677b7-38e4-4b11-90b2-95763e9bf067"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7706312") (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7773e6cbacad9001ab14740c4780060")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_946d63c7f1af0b5e870b894d0a4e235e")
       (:PMID . "15342917") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "10af857b-7912-4352-8d79-f3007516ba84"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "0399f140-0a44-458c-ba4f-507602258c1b"
      "0ef2acca-a3a7-4a07-b2ca-26372a80ac74"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7706312") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bebbeec9aeb20c806f9844184a9f9842")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_946d63c7f1af0b5e870b894d0a4e235e")
       (:PMID . "15342917") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "6399357a-d7d7-4f32-adac-fc2aeeb6984b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "0e45d26d-86ad-4325-9d6a-aa460c8b1af4"
      "28256403-d74a-4ab7-a74d-2f35bacb46fa"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7706312") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bebbeec9aeb20c806f9844184a9f9842")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_946d63c7f1af0b5e870b894d0a4e235e")
       (:PMID . "15342917") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "eb6cd86f-3941-4ec5-a0e0-ad0db4ecf40a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "df0e7305-777f-457b-af63-2daffa749f01"
      "e788d7fe-5165-4d05-958c-8c543032ee5a"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7706312") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bebbeec9aeb20c806f9844184a9f9842")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_946d63c7f1af0b5e870b894d0a4e235e")
       (:PMID . "15342917") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "4dbe4099-9652-4e7b-b110-f649d3491e45"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "c941fc99-3da6-4261-886a-65f409c446e6"
      "28881ff7-fa6e-4582-babe-b960cc4e4d55"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7731720") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8921af2819f30ddd0789465393ad53aa")
       (:PMID . "7706312") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bebbeec9aeb20c806f9844184a9f9842")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_946d63c7f1af0b5e870b894d0a4e235e")
       (:PMID . "15342917") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "02bae19a-729a-4c75-bfe1-55f9ea3d85ef"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d"
      "6cda693e-9dbf-429c-8c5a-3aa8e86c8e6b"
      "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "deddb6a8-aac6-4e20-9e86-367aada325a8"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d"
      "4f4faee4-9bec-46f3-8934-1adf5adaaffd"
      "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "57305965-d457-4fe7-ae90-35355aa47d3a"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d"
      "45f6a2b7-8f1e-4de7-b857-05cb9c0afa25"
      "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "7cdade86-06f0-4648-af45-3e9a1dc1d339"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d"
      "acb01ed9-5298-41d9-9536-903015f6e761"
      "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "c838fad6-5df6-40ea-9b7e-c77727f22c70"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9"
      "17bfd324-15a9-48a2-be9c-92761b77d1a6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "a0d2c7b7-5496-4002-b100-d9c7f3fe5376"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9"
      "4625e488-7175-481c-954d-0c5438350a16")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "39e365dd-2901-4cf8-859e-37b216ee0317"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9"
      "033bd5c9-a6c6-439a-a509-4015fe97a336")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "504ccf6c-314d-49a6-8403-a033a5cb6410"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9"
      "6a880bd2-9752-4960-9ba7-201de9d6d901")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "358acabc-19b2-4ab8-a9bf-5fa0064b8e9d"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0d920125-bd7d-456d-8a90-7673e3c83616"
      "67f3dedc-ff6e-4ecd-9370-af9980e953fa"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "da48c934-ea9c-45a1-9feb-92a6ed06666a"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0d920125-bd7d-456d-8a90-7673e3c83616"
      "93493638-3119-4cdc-b5e9-90964cc92703"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "c6a6f91e-782f-4913-85a2-7841f9026fe9"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0d920125-bd7d-456d-8a90-7673e3c83616"
      "f3a87a4e-a2a0-4baa-b1dc-cf5f83d0b320"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "f6abc4e5-ff9e-4b02-a709-081be60fdcca"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0d920125-bd7d-456d-8a90-7673e3c83616"
      "3ea76830-eeaa-457a-8bbd-5d7e5a5aeb0c"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "d318faac-8948-4e27-9520-92034ee4bdbb"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "e96c4895-0a45-4836-a398-d523e0dcb483"
      "26f577cf-f031-4265-bbe6-3b1d0ace85d7"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "446") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "729") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "7580fe43-1ab8-4ce0-83e9-ca6d8c01d398"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "e96c4895-0a45-4836-a398-d523e0dcb483"
      "48ba7179-7a92-44a9-a545-6d4695c14d52"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "579") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "96c809e3-0600-492d-9016-f35e35c70f4d"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "e96c4895-0a45-4836-a398-d523e0dcb483"
      "81cf1137-46f1-462a-b64f-4c0ff1f7e1c0"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "373") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "Phosphorylation")
     (:ID . "05e99121-14ca-4725-bc39-a9a85d5dca2d"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "e96c4895-0a45-4836-a398-d523e0dcb483"
      "89c25055-83aa-4163-b8a8-0c9a661315d0"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF")
      (:MUTATIONS
       ((:POSITION . "600") (:RESIDUE--FROM . "V") (:RESIDUE--TO . "E"))))
     (:TYPE . "Phosphorylation")
     (:ID . "2f7e4d5b-f522-45fa-98a5-4bd82424f41c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P35222") (:+HGNC+ . "2514"))
      (:NAME . "CTNNB1"))
     (:SUPPORTED--BY "f284bab9-67a0-40ae-99be-40781eae45f9"
      "b79e01ae-e2cd-4988-b7ba-6b2bc70490ce"
      "bc96c7d8-d6b6-4dd5-934f-b0b393675faf"
      "2e4b14b0-a532-468c-b50d-02c2e7f43164"
      "8330a09c-18ed-4359-8952-0bb4c2e57c1a")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_CDK2_DirectlyIncreases_p_HGNC_CTNNB1_pmod_P_S_33")
       (:TEXT
        . "cyclin-CDK2 demonstrate beta-catenin phosphorylation on residues Ser(33), Ser(37), Thr(41), and Ser(45). This phosphorylation promotes rapid degradation of cytosolic beta-catenin")
       (:PMID . "14985333") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_CDK2_DirectlyIncreases_p_HGNC_CTNNB1_pmod_P_S_33")
       (:TEXT
        . "Here we demonstrate that cyclin-dependent kinase 2 (CDK2) in association with cyclin A or cyclin E directly binds to beta-catenin.  In vivo and in vitro kinase assays with cyclin-CDK2 demonstrate beta-catenin phosphorylation on residues Ser(33), Ser(37), Thr(41), and Ser(45). This phosphorylation promotes rapid degradation of cytosolic beta-catenin via the beta-TrCP-mediated proteasome pathway.")
       (:PMID . "14985333") (:SOURCE--API . "bel")))
     (:POSITION . "33")
     (:ENZ (:DB--REFS (:+UP+ . "P24941") (:+HGNC+ . "1771")) (:NAME . "CDK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "0c252ae0-ba8b-451c-84ce-c53b65fdd212"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P03372") (:+HGNC+ . "3467")) (:NAME . "ESR1"))
     (:SUPPORTED--BY "3e056022-b0df-4181-b89c-fd2f3c8d4c90"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "645b0aeb-0d65-467a-a599-6320724bbd38")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fcc57fb1e93fabec3a9f38b03fd5bf2a")
       (:SOURCE--API . "biopax")))
     (:POSITION . "118")
     (:ENZ (:DB--REFS (:+UP+ . "P24941") (:+HGNC+ . "1771")) (:NAME . "CDK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "74804c47-f26f-4d7a-8d7a-e92d6d80cbcd"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "C-MYC") (:+NCIT+ . "C53086") (:+HGNC+ . "7553")
       (:+UP+ . "P01106"))
      (:NAME . "MYC"))
     (:SUPPORTED--BY "2a130ba1-188a-4615-9842-6c35b12675c5")
     (:EVIDENCE
      ((:TEXT
        . "Furthermore, c-MYC suppression of RAS induced senescence requires CDK2 phosphorylation of c-MYC.")
       (:PMID . "21539865") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Previous reports have shown that MYC phosphorylation induced by CDK2 shifts the cellular response to oncogenic RAS expression from OIS to proliferation and transformation in rat embryonic fibroblasts XREF_BIBR, XREF_BIBR.")
       (:PMID . "23390492") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, c-MYC suppression of RAS induced senescence requires CDK2 phosphorylation of c-MYC.")
       (:PMID . "21539865") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The observations that CCND1 and CDK2 expression can cause TGF-beta resistance in mink lung epithelial and MMTVD1-K2 mouse mammary tumor cells, and that CDK2 phosphorylation of MYC abrogates RAS mediated OIS may explain how constitutive CCND1 and CDK2 activity could replace exogenous MYC overexpression and contribute to RAS driven HMEC transformation to AIG in our protocol XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR.")
       (:PMID . "23390492") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The observations that CCND1 and CDK2 expression can cause TGF-beta resistance in mink lung epithelial and MMTVD1-K2 mouse mammary tumor cells, and that CDK2 phosphorylation of MYC abrogates RAS mediated OIS may explain how constitutive CCND1 and CDK2 activity could replace exogenous MYC overexpression and contribute to RAS driven HMEC transformation to AIG in our protocol XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR.")
       (:PMID . "23390492") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "CDK-2") (:+HGNC+ . "1771") (:+UP+ . "P24941")
       (:+NCIT+ . "C25842"))
      (:NAME . "CDK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "f6022a7d-e3ed-4433-935c-4bf248ac3bd8"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P06400") (:+HGNC+ . "9884")) (:NAME . "RB1"))
     (:SUPPORTED--BY "4c7d247d-9366-43ab-a412-8e4406ebf998"
      "d31c68fe-b5ab-4d5e-a80c-4d4cee719c08"
      "db763a02-4bdb-4fec-8cb5-df5684ad610d"
      "db0fd301-874e-4e0d-ae9e-ca542802970d"
      "f69817f4-368f-4abd-805c-d33ffcc508be")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f108bb29275974b9c21dd2bed02dc58d")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "807")
     (:ENZ (:DB--REFS (:+UP+ . "P24941") (:+HGNC+ . "1771")) (:NAME . "CDK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "a0099e50-c1e5-4ec0-855c-3a27845f9617"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "RB-PROTEIN") (:+UP+ . "P06400")
       (:+NCIT+ . "C17394"))
      (:NAME . "RB1"))
     (:SUPPORTED--BY "c435cf78-6389-401e-a77e-576450e6bc47")
     (:EVIDENCE
      ((:TEXT
        . "Consequent phosphorylation of the RB protein by CDK2 releases the E2F1 transcription factor to drive expression of its target gene, such as c-myc, p107, and E2Fs.")
       (:PMID . "20504375") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "p16, a CKI of the INK4 and ARF family, whose overexpression has repeatedly been reported to be typical of dysplastic and neoplastic epithelium of the cervix, slows down the cell cycle by inactivating the CDK that phosphorylates the tumor suppressor retinoblastoma protein (pRb).")
       (:PMID . "20631637") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Upon exposure to a growth stimulus, the G 0 / G 1 -specific cyclin and cdks phosphorylate Rb proteins on multiple residues, causing the release of E2F transcription factors and promoting transcription of genes necessary for G 0 / G 1 to S transition.")
       (:PMID . "23684928") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The CDKs phosphorylate the retinoblastoma protein (pRb), which results in a conformational change leading to the interruption of the cell-cycle progression (XREF_BIBR, XREF_BIBR).")
       (:PMID . "22948376") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "CDK-2") (:+HGNC+ . "1771") (:+UP+ . "P24941")
       (:+NCIT+ . "C25842"))
      (:NAME . "CDK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "fe2149f7-e50b-40f2-88a9-2dfc19cf0478"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "SMAD-3") (:+UP+ . "P84022") (:+HGNC+ . "6769"))
      (:NAME . "SMAD3"))
     (:SUPPORTED--BY "ec699d53-2669-4c6a-b9ba-7c3f373c1114")
     (:EVIDENCE
      ((:TEXT
        . "Cyclin D1/CDK4 promotes G1/S-phase transition, and CDK phosphorylation of Smad3 has been associated with inhibition of Smad3 activity.")
       (:PMID . "20736297") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_CDK2_DirectlyIncreases_p_HGNC_SMAD3_pmod_P")
       (:TEXT
        . "Here we show that Smad3 is a major physiological substrate of the G1 cyclin-dependent kinases CDK4 and CDK2.")
       (:PMID . "15241418") (:SOURCE--API . "bel"))
      ((:TEXT
        . "Using Smad3 (-/-) mouse embryonic fibroblasts and other epithelial cell lines, we further show that Smad3 inhibits cell cycle progression from G1 to S phase and that mutation of the CDK phosphorylation sites in Smad3 increases this ability.")
       (:PMID . "15241418") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:2000042") (:ORGAN) (:CELL--LINE)
        (:TISSUE) (:LOCATION) (:FOUND--BY . "Phosphorylation_syntax_5_noun")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Abrogation of Smad3 phosphorylation by CDK increases transcriptional activity in MCF7 and T47D cells.")
       (:PMID . "20736297") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Abrogation of Smad3 phosphorylation by CDK increases transcriptional activity in MCF7 and T47D cells.")
       (:PMID . "20736297") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Cyclin D1/CDK4 promotes G1/S-phase transition, and CDK phosphorylation of Smad3 has been associated with inhibition of Smad3 activity.")
       (:PMID . "20736297") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To further examine the combined impact of CDK4 inhibition and abrogation of CDK phosphorylation of Smad3 on Smad3 transcriptional activity, MCF7 (XREF_FIG), T47D (XREF_FIG), and Hs578T (XREF_FIG) parental, vector control, and cyclin D1 overexpressing cells were transfected with Smad3 WT or Smad3 mutant constructs, the CAGA-luc reporter, and the pRenilla reporter, and then treated with vehicle or 800 nM CDK4 inhibitor.")
       (:PMID . "20736297") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Inhibition of cdks with roscovitine reduced the phosphorylation of Smad3 and the decrease in its protein levels, but impaired the ability of 2ME2 to induce an arrest in mitosis (data not shown, XREF_BIBR).")
       (:PMID . "22927969") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, we noticed in previous reports that CDK2 phosphorylates -catenin on residues that are not in the CDK-consensus phosphorylation sequence () and that G1 CDKs phosphorylate Smad proteins ().")
       (:PMID . "17208333") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, we noticed in previous reports that CDK2 phosphorylates -catenin on residues that are not in the CDK-consensus phosphorylation sequence () and that G1 CDKs phosphorylate Smad proteins ().")
       (:PMID . "17208333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "CDK2 and CDK4 phosphorylate Smad3 at Thr8 in the MH1 domain and Thr178, Ser212 at sites in the linker region and this, in turn, inhibits its transcriptional activity.")
       (:PMID . "17099224") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, cyclin E mediated inhibition of Smad3 is regulated by CDK2 phosphorylation of the Smad3 protein in MCF7 cells.")
       (:PMID . "21150326") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "CDK2") (:+UP+ . "P24941") (:+HGNC+ . "1771"))
      (:NAME . "CDK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "c779f10d-c0e4-41d0-88bf-51a6724aaa70"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "C-JUN") (:+UP+ . "P05412") (:+HGNC+ . "6204"))
      (:NAME . "JUN"))
     (:SUPPORTED--BY "06475688-c620-4857-8fa4-1d73a4521960")
     (:EVIDENCE
      ((:TEXT
        . "We show here that CDK4 directly phosphorylated c-Jun following mouse and human immune cell stimulation, leading to activation of the transcription factor AP-1 and enhanced production of AP-1 dependent cytokines.")
       (:PMID . "21559334") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here we demonstrate that CDK4 directly phosphorylates c-Jun in B lymphocytes and dendritic cells (DC) independently of cell proliferation, regulating AP-1 activity and AP-1-regulated cytokine production.")
       (:PMID . "21559334") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition to the partially redundant nature of CDKs, the common SAP kinase- phosphorylated residues of c-Jun (Ser63, 73 and Thr91 and 93) each contain a weak CDK consensus sequence (S/T - P) XREF_BIBR, indicating potential for other CDKs to phosphorylate c-Jun.")
       (:PMID . "21559334") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These data, together with previous results suggest that CDK4 phosphorylates c-Jun in vivo.")
       (:PMID . "21559334") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition to the partially redundant nature of CDKs, the common SAP kinase- phosphorylated residues of c-Jun (Ser63, 73 and Thr91 and 93) each contain a weak CDK consensus sequence (S/T - P) XREF_BIBR, indicating potential for other CDKs to phosphorylate c-Jun")
       (:PMID . "21559334") (:SOURCE--API . "sparser"))
      ((:TEXT . "These CDK4 complexes phosphorylated c-Jun (XREF_FIG).")
       (:PMID . "21559334") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show here that CDK4 directly phosphorylated c-Jun following mouse and human immune cell stimulation, leading to activation of the transcription factor AP-1 and enhanced production of AP-1 dependent cytokines.")
       (:PMID . "21559334") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "These CDK4 complexes phosphorylated c-Jun (XREF_FIG).")
       (:PMID . "21559334") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here we demonstrate that CDK4 directly phosphorylates c-Jun in B lymphocytes and dendritic cells (DC) independently of cell proliferation, regulating AP-1 activity and AP-1-regulated cytokine production.")
       (:PMID . "21559334") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Surprisingly, the regulation of c-Jun phosphorylation by CDK4 occurred in non dividing cells, indicating that this pathway is utilized for cell functions that are independent of proliferation.")
       (:PMID . "21559334") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "CDK-4") (:+HGNC+ . "1773") (:+UP+ . "P11802")
       (:+NCIT+ . "C17680"))
      (:NAME . "CDK4"))
     (:TYPE . "Phosphorylation")
     (:ID . "94525461-61eb-4669-9a26-8da965019d2b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P06400") (:+HGNC+ . "9884")) (:NAME . "RB1"))
     (:SUPPORTED--BY "4c7d247d-9366-43ab-a412-8e4406ebf998"
      "f69817f4-368f-4abd-805c-d33ffcc508be"
      "ce855a2f-ae1d-41c0-824c-cfb82b507d0b"
      "d31c68fe-b5ab-4d5e-a80c-4d4cee719c08"
      "b08aaa0f-5388-4d89-9b3c-fa1ccb652a95")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4c44364705b793102ff04c12afc69556")
       (:PMID . "14627988") (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_60a0225827bbf0d5001d83cf37eb4674")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Retinoblastoma protein (pRb) phosphorylation on Ser807 and Ser811 (p-pRb) by CDK4 and CDK6 and D-type cyclins, represents the first step of cell cycle progression after cell activation.")
       (:PMID . "25675863") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "807")
     (:ENZ (:DB--REFS (:+UP+ . "P11802") (:+HGNC+ . "1773")) (:NAME . "CDK4"))
     (:TYPE . "Phosphorylation")
     (:ID . "86797df5-8a1e-4a64-804e-226238f8c2d7"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "RETINOBLASTOMA-PROTEIN") (:+UP+ . "P06400")
       (:+NCIT+ . "C17394"))
      (:NAME . "RB1"))
     (:SUPPORTED--BY "c435cf78-6389-401e-a77e-576450e6bc47")
     (:EVIDENCE
      ((:TEXT
        . "p16, a CKI of the INK4 and ARF family, whose overexpression has repeatedly been reported to be typical of dysplastic and neoplastic epithelium of the cervix, slows down the cell cycle by inactivating the CDK that phosphorylates the tumor suppressor retinoblastoma protein (pRb).")
       (:PMID . "20631637") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Upon exposure to a growth stimulus, the G 0 / G 1 -specific cyclin and cdks phosphorylate Rb proteins on multiple residues, causing the release of E2F transcription factors and promoting transcription of genes necessary for G 0 / G 1 to S transition.")
       (:PMID . "23684928") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The CDKs phosphorylate the retinoblastoma protein (pRb), which results in a conformational change leading to the interruption of the cell-cycle progression (XREF_BIBR, XREF_BIBR).")
       (:PMID . "22948376") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ (:DB--REFS (:+TEXT+ . "CDK4") (:+UP+ . "P11802") (:+HGNC+ . "1773"))
      (:NAME . "CDK4"))
     (:TYPE . "Phosphorylation")
     (:ID . "3468d7ca-5062-4fed-920c-18ce6d40037e"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P06400") (:+HGNC+ . "9884")) (:NAME . "RB1"))
     (:SUPPORTED--BY "deb08ead-7621-4221-9c19-96689b0394c4"
      "d31c68fe-b5ab-4d5e-a80c-4d4cee719c08"
      "4c7d247d-9366-43ab-a412-8e4406ebf998"
      "f69817f4-368f-4abd-805c-d33ffcc508be"
      "60f48e17-e12d-4ffe-97c9-de547aa36510")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8520277b29f7129a529e8fc6711eed18")
       (:PMID . "14627988") (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_07b607b9a547a122807bea1479256d22")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Retinoblastoma protein (pRb) phosphorylation on Ser807 and Ser811 (p-pRb) by CDK4 and CDK6 and D-type cyclins, represents the first step of cell cycle progression after cell activation.")
       (:PMID . "25675863") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "807")
     (:ENZ (:DB--REFS (:+UP+ . "Q00534") (:+HGNC+ . "1777")) (:NAME . "CDK6"))
     (:TYPE . "Phosphorylation")
     (:ID . "e1a75a26-753a-4b80-9d40-7a5a07f016ec"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "RB-PROTEINS") (:+UP+ . "P06400")
       (:+NCIT+ . "C17394"))
      (:NAME . "RB1"))
     (:SUPPORTED--BY "c435cf78-6389-401e-a77e-576450e6bc47")
     (:EVIDENCE
      ((:TEXT
        . "Upon exposure to a growth stimulus, the G 0 / G 1 -specific cyclin and cdks phosphorylate Rb proteins on multiple residues, causing the release of E2F transcription factors and promoting transcription of genes necessary for G 0 / G 1 to S transition.")
       (:PMID . "23684928") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "p16, a CKI of the INK4 and ARF family, whose overexpression has repeatedly been reported to be typical of dysplastic and neoplastic epithelium of the cervix, slows down the cell cycle by inactivating the CDK that phosphorylates the tumor suppressor retinoblastoma protein (pRb).")
       (:PMID . "20631637") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The CDKs phosphorylate the retinoblastoma protein (pRb), which results in a conformational change leading to the interruption of the cell-cycle progression (XREF_BIBR, XREF_BIBR).")
       (:PMID . "22948376") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ (:DB--REFS (:+TEXT+ . "CDK6") (:+UP+ . "Q00534") (:+HGNC+ . "1777"))
      (:NAME . "CDK6"))
     (:TYPE . "Phosphorylation")
     (:ID . "936b4bf5-f89a-4809-a638-e998477a21c3"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "Smad3") (:+UP+ . "P84022") (:+HGNC+ . "6769"))
      (:NAME . "SMAD3"))
     (:SUPPORTED--BY "ec699d53-2669-4c6a-b9ba-7c3f373c1114")
     (:EVIDENCE
      ((:TEXT
        . "Using Smad3 (-/-) mouse embryonic fibroblasts and other epithelial cell lines, we further show that Smad3 inhibits cell cycle progression from G1 to S phase and that mutation of the CDK phosphorylation sites in Smad3 increases this ability.")
       (:PMID . "15241418") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:2000042") (:ORGAN) (:CELL--LINE)
        (:TISSUE) (:LOCATION) (:FOUND--BY . "Phosphorylation_syntax_5_noun")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To further examine the combined impact of CDK4 inhibition and abrogation of CDK phosphorylation of Smad3 on Smad3 transcriptional activity, MCF7 (XREF_FIG), T47D (XREF_FIG), and Hs578T (XREF_FIG) parental, vector control, and cyclin D1 overexpressing cells were transfected with Smad3 WT or Smad3 mutant constructs, the CAGA-luc reporter, and the pRenilla reporter, and then treated with vehicle or 800 nM CDK4 inhibitor.")
       (:PMID . "20736297") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, we noticed in previous reports that CDK2 phosphorylates -catenin on residues that are not in the CDK-consensus phosphorylation sequence () and that G1 CDKs phosphorylate Smad proteins ().")
       (:PMID . "17208333") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Abrogation of Smad3 phosphorylation by CDK increases transcriptional activity in MCF7 and T47D cells.")
       (:PMID . "20736297") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Abrogation of Smad3 phosphorylation by CDK increases transcriptional activity in MCF7 and T47D cells.")
       (:PMID . "20736297") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Cyclin D1/CDK4 promotes G1/S-phase transition, and CDK phosphorylation of Smad3 has been associated with inhibition of Smad3 activity.")
       (:PMID . "20736297") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Cyclin D1/CDK4 promotes G1/S-phase transition, and CDK phosphorylation of Smad3 has been associated with inhibition of Smad3 activity.")
       (:PMID . "20736297") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, we noticed in previous reports that CDK2 phosphorylates -catenin on residues that are not in the CDK-consensus phosphorylation sequence () and that G1 CDKs phosphorylate Smad proteins ().")
       (:PMID . "17208333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inhibition of cdks with roscovitine reduced the phosphorylation of Smad3 and the decrease in its protein levels, but impaired the ability of 2ME2 to induce an arrest in mitosis (data not shown, XREF_BIBR).")
       (:PMID . "22927969") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ (:DB--REFS (:+TEXT+ . "CDK6") (:+UP+ . "Q00534") (:+HGNC+ . "1777"))
      (:NAME . "CDK6"))
     (:TYPE . "Phosphorylation")
     (:ID . "61b1ff5e-5ebb-4a71-b592-e983b739d839"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:SUPPORTED--BY "5f37d83c-f134-43a1-81a0-29f3f2a889f7"
      "93868e97-7891-4417-96b7-aa7453443998"
      "57be154a-0f98-4999-baf6-d7036e5af809"
      "2683b9bc-7dd7-471e-b6f3-a28c42ded7ad"
      "309f1cb3-3783-42ed-a812-eb591d03cc00"
      "3818c669-ac3c-4e20-aa6a-12600de3de34"
      "fa4c3db0-d0ac-4df3-8757-afd9f623ddf3")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a0ac0bff0ea3bd743f5a29b7f82059a1")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4818ecb8134dbfd70e9e8d37bfea1f8d")
       (:PMID . "10673501") (:SOURCE--API . "biopax")))
     (:POSITION . "15")
     (:ENZ (:DB--REFS (:+UP+ . "O14757") (:+HGNC+ . "1925")) (:NAME . "CHEK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a1dc9bac-278b-4088-947b-faba2a3dda1e"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:SUPPORTED--BY "93868e97-7891-4417-96b7-aa7453443998"
      "5f37d83c-f134-43a1-81a0-29f3f2a889f7"
      "57be154a-0f98-4999-baf6-d7036e5af809"
      "3818c669-ac3c-4e20-aa6a-12600de3de34"
      "64d134ee-783a-4162-903c-a10009e46c48")
     (:EVIDENCE
      ((:TEXT
        . "Additionally, p53 is phosphorylated on Ser20 by Chk1 or Chk2, which are targets for ATR and ATM signaling respectively, although some cross-talk exists between the pathways (XREF_BIBR).")
       (:PMID . "18332866") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4818ecb8134dbfd70e9e8d37bfea1f8d")
       (:PMID . "10673501") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_edeebcc99bb3fdfd9fc35558656eb30e")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Both Chk1 and Chk2 can phosphorylate p53 on several sites including S20 (S23 in mice) [XREF_BIBR].")
       (:PMID . "19473886") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "20")
     (:ENZ (:DB--REFS (:+TEXT+ . "Chk1") (:+UP+ . "O14757") (:+HGNC+ . "1925"))
      (:NAME . "CHEK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "ab62361b-b42a-4028-aa1a-994980f0f742"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "O96017") (:+HGNC+ . "16627"))
      (:NAME . "CHEK2"))
     (:SUPPORTED--BY "c3ca82b0-8354-4cf4-860d-64f2e2943055"
      "a97ba000-d858-4b4d-a2a8-4a5cb2d3854a"
      "84fe4b6d-841c-4311-bad2-2fa715fa75a6")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Using phosphorylation of S23 (S20 in humans) on P53 as a measure of Chk2 activation, we were unable to detect any S23 phosphorylation with a S23 phosphospecific antibody in untreated cells in which Chk2 T68 is phosphorylated solely by Chk2 overexpression.")
       (:PMID . "16481012") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "One of the known endogenous phosphorylation targets of DNA-PK is the DNA damage response protein Chk2, in which DNA-PK mediates phosphorylation of Chk2 at Thr 68 in response to DNA damage (XREF_BIBR).")
       (:PMID . "18957425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "68")
     (:ENZ (:DB--REFS (:+UP+ . "O96017") (:+HGNC+ . "16627"))
      (:NAME . "CHEK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "81138825-151b-4d2a-9fe1-2af41bf9411d"))
    ((:SUB (:DB--REFS (:+TEXT+ . "pRb") (:+UP+ . "P06400") (:+HGNC+ . "9884"))
      (:NAME . "RB1"))
     (:SUPPORTED--BY "4c7d247d-9366-43ab-a412-8e4406ebf998")
     (:EVIDENCE
      ((:TEXT
        . "For example, CHK2 phosphorylates pRb which enhances the formation of the transcriptionally inactive pRb/E2F-1 complex causing G1/S arrest and apoptosis repression ( xref ).")
       (:PMID . "25404613") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "For example, CHK2 phosphorylates pRb which enhances the formation of the transcriptionally inactive pRb and E2F -1 complex causing G1/S arrest and apoptosis repression (XREF_BIBR).")
       (:PMID . "25404613") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "CHK2") (:+UP+ . "O96017") (:+HGNC+ . "16627"))
      (:NAME . "CHEK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "c24c8a4a-5ba5-4bc2-a683-3841377ec876"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:SUPPORTED--BY "5f37d83c-f134-43a1-81a0-29f3f2a889f7"
      "62f34959-cd6c-4916-9db6-b8a50056f36e"
      "fa4c3db0-d0ac-4df3-8757-afd9f623ddf3"
      "3c05b55e-c95f-4f7c-b980-8cc18b9f7bb5"
      "309f1cb3-3783-42ed-a812-eb591d03cc00"
      "93868e97-7891-4417-96b7-aa7453443998")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_83c689092ddd64e2b804ef570f42d67e")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "After DNA damage, ATM and CHK2 phosphorylate p53 (S15 and S20), thus reducing its ability to bind MDM2 and contributing to its stabilization [XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR].")
       (:PMID . "25247188") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4818ecb8134dbfd70e9e8d37bfea1f8d")
       (:PMID . "10673501") (:SOURCE--API . "biopax")))
     (:POSITION . "15")
     (:ENZ (:DB--REFS (:+UP+ . "O96017") (:+HGNC+ . "16627"))
      (:NAME . "CHEK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "dfed3a65-558d-474c-97c0-09ecb78db983"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:SUPPORTED--BY "64d134ee-783a-4162-903c-a10009e46c48"
      "3c05b55e-c95f-4f7c-b980-8cc18b9f7bb5"
      "62f34959-cd6c-4916-9db6-b8a50056f36e"
      "5f37d83c-f134-43a1-81a0-29f3f2a889f7"
      "93868e97-7891-4417-96b7-aa7453443998"
      "cdffcee0-a732-4533-bf0c-7ef8de3e85f4")
     (:EVIDENCE
      ((:TEXT
        . "While Chk2 phosphorylates p53 at Ser 20, thereby stabilizing p53 by preventing MDM2 binding XREF_BIBR, Chk2 also phosphorylates p53 at six additional sites, including Ser 313 and Ser 314 located in the nuclear localization signal domain of p53 XREF_BIBR.")
       (:PMID . "18725978") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, p53 is phosphorylated on Ser20 by Chk1 or Chk2, which are targets for ATR and ATM signaling respectively, although some cross-talk exists between the pathways (XREF_BIBR).")
       (:PMID . "18332866") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Chk2 phosphorylates p53 at Ser 20, inhibiting MDM2-p53 protein binding [XREF_BIBR] but also at several sites located in the C-terminal domain of the p53 protein [XREF_BIBR].")
       (:PMID . "22420423") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "CHK2 can be fully activated in trans by the two p53 DNA-binding-domain peptides, and can phosphorylate BOX-I transactivation-domain fragments of p53 at Thr 18 and Ser 20.")
       (:PMID . "12897801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "For example, p53 is phosphorylated at Ser20 by the checkpoint kinase Chk2 after IR, which results in p53's dissociation from Mdm2 and its subsequent stabilization ( xref ; xref ; xref ).")
       (:PMID . "20096447") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "In Atg7 deficient cells, depletion of Chk2 reduced starvation induced phosphorylation of p53 Ser 20 (XREF_FIG and XREF_SUPPLEMENTARY).")
       (:PMID . "22499945") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fbe17fbe59df1e0d93550b9468613120")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "A study published in 2000 reported that, upon DNA damage, CHK2 phosphorylates p53 on Ser20 ( xref ).")
       (:PMID . "25404613") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Chk2 phosphorylates p53 at Ser 20, inhibiting MDM2-p53 protein binding [ xref ] but also at several sites located in the C-terminal domain of the p53 protein [ xref ].")
       (:PMID . "22420423") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "A study published in 2000 reported that, upon DNA damage, CHK2 phosphorylates p53 on Ser20 (XREF_BIBR).")
       (:PMID . "25404613") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, the stabilisation of p53 after IR was normal in the heterozygous LCLs compared to controls (XREF_FIG), an event that is attributed to CHK2 phosphorylation of p53 on Ser20 (Chehab et al, 2000; Shieh et al, 2000).")
       (:PMID . "15700044") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "After DNA damage, ATM and CHK2 phosphorylate p53 (S15 and S20), thus reducing its ability to bind MDM2 and contributing to its stabilization [XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR].")
       (:PMID . "25247188") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "For example, p53 is phosphorylated at Ser20 by the checkpoint kinase Chk2 after IR, which results in p53 's dissociation from Mdm2 and its subsequent stabilization (XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "20096447") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Both Chk1 and Chk2 can phosphorylate p53 on several sites including S20 (S23 in mice) [XREF_BIBR].")
       (:PMID . "19473886") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4818ecb8134dbfd70e9e8d37bfea1f8d")
       (:PMID . "10673501") (:SOURCE--API . "biopax")))
     (:POSITION . "20")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "Chk2") (:+UP+ . "O96017") (:+HGNC+ . "16627"))
      (:NAME . "CHEK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "4fa2471f-9435-46e5-920e-ed6405f0cd24"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:SUPPORTED--BY "93868e97-7891-4417-96b7-aa7453443998"
      "fa4c3db0-d0ac-4df3-8757-afd9f623ddf3"
      "5f37d83c-f134-43a1-81a0-29f3f2a889f7"
      "309f1cb3-3783-42ed-a812-eb591d03cc00")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba1e52c92bba6bfc6152504fe6406be2")
       (:PMID . "10606744") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba1e52c92bba6bfc6152504fe6406be2")
       (:PMID . "10734067") (:SOURCE--API . "biopax")))
     (:POSITION . "15")
     (:ENZ (:DB--REFS (:+UP+ . "P48730") (:+HGNC+ . "2452"))
      (:NAME . "CSNK1D"))
     (:TYPE . "Phosphorylation")
     (:ID . "ca5ccbca-72e8-46e7-99b2-3a5cf88e0a6c"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:SUPPORTED--BY "5f37d83c-f134-43a1-81a0-29f3f2a889f7"
      "ca764cfb-20d8-4ae0-940e-46debc418320")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba1e52c92bba6bfc6152504fe6406be2")
       (:PMID . "10606744") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba1e52c92bba6bfc6152504fe6406be2")
       (:PMID . "10734067") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a7180e2c2a66a44e3b5315959d565de9")
       (:SOURCE--API . "biopax")))
     (:POSITION . "18")
     (:ENZ (:DB--REFS (:+UP+ . "P48730") (:+HGNC+ . "2452"))
      (:NAME . "CSNK1D"))
     (:TYPE . "Phosphorylation")
     (:ID . "cdf949e3-7a37-41b1-916b-267ce72ad6b2"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P22681") (:+HGNC+ . "1541")) (:NAME . "CBL"))
     (:SUPPORTED--BY "76f238ad-a593-4950-b185-60b53c7310b8"
      "bfe47156-e9c6-4bb9-a3ac-c0f431de65d4"
      "4b14d4eb-68dc-44c8-b53b-a708f0bd1359")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_EGFR_DirectlyIncreases_p_HGNC_CBL_pmod_P_Y_371")
       (:TEXT . "10635327;11997497") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_EGFR_DirectlyIncreases_p_HGNC_CBL_pmod_P_Y_371")
       (:TEXT
        . "phosphorylation of c-Cbl on tyrosine 371 by the activated EGFR")
       (:PMID . "11448952") (:SOURCE--API . "bel")))
     (:POSITION . "371")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1172") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1092") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1016") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1069") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1197") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1110") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:TYPE . "Phosphorylation")
     (:ID . "67be3701-8a72-4814-a2b8-4e17bad43b6a"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:SUPPORTED--BY "a8188ef3-2d6b-4c6f-9046-9e16d880162a"
      "f58436a8-9b1e-4230-89e4-82e1da7e1a96"
      "303b5990-d8da-49aa-9043-1dc68a410f89"
      "211e5a21-549a-4e72-9cd1-a9ace8c1fa70"
      "4417e5bb-e262-4660-b850-396573000526")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_EGFR_DirectlyIncreases_p_HGNC_EGFR_pmod_P_Y_1016")
       (:TEXT . "8845374;7680558;15302935") (:PMID . "15212693")
       (:SOURCE--API . "bel")))
     (:POSITION . "1016")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1172") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1092") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1016") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1069") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1197") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1110") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:TYPE . "Phosphorylation")
     (:ID . "3d98235b-1b35-41c0-8f4e-afea8d2445fa"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:SUPPORTED--BY "7592f25d-9e00-4d12-b0f9-4dfdcabe8ff9"
      "bb301e50-2a29-48f2-8e75-e4a525b86c17"
      "f58436a8-9b1e-4230-89e4-82e1da7e1a96"
      "7e72324b-937c-4a65-9005-2d9f2fa6c1b3"
      "211e5a21-549a-4e72-9cd1-a9ace8c1fa70")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_EGFR_DirectlyIncreases_p_HGNC_EGFR_pmod_P_Y_1092")
       (:TEXT
        . "Previously we found that short peptides surrounding major autophosphorylation sites of EGFR (VPEY(1068)INQ, DY(1148)QQD, and ENAEY(1173)LR) suppress phosphorylation of purified EGFR to 30-50% at 4000 muM")
       (:PMID . "17849478") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_EGFR_DirectlyIncreases_p_HGNC_EGFR_pmod_P_Y_1092")
       (:TEXT . "8845374;15302935;17081983") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_EGFR_DirectlyIncreases_p_HGNC_EGFR_pmod_P_Y_1092")
       (:TEXT
        . "Despite extensive overlap in the molecules recruited to the active receptors, there is some preferential modulation of signalling pathways. Tumour cells that express EGFR with kinase-domain mutations preferentially activate the pro-survival PI3K?AKT and signal transducer and activator of transcription (STAT) pathways67. Although EGFR has no consensus sequence for the p85 adaptor subunit of PI3K, it couples to this pathway through GAB1, which binds growth-factorreceptor- bound protein 2 (GRB2).")
       (:PMID . "15864276") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_EGFR_DirectlyIncreases_p_HGNC_EGFR_pmod_P_Y_1092")
       (:TEXT
        . "This is taken from supplemental table 2 from PMID 15951569 Cut-offs were 2.25 for increase and 0.5 for decrease LLID were found by converting from GI assession numbers in DAVID Spreadsheet is saved in the project folder for Cell Signaling Project # bduckworth")
       (:PMID . "15951569") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_EGFR_DirectlyIncreases_p_HGNC_EGFR_pmod_P_Y_1092")
       (:TEXT
        . "We designed oligopeptides consisting of amino-acid sequences of the major (Y1068, Y1148, and Y1173) and minor (Y992) autophosphorylation sites of EGFR.")
       (:PMID . "16402038") (:SOURCE--API . "bel")))
     (:POSITION . "1092")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1172") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1092") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1016") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1069") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1197") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1110") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:TYPE . "Phosphorylation")
     (:ID . "5f6d2024-8f77-433c-bc9e-4942dcd718dd"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:SUPPORTED--BY "211e5a21-549a-4e72-9cd1-a9ace8c1fa70"
      "0328dd68-e051-4284-9940-5696b4a73330"
      "f58436a8-9b1e-4230-89e4-82e1da7e1a96"
      "4023b882-c630-4014-bb58-569127e3880c")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "1172")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1172") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1092") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1016") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1069") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1197") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1110") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:TYPE . "Phosphorylation")
     (:ID . "a8862357-7cab-496d-bf76-6c95996ed216"))
    ((:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:TEXT
        . "The EGF receptor (EGFR) inhibitor also suppressed 17-PT-PGE2-upregulated FAK phosphorylation.")
       (:PMID . "23525457") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistically, de4 EGFR significantly upregulated the extracellular regulated protein kinase, AKT, focal adhesion kinase (FAK) and Src phosphorylation and matrix metalloproteinase-9 expression while downregulated the expression of E-cadherin.")
       (:PMID . "23764753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In order to study phosphorylation of FAK by EGF-R and alphavbeta3 activation, we determined p-FAK expression levels as a function of alphavbeta3/VN interaction and EGF-R activation by EGF.")
       (:PMID . "18577466") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1172") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1092") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1016") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1069") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1197") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1110") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "EGF receptor") (:+UP+ . "P00533")
       (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:TYPE . "Phosphorylation")
     (:ID . "71355b6f-aeb8-4cb2-970e-15d206ec467e"))
    ((:SUB (:DB--REFS (:+UP+ . "P29353") (:+HGNC+ . "10840")) (:NAME . "SHC1"))
     (:SUPPORTED--BY "5155385d-534b-4c6b-9930-a0bd655d3cea")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c724b6d0c45e888d22ee5cdeaf76fbf6")
       (:PMID . "1623525") (:SOURCE--API . "biopax"))
      ((:TEXT
        . "A combination of phosphopeptide mapping, phosphoamino-acid analysis, and site directed mutagenesis have shown that Y239 and Y240 are principal sites of Shc phosphorylation by v-Src, and by v-Src and the activated EGF receptor.")
       (:PMID . "8939605") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Epidermal growth factor receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2 and ASH association and retains mitogenic activity.")
       (:PMID . "7506413") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:FOUND--BY . "Phosphorylation_syntax_1a_noun") (:TISSUE) (:LOCATION)
        (:CELL--LINE) (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1172") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1092") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1016") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1069") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1197") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1110") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:TYPE . "Phosphorylation")
     (:ID . "8a2cee7a-5339-4f99-8e32-d7fc962681a4"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:SUPPORTED--BY "a49e8d40-a288-4151-8fd3-d4e5d64e62d5")
     (:EVIDENCE
      ((:TEXT
        . "Mechanistically, de4 EGFR significantly upregulated the extracellular regulated protein kinase, AKT, focal adhesion kinase (FAK) and Src phosphorylation and matrix metalloproteinase-9 expression while downregulated the expression of E-cadherin.")
       (:PMID . "23764753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "CCN2 inhibits EGFR mediated phosphorylation of c-Src and extracellular signal regulated kinase (ERK).")
       (:PMID . "23175185") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The phosphorylation of Src, PYK2 and EGFR in response to LPS was attenuated by pretreatment with inhibitors of c-Src (PP1, 10muM;) and EGFR (AG1478, 10muM;), respectively.Furthermore, LPS stimulated Akt phosphorylation was determined by Western blotting assay using an anti-phospho-Akt Ab.")
       (:PMID . "18182168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "While, EGFR can phosphorylate Src at Y416 position, oncogenic Src (v-Src) can lead to phosphorylation of EGFR at Y845 site xref .")
       (:PMID . "22957061") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "For the first time, we demonstrated that stimulation of the GAGAR leads to EGFR signaling activation, including elevated expression of EGFR ligands, -phosphorytion of the EGFR, and tyrosyl phosphorylation of Src in human PCa cells.")
       (:PMID . "24296312") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous reports about the involvement of AnxA2 in transportation of Src to the membrane led us to investigate whether AnxA2 downregulation interferes with EGF induced phosphorylation of Src by EGFR.")
       (:PMID . "22957061") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "On the other hand, the epidermal growth factor receptor phosphorylates and activates Src, which, in turn, phosphorylates Tks5.")
       (:PMID . "19464300") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Previous reports about the involvement of AnxA2 in transportation of Src to the membrane led us to investigate whether AnxA2 downregulation interferes with EGF induced phosphorylation of Src by EGFR.")
       (:PMID . "22957061") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1172") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1092") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1016") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1069") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1197") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1110") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "EGFR") (:+UP+ . "P00533") (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:TYPE . "Phosphorylation")
     (:ID . "cb29ed48-361c-453b-a635-975bee77bbe8"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "While investigating how HER2 activated HSF-1 independent of heat shock, we observed that HER2 activation resulted in concurrent phosphorylation of Akt and HSF-1.")
       (:PMID . "24469056") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of nuclear YB-1, clinicopathologic findings, and molecular markers [EGFR, HER2, estrogen receptor (ER) alpha, ER beta, progesterone receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), phosphorylated Akt, and major vault protein and lung resistance protein] were immunohistochemically analyzed.")
       (:PMID . "18316615") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In comparison to ErbB2 and ERalpha MCF-7 cells, ErbB2 and ERalpha C4 cells have increased receptor phosphorylation of ErbB2 and phosphorylation of AKT at residues S473 and T308 (B).")
       (:PMID . "24463007") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, the small interfering RNA mediated downregulation of ErbB2 significantly reduced not only the phosphorylation of Akt and ERK-1/2 but also the invasiveness of the cells induced by MIC-1.")
       (:PMID . "18258606") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, pertuzumab mediated inhibition of ErbB2 heterodimerization decreased AKT phosphorylation, cell growth in vitro, and xenograft growth in vivo.")
       (:PMID . "26206558") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylation is associated with HER2 expression in breast cancer [XREF_BIBR, XREF_BIBR], and it has been shown that HER2 transfection of MCF-7 cells leads to Akt phosphorylation mediated through the PI3K pathway [XREF_BIBR].")
       (:PMID . "21078168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1112") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "fa109c01-4535-4929-872b-4ad6bc13e055"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "While investigating how HER2 activated HSF-1 independent of heat shock, we observed that HER2 activation resulted in concurrent phosphorylation of Akt and HSF-1.")
       (:PMID . "24469056") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of nuclear YB-1, clinicopathologic findings, and molecular markers [EGFR, HER2, estrogen receptor (ER) alpha, ER beta, progesterone receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), phosphorylated Akt, and major vault protein and lung resistance protein] were immunohistochemically analyzed.")
       (:PMID . "18316615") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In comparison to ErbB2 and ERalpha MCF-7 cells, ErbB2 and ERalpha C4 cells have increased receptor phosphorylation of ErbB2 and phosphorylation of AKT at residues S473 and T308 (B).")
       (:PMID . "24463007") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, the small interfering RNA mediated downregulation of ErbB2 significantly reduced not only the phosphorylation of Akt and ERK-1/2 but also the invasiveness of the cells induced by MIC-1.")
       (:PMID . "18258606") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, pertuzumab mediated inhibition of ErbB2 heterodimerization decreased AKT phosphorylation, cell growth in vitro, and xenograft growth in vivo.")
       (:PMID . "26206558") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylation is associated with HER2 expression in breast cancer [XREF_BIBR, XREF_BIBR], and it has been shown that HER2 transfection of MCF-7 cells leads to Akt phosphorylation mediated through the PI3K pathway [XREF_BIBR].")
       (:PMID . "21078168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "877") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "40a6b166-24e0-4f02-8cb7-334699efb667"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "While investigating how HER2 activated HSF-1 independent of heat shock, we observed that HER2 activation resulted in concurrent phosphorylation of Akt and HSF-1.")
       (:PMID . "24469056") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In comparison to ErbB2 and ERalpha MCF-7 cells, ErbB2 and ERalpha C4 cells have increased receptor phosphorylation of ErbB2 and phosphorylation of AKT at residues S473 and T308 (B).")
       (:PMID . "24463007") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of nuclear YB-1, clinicopathologic findings, and molecular markers [EGFR, HER2, estrogen receptor (ER) alpha, ER beta, progesterone receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), phosphorylated Akt, and major vault protein and lung resistance protein] were immunohistochemically analyzed.")
       (:PMID . "18316615") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Furthermore, the small interfering RNA mediated downregulation of ErbB2 significantly reduced not only the phosphorylation of Akt and ERK-1/2 but also the invasiveness of the cells induced by MIC-1.")
       (:PMID . "18258606") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, pertuzumab mediated inhibition of ErbB2 heterodimerization decreased AKT phosphorylation, cell growth in vitro, and xenograft growth in vivo.")
       (:PMID . "26206558") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylation is associated with HER2 expression in breast cancer [XREF_BIBR, XREF_BIBR], and it has been shown that HER2 transfection of MCF-7 cells leads to Akt phosphorylation mediated through the PI3K pathway [XREF_BIBR].")
       (:PMID . "21078168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1112") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "c8ad65c5-8e7e-443f-927a-9af089d0b14e"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "While investigating how HER2 activated HSF-1 independent of heat shock, we observed that HER2 activation resulted in concurrent phosphorylation of Akt and HSF-1.")
       (:PMID . "24469056") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In comparison to ErbB2 and ERalpha MCF-7 cells, ErbB2 and ERalpha C4 cells have increased receptor phosphorylation of ErbB2 and phosphorylation of AKT at residues S473 and T308 (B).")
       (:PMID . "24463007") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of nuclear YB-1, clinicopathologic findings, and molecular markers [EGFR, HER2, estrogen receptor (ER) alpha, ER beta, progesterone receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), phosphorylated Akt, and major vault protein and lung resistance protein] were immunohistochemically analyzed.")
       (:PMID . "18316615") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Furthermore, the small interfering RNA mediated downregulation of ErbB2 significantly reduced not only the phosphorylation of Akt and ERK-1/2 but also the invasiveness of the cells induced by MIC-1.")
       (:PMID . "18258606") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, pertuzumab mediated inhibition of ErbB2 heterodimerization decreased AKT phosphorylation, cell growth in vitro, and xenograft growth in vivo.")
       (:PMID . "26206558") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylation is associated with HER2 expression in breast cancer [XREF_BIBR, XREF_BIBR], and it has been shown that HER2 transfection of MCF-7 cells leads to Akt phosphorylation mediated through the PI3K pathway [XREF_BIBR].")
       (:PMID . "21078168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "877") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "dceadf84-8c33-4e64-92b8-0bd7b5125959"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "While investigating how HER2 activated HSF-1 independent of heat shock, we observed that HER2 activation resulted in concurrent phosphorylation of Akt and HSF-1.")
       (:PMID . "24469056") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylation is associated with HER2 expression in breast cancer [XREF_BIBR, XREF_BIBR], and it has been shown that HER2 transfection of MCF-7 cells leads to Akt phosphorylation mediated through the PI3K pathway [XREF_BIBR].")
       (:PMID . "21078168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of nuclear YB-1, clinicopathologic findings, and molecular markers [EGFR, HER2, estrogen receptor (ER) alpha, ER beta, progesterone receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), phosphorylated Akt, and major vault protein and lung resistance protein] were immunohistochemically analyzed.")
       (:PMID . "18316615") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In comparison to ErbB2 and ERalpha MCF-7 cells, ErbB2 and ERalpha C4 cells have increased receptor phosphorylation of ErbB2 and phosphorylation of AKT at residues S473 and T308 (B).")
       (:PMID . "24463007") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, the small interfering RNA mediated downregulation of ErbB2 significantly reduced not only the phosphorylation of Akt and ERK-1/2 but also the invasiveness of the cells induced by MIC-1.")
       (:PMID . "18258606") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, pertuzumab mediated inhibition of ErbB2 heterodimerization decreased AKT phosphorylation, cell growth in vitro, and xenograft growth in vivo.")
       (:PMID . "26206558") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1112") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "6c56ae62-795f-40a0-b321-a6c8fa48c7ce"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "While investigating how HER2 activated HSF-1 independent of heat shock, we observed that HER2 activation resulted in concurrent phosphorylation of Akt and HSF-1.")
       (:PMID . "24469056") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylation is associated with HER2 expression in breast cancer [XREF_BIBR, XREF_BIBR], and it has been shown that HER2 transfection of MCF-7 cells leads to Akt phosphorylation mediated through the PI3K pathway [XREF_BIBR].")
       (:PMID . "21078168") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of nuclear YB-1, clinicopathologic findings, and molecular markers [EGFR, HER2, estrogen receptor (ER) alpha, ER beta, progesterone receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), phosphorylated Akt, and major vault protein and lung resistance protein] were immunohistochemically analyzed.")
       (:PMID . "18316615") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In comparison to ErbB2 and ERalpha MCF-7 cells, ErbB2 and ERalpha C4 cells have increased receptor phosphorylation of ErbB2 and phosphorylation of AKT at residues S473 and T308 (B).")
       (:PMID . "24463007") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, the small interfering RNA mediated downregulation of ErbB2 significantly reduced not only the phosphorylation of Akt and ERK-1/2 but also the invasiveness of the cells induced by MIC-1.")
       (:PMID . "18258606") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, pertuzumab mediated inhibition of ErbB2 heterodimerization decreased AKT phosphorylation, cell growth in vitro, and xenograft growth in vivo.")
       (:PMID . "26206558") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "877") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "01993941-e169-4cfd-98e1-ecd929679a4f"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:SUPPORTED--BY "ef1bae50-bbf3-4b04-a74f-0247bbc6fd07"
      "9dd1b935-e7b7-4a94-9087-471c0bf78073"
      "9b803538-7ac3-49af-9051-cee69d736ca0"
      "112c3a79-ca70-4037-ac2b-5b1c78b3748a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ERBB2_DirectlyIncreases_p_HGNC_ERBB2_pmod_P_Y_1221")
       (:TEXT . "PhosphoElm data from PMID 15212693") (:PMID . "11500516")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ERBB2_DirectlyIncreases_p_HGNC_ERBB2_pmod_P_Y_1221")
       (:TEXT
        . "ErbB2 phosphorylation at Y-1221 and Y-1222 residues, known to be auto-phosphorylated during homodimerization of ErbB2 receptors, were readily detected [30].")
       (:PMID . "19754954") (:SOURCE--API . "bel")))
     (:POSITION . "1221")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1112") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "0875341b-c30c-4eb3-8657-9721cb365b85"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:SUPPORTED--BY "53df6d75-d04d-4077-a119-d0863028c32e"
      "9dd1b935-e7b7-4a94-9087-471c0bf78073"
      "09a015f1-c5d2-42f8-b31f-a760178f58b2"
      "112c3a79-ca70-4037-ac2b-5b1c78b3748a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ERBB2_DirectlyIncreases_p_HGNC_ERBB2_pmod_P_Y_1221")
       (:TEXT . "PhosphoElm data from PMID 15212693") (:PMID . "11500516")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ERBB2_DirectlyIncreases_p_HGNC_ERBB2_pmod_P_Y_1221")
       (:TEXT
        . "ErbB2 phosphorylation at Y-1221 and Y-1222 residues, known to be auto-phosphorylated during homodimerization of ErbB2 receptors, were readily detected [30].")
       (:PMID . "19754954") (:SOURCE--API . "bel")))
     (:POSITION . "1221")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "877") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "051b8fb5-dac2-4925-a570-d14269b9157f"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:SUPPORTED--BY "9dd1b935-e7b7-4a94-9087-471c0bf78073"
      "4e1a88e6-6e8a-44cf-b3e2-05e654b9408f"
      "2834c8b4-4f50-4ba2-8da0-ddc6b2367dfd"
      "112c3a79-ca70-4037-ac2b-5b1c78b3748a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ERBB2_DirectlyIncreases_p_HGNC_ERBB2_pmod_P_Y_1222")
       (:TEXT . "PhosphoElm data from PMID 15212693") (:PMID . "11500516")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ERBB2_DirectlyIncreases_p_HGNC_ERBB2_pmod_P_Y_1222")
       (:TEXT
        . "ErbB2 phosphorylation at Y-1221 and Y-1222 residues, known to be auto-phosphorylated during homodimerization of ErbB2 receptors, were readily detected [30].")
       (:PMID . "19754954") (:SOURCE--API . "bel")))
     (:POSITION . "1222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1112") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "5eedc7d1-4be6-459b-9958-482bcc35ef5e"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:SUPPORTED--BY "9dd1b935-e7b7-4a94-9087-471c0bf78073"
      "bf781a38-01f4-4a29-bfd5-2f5ee7642225"
      "f30c9733-1be3-4d94-ac17-519e238ec3f4"
      "112c3a79-ca70-4037-ac2b-5b1c78b3748a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ERBB2_DirectlyIncreases_p_HGNC_ERBB2_pmod_P_Y_1222")
       (:TEXT . "PhosphoElm data from PMID 15212693") (:PMID . "11500516")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ERBB2_DirectlyIncreases_p_HGNC_ERBB2_pmod_P_Y_1222")
       (:TEXT
        . "ErbB2 phosphorylation at Y-1221 and Y-1222 residues, known to be auto-phosphorylated during homodimerization of ErbB2 receptors, were readily detected [30].")
       (:PMID . "19754954") (:SOURCE--API . "bel")))
     (:POSITION . "1222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "877") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04626") (:+HGNC+ . "3430")) (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "fffd68bb-56e0-413c-b5d1-a5b80704e5b9"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "TNF-alpha treatment of IECs resulted in an association between EGFR and HER2 and inhibition of HER2 using a specific inhibitor AG879 in combination with AG1478 suppressed TNF-alpha-dependent ERK phosphorylation and IL-8 release.")
       (:PMID . "22988345") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Basal ErbB tyrosine phosphorylation and ERK phosphorylation were inhibited by two different ErbB receptor tyrosine kinase inhibitors, by the ErbB1 specific neutralizing monoclonal antibody 225 IgG, by two different metalloproteinase inhibitors, and by neutralizing antibodies against amphiregulin (AR).")
       (:PMID . "15254267") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Anti-HER2 and MEK inhibitors did not only abolish ERK phosphorylation but also increased the anti-proliferative and pro apoptotic effects of PI3K inhibitors.")
       (:PMID . "21278786") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ErbB2 Inhibition Leads to a Persistent ERK Phosphorylation By Testosterone There is available data regarding a similar cross-talk between AR and ErbB2 in prostate cancer.")
       (:PMID . "18516291") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Interestingly, co-inhibition of IGF-IR and HER-2 in esophageal cancer cell lines suppressed MAPK phosphorylation underscoring their importance for this type of cancer.")
       (:PMID . "22658382") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of EGFR, HER2, phosphorylated MAPK and ERK kinase (pMEK) and phosphorylated ERK (pERK) proteins was studied by immunohistochemistry in samples of colonic non neoplastic mucosa (n = 65), adenomas (n = 149) and adenocarcinomas (n = 16) from each of the 16 FAP patients.")
       (:PMID . "21989899") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients.")
       (:PMID . "21989899") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "HER2 tyrosine kinase inhibition abrogated GDF15 mediated Akt and Erk1/2 phosphorylation and blocked GDF15 mediated trastuzumab resistance.")
       (:PMID . "21803025") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, since the major induction of Erk1/2 phosphorylation preceded Her2 phosphorylation, it is likely that there is also a HER2 independent mechanism contributing to GDF15 mediated Erk1/2 phosphorylation.")
       (:PMID . "21803025") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "A phase II trial was performed to evaluate the efficacy and safety of the tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2, lapatinib, and to explore EGFR, HER2 (EGFR2), phosphorylated ERK MAP Kinase (pERK), and Ki67 expression, as well as EGFR mutations in persistent and recurrent endometrial cancer (EC).")
       (:PMID . "22885469") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1112") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "98289191-2e8d-45aa-a8bd-461dea00e9e5"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "TNF-alpha treatment of IECs resulted in an association between EGFR and HER2 and inhibition of HER2 using a specific inhibitor AG879 in combination with AG1478 suppressed TNF-alpha-dependent ERK phosphorylation and IL-8 release.")
       (:PMID . "22988345") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Basal ErbB tyrosine phosphorylation and ERK phosphorylation were inhibited by two different ErbB receptor tyrosine kinase inhibitors, by the ErbB1 specific neutralizing monoclonal antibody 225 IgG, by two different metalloproteinase inhibitors, and by neutralizing antibodies against amphiregulin (AR).")
       (:PMID . "15254267") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Anti-HER2 and MEK inhibitors did not only abolish ERK phosphorylation but also increased the anti-proliferative and pro apoptotic effects of PI3K inhibitors.")
       (:PMID . "21278786") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ErbB2 Inhibition Leads to a Persistent ERK Phosphorylation By Testosterone There is available data regarding a similar cross-talk between AR and ErbB2 in prostate cancer.")
       (:PMID . "18516291") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Interestingly, co-inhibition of IGF-IR and HER-2 in esophageal cancer cell lines suppressed MAPK phosphorylation underscoring their importance for this type of cancer.")
       (:PMID . "22658382") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The expression of EGFR, HER2, phosphorylated MAPK and ERK kinase (pMEK) and phosphorylated ERK (pERK) proteins was studied by immunohistochemistry in samples of colonic non neoplastic mucosa (n = 65), adenomas (n = 149) and adenocarcinomas (n = 16) from each of the 16 FAP patients.")
       (:PMID . "21989899") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients.")
       (:PMID . "21989899") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "HER2 tyrosine kinase inhibition abrogated GDF15 mediated Akt and Erk1/2 phosphorylation and blocked GDF15 mediated trastuzumab resistance.")
       (:PMID . "21803025") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, since the major induction of Erk1/2 phosphorylation preceded Her2 phosphorylation, it is likely that there is also a HER2 independent mechanism contributing to GDF15 mediated Erk1/2 phosphorylation.")
       (:PMID . "21803025") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "A phase II trial was performed to evaluate the efficacy and safety of the tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2, lapatinib, and to explore EGFR, HER2 (EGFR2), phosphorylated ERK MAP Kinase (pERK), and Ki67 expression, as well as EGFR mutations in persistent and recurrent endometrial cancer (EC).")
       (:PMID . "22885469") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "877") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "5da7cb4c-4d55-4553-89fd-bc4760177fac"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "The expression of EGFR, HER2, phosphorylated MAPK and ERK kinase (pMEK) and phosphorylated ERK (pERK) proteins was studied by immunohistochemistry in samples of colonic non neoplastic mucosa (n = 65), adenomas (n = 149) and adenocarcinomas (n = 16) from each of the 16 FAP patients.")
       (:PMID . "21989899") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ErbB2 Inhibition Leads to a Persistent ERK Phosphorylation By Testosterone There is available data regarding a similar cross-talk between AR and ErbB2 in prostate cancer.")
       (:PMID . "18516291") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Anti-HER2 and MEK inhibitors did not only abolish ERK phosphorylation but also increased the anti-proliferative and pro apoptotic effects of PI3K inhibitors.")
       (:PMID . "21278786") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "TNF-alpha treatment of IECs resulted in an association between EGFR and HER2 and inhibition of HER2 using a specific inhibitor AG879 in combination with AG1478 suppressed TNF-alpha-dependent ERK phosphorylation and IL-8 release.")
       (:PMID . "22988345") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Interestingly, co-inhibition of IGF-IR and HER-2 in esophageal cancer cell lines suppressed MAPK phosphorylation underscoring their importance for this type of cancer.")
       (:PMID . "22658382") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients.")
       (:PMID . "21989899") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "A phase II trial was performed to evaluate the efficacy and safety of the tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2, lapatinib, and to explore EGFR, HER2 (EGFR2), phosphorylated ERK MAP Kinase (pERK), and Ki67 expression, as well as EGFR mutations in persistent and recurrent endometrial cancer (EC).")
       (:PMID . "22885469") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "HER2 tyrosine kinase inhibition abrogated GDF15 mediated Akt and Erk1/2 phosphorylation and blocked GDF15 mediated trastuzumab resistance.")
       (:PMID . "21803025") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Basal ErbB tyrosine phosphorylation and ERK phosphorylation were inhibited by two different ErbB receptor tyrosine kinase inhibitors, by the ErbB1 specific neutralizing monoclonal antibody 225 IgG, by two different metalloproteinase inhibitors, and by neutralizing antibodies against amphiregulin (AR).")
       (:PMID . "15254267") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, since the major induction of Erk1/2 phosphorylation preceded Her2 phosphorylation, it is likely that there is also a HER2 independent mechanism contributing to GDF15 mediated Erk1/2 phosphorylation.")
       (:PMID . "21803025") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1112") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "8960221f-06fc-4947-9897-69cc52a3da94"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "The expression of EGFR, HER2, phosphorylated MAPK and ERK kinase (pMEK) and phosphorylated ERK (pERK) proteins was studied by immunohistochemistry in samples of colonic non neoplastic mucosa (n = 65), adenomas (n = 149) and adenocarcinomas (n = 16) from each of the 16 FAP patients.")
       (:PMID . "21989899") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, knockdown of HER2 inhibited cell proliferation and phosphorylation of Akt and ERK1/2 induced by AS-miR-331-3p.")
       (:PMID . "26718987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Western blot analysis demonstrated that 5-minute HRGbeta1 stimulation promoted EGFR, erbB3, erbB2 and EGFR phosphorylation and activation of the downstream signalling components Akt and ERK1/2 in MCF-7, T47D and BT-474 breast cancer cells, as shown in Figure XREF_FIG.")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inactivation of MET, HER2 and EGFR by lapatinib and PHA-665752 were able to abolish the downstream phosphorylation of MAPK and AKT, seen in untreated and in HGF treated cells.")
       (:PMID . "22238368") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ErbB2 Inhibition Leads to a Persistent ERK Phosphorylation By Testosterone There is available data regarding a similar cross-talk between AR and ErbB2 in prostate cancer.")
       (:PMID . "18516291") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Anti-HER2 and MEK inhibitors did not only abolish ERK phosphorylation but also increased the anti-proliferative and pro apoptotic effects of PI3K inhibitors.")
       (:PMID . "21278786") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "TNF-alpha treatment of IECs resulted in an association between EGFR and HER2 and inhibition of HER2 using a specific inhibitor AG879 in combination with AG1478 suppressed TNF-alpha-dependent ERK phosphorylation and IL-8 release.")
       (:PMID . "22988345") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Interestingly, co-inhibition of IGF-IR and HER-2 in esophageal cancer cell lines suppressed MAPK phosphorylation underscoring their importance for this type of cancer.")
       (:PMID . "22658382") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients.")
       (:PMID . "21989899") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "A phase II trial was performed to evaluate the efficacy and safety of the tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2, lapatinib, and to explore EGFR, HER2 (EGFR2), phosphorylated ERK MAP Kinase (pERK), and Ki67 expression, as well as EGFR mutations in persistent and recurrent endometrial cancer (EC).")
       (:PMID . "22885469") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "HER2 tyrosine kinase inhibition abrogated GDF15 mediated Akt and Erk1/2 phosphorylation and blocked GDF15 mediated trastuzumab resistance.")
       (:PMID . "21803025") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Basal ErbB tyrosine phosphorylation and ERK phosphorylation were inhibited by two different ErbB receptor tyrosine kinase inhibitors, by the ErbB1 specific neutralizing monoclonal antibody 225 IgG, by two different metalloproteinase inhibitors, and by neutralizing antibodies against amphiregulin (AR).")
       (:PMID . "15254267") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, since the major induction of Erk1/2 phosphorylation preceded Her2 phosphorylation, it is likely that there is also a HER2 independent mechanism contributing to GDF15 mediated Erk1/2 phosphorylation.")
       (:PMID . "21803025") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "877") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "6ffa1991-6be6-4543-a9f2-f0152988a284"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "STAT3") (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:TEXT
        . "This is in agreement with the fact that HER2 interacts with and phosphorylates STAT3 [XREF_BIBR].")
       (:PMID . "22693070") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In our model system, high expression of ErbB2 led to increased activated phosphorylation of STAT3 mediated by Src kinase down-stream of ErbB2.")
       (:PMID . "19372587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1112") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "a1df8390-ee65-433d-91ae-249c74cc80b8"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "STAT3") (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:TEXT
        . "This is in agreement with the fact that HER2 interacts with and phosphorylates STAT3 [XREF_BIBR].")
       (:PMID . "22693070") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In our model system, high expression of ErbB2 led to increased activated phosphorylation of STAT3 mediated by Src kinase down-stream of ErbB2.")
       (:PMID . "19372587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1023") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1139") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1196") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "1248") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "877") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "HER2") (:+UP+ . "P04626") (:+HGNC+ . "3430"))
      (:NAME . "ERBB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "ef0ce9d4-64a4-4e30-85bb-3218a664925f"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "It has been reported that FGF1 and FGF2 can interact with the FGFR and trigger phosphorylation of p42/44 MAPK and activation of other signaling pathways even in the absence of HS (XREF_BIBR XREF_BIBR XREF_BIBR XREF_BIBR - XREF_BIBR).")
       (:PMID . "19574212") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "FGFR1") (:+UP+ . "P11362") (:+HGNC+ . "3688"))
      (:NAME . "FGFR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "5cf80c69-72d9-48b7-8c7a-adc06db1c047"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "It has been reported that FGF1 and FGF2 can interact with the FGFR and trigger phosphorylation of p42/44 MAPK and activation of other signaling pathways even in the absence of HS (XREF_BIBR XREF_BIBR XREF_BIBR XREF_BIBR - XREF_BIBR).")
       (:PMID . "19574212") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "FGFR1") (:+UP+ . "P11362") (:+HGNC+ . "3688"))
      (:NAME . "FGFR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "bee89108-35a6-4144-9304-c74359b2036a"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "It has been reported that FGF1 and FGF2 can interact with the FGFR and trigger phosphorylation of p42/44 MAPK and activation of other signaling pathways even in the absence of HS (XREF_BIBR XREF_BIBR XREF_BIBR XREF_BIBR - XREF_BIBR).")
       (:PMID . "19574212") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Membranes probed with anti-p-ERK1/2 (Cell Signaling Technology, 1/1000) and anti-alpha-tubulin (Cell Signaling Technology, 1/1000) showed that, unlike FGFR2 expressing cells, FGFR2 expressing cells are unable to activate phosphorylation of ERK1/2 (I).")
       (:PMID . "22387015") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "FGFR2") (:+UP+ . "P21802") (:+HGNC+ . "3689"))
      (:NAME . "FGFR2"))
     (:TYPE . "Phosphorylation")
     (:ID . "5e76b9b6-6bf4-477e-b87c-8a9b5a7c26a4"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "It has been reported that FGF1 and FGF2 can interact with the FGFR and trigger phosphorylation of p42/44 MAPK and activation of other signaling pathways even in the absence of HS (XREF_BIBR XREF_BIBR XREF_BIBR XREF_BIBR - XREF_BIBR).")
       (:PMID . "19574212") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Membranes probed with anti-p-ERK1/2 (Cell Signaling Technology, 1/1000) and anti-alpha-tubulin (Cell Signaling Technology, 1/1000) showed that, unlike FGFR2 expressing cells, FGFR2 expressing cells are unable to activate phosphorylation of ERK1/2 (I).")
       (:PMID . "22387015") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "FGFR2") (:+UP+ . "P21802") (:+HGNC+ . "3689"))
      (:NAME . "FGFR2"))
     (:TYPE . "Phosphorylation")
     (:ID . "2366469a-93ff-497d-95df-9e59e1ecff53"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "It has been reported that FGF1 and FGF2 can interact with the FGFR and trigger phosphorylation of p42/44 MAPK and activation of other signaling pathways even in the absence of HS (XREF_BIBR XREF_BIBR XREF_BIBR XREF_BIBR - XREF_BIBR).")
       (:PMID . "19574212") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Knockdown of FGFR3 led to a decrease in phosphorylation of the downstream kinases mitogen activated protein kinase (MAPK) and protein kinase B (PKB), which was more pronounced under hypoxic conditions.")
       (:PMID . "23778527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "FGFR3") (:+UP+ . "P22607") (:+HGNC+ . "3690"))
      (:NAME . "FGFR3"))
     (:TYPE . "Phosphorylation")
     (:ID . "b5e01fe9-1f61-4a77-bf45-f71e3f93b76b"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "5377520e-d1c5-494f-ad7e-4cdea1263c43"
      "587ed1e4-e9f9-4c73-8422-4eccb1d61e9a"
      "d7fee245-f592-40a7-a9a5-a69ebecdb61f"
      "3b085760-047b-4de6-a358-6f53aa726e61"
      "240a18e3-2e6d-442b-961c-f20a82e11b49")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "12590707") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "11369622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "15728464") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "10753828") (:SOURCE--API . "biopax")))
     (:POSITION . "397")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P09769") (:+HGNC+ . "3697")) (:NAME . "FGR"))
     (:TYPE . "Phosphorylation")
     (:ID . "8d8b0ee3-c55d-499e-8f3d-ea0c6d3a99a9"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "1f9e903b-b337-4022-b907-fc559bac1720"
      "50e293de-0110-4620-ba8e-23908491fd57"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9344858") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "10815799") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9484840") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "11404481") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P09769") (:+HGNC+ . "3697")) (:NAME . "FGR"))
     (:TYPE . "Phosphorylation")
     (:ID . "a1ff9853-5ad2-4b6f-b6dc-4dc012492a75"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "3b085760-047b-4de6-a358-6f53aa726e61"
      "7031518e-5245-47d5-b58c-b37dfd381488"
      "7e425acb-2cd2-429d-b40f-65d11d7b1b1e"
      "18fa9696-eaa4-4652-a7d5-51971213478c"
      "5377520e-d1c5-494f-ad7e-4cdea1263c43")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "12590707") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "11369622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "15728464") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "10753828") (:SOURCE--API . "biopax")))
     (:POSITION . "397")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "420") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06241") (:+HGNC+ . "4037")) (:NAME . "FYN"))
     (:TYPE . "Phosphorylation")
     (:ID . "0bfa4dd7-0001-401f-9a44-78fd3ec8c9aa"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "cccd88da-04e4-46a2-bf5c-4e44da5553b2"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "1f9e903b-b337-4022-b907-fc559bac1720")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9344858") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "10815799") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9484840") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "11404481") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "420") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06241") (:+HGNC+ . "4037")) (:NAME . "FYN"))
     (:TYPE . "Phosphorylation")
     (:ID . "1c72fc25-51c8-48be-ab61-007d5757934a"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P15498") (:+HGNC+ . "12657")) (:NAME . "VAV1"))
     (:SUPPORTED--BY "630a7296-2cb8-47e7-bab4-00ca6d7d46b8"
      "053a350c-c192-47d8-a5c3-22ed58fb20ca"
      "d3f19f24-3853-4474-aea5-e72e8708008d"
      "ba1aeead-3805-44fa-a4ee-605e41280fec")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5c1941be8c3a3c419653ec590deae3cd")
       (:PMID . "9438848") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5c1941be8c3a3c419653ec590deae3cd")
       (:PMID . "15933714") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5c1941be8c3a3c419653ec590deae3cd")
       (:PMID . "9822663") (:SOURCE--API . "biopax")))
     (:POSITION . "142")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "420") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06241") (:+HGNC+ . "4037")) (:NAME . "FYN"))
     (:TYPE . "Phosphorylation")
     (:ID . "7c0aec72-8a74-45a8-acf2-d11719194c8d"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P15498") (:+HGNC+ . "12657")) (:NAME . "VAV1"))
     (:SUPPORTED--BY "053a350c-c192-47d8-a5c3-22ed58fb20ca"
      "d3f19f24-3853-4474-aea5-e72e8708008d"
      "ecc01e2a-16da-4945-8880-c2e29333fc2e"
      "aeb887f8-ff8d-4180-aeec-65cb0eec2a3e"
      "83977049-8907-4d32-a93f-5c0a221bd288")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5c1941be8c3a3c419653ec590deae3cd")
       (:PMID . "9438848") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5c1941be8c3a3c419653ec590deae3cd")
       (:PMID . "15933714") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5c1941be8c3a3c419653ec590deae3cd")
       (:PMID . "9822663") (:SOURCE--API . "biopax")))
     (:POSITION . "160")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "420") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06241") (:+HGNC+ . "4037")) (:NAME . "FYN"))
     (:TYPE . "Phosphorylation")
     (:ID . "474f4641-620e-45e1-8ebe-3ac799982b57"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P15498") (:+HGNC+ . "12657")) (:NAME . "VAV1"))
     (:SUPPORTED--BY "7f350fc7-7501-4076-ab9a-d163841257d8"
      "91067e44-830d-4fc3-aa78-f671115e166d"
      "2287609c-7c52-4911-a15a-2a852d82154b"
      "d3f19f24-3853-4474-aea5-e72e8708008d"
      "053a350c-c192-47d8-a5c3-22ed58fb20ca")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5c1941be8c3a3c419653ec590deae3cd")
       (:PMID . "9438848") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5c1941be8c3a3c419653ec590deae3cd")
       (:PMID . "15933714") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5c1941be8c3a3c419653ec590deae3cd")
       (:PMID . "9822663") (:SOURCE--API . "biopax")))
     (:POSITION . "174")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "420") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06241") (:+HGNC+ . "4037")) (:NAME . "FYN"))
     (:TYPE . "Phosphorylation")
     (:ID . "bcefabc0-d5f4-4f79-b8ad-9b63f239f7dc"))
    ((:SUB (:DB--REFS (:+TEXT+ . "EGFR") (:+UP+ . "P00533") (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:SUPPORTED--BY "f58436a8-9b1e-4230-89e4-82e1da7e1a96")
     (:EVIDENCE
      ((:TEXT
        . "Furthermore, mouse embryonic fibroblasts (MEFs) null for the three SRC family members SRC, Yes and Fyn, (SYF cells) did not phosphorylate EGFR in response to smoke.")
       (:PMID . "21423656") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Furthermore, mouse embryonic fibroblasts (MEFs) null for the three SRC family members SRC, Yes and Fyn, (SYF cells) did not phosphorylate EGFR in response to smoke.")
       (:PMID . "21423656") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Many GPCRs utilize intracellular calcium, src, PKC and oxygen free radical generation to induce HB-EGF release and EGFR phosphorylation.")
       (:PMID . "25082749") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Loss of CIN85 phosphorylation, for example, by overexpressing the phospho defective CIN85-4F mutant, would cause a reduction in src mediated cbl phosphorylation and activation and subsequent EGFR ubiquitination, leading to receptor missorting.")
       (:PMID . "22833562") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Ionizing radiation resulted in src kinase stabilization, activation and subsequent src mediated caveolin-1 Y14- and EGFR Y845-phosphorylations.")
       (:PMID . "18789131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "420") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FYN") (:+HGNC+ . "4037") (:+UP+ . "P06241")
       (:+NCIT+ . "C17574"))
      (:NAME . "FYN"))
     (:TYPE . "Phosphorylation")
     (:ID . "89c6bab2-3a29-4411-9801-badaa5d360a1"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "GSK-3 is known for inactivating glycogen synthase and participates in the Wnt signaling pathway to phosphorylate beta-catenin; GSK-3 can be inhibited by Akt phosphorylation, which is part of insulin signal transduction.")
       (:PMID . "21906675") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These results demonstrate that CLEC-2 regulates GSK3alpha and beta phosphorylation downstream of Akt, ERK, and PKC, thus enhancing platelet activation.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The above results are consistent with a model in which rhodocytin stimulates GSK3alpha and beta phosphorylation at its negative regulatory site downstream of Akt and ERK, thereby inhibiting GSK3alpha and beta activity.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In this study, we have also shown that the PKC inhibitor Ro31-8220 significantly reduces GSK3alpha and beta phosphorylation independently of Akt and that this could not be fully rescued by the addition of ADP.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PKC also regulates GSK3alpha and beta phosphorylation at early times, independently of Akt.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In each cell line, we observed increased AKT phosphorylation at both S473 and T308 following AZD6244 treatment, as well as increased phosphorylation of several AKT targets including GSK3alpha and beta, ATP citrate lyase, and PRAS40 (XREF_FIG).")
       (:PMID . "22552284") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, silencing of GSK-3beta, but not GSK-3alpha, reduced Akt phosphorylation.")
       (:PMID . "22539113") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:TYPE . "Phosphorylation")
     (:ID . "e369dfc2-2410-49ea-a2fc-a5b7b72af575"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "The above results are consistent with a model in which rhodocytin stimulates GSK3alpha and beta phosphorylation at its negative regulatory site downstream of Akt and ERK, thereby inhibiting GSK3alpha and beta activity.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These results demonstrate that CLEC-2 regulates GSK3alpha and beta phosphorylation downstream of Akt, ERK, and PKC, thus enhancing platelet activation.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "GSK-3 is known for inactivating glycogen synthase and participates in the Wnt signaling pathway to phosphorylate beta-catenin; GSK-3 can be inhibited by Akt phosphorylation, which is part of insulin signal transduction.")
       (:PMID . "21906675") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, silencing of GSK-3beta, but not GSK-3alpha, reduced Akt phosphorylation.")
       (:PMID . "22539113") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In this study, we have also shown that the PKC inhibitor Ro31-8220 significantly reduces GSK3alpha and beta phosphorylation independently of Akt and that this could not be fully rescued by the addition of ADP.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PKC also regulates GSK3alpha and beta phosphorylation at early times, independently of Akt.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In each cell line, we observed increased AKT phosphorylation at both S473 and T308 following AZD6244 treatment, as well as increased phosphorylation of several AKT targets including GSK3alpha and beta, ATP citrate lyase, and PRAS40 (XREF_FIG).")
       (:PMID . "22552284") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3alpha") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:TYPE . "Phosphorylation")
     (:ID . "8f41c4be-65d0-4a7b-957e-c85a33a8acfe"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "These results demonstrate that CLEC-2 regulates GSK3alpha and beta phosphorylation downstream of Akt, ERK, and PKC, thus enhancing platelet activation.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, silencing of GSK-3beta, but not GSK-3alpha, reduced Akt phosphorylation.")
       (:PMID . "22539113") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In each cell line, we observed increased AKT phosphorylation at both S473 and T308 following AZD6244 treatment, as well as increased phosphorylation of several AKT targets including GSK3alpha and beta, ATP citrate lyase, and PRAS40 (XREF_FIG).")
       (:PMID . "22552284") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The above results are consistent with a model in which rhodocytin stimulates GSK3alpha and beta phosphorylation at its negative regulatory site downstream of Akt and ERK, thereby inhibiting GSK3alpha and beta activity.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "GSK-3 is known for inactivating glycogen synthase and participates in the Wnt signaling pathway to phosphorylate beta-catenin; GSK-3 can be inhibited by Akt phosphorylation, which is part of insulin signal transduction.")
       (:PMID . "21906675") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In this study, we have also shown that the PKC inhibitor Ro31-8220 significantly reduces GSK3alpha and beta phosphorylation independently of Akt and that this could not be fully rescued by the addition of ADP.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PKC also regulates GSK3alpha and beta phosphorylation at early times, independently of Akt.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3alpha") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:TYPE . "Phosphorylation")
     (:ID . "660db778-1ac0-4a98-b7c4-ef826fee7f04"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "BETA-CATENIN") (:+HGNC+ . "2514")
       (:+UP+ . "P35222") (:+NCIT+ . "C17478"))
      (:NAME . "CTNNB1"))
     (:SUPPORTED--BY "bc96c7d8-d6b6-4dd5-934f-b0b393675faf"
      "2e4b14b0-a532-468c-b50d-02c2e7f43164"
      "7555ca35-63d0-4ba0-b273-0c68b14ea585"
      "f284bab9-67a0-40ae-99be-40781eae45f9"
      "3a90df4b-eb93-4f62-8c54-31cc45b81adb"
      "3b404f08-d70d-47c9-be34-4404c13da75e")
     (:EVIDENCE
      ((:TEXT
        . "This correlates with the fact that Wnt signaling primarily inhibits beta-catenin phosphorylation at Ser33/Ser37/Thr41 by GSK3 but not Ser45 phosphorylation by CK1 XREF_BIBR, XREF_BIBR; (iv) finally we found that injection of a phosphorylated PPPSPXS peptide, but not the mutant PPPAPXA peptide, into Xenopus embryos is able to induce axis duplication and the expression of Xnr3, a Wnt and beta-catenin target gene (XREF_FIG), consistent with the notion that phosphorylated PPPSPXS inhibits GSK3 in vivo.")
       (:PMID . "19293931") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This inhibitory effect of phosphorylated PPPSPXS motifs is direct and specific for GSK3 phosphorylation of beta-catenin at Ser33/Ser37/Thr41 but not for CK1 phosphorylation of beta-catenin at Ser45, and is independent of Axin function.")
       (:PMID . "19293931") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ff0533409e4d4fdf301082e268530676")
       (:SOURCE--API . "biopax")))
     (:POSITION . "33")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:TYPE . "Phosphorylation")
     (:ID . "3ebc1af5-fb21-4e6c-a37b-509664408366"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "94eb09e8-bd5b-4c43-b835-1655f82c0883"
      "11656290-4b53-44ab-a8d2-ee3e59b295fd")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "21")
     (:ENZ (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:TYPE . "Phosphorylation")
     (:ID . "eeaf66a8-6fbb-46ad-9c3f-95e3a33f3ccc"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "IRS-1") (:+UP+ . "P35568") (:+HGNC+ . "6125"))
      (:NAME . "IRS1"))
     (:SUPPORTED--BY "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE
      ((:TEXT
        . "Alternatively, GSK-3 could directly stimulate IRS-1 phosphorylation and degradation.")
       (:PMID . "15375789") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Augmented serine phosphorylation of IRS-1 can also increase degradation of the protein (XREF_BIBR) and it is possible that GSK-3alpha is phosphorylating and targeting a specific pool of IRS-1 toward the degradative pathway.")
       (:PMID . "19505532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:TYPE . "Phosphorylation")
     (:ID . "cf34fdde-a3e8-40ef-838c-fc96b32dcb00"))
    ((:RESIDUE . "T")
     (:SUB
      (:DB--REFS (:+TEXT+ . "C-MYC") (:+NCIT+ . "C53086") (:+HGNC+ . "7553")
       (:+UP+ . "P01106"))
      (:NAME . "MYC"))
     (:SUPPORTED--BY "64952ac6-62a5-44dc-8396-2ea9a02d4c8b"
      "2a130ba1-188a-4615-9842-6c35b12675c5"
      "171c8e01-0369-4a8e-a8e9-4652b54fd8d7")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of c-Myc on T58 by GSK3 regulates the binding of Fbw7, which in turn triggers c-Myc ubiquitination and degradation [XREF_BIBR].")
       (:PMID . "18426604") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_30dfbc1eafb1ce2c401ee168189a5d0b")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Conversely, when LANA is eliminated from PEL cells using RNA interference, GSK-3beta-mediated c-Myc T58 phosphorylation is restored.")
       (:PMID . "17310999") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of c-Myc on T58, which is catalyzed by GSK3 beta kinase, is necessary for activating the ubiquitin and proteasome pathway to destroy c-Myc protein.")
       (:PMID . "18426604") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "In LANA expressing cells, inactivation of nuclear GSK-3 reduced phosphorylation of c-Myc at Thr58 and contributed to c-Myc stabilization by decreasing c-Myc ubiquitination.")
       (:PMID . "17634226") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here we show that inhibition of glycogen synthase kinase-3 (GSK-3) activity with lithium increases c-Myc stability and inhibits phosphorylation of c-Myc specifically at Thr 58 in vivo.")
       (:PMID . "14563837") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistic analyses indicated that RhoB facilitated nuclear accumulation of GSK-3 and GSK-3-mediated phosphorylation of c-Myc T58, the critical site for ubiquitination and degradation of c-Myc.")
       (:PMID . "16247449") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "58")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:TYPE . "Phosphorylation")
     (:ID . "ddba415e-752c-4882-b542-44ba7fa1fa37"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "TSC-2") (:+HGNC+ . "12363") (:+UP+ . "P49815")
       (:+NCIT+ . "C17913"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef")
     (:EVIDENCE
      ((:TEXT
        . "These data demonstrate that TSC2 phosphorylation by GSK3 is important for mTOR inhibition and, consequently, cell viability in response to energy starvation.The functional importance of TSC2 phosphorylation by GSK3 in the Wnt signaling was also investigated.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "showed that TSC2 was coimmunoprecipitated with GSK3  (), lending additional support to our hypothesis that TSC2 could be a direct substrate of GSK3.We investigated whether GSK3 phosphorylates TSC2 on the predicted sites and whether this requires AMPK priming phosphorylation.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We propose that AMPK and GSK3 coordinately phosphorylate TSC2 and depend on each other to repress mTOR signaling ().")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The role of GSK3 phosphorylation of TSC2 in cellular energy response was investigated.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We proposed that phosphorylation of TSC2 by GSK3 after the AMPK priming phosphorylation enhances the ability of TSC2 to inhibit mTOR signaling.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Although mechanisms by which Wnt signaling regulates gene transcription have been extensively studied, little knowledge exists as to whether Wnt signaling also regulates protein translation.Here we report that TSC2 is a physiological substrate of GSK3 and that Wnt stimulates the mTOR signaling pathway via inhibiting GSK3 phosphorylation of TSC2.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "discovered that GSK-3 functions as a priming kinase in assisting AMPK to phosphorylate and activate TSC2.")
       (:PMID . "17993259") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "If GSK3 phosphorylates TSC2 following the AMPK priming phosphorylation, then inhibition of GSK3 should compromise AMPK induced TSC2 phosphorylation.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These results suggest that phosphorylation of TSC2 by GSK3 increases the ability of TSC2 to inhibit mTOR signaling.Previously, we found that mTOR activity contributed to cell apoptosis under glucose starvation ().")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "It has been suggested that GSK3 can inhibit the mTOR pathway by phosphorylating TSC2 in a manner dependent on AMPK priming phosphorylation (XREF_BIBR).")
       (:PMID . "24626091") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Among many other substrates involved in these functions, GSK3 also phosphorylates TSC2, thereby activating TSC2 and inactivating mTORC1 [XREF_BIBR].")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Among many other substrates involved in these functions, GSK3 also phosphorylates TSC2, thereby activating TSC2 and inactivating mTORC1 [XREF_BIBR].")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Therefore, our studies demonstrating the coordinated phosphorylation of TSC2 by AMPK and GSK3 provide a clear mechanism to explain how different signaling pathways are integrated ata molecular level.It is worth noting that TSC2 is also phosphorylated by other kinases, including Akt, MK2, CDK, ERK, and RSK1.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "To confirm that GSK3 phosphorylates TSC2 on the predicted sites in vivo, we performed two-dimensional mapping analyses for TSC2 mutants in the presence of kinase-inactive GSK3-KD and 2DG.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These observations lend additional support to our hypothesis that Wnt inhibits the GSK3 dependent phosphorylation of TSC2, although Mak etal.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Therefore, our studies demonstrating the coordinated phosphorylation of TSC2 by AMPK and GSK3 provide a clear mechanism to explain how different signaling pathways are integrated ata molecular level.It is worth noting that TSC2 is also phosphorylated by other kinases, including Akt, MK2, CDK, ERK, and RSK1.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We found that GSK3 phosphorylated TSC2 only when TSC2 had been previously phosphorylated by AMPK (B).")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "If GSK3 phosphorylates TSC2 following the AMPK priming phosphorylation, then inhibition of GSK3 should compromise AMPK induced TSC2 phosphorylation.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To confirm that GSK3 phosphorylates TSC2 on the predicted sites in vivo, we performed two-dimensional mapping analyses for TSC2 mutants in the presence of kinase-inactive GSK3-KD and 2DG.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Together, these data demonstrate that both AMPK and GSK3 phosphorylate TSC2 in a coordinated manner.Next, we addressed whether AMPK and GSK3 depend on each other to repress mTOR pathway.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The role of GSK3 phosphorylation of TSC2 in cellular energy response was investigated.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These data demonstrate that TSC2 phosphorylation by GSK3 is important for mTOR inhibition and, consequently, cell viability in response to energy starvation.The functional importance of TSC2 phosphorylation by GSK3 in the Wnt signaling was also investigated.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Although mechanisms by which Wnt signaling regulates gene transcription have been extensively studied, little knowledge exists as to whether Wnt signaling also regulates protein translation.Here we report that TSC2 is a physiological substrate of GSK3 and that Wnt stimulates the mTOR signaling pathway via inhibiting GSK3 phosphorylation of TSC2.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:TYPE . "Phosphorylation")
     (:ID . "3544be33-fee0-4dfd-878e-af993ce61c04"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "FGF-2 significantly stimulated the phosphorylation of AKT, ERK-1/2, and GSK-3beta in H9 cells in 15 minutes (XREF_FIG) as described previously XREF_BIBR, XREF_BIBR.")
       (:PMID . "23349801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, silencing of GSK-3beta, but not GSK-3alpha, reduced Akt phosphorylation.")
       (:PMID . "22539113") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "GSK3beta knockdown or GSK3 inhibitor suppresses IGF-I-induced IGF-IR, Akt, and ERK1/2 phosphorylation.")
       (:PMID . "25053419") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, p38 inhibition affected neither Akt phosphorylation nor phosphorylation of the Akt target GSK3beta following H 2 O 2 (XREF_FIG; see right panel for quantification).")
       (:PMID . "22001647") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "GSK-3 is known for inactivating glycogen synthase and participates in the Wnt signaling pathway to phosphorylate beta-catenin; GSK-3 can be inhibited by Akt phosphorylation, which is part of insulin signal transduction.")
       (:PMID . "21906675") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Neither BMP-4 nor activin A in the absence of FGF-2 induced the phosphorylation of AKT, ERK-1/2, or GSK-3beta in 201B7 iPS cells (XREF_FIG, XREF_SUPPLEMENTARY).")
       (:PMID . "23349801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "LMP2A also induced phosphorylation of the Akt target GSK3beta, a Wnt signaling mediator that has been shown to regulate the activity of focal adhesion kinase (FAK), a tyrosine kinase activated by clustering and ligand interaction of integrins.")
       (:PMID . "22837212") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK-3beta") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "88257edf-0ae6-4f90-90f6-56899a5f4bb2"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "However, p38 inhibition affected neither Akt phosphorylation nor phosphorylation of the Akt target GSK3beta following H 2 O 2 (XREF_FIG; see right panel for quantification).")
       (:PMID . "22001647") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, silencing of GSK-3beta, but not GSK-3alpha, reduced Akt phosphorylation.")
       (:PMID . "22539113") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "GSK-3 is known for inactivating glycogen synthase and participates in the Wnt signaling pathway to phosphorylate beta-catenin; GSK-3 can be inhibited by Akt phosphorylation, which is part of insulin signal transduction.")
       (:PMID . "21906675") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Neither BMP-4 nor activin A in the absence of FGF-2 induced the phosphorylation of AKT, ERK-1/2, or GSK-3beta in 201B7 iPS cells (XREF_FIG, XREF_SUPPLEMENTARY).")
       (:PMID . "23349801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "LMP2A also induced phosphorylation of the Akt target GSK3beta, a Wnt signaling mediator that has been shown to regulate the activity of focal adhesion kinase (FAK), a tyrosine kinase activated by clustering and ligand interaction of integrins.")
       (:PMID . "22837212") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "GSK3beta knockdown or GSK3 inhibitor suppresses IGF-I-induced IGF-IR, Akt, and ERK1/2 phosphorylation.")
       (:PMID . "25053419") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "FGF-2 significantly stimulated the phosphorylation of AKT, ERK-1/2, and GSK-3beta in H9 cells in 15 minutes (XREF_FIG) as described previously XREF_BIBR, XREF_BIBR.")
       (:PMID . "23349801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3beta") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "ff416646-60b6-4366-9886-30c7a3340832"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "GSK-3 is known for inactivating glycogen synthase and participates in the Wnt signaling pathway to phosphorylate beta-catenin; GSK-3 can be inhibited by Akt phosphorylation, which is part of insulin signal transduction.")
       (:PMID . "21906675") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In addition, silencing of GSK-3beta, but not GSK-3alpha, reduced Akt phosphorylation.")
       (:PMID . "22539113") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "LMP2A also induced phosphorylation of the Akt target GSK3beta, a Wnt signaling mediator that has been shown to regulate the activity of focal adhesion kinase (FAK), a tyrosine kinase activated by clustering and ligand interaction of integrins.")
       (:PMID . "22837212") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, p38 inhibition affected neither Akt phosphorylation nor phosphorylation of the Akt target GSK3beta following H 2 O 2 (XREF_FIG; see right panel for quantification).")
       (:PMID . "22001647") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "GSK3beta knockdown or GSK3 inhibitor suppresses IGF-I-induced IGF-IR, Akt, and ERK1/2 phosphorylation.")
       (:PMID . "25053419") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "FGF-2 significantly stimulated the phosphorylation of AKT, ERK-1/2, and GSK-3beta in H9 cells in 15 minutes (XREF_FIG) as described previously XREF_BIBR, XREF_BIBR.")
       (:PMID . "23349801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Neither BMP-4 nor activin A in the absence of FGF-2 induced the phosphorylation of AKT, ERK-1/2, or GSK-3beta in 201B7 iPS cells (XREF_FIG, XREF_SUPPLEMENTARY).")
       (:PMID . "23349801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "e369dfc2-2410-49ea-a2fc-a5b7b72af575"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P35222") (:+HGNC+ . "2514"))
      (:NAME . "CTNNB1"))
     (:SUPPORTED--BY "bc96c7d8-d6b6-4dd5-934f-b0b393675faf"
      "f284bab9-67a0-40ae-99be-40781eae45f9"
      "be20849b-c29b-4aaf-b197-4d4509075d20"
      "2e4b14b0-a532-468c-b50d-02c2e7f43164"
      "437f0f39-8c3d-4ff5-b3bc-4d09f0d6e4dd"
      "4324f074-4775-4935-bf85-3d76a124f9f3")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "The inhibition of GSK3beta suppresses the phosphorylation of beta-catenin at S33, ultimately resulting in its cytoplasmic accumulation.")
       (:PMID . "25360740") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This correlates with the fact that Wnt signaling primarily inhibits beta-catenin phosphorylation at Ser33/Ser37/Thr41 by GSK3 but not Ser45 phosphorylation by CK1 XREF_BIBR, XREF_BIBR; (iv) finally we found that injection of a phosphorylated PPPSPXS peptide, but not the mutant PPPAPXA peptide, into Xenopus embryos is able to induce axis duplication and the expression of Xnr3, a Wnt and beta-catenin target gene (XREF_FIG), consistent with the notion that phosphorylated PPPSPXS inhibits GSK3 in vivo.")
       (:PMID . "19293931") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Following casein kinase 1 mediated phosphorylation of beta-catenin at serine 45, GSK3beta phosphorylates beta-catenin at Thr 41, Ser 33, and Ser 37, which tags beta-catenin for ubiquitination by betaTrCP and proteomic degradation.")
       (:PMID . "21562161") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This inhibitory effect of phosphorylated PPPSPXS motifs is direct and specific for GSK3 phosphorylation of beta-catenin at Ser33/Ser37/Thr41 but not for CK1 phosphorylation of beta-catenin at Ser45, and is independent of Axin function.")
       (:PMID . "19293931") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8e42d6ed6c73c9dfd36fb078cd840085")
       (:PMID . "9233789") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8e42d6ed6c73c9dfd36fb078cd840085")
       (:PMID . "11955436") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4cad0e224a6bf112e3caf3d5af5bcf17")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "GSK-3beta phosphorylates cytosolic beta-catenin at Ser 33, Ser 37, and Thr 41 prior to beta-catenin degradation, but phosphorylation of GSK-3beta at Ser 9 inhibits its kinase activity.")
       (:PMID . "20302655") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Although CK1 is known to be required as a priming kinase for GSK-3beta phosphorylation of beta-catenin in vivo (), in vitro beta-catenin can be directly phosphorylated at S33, S37, and T41 residues by GSK-3beta without priming by CK1 () ().")
       (:PMID . "16039586") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In non stimulated cells, the protein level of free beta-catenin is kept low by a so called destruction complex consisting mainly of the tumor suppressor adenomatous polyposis coli (APC) and Axin, which build a scaffold on which the serine/threonine kinases casein kinase 1alpha (CK1alpha) and glycogen synthase kinase 3beta (GSK3beta) function to phosphorylate beta-catenin on N-terminal residues Ser 45 (CK1alpha) and Ser 33, Ser 37, and Thr 41 (GSK3beta) [XREF_BIBR].")
       (:PMID . "20137080") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In this complex, beta-catenin is phosphorylated at S45 by CKIalpha, and subsequently by GSK3beta at residues S33, S37, and T41.")
       (:PMID . "26189775") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_GSK3B_DirectlyIncreases_p_HGNC_CTNNB1_pmod_P_S_33")
       (:TEXT
        . "Figure 3A  regulation of B-catenin activity and TCF4 transcriptional activity.")
       (:PMID . "16520547") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_GSK3B_DirectlyIncreases_p_HGNC_CTNNB1_pmod_P_S_33")
       (:TEXT
        . "Serine-33 and -37 of beta-catenin are GSK3 phosphorylation sites that serve as recognition sites for the beta-TRCP-ubiquitin ligase complex, which ultimately triggers beta-catenin degradation.")
       (:PMID . "12417018") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_GSK3B_DirectlyIncreases_p_HGNC_CTNNB1_pmod_P_S_33")
       (:TEXT
        . "Indeed, we found that GSK-3 enhanced, whereas GSK-3KM inhibited, T41, S37, and S33 phosphorylation (Figure 2A). ")
       (:PMID . "11955436") (:SOURCE--API . "bel"))
      ((:TEXT
        . "In addition to disruption of VE-cadherin and beta-catenin complexes, treatment of vascular EC with apo (a) attenuates the phosphorylation of beta-catenin at Ser 33,-37/Thr-41 by GSK-3beta (XREF_FIG), thus causing a decrease in the degradation of cytoplasmic beta-catenin.")
       (:PMID . "23243000") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "33")
     (:ENZ (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "2466cb38-301e-42a7-98bd-2e471ad08c1b"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c"
      "74bf2351-bd5c-4b31-8cda-96f37d83e1d9")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a1f6da87a9346fb77b6309624d577a39")
       (:SOURCE--API . "biopax")))
     (:POSITION . "37")
     (:ENZ (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "e4954251-2deb-4de6-8d0d-3b44c770ae00"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P03372") (:+HGNC+ . "3467")) (:NAME . "ESR1"))
     (:SUPPORTED--BY "3e056022-b0df-4181-b89c-fd2f3c8d4c90"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "49d0da65-cf43-426d-b201-85a6d6d26218")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Furthermore, in vitro kinase assay depicted that GSK-3beta phosphorylates ERalpha at Ser 118.")
       (:PMID . "17609434") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_GSK3B_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_118")
       (:TEXT
        . "7838153;12093745;9528769;10949034;16076840;15528270;15461668;15059947;12118371;7491495")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_GSK3B_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_118")
       (:TEXT
        . "Furthermore, in vitro kinase assay depicted that GSK-3beta phosphorylates ERalpha at Ser-118.")
       (:PMID . "17609434") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2930e572c5ad5d5c15a48ac4adaac7e2")
       (:SOURCE--API . "biopax")))
     (:POSITION . "118")
     (:ENZ (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "26babe35-1711-4daa-b1c5-a4a57f7474c7"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:SUPPORTED--BY "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:TEXT
        . "Physiologic GSK-3 inactivation using conditional AKT (CA-AKT-ER), which avoids potential non specific effects of chemical GSK-3 inhibitors, induced hyper-phosphorylation of GSK-3 and inhibited the growth of HOXA9 and MEIS1 cells (XREF_SUPPLEMENTARY).")
       (:PMID . "20541704") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It is unknown whether this regulation of MDM2 involves a preferential PKB isozyme.Secondly, active PKB mediates GSK3 phosphorylation and inhibition of GSK3 activity.")
       (:PMID . "21539865") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Reduction of GSK-3 protein levels, either by RNA interference or by disruption of the mouse GSK-3beta gene, causes increased N-terminal phosphorylation of GSK-3, confirming that GSK-3 regulates its own phosphorylation status.")
       (:PMID . "12796505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation mediated inhibition of GSK-3 is not limited to Akt and other protein kinases such as protein kinase A (PKA) and protein kinase C (PKC) also phosphorylate GSK-3.")
       (:PMID . "25829335") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, a selective PKCb inhibitor, LY379196, reduced NT mediated GSK-3b (but not GSK-3a) phosphorylation, suggesting a role for PKCb1 in the NT mediated phosphorylation of GSK-3b and an undefined kinase in the NT mediated phosphorylation of GSK-3a.")
       (:PMID . "16984735") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "5cd92942-6975-4854-bd84-ab6eddd7fbe8"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "9316156b-0641-48dd-b950-8c1c76a39d59"
      "11656290-4b53-44ab-a8d2-ee3e59b295fd"
      "3df8bed6-3471-4e43-a719-d9c6b47050ce")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "21")
     (:ENZ (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "e6dbaf3b-4506-4ba4-a11d-336cf65126c2"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P01106") (:+HGNC+ . "7553")) (:NAME . "MYC"))
     (:SUPPORTED--BY "64952ac6-62a5-44dc-8396-2ea9a02d4c8b"
      "07399148-55a4-453a-b982-dfd7a59f50ba"
      "2a130ba1-188a-4615-9842-6c35b12675c5")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b3a4467b93214423a1ccbdb54cfa08f4")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Phosphorylation of c-Myc on T58 by GSK3 regulates the binding of Fbw7, which in turn triggers c-Myc ubiquitination and degradation [XREF_BIBR].")
       (:PMID . "18426604") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In LANA expressing cells, inactivation of nuclear GSK-3 reduced phosphorylation of c-Myc at Thr58 and contributed to c-Myc stabilization by decreasing c-Myc ubiquitination.")
       (:PMID . "17634226") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_GSK3B_DirectlyIncreases_p_HGNC_MYC_pmod_P_T_58")
       (:TEXT
        . "Small inhibitory RNA-induced silencing of GSK3beta prevents phosphorylation of MYC on T58, thereby inhibiting recognition of MYC by the E3 ubiquitin ligase component FBW7. Attenuating the GSK3beta-FBW7 axis results in stabilization of MYC")
       (:PMID . "16210249") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_GSK3B_DirectlyIncreases_p_HGNC_MYC_pmod_P_T_58")
       (:TEXT . "11018017;14563837;15150404;17081983") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "The ERK and GSK-3beta can phosphorylate c-Myc at Ser62 and Thr58, respectively.")
       (:PMID . "26751215") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Mechanistic analyses indicated that RhoB facilitated nuclear accumulation of GSK-3 and GSK-3-mediated phosphorylation of c-Myc T58, the critical site for ubiquitination and degradation of c-Myc.")
       (:PMID . "16247449") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of c-Myc on T58, which is catalyzed by GSK3 beta kinase, is necessary for activating the ubiquitin and proteasome pathway to destroy c-Myc protein.")
       (:PMID . "18426604") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Conversely, when LANA is eliminated from PEL cells using RNA interference, GSK-3beta-mediated c-Myc T58 phosphorylation is restored.")
       (:PMID . "17310999") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here we show that inhibition of glycogen synthase kinase-3 (GSK-3) activity with lithium increases c-Myc stability and inhibits phosphorylation of c-Myc specifically at Thr 58 in vivo.")
       (:PMID . "14563837") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Small inhibitory RNA induced silencing of GSK3beta prevents phosphorylation of MYC on T58, thereby inhibiting recognition of MYC by the E3 ubiquitin ligase component FBW7.")
       (:PMID . "16210249") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "58")
     (:ENZ (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "6e5a2ce7-2437-46e9-a02a-2acfad00c597"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "p70S6K") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "bce35404-793e-40df-b05c-6beb07c56696")
     (:EVIDENCE
      ((:TEXT
        . "A recent study has shown that GSK3 phosphorylates the turn motif of p70S6K and cooperates with mTOR to control the activity of p70S6K and cell proliferation (XREF_BIBR), thus providing a rationale for co-targeting mTOR and GSK3 to treat diseases such as cancer.")
       (:PMID . "24626091") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "GSK3beta inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility.")
       (:PMID . "21228102") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "ebcf1807-a013-4cde-9136-70f2c063f43a"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "SMAD3") (:+UP+ . "P84022") (:+HGNC+ . "6769"))
      (:NAME . "SMAD3"))
     (:SUPPORTED--BY "ec699d53-2669-4c6a-b9ba-7c3f373c1114")
     (:EVIDENCE
      ((:TEXT
        . "This latter observation suggested that part of the enhanced Smad signaling is due to lower degradation of Smad1 in presence of RTK inhibitors and is consistent with previous reports on interactions between growth factor receptor signaling and Smad phosphorylation by ERK and GSK3 ().")
       (:PMID . "24060635") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Non activated Smad3 can also be phosphorylated in its MH1 domain by GSK3-beta in association with the scaffolding protein Axin.")
       (:PMID . "22617150") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This latter observation suggested that part of the enhanced Smad signaling is due to lower degradation of Smad1 in presence of RTK inhibitors and is consistent with previous reports on interactions between growth factor receptor signaling and Smad phosphorylation by ERK and GSK3 ().")
       (:PMID . "24060635") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Non-activated Smad3 can also be phosphorylated in its MH1 domain by GSK3-β in association with the scaffolding protein Axin.")
       (:PMID . "22617150") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "To directly demonstrate that GSK3 mediated the Smad linker phosphorylation induced by riluzole, melanoma cell lines were treated with riluzole, in the absence or presence of pharmacological inhibitors of GSK3, LiCl and CT99021.")
       (:PMID . "23077590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because we have demonstrated that GSK3 is involved in the phosphorylation of two downstream effectors of transforming growth factor beta (TGFbeta), Smad2 and Smad3, at their linker domain, our aim was to determine whether riluzole could induce GSK3beta mediated linker phosphorylation of Smad2 and Smad3.")
       (:PMID . "23077590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In this melanoma cell line, like in the others, GSK3 mediated the riluzole induced Smad linker phosphorylation.")
       (:PMID . "23077590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, in vitro kinase assays confirmed that GSK3beta could phosphorylate Smad2 and Smad3 at the cluster of serines 245/250/255 and serine 204 respectively.")
       (:PMID . "23077590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "c508892e-0691-468a-9e98-789f51f58f5c"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "TSC-2") (:+NCIT+ . "C17913") (:+UP+ . "P49815")
       (:+HGNC+ . "12363"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef")
     (:EVIDENCE
      ((:TEXT
        . "These data demonstrate that TSC2 phosphorylation by GSK3 is important for mTOR inhibition and, consequently, cell viability in response to energy starvation.The functional importance of TSC2 phosphorylation by GSK3 in the Wnt signaling was also investigated.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Together, these data demonstrate that both AMPK and GSK3 phosphorylate TSC2 in a coordinated manner.Next, we addressed whether AMPK and GSK3 depend on each other to repress mTOR pathway.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Although mechanisms by which Wnt signaling regulates gene transcription have been extensively studied, little knowledge exists as to whether Wnt signaling also regulates protein translation.Here we report that TSC2 is a physiological substrate of GSK3 and that Wnt stimulates the mTOR signaling pathway via inhibiting GSK3 phosphorylation of TSC2.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Among many other substrates involved in these functions, GSK3 also phosphorylates TSC2, thereby activating TSC2 and inactivating mTORC1 [XREF_BIBR].")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "discovered that GSK-3 functions as a priming kinase in assisting AMPK to phosphorylate and activate TSC2.")
       (:PMID . "17993259") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These results suggest that phosphorylation of TSC2 by GSK3 increases the ability of TSC2 to inhibit mTOR signaling.Previously, we found that mTOR activity contributed to cell apoptosis under glucose starvation ().")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "showed that TSC2 was coimmunoprecipitated with GSK3  (), lending additional support to our hypothesis that TSC2 could be a direct substrate of GSK3.We investigated whether GSK3 phosphorylates TSC2 on the predicted sites and whether this requires AMPK priming phosphorylation.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We found that GSK3 phosphorylated TSC2 only when TSC2 had been previously phosphorylated by AMPK (B).")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We proposed that phosphorylation of TSC2 by GSK3 after the AMPK priming phosphorylation enhances the ability of TSC2 to inhibit mTOR signaling.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "If GSK3 phosphorylates TSC2 following the AMPK priming phosphorylation, then inhibition of GSK3 should compromise AMPK induced TSC2 phosphorylation.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Among many other substrates involved in these functions, GSK3 also phosphorylates TSC2, thereby activating TSC2 and inactivating mTORC1 [XREF_BIBR].")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "It has been suggested that GSK3 can inhibit the mTOR pathway by phosphorylating TSC2 in a manner dependent on AMPK priming phosphorylation (XREF_BIBR).")
       (:PMID . "24626091") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "GSK-3beta phosphorylates and activates TSC2, which in turn inhibits mTOR 11, where GSK-3beta is required for mTOR regulation by energy starvation 11.")
       (:PMID . "21737790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Therefore, our studies demonstrating the coordinated phosphorylation of TSC2 by AMPK and GSK3 provide a clear mechanism to explain how different signaling pathways are integrated ata molecular level.It is worth noting that TSC2 is also phosphorylated by other kinases, including Akt, MK2, CDK, ERK, and RSK1.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "To confirm that GSK3 phosphorylates TSC2 on the predicted sites in vivo, we performed two-dimensional mapping analyses for TSC2 mutants in the presence of kinase-inactive GSK3-KD and 2DG.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We propose that AMPK and GSK3 coordinately phosphorylate TSC2 and depend on each other to repress mTOR signaling ().")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These data demonstrate that TSC2 phosphorylation by GSK3 is important for mTOR inhibition and, consequently, cell viability in response to energy starvation.The functional importance of TSC2 phosphorylation by GSK3 in the Wnt signaling was also investigated.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The role of GSK3 phosphorylation of TSC2 in cellular energy response was investigated.")
       (:PMID . "16959574") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This is a mechanism of action analogous to that observed for AMPK mediated mTOR inhibition, and it appears that the phosphorylation of TSC2 by GSK-3beta is dependent on prior phosphorylation of the substrate by AMPK at the S1345 residue (XREF_BIBR).")
       (:PMID . "22556133") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "If GSK3 phosphorylates TSC2 following the AMPK priming phosphorylation, then inhibition of GSK3 should compromise AMPK induced TSC2 phosphorylation.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To confirm that GSK3 phosphorylates TSC2 on the predicted sites in vivo, we performed two-dimensional mapping analyses for TSC2 mutants in the presence of kinase-inactive GSK3-KD and 2DG.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The role of GSK3 phosphorylation of TSC2 in cellular energy response was investigated.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These observations lend additional support to our hypothesis that Wnt inhibits the GSK3 dependent phosphorylation of TSC2, although Mak etal.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Therefore, our studies demonstrating the coordinated phosphorylation of TSC2 by AMPK and GSK3 provide a clear mechanism to explain how different signaling pathways are integrated ata molecular level.It is worth noting that TSC2 is also phosphorylated by other kinases, including Akt, MK2, CDK, ERK, and RSK1.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Although mechanisms by which Wnt signaling regulates gene transcription have been extensively studied, little knowledge exists as to whether Wnt signaling also regulates protein translation.Here we report that TSC2 is a physiological substrate of GSK3 and that Wnt stimulates the mTOR signaling pathway via inhibiting GSK3 phosphorylation of TSC2.")
       (:PMID . "16959574") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:TYPE . "Phosphorylation")
     (:ID . "fa98c4c7-cca6-4d96-85c4-2b3864e558c9"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "5377520e-d1c5-494f-ad7e-4cdea1263c43"
      "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "12590707") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "11369622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "15728464") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "10753828") (:SOURCE--API . "biopax")))
     (:POSITION . "397")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "411") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08631") (:+HGNC+ . "4840")) (:NAME . "HCK"))
     (:TYPE . "Phosphorylation")
     (:ID . "e80379aa-580b-4d83-88cd-88b81323790d"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "1f9e903b-b337-4022-b907-fc559bac1720"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9344858") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "10815799") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9484840") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "11404481") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "411") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08631") (:+HGNC+ . "4840")) (:NAME . "HCK"))
     (:TYPE . "Phosphorylation")
     (:ID . "22af8031-38da-4380-a684-6b8a94f9650b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "b4bcefa8-5825-404c-9e20-1f9a11bcb142"
      "5757b142-0a4a-4a74-be36-db6f3c483dac"
      "353fe04b-8114-46f8-8993-e5af7daf0cc6"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "IR increased the levels of NBS1 and phosphorylated Akt (pAkt Ser 473) in two different cell lines (XREF_FIG).")
       (:PMID . "23762398") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "A recent study suggested that IR upregulates alphavbeta3 expression in ECs and consecutively phosphorylates AKT (Ser 473), which may provide a tumor escape mechanism from radiation injury mediated by integrin survival signaling (XREF_BIBR).")
       (:PMID . "23381805") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Pre-incubation with KU55933 prevented IR induced ATM phosphorylation but also inhibited IR phosphorylation of Akt at S473 and activation of its kinase activity as indicated by reduced phosphorylation of mTOR.")
       (:PMID . "22029423") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "IR increased the levels of NBS1 and phosphorylated Akt (pAkt Ser 473) in two different cell lines (XREF_FIG).")
       (:PMID . "23762398") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "473")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "IR") (:+UP+ . "P06213") (:+HGNC+ . "6091"))
      (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "b7d32213-feb3-4c77-9796-f1f76e93d49c"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT . "IR increased the levels of NBS1 and phosphorylated Akt.")
       (:PMID . "23762398") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In HCT 116 cells IR did not induce an immediate Akt phosphorylation (C and D) as it is apparent in A549 cells (see).")
       (:PMID . "21723633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pre-incubation with KU55933 prevented IR induced ATM phosphorylation but also inhibited IR phosphorylation of Akt at S473 and activation of its kinase activity as indicated by reduced phosphorylation of mTOR.")
       (:PMID . "22029423") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In the response of insulin, insulin receptor (IR) phosphorylates insulin receptor substrate (IRS) proteins, which are linked to the activation of two main signaling pathways : the phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway, which is responsible for the majority of the metabolic actions of insulin, and the Ras-mitogen-activated protein kinase (MAPK) pathway, which regulates the expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation XREF_BIBR.")
       (:PMID . "20351777") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "IR increased the levels of NBS1 and phosphorylated Akt.")
       (:PMID . "23762398") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "IR") (:+UP+ . "P06213") (:+HGNC+ . "6091"))
      (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "50fd8dd1-18d7-47f6-9e39-44b2a82d9da8"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "In HCT 116 cells IR did not induce an immediate Akt phosphorylation (C and D) as it is apparent in A549 cells (see).")
       (:PMID . "21723633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the response of insulin, insulin receptor (IR) phosphorylates insulin receptor substrate (IRS) proteins, which are linked to the activation of two main signaling pathways : the phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway, which is responsible for the majority of the metabolic actions of insulin, and the Ras-mitogen-activated protein kinase (MAPK) pathway, which regulates the expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation XREF_BIBR.")
       (:PMID . "20351777") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "IR increased the levels of NBS1 and phosphorylated Akt.")
       (:PMID . "23762398") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Pre-incubation with KU55933 prevented IR induced ATM phosphorylation but also inhibited IR phosphorylation of Akt at S473 and activation of its kinase activity as indicated by reduced phosphorylation of mTOR.")
       (:PMID . "22029423") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT . "IR increased the levels of NBS1 and phosphorylated Akt.")
       (:PMID . "23762398") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "IR") (:+UP+ . "P06213") (:+HGNC+ . "6091"))
      (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "aca106e4-9beb-4eba-969b-135c6cf74cd0"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ATM") (:+UP+ . "Q13315") (:+HGNC+ . "795"))
      (:NAME . "ATM"))
     (:SUPPORTED--BY "977914f6-6bfc-41b2-a423-9ffa08f49fda")
     (:EVIDENCE
      ((:TEXT
        . "Thus, we present new data demonstrating that ATM independent GSK-3 phosphorylation by IR functions on NF-kappaB transcriptional activation and that compared to the normal cells, ATM deficient cells are resistant to LiCl induced apoptosis, possibly through the phosphorylation of GSK-3 and p53.Embryonic lung human fibroblasts MRC5CV1 and ATM deficient fibroblasts AT5BIVA were maintained in RPMI 1640 medium supplemented with 2mM -glutamine, hydrocortisone (0.5 mug/ml) and 10% heat inactivated fetal bovine serum, and were cultured in a humidified CO incubator at 37degreesC.")
       (:PMID . "18243662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Western blot analyses showed that IR increased the phosphorylation of ataxia telangiectasia mutated (ATM) kinase, checkpoint kinase 2 (CHK2), ataxia telangiectasia and Rad3 related (ATR) protein, checkpoint kinase 1 (CHK1) and p53.")
       (:PMID . "25962492") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "VRK1 knockdown also prevented the activating phosphorylation of ATM, CHK2, and DNA dependent protein kinase in response to IR.")
       (:PMID . "22621922") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The involvement of hSNM1B in ATM phosphorylation in response to IR, as described here, provides a novel insight into its cellular role.")
       (:PMID . "18468965") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Large-scale proteomic analyses of proteins phosphorylated on the ATM consensus sites in response to IR have identified more than 900 phosphorylation sites encompassing over 700 proteins (XREF_BIBR).")
       (:PMID . "22099307") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that PTEN deficient cells displayed a normal DNA damage response (DDR) as evidenced by the ionizing radiation (IR)-induced phosphorylation of Ataxia Telangiectasia Mutated (ATM) as well as its effectors.")
       (:PMID . "19502790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "IR") (:+UP+ . "P06213") (:+HGNC+ . "6091"))
      (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "27019396-4f69-4099-96e5-2bc0db1d95c7"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Chk1") (:+UP+ . "O14757") (:+HGNC+ . "1925"))
      (:NAME . "CHEK1"))
     (:SUPPORTED--BY "e98af424-48cc-47d8-80fa-652306775da2")
     (:EVIDENCE
      ((:TEXT
        . "Toinvestigate this possibility, we examined Chk1 and Chk2 phosphorylation in response to UV and IR (targets of Atr and Atm activation, respectively).")
       (:PMID . "20864032") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Western blot analyses showed that IR increased the phosphorylation of ataxia telangiectasia mutated (ATM) kinase, checkpoint kinase 2 (CHK2), ataxia telangiectasia and Rad3 related (ATR) protein, checkpoint kinase 1 (CHK1) and p53.")
       (:PMID . "25962492") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additional studies in this report indicate that the inhibition of IR induced Rac1 activation abolishes IR induced activation of Chk1 and Chk2 kinases and subsequent Cdc2-Tyr15 phosphorylation.")
       (:PMID . "22494620") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Similar to Tel2 (WT), Tel2 deficient MEFs expressing either the Tel2 (2A) or (4A) mutants exhibited robust Chk1 Ser345 phosphorylation and Chk2 phosphorylation in response to UV and IR, respectively (B).")
       (:PMID . "20864032") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ATR dependent phosphorylation of Chk1 in response to IR has also been observed in mouse embryo fibroblasts harboring conditional ATR alleles (XREF_BIBR).")
       (:PMID . "16461339") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In contrast with this view, we now have data showing that this Chk1 phosphorylation in response to IR is the outcome of a fine regulation that derives from the coordinated action of both ATM and ATR.")
       (:PMID . "16461339") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Altogether, our data demonstrates that whereas Chk1 activation in response to DSBs arising at stalled replication forks is strictly dependent on ATR, the phosphorylation of Chk1 in response to IR is coordinately regulated by a sequential ATM --> ATR dependent pathway.")
       (:PMID . "16461339") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "IR") (:+UP+ . "P06213") (:+HGNC+ . "6091"))
      (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "afb8599f-1a30-4088-abfd-496a58e7eb29"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:SUPPORTED--BY "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:TEXT
        . "From these results, it was presumed that the small but obvious induction of NF-kappaB transcriptional activation by IR in AT5BIVA cells could be due to the increased phosphorylation of GSK-3beta by IR in these cells as in B, and that high level of activation seen in MRC5CV1 could be attributable to the additive effects from both IkappaBalpha degradation pathway and GSK-3beta phosphorylation.")
       (:PMID . "18243662") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "At any rate, we have provided clear evidence that phosphorylation of GSK-3 in response to IR could also occur in ATM deficient cells.The crucial role of GSK-3 phosphorylation has been observed in a variety of biological processes.")
       (:PMID . "18243662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, we present new data demonstrating that ATM independent GSK-3 phosphorylation by IR functions on NF-kappaB transcriptional activation and that compared to the normal cells, ATM deficient cells are resistant to LiCl induced apoptosis, possibly through the phosphorylation of GSK-3 and p53.Embryonic lung human fibroblasts MRC5CV1 and ATM deficient fibroblasts AT5BIVA were maintained in RPMI 1640 medium supplemented with 2mM -glutamine, hydrocortisone (0.5 mug/ml) and 10% heat inactivated fetal bovine serum, and were cultured in a humidified CO incubator at 37degreesC.")
       (:PMID . "18243662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "IR") (:+NCIT+ . "C17072") (:+UP+ . "P06213")
       (:+HGNC+ . "6091"))
      (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "8ce84f92-acf4-4dca-9a0e-b914521951a1"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE
      ((:TEXT
        . "From these results, it was presumed that the small but obvious induction of NF-kappaB transcriptional activation by IR in AT5BIVA cells could be due to the increased phosphorylation of GSK-3beta by IR in these cells as in B, and that high level of activation seen in MRC5CV1 could be attributable to the additive effects from both IkappaBalpha degradation pathway and GSK-3beta phosphorylation.")
       (:PMID . "18243662") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Given that transcriptional activation of NF-kappaB and the increased phosphorylation of GSK-3beta in response to IR could be detected both in ATM deficient cells and in normal cells (A), their possible association was examined using the PI3K inhibitors, wortmannin and LY294002.")
       (:PMID . "18243662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although the data are expressed in fold induction, the level of actual activation was similar in both cell types (data not shown), confirming the suggestion that GSK-3 phosphorylation could be induced independently of ATM, and that transcriptional activation of NF-kappaB by IR could be mediated through GSK-3 phosphorylation even without ATM expression.Given that IR increased the phosphorylation of GSK-3beta and NF-kappaB transcriptional activation as described above, we examined whether another potent DNA damaging agent, camptothecin (CPT), could also induce the similar signaling in both cell types.")
       (:PMID . "18243662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, we present new data demonstrating that ATM independent GSK-3 phosphorylation by IR functions on NF-kappaB transcriptional activation and that compared to the normal cells, ATM deficient cells are resistant to LiCl induced apoptosis, possibly through the phosphorylation of GSK-3 and p53.Embryonic lung human fibroblasts MRC5CV1 and ATM deficient fibroblasts AT5BIVA were maintained in RPMI 1640 medium supplemented with 2mM -glutamine, hydrocortisone (0.5 mug/ml) and 10% heat inactivated fetal bovine serum, and were cultured in a humidified CO incubator at 37degreesC.")
       (:PMID . "18243662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "At any rate, we have provided clear evidence that phosphorylation of GSK-3 in response to IR could also occur in ATM deficient cells.The crucial role of GSK-3 phosphorylation has been observed in a variety of biological processes.")
       (:PMID . "18243662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "IR") (:+UP+ . "P06213") (:+HGNC+ . "6091"))
      (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "8ce84f92-acf4-4dca-9a0e-b914521951a1"))
    ((:RESIDUE . "Y")
     (:SUB
      (:DB--REFS (:+TEXT+ . "IRS-1") (:+UP+ . "P35568") (:+HGNC+ . "6125"))
      (:NAME . "IRS1"))
     (:SUPPORTED--BY "2b636656-1eac-463d-8a0b-b2a3bb7ad0e6"
      "58c9d1e3-84d1-43d9-91e9-ce26c19c85b9"
      "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE
      ((:TEXT
        . "One mechanism whereby GSK3beta increases insulin resistance is by phosphorylating IRS-1 on Ser332, resulting in reduced tyrosine phosphorylation of IRS-1 by the insulin receptor and reduced signaling to downstream components (XREF_BIBR).")
       (:PMID . "18178198") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "A similar result was observed in cells expressing the PKCdelta shRNA 2 construct (), suggesting that changes in IRS-1 Ser24 phosphorylation were not due to off target effects of the PKCdelta shRNA.A proximal event in the transduction of the insulin signal is the Tyr phosphorylation of IRS proteins catalyzed by the insulin receptor kinase.")
       (:PMID . "16970908") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Insulin stimulated tyrosine phosphorylation of IRS-1 by the insulin receptor (IR) results in intracellular transduction of the insulin signal, whereas serine/threonine phosphorylation modulates the function of tyrosine phosphorylated IRS-1 in either a positive or negative manner [XREF_BIBR].")
       (:PMID . "21850561") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Evidence of an EGFR-IRS-1 interaction arises from reports by Fujioka and colleagues [XREF_BIBR, XREF_BIBR], who reported that the phosphorylated NPXY motifs in activated IR and IGF-IR to which IRS molecules bind are also present in the C-terminus region of activated EGFR and were indispensable for EGF induced IRS-1 tyrosine phosphorylation in EGFR transfected CHO cells [XREF_BIBR].")
       (:PMID . "21939528") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_PFH_IRS_Family_pmod_P_Y")
       (:TEXT
        . "insulin receptor is a tyrosine kinase that catalyzes the phosphorylation of several intracellular substrates, including the insulin receptor substrate (IRS) proteins, GAB-1, Shc, APS, p60(DOK), SIRPS, and c-Cbl")
       (:PMID . "11849969") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "At least nine intracellular substrates of the insulin/IGF-I receptor kinases have been identified (Fig. 2). Four of these belong to the family of insulin-receptor substrate (IRS) proteins9. Other substrates include Gab-1, p60dok, Cbl, APS and isoforms of Shc10.")
       (:PMID . "11742412") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "inhibition of PKCalpha expression caused an increase in IRS phosphorylation by the insulin receptor this effect was independent of insulin")
       (:PMID . "10497232") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "Peptides corresponding to the scaffolding domain of caveolin potently stimulated insulin receptor kinase activity toward insulin receptor substrate-1 or a Src-derived peptide in vitro and in a caveolin subtype-dependent fashion. Peptides from caveolin-2 exhibited no effect, whereas caveolin-1 and -3 stimulated activity 10- and 17-fold, respectively.")
       (:PMID . "9756945") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "Insulin receptor substrates are a growing family of proteins that are phosphorylated by the activated insulin receptor. To date, nine members of this family have been identified, including IRS-1 (17, 18), IRS-2 (19), IRS-3 (20), and IRS-4 (21), which are generally viewed as the most specific for insulin signaling; Gab-1 (22); Shc, which has three isoforms (23); and p62dok Following insulin binding, the receptor undergoes autophosphorylation on multiple tyrosine residues. This results in activation of the receptor kinase and tyrosine phosphorylation of a family of insulin receptor substrate (IRS) proteins.")
       (:PMID . "10194465") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "Ser/Thr phosphorylation decreases the ability of IRS-1 to be tyrosine-phosphorylated by the insulin receptor. An additional mechanism for modulating insulin signaling is via the down-regulation of IRS-1 protein levels.")
       (:PMID . "12510059") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "acti-Fig. 3. PKCb in insulin signal-ing. Insulin-stimulated insulin receptor (IR) phosphorylates IRS1. IRS1 recruit various signaling molecules through SH2-phos-photyrosine interactions. IRS1-binding proteins containing an SH2 domain include Grb2, PI3K, SHP-2, and Nck. Insulin-induced ERK activation in L6 myocytes occurs largely through Raf-1 rather than Ras activation. In contrast, EGF-induced ERK acti-vation is dependent on Grb2/Sos-mediated Ras activation.")
       (:PMID . "12417015") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "during insulin stimulation, IRS1 undergoes tyrosine phosphorylation and binds PI3K the binding of insulin to its receptor induces the phosphorylation of the cytosolic substrate IRS1 and IRS2")
       (:PMID . "1648180") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "high glucose concentration also activated the insulin receptor kinase toward the endogenous insulin receptor substrates IRS1 and IRS2")
       (:PMID . "10497232") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "Phosphotyrosine at site 960 of the b subunit just inside the membrane creates an NPXpY-recognition motif for the PTB domain of the IRS proteins. Modification of this tyrosine completely inhibits subsequent phosphorylation of IRS-1 and other insulin receptor substrates and leads to loss of most insulin-dependent biological actions")
       (:PMID . "10194465") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "The insulin receptor, a ligand-stimulated tyrosine kinase, mediates the first steps in insulin action (White and Yenush, 1998). The activated receptor phosphorylates multiple proteins-e.g., insulin receptor substrates (IRS)-1, -2, -3, and -4. Phosphorylation of tyrosine residues in these substrates leads to activation of multiple downstream signaling pathways.")
       (:PMID . "10199397") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "insulin stimulates the mitogen-activated protein (MAP) kinase extracellular signalregulated kinase (ERK) (Fig. 2). This pathway involves the tyrosine phosphorylation of IRS proteins and/or Shc, which in turn interact with the adapter protein Grb2, recruiting the Son-of-sevenless (SOS) exchange protein to the plasma membrane for activation of Ras.")
       (:PMID . "11742412") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "hGrb10gamma inhibited insulin-stimulated IRS-1 tyrosine phosphorylation in a dose-dependent manner, but did not affect IR catalytic activity toward Tyr(972) in the juxtamembrane region and Tyr(1158/1162/1163) in the regulatory domain")
       (:PMID . "12493740") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "Insulin binding to its receptor induces the phosphorylation of cytosolic substrates, insulin receptor substrate (IRS)-1 and IRS-2")
       (:PMID . "9312143") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_IRS1_pmod_P_Y")
       (:TEXT
        . "These findings couple reduced insulin-stimulated IRS-1 tyrosine phosphorylation and PI3 Kinase activity to impaired insulin stimulated glucose transport in skeletal muscle from lean to moderately obese type II diabetic subjects.")
       (:PMID . "12079842") (:SOURCE--API . "bel"))
      ((:TEXT
        . "In fact, obesity leads to sustained activation of IRE1alpha that impairs insulin signaling through IRE1alpha and JNK mediated phosphorylation of IRS-1 that prevents IRS-1 tyrosine phosphorylation by activated IR [XREF_BIBR].")
       (:PMID . "25398386") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) by the insulin receptor permits this docking protein to interact with signaling proteins that promote insulin action.")
       (:PMID . "11287630") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "insulin receptor") (:+UP+ . "P06213")
       (:+HGNC+ . "6091"))
      (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "c9708a47-c937-41ba-be04-f199d9627de4"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P29353") (:+HGNC+ . "10840")) (:NAME . "SHC1"))
     (:SUPPORTED--BY "c152fe2a-86a6-4991-a393-51aa22cdd939"
      "5155385d-534b-4c6b-9930-a0bd655d3cea")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y")
       (:TEXT
        . "Phosphotyrosine at site 960 of the b subunit just inside the membrane creates an NPXpY-recognition motif for the PTB domain of the IRS proteins. Modification of this tyrosine completely inhibits subsequent phosphorylation of IRS-1 and other insulin receptor substrates and leads to loss of most insulin-dependent biological actions")
       (:PMID . "10194465") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y")
       (:TEXT
        . "Insulin receptor substrates are a growing family of proteins that are phosphorylated by the activated insulin receptor. To date, nine members of this family have been identified, including IRS-1 (17, 18), IRS-2 (19), IRS-3 (20), and IRS-4 (21), which are generally viewed as the most specific for insulin signaling; Gab-1 (22); Shc, which has three isoforms (23); and p62dok Following insulin binding, the receptor undergoes autophosphorylation on multiple tyrosine residues. This results in activation of the receptor kinase and tyrosine phosphorylation of a family of insulin receptor substrate (IRS) proteins.")
       (:PMID . "10194465") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y")
       (:TEXT
        . "insulin receptor phosphorylates a number of intracellular substrates on tyrosine including members of the insulin receptor substrate family (IRS1/2/3/4), the Shc adaptor...")
       (:PMID . "11239409") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y")
       (:TEXT
        . "insulin receptor is a tyrosine kinase that catalyzes the phosphorylation of several intracellular substrates, including the insulin receptor substrate (IRS) proteins, GAB-1, Shc, APS, p60(DOK), SIRPS, and c-Cbl")
       (:PMID . "11849969") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_INSR_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y")
       (:TEXT
        . "insulin stimulates the mitogen-activated protein (MAP) kinase extracellular signalregulated kinase (ERK) (Fig. 2). This pathway involves the tyrosine phosphorylation of IRS proteins and/or Shc, which in turn interact with the adapter protein Grb2, recruiting the Son-of-sevenless (SOS) exchange protein to the plasma membrane for activation of Ras.")
       (:PMID . "11742412") (:SOURCE--API . "bel")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06213") (:+HGNC+ . "6091")) (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "bcf0da3d-e4ac-4f2d-a395-61b5872d4c6e"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "STAT5A") (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "90083100-66a7-43e0-bfaf-02db6a90f675")
     (:EVIDENCE
      ((:TEXT
        . "Increasing the concentration of Stat5 proteins in cells favors the direct phosphorylation of Stat5 by the IR kinase where the DN-JAK inhibition of insulin stimulated Stat5 activation becomes insignificant.")
       (:PMID . "12456798") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This likely represents phosphorylation of Stat5 proteins by the IR, as we find that IR kinase domain phosphorylates Stat5b in vitro on Y699 as efficiently as JAK2.")
       (:PMID . "12456798") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Increasing the concentration of Stat5 proteins in cells favors the direct phosphorylation of Stat5 by the IR kinase where the DN-JAK inhibition of insulin stimulated Stat5 activation becomes insignificant.")
       (:PMID . "12456798") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This likely represents phosphorylation of Stat5 proteins by the IR, as we find that IR kinase domain phosphorylates Stat5b in vitro on Y699 as efficiently as JAK2.")
       (:PMID . "12456798") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "999") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "IR") (:+NCIT+ . "C17072") (:+UP+ . "P06213")
       (:+HGNC+ . "6091"))
      (:NAME . "INSR"))
     (:TYPE . "Phosphorylation")
     (:ID . "d714ef19-c545-4d29-a753-6c8e8492478b"))
    ((:SUB (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:SUPPORTED--BY "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_dec17861d7f2717084bfc538e299f448")
       (:PMID . "7499365") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_220ed7bf5e4a30546f0b1712620d2c9b")
       (:PMID . "7544789") (:SOURCE--API . "biopax")))
     (:ENZ (:DB--REFS (:+UP+ . "P23458") (:+HGNC+ . "6190")) (:NAME . "JAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "86f67c17-c285-4812-a32d-015dca2b0467"))
    ((:SUB (:DB--REFS (:+UP+ . "P29353") (:+HGNC+ . "10840")) (:NAME . "SHC1"))
     (:SUPPORTED--BY "5155385d-534b-4c6b-9930-a0bd655d3cea")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_565b0a97520a45b5719be5afffb5293c")
       (:PMID . "10851055") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_565b0a97520a45b5719be5afffb5293c")
       (:PMID . "8700888") (:SOURCE--API . "biopax")))
     (:ENZ (:DB--REFS (:+UP+ . "P23458") (:+HGNC+ . "6190")) (:NAME . "JAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a475e548-16e2-4049-ae7f-5c2ade333050"))
    ((:RESIDUE . "Y")
     (:SUB
      (:DB--REFS (:+TEXT+ . "STAT-3") (:+NCIT+ . "C28664") (:+UP+ . "P40763")
       (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "2247e004-7bf2-403e-b439-3d6b931c9a11"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "f00f2160-efa1-420e-ba3c-cb43c8c28407"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "1f9e903b-b337-4022-b907-fc559bac1720")
     (:EVIDENCE
      ((:TEXT
        . "Once recruited to those sites, STAT3 is phosphorylated by JAK1 on Y705, leading to its dimerization, translocation to the nucleus, and increased transcription.")
       (:PMID . "22905257") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Once recruited to those sites, STAT3 is phosphorylated by JAK1 on Y705, leading to its dimerization, translocation to the nucleus, and increased transcription")
       (:PMID . "22905257") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "17 Latent STAT3 is recruited to the activated receptor via phosphotyrosine-SH2 recognition, and is phosphorylated at Tyr705 by JAK and Src.")
       (:PMID . "24922077") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AG490, a JAK specific inhibitor, can significantly suppress STAT3 signaling by inhibiting the phosphorylation of Tyr705 of STAT3 [38].")
       (:PMID . "18592012") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Conditioned medium of ADSC activated the downstream JAK1 and JAK2 and TYK2 that lead to their target STAT3 Tyr 705 phosphorylation in rnCM and HL-1 cardiomyocytes.")
       (:PMID . "23406316") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Members of the JAK and Tyk family of tyrosine kinases mediate phosphorylation of STAT3 at Tyr705 during CNTF signaling; however, the kinase responsible for phosphorylation at STAT3 Tyr727 appears to depend on both the extracellular stimulus and the cellular context.")
       (:PMID . "10660304") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "26 STAT3 is phosphorylated by JAK tyrosine kinases at Tyr705 which transduces the signals of IL6.")
       (:PMID . "24687132") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "17 Latent STAT3 is recruited to the activated receptor via phosphotyrosine-SH2 recognition, and is phosphorylated at Tyr705 by JAK and Src.")
       (:PMID . "24922077") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In response to cytokines binding to their receptors on the cell surface, STAT3 is phosphorylated on Y705 by activated JAKs.")
       (:PMID . "24129709") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Once recruited to those sites, STAT3 is phosphorylated by JAK1 on Y705, leading to its dimerization, translocation to the nucleus, and increased transcription.")
       (:PMID . "22905257") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "We found that phosphorylation of STAT3 at Y705, which is mediated by JAK kinases and is critical for its activation, is inhibited at 24h by ibrutinib and AZD2014, but not at earlier timepoints (Fig XREF_FIG).")
       (:PMID . "24970801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Once recruited to those sites, STAT3 is phosphorylated by JAK1 on Y705, leading to its dimerization, translocation to the nucleus, and increased transcription.")
       (:PMID . "22905257") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "705")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "JAK-1") (:+NCIT+ . "C28493") (:+UP+ . "P23458")
       (:+HGNC+ . "6190"))
      (:NAME . "JAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "6622b638-a0e0-4576-a115-967b1bb96a33"))
    ((:RESIDUE . "Y")
     (:SUB
      (:DB--REFS (:+TEXT+ . "STAT5a") (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "7e2a23f4-b5ba-4462-8d06-ecfee696315a"
      "90083100-66a7-43e0-bfaf-02db6a90f675"
      "aaa09a17-4573-40aa-8b17-dad0e95d6a12"
      "5d567f66-b2a7-42ed-ad32-aee1d86f88da"
      "49c993fa-b398-4b4c-a732-182efc9277a1")
     (:EVIDENCE
      ((:TEXT
        . "STAT5a and STAT5b are subsequently phosphorylated by JAK kinases on tyrosine residues Y694 and Y699, respectively.")
       (:PMID . "15313458") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_824bd9a8886539b6fc8e6a0846eae467")
       (:PMID . "15226449") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_824bd9a8886539b6fc8e6a0846eae467")
       (:PMID . "7489741") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_824bd9a8886539b6fc8e6a0846eae467")
       (:PMID . "9916685") (:SOURCE--API . "biopax")))
     (:POSITION . "694")
     (:ENZ (:DB--REFS (:+TEXT+ . "JAK1") (:+UP+ . "P23458") (:+HGNC+ . "6190"))
      (:NAME . "JAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "8042710a-94fb-4f00-835e-e8dabb38392b"))
    ((:SUB (:DB--REFS (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "90083100-66a7-43e0-bfaf-02db6a90f675"
      "ac633cf0-1532-48e4-8c08-fe60532449da")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_264f95d1edb998fe9f50d6606cffce2c")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1007") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O60674") (:+HGNC+ . "6192")) (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "9d42f5b8-16f6-41c1-aaf3-6a8d923c8995"))
    ((:SUB (:DB--REFS (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "90083100-66a7-43e0-bfaf-02db6a90f675"
      "0a81676d-a60e-4633-b28a-01e358359c40")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_264f95d1edb998fe9f50d6606cffce2c")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1008") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O60674") (:+HGNC+ . "6192")) (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "455ee0da-bd17-46b7-8b06-8d677e4a08da"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "4165583a-5ca7-474e-b596-83e5474e3083"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "1f8a6c79-c2a1-4e3e-a8fd-1f3e42023306"
      "a948f9e5-d44c-4dfc-bf1e-e5f079cd1f15"
      "c88ea509-e91e-4950-b0d2-731fbc78ad4a"
      "1f9e903b-b337-4022-b907-fc559bac1720"
      "0be8b0a0-479d-4939-8311-f28cb7158d13")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1a0467fdb9b5764588153795e301dea1")
       (:PMID . "12529382") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1a0467fdb9b5764588153795e301dea1")
       (:PMID . "15322111") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1a0467fdb9b5764588153795e301dea1")
       (:PMID . "10207096") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1007") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O60674") (:+HGNC+ . "6192")) (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "25f44799-88db-4f99-8432-a74e32d7313f"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "03aa6989-72e1-43ef-8b6a-4379e54e580c"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "f7c8d2ae-c7f2-4e5f-9996-61b52ceda0e6"
      "a948f9e5-d44c-4dfc-bf1e-e5f079cd1f15"
      "b3249f19-7628-45c9-8b42-8508c8707786"
      "1f9e903b-b337-4022-b907-fc559bac1720"
      "be9709ec-c72d-4ab0-9c07-e0c2161b0135")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1a0467fdb9b5764588153795e301dea1")
       (:PMID . "12529382") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1a0467fdb9b5764588153795e301dea1")
       (:PMID . "15322111") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1a0467fdb9b5764588153795e301dea1")
       (:PMID . "10207096") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1008") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O60674") (:+HGNC+ . "6192")) (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "8d456534-ae81-4e9d-896c-d4133cd3a7ed"))
    ((:SUB (:DB--REFS (:+TEXT+ . "EGFR") (:+UP+ . "P00533") (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:SUPPORTED--BY "f58436a8-9b1e-4230-89e4-82e1da7e1a96")
     (:EVIDENCE
      ((:TEXT
        . "Knockout of JAK2 (JAK2 -/-) in MEFs substantially inhibited the phosphorylation of EGFR, STAT3, and rpS6 (XREF_FIG).")
       (:PMID . "23838182") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "JAK2 directly phosphorylates EGFR on Tyr 1068 in the kinase domain, stimulating its activity ( xref ).")
       (:PMID . "23838182") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Instead, we found that G5-7 can directly block JAK2, which phosphorylates EGFR on Tyr 1068 (XREF_BIBR).")
       (:PMID . "23838182") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1007") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "JAK2") (:+UP+ . "O60674") (:+HGNC+ . "6192"))
      (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "8ed0f8e1-567b-45d6-8ee6-c9fd77aebf0b"))
    ((:SUB (:DB--REFS (:+TEXT+ . "EGFR") (:+UP+ . "P00533") (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:SUPPORTED--BY "f58436a8-9b1e-4230-89e4-82e1da7e1a96")
     (:EVIDENCE
      ((:TEXT
        . "Knockout of JAK2 (JAK2 -/-) in MEFs substantially inhibited the phosphorylation of EGFR, STAT3, and rpS6 (XREF_FIG).")
       (:PMID . "23838182") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "JAK2 directly phosphorylates EGFR on Tyr 1068 in the kinase domain, stimulating its activity ( xref ).")
       (:PMID . "23838182") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Instead, we found that G5-7 can directly block JAK2, which phosphorylates EGFR on Tyr 1068 (XREF_BIBR).")
       (:PMID . "23838182") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1008") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "JAK2") (:+UP+ . "O60674") (:+HGNC+ . "6192"))
      (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "92d4c06e-4a8a-412b-a617-4e3f4d324a76"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "ERALPHA") (:+HGNC+ . "3467") (:+UP+ . "P03372")
       (:+NCIT+ . "C38361"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "e2df7413-ee90-45cb-9264-7f35c860d4cf")
     (:EVIDENCE
      ((:TEXT
        . "However, we could neither find any direct phosphorylation of ERalpha by JAK2 nor did we observe a direct physical interaction between the two proteins.")
       (:PMID . "21907792") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, we could neither find any direct phosphorylation of ERalpha by JAK2 nor did we observe a direct physical interaction between the two proteins ().")
       (:PMID . "21907792") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We investigated whether JAK2 phosphorylates ERalpha resulting in its ubiquitination and proteasomal degradation.")
       (:PMID . "21907792") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, we could neither find any direct phosphorylation of ERalpha by JAK2 nor did we observe a direct physical interaction between the two proteins.")
       (:PMID . "21907792") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, we could neither find any direct phosphorylation of ERalpha by JAK2 nor did we observe a direct physical interaction between the two proteins ().")
       (:PMID . "21907792") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1007") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "JAK-2") (:+NCIT+ . "C28494") (:+UP+ . "O60674")
       (:+HGNC+ . "6192"))
      (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "8aa3f6f9-3b76-4ed5-a9e1-1f0e09b7686b"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "ERALPHA") (:+HGNC+ . "3467") (:+UP+ . "P03372")
       (:+NCIT+ . "C38361"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "e2df7413-ee90-45cb-9264-7f35c860d4cf")
     (:EVIDENCE
      ((:TEXT
        . "However, we could neither find any direct phosphorylation of ERalpha by JAK2 nor did we observe a direct physical interaction between the two proteins.")
       (:PMID . "21907792") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, we could neither find any direct phosphorylation of ERalpha by JAK2 nor did we observe a direct physical interaction between the two proteins ().")
       (:PMID . "21907792") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We investigated whether JAK2 phosphorylates ERalpha resulting in its ubiquitination and proteasomal degradation.")
       (:PMID . "21907792") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, we could neither find any direct phosphorylation of ERalpha by JAK2 nor did we observe a direct physical interaction between the two proteins.")
       (:PMID . "21907792") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, we could neither find any direct phosphorylation of ERalpha by JAK2 nor did we observe a direct physical interaction between the two proteins ().")
       (:PMID . "21907792") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1008") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "JAK-2") (:+NCIT+ . "C28494") (:+UP+ . "O60674")
       (:+HGNC+ . "6192"))
      (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "8aa3f6f9-3b76-4ed5-a9e1-1f0e09b7686b"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ERK2") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "TEL-JAK2 (5-12) and TEL-JAK2 (5-19) preferentially phosphorylate ERK2, whereas TEL-JAK2 (4-17) phosphorylated ERK2 at lower levels.")
       (:PMID . "12149229") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "JAK2V617F expression also confers factor independence to cytokine dependent cell-lines (XREF_BIBR - XREF_BIBR), and results in constitutive JAK2 phosphorylation and consequent activation of the STAT, AKT and ERK signaling pathways.")
       (:PMID . "22641564") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1007") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "TEL-JAK2") (:+UP+ . "O60674") (:+HGNC+ . "6192"))
      (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "19e2bf37-313a-4b8f-9d74-d19ef80e19ca"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ERK2") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "TEL-JAK2 (5-12) and TEL-JAK2 (5-19) preferentially phosphorylate ERK2, whereas TEL-JAK2 (4-17) phosphorylated ERK2 at lower levels.")
       (:PMID . "12149229") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "JAK2V617F expression also confers factor independence to cytokine dependent cell-lines (XREF_BIBR - XREF_BIBR), and results in constitutive JAK2 phosphorylation and consequent activation of the STAT, AKT and ERK signaling pathways.")
       (:PMID . "22641564") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1008") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "TEL-JAK2") (:+UP+ . "O60674") (:+HGNC+ . "6192"))
      (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "6b83913e-8461-4c5c-974f-7a2f1cac0062"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "eb42dbb1-f0bd-44c8-a731-398c38232332"
      "68749616-8fb1-4911-a761-2a44e3c44b94"
      "90083100-66a7-43e0-bfaf-02db6a90f675"
      "7e2a23f4-b5ba-4462-8d06-ecfee696315a"
      "49c993fa-b398-4b4c-a732-182efc9277a1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a5f03016ba1f80a13a7b72bad1964aa7")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "STAT5a and STAT5b are subsequently phosphorylated by JAK kinases on tyrosine residues Y694 and Y699, respectively.")
       (:PMID . "15313458") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "694")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1007") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O60674") (:+HGNC+ . "6192")) (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "719592ee-6fbe-400d-861a-2eba62d60113"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "0407a219-fd74-4f66-99bd-51e486a92710"
      "3544c710-5d10-4b67-b153-c68cb7c9c379"
      "90083100-66a7-43e0-bfaf-02db6a90f675"
      "7e2a23f4-b5ba-4462-8d06-ecfee696315a"
      "49c993fa-b398-4b4c-a732-182efc9277a1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a5f03016ba1f80a13a7b72bad1964aa7")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "STAT5a and STAT5b are subsequently phosphorylated by JAK kinases on tyrosine residues Y694 and Y699, respectively.")
       (:PMID . "15313458") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "694")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1008") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O60674") (:+HGNC+ . "6192")) (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "72caa130-6eee-4024-aa4f-482aa20425d9"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "STAT6") (:+UP+ . "P42226") (:+HGNC+ . "11368"))
      (:NAME . "STAT6"))
     (:SUPPORTED--BY "3bd8cbdf-e4aa-4d6d-8164-41f93270d10e")
     (:EVIDENCE
      ((:TEXT
        . "In addition to targeting EGFR, JAK2 mainly phosphorylates STAT transcription factors, including STAT3 (XREF_BIBR).")
       (:PMID . "23838182") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "SOCS3 is able to block JAK phosphorylation of STAT and thereby inhibit further signaling XREF_BIBR; XREF_BIBR.")
       (:PMID . "24438103") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The 643P mutation is found in the C-terminal domain of STAT6 and is a critical JAK phosphorylation site in STAT6.")
       (:PMID . "26945968") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "STAT6 is recruited to the activated IL-4Ralpha in response to either IL-4 or IL-13 and is thereafter phosphorylated by the JAK.")
       (:PMID . "24960198") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The activated JAK molecules then phosphorylate multiple sites on the cytokine receptor that allow for STAT binding and phosphorylation by JAK (XREF_BIBR).")
       (:PMID . "19223541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Chemical JAK2 inhibition decreased phosphorylation of JAK2, STAT1, STAT3 and STAT6 and reduced the expression of additional downstream targets, including PD-L1, in a copy number dependent manner.")
       (:PMID . "24610827") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "JAK2 leads to phosphorylation of STAT proteins, specifically STAT3; the active form of STAT3 has been identified in many human cancers and appears to be required for continued cellular growth (XREF_BIBR).")
       (:PMID . "21785467") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "JAK2V617F expression also confers factor independence to cytokine dependent cell-lines (XREF_BIBR - XREF_BIBR), and results in constitutive JAK2 phosphorylation and consequent activation of the STAT, AKT and ERK signaling pathways.")
       (:PMID . "22641564") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The IL-13-induced phosphorylation of STAT6 was abolished by JAK inhibitor-I, whereas the other inhibitors had no significant effect.")
       (:PMID . "22661199") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1007") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "JAK2") (:+UP+ . "O60674") (:+HGNC+ . "6192"))
      (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "5b7dd37f-dd16-47dd-96e6-608a592d1d3f"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "STAT6") (:+UP+ . "P42226") (:+HGNC+ . "11368"))
      (:NAME . "STAT6"))
     (:SUPPORTED--BY "3bd8cbdf-e4aa-4d6d-8164-41f93270d10e")
     (:EVIDENCE
      ((:TEXT
        . "In addition to targeting EGFR, JAK2 mainly phosphorylates STAT transcription factors, including STAT3 (XREF_BIBR).")
       (:PMID . "23838182") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "SOCS3 is able to block JAK phosphorylation of STAT and thereby inhibit further signaling XREF_BIBR; XREF_BIBR.")
       (:PMID . "24438103") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The 643P mutation is found in the C-terminal domain of STAT6 and is a critical JAK phosphorylation site in STAT6.")
       (:PMID . "26945968") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "STAT6 is recruited to the activated IL-4Ralpha in response to either IL-4 or IL-13 and is thereafter phosphorylated by the JAK.")
       (:PMID . "24960198") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The activated JAK molecules then phosphorylate multiple sites on the cytokine receptor that allow for STAT binding and phosphorylation by JAK (XREF_BIBR).")
       (:PMID . "19223541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Chemical JAK2 inhibition decreased phosphorylation of JAK2, STAT1, STAT3 and STAT6 and reduced the expression of additional downstream targets, including PD-L1, in a copy number dependent manner.")
       (:PMID . "24610827") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "JAK2 leads to phosphorylation of STAT proteins, specifically STAT3; the active form of STAT3 has been identified in many human cancers and appears to be required for continued cellular growth (XREF_BIBR).")
       (:PMID . "21785467") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "JAK2V617F expression also confers factor independence to cytokine dependent cell-lines (XREF_BIBR - XREF_BIBR), and results in constitutive JAK2 phosphorylation and consequent activation of the STAT, AKT and ERK signaling pathways.")
       (:PMID . "22641564") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The IL-13-induced phosphorylation of STAT6 was abolished by JAK inhibitor-I, whereas the other inhibitors had no significant effect.")
       (:PMID . "22661199") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1008") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "JAK2") (:+UP+ . "O60674") (:+HGNC+ . "6192"))
      (:NAME . "JAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "1c9ba9c5-dc15-468b-a710-34529454ac4a"))
    ((:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "357006aa-d6ac-4993-8d12-ae840d501472"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_264f95d1edb998fe9f50d6606cffce2c")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8d4166dbf2a7333bf20ebcbdfd60878e")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "980") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "981") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P52333") (:+HGNC+ . "6193")) (:NAME . "JAK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "2c2d33fb-6180-4145-ad4e-a94fa4c992c8"))
    ((:SUB (:DB--REFS (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "978b9395-b9fb-4c44-bb2c-dfbe66daf1e9"
      "90083100-66a7-43e0-bfaf-02db6a90f675")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8d4166dbf2a7333bf20ebcbdfd60878e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_264f95d1edb998fe9f50d6606cffce2c")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "980") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "981") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P52333") (:+HGNC+ . "6193")) (:NAME . "JAK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "3960adf1-7756-4fde-a8c4-051a2830e438"))
    ((:SUB (:DB--REFS (:+UP+ . "P42226") (:+HGNC+ . "11368"))
      (:NAME . "STAT6"))
     (:SUPPORTED--BY "4e1f68b4-6024-4919-a2c0-9899232d69b3"
      "3bd8cbdf-e4aa-4d6d-8164-41f93270d10e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8d4166dbf2a7333bf20ebcbdfd60878e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_264f95d1edb998fe9f50d6606cffce2c")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "980") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "981") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P52333") (:+HGNC+ . "6193")) (:NAME . "JAK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "e01364b9-a364-4ed6-9ead-4fd830bdde61"))
    ((:SUB (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:SUPPORTED--BY "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e8a8854db8673aeb0ecf7f013f613a48")
       (:PMID . "7544789") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ce1594379dd94624a5166cb32e6d320a")
       (:PMID . "7499365") (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "980") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "981") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P52333") (:+HGNC+ . "6193")) (:NAME . "JAK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "0513d79e-03ee-4e4e-8cee-f2936879e2b5"))
    ((:RESIDUE . "Y")
     (:SUB
      (:DB--REFS (:+TEXT+ . "STAT-3") (:+HGNC+ . "11364") (:+UP+ . "P40763")
       (:+NCIT+ . "C28664"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "1f9e903b-b337-4022-b907-fc559bac1720"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "357006aa-d6ac-4993-8d12-ae840d501472"
      "91653ed6-3f21-4416-9391-68265ff39ae0")
     (:EVIDENCE
      ((:TEXT
        . "17 Latent STAT3 is recruited to the activated receptor via phosphotyrosine-SH2 recognition, and is phosphorylated at Tyr705 by JAK and Src.")
       (:PMID . "24922077") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "17 Latent STAT3 is recruited to the activated receptor via phosphotyrosine-SH2 recognition, and is phosphorylated at Tyr705 by JAK and Src.")
       (:PMID . "24922077") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In response to cytokines binding to their receptors on the cell surface, STAT3 is phosphorylated on Y705 by activated JAKs.")
       (:PMID . "24129709") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "AG490, a JAK specific inhibitor, can significantly suppress STAT3 signaling by inhibiting the phosphorylation of Tyr705 of STAT3 [38].")
       (:PMID . "18592012") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Members of the JAK and Tyk family of tyrosine kinases mediate phosphorylation of STAT3 at Tyr705 during CNTF signaling; however, the kinase responsible for phosphorylation at STAT3 Tyr727 appears to depend on both the extracellular stimulus and the cellular context.")
       (:PMID . "10660304") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "26 STAT3 is phosphorylated by JAK tyrosine kinases at Tyr705 which transduces the signals of IL6.")
       (:PMID . "24687132") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We found that phosphorylation of STAT3 at Y705, which is mediated by JAK kinases and is critical for its activation, is inhibited at 24h by ibrutinib and AZD2014, but not at earlier timepoints (Fig XREF_FIG).")
       (:PMID . "24970801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "980") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "981") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "JAK3") (:+UP+ . "P52333") (:+HGNC+ . "6193"))
      (:NAME . "JAK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "a948f9e5-d44c-4dfc-bf1e-e5f079cd1f15"))
    ((:RESIDUE . "Y")
     (:SUB
      (:DB--REFS (:+TEXT+ . "STAT5a") (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "065bc4f3-aeda-45f7-a883-c412bec7fbc1"
      "0d9ebc89-8584-47d6-9dc5-18c94bb23ab2"
      "7e2a23f4-b5ba-4462-8d06-ecfee696315a"
      "49c993fa-b398-4b4c-a732-182efc9277a1"
      "90083100-66a7-43e0-bfaf-02db6a90f675")
     (:EVIDENCE
      ((:TEXT
        . "STAT5a and STAT5b are subsequently phosphorylated by JAK kinases on tyrosine residues Y694 and Y699, respectively.")
       (:PMID . "15313458") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_72b9bf1022f7f34f5ce518c8b97f08ec")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_654b2d3eb090ba38f5bfce281c3a05f6")
       (:PMID . "19414780") (:SOURCE--API . "biopax")))
     (:POSITION . "694")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "980") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "981") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "JAK3") (:+UP+ . "P52333") (:+HGNC+ . "6193"))
      (:NAME . "JAK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "66b0b03e-9ed4-4290-8877-c9be7a6fab47"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "Regardless of whether direct or indirect, the down-regulation of the KIT dependent phosphorylation of KIT, SFKs and ERK by the interaction of SHP-1 with phosphorylated CD72 would certainly account for the ability of ligated CD72 to down-regulate KIT mediated responses in human mast cells.")
       (:PMID . "20100931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Again, blockage of c-kit activity by imatinib evidently inhibited ERK phosphorylation and ETV4 expression in HCT-116 cells (P < 0.05, 0.01, or 0.001, Figure XREF_FIG).")
       (:PMID . "26356816") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "KIT") (:+UP+ . "P10721") (:+HGNC+ . "6342"))
      (:NAME . "KIT"))
     (:TYPE . "Phosphorylation")
     (:ID . "029d91ad-1993-42c4-9b95-851777977bdf"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Again, blockage of c-kit activity by imatinib evidently inhibited ERK phosphorylation and ETV4 expression in HCT-116 cells (P < 0.05, 0.01, or 0.001, Figure XREF_FIG).")
       (:PMID . "26356816") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Regardless of whether direct or indirect, the down-regulation of the KIT dependent phosphorylation of KIT, SFKs and ERK by the interaction of SHP-1 with phosphorylated CD72 would certainly account for the ability of ligated CD72 to down-regulate KIT mediated responses in human mast cells.")
       (:PMID . "20100931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal regulated kinase and phosphorylated AKT in Japanese melanoma patients.")
       (:PMID . "25766129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "c-kit") (:+UP+ . "P10721") (:+HGNC+ . "6342"))
      (:NAME . "KIT"))
     (:TYPE . "Phosphorylation")
     (:ID . "bbdfcd9f-1b61-4a81-a4d1-842528927cb9"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "STAT5") (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "90083100-66a7-43e0-bfaf-02db6a90f675")
     (:EVIDENCE
      ((:TEXT
        . "KIT cITD constitutively activated the PI3K and AKT pathway and phosphorylated STAT1, STAT3, STAT5, and SHP-2.")
       (:PMID . "16840725") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "By contrast, the wild-type form of KIT did not induce comparable phosphorylation of STAT5 in Ba/F3 cells.")
       (:PMID . "19893034") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9c9e9521f7d5d202c03e598442c01b9f")
       (:PMID . "10358045") (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "KIT") (:+UP+ . "P10721") (:+HGNC+ . "6342"))
      (:NAME . "KIT"))
     (:TYPE . "Phosphorylation")
     (:ID . "acf08573-81bc-484e-858d-d18ed0f7cedf"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "1462ed4d-ae07-4fdc-97dc-85aa277b7654"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_aafaca2cc4b7ff666504dcd00b68dd5c")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "8503013") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "33a1208a-813b-4bc6-9e92-cfaf984d82ab"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "1462ed4d-ae07-4fdc-97dc-85aa277b7654"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0853d91d7326e9659d1d2bd29b71e104")
       (:PMID . "8503013") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_aafaca2cc4b7ff666504dcd00b68dd5c")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "3197ace7-49c8-4935-9409-5849ebfe130c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "1462ed4d-ae07-4fdc-97dc-85aa277b7654"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3dc8b39088e4f5fb3efab221b3d822a1")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3dc8b39088e4f5fb3efab221b3d822a1")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_494466d32aad3fcfa8c3d156afa01881")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "9d6aad99-69d6-4700-b669-c110bf5fe445"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "1462ed4d-ae07-4fdc-97dc-85aa277b7654"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_494466d32aad3fcfa8c3d156afa01881")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3dc8b39088e4f5fb3efab221b3d822a1")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3dc8b39088e4f5fb3efab221b3d822a1")
       (:PMID . "19219045") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a0aabdea-cab5-4eef-815d-3e5daf8d6d05"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef"
      "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f2537ef31daa679dc541742f3fe64581")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f2537ef31daa679dc541742f3fe64581")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "8248196") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "21c35461-3853-4f7a-a8ec-488c28a45e67"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "ee7aca37-7cd0-4675-a4e8-167017d5cdc9"
      "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f2537ef31daa679dc541742f3fe64581")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f2537ef31daa679dc541742f3fe64581")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "8248196") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "eb234e0d-5e22-4d1b-8c29-3d1b419f5e12"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "0d920125-bd7d-456d-8a90-7673e3c83616")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f2537ef31daa679dc541742f3fe64581")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f2537ef31daa679dc541742f3fe64581")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "8248196") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "d9e8ee54-090b-47ac-ac1e-617798568fea"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "e96c4895-0a45-4836-a398-d523e0dcb483"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f2537ef31daa679dc541742f3fe64581")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f2537ef31daa679dc541742f3fe64581")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_19fa644f986ac5da677e5dfa83e1eb25")
       (:PMID . "8248196") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "87f8c80e-4aaf-4376-9170-279b70827bd3"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "65784ab9-a1c1-48c4-a3a3-397b9e9b09ce"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "11781878-54aa-4b12-9f73-29a604cc62e7")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "9665134") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8180183") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "19595761") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "11134016") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "16093354") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "1990291") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8332195") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8503013") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "18775988") (:SOURCE--API . "biopax")))
     (:POSITION . "338")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "8c0d42c5-7f21-49e4-9841-32406d88141c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "65784ab9-a1c1-48c4-a3a3-397b9e9b09ce"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "9665134") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8180183") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "19595761") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "11134016") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "16093354") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "1990291") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8332195") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8503013") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "18775988") (:SOURCE--API . "biopax")))
     (:POSITION . "471")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "475ac402-9797-4125-8d79-a8b14b1f1220"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "a4c02905-6eba-40d8-ac1a-09529665ba79"
      "65784ab9-a1c1-48c4-a3a3-397b9e9b09ce")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "9665134") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8180183") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "19595761") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "11134016") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "16093354") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "1990291") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8332195") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8503013") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "18775988") (:SOURCE--API . "biopax")))
     (:POSITION . "621")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "20e0c878-0683-4836-a81d-0d1b11763001"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "65784ab9-a1c1-48c4-a3a3-397b9e9b09ce")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4620a1005e15a84f3ce7538354e2021e")
       (:PMID . "19766101") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e1d8f311fa27f294dc0d6cac7624d74b")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "9665134") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8180183") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "19595761") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "11134016") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "16093354") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "1990291") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8332195") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "8503013") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_747e09bf69f221e82e9f9bec7da083e6")
       (:PMID . "18775988") (:SOURCE--API . "biopax")))
     (:POSITION . "269")
     (:ENZ (:DB--REFS (:+UP+ . "Q8IVT5") (:+HGNC+ . "6465")) (:NAME . "KSR1"))
     (:TYPE . "Phosphorylation")
     (:ID . "b6a2cae7-7fbc-4e04-af84-3bf96c3ee729"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "b897baea-ac02-440e-ac21-696573e698d1"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "218")
     (:ENZ (:DB--REFS (:+UP+ . "Q6VAB6") (:+HGNC+ . "18610")) (:NAME . "KSR2"))
     (:TYPE . "Phosphorylation")
     (:ID . "b873c2e1-c4f5-4e90-a208-160806317131"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "b32c0634-7af3-4c82-8bd0-8f613591fba4"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "5377520e-d1c5-494f-ad7e-4cdea1263c43"
      "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "12590707") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "11369622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "15728464") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "10753828") (:SOURCE--API . "biopax")))
     (:POSITION . "397")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "394") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06239") (:+HGNC+ . "6524")) (:NAME . "LCK"))
     (:TYPE . "Phosphorylation")
     (:ID . "08c5afd4-e09f-4d9a-9d97-5833fad572b2"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "1f9e903b-b337-4022-b907-fc559bac1720"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9344858") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "10815799") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9484840") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "11404481") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "394") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06239") (:+HGNC+ . "6524")) (:NAME . "LCK"))
     (:TYPE . "Phosphorylation")
     (:ID . "4634c79a-9e36-49e0-b96e-6accfbe1ac2a"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P29353") (:+HGNC+ . "10840")) (:NAME . "SHC1"))
     (:SUPPORTED--BY "caaac4ae-ef68-4fde-b910-70ef6d06227b"
      "5155385d-534b-4c6b-9930-a0bd655d3cea"
      "d0a2fcf3-1735-4eb0-bb5f-037524465fa5"
      "c152fe2a-86a6-4991-a393-51aa22cdd939")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_58371b613606f0bbbbecb8afbc827f6f")
       (:SOURCE--API . "biopax")))
     (:POSITION . "427")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "394") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06239") (:+HGNC+ . "6524")) (:NAME . "LCK"))
     (:TYPE . "Phosphorylation")
     (:ID . "299c2cc7-2af4-4986-95fa-ba210d0d447a"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "49c993fa-b398-4b4c-a732-182efc9277a1"
      "90083100-66a7-43e0-bfaf-02db6a90f675"
      "dc187539-00eb-4b5d-9938-949868884c7a"
      "7e2a23f4-b5ba-4462-8d06-ecfee696315a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b4d9bafc9813efaf11865613849d84ce")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "694")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "394") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P06239") (:+HGNC+ . "6524")) (:NAME . "LCK"))
     (:TYPE . "Phosphorylation")
     (:ID . "740aaacf-8ba0-4a09-b7d6-59d6ee7ff852"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "5377520e-d1c5-494f-ad7e-4cdea1263c43"
      "3b085760-047b-4de6-a358-6f53aa726e61"
      "240a18e3-2e6d-442b-961c-f20a82e11b49")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "12590707") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "11369622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "15728464") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "10753828") (:SOURCE--API . "biopax")))
     (:POSITION . "397")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P07948") (:+HGNC+ . "6735")) (:NAME . "LYN"))
     (:TYPE . "Phosphorylation")
     (:ID . "f3ed03a2-bf2f-4c80-a581-3bfffd708e33"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "1f9e903b-b337-4022-b907-fc559bac1720")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9344858") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "10815799") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9484840") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "11404481") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P07948") (:+HGNC+ . "6735")) (:NAME . "LYN"))
     (:TYPE . "Phosphorylation")
     (:ID . "fcdffc4d-5d5e-4d2b-890b-485a9792033a"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "041d1727-e16f-47d7-b9e1-125ded56918d"
      "6972a59d-f263-492b-b508-77c9425eb9d1"
      "b0ddfd06-5ca2-4112-bd4e-f6e28fb18adc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_61992befe5804e9a1c6868b4ba75d8cc")
       (:PMID . "16157584") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_61992befe5804e9a1c6868b4ba75d8cc")
       (:PMID . "15632082") (:SOURCE--API . "biopax")))
     (:POSITION . "180")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:TYPE . "Phosphorylation")
     (:ID . "ee6071e7-ac00-4839-8297-360f4767d5b2"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "415127e2-27e9-4deb-8378-60bf69738557"
      "24f7f8c1-a46c-4956-bdb2-1add72cc582c"
      "b0ddfd06-5ca2-4112-bd4e-f6e28fb18adc"
      "6972a59d-f263-492b-b508-77c9425eb9d1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_61992befe5804e9a1c6868b4ba75d8cc")
       (:PMID . "16157584") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_61992befe5804e9a1c6868b4ba75d8cc")
       (:PMID . "15632082") (:SOURCE--API . "biopax")))
     (:POSITION . "182")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:TYPE . "Phosphorylation")
     (:ID . "8f3cb41c-9b9e-4886-a56d-b2110248ae16"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "92a45c00-8b8b-4679-85a0-b23c494dfe05"
      "257f0d83-cb27-4b00-83b6-1a40c97de77a"
      "e66406d9-2291-4a68-b792-0e94bb5891bb"
      "8020c196-7442-4323-bbcc-bef7712794ef"
      "78b43a7f-07fd-4fff-8e3b-1f3095d28b51"
      "c990d1bc-6664-4469-baa4-c2da9ea31460"
      "d742452d-e2bd-433b-80c9-9c76ec088807"
      "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6852c2852af88ab6853597b091c147e9")
       (:PMID . "9560161") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4ebae9473c92a42cbbc2aee3e2cfea88")
       (:PMID . "12925710") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "10777511") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "12952943") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "9032297") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "10998418") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "9148935") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "14743221") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5beb28be93e4c84acb7d5da95d7eeb3b")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2c317c55f8a5163bc35ac0014b3aa625")
       (:PMID . "10995751") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2c317c55f8a5163bc35ac0014b3aa625")
       (:PMID . "12048245") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6cdc0d1422c0775aa127ad0d5747b19f")
       (:PMID . "9765155") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c4b9cdcce0f05f8df22cfb9064c76288")
       (:PMID . "1381507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_68cdbf357ccd3d8eb1f5618d5c458a1e")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56e28fdd9a12d3ec084c2693233c41c0")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a789570fb4f52d56e889b65613e1ae35")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11118451") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "11319218") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "15466214") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:TYPE . "Phosphorylation")
     (:ID . "32183c94-6e99-4898-9298-082251e3a8da"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "39b0a51d-051c-4bff-9154-dd617420ee4d"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9"
      "587e979c-73c7-4be1-866b-68f0154f7893"
      "e5e37a68-0df0-464b-97c1-b5e20c2815b8"
      "921ce7a1-e350-47f1-9ade-da4ec4711297"
      "8020c196-7442-4323-bbcc-bef7712794ef"
      "5418c2d2-74fa-4684-80f9-4380e5623abf"
      "8d996f71-2d10-4f7f-85a0-7d894b300d7b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "11319218") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5beb28be93e4c84acb7d5da95d7eeb3b")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11118451") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c4b9cdcce0f05f8df22cfb9064c76288")
       (:PMID . "1381507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6852c2852af88ab6853597b091c147e9")
       (:PMID . "9560161") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6cdc0d1422c0775aa127ad0d5747b19f")
       (:PMID . "9765155") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_68cdbf357ccd3d8eb1f5618d5c458a1e")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56e28fdd9a12d3ec084c2693233c41c0")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2c317c55f8a5163bc35ac0014b3aa625")
       (:PMID . "10995751") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2c317c55f8a5163bc35ac0014b3aa625")
       (:PMID . "12048245") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4ebae9473c92a42cbbc2aee3e2cfea88")
       (:PMID . "12925710") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a789570fb4f52d56e889b65613e1ae35")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "10777511") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "12952943") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "9032297") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "10998418") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "9148935") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_50de2cf5203dcafbf42faca8f817afc5")
       (:PMID . "14743221") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:TYPE . "Phosphorylation")
     (:ID . "69bf8975-6894-49c2-b3e3-af16e7e0ab85"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0d920125-bd7d-456d-8a90-7673e3c83616"
      "ef6462d9-c528-4d36-b304-a5da24d22be4"
      "55e33d15-87b1-4c4f-ad9e-3850f254c88a"
      "daa8e19a-bb58-49b5-b2cd-65817cce2a60"
      "0f40084d-09d6-4810-8360-28cbb087dceb"
      "41824378-d8c0-487c-acd6-d29e77b534f4"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "3a6f9a19-7545-4d0d-8a41-60cb62a4d000")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5beb28be93e4c84acb7d5da95d7eeb3b")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c4b9cdcce0f05f8df22cfb9064c76288")
       (:PMID . "1381507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56e28fdd9a12d3ec084c2693233c41c0")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_68cdbf357ccd3d8eb1f5618d5c458a1e")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6852c2852af88ab6853597b091c147e9")
       (:PMID . "9560161") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11118451") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "11319218") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2c317c55f8a5163bc35ac0014b3aa625")
       (:PMID . "10995751") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2c317c55f8a5163bc35ac0014b3aa625")
       (:PMID . "12048245") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4ebae9473c92a42cbbc2aee3e2cfea88")
       (:PMID . "12925710") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a789570fb4f52d56e889b65613e1ae35")
       (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:TYPE . "Phosphorylation")
     (:ID . "86bec464-9b6d-4d4c-9b1b-6fba229b2a11"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "e2c83c9e-ea94-41f8-ac6e-74a0e30ef373"
      "84b662f6-635a-4041-947b-232fc3c22ab9"
      "e96c4895-0a45-4836-a398-d523e0dcb483"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "948cf6dd-c802-409d-972d-360fa2d6d199"
      "ff9c39bc-c2f1-4971-ae58-f55d13dee28c"
      "eb5b7148-83e4-4158-8166-3db9e83ee3c0"
      "b559dcb5-e496-4cd2-88c4-f04fe9a4b553")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56e28fdd9a12d3ec084c2693233c41c0")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4ebae9473c92a42cbbc2aee3e2cfea88")
       (:PMID . "12925710") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5beb28be93e4c84acb7d5da95d7eeb3b")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c4b9cdcce0f05f8df22cfb9064c76288")
       (:PMID . "1381507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2c317c55f8a5163bc35ac0014b3aa625")
       (:PMID . "10995751") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2c317c55f8a5163bc35ac0014b3aa625")
       (:PMID . "12048245") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6852c2852af88ab6853597b091c147e9")
       (:PMID . "9560161") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "16135787") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "11319218") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "17563371") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7508636e7ba3654271ab9768f1c5fdd")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "10567369") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "8226933") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5598320dc4989b81cefba851b39d4c73")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_68cdbf357ccd3d8eb1f5618d5c458a1e")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a789570fb4f52d56e889b65613e1ae35")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11118451") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:TYPE . "Phosphorylation")
     (:ID . "275ad75f-a3e8-45d0-ae2a-2990ad9b3c47"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P84022") (:+HGNC+ . "6769")) (:NAME . "SMAD3"))
     (:SUPPORTED--BY "ec699d53-2669-4c6a-b9ba-7c3f373c1114"
      "0010ba73-bd7c-4a91-b4da-2370266c1f97")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "423")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:TYPE . "Phosphorylation")
     (:ID . "f4d5bbd3-fa90-42cb-993a-6dfe2c74d945"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "c4de9bbf-3087-4235-82a1-663bdb028b62"
      "6d71f18e-496a-422d-b694-531531805fdc"
      "2eeeaba3-098c-44b3-866d-94e607e66258")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7528668") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7568001") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7719938") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7719937") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7544001") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "10602027") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "12681450") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "9305919") (:SOURCE--API . "biopax")))
     (:POSITION . "727")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:TYPE . "Phosphorylation")
     (:ID . "610b4312-0583-4895-9e67-5e7a9b156f97"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "1f9e903b-b337-4022-b907-fc559bac1720"
      "e6dff116-4298-4e0f-9bce-9d9372a41701"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7528668") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7568001") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7719938") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7719937") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7544001") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "10602027") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "12681450") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "9305919") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "286") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "292") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840")) (:NAME . "MAP2K1"))
     (:TYPE . "Phosphorylation")
     (:ID . "aae8345a-4e36-400b-a5e3-c51fee9c5719"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a1df0a8d-b26b-407c-b1b5-a814fb3d7f47"
      "2f02a358-c5bc-4d78-ad9a-82003c335395"
      "8020c196-7442-4323-bbcc-bef7712794ef"
      "ce87375e-4383-4697-b36c-0667cbe89931"
      "53d6c026-5a05-429e-bce5-1addfd52550f"
      "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d"
      "9d610c57-eb3c-4872-8195-162c756c998d"
      "daa0cfce-6c59-4b59-9e8d-cc1db788ef79")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_68cdbf357ccd3d8eb1f5618d5c458a1e")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_eb52fb020a0201f203a06b24d7e30f79")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_eb52fb020a0201f203a06b24d7e30f79")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_876a065ea3df56065964098f19074b39")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11118451") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5beb28be93e4c84acb7d5da95d7eeb3b")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d022b8f4cdd9670a5e03498c3554a87c")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "15466214") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "226") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842")) (:NAME . "MAP2K2"))
     (:TYPE . "Phosphorylation")
     (:ID . "81861b45-15c9-497c-a13d-9f496cee85fd"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "7df876b6-9fd9-4d1a-bd5f-65e33dd259bd"
      "a69ca417-0c74-4d8f-bda6-c1403a798f55"
      "a11a2706-db94-427f-82db-7cc6acc6bab1"
      "0f13fe4e-e411-4a63-8760-c6d618202ddb"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9"
      "67a089f1-60a6-47fe-8810-7e94633c09f0"
      "8020c196-7442-4323-bbcc-bef7712794ef"
      "11e587a9-f2c3-40e9-afec-d283b793258f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_eb52fb020a0201f203a06b24d7e30f79")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_eb52fb020a0201f203a06b24d7e30f79")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d022b8f4cdd9670a5e03498c3554a87c")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_68cdbf357ccd3d8eb1f5618d5c458a1e")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11118451") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5beb28be93e4c84acb7d5da95d7eeb3b")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_876a065ea3df56065964098f19074b39")
       (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "226") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842")) (:NAME . "MAP2K2"))
     (:TYPE . "Phosphorylation")
     (:ID . "77ac4878-f14e-4f7d-9ac9-a1a826427f32"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "be25e84b-d5d2-4f77-a999-1ace52d40e33"
      "22a74724-1b00-4d3b-b67b-355a6ba97628"
      "ed6e0723-6647-4a14-bd0b-42601d783ea8"
      "0d920125-bd7d-456d-8a90-7673e3c83616"
      "9f39a283-efe1-4f80-8fed-255e3f9af469"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "98a7eb48-6ab3-4af1-87b1-8c1174f241d9"
      "48d3363c-ff30-4b0c-9abd-318eea3e2121")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_876a065ea3df56065964098f19074b39")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5beb28be93e4c84acb7d5da95d7eeb3b")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_68cdbf357ccd3d8eb1f5618d5c458a1e")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11118451") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d022b8f4cdd9670a5e03498c3554a87c")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_eb52fb020a0201f203a06b24d7e30f79")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_eb52fb020a0201f203a06b24d7e30f79")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "15466214") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "226") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842")) (:NAME . "MAP2K2"))
     (:TYPE . "Phosphorylation")
     (:ID . "69127202-95a7-4c75-a752-54bcaa744f73"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "da9f0f97-d934-4f13-95b7-0a6579000948"
      "744bf2b3-f84b-4a38-b102-71140793ffa1"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "4e15fe05-7059-4310-87e4-76d44971e2fc"
      "e96c4895-0a45-4836-a398-d523e0dcb483"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "0e01dd89-69e7-4f41-a7ec-4c5007d77acb"
      "ff9c39bc-c2f1-4971-ae58-f55d13dee28c"
      "d061abde-098e-49c0-8ac8-0e3f96a34627")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_876a065ea3df56065964098f19074b39")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5beb28be93e4c84acb7d5da95d7eeb3b")
       (:PMID . "17569879") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "7898932") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "8223433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "12920017") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9447970") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0c30decd55952e3e79856a4a641a9f18")
       (:PMID . "9731057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "15811950") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_99367253e497ce94bbd253ef80a68356")
       (:PMID . "11986622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b90f6415975ed5c77c2943071a14e4d1")
       (:PMID . "12750173") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "9694850") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b28dd6ed51ca2be7ee4ca90572ae26c3")
       (:PMID . "18799465") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11948414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_95548735be79318b671115c13dcf5d38")
       (:PMID . "11118451") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "17272394") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5d847e70ff41a69e7fc0702c6324d3d5")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "12932319") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "19933846") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_28701271faa47b62c6e1a5ab64d583ab")
       (:PMID . "10746662") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_eb52fb020a0201f203a06b24d7e30f79")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_eb52fb020a0201f203a06b24d7e30f79")
       (:PMID . "19219045") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d022b8f4cdd9670a5e03498c3554a87c")
       (:PMID . "7559390") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_56a8c0efd3715dd4a60b2dac83999575")
       (:PMID . "15851026") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_68cdbf357ccd3d8eb1f5618d5c458a1e")
       (:PMID . "11704645") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "226") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842")) (:NAME . "MAP2K2"))
     (:TYPE . "Phosphorylation")
     (:ID . "217d4f12-e5aa-4170-87bf-b8e84d8837ba"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "GSK-3beta") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE
      ((:TEXT
        . "If MEK1/2 could phosphorylate GSK-3beta, GSK-3beta molecules should be physically associated with MEK1/2.")
       (:PMID . "15020233") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "If MEK1/2 could phosphorylate GSK-3beta, GSK-3beta molecules should be physically associated with MEK1/2.")
       (:PMID . "15020233") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "226") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAP2K2") (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:TYPE . "Phosphorylation")
     (:ID . "0579f6e8-1c52-4b5f-81cc-7b355c55cf67"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "6972a59d-f263-492b-b508-77c9425eb9d1")
     (:EVIDENCE
      ((:TEXT
        . "Upon activation, Raf-1 phosphorylates mitogen activated protein kinase kinase (MEK), which in turn activates mitogen activated protein kinase and extracellular signal regulated kinases (MAPK and ERKs), leading to the propagation of signals.")
       (:PMID . "11427728") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "MEK1/2 kinases phosphorylate and activate the mitogen activated protein kinases (MAPKs) ERK1/2.")
       (:PMID . "24269383") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In response to mitogenic stimuli, ERK1/2 MAP kinases are activated through dual phosphorylation by MEK.")
       (:PMID . "12049732") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "MEK1/2 phosphorylates MAPK on both a threonine and a tyrosine residue.")
       (:PMID . "15763428") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "226") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAP2K2") (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:TYPE . "Phosphorylation")
     (:ID . "dde1f4d3-82e9-4e33-bb96-edd001f1d03a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "2eeeaba3-098c-44b3-866d-94e607e66258"
      "4e6f41b6-a544-4835-8386-d3b40d048871"
      "c4de9bbf-3087-4235-82a1-663bdb028b62"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7528668") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7568001") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7719938") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7719937") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7544001") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "10602027") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "12681450") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "9305919") (:SOURCE--API . "biopax")))
     (:POSITION . "727")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "226") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842")) (:NAME . "MAP2K2"))
     (:TYPE . "Phosphorylation")
     (:ID . "5af517ca-c5b5-44f4-bc48-4646f430b27f"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "1f9e903b-b337-4022-b907-fc559bac1720"
      "06c47104-caec-4955-95d7-a4a4f2e26221"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7528668") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7568001") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7719938") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7719937") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "7544001") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "10602027") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "12681450") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_168fe9a8a6e26d011bc2d9f1158afdab")
       (:PMID . "9305919") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "222") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "226") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842")) (:NAME . "MAP2K2"))
     (:TYPE . "Phosphorylation")
     (:ID . "ae15d31a-72d9-40ea-b692-7fb675c15c7d"))
    ((:SUB (:DB--REFS (:+UP+ . "P19419") (:+HGNC+ . "3321")) (:NAME . "ELK1"))
     (:SUPPORTED--BY "598742e8-6de0-45c8-9920-8e2e07e67732"
      "71e84804-8b59-4792-85c9-69e7caa8f847")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e0f4c2feb057f26919f1fe84358f35d4")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b7341faa43f9c9c4416f687afde88839")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876")) (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "1095e819-f6af-4e7e-8977-f088eeded995"))
    ((:SUB (:DB--REFS (:+UP+ . "P05412") (:+HGNC+ . "6204")) (:NAME . "JUN"))
     (:SUPPORTED--BY "06475688-c620-4857-8fa4-1d73a4521960"
      "3608e672-d219-4c90-b8b4-b2e0ef374777")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_da07d4334b443d6481cd6294ead93b93")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876")) (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "d6962f3f-f571-4d37-8957-f78d88ec29b3"))
    ((:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "c09ac993-bac3-496d-bf9e-82806d99d05e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f7930a7625b80e589f5aef03c685282e")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876")) (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "2e5b555b-1caf-4222-9171-bebcc5501593"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "Inhibition of the p38 MAPK did not reverse hormone mediated reduction of AKT phosphorylation, suggesting that PP2A activity on AKT is independent of the p38 MAPK pathway (not shown).")
       (:PMID . "20005908") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "P-cadherin prolonged activation of the mitogen activated protein kinase (MAPK) in both cell lines and also increased the magnitude of AKT phosphorylation in dysplastic cells.")
       (:PMID . "25322858") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, phosphorylation of Akt is abolished by inhibitors of ERK1/2 (PD98059) and p38 MAPK (SB203580).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in XREF_FIG, the addition of tumor conditioned medium from vector-ARP-1, but not p38 shRNA-ARP-1 cells, upregulated the phosphorylation of IkappaBalpha, p38, ERK1/2 and Akt, and slightly decreased the phosphorylation of JNK during osteoclast differentiation.")
       (:PMID . "23066034") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistic studies showed that biological effects of IP6 were associated with inhibition of both constitutive and ligand induced Akt phosphorylation together with a decrease in total Akt levels, but a differential inhibitory effect on MAPKs ERK1/2, JNK1/2 and p38 under constitutive and ligand activated conditions.")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Hsp27 also inhibits apoptosis in stressed cells, by regulating upstream signaling pathways such as Akt activation by forming a signaling complex with p38MAPK and MAPKAP-2, a kinase that phosphorylates Akt (XREF_BIBR - XREF_BIBR).")
       (:PMID . "20858736") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "75e4c56e-c013-484f-8193-71ab93a55f51"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "Inhibition of the p38 MAPK did not reverse hormone mediated reduction of AKT phosphorylation, suggesting that PP2A activity on AKT is independent of the p38 MAPK pathway (not shown).")
       (:PMID . "20005908") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "P-cadherin prolonged activation of the mitogen activated protein kinase (MAPK) in both cell lines and also increased the magnitude of AKT phosphorylation in dysplastic cells.")
       (:PMID . "25322858") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Hsp27 also inhibits apoptosis in stressed cells, by regulating upstream signaling pathways such as Akt activation by forming a signaling complex with p38MAPK and MAPKAP-2, a kinase that phosphorylates Akt (XREF_BIBR - XREF_BIBR).")
       (:PMID . "20858736") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Mechanistic studies showed that biological effects of IP6 were associated with inhibition of both constitutive and ligand induced Akt phosphorylation together with a decrease in total Akt levels, but a differential inhibitory effect on MAPKs ERK1/2, JNK1/2 and p38 under constitutive and ligand activated conditions.")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, phosphorylation of Akt is abolished by inhibitors of ERK1/2 (PD98059) and p38 MAPK (SB203580).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in XREF_FIG, the addition of tumor conditioned medium from vector-ARP-1, but not p38 shRNA-ARP-1 cells, upregulated the phosphorylation of IkappaBalpha, p38, ERK1/2 and Akt, and slightly decreased the phosphorylation of JNK during osteoclast differentiation.")
       (:PMID . "23066034") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "b8ff0fb8-c296-44c5-a568-f5f8d6ba5f73"))
    ((:SUB (:DB--REFS (:+TEXT+ . "EGFR") (:+UP+ . "P00533") (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:SUPPORTED--BY "f58436a8-9b1e-4230-89e4-82e1da7e1a96")
     (:EVIDENCE
      ((:TEXT
        . "p38 MAPK induces the phosphorylation of EGFR at Ser1046/7 that results in its degradation.")
       (:PMID . "19138820") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results indicated that the mobility shift of EGFR was not due to autophosphorylation or ubiquitylation.Next, we examined whether ERK or p38 MAP kinase directly phosphorylated EGFR to induce the mobility shift after TNFalpha treatment.")
       (:PMID . "23220022") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These results strongly suggest that the anisomycin induced phosphorylation of EGFR at Ser1046/7 was mediated through p38 MAPK.The present study provides the first evidence that p38 MAPK induces the phosphorylation of EGFR at Ser1046/7, a site which is important for its downregulation.")
       (:PMID . "19138820") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Therefore, the finding that p38 MAPK activation in addition to CaM kinase II caused EGFR phosphorylation at Ser1046/7 and its subsequent downregulation introduces a new therapeutic strategy to counter cancer cells that strongly express EGFR including colon, lung, pancreas and breast.")
       (:PMID . "19138820") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Small interference RNA silencing of E-cadherin resulted in loss of E-cadherin-mediated junctions, enhanced phosphorylation of epidermal growth factor receptor (EGFR), and the downstream targets MEK/ERK-1/2 and p38 MAPK, finally resulting in up-regulation of TARC as well as thymic stromal lymphopoietin expression.")
       (:PMID . "17548604") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "P38 is a key regulator of EGFR and can phosphorylate EGFR at Ser 1046/1047, which is closely linked to internalization of the receptor (Nishimura et al, XREF_BIBR).")
       (:PMID . "22649008") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "932a8de9-41ab-4e93-96f3-73bdd301b727"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P19419") (:+HGNC+ . "3321")) (:NAME . "ELK1"))
     (:SUPPORTED--BY "598742e8-6de0-45c8-9920-8e2e07e67732"
      "48fcffac-ca4d-4510-bfc6-4df168eb9153"
      "71e84804-8b59-4792-85c9-69e7caa8f847")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK14_DirectlyIncreases_p_HGNC_ELK1_pmod_P_S_383")
       (:TEXT . "9130707;8548291;8262053;11145955;11309409;8887554")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_85701a3ba9d77dbb0150fa6760238c5f")
       (:SOURCE--API . "biopax")))
     (:POSITION . "383")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876")) (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "56f067ee-cff2-4958-8541-06ebbbd01ee4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P03372") (:+HGNC+ . "3467")) (:NAME . "ESR1"))
     (:SUPPORTED--BY "2b67ddc1-e6ab-4bf8-89a4-e5e17f42469d"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "3e056022-b0df-4181-b89c-fd2f3c8d4c90")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4a644a09c837a31034f33ceb4f0918b7")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Phosphorylation of ERalpha at S118 by MAPK increased steroid receptor coactivator 3 (SRC3) binding () and induced ERalpha hypersensitivity to E2 ().")
       (:PMID . "25597633") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:POSITION . "118")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876")) (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "de36689d-5af1-456a-b646-72886dc7deeb"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "ER") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d"
      "627b0e27-111e-456a-acc7-2ffeb1ba19a4"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf")
     (:EVIDENCE
      ((:TEXT
        . "Both AKT and the kinase downstream of mitogen activated protein kinase, p90 ribosomal S6 kinase (pp90Rsk), can also phosphorylate ER at Ser167.")
       (:PMID . "25283475") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "MAPK also indirectly phosphorylates ERalpha at serine 167 via p90rsk.")
       (:PMID . "23265704") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Both AKT and the kinase downstream of mitogen activated protein kinase, p90 ribosomal S6 kinase (pp90Rsk), can also phosphorylate ER at Ser167.")
       (:PMID . "25283475") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "cdc6daed-a492-41d6-ad93-2bcfd58c020e"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:SUPPORTED--BY "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:TEXT
        . "Akt and p38 phosphorylate the glycogen synthase kinase 3 (GSK3), which switches the transcription from the pro inflammatory NF-kappaB to the anti-inflammatory CREB activation XREF_BIBR.")
       (:PMID . "24489729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The un phosphorylated form of GSK3 promotes NF-kappaB activation, while phosphorylation of GSK3 by p38 and Akt promotes CREB anti-inflammatory activation.")
       (:PMID . "24489729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While Akt, inhibits both GSK3alpha and GSK3beta, p38 MAPK does not phosphorylate GSK3alpha (ref.")
       (:PMID . "26822034") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While Akt, inhibits both GSK3alpha and GSK3beta, p38 MAPK does not phosphorylate GSK3alpha (ref.")
       (:PMID . "26822034") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "GSK3 is constitutively active in resting cells leading to the pro inflammatory NF-kappaB transcription, but p38 and Akt phosphorylation of GSK3 switches the transcriptional activity to cAMP response element binding protein (CREB) XREF_BIBR.")
       (:PMID . "24489729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While Akt, inhibits both GSK3alpha and GSK3beta, p38 MAPK does not phosphorylate GSK3alpha (ref")
       (:PMID . "26822034") (:SOURCE--API . "sparser")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "a2243978-4c60-47c4-9d10-e9a52d38ff0a"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "cf68e083-7ad2-430f-ad2f-e8548c3c17fa"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE
      ((:TEXT
        . "GSK3 can also be phosphorylated at Ser and Ser by the most downstream kinase of the classical mitogen activated protein kinase (MAPK) cascade, called MAPK activated protein kinase-1 (MAPKAP-K1, also called RSK).")
       (:PMID . "18602000") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "6aca0731-bff4-449b-99f3-63e9af105755"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "c-Jun") (:+UP+ . "P05412") (:+HGNC+ . "6204"))
      (:NAME . "JUN"))
     (:SUPPORTED--BY "5dca9682-4d81-4402-b437-e2e78195930b"
      "06475688-c620-4857-8fa4-1d73a4521960"
      "1823585d-8fd6-4103-bba5-83bbe21683b9")
     (:EVIDENCE
      ((:TEXT
        . "Results shown in A demonstrated that, upon activation of the T-cell synapse, p38 dependent phosphorylation of c-Jun on Ser 63 and Ser 73 occurred in both CD4 and CD8 T-cells to a similar extent.")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in A, the p38 MAPK specifically phosphorylated c-Jun on Ser 63 and on Ser 73 whereas the retinoblastoma protein (pRb) was not phosphorylated by p38 (B, unspecific control).")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Here we show that p38 MAPK, like JNK1/2, efficiently phosphorylates c-Jun at Ser 63 and Ser 73 and thus modulates the transcriptional activity of AP-1.")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "63")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "f6afeedb-b792-4744-863e-73ef0997bdb8"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "c-Jun") (:+UP+ . "P05412") (:+HGNC+ . "6204"))
      (:NAME . "JUN"))
     (:SUPPORTED--BY "8d998659-f330-4e86-8156-882f5ea1f3b6"
      "177c5dcc-16be-4287-aaf0-cca0687a040d"
      "06475688-c620-4857-8fa4-1d73a4521960")
     (:EVIDENCE
      ((:TEXT
        . "Results shown in A demonstrated that, upon activation of the T-cell synapse, p38 dependent phosphorylation of c-Jun on Ser 63 and Ser 73 occurred in both CD4 and CD8 T-cells to a similar extent.")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Here we show that p38 MAPK, like JNK1/2, efficiently phosphorylates c-Jun at Ser 63 and Ser 73 and thus modulates the transcriptional activity of AP-1.")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in A, the p38 MAPK specifically phosphorylated c-Jun on Ser 63 and on Ser 73 whereas the retinoblastoma protein (pRb) was not phosphorylated by p38 (B, unspecific control).")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "73")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "17bcb879-aace-4225-bfe1-8bd15bd33972"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "57c58b95-ca95-474d-bbc0-7305a445e404"
      "43bd8290-b167-44fb-9a15-f3c5eb25d0b7"
      "041d1727-e16f-47d7-b9e1-125ded56918d"
      "6972a59d-f263-492b-b508-77c9425eb9d1")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "180")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876")) (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "18ef3ba9-9e06-493f-bcfd-7f7586ac4a2f"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "DLK expression (MOI of 50) induced phosphorylation of ERK and JNK MAPKs but not p38 ().")
       (:PMID . "19675578") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "A mitogen activated protein kinase kinase 1/2 inhibitor inhibited both renin and prorenin induced ERK 1/2 phosphorylation.")
       (:PMID . "18212269") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p38 MAPKalpha siRNA transfection did not affect the inhibition of FAK-Y397 phosphorylation by pressure but prevented inhibition of ERK phosphorylation.")
       (:PMID . "15625302") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in XREF_FIG, the addition of tumor conditioned medium from vector-ARP-1, but not p38 shRNA-ARP-1 cells, upregulated the phosphorylation of IkappaBalpha, p38, ERK1/2 and Akt, and slightly decreased the phosphorylation of JNK during osteoclast differentiation.")
       (:PMID . "23066034") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The ERK specific inhibitor U0126 and the p38 specific inhibitor SB202190 blocked ERK and p38 phosphorylation, but did not prevent PA induced LC3-II accumulation (XREF_SUPPLEMENTARY and XREF_SUPPLEMENTARY).")
       (:PMID . "24608675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We therefore examined whether inhibition of p38 MAPK activity by SB203580 abolishes p38 MAPK phosphorylation induced by HO.")
       (:PMID . "24780446") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "EC silencing of integrin beta4 (siITGB4) resulted in significant increases in both basal and LPS induced phosphorylation of ERK 1/2, JNK, and p38 MAPK, consistent with robust MAPK activation.")
       (:PMID . "20512931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, stimulatory phosphorylations of ERK and c-Jun N-terminal protein kinase (JNK), but not p38 MAPK, have been observed in human erythroleukemia (HEL) cells upon activation of hIP.")
       (:PMID . "18755267") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The p38 MAPK specific inhibitor SB203580 (1muM) had no effect on hypoxia induced ERK 1/2 phosphorylation ().")
       (:PMID . "12200131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "HBEC stimulation with AA resulted in sustained p38-MAPK activation and subsequent phosphorylation of mitogen activated protein kinase activated protein-2 (MAPKAP-2) kinase and heat shock protein-27 (Hsp27).")
       (:PMID . "24802256") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Using conditions in vitro under which two proline directed protein kinases, glycogen synthase kinase-3beta (GSK-3beta) and mitogen activated protein kinase (MAPK), were able to hyperphosphorylate tau, GSK-3beta but not MAPK phosphorylated recombinant APPcyt.")
       (:PMID . "8764598") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Silencing of integrin beta4 (siITGB4) in human lung EC resulted in significant increases in both basal and LPS induced phosphorylation of ERK 1/2, JNK, and p38 MAPK, consistent with robust integrin beta4 regulation of MAPK activation.")
       (:PMID . "20512931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The phosphorylation of JNK and ERK, but not p38, was significantly induced by knockdown of NAPA in HEK293 cells (A, compare lanes 5 and 1).")
       (:PMID . "21903092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Further, p38 MAPK inhibition promoted ERK1/2 phosphorylation, providing additional evidence for cross-talk between MAPK pathways.")
       (:PMID . "15247230") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In fact, independently from the effects elicited by melatonin, p38 MAPK inhibition by SB produced an enhanced ERK phosphorylation, but the pharmacological inhibition of ERK 1/2 did not influence the UVB induced activation of p38 MAPK.")
       (:PMID . "18930812") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of p38 increased ERK and Rsk phosphorylation at all residues (presumably due to loss of negative feedback).")
       (:PMID . "23901045") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Tyrosine phosphorylation of MEKK4 correlates with its activity to phosphorylate MKK6 (MAPK kinase 6) in vitro and subsequent p38 MAPK activation in an IFNgamma dependent manner.")
       (:PMID . "15601262") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These findings showed that the phosphorylation of ERK induced by cicaprost was specifically attenuated by its upstream kinase inhibitors, but not by inhibitors of JNK and p38 MAPK.")
       (:PMID . "15979846") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Regarding the effect of IP6 on MAPKs ERK1/2, JNK1/2 and p38, EGF and IGF-1 treatment strongly induced the phosphorylation of ERK1/2 in starved cells which was almost completely inhibited by co-treatment with IP6 without any effect on total ERK1/2 protein levels (XREF_FIG).")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "63bd95ca-8ee4-4fc6-b5f2-ce505d459868"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Inhibition of p38 increased ERK and Rsk phosphorylation at all residues (presumably due to loss of negative feedback).")
       (:PMID . "23901045") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In fact, independently from the effects elicited by melatonin, p38 MAPK inhibition by SB produced an enhanced ERK phosphorylation, but the pharmacological inhibition of ERK 1/2 did not influence the UVB induced activation of p38 MAPK.")
       (:PMID . "18930812") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, stimulatory phosphorylations of ERK and c-Jun N-terminal protein kinase (JNK), but not p38 MAPK, have been observed in human erythroleukemia (HEL) cells upon activation of hIP.")
       (:PMID . "18755267") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The ERK specific inhibitor U0126 and the p38 specific inhibitor SB202190 blocked ERK and p38 phosphorylation, but did not prevent PA induced LC3-II accumulation (XREF_SUPPLEMENTARY and XREF_SUPPLEMENTARY).")
       (:PMID . "24608675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "EC silencing of integrin beta4 (siITGB4) resulted in significant increases in both basal and LPS induced phosphorylation of ERK 1/2, JNK, and p38 MAPK, consistent with robust MAPK activation.")
       (:PMID . "20512931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We therefore examined whether inhibition of p38 MAPK activity by SB203580 abolishes p38 MAPK phosphorylation induced by HO.")
       (:PMID . "24780446") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "A mitogen activated protein kinase kinase 1/2 inhibitor inhibited both renin and prorenin induced ERK 1/2 phosphorylation.")
       (:PMID . "18212269") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Using conditions in vitro under which two proline directed protein kinases, glycogen synthase kinase-3beta (GSK-3beta) and mitogen activated protein kinase (MAPK), were able to hyperphosphorylate tau, GSK-3beta but not MAPK phosphorylated recombinant APPcyt.")
       (:PMID . "8764598") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in XREF_FIG, the addition of tumor conditioned medium from vector-ARP-1, but not p38 shRNA-ARP-1 cells, upregulated the phosphorylation of IkappaBalpha, p38, ERK1/2 and Akt, and slightly decreased the phosphorylation of JNK during osteoclast differentiation.")
       (:PMID . "23066034") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Under such conditions Elk-1 could be phosphorylated by the mitogen activated protein kinases (MAPKs) ERK1 and ERK2.")
       (:PMID . "8846788") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Regarding the effect of IP6 on MAPKs ERK1/2, JNK1/2 and p38, EGF and IGF-1 treatment strongly induced the phosphorylation of ERK1/2 in starved cells which was almost completely inhibited by co-treatment with IP6 without any effect on total ERK1/2 protein levels (XREF_FIG).")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "DLK expression (MOI of 50) induced phosphorylation of ERK and JNK MAPKs but not p38 ().")
       (:PMID . "19675578") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These findings showed that the phosphorylation of ERK induced by cicaprost was specifically attenuated by its upstream kinase inhibitors, but not by inhibitors of JNK and p38 MAPK.")
       (:PMID . "15979846") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Further, p38 MAPK inhibition promoted ERK1/2 phosphorylation, providing additional evidence for cross-talk between MAPK pathways.")
       (:PMID . "15247230") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The p38 MAPK specific inhibitor SB203580 (1muM) had no effect on hypoxia induced ERK 1/2 phosphorylation ().")
       (:PMID . "12200131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Tyrosine phosphorylation of MEKK4 correlates with its activity to phosphorylate MKK6 (MAPK kinase 6) in vitro and subsequent p38 MAPK activation in an IFNgamma dependent manner.")
       (:PMID . "15601262") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "p38 MAPKalpha siRNA transfection did not affect the inhibition of FAK-Y397 phosphorylation by pressure but prevented inhibition of ERK phosphorylation.")
       (:PMID . "15625302") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "HBEC stimulation with AA resulted in sustained p38-MAPK activation and subsequent phosphorylation of mitogen activated protein kinase activated protein-2 (MAPKAP-2) kinase and heat shock protein-27 (Hsp27).")
       (:PMID . "24802256") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The phosphorylation of JNK and ERK, but not p38, was significantly induced by knockdown of NAPA in HEK293 cells (A, compare lanes 5 and 1).")
       (:PMID . "21903092") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Silencing of integrin beta4 (siITGB4) in human lung EC resulted in significant increases in both basal and LPS induced phosphorylation of ERK 1/2, JNK, and p38 MAPK, consistent with robust integrin beta4 regulation of MAPK activation.")
       (:PMID . "20512931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "dca275ee-654a-4e32-913d-1bb77699d201"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "Smad3") (:+UP+ . "P84022") (:+HGNC+ . "6769"))
      (:NAME . "SMAD3"))
     (:SUPPORTED--BY "ec699d53-2669-4c6a-b9ba-7c3f373c1114")
     (:EVIDENCE
      ((:TEXT
        . "ERK1/2, JNK, and p38 MAPKs can activate or inhibit the Smad signaling pathway by phosphorylating Smad2 or Smad3 XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR.")
       (:PMID . "23468994") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Finally, we show that Smad3 is phosphorylated by p38 MAP kinase in vitro.")
       (:PMID . "12894225") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, Smad3 phosphorylation mediated by the activated TbetaRI was impaired severely in MFBs during chronic liver injury, whereas Smad3 phosphorylation at the linker region was remarkably induced by p38 MAPK pathway.")
       (:PMID . "14512875") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The middle linker regions of Smad2 and Smad3 also are phosphorylated by mitogen activated protein kinase (MAPK).")
       (:PMID . "14512875") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "fd7e4b58-eeef-4b8b-be30-612825a99dfd"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "277dbf12-39c0-405f-a70c-9ff3fa05b8d9"
      "2eeeaba3-098c-44b3-866d-94e607e66258"
      "b715bfbf-7b86-4a74-b967-1c4b6a8b9b9c"
      "c4de9bbf-3087-4235-82a1-663bdb028b62")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9283d4bde1df9b4de2bccf1c03c0dbbb")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "We provide in vitro and in vivo evidence that the ERK family of mitogen activated protein (MAP) kinases, but not JNK or p38, specifically phosphorylate STAT3 at serine 727 in response to growth factors.")
       (:PMID . "9343414") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "727")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876")) (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "606e0817-7df8-4e75-96c4-bb44fe7929a3"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "p53") (:+UP+ . "P04637") (:+HGNC+ . "11998"))
      (:NAME . "TP53"))
     (:SUPPORTED--BY "309f1cb3-3783-42ed-a812-eb591d03cc00"
      "bfaf3643-935b-4d40-96a6-8e54bb1a8acf"
      "93868e97-7891-4417-96b7-aa7453443998"
      "70e42712-3f69-42b0-8374-2b5d5223b7ef"
      "b85dad36-eacc-45da-b53a-6be061735c1c"
      "2aa97a6f-c471-47e7-9843-bbb85fda3dae"
      "5f37d83c-f134-43a1-81a0-29f3f2a889f7")
     (:EVIDENCE
      ((:TEXT
        . "In these cells, UVB triggered a p38 dependent phosphorylation of p53 on Ser 15.")
       (:PMID . "12071847") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In vitro, recombinant p38 MAPK can phosphorylate recombinant p53 protein on S15 and S46.")
       (:PMID . "15865925") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In these cells, UVB triggered a p38 dependent phosphorylation of p53 on Ser 15.")
       (:PMID . "12071847") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In vitro, recombinant p38 MAPK can phosphorylate recombinant p53 protein on S15 and S46.")
       (:PMID . "15865925") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_61244c4d54febf6bb56e637ea16d0881")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "As a side observation, p38 MAPK also phosphorylated p53 on S15 (XREF_FIG C), but this reaction is likely to play a minor role in vivo, given that p38 MAPK inhibition alone did not reduce p53S15P and only became effective when the principal p53S15 kinase operating in this system, mTOR (XREF_BIBR, XREF_BIBR), was also inhibited (XREF_FIG E).")
       (:PMID . "15642743") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "15")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "7bde7a2b-f879-4594-bfb5-7bcbae26ebe4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:SUPPORTED--BY "93868e97-7891-4417-96b7-aa7453443998"
      "5f37d83c-f134-43a1-81a0-29f3f2a889f7"
      "b8bc330a-62ff-4ce0-b424-744c7ab53ce4"
      "cbb80191-24c2-4004-b7dd-ed9b00c31a60"
      "8f6c9dd8-b103-4d5d-87ad-ea345f9596cb"
      "85c48380-c902-4629-8e1a-b740069b21cd")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_882ceb51b84a59639786d80fea900505")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "As shown above, specific inhibition of p38 MAPK by SB203580, used at a concentration of 100 nM, fully prevents the apoptogenic phosphorylation of p53 on S46 in HeLa Env-CD4 syncytia.")
       (:PMID . "15642743") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It appears plausible that p38 phosphorylates p53 in a direct fashion because both proteins colocalized and coimmunoprecipitated in Env elicited syncytia (XREF_FIG) and because recombinant p38 MAPK phosphorylated recombinant p53 on S46 in vitro (XREF_FIG C).")
       (:PMID . "15642743") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The phosphorylated p38 can in turn phosphorylate p53 on Ser 33 and Ser 46 and increase p53 activity.")
       (:PMID . "15327777") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In vitro, recombinant p38 MAPK can phosphorylate recombinant p53 protein on S15 and S46.")
       (:PMID . "15865925") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In vitro, recombinant p38 MAPK can phosphorylate recombinant p53 protein on S15 and S46.")
       (:PMID . "15865925") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Recombinant p38 phosphorylated recombinant p53 on serine 46 in vitro.")
       (:PMID . "15642743") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Among the kinases targeting p53, p38 MAP kinase phosphorylates p53 at Ser33 and Ser46.")
       (:PMID . "15327777") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "46")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q16539") (:+HGNC+ . "6876")) (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "0fbdee37-1017-402a-97e9-bb1e3a4cc06f"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "TSC-2") (:+NCIT+ . "C17913") (:+UP+ . "P49815")
       (:+HGNC+ . "12363"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef")
     (:EVIDENCE
      ((:TEXT
        . "Active MAP kinase can inhibit the TSC1 and TSC2 complex by specifically phosphorylating TSC2, or indirectly through activation of RSK, and thereby activating mTOR1 (;).")
       (:PMID . "26763419") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Similarly, Ras induced activation of phosphatidylinositol 3 '-kinase/Akt () and ribosomal S6 kinase would be predicted to inactivate TSC2 (), resulting in activation of Rheb and mTOR.Interestingly, B-Raf activation should also theoretically result in mTOR activation, because p42 mitogen activated protein kinase, which is a downstream effector of B-Raf, directly phosphorylates and inactivates TSC2 ().")
       (:PMID . "17914450") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3.")
       (:PMID . "12582162") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activation of the phosphoinositide-3-kinase (PI3K)/Akt or Ras and mitogen activated protein kinase (MAPK) pathway by growth factors leads to TSC2 phosphorylation and inhibition of the TSC protein complex by Akt, extracellular signal regulated kinase (ERK), and p90 ribosomal S6 kinase 1 (RSK1) kinases (XREF_FIG).")
       (:PMID . "19276265") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "180") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "182") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:TYPE . "Phosphorylation")
     (:ID . "d7a7bef9-8066-43d4-a889-490d870b3057"))
    ((:SUB (:DB--REFS (:+UP+ . "P05412") (:+HGNC+ . "6204")) (:NAME . "JUN"))
     (:SUPPORTED--BY "06475688-c620-4857-8fa4-1d73a4521960"
      "63038ffe-0a81-457a-b85e-3548809724a8")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_27bbf47d1fcf0299a0435aad5390d3e2")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_568a5e821897e687202e4d679940179a")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a82f691a-f365-40de-b049-2b4353430344"))
    ((:SUB (:DB--REFS (:+UP+ . "P01106") (:+HGNC+ . "7553")) (:NAME . "MYC"))
     (:SUPPORTED--BY "2a130ba1-188a-4615-9842-6c35b12675c5"
      "38703b38-0493-4cca-8277-a0769e63d416")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a432457a7080cf28bfabc4890175d3db")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_18d6517dec7423319b27a69767cc546a")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "eaf7d206-e32a-42e7-b765-66a675b5b16c"))
    ((:SUB (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "b46bd837-c9ed-40c5-814a-d2e848f35da3"
      "c0bb5098-c401-413b-a03f-778dfef70afd")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3f2496a8795ee1f689f050baa5619a1c")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9b771bc8b872011ec7b0dac648f52df9")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "f2396a4f-47f0-41ec-877f-c79073fe4f92"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "77dd0129-eaec-4dc0-b3fb-2c05328ec75f"
      "05e88bd6-921f-4b71-a3df-f4281e42d1c2"
      "d5d0707a-a034-4a72-a3d3-a3d69c2b8962")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d6f38ec1ef74e46fdcb92077484cfa01")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2b6110c9d65e5c3c7f6df88377dce51b")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d4ea9f4ed81034b49579a6a98893bb6b")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "151")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "2e81fb6d-3995-4306-b8d7-a7661f0488e9"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "77dd0129-eaec-4dc0-b3fb-2c05328ec75f"
      "d5d0707a-a034-4a72-a3d3-a3d69c2b8962"
      "05e88bd6-921f-4b71-a3df-f4281e42d1c2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d6f38ec1ef74e46fdcb92077484cfa01")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d4ea9f4ed81034b49579a6a98893bb6b")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2b6110c9d65e5c3c7f6df88377dce51b")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "750")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "b68022da-4b54-4af2-8efd-8994b8c7a9fd"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "05e88bd6-921f-4b71-a3df-f4281e42d1c2"
      "b2ecbd0a-351c-43bc-8765-ace4c850bcb5"
      "77dd0129-eaec-4dc0-b3fb-2c05328ec75f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d6f38ec1ef74e46fdcb92077484cfa01")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d4ea9f4ed81034b49579a6a98893bb6b")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2b6110c9d65e5c3c7f6df88377dce51b")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "401")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "93b926af-a449-476c-9431-b231f3481330"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "f0bb1c77-848f-4cec-b234-3f4d7c1cbaaa"
      "77dd0129-eaec-4dc0-b3fb-2c05328ec75f"
      "05e88bd6-921f-4b71-a3df-f4281e42d1c2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d4ea9f4ed81034b49579a6a98893bb6b")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d6f38ec1ef74e46fdcb92077484cfa01")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2b6110c9d65e5c3c7f6df88377dce51b")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "753")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "73407801-916b-410e-b82e-145a375b68e2"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P19419") (:+HGNC+ . "3321")) (:NAME . "ELK1"))
     (:SUPPORTED--BY "f6c48844-2ae1-44fa-b808-fb1bf240f7bc"
      "48fcffac-ca4d-4510-bfc6-4df168eb9153"
      "022e431f-d19c-47ca-a338-fe896a029e20"
      "872d2dc1-d7ac-4ecd-b334-46e3a8902aad"
      "71e84804-8b59-4792-85c9-69e7caa8f847")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8464740d10bccbf8d83a14cdccaf307c")
       (:PMID . "7889942") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8386592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "10716983") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8007980") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "15014501") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8477450") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8262053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "18334532") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "7889942") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "8386592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "9927426") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "8262053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "7889942") (:SOURCE--API . "biopax")))
     (:POSITION . "383")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "787d3ddd-1060-4e8f-8736-488242333748"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P19419") (:+HGNC+ . "3321")) (:NAME . "ELK1"))
     (:SUPPORTED--BY "4762ca35-41f4-4d2b-8387-07713d7f551b"
      "71e84804-8b59-4792-85c9-69e7caa8f847"
      "e9faba78-3c33-4f35-a865-5d7587021262")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8464740d10bccbf8d83a14cdccaf307c")
       (:PMID . "7889942") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8386592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "10716983") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8007980") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "15014501") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8477450") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8262053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "18334532") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "7889942") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "8386592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "9927426") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "8262053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "7889942") (:SOURCE--API . "biopax")))
     (:POSITION . "389")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "f3f5e763-e4f7-4bc4-aa90-4e136d794a29"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "ca123c61-99a0-4c4c-8404-a847c1e6b074"
      "f8f3baac-0058-4563-90f3-2bcc2b431ae7"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "3b085760-047b-4de6-a358-6f53aa726e61"
      "2a8e70cd-59c0-460a-b61e-15f66e6254e6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e927859023a68c32fa12bc640a1d243")
       (:PMID . "14636584") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e927859023a68c32fa12bc640a1d243")
       (:PMID . "19272169") (:SOURCE--API . "biopax")))
     (:POSITION . "925")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "53baed11-0008-41f8-a955-7243fdebd927"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "11781878-54aa-4b12-9f73-29a604cc62e7"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "610d6757-2da0-498a-ab67-669aaaa24c77"
      "099d026e-8c87-450f-a08b-4bd7a2e368c6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad75aa814cdbfad81314a982573b2940")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e27ae9bc47f47001e3957c0487c24dd6")
       (:PMID . "16407412") (:SOURCE--API . "biopax")))
     (:POSITION . "338")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "ce24e180-a257-405b-8cd3-3d55ce455bc0"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "a4c02905-6eba-40d8-ac1a-09529665ba79"
      "610d6757-2da0-498a-ab67-669aaaa24c77")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e27ae9bc47f47001e3957c0487c24dd6")
       (:PMID . "16407412") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad75aa814cdbfad81314a982573b2940")
       (:SOURCE--API . "biopax")))
     (:POSITION . "621")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "f4188844-e5d5-4885-82b6-7dd7b7ed1c85"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "cb34d359-62b8-43ea-a877-a628088dd0f5"
      "550e7957-e09d-4845-ad8d-846e45603fec"
      "77fdd7db-0d3c-4483-afec-9e8c09d90673"
      "bddee8f5-87f6-41ed-9c32-d14a66eb008e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "221")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "86ed6c0b-ecdf-43b9-88f3-e75c616314fc"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "7bb4f60a-7d53-4fb7-8d3d-bff76b637458"
      "20d4e46b-3743-40ae-a53d-8a9d1a197592"
      "0be99bed-848c-426b-96f4-a4ec31dfce17"
      "550e7957-e09d-4845-ad8d-846e45603fec"
      "589ab28f-ea90-40ea-aa57-d387a0417f3c")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0465b2910b9ef1d8cca1810ba3b8fafb")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad1ffafb51ddab8c00a9fc6c5f5ba335")
       (:PMID . "14966081") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "363")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "c357155d-c709-465c-88c9-d69ec1870165"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "550e7957-e09d-4845-ad8d-846e45603fec"
      "942dcf7c-77dd-48d3-82f9-8d20c9cb4660"
      "10ea9f34-37e2-4440-91c8-40161f9e75b3")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0465b2910b9ef1d8cca1810ba3b8fafb")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7b1d30a602c2f5ef98b93e26346180c3")
       (:PMID . "11532940") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7b1d30a602c2f5ef98b93e26346180c3")
       (:PMID . "11335727") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax")))
     (:POSITION . "380")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "23b25721-4820-4865-b699-4d16c2df70f4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "14f068bc-3cf7-4650-837b-7274c27a9b21"
      "550e7957-e09d-4845-ad8d-846e45603fec"
      "71638fd3-67ca-44ae-87c8-1774b13354f4")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax")))
     (:POSITION . "732")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "7721e9aa-6c85-49d9-8452-feb8ac9ce860"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "550e7957-e09d-4845-ad8d-846e45603fec"
      "7b7d0c19-a2bd-4e67-b3f2-6d46843c7ffc"
      "6a9558cc-22fd-4caa-b92c-da8776a18cb3"
      "2d8bb4c4-896f-4ede-9327-e5deedf3a5b2"
      "1d3d6f8f-2b9c-4e7d-988b-79feeef1dad4")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad1ffafb51ddab8c00a9fc6c5f5ba335")
       (:PMID . "14966081") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "359")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "78961c3d-5689-4c9b-872f-0a401dcbf03b"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "2e722255-2a8a-4c37-a0ba-143a407bef93"
      "ed408000-dc02-47e4-a7ff-12b6495ecc3e"
      "550e7957-e09d-4845-ad8d-846e45603fec"
      "fbf351e5-bc65-416d-b79b-444e788a1967"
      "a09ae21d-dad0-4e68-a88e-a4784e0c4fde")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0465b2910b9ef1d8cca1810ba3b8fafb")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "573")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "143a868a-c0b8-4bc7-9b8a-ed70f0646b0d"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15349") (:+HGNC+ . "10431"))
      (:NAME . "RPS6KA2"))
     (:SUPPORTED--BY "972a263b-0370-43b5-9943-24ed4b264b5e"
      "74a75103-2e3b-4ade-b1f4-8e2021cbc6ce"
      "16e10afb-8e63-45bb-9efd-25af86b188d8")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0465b2910b9ef1d8cca1810ba3b8fafb")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "360")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "9171d9f5-f957-4a9a-954d-63e175168e8b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15349") (:+HGNC+ . "10431"))
      (:NAME . "RPS6KA2"))
     (:SUPPORTED--BY "edd3826b-7de2-42c2-97ca-57069779e9cd"
      "972a263b-0370-43b5-9943-24ed4b264b5e"
      "b9b11092-750e-4ff5-a346-332c24abd95a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0465b2910b9ef1d8cca1810ba3b8fafb")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "377")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "2994a5ed-295e-4105-8954-5d29c70d7c94"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q15349") (:+HGNC+ . "10431"))
      (:NAME . "RPS6KA2"))
     (:SUPPORTED--BY "9b662bac-3e21-48fd-b6df-cae07ba9c0a3"
      "718a12a4-1877-4727-afc2-2b0d581c8d71"
      "972a263b-0370-43b5-9943-24ed4b264b5e"
      "e9f3ada4-aba0-4e0c-bbe9-8f34a793fc02")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0465b2910b9ef1d8cca1810ba3b8fafb")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "570")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "34cb7924-59e4-4e70-a5d3-b48102569a2f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:SUPPORTED--BY "dc866ea3-a450-4098-82e0-fd430923eb02"
      "f9dd2367-b3ae-4c13-9739-30f5da9108c4"
      "6af10ff1-80fb-4126-bf38-edfbb93706e4")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0465b2910b9ef1d8cca1810ba3b8fafb")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "12832467") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "10856237") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "18156174") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "369")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "dfc58731-3daa-41cf-835d-cc2756a77006"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:SUPPORTED--BY "24696717-1c37-415c-8fa1-c90ea9b750fd"
      "6751eedd-22e5-4577-9c89-fd0a36952123"
      "df7f909a-017b-41ff-a631-62d6d7c43089"
      "6af10ff1-80fb-4126-bf38-edfbb93706e4")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0465b2910b9ef1d8cca1810ba3b8fafb")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "386")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "6fbc740f-1a8e-4a1e-a79d-4dd28c01275d"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:SUPPORTED--BY "6af10ff1-80fb-4126-bf38-edfbb93706e4"
      "37686a31-0785-4344-b50a-0c1d21a5c150"
      "16f49b7d-06ac-480b-b3de-ae6050493f12"
      "0274f13d-1ac5-4007-9e76-2b77bb5358ac"
      "d00b8256-5557-4ad8-aec4-9c41162c352e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "12832467") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "10856237") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "18156174") (:SOURCE--API . "biopax")))
     (:POSITION . "529")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "85cfabd2-c7ad-4e0d-9ffc-821cb8e5992f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "c613960c-874c-4c8c-8838-78e03856498f"
      "2eeeaba3-098c-44b3-866d-94e607e66258"
      "c516bde3-32eb-4f7c-bb71-5ecc5af07218"
      "d59fef47-6be6-4ef3-a7d8-caa9f95cc655"
      "c4de9bbf-3087-4235-82a1-663bdb028b62"
      "00a762b5-2139-4fd5-9e17-9394c8b0f490")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0efc20911c11fe20e633fc2b26c10af8")
       (:PMID . "9343414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0efc20911c11fe20e633fc2b26c10af8")
       (:PMID . "11404481") (:SOURCE--API . "biopax")))
     (:POSITION . "727")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "889a3747-aebe-4d0b-96cc-5dafebb6e945"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activation of MAPK signalling ultimately leads to phosphorylation of the terminal kinase in the cascade, MAPK (p42/44 MAPK) whereas PI3K activation leads to the phosphorylation of PKB (XREF_BIBR).")
       (:PMID . "23778527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in Figure XREF_FIG, CMTM7 knockdown increased the phosphorylation of EGFR and AKT but not ERK.")
       (:PMID . "26528697") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that VEGF-A and VEGFR2 activation in LECs stimulates PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "EGCG induced Erk phosphorylation and activation of the Akt pathway was found to promote keratinocyte survival [XREF_BIBR].")
       (:PMID . "26130135") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In conclusion, we report an ERK 1,2 -dependent attenuation of Akt phosphorylation and activity in the response of human preadipose cells to angiotensin II.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, phosphorylation of Akt is abolished by inhibitors of ERK1/2 (PD98059) and p38 MAPK (SB203580).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Likewise, when bone marrow derived mesenchymal stems cells were stimulated to adipogenic differentiation and exposed to high glucose, an ERK 1,2 -dependent increase in Akt phosphorylation was reported XREF_BIBR.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, ERK mediates delayed phosphorylation of Akt and GSK3alpha and beta.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The downstream MAPK and PI3K activation of Rac1 will result in the phosphorylation of ERK1/2 and AKT respectively.")
       (:PMID . "18086571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, phosphorylation of P38MAPK and AKT, but not ERK1/2 or JNKs was specifically decreased in SGC7901 and DDP cells after ANXA2 siRNA delivery.")
       (:PMID . "25150310") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, as demonstrated in this study, the inhibition of ERK1/2 activity with its specific inhibitor PD98059 completely abolished 20-HETE-induced IRS-1 serine phosphorylation and restored the insulin sensitivity of IRS-1 tyrosine phosphorylation, Akt phosphorylation, and eNOS activity in the presence of 20-HETE.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistic studies showed that biological effects of IP6 were associated with inhibition of both constitutive and ligand induced Akt phosphorylation together with a decrease in total Akt levels, but a differential inhibitory effect on MAPKs ERK1/2, JNK1/2 and p38 under constitutive and ligand activated conditions.")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, an Akt nonphosphorylatable mutant (TSC2) was phosphorylated by Erk at levels comparable to the wild-type TSC2 (D).")
       (:PMID . "15851026") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To investigate further the downstream pathways involved in PDGF-BB stimulation of MSC proliferation, we assessed the alteration in phosphorylation of PDGFRbeta, SHP2, Akt and P44 and P42 MAPK in response to stimulation with PDGF-BB.")
       (:PMID . "22805337") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that VEGF-A stimulation of LECs leads to the phosphorylation of VEGFR2 (Tyr 951, 1054, 1059, 1175, and 1214) which subsequently triggers PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "P-cadherin prolonged activation of the mitogen activated protein kinase (MAPK) in both cell lines and also increased the magnitude of AKT phosphorylation in dysplastic cells.")
       (:PMID . "25322858") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mutp53 levels also proportionally modulate the activated downstream EGFR signaling pathways PI3K and MAPK, which phosphorylate AKT and ERK, respectively (XREF_FIG).")
       (:PMID . "25573952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "989118a4-f3b5-48e0-9831-07b6ee456b99"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "As shown in Figure XREF_FIG, CMTM7 knockdown increased the phosphorylation of EGFR and AKT but not ERK.")
       (:PMID . "26528697") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In conclusion, we report an ERK 1,2 -dependent attenuation of Akt phosphorylation and activity in the response of human preadipose cells to angiotensin II.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistic studies showed that biological effects of IP6 were associated with inhibition of both constitutive and ligand induced Akt phosphorylation together with a decrease in total Akt levels, but a differential inhibitory effect on MAPKs ERK1/2, JNK1/2 and p38 under constitutive and ligand activated conditions.")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mutp53 levels also proportionally modulate the activated downstream EGFR signaling pathways PI3K and MAPK, which phosphorylate AKT and ERK, respectively (XREF_FIG).")
       (:PMID . "25573952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, ERK mediates delayed phosphorylation of Akt and GSK3alpha and beta.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "EGCG induced Erk phosphorylation and activation of the Akt pathway was found to promote keratinocyte survival [XREF_BIBR].")
       (:PMID . "26130135") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activation of MAPK signalling ultimately leads to phosphorylation of the terminal kinase in the cascade, MAPK (p42/44 MAPK) whereas PI3K activation leads to the phosphorylation of PKB (XREF_BIBR).")
       (:PMID . "23778527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Likewise, when bone marrow derived mesenchymal stems cells were stimulated to adipogenic differentiation and exposed to high glucose, an ERK 1,2 -dependent increase in Akt phosphorylation was reported XREF_BIBR.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, phosphorylation of Akt is abolished by inhibitors of ERK1/2 (PD98059) and p38 MAPK (SB203580).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, as demonstrated in this study, the inhibition of ERK1/2 activity with its specific inhibitor PD98059 completely abolished 20-HETE-induced IRS-1 serine phosphorylation and restored the insulin sensitivity of IRS-1 tyrosine phosphorylation, Akt phosphorylation, and eNOS activity in the presence of 20-HETE.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To investigate further the downstream pathways involved in PDGF-BB stimulation of MSC proliferation, we assessed the alteration in phosphorylation of PDGFRbeta, SHP2, Akt and P44 and P42 MAPK in response to stimulation with PDGF-BB.")
       (:PMID . "22805337") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, phosphorylation of P38MAPK and AKT, but not ERK1/2 or JNKs was specifically decreased in SGC7901 and DDP cells after ANXA2 siRNA delivery.")
       (:PMID . "25150310") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, an Akt nonphosphorylatable mutant (TSC2) was phosphorylated by Erk at levels comparable to the wild-type TSC2 (D).")
       (:PMID . "15851026") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that VEGF-A stimulation of LECs leads to the phosphorylation of VEGFR2 (Tyr 951, 1054, 1059, 1175, and 1214) which subsequently triggers PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "P-cadherin prolonged activation of the mitogen activated protein kinase (MAPK) in both cell lines and also increased the magnitude of AKT phosphorylation in dysplastic cells.")
       (:PMID . "25322858") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We show that VEGF-A and VEGFR2 activation in LECs stimulates PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The downstream MAPK and PI3K activation of Rac1 will result in the phosphorylation of ERK1/2 and AKT respectively.")
       (:PMID . "18086571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "59177e93-6af1-4c70-bfc2-1cc2126b683f"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "EGCG induced Erk phosphorylation and activation of the Akt pathway was found to promote keratinocyte survival [XREF_BIBR].")
       (:PMID . "26130135") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Likewise, when bone marrow derived mesenchymal stems cells were stimulated to adipogenic differentiation and exposed to high glucose, an ERK 1,2 -dependent increase in Akt phosphorylation was reported XREF_BIBR.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mutp53 levels also proportionally modulate the activated downstream EGFR signaling pathways PI3K and MAPK, which phosphorylate AKT and ERK, respectively (XREF_FIG).")
       (:PMID . "25573952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, ERK mediates delayed phosphorylation of Akt and GSK3alpha and beta.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activation of MAPK signalling ultimately leads to phosphorylation of the terminal kinase in the cascade, MAPK (p42/44 MAPK) whereas PI3K activation leads to the phosphorylation of PKB (XREF_BIBR).")
       (:PMID . "23778527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistic studies showed that biological effects of IP6 were associated with inhibition of both constitutive and ligand induced Akt phosphorylation together with a decrease in total Akt levels, but a differential inhibitory effect on MAPKs ERK1/2, JNK1/2 and p38 under constitutive and ligand activated conditions.")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In conclusion, we report an ERK 1,2 -dependent attenuation of Akt phosphorylation and activity in the response of human preadipose cells to angiotensin II.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, phosphorylation of Akt is abolished by inhibitors of ERK1/2 (PD98059) and p38 MAPK (SB203580).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, as demonstrated in this study, the inhibition of ERK1/2 activity with its specific inhibitor PD98059 completely abolished 20-HETE-induced IRS-1 serine phosphorylation and restored the insulin sensitivity of IRS-1 tyrosine phosphorylation, Akt phosphorylation, and eNOS activity in the presence of 20-HETE.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To investigate further the downstream pathways involved in PDGF-BB stimulation of MSC proliferation, we assessed the alteration in phosphorylation of PDGFRbeta, SHP2, Akt and P44 and P42 MAPK in response to stimulation with PDGF-BB.")
       (:PMID . "22805337") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, phosphorylation of P38MAPK and AKT, but not ERK1/2 or JNKs was specifically decreased in SGC7901 and DDP cells after ANXA2 siRNA delivery.")
       (:PMID . "25150310") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, an Akt nonphosphorylatable mutant (TSC2) was phosphorylated by Erk at levels comparable to the wild-type TSC2 (D).")
       (:PMID . "15851026") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that VEGF-A stimulation of LECs leads to the phosphorylation of VEGFR2 (Tyr 951, 1054, 1059, 1175, and 1214) which subsequently triggers PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "P-cadherin prolonged activation of the mitogen activated protein kinase (MAPK) in both cell lines and also increased the magnitude of AKT phosphorylation in dysplastic cells.")
       (:PMID . "25322858") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We show that VEGF-A and VEGFR2 activation in LECs stimulates PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in Figure XREF_FIG, CMTM7 knockdown increased the phosphorylation of EGFR and AKT but not ERK.")
       (:PMID . "26528697") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The downstream MAPK and PI3K activation of Rac1 will result in the phosphorylation of ERK1/2 and AKT respectively.")
       (:PMID . "18086571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "fe93c3b6-73d3-46a7-a935-8a7e5c77a73e"))
    ((:SUB (:DB--REFS (:+TEXT+ . "EGFR") (:+UP+ . "P00533") (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:SUPPORTED--BY "f58436a8-9b1e-4230-89e4-82e1da7e1a96")
     (:EVIDENCE
      ((:TEXT
        . "These results indicated that the mobility shift of EGFR was not due to autophosphorylation or ubiquitylation.Next, we examined whether ERK or p38 MAP kinase directly phosphorylated EGFR to induce the mobility shift after TNFalpha treatment.")
       (:PMID . "23220022") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "TK induced migration was associated with increased phosphorylation of epidermal growth factor receptor (EGFR) and extracellular signal regulated kinase (ERK), which was blocked by inhibition of protein kinase C (PKC), Src, EGFR and ERK.")
       (:PMID . "19879874") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In the aggregate, our current findings are important in that they implicate ERK dependent phosphorylation of EGFR 669 T as a regulator of EGF induced receptor kinase activation and downregulation.")
       (:PMID . "18762250") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that vandetanib inhibited EGF stimulated phosphorylation of EGFR and VEGFR2, as well as AKT and MAPK, in a dose dependent manner (XREF_FIG).")
       (:PMID . "21220477") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These observations led us to examine the possibility of a putative EGF-R phosphorylation pattern that could be mediated by the ERK1/2 MAP kinases, when endothelial cells are stimulated with BK.")
       (:PMID . "24960080") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activated ERK1/2 directly phosphorylate EGF-R at Ser/Thr residues, this post-translational modification confers greater receptor stability.")
       (:PMID . "24960080") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We hypothesized that MEK inhibition activates AKT by inhibiting ERK activity, which blocks an inhibitory threonine phosphorylation on the JM domains of EGFR and HER2, thereby increasing ERBB3 phosphorylation.")
       (:PMID . "22552284") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_5_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous studies have demonstrated that EGFR targeting agents such as cetuximab and gefitinib inhibit the activation specific phosphorylation of EGFR downstream targets such as Akt and Erk [XREF_BIBR, XREF_BIBR].")
       (:PMID . "21411223") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 dependent phosphorylation of upstream components SOS, RAF, and EGFR () dampens further pathway activation, and a second, kinetically slower, negative feedback loop involves the induction of DUSP phosphatases that directly dephosphorylate ERK1/2 ().")
       (:PMID . "24525234") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Indeed, several levels of feedback exist between the RAF-MEK-ERK axis and upstream receptor tyrosine kinases such as EGFR : firstly, active ERK phosphorylates EGFR and EGFR signaling adaptor molecules at inhibitory residues, thus keeping signal transduction of the ligand bound receptor to RAS in check [XREF_BIBR - XREF_BIBR].")
       (:PMID . "26299805") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pretreatment with calcitriol, enhanced TNF induced EGFR-Src dependent ERK activation and tyrosine phosphorylation of the EGFR, but abolished the EGFR-Src independent ERK activation.")
       (:PMID . "18080320") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Treatment of KMBC cells with rhTFF2 stimulated proliferation, triggered phosphorylation of EGFR and downstream extracellular signal related kinase (ERK), whereas co-incubation with the EGFR tyrosine kinase inhibitor, PD153035, blocked rhTFF2 dependent proliferation and EGFR and ERK responses.")
       (:PMID . "21472131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "7d0406e5-0396-4222-91a0-ae28d2360980"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "a9547dab-7efc-4cf7-adda-04e115fba447"
      "410b091b-404d-4eee-9c8e-d4ea272775ad"
      "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1a10fc419230554cdc28a3996a15d4bb")
       (:SOURCE--API . "biopax")))
     (:POSITION . "65")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "84d5115b-8dda-40d0-a89f-9b6ef59de7a2"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c"
      "dbccfe26-7b8e-4b61-ac6f-2e3e2e11cdf1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba2094ffb099de6c97ea4bf7e0c85a9c")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "37")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "b8aa9209-899c-4a43-ba5d-4253414eaf41"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "6d3bd854-c244-40e4-80a4-8774ab658d52"
      "d70fa808-99cf-4d1d-b42e-cb2ebf15430c"
      "4b492425-5202-4090-9c32-2ab9ea8af5c3")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_059a52893ed9f60685c5286ac0e09803")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "70")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "b9429cb3-cb0c-4b97-887c-3ee16146d1d9"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERalpha") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "1789ea88-4ca6-41b1-9653-ed24f59c8543"
      "3e056022-b0df-4181-b89c-fd2f3c8d4c90")
     (:EVIDENCE
      ((:TEXT
        . "To provide further evidence that ERalpha may be phosphorylated by phospho-p44/42 MAPK at Ser 118 in fibroids, immunoprecipitation assays were done and showed an increased association of ERalpha-phospho-Ser118 and phospho-p44/42 MAPK proteins in leiomyomas compared to myometrial tissue.")
       (:PMID . "18853184") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Continuous activation of the MAPK pathway increases ERalpha S118 phosphorylation that bypasses the ligand dependent ERalpha signaling pathway, thereby rendering tumors hormone independent.")
       (:PMID . "25597633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bebb553fa908499c3a1f91df2abfbf5b")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Also, these data show that ERalpha may be phosphorylated by phospho-p44/42 MAPK at Ser 118 and possibly play an important role in the growth of fibroids.")
       (:PMID . "18853184") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We found that MAPK siRNA treatment significantly decreased MYC expression as well as the phosphorylation of ERalpha (Ser118) and total ERalpha (C).")
       (:PMID . "25683269") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in B, TNF-alpha mediated phosphorylation peaked at 5min and declined after 15min, as also observed in E2 treated cells.ERalpha can be activated by growth factors through ERK 1/2 catalyzed phosphorylation of ERalpha serine 118.")
       (:PMID . "21784129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that MAPK siRNA treatment significantly decreased MYC expression as well as the phosphorylation of ERalpha (Ser118) and total ERalpha (C).")
       (:PMID . "25683269") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "p68 was originally identified as an ERalpha co-activator following in vitro purification of proteins that interacted preferentially with ERalpha phosphorylated at ser 118 by MAPK (XREF_BIBR).")
       (:PMID . "19718048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In agreement with the above findings, purified Erk2 readily phosphorylated GST-ERalpha at S104, S106, and S118 (XREF_FIG A).")
       (:PMID . "18372406") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of ERalpha at S118 by MAPK increased steroid receptor coactivator 3 (SRC3) binding () and induced ERalpha hypersensitivity to E2 ().")
       (:PMID . "25597633") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Shigeaki Kato et al. [XREF_BIBR] reported that MAPKs could be activated through EGF-HER2 signaling pathway and the activated MAPK was able to phosphorylate the Ser 118 of ERalpha.")
       (:PMID . "25956130") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "118")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a65b9a9f-a82c-4195-a2d2-a196df7b8a2f"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERALPHA") (:+HGNC+ . "3467") (:+UP+ . "P03372")
       (:+NCIT+ . "C38361"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "83f5e53e-2c35-43ad-8b06-7c464087d7d5"
      "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf")
     (:EVIDENCE
      ((:TEXT
        . "MAPK also indirectly phosphorylates ERalpha at serine 167 via p90rsk.")
       (:PMID . "23265704") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Both AKT and the kinase downstream of mitogen activated protein kinase, p90 ribosomal S6 kinase (pp90Rsk), can also phosphorylate ER at Ser167.")
       (:PMID . "25283475") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Both AKT and the kinase downstream of mitogen activated protein kinase, p90 ribosomal S6 kinase (pp90Rsk), can also phosphorylate ER at Ser167.")
       (:PMID . "25283475") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "MAPK also indirectly phosphorylates ERalpha at serine 167 via p90rsk.")
       (:PMID . "23265704") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "8f0f2893-37d8-40c1-8a26-8541487d2142"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P14921") (:+HGNC+ . "3488")) (:NAME . "ETS1"))
     (:SUPPORTED--BY "d76f3574-118e-46f8-904c-3cb6d917200a"
      "67d16e95-3b95-429f-ac62-1ecece4fb935"
      "71dec232-130e-4e5f-afb6-2f886b313086"
      "cdceb2e6-deb4-4d02-9193-7c8631f8ad56")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ea1c473d5b7827266e3798559103631e")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "This effect of NO is mediated by Ras-SNO modification and subsequent MEK and ERK signaling to phosphorylate Ets-1 (thr 38).")
       (:PMID . "22971289") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "38")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "0459d0aa-3874-4902-920e-b196bc94a0a5"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:SUPPORTED--BY "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "81e9ca7a-5b41-45c0-a780-59c13b83a015"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:TEXT
        . "As ERK1/2, GSK3 beta and FAK are affected by the same inhibitors; this suggests a feedback loop is in place, where kp-10 phosphorylation of ERK1/2 via EGFR transactivation can initiate phosphorylation of GSK3 beta at Ser, probably through p90rsk, an ERK1/2 specific mediator of GSK3 beta phosphorylation.")
       (:PMID . "22349353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As ERK1/2 is also important for the phosphorylation of GSK3 beta via p90rsk, this suggests a longer feedback loop where ERK1/2 via p90rsk would phosphorylate Ser of GSK3 beta, which could in turn lead to phosphorylation at Tyr of FAK to increase ERK1/2 phosphorylation ().")
       (:PMID . "22349353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "GSK3 can also be phosphorylated at Ser and Ser by the most downstream kinase of the classical mitogen activated protein kinase (MAPK) cascade, called MAPK activated protein kinase-1 (MAPKAP-K1, also called RSK).")
       (:PMID . "18602000") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "129eac9a-db28-43d7-9cb9-77338bb26566"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:SUPPORTED--BY "bcac201f-07ed-4193-8c6a-f018f5738804"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE
      ((:TEXT
        . "GSK3 can also be phosphorylated at Ser and Ser by the most downstream kinase of the classical mitogen activated protein kinase (MAPK) cascade, called MAPK activated protein kinase-1 (MAPKAP-K1, also called RSK).")
       (:PMID . "18602000") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As ERK1/2, GSK3 beta and FAK are affected by the same inhibitors; this suggests a feedback loop is in place, where kp-10 phosphorylation of ERK1/2 via EGFR transactivation can initiate phosphorylation of GSK3 beta at Ser, probably through p90rsk, an ERK1/2 specific mediator of GSK3 beta phosphorylation.")
       (:PMID . "22349353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As ERK1/2 is also important for the phosphorylation of GSK3 beta via p90rsk, this suggests a longer feedback loop where ERK1/2 via p90rsk would phosphorylate Ser of GSK3 beta, which could in turn lead to phosphorylation at Tyr of FAK to increase ERK1/2 phosphorylation ().")
       (:PMID . "22349353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "bc74c35c-876f-4738-b745-6b2c765c5946"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "c-Jun") (:+UP+ . "P05412") (:+HGNC+ . "6204"))
      (:NAME . "JUN"))
     (:SUPPORTED--BY "b515d465-61cf-4261-b30a-955853d1bf0e"
      "06475688-c620-4857-8fa4-1d73a4521960"
      "5dca9682-4d81-4402-b437-e2e78195930b")
     (:EVIDENCE
      ((:TEXT
        . "Upstream from the AP-1 complex, up-regulation of IL-8 transcription by Ang-1 was mediated through the Erk1/2, SAPK and JNK, and PI-3 kinase pathways, which triggered c-Jun phosphorylation on Ser63 and Ser73.")
       (:PMID . "18252863") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "XREF_BIBR Moreover, TRAF6 specifically regulates both expression and activity of c-Jun, by p38alpha MAPK dependent phosphorylation of c-Jun at Ser63 in cancer cells.")
       (:PMID . "25483191") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Herein we demonstrate that TRAF6 plays an important role for activation of c-Jun in cancer cells, due to its ability to promote activation of p38alpha MAPK, which subsequently phosphorylates c-Jun on Ser63, thereby causing its activation.")
       (:PMID . "25483191") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Likewise, ERK1/2 was unable to phosphorylate c-Jun at Ser 63 or Ser 73 (C).")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "c-Jun, a critical component of the AP1 complex, can be phosphorylated by ERK1/2 on Ser63 and Ser73, and the phosphorylation of these sites are required for AP1 to become transcriptionally active (XREF_BIBR).")
       (:PMID . "19199380") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "63")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "d3e4fd81-70f2-4d9f-a259-c2b581e7cdf8"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "c-Jun") (:+UP+ . "P05412") (:+HGNC+ . "6204"))
      (:NAME . "JUN"))
     (:SUPPORTED--BY "177c5dcc-16be-4287-aaf0-cca0687a040d"
      "110588b4-6321-4337-bff2-8a98e3f1fed5"
      "06475688-c620-4857-8fa4-1d73a4521960")
     (:EVIDENCE
      ((:TEXT
        . "Likewise, ERK1/2 was unable to phosphorylate c-Jun at Ser 63 or Ser 73 (C).")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "c-Jun, a critical component of the AP1 complex, can be phosphorylated by ERK1/2 on Ser63 and Ser73, and the phosphorylation of these sites are required for AP1 to become transcriptionally active (XREF_BIBR).")
       (:PMID . "19199380") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Upstream from the AP-1 complex, up-regulation of IL-8 transcription by Ang-1 was mediated through the Erk1/2, SAPK and JNK, and PI-3 kinase pathways, which triggered c-Jun phosphorylation on Ser63 and Ser73.")
       (:PMID . "18252863") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "73")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "168c43a7-df18-4457-b43c-49cfe3e7be4e"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAP2K2") (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:TEXT
        . "Estrogen binds to the ER-alpha and stimulates MAPK mediated phosphorylation of MEK1/2, which in turn phosphorylates ERK1/2 (extracellular signal regulated kinase1/2) [XREF_BIBR].")
       (:PMID . "18377656") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "Phosphorylation of MEK is also stimulated by ERK.")
       (:PMID . "8226933") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In enzymatic and cellular studies, trametinib inhibited kinase activity of MEK1 and MEK2, prevented RAF dependent MEK phosphorylation, and prolonged inhibition of phosphorylated ERK (a substrate of MEK).")
       (:PMID . "22805291") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Raf kinases are the entry point to the ERK and MAPK pathway, a three tiered kinase cascade where Raf phosphorylates and activates MEK which in turn phosphorylates and activates ERK.")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Only one increased signal was observed across all six RTKs [the phosphorylation of MEK1 and MEK2 (MEK1/2) in response to ERK pooled shRNA knockdown], and only three increases were observed across five RTKs (the phosphorylation of MEK1/2 and ERK1/2 in response to GSK3 pooled shRNA knockdown, and the phosphorylation of Akt in response to PTPN pooled shRNA knockdown).")
       (:PMID . "23861540") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "b85d1bfc-8e86-47e8-87e9-ba96ea02ade0"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "6972a59d-f263-492b-b508-77c9425eb9d1")
     (:EVIDENCE
      ((:TEXT
        . "In addition, the inhibition of ERK by U0126 increased the phosphorylation of p38, and the inhibition of p38 by SB203580 activated ERK1/2 (with cisplatin treatment); however, the inhibition of both ERK and p38 had no obvious effect on p-AKT (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Indeed, we have previously shown that VEGF induction of MKP-1 is JNK MAPK dependent, and VEGF induced MKP-1 regulates phosphorylation of both JNK and p38, but not ERK1/2, in HUVEC 18.")
       (:PMID . "24578378") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "ACTH also induces a rapid phosphorylation of p38 kinase and ERKs in human keratinocytes () and modulates ERK activation in adrenal gland ().")
       (:PMID . "19428994") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PGC-1alpha is phosphorylated by both Mitogen activated protein kinase p38 (XREF_BIBR), and the AMP dependent kinase (AMPK) in skeletal muscle (XREF_BIBR), which also stabilizes the protein and increases its activity.")
       (:PMID . "26831453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "shows that costimulation with or without the treatment of IL-25 could activate Th cells by rapid inducing the phosphorylation of p38 MAPK and JNK but not ERK within 10min, implying the activation of p38 MAPK and JNK by costimulation.")
       (:PMID . "17719653") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The ERK specific inhibitor U0126 and the p38 specific inhibitor SB202190 blocked ERK and p38 phosphorylation, but did not prevent PA induced LC3-II accumulation (XREF_SUPPLEMENTARY and XREF_SUPPLEMENTARY).")
       (:PMID . "24608675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Fotillin-2 knockdown showed a significant reduction of p38 MAPK phosphorylation but not ERK1/2 phosphorylation, although the knockdown of flotillin-1 had no effect (C, D).")
       (:PMID . "17307333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In response to LPS binding to TLR-4, MAPK kinase-3/6 (MKK3/6) phosphorylates and activates p38 MAPK, which in turn may activate the transcription factor AP-1 ().")
       (:PMID . "21628073") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The canonical activation pathway of p38 MAPK includes the serine / threonine kinases (MKKKs or MLKs), which phosphorylate and activate the dual specificity MAPK kinases (MKKs such as MKK3, MKK4, and MKK6), which in turn phosphorylate p38 MAPK isoforms (XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "21286833") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Four isoforms of p38, known as p38alpha, p38beta, p38gamma, and p38delta have been identified, which can all be phosphorylated by the MAPK kinase MKK6 (SKK3) and MKK3, respectively [XREF_BIBR].")
       (:PMID . "26555773") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This translocation may be an important process for the transduction of signals induced primarily by binding of contact sensitizers to as yet unidentified cellular structures.To elucidate the upstream events involved in the process of translocation future studies have to focus on two MAPK kinases that specifically phosphorylate p38 (MKK3, MKK6) () as well as a further MAPKK, termed MKK4 or JNKK, with a dual specificity for p38 and c-Jun N-terminal kinase (;).")
       (:PMID . "12164931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "fe7bdabe-dddf-4dd2-a85f-6931a6c8e972"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P01106") (:+HGNC+ . "7553")) (:NAME . "MYC"))
     (:SUPPORTED--BY "93939a97-500c-46b3-bbdf-e9036b2a0b92"
      "2a130ba1-188a-4615-9842-6c35b12675c5"
      "8d20a4ee-9ba8-4090-a8f7-fd3dc43ae817"
      "57690175-fe8e-4ddf-a8f7-a15078ab086a"
      "22508fa7-e0e1-4495-9f68-2548dd0d4a0a"
      "1c9542fd-881d-4a64-a86e-200038c23f5b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK1_DirectlyIncreases_p_HGNC_MYC_pmod_P_S_62")
       (:TEXT
        . "We now show that the phosphorylation of these two residues is critical for determining the stability of Myc. Phosphorylation of Ser 62 is required for Ras-induced stabilization of Myc, likely mediated through the action of ERK.")
       (:PMID . "11018017") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK1_DirectlyIncreases_p_HGNC_MYC_pmod_P_S_62")
       (:TEXT . "91332050;1651323;17081983") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK1_DirectlyIncreases_p_HGNC_MYC_pmod_P_S_62")
       (:TEXT
        . "Exposure to H2O2 enhances c-Myc recruitment to gamma-GCS regulatory regions through ERK-dependent phosphorylation. Phosphorylation at Ser-62 is required for c-Myc recruitment to gamma-GCS promoters and determines the cellular response to oxidative stress induced by different stimuli.")
       (:PMID . "16483932") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK1_DirectlyIncreases_p_HGNC_MYC_pmod_P_S_62")
       (:TEXT
        . "Exposure to H2O2 enhances c-Myc recruitment to gamma-GCS regulatory regions through ERK-dependent phosphorylation. Phosphorylation at Ser-62 is required for c-Myc recruitment to gamma-GCS promoters and determines the cellular response to oxidative stress induced by different stimuli.")
       (:PMID . "16483932") (:SOURCE--API . "bel"))
      ((:TEXT
        . "Phosphorylation of c-myc by ERK on Ser62 has been shown to promote c-myc stabilization (XREF_BIBR).")
       (:PMID . "22826122") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Newly synthesized c-myc can, in turn, be phosphorylated by ERK on Ser 62 to induce the stabilization of c-myc (and hence c-myc accumulation), resulting in increased expression levels and enhanced transcriptional activity (see for review).")
       (:PMID . "23266555") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We now show that LANA increases the level of phosphorylated extracellular signal regulated kinase 1 (ERK1) and increases ERK phosphorylation of c-Myc on Ser62.")
       (:PMID . "17634226") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Simultaneously, cellular oxidative stress activates ERK which can phosphorylate c-Myc at Ser62.")
       (:PMID . "26751215") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of c-myc by ERK on Ser62 has been shown to promote c-myc stabilization (XREF_BIBR).")
       (:PMID . "22826122") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We now show that LANA increases the level of phosphorylated extracellular signal regulated kinase 1 (ERK1) and increases ERK phosphorylation of c-Myc on Ser62.")
       (:PMID . "17634226") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fa9be9db758385bb47b5c76ff4f5fda5")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "The ERK and GSK-3beta can phosphorylate c-Myc at Ser62 and Thr58, respectively.")
       (:PMID . "26751215") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Simultaneously, cellular oxidative stress activates ERK which can phosphorylate c-Myc at Ser62.")
       (:PMID . "26751215") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "62")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "bb86a806-7212-4a91-8d70-46f204201cc7"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P01106") (:+HGNC+ . "7553")) (:NAME . "MYC"))
     (:SUPPORTED--BY "2a130ba1-188a-4615-9842-6c35b12675c5"
      "e20ba878-dd08-48a1-92f5-3b4bb418f0fc"
      "64952ac6-62a5-44dc-8396-2ea9a02d4c8b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3e4b4d3e4665a321c338df4425558a05")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "The ERK and GSK-3beta can phosphorylate c-Myc at Ser62 and Thr58, respectively.")
       (:PMID . "26751215") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "58")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "6d610bc3-d79e-4ea8-a7ab-1a65fd13b768"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "PKCalpha") (:+UP+ . "P17252") (:+HGNC+ . "9393"))
      (:NAME . "PRKCA"))
     (:SUPPORTED--BY "20ef1836-ea28-4546-aed3-a396a32b3771")
     (:EVIDENCE
      ((:TEXT
        . "Employing PKCalpha and Erk mutants we next demonstrated that Erk causes direct phosphorylation and activation of PKCalpha.")
       (:PMID . "20513439") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To confirm that Erk indeed catalyzes phosphorylation of PKCalpha at T 638, we used a mutant Erk construct in which a bulky amino acid residue in the ATP binding site (Q 103) had been replaced with glycine, enabling this mutant to utilize a bulky analog of ATP, cyclopentyl ATP.")
       (:PMID . "20513439") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previously we have demonstrated that stimulation of 5-HT 1A -R causes Erk1/2 dependent phosphorylation of PKCalpha in both mouse hippocampus (P15) and hippocampal derived HN2-5 cells [XREF_BIBR].")
       (:PMID . "20513439") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "2b0f43ba-3bb7-471c-8753-4b9caedd3805"))
    ((:RESIDUE . "T")
     (:SUB
      (:DB--REFS (:+TEXT+ . "p70S6 kinase") (:+UP+ . "P23443")
       (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "c50fc9ff-e9dd-4b12-bcf8-006a59ecd46e"
      "4b19ea61-5a9a-4577-b1bf-8e6fd0069259")
     (:EVIDENCE
      ((:TEXT
        . "These data indicate that p70S6 kinase activation triggered by GM3 depends on uPAR signaling.Activation of uPAR in cells that overexpress GM3 induces ERK independent phosphorylation of p70S6 kinase at threonine 421/serine 424, threonine 389, and serine 411 sites (, lane 3 of the second, third and bottom rows) in comparison with control cells (lanes 1 and 2).")
       (:PMID . "16826166") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "19162cd9-225a-4d7a-8462-1d353b8b7a9f"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "SHC1") (:+UP+ . "P29353") (:+HGNC+ . "10840"))
      (:NAME . "SHC1"))
     (:SUPPORTED--BY "5155385d-534b-4c6b-9930-a0bd655d3cea")
     (:EVIDENCE
      ((:TEXT
        . "Incubation of cells with the specific EGFR inhibitor AG4178 blocked MbetaCD induced phosphorylation of EGFR, SHC, phospholipase C-gamma, and Gab-1 as well as MAPK activation.")
       (:PMID . "12397069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylated Shc can then bind Grb2 and Sos complexes to activate p21, Raf-1 and the MAPK pathway.")
       (:PMID . "9824671") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "755fd8d4-d1de-4456-a60b-6d35a08b0dad"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "c-Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:SUPPORTED--BY "a49e8d40-a288-4151-8fd3-d4e5d64e62d5")
     (:EVIDENCE
      ((:TEXT
        . "c-Src fails to interact with mRon when the three tyrosines required for MAP kinase activation are mutated, whereas the presence of any one of these tyrosines alone restores Erk phosphorylation and recruitment of c-Src.")
       (:PMID . "16103119") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Besides affecting Bim transcription, PINCH-1 promotes activating phosphorylation of Src family kinases and ERK1/2 that leads to Ser69 phosphorylation of Bim resulting in enhanced degradation [XREF_BIBR].")
       (:PMID . "26405162") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "4) Phosphorylation of SRC-1 by MAPK was required for optimal ligand independent activation of the AR by IL-6.")
       (:PMID . "12163482") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Taken together, these data suggest that, consistent with other ligand independent mechanisms shown to functionally transactivate the AR, activation of the CXCL12 and CXCR4 axis promotes MAPK MEK and ERK kinase mediated SRC-1 phosphorylation.")
       (:PMID . "22245379") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, XREF_BIBR had elegantly demonstrated that phosphorylation of SRC-1 by MAPK was required for optimal ligand independent activation of the AR by IL-6.")
       (:PMID . "22245379") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "187") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "421b2ee6-7dec-4081-a606-4411f29ccf60"))
    ((:SUB (:DB--REFS (:+UP+ . "P05412") (:+HGNC+ . "6204")) (:NAME . "JUN"))
     (:SUPPORTED--BY "3e20beea-8341-407a-bba7-4c0a10de6a0b"
      "06475688-c620-4857-8fa4-1d73a4521960")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_27bbf47d1fcf0299a0435aad5390d3e2")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_568a5e821897e687202e4d679940179a")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "695e900f-ef3c-4779-a829-9a6a702d30c0"))
    ((:SUB (:DB--REFS (:+UP+ . "P01106") (:+HGNC+ . "7553")) (:NAME . "MYC"))
     (:SUPPORTED--BY "2a130ba1-188a-4615-9842-6c35b12675c5"
      "b1659710-0a12-40c2-af59-3225711c0e01")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a432457a7080cf28bfabc4890175d3db")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_18d6517dec7423319b27a69767cc546a")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "9c3a1ae3-df07-4c53-be99-f412c1ba241e"))
    ((:SUB (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "a9f3a67f-e833-4fca-9c13-a7540273bc7f"
      "ae3f7b7b-7824-4d36-b5c9-dcdefe771a69")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9b771bc8b872011ec7b0dac648f52df9")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3f2496a8795ee1f689f050baa5619a1c")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "00c7f5b9-03cb-4989-9649-64fce00f22a2"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "05e88bd6-921f-4b71-a3df-f4281e42d1c2"
      "d5d0707a-a034-4a72-a3d3-a3d69c2b8962"
      "77dd0129-eaec-4dc0-b3fb-2c05328ec75f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d6f38ec1ef74e46fdcb92077484cfa01")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d4ea9f4ed81034b49579a6a98893bb6b")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2b6110c9d65e5c3c7f6df88377dce51b")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "151")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "8956b8fe-01d6-4858-bb1c-d4b502bd43e3"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "77dd0129-eaec-4dc0-b3fb-2c05328ec75f"
      "05e88bd6-921f-4b71-a3df-f4281e42d1c2"
      "d5d0707a-a034-4a72-a3d3-a3d69c2b8962")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d6f38ec1ef74e46fdcb92077484cfa01")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d4ea9f4ed81034b49579a6a98893bb6b")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2b6110c9d65e5c3c7f6df88377dce51b")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "750")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "ffac73ef-e395-4b3f-bb14-e79a59502d55"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "05e88bd6-921f-4b71-a3df-f4281e42d1c2"
      "75ade231-42f6-4f75-87f5-1b717319f031"
      "77dd0129-eaec-4dc0-b3fb-2c05328ec75f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d6f38ec1ef74e46fdcb92077484cfa01")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d4ea9f4ed81034b49579a6a98893bb6b")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2b6110c9d65e5c3c7f6df88377dce51b")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "401")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "72c53b2b-4e5b-4e4a-b826-d849078fad7f"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "05e88bd6-921f-4b71-a3df-f4281e42d1c2"
      "77dd0129-eaec-4dc0-b3fb-2c05328ec75f"
      "b3fcd85e-f851-4c53-86bf-92cd754790cf")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d4ea9f4ed81034b49579a6a98893bb6b")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d6f38ec1ef74e46fdcb92077484cfa01")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2b6110c9d65e5c3c7f6df88377dce51b")
       (:PMID . "19541618") (:SOURCE--API . "biopax")))
     (:POSITION . "753")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "580a5745-aa0e-46e3-8de4-f65972649364"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P19419") (:+HGNC+ . "3321")) (:NAME . "ELK1"))
     (:SUPPORTED--BY "48fcffac-ca4d-4510-bfc6-4df168eb9153"
      "71e84804-8b59-4792-85c9-69e7caa8f847"
      "b4d9605d-d9df-49bb-8d38-a7216e69528b"
      "755baed9-8860-46d8-a2ab-c1f8058b167e"
      "c420af9a-cfe4-41be-8762-3a0286874136")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8464740d10bccbf8d83a14cdccaf307c")
       (:PMID . "7889942") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8386592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "10716983") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8007980") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "15014501") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8477450") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8262053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "18334532") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "7889942") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "8386592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "9927426") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "8262053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "7889942") (:SOURCE--API . "biopax")))
     (:POSITION . "383")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "a0d82f06-dd1c-49ac-833f-46de5f198964"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P19419") (:+HGNC+ . "3321")) (:NAME . "ELK1"))
     (:SUPPORTED--BY "15e458bf-bef5-4323-801b-b689dce8d281"
      "6ff7c433-8911-4b83-a441-b2dc7a343d97"
      "71e84804-8b59-4792-85c9-69e7caa8f847"
      "cb4e8df0-a00f-4aa5-bfe5-5533d9556f49")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8386592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "10716983") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8007980") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "15014501") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8477450") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "8262053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "18334532") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c3f778025b46d51cc66401eb5065820b")
       (:PMID . "7889942") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8464740d10bccbf8d83a14cdccaf307c")
       (:PMID . "7889942") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "8386592") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "9927426") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "8262053") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a64941be409ef69cc3b13c5690a2403")
       (:PMID . "7889942") (:SOURCE--API . "biopax")))
     (:POSITION . "389")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "dccbe284-536b-489b-877f-19dc984e4958"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "3b085760-047b-4de6-a358-6f53aa726e61"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "b40ece75-6912-4543-b194-49dd5c54240e"
      "ca123c61-99a0-4c4c-8404-a847c1e6b074"
      "dee07f0e-3794-4649-b41a-202969e6e6e5")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e927859023a68c32fa12bc640a1d243")
       (:PMID . "14636584") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e927859023a68c32fa12bc640a1d243")
       (:PMID . "19272169") (:SOURCE--API . "biopax")))
     (:POSITION . "925")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "5378098e-efc0-4660-9b8b-2475e94b0ac4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "ef5e26f1-8cd4-492e-ab67-cbaa4375ee18"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "b58ae87d-df02-4f01-b13e-743bb73bef35"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "11781878-54aa-4b12-9f73-29a604cc62e7")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad75aa814cdbfad81314a982573b2940")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e27ae9bc47f47001e3957c0487c24dd6")
       (:PMID . "16407412") (:SOURCE--API . "biopax")))
     (:POSITION . "338")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "cbdd7b19-f200-412b-8c12-f0cfad7d620f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "ef5e26f1-8cd4-492e-ab67-cbaa4375ee18"
      "a4c02905-6eba-40d8-ac1a-09529665ba79"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "d2637bd7-ddaf-458e-8724-552eafe180b3")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e27ae9bc47f47001e3957c0487c24dd6")
       (:PMID . "16407412") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad75aa814cdbfad81314a982573b2940")
       (:SOURCE--API . "biopax")))
     (:POSITION . "621")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "57d7aff0-9c3a-4974-9192-9d7edbd3633d"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "550e7957-e09d-4845-ad8d-846e45603fec"
      "bddee8f5-87f6-41ed-9c32-d14a66eb008e"
      "32dc6cef-8600-4df5-bddc-3d607f30d421"
      "39a5039d-a241-4fd1-9698-f712d4cbbb74")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax")))
     (:POSITION . "221")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "dd07d6c2-4351-45e4-b290-3c6968de7114"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "be50f2d6-e296-4eea-8361-7670b00b4e0d"
      "7bb4f60a-7d53-4fb7-8d3d-bff76b637458"
      "550e7957-e09d-4845-ad8d-846e45603fec"
      "80d03abf-9de8-43e2-80c0-6390d8dabb90"
      "927d62fd-df47-4d1b-910f-05e44eb31fa1")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad1ffafb51ddab8c00a9fc6c5f5ba335")
       (:PMID . "14966081") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "363")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "31c9a7ac-13d2-4e00-ba61-cce4855e2b12"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "79bd795a-43ed-414e-892c-d905dfb1238d"
      "550e7957-e09d-4845-ad8d-846e45603fec"
      "0afd31b7-b6c0-440e-9ed0-e2318bd991b3")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7b1d30a602c2f5ef98b93e26346180c3")
       (:PMID . "11532940") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7b1d30a602c2f5ef98b93e26346180c3")
       (:PMID . "11335727") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "380")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "a3c38daa-37c7-4daf-9669-025f13bea104"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "f52e73bf-bc84-4606-a5d8-a8fde03ba7fb"
      "bd9c532f-1729-43d9-9ffd-331fc80e842e"
      "550e7957-e09d-4845-ad8d-846e45603fec")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "732")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "70c92f42-f7ad-433c-9fbe-a6cffdef3cf2"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "6a9558cc-22fd-4caa-b92c-da8776a18cb3"
      "270d1783-2180-4cca-b279-44bc41142924"
      "7afa7dce-5120-4de1-84b8-f7512b8a9c61"
      "d8bd6ebe-b843-4d5f-81db-8a0403a48497"
      "550e7957-e09d-4845-ad8d-846e45603fec")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ad1ffafb51ddab8c00a9fc6c5f5ba335")
       (:PMID . "14966081") (:SOURCE--API . "biopax")))
     (:POSITION . "359")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "e54da150-b55b-42f7-af04-f9aa9a1ecd50"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "2e722255-2a8a-4c37-a0ba-143a407bef93"
      "550e7957-e09d-4845-ad8d-846e45603fec"
      "a4db6bb5-db2f-4b48-a2fb-c0b68d31f868"
      "ed408000-dc02-47e4-a7ff-12b6495ecc3e"
      "f09f7d7d-bd90-4bd6-b34b-c6da5d8b941a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_70f13eb85ee9c5a2c510c928aede8ea8")
       (:PMID . "8387505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba733730b19234df0963e1035196a405")
       (:PMID . "15342917") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "573")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "7c9de1c9-4fe4-423b-a431-cbe6384507f0"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:SUPPORTED--BY "b7622fb7-a505-4ff5-9916-3f5d3ae8d115"
      "f973e536-a5a1-41ee-9ba1-6301ba33bd23"
      "6af10ff1-80fb-4126-bf38-edfbb93706e4")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "12832467") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "10856237") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "18156174") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a241e0beb712bc3d1087fecee30a5e2b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "369")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "492401b4-c459-4db2-909b-1976ccdab312"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:SUPPORTED--BY "6af10ff1-80fb-4126-bf38-edfbb93706e4"
      "f973e536-a5a1-41ee-9ba1-6301ba33bd23"
      "16f49b7d-06ac-480b-b3de-ae6050493f12"
      "5da7e4e5-8480-4c67-9a58-747b12ab7246")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "12832467") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "10856237") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_29fb95ed02de10472e7c039dee279f5f")
       (:PMID . "18156174") (:SOURCE--API . "biopax")))
     (:POSITION . "529")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "9e2004c3-d4e3-4739-b31d-4534d8817c1e"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "2eeeaba3-098c-44b3-866d-94e607e66258"
      "c4de9bbf-3087-4235-82a1-663bdb028b62"
      "00a762b5-2139-4fd5-9e17-9394c8b0f490"
      "842e2e17-c29d-406a-8dca-5b5819152373"
      "e9a70ac2-676e-4bcf-bc92-f9bf48dcc8eb"
      "e30a25e3-ea82-4c2d-ae4c-70044afefa04")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0efc20911c11fe20e633fc2b26c10af8")
       (:PMID . "9343414") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0efc20911c11fe20e633fc2b26c10af8")
       (:PMID . "11404481") (:SOURCE--API . "biopax")))
     (:POSITION . "727")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "26f34cf3-846c-4203-adab-fe21bf831792"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activation of MAPK signalling ultimately leads to phosphorylation of the terminal kinase in the cascade, MAPK (p42/44 MAPK) whereas PI3K activation leads to the phosphorylation of PKB (XREF_BIBR).")
       (:PMID . "23778527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "EGCG induced Erk phosphorylation and activation of the Akt pathway was found to promote keratinocyte survival [XREF_BIBR].")
       (:PMID . "26130135") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We show that VEGF-A and VEGFR2 activation in LECs stimulates PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Mutp53 levels also proportionally modulate the activated downstream EGFR signaling pathways PI3K and MAPK, which phosphorylate AKT and ERK, respectively (XREF_FIG).")
       (:PMID . "25573952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The downstream MAPK and PI3K activation of Rac1 will result in the phosphorylation of ERK1/2 and AKT respectively.")
       (:PMID . "18086571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, phosphorylation of P38MAPK and AKT, but not ERK1/2 or JNKs was specifically decreased in SGC7901 and DDP cells after ANXA2 siRNA delivery.")
       (:PMID . "25150310") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, ERK mediates delayed phosphorylation of Akt and GSK3alpha and beta.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, as demonstrated in this study, the inhibition of ERK1/2 activity with its specific inhibitor PD98059 completely abolished 20-HETE-induced IRS-1 serine phosphorylation and restored the insulin sensitivity of IRS-1 tyrosine phosphorylation, Akt phosphorylation, and eNOS activity in the presence of 20-HETE.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistic studies showed that biological effects of IP6 were associated with inhibition of both constitutive and ligand induced Akt phosphorylation together with a decrease in total Akt levels, but a differential inhibitory effect on MAPKs ERK1/2, JNK1/2 and p38 under constitutive and ligand activated conditions.")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In conclusion, we report an ERK 1,2 -dependent attenuation of Akt phosphorylation and activity in the response of human preadipose cells to angiotensin II.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Likewise, when bone marrow derived mesenchymal stems cells were stimulated to adipogenic differentiation and exposed to high glucose, an ERK 1,2 -dependent increase in Akt phosphorylation was reported XREF_BIBR.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, phosphorylation of Akt is abolished by inhibitors of ERK1/2 (PD98059) and p38 MAPK (SB203580).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, an Akt nonphosphorylatable mutant (TSC2) was phosphorylated by Erk at levels comparable to the wild-type TSC2 (D).")
       (:PMID . "15851026") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To investigate further the downstream pathways involved in PDGF-BB stimulation of MSC proliferation, we assessed the alteration in phosphorylation of PDGFRbeta, SHP2, Akt and P44 and P42 MAPK in response to stimulation with PDGF-BB.")
       (:PMID . "22805337") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that VEGF-A stimulation of LECs leads to the phosphorylation of VEGFR2 (Tyr 951, 1054, 1059, 1175, and 1214) which subsequently triggers PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "P-cadherin prolonged activation of the mitogen activated protein kinase (MAPK) in both cell lines and also increased the magnitude of AKT phosphorylation in dysplastic cells.")
       (:PMID . "25322858") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in Figure XREF_FIG, CMTM7 knockdown increased the phosphorylation of EGFR and AKT but not ERK.")
       (:PMID . "26528697") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The decrease in EGFR phosphorylation was specific for SFK inhibition as the Mek and Erk1,2 inhibitor U0126 did not inhibit EGFR or Akt phosphorylation, but did block phosphorylation of Erk1,2 as reported.")
       (:PMID . "23866081") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "28d86ed9-de2f-4aa6-b891-20fa1ffde6d4"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activation of MAPK signalling ultimately leads to phosphorylation of the terminal kinase in the cascade, MAPK (p42/44 MAPK) whereas PI3K activation leads to the phosphorylation of PKB (XREF_BIBR).")
       (:PMID . "23778527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, phosphorylation of Akt is abolished by inhibitors of ERK1/2 (PD98059) and p38 MAPK (SB203580).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "EGCG induced Erk phosphorylation and activation of the Akt pathway was found to promote keratinocyte survival [XREF_BIBR].")
       (:PMID . "26130135") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In conclusion, we report an ERK 1,2 -dependent attenuation of Akt phosphorylation and activity in the response of human preadipose cells to angiotensin II.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Likewise, when bone marrow derived mesenchymal stems cells were stimulated to adipogenic differentiation and exposed to high glucose, an ERK 1,2 -dependent increase in Akt phosphorylation was reported XREF_BIBR.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mutp53 levels also proportionally modulate the activated downstream EGFR signaling pathways PI3K and MAPK, which phosphorylate AKT and ERK, respectively (XREF_FIG).")
       (:PMID . "25573952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, ERK mediates delayed phosphorylation of Akt and GSK3alpha and beta.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistic studies showed that biological effects of IP6 were associated with inhibition of both constitutive and ligand induced Akt phosphorylation together with a decrease in total Akt levels, but a differential inhibitory effect on MAPKs ERK1/2, JNK1/2 and p38 under constitutive and ligand activated conditions.")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "P-cadherin prolonged activation of the mitogen activated protein kinase (MAPK) in both cell lines and also increased the magnitude of AKT phosphorylation in dysplastic cells.")
       (:PMID . "25322858") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, as demonstrated in this study, the inhibition of ERK1/2 activity with its specific inhibitor PD98059 completely abolished 20-HETE-induced IRS-1 serine phosphorylation and restored the insulin sensitivity of IRS-1 tyrosine phosphorylation, Akt phosphorylation, and eNOS activity in the presence of 20-HETE.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To investigate further the downstream pathways involved in PDGF-BB stimulation of MSC proliferation, we assessed the alteration in phosphorylation of PDGFRbeta, SHP2, Akt and P44 and P42 MAPK in response to stimulation with PDGF-BB.")
       (:PMID . "22805337") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, phosphorylation of P38MAPK and AKT, but not ERK1/2 or JNKs was specifically decreased in SGC7901 and DDP cells after ANXA2 siRNA delivery.")
       (:PMID . "25150310") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, an Akt nonphosphorylatable mutant (TSC2) was phosphorylated by Erk at levels comparable to the wild-type TSC2 (D).")
       (:PMID . "15851026") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that VEGF-A stimulation of LECs leads to the phosphorylation of VEGFR2 (Tyr 951, 1054, 1059, 1175, and 1214) which subsequently triggers PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that VEGF-A and VEGFR2 activation in LECs stimulates PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in Figure XREF_FIG, CMTM7 knockdown increased the phosphorylation of EGFR and AKT but not ERK.")
       (:PMID . "26528697") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The decrease in EGFR phosphorylation was specific for SFK inhibition as the Mek and Erk1,2 inhibitor U0126 did not inhibit EGFR or Akt phosphorylation, but did block phosphorylation of Erk1,2 as reported.")
       (:PMID . "23866081") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The downstream MAPK and PI3K activation of Rac1 will result in the phosphorylation of ERK1/2 and AKT respectively.")
       (:PMID . "18086571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "d4b459c6-8cd1-460c-afcf-a122d4a83f7a"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "Moreover, phosphorylation of Akt is abolished by inhibitors of ERK1/2 (PD98059) and p38 MAPK (SB203580).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activation of MAPK signalling ultimately leads to phosphorylation of the terminal kinase in the cascade, MAPK (p42/44 MAPK) whereas PI3K activation leads to the phosphorylation of PKB (XREF_BIBR).")
       (:PMID . "23778527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, phosphorylation of P38MAPK and AKT, but not ERK1/2 or JNKs was specifically decreased in SGC7901 and DDP cells after ANXA2 siRNA delivery.")
       (:PMID . "25150310") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Treatment of MCF7-neo and MCF7-HER2 cells with LY294002 or PD98059 specifically inhibited the respective pathways, as shown by inhibition of Akt phosphorylation but not Erk phosphorylation by LY294002 and by inhibition of Erk phosphorylation but not Akt phosphorylation by PD98059 (XREF_FIG).")
       (:PMID . "23707532") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mechanistic studies showed that biological effects of IP6 were associated with inhibition of both constitutive and ligand induced Akt phosphorylation together with a decrease in total Akt levels, but a differential inhibitory effect on MAPKs ERK1/2, JNK1/2 and p38 under constitutive and ligand activated conditions.")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "EGCG induced Erk phosphorylation and activation of the Akt pathway was found to promote keratinocyte survival [XREF_BIBR].")
       (:PMID . "26130135") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Likewise, when bone marrow derived mesenchymal stems cells were stimulated to adipogenic differentiation and exposed to high glucose, an ERK 1,2 -dependent increase in Akt phosphorylation was reported XREF_BIBR.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We thus propose a signaling network with novel intersects, where CD44 senses of the degree of confluence to modulate a signaling network consisting of ERK, AKT and Hippo-YAP pathways, whereby it promotes the phosphorylation of AKT and ERK but inhibits the phosphorylation of YAP to activate oncogenic YAP activity.")
       (:PMID . "25605020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mutp53 levels also proportionally modulate the activated downstream EGFR signaling pathways PI3K and MAPK, which phosphorylate AKT and ERK, respectively (XREF_FIG).")
       (:PMID . "25573952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The downstream MAPK and PI3K activation of Rac1 will result in the phosphorylation of ERK1/2 and AKT respectively.")
       (:PMID . "18086571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, ERK mediates delayed phosphorylation of Akt and GSK3alpha and beta.")
       (:PMID . "25858425") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To investigate further the downstream pathways involved in PDGF-BB stimulation of MSC proliferation, we assessed the alteration in phosphorylation of PDGFRbeta, SHP2, Akt and P44 and P42 MAPK in response to stimulation with PDGF-BB.")
       (:PMID . "22805337") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In conclusion, we report an ERK 1,2 -dependent attenuation of Akt phosphorylation and activity in the response of human preadipose cells to angiotensin II.")
       (:PMID . "24098385") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, an Akt nonphosphorylatable mutant (TSC2) was phosphorylated by Erk at levels comparable to the wild-type TSC2 (D).")
       (:PMID . "15851026") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that VEGF-A stimulation of LECs leads to the phosphorylation of VEGFR2 (Tyr 951, 1054, 1059, 1175, and 1214) which subsequently triggers PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that VEGF-A and VEGFR2 activation in LECs stimulates PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The decrease in EGFR phosphorylation was specific for SFK inhibition as the Mek and Erk1,2 inhibitor U0126 did not inhibit EGFR or Akt phosphorylation, but did block phosphorylation of Erk1,2 as reported.")
       (:PMID . "23866081") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, as demonstrated in this study, the inhibition of ERK1/2 activity with its specific inhibitor PD98059 completely abolished 20-HETE-induced IRS-1 serine phosphorylation and restored the insulin sensitivity of IRS-1 tyrosine phosphorylation, Akt phosphorylation, and eNOS activity in the presence of 20-HETE.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "P-cadherin prolonged activation of the mitogen activated protein kinase (MAPK) in both cell lines and also increased the magnitude of AKT phosphorylation in dysplastic cells.")
       (:PMID . "25322858") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in Figure XREF_FIG, CMTM7 knockdown increased the phosphorylation of EGFR and AKT but not ERK.")
       (:PMID . "26528697") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "b3c937ae-c5ed-4565-9eb8-b5cb8f1c81d7"))
    ((:SUB (:DB--REFS (:+TEXT+ . "EGFR") (:+UP+ . "P00533") (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:SUPPORTED--BY "f58436a8-9b1e-4230-89e4-82e1da7e1a96")
     (:EVIDENCE
      ((:TEXT
        . "In the aggregate, our current findings are important in that they implicate ERK dependent phosphorylation of EGFR 669 T as a regulator of EGF induced receptor kinase activation and downregulation.")
       (:PMID . "18762250") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These observations led us to examine the possibility of a putative EGF-R phosphorylation pattern that could be mediated by the ERK1/2 MAP kinases, when endothelial cells are stimulated with BK.")
       (:PMID . "24960080") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activated ERK1/2 directly phosphorylate EGF-R at Ser/Thr residues, this post-translational modification confers greater receptor stability.")
       (:PMID . "24960080") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "TK induced migration was associated with increased phosphorylation of epidermal growth factor receptor (EGFR) and extracellular signal regulated kinase (ERK), which was blocked by inhibition of protein kinase C (PKC), Src, EGFR and ERK.")
       (:PMID . "19879874") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "ERK1/2 dependent phosphorylation of upstream components SOS, RAF, and EGFR () dampens further pathway activation, and a second, kinetically slower, negative feedback loop involves the induction of DUSP phosphatases that directly dephosphorylate ERK1/2 ().")
       (:PMID . "24525234") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These results indicated that the mobility shift of EGFR was not due to autophosphorylation or ubiquitylation.Next, we examined whether ERK or p38 MAP kinase directly phosphorylated EGFR to induce the mobility shift after TNFalpha treatment.")
       (:PMID . "23220022") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We found that vandetanib inhibited EGF stimulated phosphorylation of EGFR and VEGFR2, as well as AKT and MAPK, in a dose dependent manner (XREF_FIG).")
       (:PMID . "21220477") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous studies have demonstrated that EGFR targeting agents such as cetuximab and gefitinib inhibit the activation specific phosphorylation of EGFR downstream targets such as Akt and Erk [XREF_BIBR, XREF_BIBR].")
       (:PMID . "21411223") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Indeed, several levels of feedback exist between the RAF-MEK-ERK axis and upstream receptor tyrosine kinases such as EGFR : firstly, active ERK phosphorylates EGFR and EGFR signaling adaptor molecules at inhibitory residues, thus keeping signal transduction of the ligand bound receptor to RAS in check [XREF_BIBR - XREF_BIBR].")
       (:PMID . "26299805") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We hypothesized that MEK inhibition activates AKT by inhibiting ERK activity, which blocks an inhibitory threonine phosphorylation on the JM domains of EGFR and HER2, thereby increasing ERBB3 phosphorylation.")
       (:PMID . "22552284") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_5_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As analyzed by Western blot experiments using phospho specific antibodies recognizing activated EGFR (pEGFR; PY20), AKT (pAkt; Ser473) and MAPK (pMAPK; Thr202/204) both substances were found to block EGFR phosphorylation as well as MAPK activation, but only erlotinib was able to induce a distinct block of AKT signalling as indicated by the strongly reduced phosphorylation of AKT (A).")
       (:PMID . "20615764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Treatment of KMBC cells with rhTFF2 stimulated proliferation, triggered phosphorylation of EGFR and downstream extracellular signal related kinase (ERK), whereas co-incubation with the EGFR tyrosine kinase inhibitor, PD153035, blocked rhTFF2 dependent proliferation and EGFR and ERK responses.")
       (:PMID . "21472131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pretreatment with calcitriol, enhanced TNF induced EGFR-Src dependent ERK activation and tyrosine phosphorylation of the EGFR, but abolished the EGFR-Src independent ERK activation.")
       (:PMID . "18080320") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The decrease in EGFR phosphorylation was specific for SFK inhibition as the Mek and Erk1,2 inhibitor U0126 did not inhibit EGFR or Akt phosphorylation, but did block phosphorylation of Erk1,2 as reported.")
       (:PMID . "23866081") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "e4657b47-0d26-45fb-ad3e-9d04967b2958"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P03372") (:+HGNC+ . "3467")) (:NAME . "ESR1"))
     (:SUPPORTED--BY "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "77bdd200-590d-466e-8cf2-d489a5464dcd"
      "3e056022-b0df-4181-b89c-fd2f3c8d4c90")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK3_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_118")
       (:TEXT
        . "7838153;12093745;9528769;10949034;16076840;15528270;15461668;15059947;12118371;7491495")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK3_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_118")
       (:TEXT
        . "Cyclooxygenase-2 (COX-2) antagonists, by blocking prostaglandin production, might inhibit this pathway 149.")
       (:PMID . "12635173") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK3_DirectlyIncreases_p_HGNC_ESR1_pmod_P_S_118")
       (:TEXT
        . "For instance, activation of epidermal growth factor receptor (EGFR) by EGF leads to phosphorylation of the Ser118 residue in the ERalpha AF-1 domain by p44/42 mitogen-activated protein kinase (MAPK), which in turn recruits the coactivator p68/p72 and activates target gene transcription in a ligand-independent manner [80,81].")
       (:PMID . "14680484") (:SOURCE--API . "bel"))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Shigeaki Kato et al. [XREF_BIBR] reported that MAPKs could be activated through EGF-HER2 signaling pathway and the activated MAPK was able to phosphorylate the Ser 118 of ERalpha.")
       (:PMID . "25956130") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Continuous activation of the MAPK pathway increases ERalpha S118 phosphorylation that bypasses the ligand dependent ERalpha signaling pathway, thereby rendering tumors hormone independent.")
       (:PMID . "25597633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that MAPK siRNA treatment significantly decreased MYC expression as well as the phosphorylation of ERalpha (Ser118) and total ERalpha (C).")
       (:PMID . "25683269") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that MAPK siRNA treatment significantly decreased MYC expression as well as the phosphorylation of ERalpha (Ser118) and total ERalpha (C).")
       (:PMID . "25683269") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9fe66be8c2208706bbf5d8e636e759ef")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Also, these data show that ERalpha may be phosphorylated by phospho-p44/42 MAPK at Ser 118 and possibly play an important role in the growth of fibroids.")
       (:PMID . "18853184") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To provide further evidence that ERalpha may be phosphorylated by phospho-p44/42 MAPK at Ser 118 in fibroids, immunoprecipitation assays were done and showed an increased association of ERalpha-phospho-Ser118 and phospho-p44/42 MAPK proteins in leiomyomas compared to myometrial tissue.")
       (:PMID . "18853184") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in B, TNF-alpha mediated phosphorylation peaked at 5min and declined after 15min, as also observed in E2 treated cells.ERalpha can be activated by growth factors through ERK 1/2 catalyzed phosphorylation of ERalpha serine 118.")
       (:PMID . "21784129") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p68 was originally identified as an ERalpha co-activator following in vitro purification of proteins that interacted preferentially with ERalpha phosphorylated at ser 118 by MAPK (XREF_BIBR).")
       (:PMID . "19718048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of ERalpha at S118 by MAPK increased steroid receptor coactivator 3 (SRC3) binding () and induced ERalpha hypersensitivity to E2 ().")
       (:PMID . "25597633") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:POSITION . "118")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "ee7510f3-1009-4fb2-bc6d-59aec93b9be3"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERALPHA") (:+NCIT+ . "C38361") (:+UP+ . "P03372")
       (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d"
      "44294994-ac5b-4225-b3f5-1ee3bd8e84c3")
     (:EVIDENCE
      ((:TEXT
        . "MAPK also indirectly phosphorylates ERalpha at serine 167 via p90rsk.")
       (:PMID . "23265704") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Both AKT and the kinase downstream of mitogen activated protein kinase, p90 ribosomal S6 kinase (pp90Rsk), can also phosphorylate ER at Ser167.")
       (:PMID . "25283475") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Both AKT and the kinase downstream of mitogen activated protein kinase, p90 ribosomal S6 kinase (pp90Rsk), can also phosphorylate ER at Ser167.")
       (:PMID . "25283475") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "MAPK also indirectly phosphorylates ERalpha at serine 167 via p90rsk.")
       (:PMID . "23265704") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "8f0f2893-37d8-40c1-8a26-8541487d2142"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "GSK3A") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:SUPPORTED--BY "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f"
      "bcac201f-07ed-4193-8c6a-f018f5738804")
     (:EVIDENCE
      ((:TEXT
        . "As ERK1/2, GSK3 beta and FAK are affected by the same inhibitors; this suggests a feedback loop is in place, where kp-10 phosphorylation of ERK1/2 via EGFR transactivation can initiate phosphorylation of GSK3 beta at Ser, probably through p90rsk, an ERK1/2 specific mediator of GSK3 beta phosphorylation.")
       (:PMID . "22349353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As ERK1/2 is also important for the phosphorylation of GSK3 beta via p90rsk, this suggests a longer feedback loop where ERK1/2 via p90rsk would phosphorylate Ser of GSK3 beta, which could in turn lead to phosphorylation at Tyr of FAK to increase ERK1/2 phosphorylation ().")
       (:PMID . "22349353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "GSK3 can also be phosphorylated at Ser and Ser by the most downstream kinase of the classical mitogen activated protein kinase (MAPK) cascade, called MAPK activated protein kinase-1 (MAPKAP-K1, also called RSK).")
       (:PMID . "18602000") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "09ec4c36-2899-4164-8477-a4ae1f282d75"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "GSK3B") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:SUPPORTED--BY "81e9ca7a-5b41-45c0-a780-59c13b83a015"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE
      ((:TEXT
        . "GSK3 can also be phosphorylated at Ser and Ser by the most downstream kinase of the classical mitogen activated protein kinase (MAPK) cascade, called MAPK activated protein kinase-1 (MAPKAP-K1, also called RSK).")
       (:PMID . "18602000") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As ERK1/2, GSK3 beta and FAK are affected by the same inhibitors; this suggests a feedback loop is in place, where kp-10 phosphorylation of ERK1/2 via EGFR transactivation can initiate phosphorylation of GSK3 beta at Ser, probably through p90rsk, an ERK1/2 specific mediator of GSK3 beta phosphorylation.")
       (:PMID . "22349353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As ERK1/2 is also important for the phosphorylation of GSK3 beta via p90rsk, this suggests a longer feedback loop where ERK1/2 via p90rsk would phosphorylate Ser of GSK3 beta, which could in turn lead to phosphorylation at Tyr of FAK to increase ERK1/2 phosphorylation ().")
       (:PMID . "22349353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "4a4265c7-33ce-439c-8a5d-8dffd72d67f0"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "c-Jun") (:+UP+ . "P05412") (:+HGNC+ . "6204"))
      (:NAME . "JUN"))
     (:SUPPORTED--BY "06475688-c620-4857-8fa4-1d73a4521960"
      "3ed435d1-8907-49eb-a97d-0f00b073e8bf"
      "5dca9682-4d81-4402-b437-e2e78195930b")
     (:EVIDENCE
      ((:TEXT
        . "Likewise, ERK1/2 was unable to phosphorylate c-Jun at Ser 63 or Ser 73 (C).")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "XREF_BIBR Moreover, TRAF6 specifically regulates both expression and activity of c-Jun, by p38alpha MAPK dependent phosphorylation of c-Jun at Ser63 in cancer cells.")
       (:PMID . "25483191") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Herein we demonstrate that TRAF6 plays an important role for activation of c-Jun in cancer cells, due to its ability to promote activation of p38alpha MAPK, which subsequently phosphorylates c-Jun on Ser63, thereby causing its activation.")
       (:PMID . "25483191") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Upstream from the AP-1 complex, up-regulation of IL-8 transcription by Ang-1 was mediated through the Erk1/2, SAPK and JNK, and PI-3 kinase pathways, which triggered c-Jun phosphorylation on Ser63 and Ser73.")
       (:PMID . "18252863") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "c-Jun, a critical component of the AP1 complex, can be phosphorylated by ERK1/2 on Ser63 and Ser73, and the phosphorylation of these sites are required for AP1 to become transcriptionally active (XREF_BIBR).")
       (:PMID . "19199380") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65de638f898bd6518af6a9dcd4a924d6")
       (:SOURCE--API . "biopax")))
     (:POSITION . "63")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "84c73e10-8168-4dfb-a61a-ee86afd143ca"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "c-Jun") (:+UP+ . "P05412") (:+HGNC+ . "6204"))
      (:NAME . "JUN"))
     (:SUPPORTED--BY "177c5dcc-16be-4287-aaf0-cca0687a040d"
      "c0f61aaf-813e-473b-a4d2-2f246a3cb2ca"
      "06475688-c620-4857-8fa4-1d73a4521960")
     (:EVIDENCE
      ((:TEXT
        . "Likewise, ERK1/2 was unable to phosphorylate c-Jun at Ser 63 or Ser 73 (C).")
       (:PMID . "17689131") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65de638f898bd6518af6a9dcd4a924d6")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "c-Jun, a critical component of the AP1 complex, can be phosphorylated by ERK1/2 on Ser63 and Ser73, and the phosphorylation of these sites are required for AP1 to become transcriptionally active (XREF_BIBR).")
       (:PMID . "19199380") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Upstream from the AP-1 complex, up-regulation of IL-8 transcription by Ang-1 was mediated through the Erk1/2, SAPK and JNK, and PI-3 kinase pathways, which triggered c-Jun phosphorylation on Ser63 and Ser73.")
       (:PMID . "18252863") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "73")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "9e1515bf-d0e9-464e-a680-5d93d44de2f0"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAP2K2") (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:TEXT . "Phosphorylation of MEK is also stimulated by ERK.")
       (:PMID . "8226933") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Raf kinases are the entry point to the ERK and MAPK pathway, a three tiered kinase cascade where Raf phosphorylates and activates MEK which in turn phosphorylates and activates ERK.")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Estrogen binds to the ER-alpha and stimulates MAPK mediated phosphorylation of MEK1/2, which in turn phosphorylates ERK1/2 (extracellular signal regulated kinase1/2) [XREF_BIBR].")
       (:PMID . "18377656") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Only one increased signal was observed across all six RTKs [the phosphorylation of MEK1 and MEK2 (MEK1/2) in response to ERK pooled shRNA knockdown], and only three increases were observed across five RTKs (the phosphorylation of MEK1/2 and ERK1/2 in response to GSK3 pooled shRNA knockdown, and the phosphorylation of Akt in response to PTPN pooled shRNA knockdown).")
       (:PMID . "23861540") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In enzymatic and cellular studies, trametinib inhibited kinase activity of MEK1 and MEK2, prevented RAF dependent MEK phosphorylation, and prolonged inhibition of phosphorylated ERK (a substrate of MEK).")
       (:PMID . "22805291") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "3c2a1422-08b3-4809-b3f4-9b7c32931ca4"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "6972a59d-f263-492b-b508-77c9425eb9d1")
     (:EVIDENCE
      ((:TEXT
        . "PGC-1alpha is phosphorylated by both Mitogen activated protein kinase p38 (XREF_BIBR), and the AMP dependent kinase (AMPK) in skeletal muscle (XREF_BIBR), which also stabilizes the protein and increases its activity.")
       (:PMID . "26831453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Indeed, we have previously shown that VEGF induction of MKP-1 is JNK MAPK dependent, and VEGF induced MKP-1 regulates phosphorylation of both JNK and p38, but not ERK1/2, in HUVEC 18.")
       (:PMID . "24578378") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "ACTH also induces a rapid phosphorylation of p38 kinase and ERKs in human keratinocytes () and modulates ERK activation in adrenal gland ().")
       (:PMID . "19428994") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, the inhibition of ERK by U0126 increased the phosphorylation of p38, and the inhibition of p38 by SB203580 activated ERK1/2 (with cisplatin treatment); however, the inhibition of both ERK and p38 had no obvious effect on p-AKT (XREF_FIG).")
       (:PMID . "26310353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The ERK specific inhibitor U0126 and the p38 specific inhibitor SB202190 blocked ERK and p38 phosphorylation, but did not prevent PA induced LC3-II accumulation (XREF_SUPPLEMENTARY and XREF_SUPPLEMENTARY).")
       (:PMID . "24608675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Fotillin-2 knockdown showed a significant reduction of p38 MAPK phosphorylation but not ERK1/2 phosphorylation, although the knockdown of flotillin-1 had no effect (C, D).")
       (:PMID . "17307333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Analysis of signal transduction pathways activated in response to treatment of ECs with vWF revealed that vWF stimulates the phosphorylation and activation of p38 MAPK and ERK-1,2 in HUVECs.")
       (:PMID . "21083900") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "shows that costimulation with or without the treatment of IL-25 could activate Th cells by rapid inducing the phosphorylation of p38 MAPK and JNK but not ERK within 10min, implying the activation of p38 MAPK and JNK by costimulation.")
       (:PMID . "17719653") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The canonical activation pathway of p38 MAPK includes the serine / threonine kinases (MKKKs or MLKs), which phosphorylate and activate the dual specificity MAPK kinases (MKKs such as MKK3, MKK4, and MKK6), which in turn phosphorylate p38 MAPK isoforms (XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "21286833") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Four isoforms of p38, known as p38alpha, p38beta, p38gamma, and p38delta have been identified, which can all be phosphorylated by the MAPK kinase MKK6 (SKK3) and MKK3, respectively [XREF_BIBR].")
       (:PMID . "26555773") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In response to LPS binding to TLR-4, MAPK kinase-3/6 (MKK3/6) phosphorylates and activates p38 MAPK, which in turn may activate the transcription factor AP-1 ().")
       (:PMID . "21628073") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "VWF induces the phosphorylation and activation of p38 MAPK and ERK-1,2 in HUVECs.")
       (:PMID . "21083900") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This translocation may be an important process for the transduction of signals induced primarily by binding of contact sensitizers to as yet unidentified cellular structures.To elucidate the upstream events involved in the process of translocation future studies have to focus on two MAPK kinases that specifically phosphorylate p38 (MKK3, MKK6) () as well as a further MAPKK, termed MKK4 or JNKK, with a dual specificity for p38 and c-Jun N-terminal kinase (;).")
       (:PMID . "12164931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "14a083b3-54f8-4f8a-88f2-23619d47d32d"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "C-MYC") (:+HGNC+ . "7553") (:+NCIT+ . "C53086")
       (:+UP+ . "P01106"))
      (:NAME . "MYC"))
     (:SUPPORTED--BY "6fa7964a-6f5b-4bf2-8516-7b1f003601f5"
      "57690175-fe8e-4ddf-a8f7-a15078ab086a"
      "2a130ba1-188a-4615-9842-6c35b12675c5"
      "76a4223c-d8a4-49df-82e8-b2eda171cf27"
      "0c17f182-d45a-4f0f-9296-4a4e2fa5dcf1"
      "1c9542fd-881d-4a64-a86e-200038c23f5b")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of c-myc by ERK on Ser62 has been shown to promote c-myc stabilization (XREF_BIBR).")
       (:PMID . "22826122") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Newly synthesized c-myc can, in turn, be phosphorylated by ERK on Ser 62 to induce the stabilization of c-myc (and hence c-myc accumulation), resulting in increased expression levels and enhanced transcriptional activity (see for review).")
       (:PMID . "23266555") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We now show that LANA increases the level of phosphorylated extracellular signal regulated kinase 1 (ERK1) and increases ERK phosphorylation of c-Myc on Ser62.")
       (:PMID . "17634226") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Simultaneously, cellular oxidative stress activates ERK which can phosphorylate c-Myc at Ser62.")
       (:PMID . "26751215") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The ERK and GSK-3beta can phosphorylate c-Myc at Ser62 and Thr58, respectively.")
       (:PMID . "26751215") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of c-myc by ERK on Ser62 has been shown to promote c-myc stabilization (XREF_BIBR).")
       (:PMID . "22826122") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK3_DirectlyIncreases_p_HGNC_MYC_pmod_P_S_62")
       (:TEXT
        . "Exposure to H2O2 enhances c-Myc recruitment to gamma-GCS regulatory regions through ERK-dependent phosphorylation. Phosphorylation at Ser-62 is required for c-Myc recruitment to gamma-GCS promoters and determines the cellular response to oxidative stress induced by different stimuli.")
       (:PMID . "16483932") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MAPK3_DirectlyIncreases_p_HGNC_MYC_pmod_P_S_62")
       (:TEXT
        . "We now show that the phosphorylation of these two residues is critical for determining the stability of Myc. Phosphorylation of Ser 62 is required for Ras-induced stabilization of Myc, likely mediated through the action of ERK.")
       (:PMID . "11018017") (:SOURCE--API . "bel"))
      ((:TEXT
        . "We now show that LANA increases the level of phosphorylated extracellular signal regulated kinase 1 (ERK1) and increases ERK phosphorylation of c-Myc on Ser62.")
       (:PMID . "17634226") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Simultaneously, cellular oxidative stress activates ERK which can phosphorylate c-Myc at Ser62.")
       (:PMID . "26751215") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "62")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "c9796a05-647f-40a7-878c-1f26f6e2e97a"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "PKCalpha") (:+UP+ . "P17252") (:+HGNC+ . "9393"))
      (:NAME . "PRKCA"))
     (:SUPPORTED--BY "20ef1836-ea28-4546-aed3-a396a32b3771")
     (:EVIDENCE
      ((:TEXT
        . "To confirm that Erk indeed catalyzes phosphorylation of PKCalpha at T 638, we used a mutant Erk construct in which a bulky amino acid residue in the ATP binding site (Q 103) had been replaced with glycine, enabling this mutant to utilize a bulky analog of ATP, cyclopentyl ATP.")
       (:PMID . "20513439") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previously we have demonstrated that stimulation of 5-HT 1A -R causes Erk1/2 dependent phosphorylation of PKCalpha in both mouse hippocampus (P15) and hippocampal derived HN2-5 cells [XREF_BIBR].")
       (:PMID . "20513439") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Employing PKCalpha and Erk mutants we next demonstrated that Erk causes direct phosphorylation and activation of PKCalpha.")
       (:PMID . "20513439") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "90632bc8-9ad6-4e3a-916a-da71c7daf31e"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "SHC1") (:+UP+ . "P29353") (:+HGNC+ . "10840"))
      (:NAME . "SHC1"))
     (:SUPPORTED--BY "5155385d-534b-4c6b-9930-a0bd655d3cea")
     (:EVIDENCE
      ((:TEXT
        . "Incubation of cells with the specific EGFR inhibitor AG4178 blocked MbetaCD induced phosphorylation of EGFR, SHC, phospholipase C-gamma, and Gab-1 as well as MAPK activation.")
       (:PMID . "12397069") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylated Shc can then bind Grb2 and Sos complexes to activate p21, Raf-1 and the MAPK pathway.")
       (:PMID . "9824671") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "0f3faab4-f5e1-46c1-b991-62c0493e6f81"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "Smad3") (:+UP+ . "P84022") (:+HGNC+ . "6769"))
      (:NAME . "SMAD3"))
     (:SUPPORTED--BY "ec699d53-2669-4c6a-b9ba-7c3f373c1114")
     (:EVIDENCE
      ((:TEXT
        . "The inhibition of Ras and ERK activity with specific inhibitors significantly suppressed Ox-LDL-induced TGF-beta1 production, Smad3 phosphorylation and PLTP expression.")
       (:PMID . "22034170") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This latter observation suggested that part of the enhanced Smad signaling is due to lower degradation of Smad1 in presence of RTK inhibitors and is consistent with previous reports on interactions between growth factor receptor signaling and Smad phosphorylation by ERK and GSK3 ().")
       (:PMID . "24060635") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2, JNK, and p38 MAPKs can activate or inhibit the Smad signaling pathway by phosphorylating Smad2 or Smad3 XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR.")
       (:PMID . "23468994") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This latter observation suggested that part of the enhanced Smad signaling is due to lower degradation of Smad1 in presence of RTK inhibitors and is consistent with previous reports on interactions between growth factor receptor signaling and Smad phosphorylation by ERK and GSK3 ().")
       (:PMID . "24060635") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Erk MAP kinase pathway activation inhibits TGF-beta-induced Smad3 phosphorylation.")
       (:PMID . "19595713") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous studies have shown that Erk kinases can phosphorylate the linker region of Smad2/3 to inactivate p-Smad2/3C (refs XREF_BIBR, XREF_BIBR, XREF_BIBR).")
       (:PMID . "23591895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Erk MAP kinases also phosphorylate the linker regions of Smad2 and Smad3, thus regulating the activities of these Smads.")
       (:PMID . "19595713") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The Smad activities are also regulated by kinases other than the TGF-beta receptor kinases, most notably by Erk MAP kinases, which are activated in response to growth factors and phosphorylate the Smad linker segments (XREF_BIBR; XREF_BIBR).")
       (:PMID . "19595713") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Smad3 is phosphorylated by ERK MAP kinase upon EGF treatment.")
       (:PMID . "16156666") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our mechanism study clearly demonstrate that HO represses TGF-beta1-induced transcriptional activation potential of Smad3, but not Smad2, without affecting its COOH-tail phosphorylation and nuclear translocation, and this repression is accompanied with Akt mediated ERK1/2 dependent phosphorylation of Smad3 in the linker region.")
       (:PMID . "23685151") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "TGF-beta1 also enhances the phosphorylation of the Smad2/3 linker regions by MAPK, which is involved with E3 Ub ligases, such as Nedd4L XREF_BIBR.")
       (:PMID . "22195013") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The middle linker regions of Smad2 and Smad3 also are phosphorylated by mitogen activated protein kinase (MAPK).")
       (:PMID . "14512875") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "a1e9b937-7bf2-4ebc-8dda-7fcebfb1e74a"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "c-Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:SUPPORTED--BY "a49e8d40-a288-4151-8fd3-d4e5d64e62d5")
     (:EVIDENCE
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Moreover, XREF_BIBR had elegantly demonstrated that phosphorylation of SRC-1 by MAPK was required for optimal ligand independent activation of the AR by IL-6.")
       (:PMID . "22245379") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "4) Phosphorylation of SRC-1 by MAPK was required for optimal ligand independent activation of the AR by IL-6.")
       (:PMID . "12163482") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Besides affecting Bim transcription, PINCH-1 promotes activating phosphorylation of Src family kinases and ERK1/2 that leads to Ser69 phosphorylation of Bim resulting in enhanced degradation [XREF_BIBR].")
       (:PMID . "26405162") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "c-Src fails to interact with mRon when the three tyrosines required for MAP kinase activation are mutated, whereas the presence of any one of these tyrosines alone restores Erk phosphorylation and recruitment of c-Src.")
       (:PMID . "16103119") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Taken together, these data suggest that, consistent with other ligand independent mechanisms shown to functionally transactivate the AR, activation of the CXCL12 and CXCR4 axis promotes MAPK MEK and ERK kinase mediated SRC-1 phosphorylation.")
       (:PMID . "22245379") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "202") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "59c11ab1-67c7-46ca-9f97-f7f83e7d072b"))
    ((:SUB (:DB--REFS (:+UP+ . "P19419") (:+HGNC+ . "3321")) (:NAME . "ELK1"))
     (:SUPPORTED--BY "f2ab2a74-a409-4ead-b065-41e4f0a1ed5b"
      "71e84804-8b59-4792-85c9-69e7caa8f847")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_77374e43ccf4d5864d041409d6a35a64")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8a8435797a3272e26de39f6cff87cdaf")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P45984") (:+HGNC+ . "6886")) (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "076e9be2-fd45-4fb0-9ef0-bd4c00e1e8c2"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P05412") (:+HGNC+ . "6204")) (:NAME . "JUN"))
     (:SUPPORTED--BY "7e297f27-8dba-40e1-9bdb-508a7e4975c2"
      "4a79e261-ecda-44d5-8ece-131abe93cd1a"
      "30b49281-43bb-47cb-af69-aa482c9bf738"
      "5dca9682-4d81-4402-b437-e2e78195930b"
      "aaa273c1-56cc-42ee-bbe7-113f8a1ea9d0"
      "06475688-c620-4857-8fa4-1d73a4521960"
      "c8cd2e5b-c81d-4a5e-864c-6a9d098a45fb")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "9305638") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "12881422") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "9315636") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "7600582") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c870611b6b1bcd0254ddb6e333ac32e6")
       (:PMID . "11801649") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_38acc9ed6b4564a7ebf7a5090d952ceb")
       (:PMID . "17143273") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5cefa4f4b1e73c0857d311ab7ee6b730")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e775d3b7bc5b0163e8a0695c437d55ad")
       (:PMID . "18362184") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e775d3b7bc5b0163e8a0695c437d55ad")
       (:PMID . "10385525") (:SOURCE--API . "biopax")))
     (:POSITION . "63")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P45984") (:+HGNC+ . "6886")) (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "6f52436c-6b98-4aea-a583-c0e57c9c049b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P05412") (:+HGNC+ . "6204")) (:NAME . "JUN"))
     (:SUPPORTED--BY "bc42ccba-5f8c-4841-87e0-f3ceb058707e"
      "27447bf5-50bb-4068-9561-4134abe5414f"
      "a0d6ea18-fb57-4c8d-a8a8-3f8cade349a1"
      "177c5dcc-16be-4287-aaf0-cca0687a040d"
      "904dfb27-f09d-4a0b-a98f-bd4b1bbfb882"
      "06475688-c620-4857-8fa4-1d73a4521960"
      "3db33f8e-5c83-4bd1-93dc-7469e3d94f8d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_38acc9ed6b4564a7ebf7a5090d952ceb")
       (:PMID . "17143273") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "9305638") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "12881422") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "9315636") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ebead40a8837c81dd3ea2c286775219d")
       (:PMID . "7600582") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5cefa4f4b1e73c0857d311ab7ee6b730")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e775d3b7bc5b0163e8a0695c437d55ad")
       (:PMID . "18362184") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e775d3b7bc5b0163e8a0695c437d55ad")
       (:PMID . "10385525") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c870611b6b1bcd0254ddb6e333ac32e6")
       (:PMID . "11801649") (:SOURCE--API . "biopax")))
     (:POSITION . "73")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P45984") (:+HGNC+ . "6886")) (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "94dc105c-ff44-49fd-8295-d5d556bfa6c5"))
    ((:SUB (:DB--REFS (:+TEXT+ . "BAD") (:+UP+ . "Q92934") (:+HGNC+ . "936"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "46 Of note, the phosphorylation of Bad by JNK also increases its mitochondrial localization, thus enhancing apoptosis.")
       (:PMID . "25077544") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "46 Of note, the phosphorylation of Bad by JNK also increases its mitochondrial localization, thus enhancing apoptosis.")
       (:PMID . "25077544") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "e3cd01a9-12fc-4ce5-bf77-f62bb0c0c0b7"))
    ((:SUB (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:SUPPORTED--BY "05e88bd6-921f-4b71-a3df-f4281e42d1c2")
     (:EVIDENCE
      ((:TEXT
        . "In in vitro experiments in which immunobead bound raf is phosphorylated by activated JNK, we find strong phosphorylation signals at raf-Ser259 and Ser338.")
       (:PMID . "18316782") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We have corroborated these findings in studies with isolated protein components from a human astrocyte (U-251) cell line; that is, JNK phosphorylates raf but not the reverse; MEK phosphorylates JNK but not the reverse.")
       (:PMID . "16086581") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In a study of interactions between the raf-MEK-MAPK (ERK) and JNK-jun pathways, we found previously that JNK can induce phosphorylation of raf but not vice versa.")
       (:PMID . "18316782") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In in vitro experiments in which immunobead bound raf is phosphorylated by activated JNK, we find strong phosphorylation signals at raf-Ser259 and Ser338.")
       (:PMID . "18316782") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "6bf3030d-df52-4cb9-81e0-3153c84f880e"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "beta-catenin") (:+UP+ . "P35222")
       (:+HGNC+ . "2514"))
      (:NAME . "CTNNB1"))
     (:SUPPORTED--BY "f284bab9-67a0-40ae-99be-40781eae45f9"
      "5aed1e71-b2f1-4675-8e1d-ea0d9f252d2c"
      "bc96c7d8-d6b6-4dd5-934f-b0b393675faf")
     (:EVIDENCE
      ((:TEXT
        . "Specifically, we provide evidence that JNK binds to E, cadherin, beta, and catenin complex and phosphorylates beta-catenin at serine 37 and threonine 41, the sites also phosphorylated by GSK-3beta.")
       (:PMID . "19667122") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "3d44689d-b2ea-458f-958e-da9708af3fa0"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P19419") (:+HGNC+ . "3321")) (:NAME . "ELK1"))
     (:SUPPORTED--BY "f2ab2a74-a409-4ead-b065-41e4f0a1ed5b"
      "48fcffac-ca4d-4510-bfc6-4df168eb9153"
      "71e84804-8b59-4792-85c9-69e7caa8f847")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_MAPK_JNK_Family_DirectlyIncreases_p_HGNC_ELK1_pmod_P_S_383")
       (:TEXT
        . "Here we have identified human Rev7 (hRev7)/MAD2B/MAD2L2 as an interaction partner for Elk-1 and demonstrate that hRev7 acts to promote Elk-1 phosphorylation by the c-Jun N-terminal protein kinase (JNK) MAP kinases.")
       (:PMID . "17296730") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_MAPK_JNK_Family_DirectlyIncreases_p_HGNC_ELK1_pmod_P_S_383")
       (:TEXT
        . "Here we have identified human Rev7 (hRev7)/MAD2B/MAD2L2 as an interaction partner for Elk-1 and demonstrate that hRev7 acts to promote Elk-1 phosphorylation by the c-Jun N-terminal protein kinase (JNK) MAP kinases.")
       (:PMID . "17296730") (:SOURCE--API . "bel")))
     (:POSITION . "383")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "723df911-4ce1-402d-89c3-2dccb1a1ea9a"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERALPHA") (:+HGNC+ . "3467") (:+UP+ . "P03372")
       (:+NCIT+ . "C38361"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d"
      "0daf90ff-7e79-435a-ba05-ac7a3e7c04e8")
     (:EVIDENCE
      ((:TEXT
        . "MAPK also indirectly phosphorylates ERalpha at serine 167 via p90rsk.")
       (:PMID . "23265704") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Both AKT and the kinase downstream of mitogen activated protein kinase, p90 ribosomal S6 kinase (pp90Rsk), can also phosphorylate ER at Ser167.")
       (:PMID . "25283475") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Both AKT and the kinase downstream of mitogen activated protein kinase, p90 ribosomal S6 kinase (pp90Rsk), can also phosphorylate ER at Ser167.")
       (:PMID . "25283475") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "8f0f2893-37d8-40c1-8a26-8541487d2142"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK14") (:+UP+ . "Q16539") (:+HGNC+ . "6876"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "6972a59d-f263-492b-b508-77c9425eb9d1")
     (:EVIDENCE
      ((:TEXT
        . "PGC-1alpha is phosphorylated by both Mitogen activated protein kinase p38 (XREF_BIBR), and the AMP dependent kinase (AMPK) in skeletal muscle (XREF_BIBR), which also stabilizes the protein and increases its activity.")
       (:PMID . "26831453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Concerning the dependence of (+)-MA-induced MAPK phosphorylation on an intact integrity of membrane lipid rafts, our data are in good line with a recent report showing an inhibitory effect of MCD on anandamide induced phosphorylation of p38 MAPK and c-jun N-terminal kinase (JNK) in rat pheochromocytoma cells.")
       (:PMID . "15474472") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Compared to control, treatment with ADMA (10muM) for 2, 4 and 6h, significantly increased the phosphorylation of p38 MAPK, but not JNK, assessed by Western blot using antibodies to phosphorylated and total JNK and p38 MAPK (A, data about JNK were not showed).")
       (:PMID . "16516911") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We further have found that JNK does not phosphorylate MAPK and that MAPK does not phosphorylate JNK.")
       (:PMID . "16086581") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Expression of VZV ORF12 protein in cells resulted in phosphorylation of ERK1/2 and p38 but not JNK.")
       (:PMID . "22238304") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "MoDC stimulated with DNCB induced strong phosphorylation of p38 MAPK and SAPK and JNK in a concentration dependent manner, 1h after treatment.")
       (:PMID . "12603851") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "b2e70d51-6ea5-45c9-a1d8-3a8cce4ac80d"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "ERK1/2 phosphorylation increased upon ectopic DUSP4 expression in U-2932 cells, a finding which is in line with the documented negative regulation of ERK phosphorylation by active JNK (XREF_BIBR; XREF_BIBR).")
       (:PMID . "25847947") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We further have found that JNK does not phosphorylate MAPK and that MAPK does not phosphorylate JNK.")
       (:PMID . "16086581") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In A431 cells, the JNK pathway can be induced by 20muM ATO to antagonize sustained ERK1/2 phosphorylation, expression and apoptosis ().")
       (:PMID . "25791921") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Using conditions in vitro under which two proline directed protein kinases, glycogen synthase kinase-3beta (GSK-3beta) and mitogen activated protein kinase (MAPK), were able to hyperphosphorylate tau, GSK-3beta but not MAPK phosphorylated recombinant APPcyt.")
       (:PMID . "8764598") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We further have found that JNK does not phosphorylate MAPK and that MAPK does not phosphorylate JNK.")
       (:PMID . "16086581") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Additionally, 20-HETE treatment also induced a time dependent increase in the phosphorylation of ERK1/2 but not JNK in HUVECs (XREF_FIG), with the maximal effects occurring after 30 min of incubation.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "A mitogen activated protein kinase kinase 1/2 inhibitor inhibited both renin and prorenin induced ERK 1/2 phosphorylation.")
       (:PMID . "18212269") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our results demonstrated that JNK mediated phosphorylation is abolished in the Bcl-2 and T56A mutant, but not ERK2 mediated phosphorylation.")
       (:PMID . "23272207") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "EC silencing of integrin beta4 (siITGB4) resulted in significant increases in both basal and LPS induced phosphorylation of ERK 1/2, JNK, and p38 MAPK, consistent with robust MAPK activation.")
       (:PMID . "20512931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These findings showed that the phosphorylation of ERK induced by cicaprost was specifically attenuated by its upstream kinase inhibitors, but not by inhibitors of JNK and p38 MAPK.")
       (:PMID . "15979846") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Regarding the effect of IP6 on MAPKs ERK1/2, JNK1/2 and p38, EGF and IGF-1 treatment strongly induced the phosphorylation of ERK1/2 in starved cells which was almost completely inhibited by co-treatment with IP6 without any effect on total ERK1/2 protein levels (XREF_FIG).")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As shown in the present study, 20-HETE treatment caused a dose dependent increase in the phosphorylation of ERK1/2 but not JNK in HUVECs (XREF_FIG), with the maximal effects occurring at 5 nm.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "3c8cc335-5584-4881-9f0c-a8dc93fc731d"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "ERK1/2 phosphorylation increased upon ectopic DUSP4 expression in U-2932 cells, a finding which is in line with the documented negative regulation of ERK phosphorylation by active JNK (XREF_BIBR; XREF_BIBR).")
       (:PMID . "25847947") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in the present study, 20-HETE treatment caused a dose dependent increase in the phosphorylation of ERK1/2 but not JNK in HUVECs (XREF_FIG), with the maximal effects occurring at 5 nm.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, 20-HETE treatment also induced a time dependent increase in the phosphorylation of ERK1/2 but not JNK in HUVECs (XREF_FIG), with the maximal effects occurring after 30 min of incubation.")
       (:PMID . "24763529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Using conditions in vitro under which two proline directed protein kinases, glycogen synthase kinase-3beta (GSK-3beta) and mitogen activated protein kinase (MAPK), were able to hyperphosphorylate tau, GSK-3beta but not MAPK phosphorylated recombinant APPcyt.")
       (:PMID . "8764598") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In A431 cells, the JNK pathway can be induced by 20muM ATO to antagonize sustained ERK1/2 phosphorylation, expression and apoptosis ().")
       (:PMID . "25791921") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "A mitogen activated protein kinase kinase 1/2 inhibitor inhibited both renin and prorenin induced ERK 1/2 phosphorylation.")
       (:PMID . "18212269") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Under such conditions Elk-1 could be phosphorylated by the mitogen activated protein kinases (MAPKs) ERK1 and ERK2.")
       (:PMID . "8846788") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "EC silencing of integrin beta4 (siITGB4) resulted in significant increases in both basal and LPS induced phosphorylation of ERK 1/2, JNK, and p38 MAPK, consistent with robust MAPK activation.")
       (:PMID . "20512931") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We further have found that JNK does not phosphorylate MAPK and that MAPK does not phosphorylate JNK.")
       (:PMID . "16086581") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We further have found that JNK does not phosphorylate MAPK and that MAPK does not phosphorylate JNK.")
       (:PMID . "16086581") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These findings showed that the phosphorylation of ERK induced by cicaprost was specifically attenuated by its upstream kinase inhibitors, but not by inhibitors of JNK and p38 MAPK.")
       (:PMID . "15979846") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Total MAPK (# 9102), phosphorylated MAPK (# 9101), total Akt (# 9272), phosphorylated Akt (# 9271), phosphorylated c-Src (# 2101), E-cadherin (# 3195), N-cadherin (# 4061), and Snail (# 3879) antibodies were from Cell Signaling Technology (Beverly, MA).")
       (:PMID . "24183378") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Regarding the effect of IP6 on MAPKs ERK1/2, JNK1/2 and p38, EGF and IGF-1 treatment strongly induced the phosphorylation of ERK1/2 in starved cells which was almost completely inhibited by co-treatment with IP6 without any effect on total ERK1/2 protein levels (XREF_FIG).")
       (:PMID . "19544333") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "47cb50c4-3be0-4326-b270-5a914f77d811"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "c-Myc") (:+UP+ . "P01106") (:+HGNC+ . "7553"))
      (:NAME . "MYC"))
     (:SUPPORTED--BY "2a130ba1-188a-4615-9842-6c35b12675c5")
     (:EVIDENCE
      ((:TEXT
        . "However, since JNK induced apoptosis does not require either ectopic c-Myc expression or serum starvation, the role of c-Myc phosphorylation by JNK is unclear.The considerations outlined above indicate that a new approach that allows the direct biochemical analysis of apoptotic signaling in the absence of JNK is required.")
       (:PMID . "11057897") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "59d46781-03fa-4a57-ae50-ea0fc6822a32"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "2eeeaba3-098c-44b3-866d-94e607e66258"
      "1ab7146c-bdaf-476c-8f66-2b0174b78935"
      "c4de9bbf-3087-4235-82a1-663bdb028b62"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "500ac585-1c29-4aff-9c11-cd43015e1b16")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_98c970577b57e3b70bc3d73f48a2864e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Induction of STAT3 Tyr705 and Ser727 phosphorylations by Galpha (s) QL was suppressed by inhibition of protein kinase A, Janus kinase 2/3, Rac1, c-Jun N-terminal kinase (JNK), or phosphatidylinositol 3-kinase, and a similar profile was observed in response to beta2-adrenergic receptor stimulation.")
       (:PMID . "17008315") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We provide in vitro and in vivo evidence that the ERK family of mitogen activated protein (MAP) kinases, but not JNK or p38, specifically phosphorylate STAT3 at serine 727 in response to growth factors.")
       (:PMID . "9343414") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Here, we report that Ser 727 phosphorylation of Stat3 can also be induced by JNK and activated either by stress or by its upstream kinase and that various stress treatments induce serine phosphorylation of Stat3 in the absence of tyrosine phosphorylation.")
       (:PMID . "10521505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "727")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P45984") (:+HGNC+ . "6886")) (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "efc1948a-fb67-4970-8a59-bb9ac742dafb"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "TSC-2") (:+NCIT+ . "C17913") (:+UP+ . "P49815")
       (:+HGNC+ . "12363"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef")
     (:EVIDENCE
      ((:TEXT
        . "Active MAP kinase can inhibit the TSC1 and TSC2 complex by specifically phosphorylating TSC2, or indirectly through activation of RSK, and thereby activating mTOR1 (;).")
       (:PMID . "26763419") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Similarly, Ras induced activation of phosphatidylinositol 3 '-kinase/Akt () and ribosomal S6 kinase would be predicted to inactivate TSC2 (), resulting in activation of Rheb and mTOR.Interestingly, B-Raf activation should also theoretically result in mTOR activation, because p42 mitogen activated protein kinase, which is a downstream effector of B-Raf, directly phosphorylates and inactivates TSC2 ().")
       (:PMID . "17914450") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activation of the phosphoinositide-3-kinase (PI3K)/Akt or Ras and mitogen activated protein kinase (MAPK) pathway by growth factors leads to TSC2 phosphorylation and inhibition of the TSC protein complex by Akt, extracellular signal regulated kinase (ERK), and p90 ribosomal S6 kinase 1 (RSK1) kinases (XREF_FIG).")
       (:PMID . "19276265") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "d7a7bef9-8066-43d4-a889-490d870b3057"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "YAP-1") (:+HGNC+ . "16262") (:+UP+ . "P46937")
       (:+NCIT+ . "C96031"))
      (:NAME . "YAP1"))
     (:SUPPORTED--BY "9f45cc54-8c1c-4abb-a11c-5f205594be93")
     (:EVIDENCE
      ((:TEXT
        . "10 As JNK phosphorylates YAP1 to regulate its function in apoptosis, 11 and as pATM levels are elevated in Chaetocin treated cells, we determined the status of JNK activation in these cells.")
       (:PMID . "24810048") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "To determine whether JNK phosphorylates endogenous YAP1, we activated JNK by treating cells with anisomycin and detected the YAP band shift in a number of cells, including the HaCaT keratinocyte, U20S osteosarcoma, MCF-7 breast cancer and 293 human embryonic kidney cell lines (XREF_FIG).")
       (:PMID . "21364637") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "JNK phosphorylation of YAP1 is required to stabilize p63 through direct binding with YAP1 XREF_BIBR.")
       (:PMID . "24621512") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "JNK phosphorylation of YAP1 is required to stabilize p63 through direct binding with YAP1 XREF_BIBR.")
       (:PMID . "24621512") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "10 As JNK phosphorylates YAP1 to regulate its function in apoptosis, 11 and as pATM levels are elevated in Chaetocin treated cells, we determined the status of JNK activation in these cells.")
       (:PMID . "24810048") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "10 As JNK phosphorylates YAP1 to regulate its function in apoptosis, 11 and as pATM levels are elevated in Chaetocin treated cells, we determined the status of JNK activation in these cells")
       (:PMID . "24810048") (:SOURCE--API . "sparser")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "185") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "183") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "MAPK9") (:+UP+ . "P45984") (:+HGNC+ . "6886"))
      (:NAME . "MAPK9"))
     (:TYPE . "Phosphorylation")
     (:ID . "b7f7da02-31c1-4e68-9338-db84dc217e82"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:SUPPORTED--BY "f4b99b24-460e-49eb-8634-cd104d801e57"
      "8f7a9f67-8584-426c-b366-fb7c522e7a76"
      "bf493c0f-0d9f-4153-a917-344a407c3e74")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MET_DirectlyIncreases_p_HGNC_MET_pmod_P_Y_1234")
       (:TEXT . "1247597;8302603;7961992") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MET_DirectlyIncreases_p_HGNC_MET_pmod_P_Y_1234")
       (:TEXT
        . "Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356))")
       (:PMID . "10506185") (:SOURCE--API . "bel")))
     (:POSITION . "1234")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1234") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:TYPE . "Phosphorylation")
     (:ID . "baff17eb-5f0f-4818-afd4-6d512bbc4bbf"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:SUPPORTED--BY "ccbd2b46-02c4-441d-9f47-818ee6d4c814"
      "8f7a9f67-8584-426c-b366-fb7c522e7a76"
      "bf493c0f-0d9f-4153-a917-344a407c3e74")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MET_DirectlyIncreases_p_HGNC_MET_pmod_P_Y_1234")
       (:TEXT . "1247597;8302603;7961992") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MET_DirectlyIncreases_p_HGNC_MET_pmod_P_Y_1234")
       (:TEXT
        . "Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356))")
       (:PMID . "10506185") (:SOURCE--API . "bel")))
     (:POSITION . "1234")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1235") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:TYPE . "Phosphorylation")
     (:ID . "8c2eeddf-2bce-40b2-b73a-e390ba6a426e"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:SUPPORTED--BY "baa5995d-1cd2-452b-b12b-54e2a8e3dbdc"
      "8f7a9f67-8584-426c-b366-fb7c522e7a76")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MET_DirectlyIncreases_p_HGNC_MET_pmod_P_Y_1235")
       (:TEXT . "1247597;8302603") (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MET_DirectlyIncreases_p_HGNC_MET_pmod_P_Y_1235")
       (:TEXT
        . "Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356))")
       (:PMID . "10506185") (:SOURCE--API . "bel")))
     (:POSITION . "1235")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1234") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:TYPE . "Phosphorylation")
     (:ID . "7256fb4b-2d35-434d-bf0c-b11f99190f8e"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:SUPPORTED--BY "4bafaf08-da2e-4bce-8092-8920336af2d2"
      "8f7a9f67-8584-426c-b366-fb7c522e7a76")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MET_DirectlyIncreases_p_HGNC_MET_pmod_P_Y_1235")
       (:TEXT . "1247597;8302603") (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_MET_DirectlyIncreases_p_HGNC_MET_pmod_P_Y_1235")
       (:TEXT
        . "Met-mediated invasive growth requires autophosphorylation of the receptor on tyrosines located in the kinase activation loop (Tyr(1234)-Tyr(1235)) and in the carboxyl-terminal tail (Tyr(1349)-Tyr(1356))")
       (:PMID . "10506185") (:SOURCE--API . "bel")))
     (:POSITION . "1235")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1235") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:TYPE . "Phosphorylation")
     (:ID . "713fdb8a-8a1a-4544-9807-a2032876c641"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "3b085760-047b-4de6-a358-6f53aa726e61"
      "16219b92-62f4-4f37-a08c-952d8ac46555"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "5377520e-d1c5-494f-ad7e-4cdea1263c43")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f8a94a1b45fd162d025d09a086fafb2a")
       (:SOURCE--API . "biopax")))
     (:POSITION . "397")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1234") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:TYPE . "Phosphorylation")
     (:ID . "9c6b3c3c-53ca-4fac-874f-f0615aa81f23"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "3b085760-047b-4de6-a358-6f53aa726e61"
      "a6d55366-938a-46bf-b83c-13bfc10f46b8"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "5377520e-d1c5-494f-ad7e-4cdea1263c43")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f8a94a1b45fd162d025d09a086fafb2a")
       (:SOURCE--API . "biopax")))
     (:POSITION . "397")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "1235") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P08581") (:+HGNC+ . "7029")) (:NAME . "MET"))
     (:TYPE . "Phosphorylation")
     (:ID . "9c6b3c3c-53ca-4fac-874f-f0615aa81f23"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "f96afb09-ee72-4067-a568-1047c7c76893"
      "d5d0707a-a034-4a72-a3d3-a3d69c2b8962"
      "05e88bd6-921f-4b71-a3df-f4281e42d1c2")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2671bfada9254109a6719146369e06e1")
       (:SOURCE--API . "biopax")))
     (:POSITION . "446")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "144") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13153") (:+HGNC+ . "8590")) (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "0bf6d503-ac45-4b02-bcb3-201145249787"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "e3bd1dbf-1649-47a4-8e32-cf3a39734918"
      "d5d0707a-a034-4a72-a3d3-a3d69c2b8962"
      "05e88bd6-921f-4b71-a3df-f4281e42d1c2")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2671bfada9254109a6719146369e06e1")
       (:SOURCE--API . "biopax")))
     (:POSITION . "446")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "199") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13153") (:+HGNC+ . "8590")) (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "0bf6d503-ac45-4b02-bcb3-201145249787"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "ce62ce42-89b5-48f0-989c-3f4b308c5694"
      "d5d0707a-a034-4a72-a3d3-a3d69c2b8962"
      "05e88bd6-921f-4b71-a3df-f4281e42d1c2")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2671bfada9254109a6719146369e06e1")
       (:SOURCE--API . "biopax")))
     (:POSITION . "446")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "423") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13153") (:+HGNC+ . "8590")) (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "0bf6d503-ac45-4b02-bcb3-201145249787"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAP2K2") (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:TEXT
        . "Moreover, in melanoma cells, the BRAFV600E specific kinase inhibitor vemurafinib did not inhibit PAK phosphorylation of MEK in cells homozygous for BRAFV600E, suggesting that that mutant BRAF may not signal through PAK as efficiently in these cells (XREF_BIBR).")
       (:PMID . "25228413") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Although PAK1 phosphorylates mitogen activated protein kinase kinase 1/2 (MEK1/2) directly and activates the Rac1-PAK-Mek1/2-Erk1/2 pathway in non small cell lung cancer, PAK1 and PAK3 promote anchorage independent cell growth through Raf1 phosphorylation.")
       (:PMID . "18639460") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition to the scaffolding function, PAK1 phosphorylates both MEK and Raf-1 to amplify the ERK signaling [XREF_BIBR].")
       (:PMID . "25472536") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK1 phosphorylates Raf and MEK and facilitates the Ras/Raf/MAPK signalling pathway in COS fibroblasts and hence could play an important role in CRC development.")
       (:PMID . "20595063") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Moreover, in melanoma cells, the BRAFV600E specific kinase inhibitor vemurafinib did not inhibit PAK phosphorylation of MEK in cells homozygous for BRAFV600E, suggesting that that mutant BRAF may not signal through PAK as efficiently in these cells (XREF_BIBR).")
       (:PMID . "25228413") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK1 phosphorylates Raf and MEK and facilitates the Ras/Raf/MAPK signalling pathway in COS fibroblasts and hence could play an important role in CRC development.")
       (:PMID . "20595063") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "144") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PAK1") (:+UP+ . "Q13153") (:+HGNC+ . "8590"))
      (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4c4c55c6-c43b-4389-abdf-5e96ca1fddb4"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAP2K2") (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:TEXT
        . "Moreover, in melanoma cells, the BRAFV600E specific kinase inhibitor vemurafinib did not inhibit PAK phosphorylation of MEK in cells homozygous for BRAFV600E, suggesting that that mutant BRAF may not signal through PAK as efficiently in these cells (XREF_BIBR).")
       (:PMID . "25228413") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Although PAK1 phosphorylates mitogen activated protein kinase kinase 1/2 (MEK1/2) directly and activates the Rac1-PAK-Mek1/2-Erk1/2 pathway in non small cell lung cancer, PAK1 and PAK3 promote anchorage independent cell growth through Raf1 phosphorylation.")
       (:PMID . "18639460") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition to the scaffolding function, PAK1 phosphorylates both MEK and Raf-1 to amplify the ERK signaling [XREF_BIBR].")
       (:PMID . "25472536") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK1 phosphorylates Raf and MEK and facilitates the Ras/Raf/MAPK signalling pathway in COS fibroblasts and hence could play an important role in CRC development.")
       (:PMID . "20595063") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Moreover, in melanoma cells, the BRAFV600E specific kinase inhibitor vemurafinib did not inhibit PAK phosphorylation of MEK in cells homozygous for BRAFV600E, suggesting that that mutant BRAF may not signal through PAK as efficiently in these cells (XREF_BIBR).")
       (:PMID . "25228413") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK1 phosphorylates Raf and MEK and facilitates the Ras/Raf/MAPK signalling pathway in COS fibroblasts and hence could play an important role in CRC development.")
       (:PMID . "20595063") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "199") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PAK1") (:+UP+ . "Q13153") (:+HGNC+ . "8590"))
      (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4c4c55c6-c43b-4389-abdf-5e96ca1fddb4"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAP2K2") (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564")
     (:EVIDENCE
      ((:TEXT
        . "Moreover, in melanoma cells, the BRAFV600E specific kinase inhibitor vemurafinib did not inhibit PAK phosphorylation of MEK in cells homozygous for BRAFV600E, suggesting that that mutant BRAF may not signal through PAK as efficiently in these cells (XREF_BIBR).")
       (:PMID . "25228413") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Although PAK1 phosphorylates mitogen activated protein kinase kinase 1/2 (MEK1/2) directly and activates the Rac1-PAK-Mek1/2-Erk1/2 pathway in non small cell lung cancer, PAK1 and PAK3 promote anchorage independent cell growth through Raf1 phosphorylation.")
       (:PMID . "18639460") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition to the scaffolding function, PAK1 phosphorylates both MEK and Raf-1 to amplify the ERK signaling [XREF_BIBR].")
       (:PMID . "25472536") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK1 phosphorylates Raf and MEK and facilitates the Ras/Raf/MAPK signalling pathway in COS fibroblasts and hence could play an important role in CRC development.")
       (:PMID . "20595063") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Moreover, in melanoma cells, the BRAFV600E specific kinase inhibitor vemurafinib did not inhibit PAK phosphorylation of MEK in cells homozygous for BRAFV600E, suggesting that that mutant BRAF may not signal through PAK as efficiently in these cells (XREF_BIBR).")
       (:PMID . "25228413") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK1 phosphorylates Raf and MEK and facilitates the Ras/Raf/MAPK signalling pathway in COS fibroblasts and hence could play an important role in CRC development.")
       (:PMID . "20595063") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "423") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PAK1") (:+UP+ . "Q13153") (:+HGNC+ . "8590"))
      (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4c4c55c6-c43b-4389-abdf-5e96ca1fddb4"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "In NRAS-mutant and BRAF and NRAS-wild-type melanomas, inhibition of PAK1 through either siRNA knockdown or the PAK1 inhibitor PF-3758309 suppresses ERK phosphorylation and was associated with the reduction growth in a BRAF and NRAS-wild-type melanoma xenograft model (XREF_BIBR).")
       (:PMID . "25180764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although PAK1 phosphorylates mitogen activated protein kinase kinase 1/2 (MEK1/2) directly and activates the Rac1-PAK-Mek1/2-Erk1/2 pathway in non small cell lung cancer, PAK1 and PAK3 promote anchorage independent cell growth through Raf1 phosphorylation.")
       (:PMID . "18639460") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Importantly, activated Pak1 elicited phosphorylation of the ERK and JNK dependent pathway in gastric cancer cell lines.")
       (:PMID . "22293972") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, loss of Pak activity did not reduce Erk phosphorylation.")
       (:PMID . "25596744") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here, we found that the PAK selective inhibitor peptide PAK18, which has been used to interfere selectively with the activation of PAKs 1-3 in cell cultures and experiments, not only reduced infectious viral titers but also significantly suppressed ERK 1/2 phosphorylation ().")
       (:PMID . "21982772") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "144") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PAK1") (:+UP+ . "Q13153") (:+HGNC+ . "8590"))
      (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "aa190ac6-d42c-47fa-b34d-71d6041a337d"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "In NRAS-mutant and BRAF and NRAS-wild-type melanomas, inhibition of PAK1 through either siRNA knockdown or the PAK1 inhibitor PF-3758309 suppresses ERK phosphorylation and was associated with the reduction growth in a BRAF and NRAS-wild-type melanoma xenograft model (XREF_BIBR).")
       (:PMID . "25180764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although PAK1 phosphorylates mitogen activated protein kinase kinase 1/2 (MEK1/2) directly and activates the Rac1-PAK-Mek1/2-Erk1/2 pathway in non small cell lung cancer, PAK1 and PAK3 promote anchorage independent cell growth through Raf1 phosphorylation.")
       (:PMID . "18639460") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Importantly, activated Pak1 elicited phosphorylation of the ERK and JNK dependent pathway in gastric cancer cell lines.")
       (:PMID . "22293972") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, loss of Pak activity did not reduce Erk phosphorylation.")
       (:PMID . "25596744") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here, we found that the PAK selective inhibitor peptide PAK18, which has been used to interfere selectively with the activation of PAKs 1-3 in cell cultures and experiments, not only reduced infectious viral titers but also significantly suppressed ERK 1/2 phosphorylation ().")
       (:PMID . "21982772") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "199") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PAK1") (:+UP+ . "Q13153") (:+HGNC+ . "8590"))
      (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "757d58fb-1d5c-4213-93e9-93e6764ced59"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "In NRAS-mutant and BRAF and NRAS-wild-type melanomas, inhibition of PAK1 through either siRNA knockdown or the PAK1 inhibitor PF-3758309 suppresses ERK phosphorylation and was associated with the reduction growth in a BRAF and NRAS-wild-type melanoma xenograft model (XREF_BIBR).")
       (:PMID . "25180764") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Although PAK1 phosphorylates mitogen activated protein kinase kinase 1/2 (MEK1/2) directly and activates the Rac1-PAK-Mek1/2-Erk1/2 pathway in non small cell lung cancer, PAK1 and PAK3 promote anchorage independent cell growth through Raf1 phosphorylation.")
       (:PMID . "18639460") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Importantly, activated Pak1 elicited phosphorylation of the ERK and JNK dependent pathway in gastric cancer cell lines.")
       (:PMID . "22293972") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, loss of Pak activity did not reduce Erk phosphorylation.")
       (:PMID . "25596744") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here, we found that the PAK selective inhibitor peptide PAK18, which has been used to interfere selectively with the activation of PAKs 1-3 in cell cultures and experiments, not only reduced infectious viral titers but also significantly suppressed ERK 1/2 phosphorylation ().")
       (:PMID . "21982772") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "423") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PAK1") (:+UP+ . "Q13153") (:+HGNC+ . "8590"))
      (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "09511649-10d1-491b-9b88-fb59457db6c1"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "b28645ac-5b5f-459e-af78-4d0112ed6238"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "11781878-54aa-4b12-9f73-29a604cc62e7")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_901da14fdc4a0b9b9a555e808994e963")
       (:PMID . "16129686") (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In Ras and ERK signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (XREF_BIBR, XREF_BIBR).")
       (:PMID . "23576562") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In comparison to other Pak1 substrates, S111 is very similar to two other widely documented sequences that Pak1 phosphorylates, S338 of Raf-1, RPRGQRDSSYYWEIE and S297 of MEK, RTPGRPLSSYGMDSR.")
       (:PMID . "22096607") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "PAK1 phosphorylates Raf1 at S338 and S339, thus initiating a Raf1-BAD interaction, which disrupts BAD-B-cell lymphoma protein 2 (Bcl-2) and BAD-Bcl-xL interactions in mitochondria.")
       (:PMID . "18639460") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Rac regulates Raf-1 activation via its downstream target PAK, which phosphorylates Raf-1 at serine 338 [XREF_BIBR, XREF_BIBR].")
       (:PMID . "24342356") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous studies showed that the phosphorylation of c-Raf at Ser338 was caused by p21 activated kinase 1 (PAK1) and PAK2 and that PAK1 and PAK2 knockdown inhibited p38 activation.")
       (:PMID . "25725287") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_53ca8a3ee84671deeb1039ce9b5239cb")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "In Ras and ERK signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (XREF_BIBR, XREF_BIBR).")
       (:PMID . "23576562") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In Erk signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (XREF_BIBR, XREF_BIBR).")
       (:PMID . "22983922") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK directly phosphorylates MEK1 on S298, which then induces MEK1 autophosphorylation on S218/222 and increases kinase activity toward ERK XREF_BIBR and phosphorylates Raf on Ser338 XREF_BIBR, which is known as MEK activator.")
       (:PMID . "21209852") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak phosphorylates two mediators of the MAP kinase pathway, MEK1 and Raf1, at Ser298 and at Ser338, respectively [XREF_BIBR - XREF_BIBR].")
       (:PMID . "19165420") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak1, and as well Pak5, induce phosphorylation of Raf1 at Ser338 and stimulate translocation of a subpopulation of Raf1 to the mitochondria [XREF_BIBR - XREF_BIBR].")
       (:PMID . "19165420") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pak phosphorylates S338 on Raf-1, a critical modification for Raf-1 activation in many systems ().")
       (:PMID . "16916643") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "338")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "144") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13153") (:+HGNC+ . "8590")) (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "3d00d0ca-cb71-4d67-9abb-6e5225ef094c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "d9662027-9352-467b-a022-622f16fdc123"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "11781878-54aa-4b12-9f73-29a604cc62e7")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_901da14fdc4a0b9b9a555e808994e963")
       (:PMID . "16129686") (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In Ras and ERK signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (XREF_BIBR, XREF_BIBR).")
       (:PMID . "23576562") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In comparison to other Pak1 substrates, S111 is very similar to two other widely documented sequences that Pak1 phosphorylates, S338 of Raf-1, RPRGQRDSSYYWEIE and S297 of MEK, RTPGRPLSSYGMDSR.")
       (:PMID . "22096607") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "PAK1 phosphorylates Raf1 at S338 and S339, thus initiating a Raf1-BAD interaction, which disrupts BAD-B-cell lymphoma protein 2 (Bcl-2) and BAD-Bcl-xL interactions in mitochondria.")
       (:PMID . "18639460") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Rac regulates Raf-1 activation via its downstream target PAK, which phosphorylates Raf-1 at serine 338 [XREF_BIBR, XREF_BIBR].")
       (:PMID . "24342356") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous studies showed that the phosphorylation of c-Raf at Ser338 was caused by p21 activated kinase 1 (PAK1) and PAK2 and that PAK1 and PAK2 knockdown inhibited p38 activation.")
       (:PMID . "25725287") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_53ca8a3ee84671deeb1039ce9b5239cb")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "In Ras and ERK signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (XREF_BIBR, XREF_BIBR).")
       (:PMID . "23576562") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In Erk signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (XREF_BIBR, XREF_BIBR).")
       (:PMID . "22983922") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK directly phosphorylates MEK1 on S298, which then induces MEK1 autophosphorylation on S218/222 and increases kinase activity toward ERK XREF_BIBR and phosphorylates Raf on Ser338 XREF_BIBR, which is known as MEK activator.")
       (:PMID . "21209852") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak phosphorylates two mediators of the MAP kinase pathway, MEK1 and Raf1, at Ser298 and at Ser338, respectively [XREF_BIBR - XREF_BIBR].")
       (:PMID . "19165420") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak1, and as well Pak5, induce phosphorylation of Raf1 at Ser338 and stimulate translocation of a subpopulation of Raf1 to the mitochondria [XREF_BIBR - XREF_BIBR].")
       (:PMID . "19165420") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pak phosphorylates S338 on Raf-1, a critical modification for Raf-1 activation in many systems ().")
       (:PMID . "16916643") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "338")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "199") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13153") (:+HGNC+ . "8590")) (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "0a5aa74f-ec0f-4bc2-ac10-2b17b078a421"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "52ff0a27-3b50-4582-833d-c2f58974f5af"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "11781878-54aa-4b12-9f73-29a604cc62e7")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_901da14fdc4a0b9b9a555e808994e963")
       (:PMID . "16129686") (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In Ras and ERK signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (XREF_BIBR, XREF_BIBR).")
       (:PMID . "23576562") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In comparison to other Pak1 substrates, S111 is very similar to two other widely documented sequences that Pak1 phosphorylates, S338 of Raf-1, RPRGQRDSSYYWEIE and S297 of MEK, RTPGRPLSSYGMDSR.")
       (:PMID . "22096607") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "PAK1 phosphorylates Raf1 at S338 and S339, thus initiating a Raf1-BAD interaction, which disrupts BAD-B-cell lymphoma protein 2 (Bcl-2) and BAD-Bcl-xL interactions in mitochondria.")
       (:PMID . "18639460") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Rac regulates Raf-1 activation via its downstream target PAK, which phosphorylates Raf-1 at serine 338 [XREF_BIBR, XREF_BIBR].")
       (:PMID . "24342356") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previous studies showed that the phosphorylation of c-Raf at Ser338 was caused by p21 activated kinase 1 (PAK1) and PAK2 and that PAK1 and PAK2 knockdown inhibited p38 activation.")
       (:PMID . "25725287") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_53ca8a3ee84671deeb1039ce9b5239cb")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "In Ras and ERK signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (XREF_BIBR, XREF_BIBR).")
       (:PMID . "23576562") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In Erk signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (XREF_BIBR, XREF_BIBR).")
       (:PMID . "22983922") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK directly phosphorylates MEK1 on S298, which then induces MEK1 autophosphorylation on S218/222 and increases kinase activity toward ERK XREF_BIBR and phosphorylates Raf on Ser338 XREF_BIBR, which is known as MEK activator.")
       (:PMID . "21209852") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak phosphorylates two mediators of the MAP kinase pathway, MEK1 and Raf1, at Ser298 and at Ser338, respectively [XREF_BIBR - XREF_BIBR].")
       (:PMID . "19165420") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak1, and as well Pak5, induce phosphorylation of Raf1 at Ser338 and stimulate translocation of a subpopulation of Raf1 to the mitochondria [XREF_BIBR - XREF_BIBR].")
       (:PMID . "19165420") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pak phosphorylates S338 on Raf-1, a critical modification for Raf-1 activation in many systems ().")
       (:PMID . "16916643") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "338")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "423") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "204") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q13153") (:+HGNC+ . "8590")) (:NAME . "PAK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "d347c4cd-cfb9-4e0a-bc57-b3af7e390040"))
    ((:SUB (:DB--REFS (:+TEXT+ . "MYC") (:+UP+ . "P01106") (:+HGNC+ . "7553"))
      (:NAME . "MYC"))
     (:SUPPORTED--BY "2a130ba1-188a-4615-9842-6c35b12675c5")
     (:EVIDENCE
      ((:TEXT
        . "Here we demonstrate that Pak2 phosphorylates Myc at three sites (T358, S373, and T400) and affects Myc functions both in vitro and in vivo.")
       (:PMID . "14749374") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, if c-Myc is phosphorylated by the kinase Pak2, the c, Myc, and RARalpha complex activates transcription of those same genes to stimulate differentiation, thus reducing tumor burden.")
       (:PMID . "22510570") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PAK-2") (:+UP+ . "Q13177") (:+HGNC+ . "8591"))
      (:NAME . "PAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "c309abe1-e066-4f88-bab7-82157f6fab61"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "Raf1") (:+UP+ . "P04049") (:+HGNC+ . "9829"))
      (:NAME . "RAF1"))
     (:SUPPORTED--BY "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "11781878-54aa-4b12-9f73-29a604cc62e7"
      "1a912d8f-b2de-4fdc-bbb3-5a5bedf1d96d")
     (:EVIDENCE
      ((:TEXT
        . "Pak phosphorylates two mediators of the MAP kinase pathway, MEK1 and Raf1, at Ser298 and at Ser338, respectively [XREF_BIBR - XREF_BIBR].")
       (:PMID . "19165420") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "PAK directly phosphorylates MEK1 on S298, which then induces MEK1 autophosphorylation on S218/222 and increases kinase activity toward ERK XREF_BIBR and phosphorylates Raf on Ser338 XREF_BIBR, which is known as MEK activator.")
       (:PMID . "21209852") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak phosphorylates S338 on Raf-1, a critical modification for Raf-1 activation in many systems ().")
       (:PMID . "16916643") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Rac regulates Raf-1 activation via its downstream target PAK, which phosphorylates Raf-1 at serine 338 [XREF_BIBR, XREF_BIBR].")
       (:PMID . "24342356") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "338")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PAK2") (:+UP+ . "Q13177") (:+HGNC+ . "8591"))
      (:NAME . "PAK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "b38864cd-8289-4539-a336-81424c143dc5"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "RAF1") (:+UP+ . "P04049") (:+HGNC+ . "9829"))
      (:NAME . "RAF1"))
     (:SUPPORTED--BY "9c1e52ea-24f7-405c-9b91-700f1dea136a"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "11781878-54aa-4b12-9f73-29a604cc62e7")
     (:EVIDENCE
      ((:TEXT
        . "PAK directly phosphorylates MEK1 on S298, which then induces MEK1 autophosphorylation on S218/222 and increases kinase activity toward ERK XREF_BIBR and phosphorylates Raf on Ser338 XREF_BIBR, which is known as MEK activator.")
       (:PMID . "21209852") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Rac regulates Raf-1 activation via its downstream target PAK, which phosphorylates Raf-1 at serine 338 [XREF_BIBR, XREF_BIBR].")
       (:PMID . "24342356") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pak phosphorylates two mediators of the MAP kinase pathway, MEK1 and Raf1, at Ser298 and at Ser338, respectively [XREF_BIBR - XREF_BIBR].")
       (:PMID . "19165420") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Here we show that the p21 activated protein kinase Pak3 phosphorylates Raf-1 on serine 338 in vitro and in vivo")
       (:PMID . "9823899") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Pak phosphorylates S338 on Raf-1, a critical modification for Raf-1 activation in many systems ().")
       (:PMID . "16916643") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "338")
     (:ENZ (:DB--REFS (:+TEXT+ . "PAK3") (:+UP+ . "O75914") (:+HGNC+ . "8592"))
      (:NAME . "PAK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "14416f12-3a94-470b-a51d-961a06dda5f8"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "Raf-1") (:+UP+ . "P04049") (:+HGNC+ . "9829"))
      (:NAME . "RAF1"))
     (:SUPPORTED--BY "11781878-54aa-4b12-9f73-29a604cc62e7"
      "0b82f6a1-b2ce-4915-b562-8c0243a14802"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc")
     (:EVIDENCE
      ((:TEXT
        . "Pak phosphorylates S338 on Raf-1, a critical modification for Raf-1 activation in many systems ().")
       (:PMID . "16916643") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Rac regulates Raf-1 activation via its downstream target PAK, which phosphorylates Raf-1 at serine 338 [XREF_BIBR, XREF_BIBR].")
       (:PMID . "24342356") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK directly phosphorylates MEK1 on S298, which then induces MEK1 autophosphorylation on S218/222 and increases kinase activity toward ERK XREF_BIBR and phosphorylates Raf on Ser338 XREF_BIBR, which is known as MEK activator.")
       (:PMID . "21209852") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Pak can phosphorylate Raf-1 on serine 338 and induce phosphorylation of Mek1 on serine 298.")
       (:PMID . "14580336") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Pak phosphorylates two mediators of the MAP kinase pathway, MEK1 and Raf1, at Ser298 and at Ser338, respectively [XREF_BIBR - XREF_BIBR].")
       (:PMID . "19165420") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "338")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PAK4") (:+UP+ . "O96013") (:+HGNC+ . "16059"))
      (:NAME . "PAK4"))
     (:TYPE . "Phosphorylation")
     (:ID . "5f73188e-ed81-4a33-822a-1a4916882ed8"))
    ((:SUB (:DB--REFS (:+UP+ . "P31751") (:+HGNC+ . "392")) (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8"
      "efc0f401-59d0-4d16-9d47-b9fd38be3c85"
      "de18b151-2fbd-4068-a0b9-cf840f8f2dca")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9bce0d6f7efc47536af3b6d6a1c2ab0e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fa628c3c2673262f94aae8f2ca06de88")
       (:SOURCE--API . "biopax")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "c0039a13-f3de-40d9-b119-0a941a042826"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:SUPPORTED--BY "76213862-00a2-4131-bf9a-a86493a639e8"
      "b4bcefa8-5825-404c-9e20-1f9a11bcb142"
      "11e6cc2a-e17a-4cf5-a2e3-362b875b77dd"
      "5757b142-0a4a-4a74-be36-db6f3c483dac"
      "01e738db-5c16-4feb-b774-6ff1c9f84347"
      "30a62049-97f7-4142-868b-0b87bbdc7bd1"
      "2fa47658-c175-405a-8bd4-cc2c58818d80"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4da279fae06b450264d4c9135d862652")
       (:PMID . "11809791") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4376f1cd673e62bbe17fdf657219730c")
       (:PMID . "11241670") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4376f1cd673e62bbe17fdf657219730c")
       (:PMID . "14666721") (:SOURCE--API . "biopax")))
     (:POSITION . "473")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "9ca46d75-df69-46e7-978f-bfd3a3f58e7f"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:SUPPORTED--BY "57d48642-54a7-4190-9c5e-12b6582a1bb5"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "cc7b2ae3-2e7e-490f-adff-fd32f73713af"
      "b0cbde8b-46e3-4757-819f-18c35f74fbb4"
      "1187c0cf-a302-45b7-b46e-a7aba1100c71"
      "10a8b38e-d77f-4b93-8f44-7ea09d05eaf6"
      "2d0c1b00-41a3-41a5-b9c5-41366e2ba7ec"
      "495b65ed-2dbc-46ee-97cb-fc01bd550c1f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_520e74f127490cccd8f401a6b56bbc85")
       (:PMID . "20153221") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_520e74f127490cccd8f401a6b56bbc85")
       (:PMID . "16033886") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba0bcfabc1d485d88b069931c0b73b91")
       (:PMID . "10570282") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ba0bcfabc1d485d88b069931c0b73b91")
       (:PMID . "18596232") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4da279fae06b450264d4c9135d862652")
       (:PMID . "11809791") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4376f1cd673e62bbe17fdf657219730c")
       (:PMID . "11241670") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4376f1cd673e62bbe17fdf657219730c")
       (:PMID . "14666721") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ff50bb6c9a899706312d36f0ba5b7945")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ff50bb6c9a899706312d36f0ba5b7945")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "308")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "c8842f30-a4fe-4698-8cda-d4d0a0e37c7b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:SUPPORTED--BY "6af10ff1-80fb-4126-bf38-edfbb93706e4"
      "bdbf4e19-7435-4156-8c34-5f707713abc8"
      "257f8d8b-517d-4cc2-aecb-8f67f052b924")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1cc98bc10d37501e16082900b1a2b280")
       (:PMID . "10856237") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1cc98bc10d37501e16082900b1a2b280")
       (:PMID . "10480933") (:SOURCE--API . "biopax")))
     (:POSITION . "369")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a99f7537-b1f5-4935-8942-ff4a0ae89d1a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:SUPPORTED--BY "72fdafb3-8293-407e-ba36-c6f54b4e67fd"
      "df7f909a-017b-41ff-a631-62d6d7c43089"
      "797c7512-7dfa-4d21-b5ce-118d3ece1c95"
      "6af10ff1-80fb-4126-bf38-edfbb93706e4")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1cc98bc10d37501e16082900b1a2b280")
       (:PMID . "10856237") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1cc98bc10d37501e16082900b1a2b280")
       (:PMID . "10480933") (:SOURCE--API . "biopax")))
     (:POSITION . "386")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "3285c644-6c92-4f79-b617-175d951e51d2"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:SUPPORTED--BY "6af10ff1-80fb-4126-bf38-edfbb93706e4"
      "fc3a3cef-2ac8-4c1a-a3a2-78ebba10add5"
      "16f49b7d-06ac-480b-b3de-ae6050493f12")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1cc98bc10d37501e16082900b1a2b280")
       (:PMID . "10856237") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1cc98bc10d37501e16082900b1a2b280")
       (:PMID . "10480933") (:SOURCE--API . "biopax")))
     (:POSITION . "529")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "f1ac5246-a3a4-4b23-b841-7db582208fc7"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "c7c0c0e8-89cb-40cb-b54f-98fd124ddf22"
      "113e7479-98be-4e80-ab46-469caa10ad7e"
      "1b799fc3-f210-403a-a76a-416d9f326ba9"
      "86985bda-3413-4c55-a011-c234f88b1c44")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_10e3aba17b81d1b1036d86ade8060ed0")
       (:PMID . "9445476") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_10e3aba17b81d1b1036d86ade8060ed0")
       (:PMID . "9427642") (:SOURCE--API . "biopax")))
     (:POSITION . "412")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a87e8770-696e-40fd-9ba0-4b7c388b8c8b"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:SUPPORTED--BY "5cc43c3a-5542-43e0-a429-6831079a3853"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "dd986471-ddba-4967-b891-19ee9d3e6242")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4c50eb335bfab46a3331cbb82dd38d0e")
       (:PMID . "16787925") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_343dd0ea4b35372bae584f14af0f1345")
       (:PMID . "9094314") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4f2914806fb5cf814e24879462ec0bab")
       (:PMID . "9094314") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2012d5742afdf5451c64fea34415cdbe")
       (:PMID . "12538620") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a61e18e126fdfc99b882ad2bf244758a")
       (:PMID . "9094314") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ef61536c02abdfc993a0fb788a252245")
       (:SOURCE--API . "biopax")))
     (:POSITION . "474")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "fe954c69-a4f6-4e06-9336-f833856710f4"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+TEXT+ . "Akt2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8"
      "d1445cf9-2ca2-4526-898c-ae7ab9201edd"
      "bd1e9304-feaf-4ad8-8dee-63cbd9572b02"
      "d8669d4e-38a4-4652-9f1b-3cf9b767a098"
      "b0cbde8b-46e3-4757-819f-18c35f74fbb4")
     (:EVIDENCE
      ((:TEXT . "In addition, activated PDK1 phosphorylates Akt2 at Thr309.")
       (:PMID . "26491696") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_00e9890ca6a94f254d7d9e2c9ecb4200")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_377bcfb6359e3f645184a011b21de035")
       (:PMID . "9512493") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0fd3de1ecd3ca6514860b6f765746872")
       (:PMID . "11134526") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0fd3de1ecd3ca6514860b6f765746872")
       (:PMID . "10679787") (:SOURCE--API . "biopax"))
      ((:TEXT . "In addition, activated PDK1 phosphorylates Akt2 at Thr309.")
       (:PMID . "26491696") (:SOURCE--API . "sparser")))
     (:POSITION . "309")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PDK1") (:+UP+ . "O15530") (:+HGNC+ . "8816"))
      (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "7c6f243d-1de8-4559-a369-615d7ec86603"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q9Y243") (:+HGNC+ . "393")) (:NAME . "AKT3"))
     (:SUPPORTED--BY "9c136ee9-012d-438c-b255-c03ef028d9ad"
      "16977f78-8f22-4ac6-b57e-171cd466a7fe"
      "f34164fc-7fa7-42c7-9c21-eda670618949"
      "d90f2504-f0af-42b9-ad1d-83d0c30ce864")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0873099882451067f88d92f7ef5623e2")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9023c27547c5b8fb7ccb4604e5967d5a")
       (:PMID . "9512493") (:SOURCE--API . "biopax")))
     (:POSITION . "305")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "69c8ef4f-4817-479a-9991-4acc88f9ea36"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+TEXT+ . "PAK1") (:+UP+ . "Q13153") (:+HGNC+ . "8590"))
      (:NAME . "PAK1"))
     (:SUPPORTED--BY "80e713a5-4c76-473e-8bda-8a07d46a1bf6"
      "31ce3806-14a9-41d8-9fe3-2179d99aeb5e"
      "f3d2b072-d2c8-453d-bf30-548f5610977d")
     (:EVIDENCE
      ((:TEXT
        . "These data strongly suggested that, in addition to the important enzyme-substrate recognition at the active site, the interactions involving helices alphaEF and alphaG exert an auxiliary function in PAK1 -activation.Most contact residues that mediate binding in the EF and G helices are fairly conserved among the PAKs () but not in other kinases such as PDK1, which have been shown to phosphorylate PAK1 Thr423.")
       (:PMID . "22153498") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_77cdf8b3402ef2c63ca652d1d48ab155")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "The biological significance of PDK1 phosphorylation of PAK1 at threonine 423 in vitro is supported by the observation that these two proteins interact in vivo and that PDK1 phosphorylated PAK1 has an increased activity toward substrate.")
       (:PMID . "10995762") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "ROS determine the activation of PDK1, which in turn phosphorylates PAK1 on threonine 423.")
       (:PMID . "26238471") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "For example, PAK1 can be directly phosphorylated on Thr423 by PDK1 XREF_BIBR.")
       (:PMID . "21209852") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PAK1 phosphorylation at T423 in the activation loop in the kinase domain, which is mediated by PDK1 (XREF_BIBR; XREF_BIBR), plays a role in stabilizing the active site (XREF_BIBR).")
       (:PMID . "23885116") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It is interesting to note that PDK1 phosphorylation of PAK1 at T423 is involved in actin polymerization in normal cells (XREF_BIBR), but does not significantly affect tumor cell growth (XREF_BIBR).")
       (:PMID . "23885116") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PDK1 phosphorylates PAK1 on threonine 423, a conserved site in the activation loop of kinase subdomain VIII which is involved in the regulation of PAK1 kinase activity.")
       (:PMID . "26238471") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "423")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PDK1") (:+UP+ . "O15530") (:+HGNC+ . "8816"))
      (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "03324dcc-170f-4854-abc0-bd3c24228ecc"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:SUPPORTED--BY "4c3ae63d-5421-4db5-ab0a-21f8f808c98b"
      "8533aaa6-269b-4622-934c-197fe0319e91")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "241")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4534dae9-0533-410b-9a6a-a134ac6dcda6"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "PKCdelta") (:+UP+ . "Q05655") (:+HGNC+ . "9399"))
      (:NAME . "PRKCD"))
     (:SUPPORTED--BY "9197ad5a-8ef2-4c2f-8904-3c1fcf272ba1")
     (:EVIDENCE
      ((:TEXT . "PDK1 then phosphorylates and activates Akt and PKCdelta.")
       (:PMID . "17190838") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PDK1 phosphorylated the activation loop sites of PKCzeta and PKCdelta in vitro and in a phosphoinositide 3-kinase (PI 3-kinase)-dependent manner in vivo in human embryonic kidney (293) cells.")
       (:PMID . "9748166") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PDK1 dependent phosphorylation of PKCdelta in vitro was stimulated by combined PKC and PDK1 activators.")
       (:PMID . "9748166") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As a result of the defective PI3K pathway, phosphorylation of PKCdelta, which is mediated by PDK1 (XREF_BIBR), was significantly diminished (XREF_FIG).")
       (:PMID . "17190838") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PDK1") (:+UP+ . "O15530") (:+HGNC+ . "8816"))
      (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "27ce6a49-9fe8-4646-852b-c101c4665f11"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "Q05513") (:+HGNC+ . "9412")) (:NAME . "PRKCZ"))
     (:SUPPORTED--BY "d74e1ec9-166a-412e-a55a-e3b24619a16b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_215cb29d46649be7f445423849a68224")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ac1f5f20a3a928124b295dc0e0b213e6")
       (:PMID . "14604996") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c55d43beab43da9e3aeaee0ac612d6b1")
       (:SOURCE--API . "biopax")))
     (:POSITION . "410")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "26ad9478-7c46-4b9e-b44a-a7fb6c3c289a"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "RSK1") (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:SUPPORTED--BY "550e7957-e09d-4845-ad8d-846e45603fec")
     (:EVIDENCE
      ((:TEXT
        . "We have shown here that PDK1 phosphorylates wild-type avian RSK1 and is even capable of activating the isolated RSK1 amino-terminal kinase domain.")
       (:PMID . "10469565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Although PDK1 could phosphorylate full-length RSK1 (), it was possible that PDK1 did not regulate the phosphorylation of full-length RSK1.")
       (:PMID . "10469565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This basal phosphorylation is consistent with our observations that D1 ' has high basal activity relative to the serum stimulated activity level, and that expression of a kinase-inactive PDK1 can decrease D1 ' basal phosphotransferase activity.Although PDK1 does phosphorylate Akt and PKBalpha, p70 and RSK1, there are differences in the phospholipid requirement for this phosphorylation.")
       (:PMID . "10469565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "P90RSK is phosphorylated by MAPK, p38MAPK, ERK5MAPK, PDK1, TIF1alpha, GSK3alpha, GSK3alpha, and fibroblast growth factor receptor-3 (FGFR3) and is known to be up-regulated in breast and prostate cancer.")
       (:PMID . "25129346") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, recent studies indicate that the ability of PDK1 to phosphorylate S6K, SGK, and RSK is dependent on a docking site, the PIF pocket, which is located on the small lobe of the PDK1 kinase domain (XREF_BIBR).")
       (:PMID . "17371830") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "241") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PDK1") (:+UP+ . "O15530") (:+HGNC+ . "8816"))
      (:NAME . "PDPK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "ca3f3ee8-9f4b-4edf-8016-50d6d268dd93"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "b01eb641-20db-4822-b8f9-63abe1b4ea6c"
      "0cec04ee-2651-4deb-85a6-df6a8e538e28"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "b4bcefa8-5825-404c-9e20-1f9a11bcb142"
      "5757b142-0a4a-4a74-be36-db6f3c483dac")
     (:EVIDENCE
      ((:TEXT
        . "It is noted that even though the inhibitors of PI3K and PDK1 (wortmannin and OSU03012) did not completely abolish the phosphorylation of Akt (S473), it completely inhibited the association of PPP1R12A with IRS1.")
       (:PMID . "22728334") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, these effects did not persist since the inhibition of AKT T308 and AKT S473 phosphorylation by selective PI3K inhibitors as well as AKT T308 by the dual PI3K and mTOR inhibitor was lost following prolonged treatment (48h).")
       (:PMID . "23867821") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Chalecka-Franaszek and Chuang found that lithium treatment of cultured brain neurons resulted in increased PI3K activation, which in turn lead to serine 473 phosphorylation of Akt, and the subsequent inhibition of GSK-3beta.")
       (:PMID . "23768967") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The Akt Ser473 residue phosphorylation by a PI3K dependent signaling pathway causes enzymatic activation.")
       (:PMID . "24685520") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylated by PI-3K at Ser 473 phosphorylates and inactivates TSC2 and leads to the activation of mTOR [XREF_BIBR].")
       (:PMID . "24797175") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Stimulation of the PI3K pathway by growth factors, certain types of stressors, and potassium induced membrane depolarization results in the phosphorylation of Akt at its Thr308 and Ser473 sites.")
       (:PMID . "16987514") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, hydrogen peroxide induced phosphorylation of Akt on serine 473 (S473) was downregulated by both PI3K and CaM-K inhibition, indicating that hydrogen peroxideinduced phosphorylation of Akt on S473 was largely dependent on both PI3K and a CaM-K activity.")
       (:PMID . "16987028") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In a time course experiment, however, we show that the phosphorylation of AKT S473 resumes gradually up to the untreated cell levels within 24 hours of PP242 treatment and inhibition of PI3K fails to block the AKT S473 phosphorylation.")
       (:PMID . "23991179") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylated by PI-3K at Ser 473 phosphorylates and inactivates TSC2 and leads to the activation of mTOR [XREF_BIBR].")
       (:PMID . "24797175") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In the present study, we found that Akt activation in As transformed HBECs depended on PI3K activity as inhibition of PI3K diminished Akt phosphorylation at both serine 473 and threonine 308 sites.")
       (:PMID . "21954225") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3k activation induces phosphorylation of Akt (at Ser473 and Thr308), Mdm2 (at Ser166) and AR (at Ser210/213 and Ser790) this posttranslational modification can serve as a signal for AR ubiquitylation and subsequent degradation [XREF_BIBR, XREF_BIBR, XREF_BIBR, XREF_BIBR].")
       (:PMID . "26196320") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "473")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PIK3R4") (:+UP+ . "Q99570") (:+HGNC+ . "8982"))
      (:NAME . "PIK3R4"))
     (:TYPE . "Phosphorylation")
     (:ID . "2938bb02-dedd-4b57-97e9-14f51941b8f9"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "Receptor activated PI3K leads to membrane attachment and subsequent phosphorylation and activation of Akt.")
       (:PMID . "22552281") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3K promotes AKT phosphorylation and activation, a general mediator of cell survival (XREF_BIBR).")
       (:PMID . "20691427") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Following activation through receptor kinases or activated RAS, PI3K phosphorylates and activates AKT (pAKT) [XREF_BIBR].")
       (:PMID . "21910869") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In several cell lines, PI3K phosphorylates and thereby activates AKT, which then promotes survival through phosphorylation of multiple targets [XREF_BIBR, XREF_BIBR].")
       (:PMID . "16710454") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "On the other hand, BDNF induced Akt phosphorylation was unaffected by farnesyltransferase or MEK inhibitors, but could be blocked by PI-3 kinase inhibitors.")
       (:PMID . "16034442") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results demonstrate that both PI3K and PDK1 activities have to be suppressed to inhibit downstream AKT and SGK1 phosphorylation and activity in our resistant models.")
       (:PMID . "27451907") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The inhibition of the PiT-1-mediated Pi influx by PFA prevented the high Pi induced autophagy and reversed the inhibition of Akt and mTOR phosphorylation.")
       (:PMID . "24797554") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "For example, the above maturation stimuli can activate phosphatydylinositide 3-kinase (PI3K) which phosphorylates Akt (p-Akt) XREF_BIBR and this, in turn, increases expression of anti-apoptotic proteins such as Bcl-2 and Bcl-xL XREF_BIBR, XREF_BIBR.")
       (:PMID . "23382671") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This PI3K activation occurred at an early phase of the infection, and apparently did not involve PI3K mediated phosphorylation of Akt.")
       (:PMID . "23680019") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Like PP242, wortmannin (an inhibitor of phosphoinositide 3-kinase (PI3K) suppressing phosphorylation of Akt and downstream substrates (XREF_FIG)) inhibited YB-1 synthesis (XREF_FIG (cf. lane 1 and lanes 2, 4) and 8C).")
       (:PMID . "23285076") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The suppression of Akt and mTOR phosphorylation by high Pi was observed as early as 15 and 30minutes of treatment, respectively (, online only).")
       (:PMID . "24797554") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These results demonstrated that Akt phosphorylation induced by Ca mediated cell-cell adhesion is mediated by PI3K activation.After that, we tried to determine whether expression of both E-cadherin and p-Akt in the human intestinal mucosa tissue is also dependent on the differentiation status of epithelial cells.")
       (:PMID . "19059380") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3K activates Akt by phosphorylation at two sites, Thr 308 and Ser 473 XREF_BIBR.")
       (:PMID . "21253589") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Because Akt phosphorylation by PI3K is crucial for glioma proliferation, growth and survival, we examined if the PI3K site on Akt is also affected by Compound C. Compound C robustly inhibited PI3K mediated Akt phosphorylation at threonine 308 (XREF_FIG).")
       (:PMID . "24419061") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "This protein has also been found to be negatively regulated by its substrate PTEN through its lipid phosphatase activity [XREF_BIBR] that antagonizes the phosphorylation of AKT by PI3K.")
       (:PMID . "24349488") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The high glucose treatment attenuated insulin induced association of IRS-1 and phosphatidylinositol 3-kinase and insulin stimulated phosphorylation of Akt.")
       (:PMID . "10764799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibitors of PI3K (LY294002 and Wortmannin) prevented the phosphorylation of ERK1/2, p38 MAPK, and Akt PI3K).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3-K inhibition by LY294002 blocked both Akt phosphorylation and superoxide generation.")
       (:PMID . "12089369") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "CCR5 Antibodies and Inhibitors of STAT1 and PI3K Diminished HIV-1-Induced Phosphorylation of PDK-1 and AKT in HBMEC.")
       (:PMID . "20568281") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the mTOR pathway has not been defined in mononuclear phagocytes, but it is known that bacterial stimuli activate PI3K, which leads to phosphorylation of Akt ().")
       (:PMID . "18848473") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Increased PTEN activity, mediated by dephosphorylation, was discovered in Fmr1 KO mice and may serve as a feedback inhibition to compensate for abnormally increased PI3K since PTEN dephosphorylates PI3K, which reduces phosphorylation and activation of Akt [XREF_BIBR].")
       (:PMID . "22619737") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of PI3-kinase signalling in HPV16 transfected keratinocytes by chemical interference or siRNA mediated silencing of PIK3CA resulted in a decreased phosphorylation of PKB and AKT.")
       (:PMID . "21663621") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In this report, we show that in intestinal epithelial cells, HB-EGF triggered PI3K dependent phosphorylation of Akt.")
       (:PMID . "16034135") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We found that inhibitor of PI3-K inhibited PKB expression, phosphorylation, and activation.")
       (:PMID . "16564100") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Active PKCalpha phosphorylates Src to induce PI-3K to phosphorylate AKT that subsequently activates the ERK1/2 cascade to stimulate goblet cell proliferation.")
       (:PMID . "23882690") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Because Akt phosphorylation by PI3K is crucial for glioma proliferation, growth and survival, we examined if the PI3K site on Akt is also affected by Compound C. Compound C robustly inhibited PI3K mediated Akt phosphorylation at threonine 308 (XREF_FIG).")
       (:PMID . "24419061") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The PI-3 kinase inhibitor wortmannin completely blocked T. gondii induced phosphorylation of Akt, but only slightly reduced the phosphorylation of ERK1/2 and p38 at 15 minutes and had no detectable effect on ERK1/2 at 60 minutes (XREF_FIG).")
       (:PMID . "19917706") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT . "Akt is phosphorylated and thus activated by PI3K.")
       (:PMID . "24038283") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our preliminary screen demonstrated that silencing of 12% of the human kinome resulted in a 20-60% reduction in Akt (ser473) phosphorylation (fig XREF_FIG) and these include mTor, PKCalpha and PI3K which are known to modulate Akt phosphorylation.")
       (:PMID . "20042122") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Conversely, PI3K dependent phosphorylation of Akt induced by NKG2D crosslinking was not enhanced by co-crosslinking with 2B4.")
       (:PMID . "20189481") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Parallel plates of TAg-WT and TAg-PACS-2 -/- MEFs were treated with TRAIL in the presence or absence of the class I PI3K and mTOR inhibitor PI-103, which blocked Akt activation and phosphorylation of ribosomal protein S6 (XREF_FIG).")
       (:PMID . "19481529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activation of PI3K leads to AKT activation by both phosphoinositide dependent protein kinase-1 (PDK1), which phosphorylates AKT at Thr 308, and PDK1 independent mechanisms, which result in AKT phosphorylation at Ser 473.")
       (:PMID . "20005908") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Insulin and insulin like growth factors activate PI3K which phosphorylates AKT [XREF_BIBR].")
       (:PMID . "26192445") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The PI3K pathway leads to phosphorylation of AKT, which in C. trachomatis infected cells remains phosphorylated even after treatment with STS.")
       (:PMID . "16710454") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Subsequently, EGFR activates PI3K, which phosphorylates AKT and MEK1/2-ERK 1/2, respectively.")
       (:PMID . "24015256") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Also, PI3K inhibition by LY294002 blocked the basal and E induced AKt phosphorylation (B), while PDTC blocked the basal and E induced DNA binding activity of NFkappaB (C).")
       (:PMID . "19932734") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, LY294002, an inhibitor of PI-3K, can block the phosphorylation of Akt, and inactivate its downstream telomerase.")
       (:PMID . "18343732") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3K phosphorylates AKT (pAkt) which in turn regulates Bcl-xL, anti-apoptotic protein.")
       (:PMID . "24655565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "To provide further evidence that the phosphorylation of PDNF depended on host Akt, T. cruzi infected Schwann cells were treated with LY294002, a pharmacological inhibitor of PI3K, which phosphorylates and activates Akt (XREF_BIBR), and with Akti VIII, a specific allosteric inhibitor of Akt that prevents the phosphorylation of Akt at Ser 473 and Thr 308, which are critical for the activation of Akt (XREF_BIBR).")
       (:PMID . "19920252") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphatidyl-inositol 3-kinase interacts with phosphatidylinositol-3-phosphate at the membrane and catalyzes the phosphorylation of AKT, which acti-vates the downstream signaling pathway [1].")
       (:PMID . "18516290") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, like Ras, expression of activated TC21 resulted in membrane translocation and an increase in the PI3K dependent phosphorylation of Akt, and inhibition of PI3K activity interfered with TC21 focus formation.")
       (:PMID . "11788587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Cbl-b decrease of PI3K expression diminishes downstream phosphorylation of ERK and Akt (XREF_BIBR).")
       (:PMID . "19414743") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As expected, the PI3K and AKT inhibitor LY294002 inhibited AKT phosphorylation, while ERK1/2 inhibitor U 0126 inhibited ERK1/2 phosphorylation in HO-8910pm and ES-2 cells (XREF_FIG, XREF_SUPPLEMENTARY).")
       (:PMID . "24816687") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, our assumption that Akt is phosphorylated by PI3K in the nucleus is supported by the presence of the p85 subunit of PI3K in the nucleus.")
       (:PMID . "21723633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Mutp53 levels also proportionally modulate the activated downstream EGFR signaling pathways PI3K and MAPK, which phosphorylate AKT and ERK, respectively (XREF_FIG).")
       (:PMID . "25573952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The inhibition of PI3K activity also inhibited the phosphorylation of AKT and p70S6K1, but not extracellular regulated kinase 1/2.")
       (:PMID . "15028555") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "LY294002, a specific inhibitor of PI-3K, significantly inhibited Akt phosphorylation and completely abrogated HAPO stimulated proliferation of HUVECs.")
       (:PMID . "18769058") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To further probe this pathway, we overexpressed the dominant negative PI3K (p85), which was found to abrogate AKT phosphorylation and restore the expression of PUMA and p53 with IGF-I or bFGF treatment (XREF_FIG).")
       (:PMID . "19966853") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, in the resistant cells, it appeared that PI3K inhibition suppressed Akt phosphorylation, but failed to suppress CDK 4/6 activity, as measured by RB phosphorylation.")
       (:PMID . "25002028") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Conversely, treatment of cells with LY294002, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, blocked AKT phosphorylation, and increased ERK1/2 phosphorylation, since blocking of the AKT pathway removes an inhibitor of the ERK pathway XREF_BIBR; XREF_BIBR.")
       (:PMID . "21763495") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3K stimulates the phosphorylation of AKT by interaction with phosphatidylinositol-3-phosphate in the cell membrane.")
       (:PMID . "21439039") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The downstream MAPK and PI3K activation of Rac1 will result in the phosphorylation of ERK1/2 and AKT respectively.")
       (:PMID . "18086571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This pathway is prominent signal transduction pathway in cell proliferation and growth (), and infection stimulates phosphorylation of AKT by PI3K dependent manner ().")
       (:PMID . "22795649") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As expected, IGF1 stimulated AKT and ERK phosphorylation, and PI-3 kinase inhibitors blocked AKT activation and partially impaired ERK phosphorylation.")
       (:PMID . "15710331") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3K, in turn, phosphorylates the serine/threonine kinase AKT, which can be repressed by Phosphatase and TENsin homolog deleted on chromosome ten (PTEN), a tumor suppressor gene ().")
       (:PMID . "25998416") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These include control of cell growth, differentiation and programmed cell death mediated by the PI3-kinase signaling pathway and the downstream phosphorylation of Akt and PKB.")
       (:PMID . "17397984") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the abundance of growth factors activation of the PI3K (phosphatidylinositol 3-kinase) activates and phosphorylates AKT, that in turn leads to the downstream phosphorylation of TSC2 and inhibits its GAP activity towards RHEB, allowing RHEB to activate mTOR [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26255626") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, both PI3K and Akt activators, pervanadate and insulin, partly reversed the inhibition of TGF-beta1-induced Akt phosphorylation by anti-miR33a, whereas Akt specific inhibitor MK2206 did not show this reversed inhibition effect.")
       (:PMID . "24100264") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, although there is evidence that Akt activation occurs in neural and epithelial cells independently of PI3K XREF_BIBR, it is generally accepted that Akt activation is dependent on PI3K, and inhibition of PI3K activity impairs Akt phosphorylation and Akt mediated cell functions XREF_BIBR, XREF_BIBR.")
       (:PMID . "25375133") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This is in contrast to work by Lee et al, in which leucine induced Akt phosphorylation in chicken hepatocytes in a time dependent manner, and PI3K and mTOR inhibitor LY294002 inhibited leucine induced Akt phosphorylation (XREF_BIBR).")
       (:PMID . "21294052") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, TNF-alpha-stimulated Akt phosphorylation was attenuated by the inhibitors of TNFR nAb, c-Src siRNA, EGFR (AG1478) and PI3K (LY294002).")
       (:PMID . "26173590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Exclusive use of Torin2, although able to completely downregulate mTORC1 activity in the absence of MYCN, leads to a much more striking increase of AKT phosphorylation by PI3K.")
       (:PMID . "25228590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "siRNA knockdown of PI3K from pancreatic cancer cells also reduced the phosphorylation of Akt.")
       (:PMID . "22905202") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In vitro, PI3K pathway activation leads to phosphorylation of AKT and subsequently of mTOR and p70S6K [XREF_BIBR].")
       (:PMID . "24447434") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphatidyl-inositol-3-kinase (PI3K) can phosphorylate and activate Akt while PI3K is negatively regulated by the tumor suppressor gene PTEN, which has been shown to be non functional in 20 to 40% of GBM XREF_BIBR - XREF_BIBR.")
       (:PMID . "20436671") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Enhanced basal Akt phosphorylation in Nck1 depleted HepG2 cells is PI3K dependent.")
       (:PMID . "25398386") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PDK1 is recruited to cell membranes upon PI3K activation, where it phosphorylates and activates Akt, the major mediator of the PI3K signaling pathway (XREF_BIBR).")
       (:PMID . "21708979") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The inhibition of the PI3K pathway with these inhibitors blocked the phosphorylation of Akt, which is responsible for the phosphorylation of FOXO3 XREF_BIBR (data not shown).")
       (:PMID . "19636295") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3K and P-AKT inhibitors, such as GSK690693, AZD5363 [XREF_BIBR, XREF_BIBR], are shown to inhibit the phosphorylation of AKT and then suppress the progress of cancers.")
       (:PMID . "25240815") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3beta and translocation of beta-catenin/AR into the nucleus.")
       (:PMID . "17653089") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Results from the current study have led to the conclusion that infection with live H. pylori induces EGFR- and PI3K dependent phosphorylation of PDK1 and Akt, and the subsequent activation of Erk, inactivation of GSK3 and IL-8 production.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Growth factor combined with tyrosine kinase receptor activates type I PI3K, and the activated PI3K can promote the phosphorylation of downstream AKT, which could be activated.")
       (:PMID . "26363527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activation of MAPK signalling ultimately leads to phosphorylation of the terminal kinase in the cascade, MAPK (p42/44 MAPK) whereas PI3K activation leads to the phosphorylation of PKB (XREF_BIBR).")
       (:PMID . "23778527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because PI3K activity normally leads to phosphorylation of AKT family members, we extracted protein from two participants ' lipomatous overgrowths to compare its level of AKT phosphorylation to that of protein extracted from normal adipose tissue and from an adipose containing PTEN hamartoma of soft tissue (PHOST) from an individual with a mutation.")
       (:PMID . "22658544") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In uninfected cells in the presence of survival signals, the PI3K pathway leads to phosphorylation and activation of AKT and PKB, and subsequent phosphorylation of BAD, which in its phosphorylated form is sequestered in the cytoplasm by cytosolic 14-3-3 [XREF_BIBR, XREF_BIBR].")
       (:PMID . "16710454") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In previous experiments, we have shown that nonspecific PI3K inhibition with wortmannin completely abrogates bile salt (data not shown) and CPT-2-Me-cAMP-induced Akt phosphorylation [XREF_BIBR].")
       (:PMID . "20675006") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In this study, we demonstrate that PrLZ could increase Stat3 phosphorylation mediated by activation of Akt, which is further demonstrated by rescue experiments demonstrating that inhibition of PI3K by specific inhibitor could abolish both Akt and Stat3 phosphorylation in PrLZ expressing cells, whereas inhibition of Stat3 activation could not change Akt phosphorylation.")
       (:PMID . "21385902") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We show that VEGF-A and VEGFR2 activation in LECs stimulates PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Globally, these results suggested that loss of CD44 expression results in the upregulation of AKT phosphorylation.In order to test if the HT29 cell lysates illustrated in B are truly exhibiting an upregulated AKT phosphorylation in response to knocking down CD44, we used a PI3 kinase inhibitor, LY294002, which is known to inhibit AKT phosphorylation.")
       (:PMID . "17599831") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "One of the main cell survival molecular pathways involves phosphorylation of Akt and PKB mediated by phosphatidylinositol-3-kinase XREF_BIBR.")
       (:PMID . "19801972") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that CXCL12- or CCL21 induced PI3K dependent phosphorylation of Akt was normal in CBAP -/- T cells and that Ca 2+ was mobilized to a similar extent in both control (i.e., C11 and C21) and CBAP-knockdown (i.e., C17 and C29) Jurkat T-cell clones (data not shown).")
       (:PMID . "23620790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "On the other hand, the regulation of anoikis by RhoG required phosphatidylinositol 3-kinase (PI3K) activity, and constitutively active RhoG bound to the PI3K regulatory subunit p85alpha and induced the PI3K dependent phosphorylation of Akt.")
       (:PMID . "17570359") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Torre et al reported that HA/CD44 interaction increased PI-3 kinase activity in HNSCC cells; HA also promoted PI-3 kinase mediated AKT phosphorylation, resulting in increased tumor cell survival.HA/CD44 signaling not only appears to promote EGFR mediated prosurvival effects, but also leads to increased chemoresistance in HNSCC through EGFR signaling pathways.")
       (:PMID . "21356346") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "LY294002, a specific inhibitor of PI-3K, effectively blocked Akt phosphorylation induced by AMP-PNP.")
       (:PMID . "18194602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Expression of the PI3K dominant negative mutant (DeltaP85) protein in three independent clones, A6, A8 and A10, abrogated the TNF-alpha-associated phosphorylation of Akt without affecting total Akt protein levels.")
       (:PMID . "16504042") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This protein has also been found to be negatively regulated by its substrate PTEN through its lipid phosphatase activity [XREF_BIBR] that antagonizes the phosphorylation of AKT by PI3K.")
       (:PMID . "24349488") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Next, a specific inhibitor of PI3K and Akt pathway, LY294002, was used to inhibit Akt phosphorylation in wound healing assay to test whether inhibition of Akt phosphorylation has effect on VEGF 165 -induced migration.")
       (:PMID . "24987682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Having demonstrated PI3K dependent stimulation of Akt phosphorylation and the VCP-Akt interaction and that VCP phosphorylation sites were recognized by anti-PAS antibody in H. pylori infected AGS cells, we tested our hypothesis that VCP was a target of Akt kinase mediated signaling.")
       (:PMID . "23383273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Insulin and other growth factors are thought to regulate the phosphorylation of S6K1 and 4E binding protein 1 (4EBP1) through the PI3K signaling pathway via phosphorylation and activation of Akt XREF_BIBR, XREF_BIBR.")
       (:PMID . "18958173") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We show that VEGF-A stimulation of LECs leads to the phosphorylation of VEGFR2 (Tyr 951, 1054, 1059, 1175, and 1214) which subsequently triggers PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phagocytosis of AB induces PI3K dependent phosphorylation of Akt.")
       (:PMID . "19457567") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt phosphorylation and cell growth were inhibited by PI3-K specific inhibitor LY294002 in a dose dependent manner.")
       (:PMID . "16732486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3K dependent phosphorylation of Akt depended on NADPH oxidase activity and superoxide production.")
       (:PMID . "19457567") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Under conditions of growth factor deprivation, the PI3K and Akt pathway is inactivated, FKHRL1 is unphosphorylated at its Akt sites, and FKHRL1 accumulates in the nucleus where it may activate death genes, including the Fas ligand gene, and thereby participate actively in the process of apoptosis.When fibroblasts are exposed to IGF1 or serum, Akt is activated and catalyzes the phosphorylation of FKHRL1.")
       (:PMID . "10102273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Instead, PI3K inhibition reduced the nuclear level of beta-Catenin phosphorylated in the putative AKT phosphorylation site serine 552 [XREF_BIBR].")
       (:PMID . "24930890") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Indeed, inhibition of PI3K in HSV-1-infected OC3 cells not only blocked the phosphorylation of Akt, but also accelerated DNA laddering and the cleavage of PARP, suggesting that PI3K in oral epithelial cells effectively alleviate apoptosis during HSV-1 infection.")
       (:PMID . "20620179") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The Mal-p85alpha interaction drives PI3K dependent phosphorylation of Akt, phosphatidylinositol (3,4,5) P3 (PIP (3)) generation and macrophage polarization.")
       (:PMID . "19574958") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In human tracheal smooth muscle cells, TNF-alpha induced MMP-9 expression and Akt phosphorylation in a time dependent manner, which was attenuated by the inhibitors of Src (PP1), epidermal growth factor receptor (AG1478), PDGFR (AG1296), and PI3K (LY294002), respectively, revealed by reporter gene assay, RT-PCR, zymographic, and Western blot analyses.")
       (:PMID . "17158602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, our assumption that Akt is phosphorylated by PI3K in the nucleus is supported by the presence of the p85 subunit of PI3K in the nucleus.")
       (:PMID . "21723633") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "It is well known that PI3K can mediate the phosphorylation and activation of its downstream serine/threonine kinase, Akt (or PKB), participating in some important biological activities such as survival, proliferation, migration and differentiation in human cancer XREF_BIBR.")
       (:PMID . "22496919") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PIK3R4") (:+UP+ . "Q99570") (:+HGNC+ . "8982"))
      (:NAME . "PIK3R4"))
     (:TYPE . "Phosphorylation")
     (:ID . "592caa96-59f3-4b0f-b8f4-dfb19510bda2"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "This PI3K activation occurred at an early phase of the infection, and apparently did not involve PI3K mediated phosphorylation of Akt.")
       (:PMID . "23680019") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PI3K promotes AKT phosphorylation and activation, a general mediator of cell survival (XREF_BIBR).")
       (:PMID . "20691427") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Following activation through receptor kinases or activated RAS, PI3K phosphorylates and activates AKT (pAKT) [XREF_BIBR].")
       (:PMID . "21910869") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Furthermore, although there is evidence that Akt activation occurs in neural and epithelial cells independently of PI3K XREF_BIBR, it is generally accepted that Akt activation is dependent on PI3K, and inhibition of PI3K activity impairs Akt phosphorylation and Akt mediated cell functions XREF_BIBR, XREF_BIBR.")
       (:PMID . "25375133") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The high glucose treatment attenuated insulin induced association of IRS-1 and phosphatidylinositol 3-kinase and insulin stimulated phosphorylation of Akt.")
       (:PMID . "10764799") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On the other hand, BDNF induced Akt phosphorylation was unaffected by farnesyltransferase or MEK inhibitors, but could be blocked by PI-3 kinase inhibitors.")
       (:PMID . "16034442") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results demonstrate that both PI3K and PDK1 activities have to be suppressed to inhibit downstream AKT and SGK1 phosphorylation and activity in our resistant models.")
       (:PMID . "27451907") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activation of PI3K leads to AKT activation by both phosphoinositide dependent protein kinase-1 (PDK1), which phosphorylates AKT at Thr 308, and PDK1 independent mechanisms, which result in AKT phosphorylation at Ser 473.")
       (:PMID . "20005908") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "For example, the above maturation stimuli can activate phosphatydylinositide 3-kinase (PI3K) which phosphorylates Akt (p-Akt) XREF_BIBR and this, in turn, increases expression of anti-apoptotic proteins such as Bcl-2 and Bcl-xL XREF_BIBR, XREF_BIBR.")
       (:PMID . "23382671") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PI3K activates Akt by phosphorylation at two sites, Thr 308 and Ser 473 XREF_BIBR.")
       (:PMID . "21253589") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Because Akt phosphorylation by PI3K is crucial for glioma proliferation, growth and survival, we examined if the PI3K site on Akt is also affected by Compound C. Compound C robustly inhibited PI3K mediated Akt phosphorylation at threonine 308 (XREF_FIG).")
       (:PMID . "24419061") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The inhibition of PI3K activity also inhibited the phosphorylation of AKT and p70S6K1, but not extracellular regulated kinase 1/2.")
       (:PMID . "15028555") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because Akt phosphorylation by PI3K is crucial for glioma proliferation, growth and survival, we examined if the PI3K site on Akt is also affected by Compound C. Compound C robustly inhibited PI3K mediated Akt phosphorylation at threonine 308 (XREF_FIG).")
       (:PMID . "24419061") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PI3-K inhibition by LY294002 blocked both Akt phosphorylation and superoxide generation.")
       (:PMID . "12089369") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "CCR5 Antibodies and Inhibitors of STAT1 and PI3K Diminished HIV-1-Induced Phosphorylation of PDK-1 and AKT in HBMEC.")
       (:PMID . "20568281") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This protein has also been found to be negatively regulated by its substrate PTEN through its lipid phosphatase activity [XREF_BIBR] that antagonizes the phosphorylation of AKT by PI3K.")
       (:PMID . "24349488") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Torre et al reported that HA/CD44 interaction increased PI-3 kinase activity in HNSCC cells; HA also promoted PI-3 kinase mediated AKT phosphorylation, resulting in increased tumor cell survival.HA/CD44 signaling not only appears to promote EGFR mediated prosurvival effects, but also leads to increased chemoresistance in HNSCC through EGFR signaling pathways.")
       (:PMID . "21356346") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "One of the main cell survival molecular pathways involves phosphorylation of Akt and PKB mediated by phosphatidylinositol-3-kinase XREF_BIBR.")
       (:PMID . "19801972") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Increased PTEN activity, mediated by dephosphorylation, was discovered in Fmr1 KO mice and may serve as a feedback inhibition to compensate for abnormally increased PI3K since PTEN dephosphorylates PI3K, which reduces phosphorylation and activation of Akt [XREF_BIBR].")
       (:PMID . "22619737") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In this report, we show that in intestinal epithelial cells, HB-EGF triggered PI3K dependent phosphorylation of Akt.")
       (:PMID . "16034135") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The inhibition of the PiT-1-mediated Pi influx by PFA prevented the high Pi induced autophagy and reversed the inhibition of Akt and mTOR phosphorylation.")
       (:PMID . "24797554") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that inhibitor of PI3-K inhibited PKB expression, phosphorylation, and activation.")
       (:PMID . "16564100") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We show that VEGF-A and VEGFR2 activation in LECs stimulates PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "Akt is phosphorylated and thus activated by PI3K.")
       (:PMID . "24038283") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These include control of cell growth, differentiation and programmed cell death mediated by the PI3-kinase signaling pathway and the downstream phosphorylation of Akt and PKB.")
       (:PMID . "17397984") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The suppression of Akt and mTOR phosphorylation by high Pi was observed as early as 15 and 30minutes of treatment, respectively (, online only).")
       (:PMID . "24797554") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Conversely, PI3K dependent phosphorylation of Akt induced by NKG2D crosslinking was not enhanced by co-crosslinking with 2B4.")
       (:PMID . "20189481") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inhibition of PI3-kinase signalling in HPV16 transfected keratinocytes by chemical interference or siRNA mediated silencing of PIK3CA resulted in a decreased phosphorylation of PKB and AKT.")
       (:PMID . "21663621") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Parallel plates of TAg-WT and TAg-PACS-2 -/- MEFs were treated with TRAIL in the presence or absence of the class I PI3K and mTOR inhibitor PI-103, which blocked Akt activation and phosphorylation of ribosomal protein S6 (XREF_FIG).")
       (:PMID . "19481529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast, like Ras, expression of activated TC21 resulted in membrane translocation and an increase in the PI3K dependent phosphorylation of Akt, and inhibition of PI3K activity interfered with TC21 focus formation.")
       (:PMID . "11788587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Receptor activated PI3K leads to membrane attachment and subsequent phosphorylation and activation of Akt.")
       (:PMID . "22552281") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Insulin and insulin like growth factors activate PI3K which phosphorylates AKT [XREF_BIBR].")
       (:PMID . "26192445") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In several cell lines, PI3K phosphorylates and thereby activates AKT, which then promotes survival through phosphorylation of multiple targets [XREF_BIBR, XREF_BIBR].")
       (:PMID . "16710454") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "PI3K, in turn, phosphorylates the serine/threonine kinase AKT, which can be repressed by Phosphatase and TENsin homolog deleted on chromosome ten (PTEN), a tumor suppressor gene ().")
       (:PMID . "25998416") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The PI-3 kinase inhibitor wortmannin completely blocked T. gondii induced phosphorylation of Akt, but only slightly reduced the phosphorylation of ERK1/2 and p38 at 15 minutes and had no detectable effect on ERK1/2 at 60 minutes (XREF_FIG).")
       (:PMID . "19917706") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibitors of PI3K (LY294002 and Wortmannin) prevented the phosphorylation of ERK1/2, p38 MAPK, and Akt PI3K).")
       (:PMID . "20506505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, LY294002, an inhibitor of PI-3K, can block the phosphorylation of Akt, and inactivate its downstream telomerase.")
       (:PMID . "18343732") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, PI3K inhibition by LY294002 blocked the basal and E induced AKt phosphorylation (B), while PDTC blocked the basal and E induced DNA binding activity of NFkappaB (C).")
       (:PMID . "19932734") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This is in contrast to work by Lee et al, in which leucine induced Akt phosphorylation in chicken hepatocytes in a time dependent manner, and PI3K and mTOR inhibitor LY294002 inhibited leucine induced Akt phosphorylation (XREF_BIBR).")
       (:PMID . "21294052") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Subsequently, EGFR activates PI3K, which phosphorylates AKT and MEK1/2-ERK 1/2, respectively.")
       (:PMID . "24015256") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Conversely, treatment of cells with LY294002, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, blocked AKT phosphorylation, and increased ERK1/2 phosphorylation, since blocking of the AKT pathway removes an inhibitor of the ERK pathway XREF_BIBR; XREF_BIBR.")
       (:PMID . "21763495") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, TNF-alpha-stimulated Akt phosphorylation was attenuated by the inhibitors of TNFR nAb, c-Src siRNA, EGFR (AG1478) and PI3K (LY294002).")
       (:PMID . "26173590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, our assumption that Akt is phosphorylated by PI3K in the nucleus is supported by the presence of the p85 subunit of PI3K in the nucleus.")
       (:PMID . "21723633") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "PI3K phosphorylates AKT (pAkt) which in turn regulates Bcl-xL, anti-apoptotic protein.")
       (:PMID . "24655565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Expression of the PI3K dominant negative mutant (DeltaP85) protein in three independent clones, A6, A8 and A10, abrogated the TNF-alpha-associated phosphorylation of Akt without affecting total Akt protein levels.")
       (:PMID . "16504042") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our preliminary screen demonstrated that silencing of 12% of the human kinome resulted in a 20-60% reduction in Akt (ser473) phosphorylation (fig XREF_FIG) and these include mTor, PKCalpha and PI3K which are known to modulate Akt phosphorylation.")
       (:PMID . "20042122") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Cbl-b decrease of PI3K expression diminishes downstream phosphorylation of ERK and Akt (XREF_BIBR).")
       (:PMID . "19414743") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As expected, the PI3K and AKT inhibitor LY294002 inhibited AKT phosphorylation, while ERK1/2 inhibitor U 0126 inhibited ERK1/2 phosphorylation in HO-8910pm and ES-2 cells (XREF_FIG, XREF_SUPPLEMENTARY).")
       (:PMID . "24816687") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Mutp53 levels also proportionally modulate the activated downstream EGFR signaling pathways PI3K and MAPK, which phosphorylate AKT and ERK, respectively (XREF_FIG).")
       (:PMID . "25573952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To further probe this pathway, we overexpressed the dominant negative PI3K (p85), which was found to abrogate AKT phosphorylation and restore the expression of PUMA and p53 with IGF-I or bFGF treatment (XREF_FIG).")
       (:PMID . "19966853") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt phosphorylation and cell growth were inhibited by PI3-K specific inhibitor LY294002 in a dose dependent manner.")
       (:PMID . "16732486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, in the resistant cells, it appeared that PI3K inhibition suppressed Akt phosphorylation, but failed to suppress CDK 4/6 activity, as measured by RB phosphorylation.")
       (:PMID . "25002028") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phagocytosis of AB induces PI3K dependent phosphorylation of Akt.")
       (:PMID . "19457567") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Active PKCalpha phosphorylates Src to induce PI-3K to phosphorylate AKT that subsequently activates the ERK1/2 cascade to stimulate goblet cell proliferation.")
       (:PMID . "23882690") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "As expected, IGF1 stimulated AKT and ERK phosphorylation, and PI-3 kinase inhibitors blocked AKT activation and partially impaired ERK phosphorylation.")
       (:PMID . "15710331") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, our assumption that Akt is phosphorylated by PI3K in the nucleus is supported by the presence of the p85 subunit of PI3K in the nucleus.")
       (:PMID . "21723633") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The downstream MAPK and PI3K activation of Rac1 will result in the phosphorylation of ERK1/2 and AKT respectively.")
       (:PMID . "18086571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This pathway is prominent signal transduction pathway in cell proliferation and growth (), and infection stimulates phosphorylation of AKT by PI3K dependent manner ().")
       (:PMID . "22795649") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Results from the current study have led to the conclusion that infection with live H. pylori induces EGFR- and PI3K dependent phosphorylation of PDK1 and Akt, and the subsequent activation of Erk, inactivation of GSK3 and IL-8 production.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activation of MAPK signalling ultimately leads to phosphorylation of the terminal kinase in the cascade, MAPK (p42/44 MAPK) whereas PI3K activation leads to the phosphorylation of PKB (XREF_BIBR).")
       (:PMID . "23778527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Additionally, both PI3K and Akt activators, pervanadate and insulin, partly reversed the inhibition of TGF-beta1-induced Akt phosphorylation by anti-miR33a, whereas Akt specific inhibitor MK2206 did not show this reversed inhibition effect.")
       (:PMID . "24100264") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "LY294002, a specific inhibitor of PI-3K, significantly inhibited Akt phosphorylation and completely abrogated HAPO stimulated proliferation of HUVECs.")
       (:PMID . "18769058") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Exclusive use of Torin2, although able to completely downregulate mTORC1 activity in the absence of MYCN, leads to a much more striking increase of AKT phosphorylation by PI3K.")
       (:PMID . "25228590") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3K dependent phosphorylation of Akt depended on NADPH oxidase activity and superoxide production.")
       (:PMID . "19457567") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "siRNA knockdown of PI3K from pancreatic cancer cells also reduced the phosphorylation of Akt.")
       (:PMID . "22905202") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphatidyl-inositol-3-kinase (PI3K) can phosphorylate and activate Akt while PI3K is negatively regulated by the tumor suppressor gene PTEN, which has been shown to be non functional in 20 to 40% of GBM XREF_BIBR - XREF_BIBR.")
       (:PMID . "20436671") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PDK1 is recruited to cell membranes upon PI3K activation, where it phosphorylates and activates Akt, the major mediator of the PI3K signaling pathway (XREF_BIBR).")
       (:PMID . "21708979") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Enhanced basal Akt phosphorylation in Nck1 depleted HepG2 cells is PI3K dependent.")
       (:PMID . "25398386") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The inhibition of the PI3K pathway with these inhibitors blocked the phosphorylation of Akt, which is responsible for the phosphorylation of FOXO3 XREF_BIBR (data not shown).")
       (:PMID . "19636295") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphatidyl-inositol 3-kinase interacts with phosphatidylinositol-3-phosphate at the membrane and catalyzes the phosphorylation of AKT, which acti-vates the downstream signaling pathway [1].")
       (:PMID . "18516290") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Instead, PI3K inhibition reduced the nuclear level of beta-Catenin phosphorylated in the putative AKT phosphorylation site serine 552 [XREF_BIBR].")
       (:PMID . "24930890") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "On the other hand, the regulation of anoikis by RhoG required phosphatidylinositol 3-kinase (PI3K) activity, and constitutively active RhoG bound to the PI3K regulatory subunit p85alpha and induced the PI3K dependent phosphorylation of Akt.")
       (:PMID . "17570359") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PI3K and P-AKT inhibitors, such as GSK690693, AZD5363 [XREF_BIBR, XREF_BIBR], are shown to inhibit the phosphorylation of AKT and then suppress the progress of cancers.")
       (:PMID . "25240815") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Growth factor combined with tyrosine kinase receptor activates type I PI3K, and the activated PI3K can promote the phosphorylation of downstream AKT, which could be activated.")
       (:PMID . "26363527") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Because PI3K activity normally leads to phosphorylation of AKT family members, we extracted protein from two participants ' lipomatous overgrowths to compare its level of AKT phosphorylation to that of protein extracted from normal adipose tissue and from an adipose containing PTEN hamartoma of soft tissue (PHOST) from an individual with a mutation.")
       (:PMID . "22658544") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In previous experiments, we have shown that nonspecific PI3K inhibition with wortmannin completely abrogates bile salt (data not shown) and CPT-2-Me-cAMP-induced Akt phosphorylation [XREF_BIBR].")
       (:PMID . "20675006") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In this study, we demonstrate that PrLZ could increase Stat3 phosphorylation mediated by activation of Akt, which is further demonstrated by rescue experiments demonstrating that inhibition of PI3K by specific inhibitor could abolish both Akt and Stat3 phosphorylation in PrLZ expressing cells, whereas inhibition of Stat3 activation could not change Akt phosphorylation.")
       (:PMID . "21385902") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3beta and translocation of beta-catenin/AR into the nucleus.")
       (:PMID . "17653089") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The PI3K pathway leads to phosphorylation of AKT, which in C. trachomatis infected cells remains phosphorylated even after treatment with STS.")
       (:PMID . "16710454") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the abundance of growth factors activation of the PI3K (phosphatidylinositol 3-kinase) activates and phosphorylates AKT, that in turn leads to the downstream phosphorylation of TSC2 and inhibits its GAP activity towards RHEB, allowing RHEB to activate mTOR [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26255626") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results demonstrated that Akt phosphorylation induced by Ca mediated cell-cell adhesion is mediated by PI3K activation.After that, we tried to determine whether expression of both E-cadherin and p-Akt in the human intestinal mucosa tissue is also dependent on the differentiation status of epithelial cells.")
       (:PMID . "19059380") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In uninfected cells in the presence of survival signals, the PI3K pathway leads to phosphorylation and activation of AKT and PKB, and subsequent phosphorylation of BAD, which in its phosphorylated form is sequestered in the cytoplasm by cytosolic 14-3-3 [XREF_BIBR, XREF_BIBR].")
       (:PMID . "16710454") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Globally, these results suggested that loss of CD44 expression results in the upregulation of AKT phosphorylation.In order to test if the HT29 cell lysates illustrated in B are truly exhibiting an upregulated AKT phosphorylation in response to knocking down CD44, we used a PI3 kinase inhibitor, LY294002, which is known to inhibit AKT phosphorylation.")
       (:PMID . "17599831") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We show that VEGF-A stimulation of LECs leads to the phosphorylation of VEGFR2 (Tyr 951, 1054, 1059, 1175, and 1214) which subsequently triggers PKC dependent phosphorylation of ERK1/2 and PI3-K dependent phosphorylation of Akt.")
       (:PMID . "22174934") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We found that CXCL12- or CCL21 induced PI3K dependent phosphorylation of Akt was normal in CBAP -/- T cells and that Ca 2+ was mobilized to a similar extent in both control (i.e., C11 and C21) and CBAP-knockdown (i.e., C17 and C29) Jurkat T-cell clones (data not shown).")
       (:PMID . "23620790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "LY294002, a specific inhibitor of PI-3K, effectively blocked Akt phosphorylation induced by AMP-PNP.")
       (:PMID . "18194602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In human tracheal smooth muscle cells, TNF-alpha induced MMP-9 expression and Akt phosphorylation in a time dependent manner, which was attenuated by the inhibitors of Src (PP1), epidermal growth factor receptor (AG1478), PDGFR (AG1296), and PI3K (LY294002), respectively, revealed by reporter gene assay, RT-PCR, zymographic, and Western blot analyses.")
       (:PMID . "17158602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PI3K stimulates the phosphorylation of AKT by interaction with phosphatidylinositol-3-phosphate in the cell membrane.")
       (:PMID . "21439039") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Having demonstrated PI3K dependent stimulation of Akt phosphorylation and the VCP-Akt interaction and that VCP phosphorylation sites were recognized by anti-PAS antibody in H. pylori infected AGS cells, we tested our hypothesis that VCP was a target of Akt kinase mediated signaling.")
       (:PMID . "23383273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Insulin and other growth factors are thought to regulate the phosphorylation of S6K1 and 4E binding protein 1 (4EBP1) through the PI3K signaling pathway via phosphorylation and activation of Akt XREF_BIBR, XREF_BIBR.")
       (:PMID . "18958173") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Indeed, inhibition of PI3K in HSV-1-infected OC3 cells not only blocked the phosphorylation of Akt, but also accelerated DNA laddering and the cleavage of PARP, suggesting that PI3K in oral epithelial cells effectively alleviate apoptosis during HSV-1 infection.")
       (:PMID . "20620179") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To provide further evidence that the phosphorylation of PDNF depended on host Akt, T. cruzi infected Schwann cells were treated with LY294002, a pharmacological inhibitor of PI3K, which phosphorylates and activates Akt (XREF_BIBR), and with Akti VIII, a specific allosteric inhibitor of Akt that prevents the phosphorylation of Akt at Ser 473 and Thr 308, which are critical for the activation of Akt (XREF_BIBR).")
       (:PMID . "19920252") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Under conditions of growth factor deprivation, the PI3K and Akt pathway is inactivated, FKHRL1 is unphosphorylated at its Akt sites, and FKHRL1 accumulates in the nucleus where it may activate death genes, including the Fas ligand gene, and thereby participate actively in the process of apoptosis.When fibroblasts are exposed to IGF1 or serum, Akt is activated and catalyzes the phosphorylation of FKHRL1.")
       (:PMID . "10102273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Like PP242, wortmannin (an inhibitor of phosphoinositide 3-kinase (PI3K) suppressing phosphorylation of Akt and downstream substrates (XREF_FIG)) inhibited YB-1 synthesis (XREF_FIG (cf. lane 1 and lanes 2, 4) and 8C).")
       (:PMID . "23285076") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In vitro, PI3K pathway activation leads to phosphorylation of AKT and subsequently of mTOR and p70S6K [XREF_BIBR].")
       (:PMID . "24447434") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Next, a specific inhibitor of PI3K and Akt pathway, LY294002, was used to inhibit Akt phosphorylation in wound healing assay to test whether inhibition of Akt phosphorylation has effect on VEGF 165 -induced migration.")
       (:PMID . "24987682") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the mTOR pathway has not been defined in mononuclear phagocytes, but it is known that bacterial stimuli activate PI3K, which leads to phosphorylation of Akt ().")
       (:PMID . "18848473") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The Mal-p85alpha interaction drives PI3K dependent phosphorylation of Akt, phosphatidylinositol (3,4,5) P3 (PIP (3)) generation and macrophage polarization.")
       (:PMID . "19574958") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This protein has also been found to be negatively regulated by its substrate PTEN through its lipid phosphatase activity [XREF_BIBR] that antagonizes the phosphorylation of AKT by PI3K.")
       (:PMID . "24349488") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "It is well known that PI3K can mediate the phosphorylation and activation of its downstream serine/threonine kinase, Akt (or PKB), participating in some important biological activities such as survival, proliferation, migration and differentiation in human cancer XREF_BIBR.")
       (:PMID . "22496919") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PIK3R4") (:+UP+ . "Q99570") (:+HGNC+ . "8982"))
      (:NAME . "PIK3R4"))
     (:TYPE . "Phosphorylation")
     (:ID . "4b122c23-c353-4ed9-ac8a-3f1272ffa192"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Chk1") (:+UP+ . "O14757") (:+HGNC+ . "1925"))
      (:NAME . "CHEK1"))
     (:SUPPORTED--BY "e98af424-48cc-47d8-80fa-652306775da2")
     (:EVIDENCE
      ((:TEXT
        . "Chk1 phosphorylation by the PI3 like kinases ATR and ATM is critical for its activation and its role in prevention of premature mitotic entry in response to DNA damage or stalled replication.")
       (:PMID . "22743332") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PIK3R4") (:+UP+ . "Q99570") (:+HGNC+ . "8982"))
      (:NAME . "PIK3R4"))
     (:TYPE . "Phosphorylation")
     (:ID . "c12becda-ee5b-4352-8d5e-82773b6d81dc"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "FOXO3a") (:+UP+ . "O43524") (:+HGNC+ . "3821"))
      (:NAME . "FOXO3"))
     (:SUPPORTED--BY "c72805ce-5398-4ce7-bfc1-560f39139191")
     (:EVIDENCE
      ((:TEXT
        . "It is known that cells expressing the NPM and ALK fusion oncogene can drive BIM down-modulation through a phosphatidylinositide 3-kinase (PI3K)-mediated phosphorylation of the transcription factor FOXO3a [19], which is a known activator of BIM expression [20].")
       (:PMID . "23633923") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In particular, the FOXO family can be phosphorylated by PI3K and AKT signaling to induce its nuclear export and lose its activity, thus regulating multiple genes related to various cancers ().")
       (:PMID . "25791921") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "ARHI mediated downregulation of PI3K and AKT and Ras and ERK signaling also decreases phosphorylation of FOXo3a, which sequesters this transcription factor in the nucleus.")
       (:PMID . "24769729") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In conclusion, H. pylori infection induced the PI3K and Akt mediated phosphorylation, inactivation, and cytoplasmic translocation (transcriptionally inactive forms) of FoxO1 and FoxO3a.")
       (:PMID . "22515357") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Upstream of FOXO3, genistein acts via the PI3K and Akt pathway to inhibit EGF stimulated FOXO3 phosphorylation.")
       (:PMID . "23686257") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "FoxO1 and FoxO3 phosphorylation were prevented by the PI3 kinase (PI3K) inhibitor LY294002 while inhibitors of ERK1/2 (PD98059) or p38MAPK (SB203580) were ineffective.")
       (:PMID . "22552808") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Pharmacologic inhibition of PI3K or Akt potently decreased FoxO phosphorylation, as expected (XREF_FIG).")
       (:PMID . "24140020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The PI3K and AKT pathway phosphorylates all of these FOXO proteins, resulting in impairment of DNA binding ability and inhibition of FOXO dependent transcription [XREF_BIBR].")
       (:PMID . "22971992") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Moreover, PI3K phosphorylates FKHRL-1, inhibiting its transcriptional activity and leading to the decrease of the p21 and p27 mRNA ().")
       (:PMID . "20801220") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Because FOXO3a is directly phosphorylated by the PI3K regulated AGC kinases AKT (XREF_BIBR) and SGK-1 (XREF_BIBR), we sought to establish the kinetics of FOXO3a dephosphorylation at the relevant sites after PI3K inhibition.")
       (:PMID . "20110348") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The pharmacological PI3K inhibitors, wortmannin or LY294002, were used to assess the contribution of the PI3K pathway in TNFalpha induced FOXO3 phosphorylation.")
       (:PMID . "19636295") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, PI3K phosphorylates FKHRL-1, inhibiting its transcriptional activity and leading to the decrease of the p21 and p27 mRNA ().")
       (:PMID . "20801220") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We conclude that phosphorylation of an endogenous FKHRL1 related protein is induced by IGF1 by a PI3K dependent mechanism.Taken together, these experiments indicate that growth factor activation of the PI3K and Akt pathway is both necessary and sufficient to induce the phosphorylation of FKHRL1 at T32, S253, and S315 within cells.We next investigated the effect of Akt phosphorylation on the function of FKHRL1 as a transcription factor.")
       (:PMID . "10102273") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PIK3R4") (:+UP+ . "Q99570") (:+HGNC+ . "8982"))
      (:NAME . "PIK3R4"))
     (:TYPE . "Phosphorylation")
     (:ID . "7c47c2c1-d1b4-4ed4-a164-5629beb37de5"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "c-Jun") (:+UP+ . "P05412") (:+HGNC+ . "6204"))
      (:NAME . "JUN"))
     (:SUPPORTED--BY "06475688-c620-4857-8fa4-1d73a4521960")
     (:EVIDENCE
      ((:TEXT
        . "Further, insulin stimulated c-Jun phosphorylation was not blocked by inhibitors of the phosphatidylinositol 3-kinase and mammalian target of rapamycin, indicating that c-Jun N-terminal kinase is unlikely to be the kinase phosphorylating IRS-1 Ser (312) in response to insulin.")
       (:PMID . "12510059") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activated PI3-K and AKT and ERK1/2 signaling pathways phosphorylate c-Jun, which in turn transactivates MMP-1 that is responsible for the potentiation of the invasion of human chondrosarcoma cells.In this study, we found that MMP-1 is markedly induced in human chondrosarcoma tissues and shear activated chondrosarcoma cells.")
       (:PMID . "24472657") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PI3-K and AKT and ERK1/2 phosphorylate c-Jun, which in turn binds to the promoter to mediate MMP-1 mRNA and protein synthesis in shear stimulated chondrosarcoma cells.")
       (:PMID . "24472657") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PIK3R4") (:+UP+ . "Q99570") (:+HGNC+ . "8982"))
      (:NAME . "PIK3R4"))
     (:TYPE . "Phosphorylation")
     (:ID . "67192938-6808-48f7-bb9e-5793e6f1f347"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "mammalian Target of Rapamycin") (:+UP+ . "P42345")
       (:+HGNC+ . "3942"))
      (:NAME . "MTOR"))
     (:SUPPORTED--BY "e20ea4ea-43a4-4fed-b58d-5517f73f2874")
     (:EVIDENCE
      ((:TEXT
        . "The phosphoinositide 3-kinase (PI3K) pathway integrates many extracellular stimuli and triggers the phosphorylation of key downstream effectors such as AKT and the mammalian Target of Rapamycin Complex 1 and 2 (mTORC1 and 2).")
       (:PMID . "27451907") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This novel ERalpha mediated non canonical autophagy pathway, which we describe here, is mTOR and PI3K independent as the PI3K inhibitor Wortmannin did not reduce the autophagic flux in ERalpha expressing cells and phosphorylation of mTOR is not altered.")
       (:PMID . "26158518") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The inhibition of the PiT-1-mediated Pi influx by PFA prevented the high Pi induced autophagy and reversed the inhibition of Akt and mTOR phosphorylation.")
       (:PMID . "24797554") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The suppression of Akt and mTOR phosphorylation by high Pi was observed as early as 15 and 30minutes of treatment, respectively (, online only).")
       (:PMID . "24797554") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The specific inhibitor of PI3K and Akt (LY294002) in HaCaT cells exposed for 1 h and 3 h, reduced mTOR phosphorylation, more than in non exposed cells.")
       (:PMID . "26431550") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In summary, PRL stimulated phosphorylation of mTOR is mediated by PI3K.")
       (:PMID . "16899564") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our study also revealed that IL-27 activates PI3 K which in turn induces the phosphorylation of mTOR and expression of Mcl-1 at protein level to execute its effect.")
       (:PMID . "25194337") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PIK3R4") (:+UP+ . "Q99570") (:+HGNC+ . "8982"))
      (:NAME . "PIK3R4"))
     (:TYPE . "Phosphorylation")
     (:ID . "0c9f3363-97ee-4cf2-8d98-7f8778efdb06"))
    ((:SUB (:DB--REFS (:+TEXT+ . "PDK1") (:+UP+ . "O15530") (:+HGNC+ . "8816"))
      (:NAME . "PDPK1"))
     (:SUPPORTED--BY "8533aaa6-269b-4622-934c-197fe0319e91")
     (:EVIDENCE
      ((:TEXT
        . "CCR5 antibodies and inhibitors of PI3K and STAT1 diminished virus induced PDK1 phosphorylation (XREF_FIG).")
       (:PMID . "20568281") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Results from the current study have led to the conclusion that infection with live H. pylori induces EGFR- and PI3K dependent phosphorylation of PDK1 and Akt, and the subsequent activation of Erk, inactivation of GSK3 and IL-8 production.")
       (:PMID . "18782353") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The inhibition of the PDK1 phosphorylation by Arctigenin was expected because it targets PI3K (XREF_FIG), which phosphorylates PDK1.")
       (:PMID . "21765914") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activation of the IGFR leads to phosphorylation of PI3kinase which in turn leads to phosphorylation of PDK1 (XREF_BIBR), as outlined in XREF_FIG.")
       (:PMID . "20131294") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PIK3R4") (:+UP+ . "Q99570") (:+HGNC+ . "8982"))
      (:NAME . "PIK3R4"))
     (:TYPE . "Phosphorylation")
     (:ID . "236e666d-93f0-4bc5-92e4-f43d782d4e6d"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "tuberin") (:+UP+ . "P49815") (:+HGNC+ . "12363"))
      (:NAME . "TSC2"))
     (:SUPPORTED--BY "c8b6b0cc-600c-4a4c-9c51-c1d81bd5e2ef")
     (:EVIDENCE
      ((:TEXT
        . "We have also used phospho specific antibodies to T1462 to demonstrate PI3K dependent phosphorylation of endogenous tuberin.")
       (:PMID . "12150915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The positive regulation of mTORC1 by growth factor induced TSC2 inhibition occurs primarily through the activation of the PI3K and Akt pathway, whereby Akt directly phosphorylates and inhibits TSC2 (XREF_BIBR, XREF_BIBR).")
       (:PMID . "24366874") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The growth factor stimulated and PI3K dependent phosphorylation of tuberin is not limited to PDGF treated NIH-3T3 cells.")
       (:PMID . "12150915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "IGF-1 induced TSC2 phosphorylation and subcellular localization of TSC1 and TSC2 are modulated by a PI3K and Akt dependent mechanism.")
       (:PMID . "20412061") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activated PI3K and AKT and MAPK pathways phosphorylate TSC2 (tuberin), a component of tuberous sclerosis complex, which leads to its dissociation from TSC1 (hamartin).")
       (:PMID . "18807177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Therefore, mammalian tuberin is phosphorylated by a PI3K dependent S/T kinase on a site recognized by this RxRxxS and T-motif antibody.We next determined the time course of growth factor induced RxRxxS/T phosphorylation of tuberin.")
       (:PMID . "12150915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Under both conditions, tuberin phosphorylation is blocked by inhibition of PI3K with wortmannin.")
       (:PMID . "12150915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation of TSC2 by PI3K and AKT is a major mechanism controlling TSC1-TSC2 function [XREF_BIBR].")
       (:PMID . "26318033") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "IGF-1 induced TSC2 phosphorylation and subcellular localization of TSC1 and TSC2 are modulated by a PI3K and Akt dependent mechanism.")
       (:PMID . "20412061") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In the abundance of growth factors activation of the PI3K (phosphatidylinositol 3-kinase) activates and phosphorylates AKT, that in turn leads to the downstream phosphorylation of TSC2 and inhibits its GAP activity towards RHEB, allowing RHEB to activate mTOR [XREF_BIBR, XREF_BIBR].")
       (:PMID . "26255626") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The mTORC1 cascade is initiated by the PI3K dependent activation of AKT which phosphorylates and inactivates TSC1 and TSC2 (tuberin), negative regulators of mTOR activation.")
       (:PMID . "20008284") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Recent studies have shown that PI3K and AKT and MAPK pathways can coordinately phosphorylate tuberin (TSC2) of tuberous sclerosis complex, and functionally inactivate it by not allowing formation of a complex with hamartin (TSC1).")
       (:PMID . "18807177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Constitutively active PI3K or active AKT, including AKT1 and AKT2, induces phosphorylation of TSC2 [XREF_BIBR].")
       (:PMID . "26318033") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibitors of PI3 kinase (wortmannin) or Akt (MK-2206) reduced thrombin stimulated TSC2 phosphorylation to between 20% and 40% of maximal phosphorylation.")
       (:PMID . "24612393") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation of TSC2 by PI3K and AKT is a major mechanism controlling TSC1-TSC2 function [XREF_BIBR].")
       (:PMID . "26318033") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PIK3R4") (:+UP+ . "Q99570") (:+HGNC+ . "8982"))
      (:NAME . "PIK3R4"))
     (:TYPE . "Phosphorylation")
     (:ID . "e954a65a-8917-438a-9b57-32dda9c27299"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "4E-BP1") (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:TEXT . "PLK1 can phosphorylate 4E-BP1 in vitro") (:PMID . "22918237")
       (:SOURCE--API . "sparser"))
      ((:TEXT . "PLK1 can phosphorylate 4E-BP1 in vitro.") (:PMID . "22918237")
       (:SOURCE--API . "trips") (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT . "PLK1 can phosphorylate 4E-BP1 in vitro.") (:PMID . "22918237")
       (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "PLK1") (:+UP+ . "P53350") (:+HGNC+ . "9077"))
      (:NAME . "PLK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "eadb49f7-9803-4972-954a-c2ebfac1accc"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "FOXO3") (:+UP+ . "O43524") (:+HGNC+ . "3821"))
      (:NAME . "FOXO3"))
     (:SUPPORTED--BY "c72805ce-5398-4ce7-bfc1-560f39139191")
     (:EVIDENCE
      ((:TEXT
        . "Furthermore, PLK1 can directly phosphorylate FOXO3 in an in vitro kinase assay.")
       (:PMID . "26280018") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Furthermore, PLK1 can directly phosphorylate FOXO3 in an in vitro kinase assay.")
       (:PMID . "26280018") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Furthermore, PLK1 can directly phosphorylate FOXO3 in an in vitro kinase assay.")
       (:PMID . "26280018") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Furthermore, PLK1 can directly phosphorylate FOXO3 in an in vitro kinase assay")
       (:PMID . "26280018") (:SOURCE--API . "sparser")))
     (:ENZ (:DB--REFS (:+TEXT+ . "PLK1") (:+UP+ . "P53350") (:+HGNC+ . "9077"))
      (:NAME . "PLK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "ab37726f-19dc-4510-bad9-e34d524c10e5"))
    ((:SUB (:DB--REFS (:+TEXT+ . "MYC") (:+UP+ . "P01106") (:+HGNC+ . "7553"))
      (:NAME . "MYC"))
     (:SUPPORTED--BY "2a130ba1-188a-4615-9842-6c35b12675c5")
     (:EVIDENCE
      ((:TEXT
        . "Here, we report that PDK1 directly induces phosphorylation of Polo like kinase 1 (PLK1), which in turn induces MYC phosphorylation and protein accumulation.")
       (:PMID . "23887393") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation of MYC by PLK1 increases its association with beta-TrCP, thereby enhancing MYC stability.")
       (:PMID . "24771642") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of MYC by PLK1 increases its association with beta-TrCP, thereby enhancing MYC stability.")
       (:PMID . "24771642") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We report that sequential MYC phosphorylation by PKA and PLK1 protects MYC from proteasome mediated degradation.")
       (:PMID . "23504319") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "Polo-like kinase 1") (:+UP+ . "P53350")
       (:+HGNC+ . "9077"))
      (:NAME . "PLK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "7c1d7509-d2e5-4d46-a40d-a3370b4c2b7a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "CRAF") (:+UP+ . "P04049") (:+HGNC+ . "9829"))
      (:NAME . "RAF1"))
     (:SUPPORTED--BY "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "d2b513b0-b2c2-4931-8297-701409e3d6c2"
      "11781878-54aa-4b12-9f73-29a604cc62e7")
     (:EVIDENCE
      ((:TEXT
        . "Our data support a dual mechanism model of PLK1 mediated regulation of CRAF signaling (XREF_FIG) : PLK1 directly interacts with and phosphorylates CRAF at S338 and S339, which leads to CRAF activation.")
       (:PMID . "27003818") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "On the other hand, shRNA mediated downregulation of PLK1 led to dramatic reduction of CRAF phosphorylation at S338, S339, and S621, which was rescued by WT PLK1, but not KM PLK1 (XREF_FIG and XREF_FIG).")
       (:PMID . "27003818") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To further confirm that PLK1 directly phosphorylates CRAF at S338 and S339, cells were synchronized in M phase by nocodazole treatment followed by a transient inhibition of PLK1 activity with 2 different concentrations of BI 2536 for 30min.")
       (:PMID . "27003818") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Significant reduction in phosphorylation of CRAF at S338 and S339 was immediately observed upon treatment with the higher dose of the PLK1 inhibitor (XREF_FIG), thereby suggesting that PLK1 indeed directly phosphorylates CRAF at S338 and S339.")
       (:PMID . "27003818") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "To further confirm that PLK1 directly phosphorylates CRAF at S338 and S339, cells were synchronized in M phase by nocodazole treatment followed by a transient inhibition of PLK1 activity with 2 different concentrations of BI 2536 for 30min.")
       (:PMID . "27003818") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Our data support a dual mechanism model of PLK1 mediated regulation of CRAF signaling (XREF_FIG) : PLK1 directly interacts with and phosphorylates CRAF at S338 and S339, which leads to CRAF activation.")
       (:PMID . "27003818") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "An in vitro kinase assay demonstrated that PLK1 directly phosphorylated CRAF at S338 and S339, but not at S621 (XREF_FIG).")
       (:PMID . "27003818") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "338")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PLK-1") (:+NCIT+ . "C17911") (:+UP+ . "P53350")
       (:+HGNC+ . "9077"))
      (:NAME . "PLK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "fbf8e4ec-8a88-4fc1-9476-1239daa3de38"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "ACCalpha") (:+UP+ . "Q13085") (:+HGNC+ . "84"))
      (:NAME . "ACACA"))
     (:SUPPORTED--BY "7c0f2df4-05b6-418a-9e8f-732274e98acb")
     (:EVIDENCE
      ((:TEXT
        . "AMPK was activated [Thr 172 phosphorylation in the AMPK activation loop and phosphorylation of substrate ACCalpha (acetyl coenzyme A-carboxylase-alpha)] by all agents (XREF_FIG).")
       (:PMID . "20647423") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation of ACC by AMPK reduces its activity with the consequent decrease in de novo fatty acid synthesis.")
       (:PMID . "19710915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Decreased ACC activity corresponds to an increase in the activity of 5 '-AMP activated protein kinase (AMPK), which phosphorylates and inhibits ACC.")
       (:PMID . "18614968") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The motif surrounding serine 15 of p53 (serine 18 in mouse), a site known to undergo phosphorylation during p53 activation, is similar to the motif on ACC phosphorylated by AMPK (C), raising the possibility that this site is also targeted by AMPK kinase activity.")
       (:PMID . "15866171") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AMPK phosphorylates and inhibits acetyl-CoA-carboxylase (ACC), leading to a decrease in malonyl-CoA levels, which ultimately results in increased carnitine palmitoyl transferase (CPT1) dependent transport and oxidation of fatty acids in mitochondria [XREF_BIBR - XREF_BIBR].")
       (:PMID . "24296486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The increased AMPK dependent phosphorylation of ACC that we observed in Sirt4KO mice highlights the physiological significance of Sirt4-AMPK signaling in fatty acid oxidation.")
       (:PMID . "24296486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, in all tissues the greatest inhibition occurs when ACC is phosphorylated by AMPK.")
       (:PMID . "18455495") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of ACC by AMPK reduces its activity with the consequent decrease in de novo fatty acid synthesis.")
       (:PMID . "19710915") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "While in vitro synthesized NBR2 alone did not lead to ACC phosphorylation, the addition of NBR2 (but not the T1 fragment of NBR2, the AMPK non binding mutant) to the AMPK complex significantly increased ACC phosphorylation by AMPK (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "While in vitro synthesized NBR2 alone did not lead to ACC phosphorylation, the addition of NBR2 (but not the T1 fragment of NBR2 , the AMPK non-binding mutant) to the AMPK complex significantly increased ACC phosphorylation by AMPK ( xref ).")
       (:PMID . "26999735") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Similarly, AMPKalpha and ACC phosphorylation induced by the glycolysis inhibitor 2-deoxyglucose (2-DG) or the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) were compromised by Skp2 knockdown (C and C).")
       (:PMID . "25728766") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our data showed that bacterial purified GST-ACC (aa 1-130) could be readily phosphorylated by the AMPK complex precipitated from cell lysates of HEK293T cells co-transfected with AMPKalpha/beta/gamma constructs (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of ACC and SREBP-1c by AMPK leads to inhibition of ACC and SREBP-1c activity, resulting in increased fatty acid oxidation and decreased lipogenesis (XREF_BIBR; XREF_BIBR).")
       (:PMID . "24857548") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inhibition of AMPK activation by compound C or dominant negative AMPK mutant abrogated the EPO induced increase in the phosphorylation of AMPK, ACC, and eNOS, as well as nitric oxide (NO) production.")
       (:PMID . "22021095") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our data revealed that overexpression of AMPK CA in NBR2 knockdown cells restored ACC or S6 phosphorylation under glucose starvation condition as expected (XREF_FIG), and correspondingly, significantly rescued cell proliferation, apoptosis, and anchorage independence growth under glucose starvation conditions in NBR2 deficient cells (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, in all tissues the greatest inhibition occurs when ACC is phosphorylated by AMPK.")
       (:PMID . "18455495") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The motif surrounding serine 15 of p53 (serine 18 in mouse), a site known to undergo phosphorylation during p53 activation, is similar to the motif on ACC phosphorylated by AMPK (C), raising the possibility that this site is also targeted by AMPK kinase activity.")
       (:PMID . "15866171") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AMPK inhibition prevented the phosphorylation of ACC but had no effect on p53 Ser18 phosphorylation (B).")
       (:PMID . "22055193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, similar to AMPK, the minor pool of ACC localized at the mitochondria was robustly phosphorylated following AMPK activation (G).")
       (:PMID . "26437602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AMPK phosphorylates ACC1 at multiple residues, although phosphorylation at a single serine (Ser 79 in rat and Ser 80 in human ACC1) accounts for the resulting inactivation [XREF_BIBR, XREF_BIBR].")
       (:PMID . "19723334") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "bea5b86f-37f9-4e03-9ddb-cf2d9340cad0"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ACACB") (:+UP+ . "O00763") (:+HGNC+ . "85"))
      (:NAME . "ACACB"))
     (:SUPPORTED--BY "2f3bedf3-4f4a-44c4-8270-ea2386bc7fc7")
     (:EVIDENCE
      ((:TEXT
        . "While in vitro synthesized NBR2 alone did not lead to ACC phosphorylation, the addition of NBR2 (but not the T1 fragment of NBR2 , the AMPK non-binding mutant) to the AMPK complex significantly increased ACC phosphorylation by AMPK ( xref ).")
       (:PMID . "26999735") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Decreased ACC activity corresponds to an increase in the activity of 5 '-AMP activated protein kinase (AMPK), which phosphorylates and inhibits ACC.")
       (:PMID . "18614968") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, in all tissues the greatest inhibition occurs when ACC is phosphorylated by AMPK.")
       (:PMID . "18455495") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AMPK phosphorylates and inhibits acetyl-CoA-carboxylase (ACC), leading to a decrease in malonyl-CoA levels, which ultimately results in increased carnitine palmitoyl transferase (CPT1) dependent transport and oxidation of fatty acids in mitochondria [XREF_BIBR - XREF_BIBR].")
       (:PMID . "24296486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The increased AMPK dependent phosphorylation of ACC that we observed in Sirt4KO mice highlights the physiological significance of Sirt4-AMPK signaling in fatty acid oxidation.")
       (:PMID . "24296486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AMPK inhibition prevented the phosphorylation of ACC but had no effect on p53 Ser18 phosphorylation (B).")
       (:PMID . "22055193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our data revealed that overexpression of AMPK CA in NBR2 knockdown cells restored ACC or S6 phosphorylation under glucose starvation condition as expected (XREF_FIG), and correspondingly, significantly rescued cell proliferation, apoptosis, and anchorage independence growth under glucose starvation conditions in NBR2 deficient cells (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It is well established that AMPK can phosphorylate and inhibit ACCbeta activity, thereby lowering malonyl-CoA levels and stimulating mitochondrial FAO.")
       (:PMID . "20599696") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, similar to AMPK, the minor pool of ACC localized at the mitochondria was robustly phosphorylated following AMPK activation (G).")
       (:PMID . "26437602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The motif surrounding serine 15 of p53 (serine 18 in mouse), a site known to undergo phosphorylation during p53 activation, is similar to the motif on ACC phosphorylated by AMPK (C), raising the possibility that this site is also targeted by AMPK kinase activity.")
       (:PMID . "15866171") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The molecular mechanism of the phosphorylation and inactivation of human ACC2 by AMPK can be summarized as the binding of Ser222 phosphorylated by AMPK to the dimer interface of the BC domain, and thereby inhibiting polymerization, which is essential for the activity of the protein.From our structural information and the native gel experiments, we can suggest a scenario of the acute ACC regulation including polymerization of ACC and inactivation via phosphorylation by AMPK (B).")
       (:PMID . "19900410") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Similarly, AMPKalpha and ACC phosphorylation induced by the glycolysis inhibitor 2-deoxyglucose (2-DG) or the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) were compromised by Skp2 knockdown (C and C).")
       (:PMID . "25728766") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our data showed that bacterial purified GST-ACC (aa 1-130) could be readily phosphorylated by the AMPK complex precipitated from cell lysates of HEK293T cells co-transfected with AMPKalpha/beta/gamma constructs (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of ACC and SREBP-1c by AMPK leads to inhibition of ACC and SREBP-1c activity, resulting in increased fatty acid oxidation and decreased lipogenesis (XREF_BIBR; XREF_BIBR).")
       (:PMID . "24857548") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To decipher the molecular mechanism of ACCs inactivation through phosphorylation by AMPK, we determined the crystal structures of human ACC2 BC domain phosphorylated by AMPK, revealing that the phosphorylated Ser222 binds to the dimer interface of BC domain, disrupting the polymerization as soraphen A, whereas the unphosphorylated Ser222 is disordered in the previous structure of the unphosphorylated BC domain.")
       (:PMID . "19900410") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of ACC by AMPK reduces its activity with the consequent decrease in de novo fatty acid synthesis.")
       (:PMID . "19710915") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Inhibition of AMPK activation by compound C or dominant negative AMPK mutant abrogated the EPO induced increase in the phosphorylation of AMPK, ACC, and eNOS, as well as nitric oxide (NO) production.")
       (:PMID . "22021095") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "While in vitro synthesized NBR2 alone did not lead to ACC phosphorylation, the addition of NBR2 (but not the T1 fragment of NBR2, the AMPK non binding mutant) to the AMPK complex significantly increased ACC phosphorylation by AMPK (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, in all tissues the greatest inhibition occurs when ACC is phosphorylated by AMPK.")
       (:PMID . "18455495") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The motif surrounding serine 15 of p53 (serine 18 in mouse), a site known to undergo phosphorylation during p53 activation, is similar to the motif on ACC phosphorylated by AMPK (C), raising the possibility that this site is also targeted by AMPK kinase activity.")
       (:PMID . "15866171") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "XREF_BIBR, XREF_BIBR AMPK phosphorylation of ACC2 inhibits its activity and the synthesis of malonyl-CoA, a potent inhibitor of carnitine palmitoyltransferase-1 (CPT-1).")
       (:PMID . "22935535") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of ACC by AMPK reduces its activity with the consequent decrease in de novo fatty acid synthesis.")
       (:PMID . "19710915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "68c16b4e-df95-4bc2-a1de-07544b983e8f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:SUPPORTED--BY "70960294-e155-4fb7-b203-1c8afe66e5bf"
      "05e88bd6-921f-4b71-a3df-f4281e42d1c2"
      "d5d0707a-a034-4a72-a3d3-a3d69c2b8962"
      "b998ed79-82d0-4d4f-9d3f-645ff51a6826")
     (:EVIDENCE
      ((:TEXT
        . "These results suggest that the relevant effect of Ser729 phosphorylation of BRAF by AMPK does not involve the inhibition of BRAF kinase catalytic activity per se.")
       (:PMID . "24095280") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To assess whether attenuation of MEK-ERK signaling by AMPK activation is dependent on the phosphorylation of BRAF by AMPK at Ser729, we stably expressed FLAG tagged WT or FLAG tagged S729A phosphorylation deficient mutant of BRAF in Braf-null MEFs via retroviral infection.")
       (:PMID . "24095280") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_96e14fd28a856541f78d154776ef3649")
       (:SOURCE--API . "biopax"))
      ((:TEXT . "AMPK Phosphorylates BRAF at Ser729.") (:PMID . "24095280")
       (:SOURCE--API . "trips") (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Together, these results support the hypothesis that phosphorylation of BRAF Ser729 by AMPK in response to AICAR plays an inhibitory role on keratinocyte cell cycle progression and cell proliferation.")
       (:PMID . "24095280") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of BRAF at Ser729 by AMPK promotes its association with 14-3-3.")
       (:PMID . "24095280") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here we report that AMPK phosphorylates BRAF at Ser729, promotes its association with 14-3-3 signaling adaptor and disrupts the hetero-dimerization of BRAF with KSR1 and CRAF (also known as RAF1).")
       (:PMID . "24095280") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Together, these results support the hypothesis that phosphorylation of BRAF Ser729 by AMPK in response to AICAR plays an inhibitory role on keratinocyte cell cycle progression and cell proliferation.")
       (:PMID . "24095280") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Here we report that AMPK phosphorylates BRAF at Ser729, promotes its association with 14-3-3 signaling adaptor and disrupts the hetero-dimerization of BRAF with KSR1 and CRAF (also known as RAF1).")
       (:PMID . "24095280") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "AMPK Phosphorylates BRAF at Ser729.") (:PMID . "24095280")
       (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "729")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "ffa85f2f-ca51-42e5-9126-fdcbd5bd79a4"))
    ((:SUB (:DB--REFS (:+TEXT+ . "EGFR") (:+UP+ . "P00533") (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:SUPPORTED--BY "f58436a8-9b1e-4230-89e4-82e1da7e1a96")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of the LXRXX (S/T) motif increased with treatment of AICAR, indicating that AMPK directly phosphorylates HER2 and EGFR proteins.")
       (:PMID . "26143491") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AMPK directly phosphorylates HER2 and EGFR at specific sequences.")
       (:PMID . "26143491") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AMPK directly phosphorylates HER2 and EGFR at specific sequences.")
       (:PMID . "26143491") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "As shown in Figure XREF_FIG, AICAR activates AMPK at doses of less than 1 mM, and this AMPK activation results in markedly diminished phosphorylation of HER2 and EGFR at activating sites.")
       (:PMID . "26143491") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "09056514-ac56-4470-83a5-cf1a7bbcfffe"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "6a809b58-3561-46ca-98b4-47a57aedd3fe"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f"
      "a950ec98-3882-4735-8a62-508ddba18532"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKA_Family_DirectlyIncreases_p_HGNC_GSK3A_pmod_P_S_21")
       (:TEXT
        . "Here, we show that serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta are also physiological substrates of cAMP-dependent protein kinase A. Protein kinase A physically associates with, phosphorylates, and inactivates both isoforms of GSK-3")
       (:PMID . "11035810") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKA_Family_DirectlyIncreases_p_HGNC_GSK3A_pmod_P_S_21")
       (:TEXT . "11035810;11884598;11749387") (:PMID . "15212693")
       (:SOURCE--API . "bel")))
     (:POSITION . "21")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "7365e549-7309-4099-8f6b-1f628c50e98c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "80d5fd1f-20e0-4cbe-99f2-0b85f1bfea03"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "595c27db-1d32-425d-8876-a51951f4500e")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKA_Family_DirectlyIncreases_p_HGNC_GSK3B_pmod_P_S_9")
       (:TEXT
        . "Here, we show that serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta are also physiological substrates of cAMP-dependent protein kinase A. Protein kinase A physically associates with, phosphorylates, and inactivates both isoforms of GSK-3")
       (:PMID . "11035810") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKA_Family_DirectlyIncreases_p_HGNC_GSK3B_pmod_P_S_9")
       (:TEXT . "11035810;16039586") (:PMID . "15212693")
       (:SOURCE--API . "bel")))
     (:POSITION . "9")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "79ac258e-6ac4-47f7-a3a3-b965d0d4f4b4"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Irs1") (:+UP+ . "P35568") (:+HGNC+ . "6125"))
      (:NAME . "IRS1"))
     (:SUPPORTED--BY "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE
      ((:TEXT
        . "As nicotine did not alter the phosphorylation levels of Irs1 at Ser789 (XREF_SUPPLEMENTARY), a reported phosphorylation site by SIK2 and AMPK XREF_BIBR, XREF_BIBR, nicotine enhanced phosphorylation of Irs1 at Ser307 (XREF_FIG) is unlikely due to direct AMPK phosphorylation of Irs1 as the phosphorylation of Ser789 would have likely then been affected also.")
       (:PMID . "25799226") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "8d769c03-e93c-42d1-b103-eba33518107f"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "P-38") (:+NCIT+ . "C51219") (:+HGNC+ . "6876")
       (:+UP+ . "Q16539"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "6972a59d-f263-492b-b508-77c9425eb9d1")
     (:EVIDENCE
      ((:TEXT
        . "Therefore, AMPK directly phosphorylated p38 and regulated its activity.")
       (:PMID . "18276112") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Therefore, AMPK directly phosphorylated p38 and regulated its activity.")
       (:PMID . "18276112") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To examine whether AMPK directly phosphorylates p38 and regulates its activity, immunoprecipitation of cell lysates with AMPK, followed by immunoblot analysis using anti-p-p38 antibody was performed.")
       (:PMID . "18276112") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "61a980e9-6dab-4f5a-a045-c388a2f577bc"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:SUPPORTED--BY "185acd99-05fa-401d-9391-6873390c7d92")
     (:EVIDENCE
      ((:TEXT
        . "Inhibition of AMPK activity with its pharmacological inhibitor, compound C, attenuated phosphorylation of AMPK, but had no effect on nucleotide induced eNOS phosphorylation (XREF_FIG).")
       (:PMID . "19188511") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Treatment of HepG2 cells with 5-aminoimidazole-4-carboxamide 1-beta-D-ribonucleoside (AICAR), another typical AMPK activator, which action is caused by mimicking an increased AMP and ATP ratio, induced the AMPK phosphorylation but apparently showed no effect on the miR-122 level (XREF_FIG).")
       (:PMID . "22815988") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AMPK activation of human chondrocytes using A-769662 resulted in increased phosphorylation of AMPKalpha and was associated with increased expression of PGC-1alpha and FoxO3A (XREF_FIG), with an average of 2.7-, 3.1-, and 2.9-fold induction, respectively, as determined by densitometry in 3 different experiments.")
       (:PMID . "25047750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Similarly, AMPKalpha and ACC phosphorylation induced by the glycolysis inhibitor 2-deoxyglucose (2-DG) or the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) were compromised by Skp2 knockdown (C and C).")
       (:PMID . "25728766") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AMPK phosphorylated YAP as efficiently as ULK1 (XREF_SUPPLEMENTARY); the efficiency of YAP (51-270) phosphorylation by AMPK was comparable with the TSC2 fragment (1300-1367).")
       (:PMID . "25751140") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We identified an AMPK siRNA that inhibited AMPK expression and phosphorylation (XREF_FIG).")
       (:PMID . "24146957") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Decreased AMPK phosphorylation was accompanied, as expected, by a reduction in AMPK activity as indicated by lower levels of phosphorylated ACC (XREF_FIG), a downstream target of AMPK.")
       (:PMID . "25651975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, there are two other AMPK kinases that have also been shown to directly phosphorylate the AMPKalpha subunit resulting in its activation.")
       (:PMID . "19728795") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "0aea037b-f6a6-426f-92ef-128ac4c8e2d6"))
    ((:SUB (:DB--REFS (:+TEXT+ . "YAP") (:+UP+ . "P46937") (:+HGNC+ . "16262"))
      (:NAME . "YAP1"))
     (:SUPPORTED--BY "9f45cc54-8c1c-4abb-a11c-5f205594be93")
     (:EVIDENCE
      ((:TEXT
        . "AMPK phosphorylated YAP as efficiently as ULK1 (XREF_SUPPLEMENTARY); the efficiency of YAP (51-270) phosphorylation by AMPK was comparable with the TSC2 fragment (1300-1367).")
       (:PMID . "25751140") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA1") (:+UP+ . "Q13131") (:+HGNC+ . "9376"))
      (:NAME . "PRKAA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "22c9ae32-e151-4d8b-9eb7-f6e37313af50"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ACACA") (:+UP+ . "Q13085") (:+HGNC+ . "84"))
      (:NAME . "ACACA"))
     (:SUPPORTED--BY "7c0f2df4-05b6-418a-9e8f-732274e98acb")
     (:EVIDENCE
      ((:TEXT
        . "Inhibition of AMPK activation by compound C or dominant negative AMPK mutant abrogated the EPO induced increase in the phosphorylation of AMPK, ACC, and eNOS, as well as nitric oxide (NO) production.")
       (:PMID . "22021095") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AMPK was activated [Thr 172 phosphorylation in the AMPK activation loop and phosphorylation of substrate ACCalpha (acetyl coenzyme A-carboxylase-alpha)] by all agents (XREF_FIG).")
       (:PMID . "20647423") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Phosphorylation of ACC by AMPK reduces its activity with the consequent decrease in de novo fatty acid synthesis.")
       (:PMID . "19710915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Decreased ACC activity corresponds to an increase in the activity of 5 '-AMP activated protein kinase (AMPK), which phosphorylates and inhibits ACC.")
       (:PMID . "18614968") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While in vitro synthesized NBR2 alone did not lead to ACC phosphorylation, the addition of NBR2 (but not the T1 fragment of NBR2, the AMPK non binding mutant) to the AMPK complex significantly increased ACC phosphorylation by AMPK (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AMPK phosphorylates ACC1 at multiple residues, although phosphorylation at a single serine (Ser 79 in rat and Ser 80 in human ACC1) accounts for the resulting inactivation [XREF_BIBR, XREF_BIBR].")
       (:PMID . "19723334") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The increased AMPK dependent phosphorylation of ACC that we observed in Sirt4KO mice highlights the physiological significance of Sirt4-AMPK signaling in fatty acid oxidation.")
       (:PMID . "24296486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The motif surrounding serine 15 of p53 (serine 18 in mouse), a site known to undergo phosphorylation during p53 activation, is similar to the motif on ACC phosphorylated by AMPK (C), raising the possibility that this site is also targeted by AMPK kinase activity.")
       (:PMID . "15866171") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AMPK phosphorylates and inhibits acetyl-CoA-carboxylase (ACC), leading to a decrease in malonyl-CoA levels, which ultimately results in increased carnitine palmitoyl transferase (CPT1) dependent transport and oxidation of fatty acids in mitochondria [XREF_BIBR - XREF_BIBR].")
       (:PMID . "24296486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, in all tissues the greatest inhibition occurs when ACC is phosphorylated by AMPK.")
       (:PMID . "18455495") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of ACC by AMPK reduces its activity with the consequent decrease in de novo fatty acid synthesis.")
       (:PMID . "19710915") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Our data revealed that overexpression of AMPK CA in NBR2 knockdown cells restored ACC or S6 phosphorylation under glucose starvation condition as expected (XREF_FIG), and correspondingly, significantly rescued cell proliferation, apoptosis, and anchorage independence growth under glucose starvation conditions in NBR2 deficient cells (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Similarly, AMPKalpha and ACC phosphorylation induced by the glycolysis inhibitor 2-deoxyglucose (2-DG) or the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) were compromised by Skp2 knockdown (C and C).")
       (:PMID . "25728766") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "While in vitro synthesized NBR2 alone did not lead to ACC phosphorylation, the addition of NBR2 (but not the T1 fragment of NBR2 , the AMPK non-binding mutant) to the AMPK complex significantly increased ACC phosphorylation by AMPK ( xref ).")
       (:PMID . "26999735") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Phosphorylation of ACC and SREBP-1c by AMPK leads to inhibition of ACC and SREBP-1c activity, resulting in increased fatty acid oxidation and decreased lipogenesis (XREF_BIBR; XREF_BIBR).")
       (:PMID . "24857548") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our data showed that bacterial purified GST-ACC (aa 1-130) could be readily phosphorylated by the AMPK complex precipitated from cell lysates of HEK293T cells co-transfected with AMPKalpha/beta/gamma constructs (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, in all tissues the greatest inhibition occurs when ACC is phosphorylated by AMPK.")
       (:PMID . "18455495") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The motif surrounding serine 15 of p53 (serine 18 in mouse), a site known to undergo phosphorylation during p53 activation, is similar to the motif on ACC phosphorylated by AMPK (C), raising the possibility that this site is also targeted by AMPK kinase activity.")
       (:PMID . "15866171") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AMPK inhibition prevented the phosphorylation of ACC but had no effect on p53 Ser18 phosphorylation (B).")
       (:PMID . "22055193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, similar to AMPK, the minor pool of ACC localized at the mitochondria was robustly phosphorylated following AMPK activation (G).")
       (:PMID . "26437602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "abf8232c-e027-44a1-99ac-f01800701e31"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ACACB") (:+UP+ . "O00763") (:+HGNC+ . "85"))
      (:NAME . "ACACB"))
     (:SUPPORTED--BY "2f3bedf3-4f4a-44c4-8270-ea2386bc7fc7")
     (:EVIDENCE
      ((:TEXT
        . "Phosphorylation of ACC by AMPK reduces its activity with the consequent decrease in de novo fatty acid synthesis.")
       (:PMID . "19710915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The increased AMPK dependent phosphorylation of ACC that we observed in Sirt4KO mice highlights the physiological significance of Sirt4-AMPK signaling in fatty acid oxidation.")
       (:PMID . "24296486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The molecular mechanism of the phosphorylation and inactivation of human ACC2 by AMPK can be summarized as the binding of Ser222 phosphorylated by AMPK to the dimer interface of the BC domain, and thereby inhibiting polymerization, which is essential for the activity of the protein.From our structural information and the native gel experiments, we can suggest a scenario of the acute ACC regulation including polymerization of ACC and inactivation via phosphorylation by AMPK (B).")
       (:PMID . "19900410") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The motif surrounding serine 15 of p53 (serine 18 in mouse), a site known to undergo phosphorylation during p53 activation, is similar to the motif on ACC phosphorylated by AMPK (C), raising the possibility that this site is also targeted by AMPK kinase activity.")
       (:PMID . "15866171") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AMPK phosphorylates and inhibits acetyl-CoA-carboxylase (ACC), leading to a decrease in malonyl-CoA levels, which ultimately results in increased carnitine palmitoyl transferase (CPT1) dependent transport and oxidation of fatty acids in mitochondria [XREF_BIBR - XREF_BIBR].")
       (:PMID . "24296486") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While in vitro synthesized NBR2 alone did not lead to ACC phosphorylation, the addition of NBR2 (but not the T1 fragment of NBR2 , the AMPK non-binding mutant) to the AMPK complex significantly increased ACC phosphorylation by AMPK ( xref ).")
       (:PMID . "26999735") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "However, in all tissues the greatest inhibition occurs when ACC is phosphorylated by AMPK.")
       (:PMID . "18455495") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of ACC by AMPK reduces its activity with the consequent decrease in de novo fatty acid synthesis.")
       (:PMID . "19710915") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Our data revealed that overexpression of AMPK CA in NBR2 knockdown cells restored ACC or S6 phosphorylation under glucose starvation condition as expected (XREF_FIG), and correspondingly, significantly rescued cell proliferation, apoptosis, and anchorage independence growth under glucose starvation conditions in NBR2 deficient cells (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It is well established that AMPK can phosphorylate and inhibit ACCbeta activity, thereby lowering malonyl-CoA levels and stimulating mitochondrial FAO.")
       (:PMID . "20599696") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While in vitro synthesized NBR2 alone did not lead to ACC phosphorylation, the addition of NBR2 (but not the T1 fragment of NBR2, the AMPK non binding mutant) to the AMPK complex significantly increased ACC phosphorylation by AMPK (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "However, similar to AMPK, the minor pool of ACC localized at the mitochondria was robustly phosphorylated following AMPK activation (G).")
       (:PMID . "26437602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Decreased ACC activity corresponds to an increase in the activity of 5 '-AMP activated protein kinase (AMPK), which phosphorylates and inhibits ACC.")
       (:PMID . "18614968") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of ACC and SREBP-1c by AMPK leads to inhibition of ACC and SREBP-1c activity, resulting in increased fatty acid oxidation and decreased lipogenesis (XREF_BIBR; XREF_BIBR).")
       (:PMID . "24857548") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Similarly, AMPKalpha and ACC phosphorylation induced by the glycolysis inhibitor 2-deoxyglucose (2-DG) or the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) were compromised by Skp2 knockdown (C and C).")
       (:PMID . "25728766") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To decipher the molecular mechanism of ACCs inactivation through phosphorylation by AMPK, we determined the crystal structures of human ACC2 BC domain phosphorylated by AMPK, revealing that the phosphorylated Ser222 binds to the dimer interface of BC domain, disrupting the polymerization as soraphen A, whereas the unphosphorylated Ser222 is disordered in the previous structure of the unphosphorylated BC domain.")
       (:PMID . "19900410") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inhibition of AMPK activation by compound C or dominant negative AMPK mutant abrogated the EPO induced increase in the phosphorylation of AMPK, ACC, and eNOS, as well as nitric oxide (NO) production.")
       (:PMID . "22021095") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Our data showed that bacterial purified GST-ACC (aa 1-130) could be readily phosphorylated by the AMPK complex precipitated from cell lysates of HEK293T cells co-transfected with AMPKalpha/beta/gamma constructs (XREF_FIG).")
       (:PMID . "26999735") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, in all tissues the greatest inhibition occurs when ACC is phosphorylated by AMPK.")
       (:PMID . "18455495") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The motif surrounding serine 15 of p53 (serine 18 in mouse), a site known to undergo phosphorylation during p53 activation, is similar to the motif on ACC phosphorylated by AMPK (C), raising the possibility that this site is also targeted by AMPK kinase activity.")
       (:PMID . "15866171") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "XREF_BIBR, XREF_BIBR AMPK phosphorylation of ACC2 inhibits its activity and the synthesis of malonyl-CoA, a potent inhibitor of carnitine palmitoyltransferase-1 (CPT-1).")
       (:PMID . "22935535") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AMPK inhibition prevented the phosphorylation of ACC but had no effect on p53 Ser18 phosphorylation (B).")
       (:PMID . "22055193") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "40be34ab-cb50-48ae-829f-646dc80a620d"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:SUPPORTED--BY "b998ed79-82d0-4d4f-9d3f-645ff51a6826"
      "d5d0707a-a034-4a72-a3d3-a3d69c2b8962"
      "05e88bd6-921f-4b71-a3df-f4281e42d1c2"
      "77441daa-98f4-4b0f-b6af-1f844cae9a77")
     (:EVIDENCE
      ((:TEXT
        . "To assess whether attenuation of MEK-ERK signaling by AMPK activation is dependent on the phosphorylation of BRAF by AMPK at Ser729, we stably expressed FLAG tagged WT or FLAG tagged S729A phosphorylation deficient mutant of BRAF in Braf-null MEFs via retroviral infection.")
       (:PMID . "24095280") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Together, these results support the hypothesis that phosphorylation of BRAF Ser729 by AMPK in response to AICAR plays an inhibitory role on keratinocyte cell cycle progression and cell proliferation.")
       (:PMID . "24095280") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "AMPK Phosphorylates BRAF at Ser729.") (:PMID . "24095280")
       (:SOURCE--API . "trips") (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here we report that AMPK phosphorylates BRAF at Ser729, promotes its association with 14-3-3 signaling adaptor and disrupts the hetero-dimerization of BRAF with KSR1 and CRAF (also known as RAF1).")
       (:PMID . "24095280") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here we report that AMPK phosphorylates BRAF at Ser729, promotes its association with 14-3-3 signaling adaptor and disrupts the hetero-dimerization of BRAF with KSR1 and CRAF (also known as RAF1).")
       (:PMID . "24095280") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of BRAF at Ser729 by AMPK promotes its association with 14-3-3.")
       (:PMID . "24095280") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Together, these results support the hypothesis that phosphorylation of BRAF Ser729 by AMPK in response to AICAR plays an inhibitory role on keratinocyte cell cycle progression and cell proliferation.")
       (:PMID . "24095280") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "These results suggest that the relevant effect of Ser729 phosphorylation of BRAF by AMPK does not involve the inhibition of BRAF kinase catalytic activity per se.")
       (:PMID . "24095280") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "AMPK Phosphorylates BRAF at Ser729.") (:PMID . "24095280")
       (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "729")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "9570dbef-1cc2-4727-b94b-9642480538ec"))
    ((:SUB (:DB--REFS (:+TEXT+ . "EGFR") (:+UP+ . "P00533") (:+HGNC+ . "3236"))
      (:NAME . "EGFR"))
     (:SUPPORTED--BY "f58436a8-9b1e-4230-89e4-82e1da7e1a96")
     (:EVIDENCE
      ((:TEXT
        . "AMPK directly phosphorylates HER2 and EGFR at specific sequences.")
       (:PMID . "26143491") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Phosphorylation of the LXRXX (S/T) motif increased with treatment of AICAR, indicating that AMPK directly phosphorylates HER2 and EGFR proteins.")
       (:PMID . "26143491") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "As shown in Figure XREF_FIG, AICAR activates AMPK at doses of less than 1 mM, and this AMPK activation results in markedly diminished phosphorylation of HER2 and EGFR at activating sites.")
       (:PMID . "26143491") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AMPK directly phosphorylates HER2 and EGFR at specific sequences.")
       (:PMID . "26143491") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "52c52318-3f3a-422c-a697-09c823da51a0"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "a950ec98-3882-4735-8a62-508ddba18532"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f"
      "15e4af52-919e-4106-aac3-89b01856284d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKA_Family_DirectlyIncreases_p_HGNC_GSK3A_pmod_P_S_21")
       (:TEXT
        . "Here, we show that serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta are also physiological substrates of cAMP-dependent protein kinase A. Protein kinase A physically associates with, phosphorylates, and inactivates both isoforms of GSK-3")
       (:PMID . "11035810") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKA_Family_DirectlyIncreases_p_HGNC_GSK3A_pmod_P_S_21")
       (:TEXT . "11035810;11884598;11749387") (:PMID . "15212693")
       (:SOURCE--API . "bel")))
     (:POSITION . "21")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "0b8ba788-9c88-4122-bc61-ba93d31c8b7f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "a1b501bc-4437-4e4c-927c-3ca7b22e53d1"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKA_Family_DirectlyIncreases_p_HGNC_GSK3B_pmod_P_S_9")
       (:TEXT
        . "Here, we show that serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta are also physiological substrates of cAMP-dependent protein kinase A. Protein kinase A physically associates with, phosphorylates, and inactivates both isoforms of GSK-3")
       (:PMID . "11035810") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKA_Family_DirectlyIncreases_p_HGNC_GSK3B_pmod_P_S_9")
       (:TEXT . "11035810;16039586") (:PMID . "15212693")
       (:SOURCE--API . "bel")))
     (:POSITION . "9")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "b4042306-23b5-40c4-8ae9-14e7b1f36753"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Irs1") (:+UP+ . "P35568") (:+HGNC+ . "6125"))
      (:NAME . "IRS1"))
     (:SUPPORTED--BY "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE
      ((:TEXT
        . "As nicotine did not alter the phosphorylation levels of Irs1 at Ser789 (XREF_SUPPLEMENTARY), a reported phosphorylation site by SIK2 and AMPK XREF_BIBR, XREF_BIBR, nicotine enhanced phosphorylation of Irs1 at Ser307 (XREF_FIG) is unlikely due to direct AMPK phosphorylation of Irs1 as the phosphorylation of Ser789 would have likely then been affected also.")
       (:PMID . "25799226") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "0d8ccd33-c692-48a7-aa96-9d67995e6e58"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "P-38") (:+NCIT+ . "C51219") (:+HGNC+ . "6876")
       (:+UP+ . "Q16539"))
      (:NAME . "MAPK14"))
     (:SUPPORTED--BY "6972a59d-f263-492b-b508-77c9425eb9d1")
     (:EVIDENCE
      ((:TEXT
        . "Therefore, AMPK directly phosphorylated p38 and regulated its activity.")
       (:PMID . "18276112") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Therefore, AMPK directly phosphorylated p38 and regulated its activity.")
       (:PMID . "18276112") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To examine whether AMPK directly phosphorylates p38 and regulates its activity, immunoprecipitation of cell lysates with AMPK, followed by immunoblot analysis using anti-p-p38 antibody was performed.")
       (:PMID . "18276112") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "61a980e9-6dab-4f5a-a045-c388a2f577bc"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:SUPPORTED--BY "185acd99-05fa-401d-9391-6873390c7d92")
     (:EVIDENCE
      ((:TEXT
        . "Inhibition of AMPK activity with its pharmacological inhibitor, compound C, attenuated phosphorylation of AMPK, but had no effect on nucleotide induced eNOS phosphorylation (XREF_FIG).")
       (:PMID . "19188511") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We identified an AMPK siRNA that inhibited AMPK expression and phosphorylation (XREF_FIG).")
       (:PMID . "24146957") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, there are two other AMPK kinases that have also been shown to directly phosphorylate the AMPKalpha subunit resulting in its activation.")
       (:PMID . "19728795") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Similarly, AMPKalpha and ACC phosphorylation induced by the glycolysis inhibitor 2-deoxyglucose (2-DG) or the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) were compromised by Skp2 knockdown (C and C).")
       (:PMID . "25728766") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AMPK phosphorylated YAP as efficiently as ULK1 (XREF_SUPPLEMENTARY); the efficiency of YAP (51-270) phosphorylation by AMPK was comparable with the TSC2 fragment (1300-1367).")
       (:PMID . "25751140") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Decreased AMPK phosphorylation was accompanied, as expected, by a reduction in AMPK activity as indicated by lower levels of phosphorylated ACC (XREF_FIG), a downstream target of AMPK.")
       (:PMID . "25651975") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "AMPK activation of human chondrocytes using A-769662 resulted in increased phosphorylation of AMPKalpha and was associated with increased expression of PGC-1alpha and FoxO3A (XREF_FIG), with an average of 2.7-, 3.1-, and 2.9-fold induction, respectively, as determined by densitometry in 3 different experiments.")
       (:PMID . "25047750") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Treatment of HepG2 cells with 5-aminoimidazole-4-carboxamide 1-beta-D-ribonucleoside (AICAR), another typical AMPK activator, which action is caused by mimicking an increased AMP and ATP ratio, induced the AMPK phosphorylation but apparently showed no effect on the miR-122 level (XREF_FIG).")
       (:PMID . "22815988") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "11c63037-fbbf-4d44-a836-267753c30156"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "890b7335-3f60-4cab-bc2b-01c037a16ef7"
      "30e8e769-afbe-455f-be7d-076841551130"
      "b4bcefa8-5825-404c-9e20-1f9a11bcb142"
      "5757b142-0a4a-4a74-be36-db6f3c483dac")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f12a795d92ccea83b8347919344b539b")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "With this approach, we demonstrated that PKC-alpha but not PKC-beta could phosphorylate Akt at Ser 473 in a TCR dependent manner (XREF_FIG), which is consistent with other publications [XREF_BIBR].")
       (:PMID . "20691662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PKC-alpha purified from T cells can phosphorylate Akt at Ser 473 in vitro upon TCR stimulation.")
       (:PMID . "20691662") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "PKC-alpha purified from T cells can phosphorylate Akt at Ser 473 in vitro upon TCR stimulation.")
       (:PMID . "20691662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PKC-alpha purified from T cells can phosphorylate Akt at Ser 473 in vitro upon TCR stimulation")
       (:PMID . "20691662") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "PKC-alpha purified from T cells can phosphorylate Akt at Ser 473 in vitro upon TCR stimulation.")
       (:PMID . "20691662") (:SOURCE--API . "sparser")))
     (:POSITION . "473")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "6f799a24-e7b4-4570-88a2-ca6d326c2157"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:SUPPORTED--BY "2d0c1b00-41a3-41a5-b9c5-41366e2ba7ec"
      "b0cbde8b-46e3-4757-819f-18c35f74fbb4"
      "686a52d8-0b4a-442f-abb7-92809615f01f"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_40fd9ae124cd3699fa65b6139d669092")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "308")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "4a38ff37-6817-45a6-b1dc-2adffb727795"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "Then, using an in vitro kinase assay, we demonstrated that PKC-alpha from T cells could phosphorylate Akt in a TCR dependent way.")
       (:PMID . "20691662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "As shown in XREF_FIG, compared with the basal level of Akt Ser 473 phosphorylation in the IgG well, PKC-alpha on its own did not lead to higher Akt phosphorylation.")
       (:PMID . "20691662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Then, using an in vitro kinase assay, we demonstrated that PKC-alpha from T cells could phosphorylate Akt in a TCR dependent way.")
       (:PMID . "20691662") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Our preliminary screen demonstrated that silencing of 12% of the human kinome resulted in a 20-60% reduction in Akt (ser473) phosphorylation (fig XREF_FIG) and these include mTor, PKCalpha and PI3K which are known to modulate Akt phosphorylation.")
       (:PMID . "20042122") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PKC-alpha") (:+UP+ . "P17252") (:+HGNC+ . "9393"))
      (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "dd8683ec-d6a4-4558-8be4-744003722d29"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "As shown in XREF_FIG, compared with the basal level of Akt Ser 473 phosphorylation in the IgG well, PKC-alpha on its own did not lead to higher Akt phosphorylation.")
       (:PMID . "20691662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Then, using an in vitro kinase assay, we demonstrated that PKC-alpha from T cells could phosphorylate Akt in a TCR dependent way.")
       (:PMID . "20691662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Then, using an in vitro kinase assay, we demonstrated that PKC-alpha from T cells could phosphorylate Akt in a TCR dependent way.")
       (:PMID . "20691662") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Our preliminary screen demonstrated that silencing of 12% of the human kinome resulted in a 20-60% reduction in Akt (ser473) phosphorylation (fig XREF_FIG) and these include mTor, PKCalpha and PI3K which are known to modulate Akt phosphorylation.")
       (:PMID . "20042122") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PKC-alpha") (:+UP+ . "P17252") (:+HGNC+ . "9393"))
      (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "a075d52c-1582-440c-8aed-9ab979a7c2a6"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "05e88bd6-921f-4b71-a3df-f4281e42d1c2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_06e078d3803f4688420a390e27f39c5e")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_06e078d3803f4688420a390e27f39c5e")
       (:PMID . "12917261") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bea1b010d644e3545dfc6e1ad0fd3190")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bea1b010d644e3545dfc6e1ad0fd3190")
       (:PMID . "12917261") (:SOURCE--API . "biopax")))
     (:POSITION . "373")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "ea410f4b-2864-4cbe-a93c-3fb4f874cee6"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "beta-catenin") (:+UP+ . "P35222")
       (:+HGNC+ . "2514"))
      (:NAME . "CTNNB1"))
     (:SUPPORTED--BY "bc96c7d8-d6b6-4dd5-934f-b0b393675faf"
      "bfbf2b82-b240-42d9-a1a7-820c07359ff9"
      "2e4b14b0-a532-468c-b50d-02c2e7f43164"
      "f284bab9-67a0-40ae-99be-40781eae45f9")
     (:EVIDENCE
      ((:TEXT
        . "As shown in B, PKCalpha readily phosphorylated Ser33 and Ser37 / Thr41 on full-length beta-catenin (beta-catenin) and CTD deletion mutant (beta-catenin).")
       (:PMID . "25058461") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyIncreases_p_HGNC_CTNNB1_pmod_P_S_33")
       (:TEXT
        . "Enzastaurin also blocked phosphorylation of b-catenin at S33,37 phosphorylation sites essential for PKC-regulated proteasomal degradation (Figure 1C).18,19 Indeed, inhibition of translation using cycloheximide did not abrogate enzastaurin-induced up-regulation of b-catenin. These data support the hypothesis that enzastaurin inhibits degradation of b-catenin via abrogation of ubiquitination")
       (:PMID . "19018094") (:SOURCE--API . "bel")))
     (:POSITION . "33")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PKCalpha") (:+UP+ . "P17252") (:+HGNC+ . "9393"))
      (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "50e2dfd6-ceb7-42a3-8b04-0effb4ed602e"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "e4b07227-8163-468c-b415-d1fcd3762511"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "a950ec98-3882-4735-8a62-508ddba18532"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_770d1ccb1f89635f285bbd8e572bb18f")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "21")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "cb2be137-ac8f-4841-87d1-898c64a24616"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "11656290-4b53-44ab-a8d2-ee3e59b295fd"
      "2eae6d77-01fa-4f10-8f41-ee19f87a0102"
      "74a283fb-b7f1-4d82-97bf-904f529d8647"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "21")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "c553fdb7-5601-4e7b-8842-f533baa6f379"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "36ef809c-c75c-41f5-83fe-4ef917cc2142"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "801d70d2-28fc-495d-b2b7-e8977624b493"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a12b74cd8cf2c7510715ab27cd6437de")
       (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "9cf48333-f35c-4563-8c2a-8a3c272adf14"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:SUPPORTED--BY "9c55d32d-8de2-4d09-be08-9220441b11b8"
      "5364107e-5925-43a7-bc75-ea2e23e33359"
      "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "307")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "49d5b02c-895f-40af-b729-65bb691e5171"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d"
      "f21ff448-cc72-48aa-85c7-0bb62667b52b"
      "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4174fcedfdc70b32f2fddec2c61c8f85")
       (:PMID . "12598525") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4174fcedfdc70b32f2fddec2c61c8f85")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "9160888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "8903320") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "272087b2-9971-43b4-b1e5-477887b73b22"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "ee7aca37-7cd0-4675-a4e8-167017d5cdc9"
      "1c9d8d6e-24dd-4fdb-9797-e690e6494c36"
      "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4174fcedfdc70b32f2fddec2c61c8f85")
       (:PMID . "12598525") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4174fcedfdc70b32f2fddec2c61c8f85")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "9160888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "8903320") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "a9a0e90b-c2a0-4afd-b44f-08693350186b"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "cac6550c-ab98-4931-8182-21e30b202fc1"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "0d920125-bd7d-456d-8a90-7673e3c83616")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4174fcedfdc70b32f2fddec2c61c8f85")
       (:PMID . "12598525") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4174fcedfdc70b32f2fddec2c61c8f85")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "9160888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "8903320") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "4e198a92-e104-4715-b19c-cf3bbaa15feb"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "cac6550c-ab98-4931-8182-21e30b202fc1"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "e96c4895-0a45-4836-a398-d523e0dcb483")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4174fcedfdc70b32f2fddec2c61c8f85")
       (:PMID . "12598525") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4174fcedfdc70b32f2fddec2c61c8f85")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "9160888") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "11704645") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6f1990af34815bbdc16756e3b500c1d4")
       (:PMID . "8903320") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "d8b21f00-5cc2-4e02-80b9-030c38a89b21"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "d2637bd7-ddaf-458e-8724-552eafe180b3"
      "fa20efc7-8b6f-48e9-b5c4-15221da38627"
      "a4c02905-6eba-40d8-ac1a-09529665ba79"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0aa6a35ab42c520c6d12b06606c63a5e")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0aa6a35ab42c520c6d12b06606c63a5e")
       (:PMID . "12917261") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0d4e2b90691d115a83bc27d74e4ffc3f")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0d4e2b90691d115a83bc27d74e4ffc3f")
       (:PMID . "12917261") (:SOURCE--API . "biopax")))
     (:POSITION . "621")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "3c88c39b-8391-4d83-9a00-e604a323d87b"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "a131f950-95b7-4358-a2fe-88ff4ddfe698"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0aa6a35ab42c520c6d12b06606c63a5e")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0aa6a35ab42c520c6d12b06606c63a5e")
       (:PMID . "12917261") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0d4e2b90691d115a83bc27d74e4ffc3f")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0d4e2b90691d115a83bc27d74e4ffc3f")
       (:PMID . "12917261") (:SOURCE--API . "biopax")))
     (:POSITION . "268")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P17252") (:+HGNC+ . "9393")) (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "0e8b576c-2e57-41e0-b9ef-7b2edaeef364"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:SUPPORTED--BY "a49e8d40-a288-4151-8fd3-d4e5d64e62d5")
     (:EVIDENCE
      ((:TEXT
        . "Active PKCalpha phosphorylates Src to induce PI-3K to phosphorylate AKT that subsequently activates the ERK1/2 cascade to stimulate goblet cell proliferation")
       (:PMID . "23882690") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Active PKCalpha phosphorylates Src to induce PI-3K to phosphorylate AKT that subsequently activates the ERK1/2 cascade to stimulate goblet cell proliferation.")
       (:PMID . "23882690") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PKCalpha") (:+UP+ . "P17252") (:+HGNC+ . "9393"))
      (:NAME . "PRKCA"))
     (:TYPE . "Phosphorylation")
     (:ID . "e986be41-7df5-4540-a8cb-d87067a17720"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "f5d2f58e-891c-4455-ae40-16dcf5726f18"
      "5757b142-0a4a-4a74-be36-db6f3c483dac"
      "b4bcefa8-5825-404c-9e20-1f9a11bcb142"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "Since it has been shown that PKC-beta phosphorylates Akt at Ser 473 in B cells [XREF_BIBR], we wondered whether PKC (s) played similar roles in T cells.")
       (:PMID . "20691662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_6_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In contrast, PKC-beta was n't able to phosphorylate Akt at Ser 473 in vitro even with TCR stimulation (XREF_FIG).")
       (:PMID . "20691662") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Since it has been shown that PKC-beta phosphorylates Akt at Ser 473 in B cells [XREF_BIBR], we wondered whether PKC (s) played similar roles in T cells.")
       (:PMID . "20691662") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_512b668011313a2ca7c92fc982206df3")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "473")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "PKC-beta") (:+UP+ . "P05771") (:+HGNC+ . "9395"))
      (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "54769e91-0ba9-4955-b765-d1eb0f5f8d6d"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:SUPPORTED--BY "2d0c1b00-41a3-41a5-b9c5-41366e2ba7ec"
      "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "b0cbde8b-46e3-4757-819f-18c35f74fbb4")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a8be55a08ca760f8973bae898170ee8b")
       (:SOURCE--API . "biopax")))
     (:POSITION . "308")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "5df46860-5f18-417b-8489-bafc7aef06df"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:SUPPORTED--BY "05e88bd6-921f-4b71-a3df-f4281e42d1c2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_92aa66275725adaa286f90522405ad85")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_92aa66275725adaa286f90522405ad85")
       (:PMID . "12917261") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e217f91d7103d95fcf7eedf311d8f4d3")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e217f91d7103d95fcf7eedf311d8f4d3")
       (:PMID . "12917261") (:SOURCE--API . "biopax")))
     (:POSITION . "373")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "7e072c54-0857-46fc-9226-db4caa1cb6fb"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "ae05b9f3-092a-488d-a510-c58cd5836e8f"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "a950ec98-3882-4735-8a62-508ddba18532")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_dbbb7193e3ceed0626f90f240bbbd69e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fc09487c1bff051cdd6bce1dbaa75bce")
       (:SOURCE--API . "biopax")))
     (:POSITION . "21")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "b55816be-c762-435f-9c6b-c617c613de32"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "c03a06ca-37ba-415e-9f30-872eadd709c6"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "16d0735c-c1b7-40ac-a35f-b76d03c1737f")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_83e9bd31f32048a0baf4ae7dadcead6f")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fb1f42700b4ca07e5214d99e95ef7d05")
       (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "edc0d548-4a09-49ee-8119-fc56b44bf32d"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef"
      "fdaeb5ef-5e75-4df3-afc5-f18c672e957e"
      "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7926b2079d5e10ae35b7080a4a49277")
       (:PMID . "10327068") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7926b2079d5e10ae35b7080a4a49277")
       (:PMID . "8903320") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "9fb2fb1e-18a3-4a4d-b889-d5f190f32fac"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "fdaeb5ef-5e75-4df3-afc5-f18c672e957e"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9"
      "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7926b2079d5e10ae35b7080a4a49277")
       (:PMID . "10327068") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7926b2079d5e10ae35b7080a4a49277")
       (:PMID . "8903320") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "5d11f9be-6452-4a7e-917d-43c82184507d"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0d920125-bd7d-456d-8a90-7673e3c83616"
      "e25eabb3-1cda-4e02-b5d8-acf9a6a5f3db"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7926b2079d5e10ae35b7080a4a49277")
       (:PMID . "10327068") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7926b2079d5e10ae35b7080a4a49277")
       (:PMID . "8903320") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "f0df9967-63ae-4cd9-948c-c635670368be"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "e96c4895-0a45-4836-a398-d523e0dcb483"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "e25eabb3-1cda-4e02-b5d8-acf9a6a5f3db")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7926b2079d5e10ae35b7080a4a49277")
       (:PMID . "10327068") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d7926b2079d5e10ae35b7080a4a49277")
       (:PMID . "8903320") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "5d209907-88d3-4496-9a48-bf8d5747a8ea"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "a4c02905-6eba-40d8-ac1a-09529665ba79"
      "0a0dd4f2-0f7b-42c2-8721-bfdbb05a4355"
      "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "d2637bd7-ddaf-458e-8724-552eafe180b3")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_36a8e330ddb9eb037182cc67eee9f7b6")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_36a8e330ddb9eb037182cc67eee9f7b6")
       (:PMID . "12917261") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_cdd9434d8f6aee40ce32c0abe45372b1")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_cdd9434d8f6aee40ce32c0abe45372b1")
       (:PMID . "12917261") (:SOURCE--API . "biopax")))
     (:POSITION . "621")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "3bc6a58b-3c71-4382-affa-7f347b0bfacd"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:SUPPORTED--BY "4ef52e3d-72c5-4129-93d3-27d701a2f1dc"
      "0a0dd4f2-0f7b-42c2-8721-bfdbb05a4355")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_cdd9434d8f6aee40ce32c0abe45372b1")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_cdd9434d8f6aee40ce32c0abe45372b1")
       (:PMID . "12917261") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_36a8e330ddb9eb037182cc67eee9f7b6")
       (:PMID . "1386920") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_36a8e330ddb9eb037182cc67eee9f7b6")
       (:PMID . "12917261") (:SOURCE--API . "biopax")))
     (:POSITION . "268")
     (:ENZ (:DB--REFS (:+UP+ . "P05771") (:+HGNC+ . "9395")) (:NAME . "PRKCB"))
     (:TYPE . "Phosphorylation")
     (:ID . "4ef8248e-945f-44c3-9ce6-53d046097271"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "e2dc1f5e-b49a-47e8-97a8-97c46438f276"
      "0ee71c6a-4729-4fbb-8017-7eb68b0744ea"
      "391c5c6e-8c38-4001-b432-466006d63453"
      "2eeeaba3-098c-44b3-866d-94e607e66258"
      "c4de9bbf-3087-4235-82a1-663bdb028b62"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "7537214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12361954") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "9880505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8164674") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8662591") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8272872") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "7678052") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8626374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754506") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8140422") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "15677447") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "11335711") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "10446219") (:SOURCE--API . "biopax")))
     (:POSITION . "727")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "507") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "435df567-00a6-49a2-9271-ffff5b4d249f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "484a5004-75cc-4ecb-ad19-e3ddc87d219c"
      "f902184d-882b-4e28-a907-b282a0658f49"
      "6d4cd0eb-0e4a-4ff6-88cf-4b07c63b5375"
      "2eeeaba3-098c-44b3-866d-94e607e66258"
      "c4de9bbf-3087-4235-82a1-663bdb028b62"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "7537214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12361954") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "9880505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8164674") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8662591") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8272872") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "7678052") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8626374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754506") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8140422") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "15677447") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "11335711") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "10446219") (:SOURCE--API . "biopax")))
     (:POSITION . "727")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "f9e52924-7507-410b-82ee-e5af03bf0ba3"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "8137683e-350a-43cd-a49f-870c8bc687b7"
      "5cbe4627-3639-4177-9d4f-e8d948606a3d"
      "1f9e903b-b337-4022-b907-fc559bac1720"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "7537214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12361954") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "9880505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8164674") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8662591") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8272872") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "7678052") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8626374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754506") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8140422") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "15677447") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "11335711") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "10446219") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "507") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "d00cbab6-9c82-4a10-a40d-1ea0eded0078"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "c4be9f05-5a08-4d6d-b26f-f4bc051dce84"
      "663b523b-3526-4132-aecb-7f3ff2306bdc"
      "1f9e903b-b337-4022-b907-fc559bac1720"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "7537214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12361954") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "9880505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8164674") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8662591") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8272872") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "7678052") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8626374") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754506") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754505") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "12754507") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "8140422") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "15677447") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "11335711") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d40c5c2a5f14aa05de9e7843c6806e53")
       (:PMID . "10446219") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "5a96d220-4309-473a-95aa-19fbea8624dd"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "ae05b9f3-092a-488d-a510-c58cd5836e8f"
      "a950ec98-3882-4735-8a62-508ddba18532"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_23b8bfab3f2067fc79828da43d78ce3a")
       (:SOURCE--API . "biopax")))
     (:POSITION . "21")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "507") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "e64371c3-77c5-464b-aec0-e05612a11d24"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "ae05b9f3-092a-488d-a510-c58cd5836e8f"
      "a950ec98-3882-4735-8a62-508ddba18532"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_23b8bfab3f2067fc79828da43d78ce3a")
       (:SOURCE--API . "biopax")))
     (:POSITION . "21")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "e64371c3-77c5-464b-aec0-e05612a11d24"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "24746dc5-f2d7-4b3c-97fc-b0f0b13c2a88"
      "1914f289-01df-4ab1-812a-8e3e5d65818a"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ec46386688c1e16aa965617e11562edb")
       (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "507") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "03d464e6-16fc-417f-811f-e5741ca969a4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "f03e0af2-f215-4407-bd4f-10d25f8a5536"
      "0f470174-48c1-4014-9fbc-7a4aa39b362e"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ec46386688c1e16aa965617e11562edb")
       (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "03d464e6-16fc-417f-811f-e5741ca969a4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:SUPPORTED--BY "5364107e-5925-43a7-bc75-ea2e23e33359"
      "9c55d32d-8de2-4d09-be08-9220441b11b8"
      "df56aaff-4c68-43f1-821c-fe3fc6b34783"
      "caf6a37a-9e38-4488-9029-cb99ed0f98a7")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bd4fc754db169525f2b5bc98fca469a6")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_PRKCD_DirectlyIncreases_p_HGNC_IRS1_pmod_P_S_307")
       (:TEXT . "12351658;14583092;16099428;15199052;16129690")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "307")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "507") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "f7b53745-708c-4e45-910b-004d8a861dd4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:SUPPORTED--BY "5364107e-5925-43a7-bc75-ea2e23e33359"
      "9c55d32d-8de2-4d09-be08-9220441b11b8"
      "df56aaff-4c68-43f1-821c-fe3fc6b34783"
      "4a19976a-b00e-46f9-8183-9f0d9b258cab")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bd4fc754db169525f2b5bc98fca469a6")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_PRKCD_DirectlyIncreases_p_HGNC_IRS1_pmod_P_S_307")
       (:TEXT . "12351658;14583092;16099428;15199052;16129690")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "307")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "532ab107-bbbf-4342-9dd6-d765583d0cf2"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P62753") (:+HGNC+ . "10429")) (:NAME . "RPS6"))
     (:SUPPORTED--BY "9f93c547-87c7-4f56-86b3-2d4155413eae"
      "5e762d2f-73f3-4952-9222-6a3e13eb8666")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_PRKCD_DirectlyIncreases_p_HGNC_RPS6_pmod_P_S_235")
       (:TEXT . "86287375;16083285;15471950;15358595;17081983")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9b22901333b4b4930f16401dd00e2d3a")
       (:SOURCE--API . "biopax")))
     (:POSITION . "235")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "507") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "3b4dd882-7512-4323-8652-84c377ae77b0"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P62753") (:+HGNC+ . "10429")) (:NAME . "RPS6"))
     (:SUPPORTED--BY "9f93c547-87c7-4f56-86b3-2d4155413eae"
      "5e762d2f-73f3-4952-9222-6a3e13eb8666")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_PRKCD_DirectlyIncreases_p_HGNC_RPS6_pmod_P_S_235")
       (:TEXT . "86287375;16083285;15471950;15358595;17081983")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9b22901333b4b4930f16401dd00e2d3a")
       (:SOURCE--API . "biopax")))
     (:POSITION . "235")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "3b4dd882-7512-4323-8652-84c377ae77b0"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:SUPPORTED--BY "85c48380-c902-4629-8e1a-b740069b21cd"
      "5f37d83c-f134-43a1-81a0-29f3f2a889f7"
      "277fbd4a-55f7-4efd-be56-0ec953a6cf28"
      "93868e97-7891-4417-96b7-aa7453443998")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_PRKCD_DirectlyIncreases_p_HGNC_TP53_pmod_P_S_46")
       (:TEXT
        . "Moreover, upon exposure to genotoxic stress, p53DINP1 was expressed and recruited a kinase(s) to p53 that specifically phosphorylated Ser(46). Here, we show that the pro-apoptotic kinase, protein kinase C delta (PKCdelta), is involved in phosphorylation of p53 on Ser(46).")
       (:PMID . "16377624") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_67433e8943b412286fdba8acfd4c15e2")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "The results obtained showed that under stress conditions p53 is not phosphorylated by PKCdelta and epsilon at Ser15, Ser20 and Ser46.")
       (:PMID . "21338602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "46")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "507") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "5014c4b5-dac1-436c-9394-d8ff44349ca4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P04637") (:+HGNC+ . "11998")) (:NAME . "TP53"))
     (:SUPPORTED--BY "85c48380-c902-4629-8e1a-b740069b21cd"
      "5f37d83c-f134-43a1-81a0-29f3f2a889f7"
      "ea70e5e3-eb28-443e-b81a-db8886ac5bca"
      "93868e97-7891-4417-96b7-aa7453443998")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_PRKCD_DirectlyIncreases_p_HGNC_TP53_pmod_P_S_46")
       (:TEXT
        . "Moreover, upon exposure to genotoxic stress, p53DINP1 was expressed and recruited a kinase(s) to p53 that specifically phosphorylated Ser(46). Here, we show that the pro-apoptotic kinase, protein kinase C delta (PKCdelta), is involved in phosphorylation of p53 on Ser(46).")
       (:PMID . "16377624") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_67433e8943b412286fdba8acfd4c15e2")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "The results obtained showed that under stress conditions p53 is not phosphorylated by PKCdelta and epsilon at Ser15, Ser20 and Ser46.")
       (:PMID . "21338602") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "46")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05655") (:+HGNC+ . "9399")) (:NAME . "PRKCD"))
     (:TYPE . "Phosphorylation")
     (:ID . "b825c80e-f181-47aa-9d94-a82483b77605"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "d0c7e065-ad95-48bb-81ca-29e7e9cd7aad"
      "11656290-4b53-44ab-a8d2-ee3e59b295fd"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "df395cff-9cd0-4131-b11f-eaa07a4c2d9b"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "21")
     (:ENZ (:DB--REFS (:+UP+ . "Q02156") (:+HGNC+ . "9401")) (:NAME . "PRKCE"))
     (:TYPE . "Phosphorylation")
     (:ID . "868c55ea-2820-4d20-96d2-39928373970b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "4ea0a5ca-fb64-4834-bfe3-d1f2cfa683d6"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "c4de9bbf-3087-4235-82a1-663bdb028b62"
      "2eeeaba3-098c-44b3-866d-94e607e66258")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_PRKCE_DirectlyIncreases_p_HGNC_STAT3_pmod_P_S_727")
       (:TEXT
        . "PKCepsilon interaction with Stat3 was PKCepsilon isoform specific and was not observed with other protein kinases. As observed in vitro with immunocomplex kinase assay with immunopurified PKCepsilon and Stat3, PKCepsilon phosphorylated Stat3 at the serine 727 residue. PKCepsilon depletion prevented Stat3Ser727 phosphorylation, Stat3 DNA binding, and transcriptional activity")
       (:PMID . "17583567") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_66580bcbf72aca029762b1782d110a05")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Knockdown of PKCepsilon with RNA interference inhibits Stat3 Ser727 phosphorylation and reduces the activity of Stat3, measured by DNA binding and activation of transcription.")
       (:PMID . "20350291") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In prostate adenocarcinoma cells PKCepsilon forms a complex with Stat3 and phosphorylates Stat3 at Ser 727 [XREF_BIBR].")
       (:PMID . "20350291") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "727")
     (:ENZ (:DB--REFS (:+UP+ . "Q02156") (:+HGNC+ . "9401")) (:NAME . "PRKCE"))
     (:TYPE . "Phosphorylation")
     (:ID . "96e0dde7-420b-42a3-b4cc-d94bf9e3c18d"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "a950ec98-3882-4735-8a62-508ddba18532"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c6332ed5015c03e9943b6ebe81b1e6e5")
       (:SOURCE--API . "biopax")))
     (:POSITION . "21")
     (:ENZ (:DB--REFS (:+UP+ . "P05129") (:+HGNC+ . "9402")) (:NAME . "PRKCG"))
     (:TYPE . "Phosphorylation")
     (:ID . "035447ab-ed53-46dd-9718-6359cd773210"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "bfb0c46a-8c11-405f-9f9c-b4cfc66a1249")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_dadf0e336dd1e1407d05239c5e5e050c")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "9")
     (:ENZ (:DB--REFS (:+UP+ . "P05129") (:+HGNC+ . "9402")) (:NAME . "PRKCG"))
     (:TYPE . "Phosphorylation")
     (:ID . "a3516e71-7179-4be5-915a-3cc2d7d6caed"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "a950ec98-3882-4735-8a62-508ddba18532"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_242f7fbb730dc465ea230bde5007894e")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "21")
     (:ENZ (:DB--REFS (:+UP+ . "P24723") (:+HGNC+ . "9403")) (:NAME . "PRKCH"))
     (:TYPE . "Phosphorylation")
     (:ID . "a2e21076-a8f0-4ff9-ab6a-f8a81c2d2fe8"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "9488d8cb-f61d-4103-b3f0-49b44afedea3"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5f6e6d9c9657fa8a0c091146d70dedb9")
       (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ (:DB--REFS (:+UP+ . "P24723") (:+HGNC+ . "9403")) (:NAME . "PRKCH"))
     (:TYPE . "Phosphorylation")
     (:ID . "65fae0b4-ee83-475e-8b77-3acbd86fc0c5"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "O95267") (:+HGNC+ . "9878"))
      (:NAME . "RASGRP1"))
     (:SUPPORTED--BY "77e92105-13a0-48ed-8710-767f064c8db8")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6241981d060809d1557a6611922b65ee")
       (:PMID . "9819387") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6241981d060809d1557a6611922b65ee")
       (:PMID . "15899849") (:SOURCE--API . "biopax")))
     (:POSITION . "184")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "90") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "538") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "676") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "695") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q04759") (:+HGNC+ . "9410")) (:NAME . "PRKCQ"))
     (:TYPE . "Phosphorylation")
     (:ID . "6b2d3bec-6616-4cd3-8a37-d7534b239519"))
    ((:SUB (:DB--REFS (:+TEXT+ . "BAD") (:+UP+ . "Q92934") (:+HGNC+ . "936"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "These results suggest that the ability of PKCtheta to phosphorylate BAD is enhanced by the co-expression of Raf-1 and B-Raf.")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This is consistent with our results showing that PKCtheta, but not Raf-1 or B-Raf, can phosphorylate BAD directly (A).")
       (:PMID . "17011751") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "90") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "538") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "676") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "695") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PKCtheta") (:+UP+ . "Q04759") (:+HGNC+ . "9410"))
      (:NAME . "PRKCQ"))
     (:TYPE . "Phosphorylation")
     (:ID . "85b8a60e-7f91-4e70-9b14-029dfa3f7882"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_PFH_PRKC_Family_DirectlyIncreases_p_HGNC_GSK3B_pmod_P_S")
       (:SOURCE--API . "bel")))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "410") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "PRKCZ") (:+UP+ . "Q05513") (:+HGNC+ . "9412"))
      (:NAME . "PRKCZ"))
     (:TYPE . "Phosphorylation")
     (:ID . "b1bb3d50-06d5-490b-a82d-318e8e4eb1d1"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:SUPPORTED--BY "5364107e-5925-43a7-bc75-ea2e23e33359"
      "9c55d32d-8de2-4d09-be08-9220441b11b8"
      "df56aaff-4c68-43f1-821c-fe3fc6b34783")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "307")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "410") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05513") (:+HGNC+ . "9412")) (:NAME . "PRKCZ"))
     (:TYPE . "Phosphorylation")
     (:ID . "7f432c37-788c-4129-b663-f5c6b49bc1c8"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P45984") (:+HGNC+ . "6886")) (:NAME . "MAPK9"))
     (:SUPPORTED--BY "88668aa7-3dc0-44d8-a47b-d3d7b1cecb88"
      "b294fa4a-fd5d-4eda-b310-bc8254ab09f4")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5b2f1008006c751e3f62c09ebd70d2a3")
       (:PMID . "18667433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5b2f1008006c751e3f62c09ebd70d2a3")
       (:PMID . "17646398") (:SOURCE--API . "biopax")))
     (:POSITION . "183")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "410") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05513") (:+HGNC+ . "9412")) (:NAME . "PRKCZ"))
     (:TYPE . "Phosphorylation")
     (:ID . "dc72d7a6-2e83-44e6-a88b-22f4d1e1dd32"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P45984") (:+HGNC+ . "6886")) (:NAME . "MAPK9"))
     (:SUPPORTED--BY "88668aa7-3dc0-44d8-a47b-d3d7b1cecb88"
      "be4c310b-c2f5-45cc-b55d-ab3643d00212"
      "bdd6b420-d69a-4222-87b2-140de2efb582")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5b2f1008006c751e3f62c09ebd70d2a3")
       (:PMID . "18667433") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5b2f1008006c751e3f62c09ebd70d2a3")
       (:PMID . "17646398") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "410") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05513") (:+HGNC+ . "9412")) (:NAME . "PRKCZ"))
     (:TYPE . "Phosphorylation")
     (:ID . "7662f90e-7ee7-4be2-943e-36e9e5b33e58"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:SUPPORTED--BY "a49e8d40-a288-4151-8fd3-d4e5d64e62d5"
      "97ace6ac-b611-41e2-b319-a814829482ba"
      "f5eec623-512c-42df-ab4b-b373a460ea9b"
      "3ed03d5c-03d4-4d78-9f70-8c6072665393"
      "d9ef54a1-4f3e-4ccc-abd3-465825578d40"
      "e678cfe1-2dab-4d3c-a33b-710668cbe375")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c5e3906773a7771686969f194543ad02")
       (:PMID . "16679515") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c5e3906773a7771686969f194543ad02")
       (:PMID . "15485841") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c5e3906773a7771686969f194543ad02")
       (:PMID . "15277544") (:SOURCE--API . "biopax")))
     (:POSITION . "419")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "ef67c373-677b-4960-921d-08e4ea4c48ac"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:SUPPORTED--BY "a49e8d40-a288-4151-8fd3-d4e5d64e62d5"
      "97ace6ac-b611-41e2-b319-a814829482ba"
      "3194781e-f2a1-4e4e-a456-2e22f0fc7f3e"
      "ad6c6a35-39fe-430f-9978-439cbc7d37b4"
      "d1337271-3e32-4e1a-9662-dcbf4c912bd8"
      "e678cfe1-2dab-4d3c-a33b-710668cbe375")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c5e3906773a7771686969f194543ad02")
       (:PMID . "16679515") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c5e3906773a7771686969f194543ad02")
       (:PMID . "15485841") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c5e3906773a7771686969f194543ad02")
       (:PMID . "15277544") (:SOURCE--API . "biopax")))
     (:POSITION . "419")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "7dc00a1e-b955-43ca-a3ba-839280f09d5a"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:SUPPORTED--BY "a49e8d40-a288-4151-8fd3-d4e5d64e62d5"
      "97ace6ac-b611-41e2-b319-a814829482ba"
      "3d49a10c-9153-4af4-b133-5f4c7280eceb"
      "e31a4da1-e46e-4478-b864-773260baf420"
      "8bcdd2f1-b330-44ba-a9d2-d2bafd89ff23"
      "e678cfe1-2dab-4d3c-a33b-710668cbe375")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c5e3906773a7771686969f194543ad02")
       (:PMID . "16679515") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c5e3906773a7771686969f194543ad02")
       (:PMID . "15485841") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c5e3906773a7771686969f194543ad02")
       (:PMID . "15277544") (:SOURCE--API . "biopax")))
     (:POSITION . "419")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "576") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "577") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "925") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "c67bd20f-d18f-4f84-bb9e-f0624426f8cf"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "FAK siRNA did not affect pressure induced PI3K activation but blocked Akt phosphorylation.")
       (:PMID . "17317726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the levels of phosphorylated (p-) AKT, mTOR, Bad, Src, FAK, and paxillin were higher in the stable CHIP knockdown Panc-1 and BxPC-3 cells, and the levels of p-AKT, p-mTOR, p-Bad, p-Src, p-FAK, and p-paxillin significantly decreased in CHIP OE cells, while the total protein did not change in the CHIP knockdown and CHIP OE cells.")
       (:PMID . "24722501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We observed that inhibition of FAK inhibited not only Akt phosphorylation but also myofibroblast differentiation (XREF_FIG).")
       (:PMID . "21253589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "cbad2092-97dd-4a8e-8853-30b04f4dfa52"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "FAK siRNA did not affect pressure induced PI3K activation but blocked Akt phosphorylation.")
       (:PMID . "17317726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the levels of phosphorylated (p-) AKT, mTOR, Bad, Src, FAK, and paxillin were higher in the stable CHIP knockdown Panc-1 and BxPC-3 cells, and the levels of p-AKT, p-mTOR, p-Bad, p-Src, p-FAK, and p-paxillin significantly decreased in CHIP OE cells, while the total protein did not change in the CHIP knockdown and CHIP OE cells.")
       (:PMID . "24722501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We observed that inhibition of FAK inhibited not only Akt phosphorylation but also myofibroblast differentiation (XREF_FIG).")
       (:PMID . "21253589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "772a78a7-141d-4f3c-837c-428ff2095e04"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd")
     (:EVIDENCE
      ((:TEXT
        . "FAK siRNA did not affect pressure induced PI3K activation but blocked Akt phosphorylation.")
       (:PMID . "17317726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the levels of phosphorylated (p-) AKT, mTOR, Bad, Src, FAK, and paxillin were higher in the stable CHIP knockdown Panc-1 and BxPC-3 cells, and the levels of p-AKT, p-mTOR, p-Bad, p-Src, p-FAK, and p-paxillin significantly decreased in CHIP OE cells, while the total protein did not change in the CHIP knockdown and CHIP OE cells.")
       (:PMID . "24722501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We observed that inhibition of FAK inhibited not only Akt phosphorylation but also myofibroblast differentiation (XREF_FIG).")
       (:PMID . "21253589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "576") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "577") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "925") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "7f64b03a-6283-4c17-a4ba-3cbc94819244"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "FAK siRNA did not affect pressure induced PI3K activation but blocked Akt phosphorylation.")
       (:PMID . "17317726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the levels of phosphorylated (p-) AKT, mTOR, Bad, Src, FAK, and paxillin were higher in the stable CHIP knockdown Panc-1 and BxPC-3 cells, and the levels of p-AKT, p-mTOR, p-Bad, p-Src, p-FAK, and p-paxillin significantly decreased in CHIP OE cells, while the total protein did not change in the CHIP knockdown and CHIP OE cells.")
       (:PMID . "24722501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We observed that inhibition of FAK inhibited not only Akt phosphorylation but also myofibroblast differentiation (XREF_FIG).")
       (:PMID . "21253589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "9a858b23-f811-4fb7-a0f2-09c4a9ef989c"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "FAK siRNA did not affect pressure induced PI3K activation but blocked Akt phosphorylation.")
       (:PMID . "17317726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the levels of phosphorylated (p-) AKT, mTOR, Bad, Src, FAK, and paxillin were higher in the stable CHIP knockdown Panc-1 and BxPC-3 cells, and the levels of p-AKT, p-mTOR, p-Bad, p-Src, p-FAK, and p-paxillin significantly decreased in CHIP OE cells, while the total protein did not change in the CHIP knockdown and CHIP OE cells.")
       (:PMID . "24722501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We observed that inhibition of FAK inhibited not only Akt phosphorylation but also myofibroblast differentiation (XREF_FIG).")
       (:PMID . "21253589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "bef44c3b-d741-444c-8f7a-a220b0708a0c"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "FAK siRNA did not affect pressure induced PI3K activation but blocked Akt phosphorylation.")
       (:PMID . "17317726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the levels of phosphorylated (p-) AKT, mTOR, Bad, Src, FAK, and paxillin were higher in the stable CHIP knockdown Panc-1 and BxPC-3 cells, and the levels of p-AKT, p-mTOR, p-Bad, p-Src, p-FAK, and p-paxillin significantly decreased in CHIP OE cells, while the total protein did not change in the CHIP knockdown and CHIP OE cells.")
       (:PMID . "24722501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We observed that inhibition of FAK inhibited not only Akt phosphorylation but also myofibroblast differentiation (XREF_FIG).")
       (:PMID . "21253589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "576") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "577") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "925") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "7105026b-d62f-4a36-b664-1021e3bfcae3"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "FAK siRNA did not affect pressure induced PI3K activation but blocked Akt phosphorylation.")
       (:PMID . "17317726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We observed that inhibition of FAK inhibited not only Akt phosphorylation but also myofibroblast differentiation (XREF_FIG).")
       (:PMID . "21253589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the levels of phosphorylated (p-) AKT, mTOR, Bad, Src, FAK, and paxillin were higher in the stable CHIP knockdown Panc-1 and BxPC-3 cells, and the levels of p-AKT, p-mTOR, p-Bad, p-Src, p-FAK, and p-paxillin significantly decreased in CHIP OE cells, while the total protein did not change in the CHIP knockdown and CHIP OE cells.")
       (:PMID . "24722501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "adbb1939-db52-44d0-b7da-fe5756ce0d9e"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "FAK siRNA did not affect pressure induced PI3K activation but blocked Akt phosphorylation.")
       (:PMID . "17317726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We observed that inhibition of FAK inhibited not only Akt phosphorylation but also myofibroblast differentiation (XREF_FIG).")
       (:PMID . "21253589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the levels of phosphorylated (p-) AKT, mTOR, Bad, Src, FAK, and paxillin were higher in the stable CHIP knockdown Panc-1 and BxPC-3 cells, and the levels of p-AKT, p-mTOR, p-Bad, p-Src, p-FAK, and p-paxillin significantly decreased in CHIP OE cells, while the total protein did not change in the CHIP knockdown and CHIP OE cells.")
       (:PMID . "24722501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "8f9d6177-8f30-4bcd-86ac-f735317829bf"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "In LAM and TSC cells, FAK inhibition caused the reduction of Akt phosphorylation, which was followed by inhibition of phosphorylation and autophosphorylation of mTOR, and consequently by a strong reduction of S6 phosphorylation as it occurs in non adherent cells.")
       (:PMID . "24606538") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "FAK siRNA did not affect pressure induced PI3K activation but blocked Akt phosphorylation.")
       (:PMID . "17317726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We observed that inhibition of FAK inhibited not only Akt phosphorylation but also myofibroblast differentiation (XREF_FIG).")
       (:PMID . "21253589") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation.")
       (:PMID . "26892465") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that the levels of phosphorylated (p-) AKT, mTOR, Bad, Src, FAK, and paxillin were higher in the stable CHIP knockdown Panc-1 and BxPC-3 cells, and the levels of p-AKT, p-mTOR, p-Bad, p-Src, p-FAK, and p-paxillin significantly decreased in CHIP OE cells, while the total protein did not change in the CHIP knockdown and CHIP OE cells.")
       (:PMID . "24722501") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "576") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "577") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "925") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "aa608be2-6b85-4f1e-822a-4536a073cd30"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Membranes were incubated with the following primary antibodies : antiphosphotyrosine FAK (Tyr397, Tyr576/7, Tyr925), phosphorylated Src (pTyr419, (n-p) Tyr530), phosphorylated ERK (p-ERK), FAK, GAPDH, Src, and ERK, which were obtained from Cell Signaling Technology.")
       (:PMID . "24360952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Furthermore, reduction of FAK or ERK1/2 phosphorylation by FAK small interfering RNA (FAK siRNA) potentiated the effect of alpha-mangostin.")
       (:PMID . "20652762") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This model may also explain LCK-SHP2-induced ERK activation in nonattached cells, as FRNK inhibits both 397 Y-FAK phosphorylation and ERK activation in nonattached LCK-SHP2 cells.")
       (:PMID . "11956229") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We also found blockage of FAK activation by Y15 reduced the phosphorylation of Src and ERK, and inhibition of Src activation with PP2 reduced both FAK and ERK activation of JEG-3 cells induced by CsA.")
       (:PMID . "22766276") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These data provide evidence that the increased FAK activity in these tumors contributes to phosphorylation of Shc and likely to the promotion of Ras activity, extracellular signal regulated kinase-2 activation, and cell proliferation in vivo.")
       (:PMID . "11980671") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 activation in PCa cells was regulated by Class IA PI3K isoforms, Src, and FAK in LNCaP cells treated with CXCL13; however, both Class IA and Class IB PI3K isoforms as well as Src and FAK could lead to ERK1/2 phosphorylation in PC3 cells treated with CXCL13.")
       (:PMID . "20412587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results both confirm previous siRNA findings that FAK activation stimulates ERK1/2 phosphorylation and also stimulates expression of osteogenic markers.The signaling mechanisms linking integrin binding with the commitment of hMSC to the osteogenic lineage are essentially unknown.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Transient FAK silencing in Me # 28 cells induced 35% reduction of ERK phosphorylation (XREF_FIG), confirming that FAK expression and/or activation could regulate ERK phosphorylation.")
       (:PMID . "24091658") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, addition of FAK siRNA reduced ERK1 and ERK2 phosphorylation in all conditions (), demonstrating that ECM induced ERK phosphorylation occurred through a FAK signaling pathway.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, dual inhibition of FAK, using either a dominant negative construct (FAK-CD) or small interfering RNA, and IGF-1R, using a specific small molecule tyrosine kinase inhibitor (AEW-541) or stable expression of a truncated, mutated IGF-1R, led to a synergistic decrease in cell proliferation and phosphorylation of extracellular signal regulated kinase (ERK) and increase in cell detachment and apoptosis compared with inhibition of either pathway alone.")
       (:PMID . "18263593") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We investigated whether Src and FAK mediate strain induced ERK phosphorylation and migration in human Caco-2 intestinal epithelial cells on fibronectin.")
       (:PMID . "18400991") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "86d65ef4-b9b1-436e-9ed1-6fe76ac05533"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Membranes were incubated with the following primary antibodies : antiphosphotyrosine FAK (Tyr397, Tyr576/7, Tyr925), phosphorylated Src (pTyr419, (n-p) Tyr530), phosphorylated ERK (p-ERK), FAK, GAPDH, Src, and ERK, which were obtained from Cell Signaling Technology.")
       (:PMID . "24360952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Furthermore, reduction of FAK or ERK1/2 phosphorylation by FAK small interfering RNA (FAK siRNA) potentiated the effect of alpha-mangostin.")
       (:PMID . "20652762") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This model may also explain LCK-SHP2-induced ERK activation in nonattached cells, as FRNK inhibits both 397 Y-FAK phosphorylation and ERK activation in nonattached LCK-SHP2 cells.")
       (:PMID . "11956229") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We also found blockage of FAK activation by Y15 reduced the phosphorylation of Src and ERK, and inhibition of Src activation with PP2 reduced both FAK and ERK activation of JEG-3 cells induced by CsA.")
       (:PMID . "22766276") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These data provide evidence that the increased FAK activity in these tumors contributes to phosphorylation of Shc and likely to the promotion of Ras activity, extracellular signal regulated kinase-2 activation, and cell proliferation in vivo.")
       (:PMID . "11980671") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 activation in PCa cells was regulated by Class IA PI3K isoforms, Src, and FAK in LNCaP cells treated with CXCL13; however, both Class IA and Class IB PI3K isoforms as well as Src and FAK could lead to ERK1/2 phosphorylation in PC3 cells treated with CXCL13.")
       (:PMID . "20412587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results both confirm previous siRNA findings that FAK activation stimulates ERK1/2 phosphorylation and also stimulates expression of osteogenic markers.The signaling mechanisms linking integrin binding with the commitment of hMSC to the osteogenic lineage are essentially unknown.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Transient FAK silencing in Me # 28 cells induced 35% reduction of ERK phosphorylation (XREF_FIG), confirming that FAK expression and/or activation could regulate ERK phosphorylation.")
       (:PMID . "24091658") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, addition of FAK siRNA reduced ERK1 and ERK2 phosphorylation in all conditions (), demonstrating that ECM induced ERK phosphorylation occurred through a FAK signaling pathway.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, dual inhibition of FAK, using either a dominant negative construct (FAK-CD) or small interfering RNA, and IGF-1R, using a specific small molecule tyrosine kinase inhibitor (AEW-541) or stable expression of a truncated, mutated IGF-1R, led to a synergistic decrease in cell proliferation and phosphorylation of extracellular signal regulated kinase (ERK) and increase in cell detachment and apoptosis compared with inhibition of either pathway alone.")
       (:PMID . "18263593") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We investigated whether Src and FAK mediate strain induced ERK phosphorylation and migration in human Caco-2 intestinal epithelial cells on fibronectin.")
       (:PMID . "18400991") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "7f0b0361-718a-4694-8ca9-d6888951d20d"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Membranes were incubated with the following primary antibodies : antiphosphotyrosine FAK (Tyr397, Tyr576/7, Tyr925), phosphorylated Src (pTyr419, (n-p) Tyr530), phosphorylated ERK (p-ERK), FAK, GAPDH, Src, and ERK, which were obtained from Cell Signaling Technology.")
       (:PMID . "24360952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Furthermore, reduction of FAK or ERK1/2 phosphorylation by FAK small interfering RNA (FAK siRNA) potentiated the effect of alpha-mangostin.")
       (:PMID . "20652762") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This model may also explain LCK-SHP2-induced ERK activation in nonattached cells, as FRNK inhibits both 397 Y-FAK phosphorylation and ERK activation in nonattached LCK-SHP2 cells.")
       (:PMID . "11956229") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We also found blockage of FAK activation by Y15 reduced the phosphorylation of Src and ERK, and inhibition of Src activation with PP2 reduced both FAK and ERK activation of JEG-3 cells induced by CsA.")
       (:PMID . "22766276") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These data provide evidence that the increased FAK activity in these tumors contributes to phosphorylation of Shc and likely to the promotion of Ras activity, extracellular signal regulated kinase-2 activation, and cell proliferation in vivo.")
       (:PMID . "11980671") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 activation in PCa cells was regulated by Class IA PI3K isoforms, Src, and FAK in LNCaP cells treated with CXCL13; however, both Class IA and Class IB PI3K isoforms as well as Src and FAK could lead to ERK1/2 phosphorylation in PC3 cells treated with CXCL13.")
       (:PMID . "20412587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results both confirm previous siRNA findings that FAK activation stimulates ERK1/2 phosphorylation and also stimulates expression of osteogenic markers.The signaling mechanisms linking integrin binding with the commitment of hMSC to the osteogenic lineage are essentially unknown.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Transient FAK silencing in Me # 28 cells induced 35% reduction of ERK phosphorylation (XREF_FIG), confirming that FAK expression and/or activation could regulate ERK phosphorylation.")
       (:PMID . "24091658") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, addition of FAK siRNA reduced ERK1 and ERK2 phosphorylation in all conditions (), demonstrating that ECM induced ERK phosphorylation occurred through a FAK signaling pathway.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, dual inhibition of FAK, using either a dominant negative construct (FAK-CD) or small interfering RNA, and IGF-1R, using a specific small molecule tyrosine kinase inhibitor (AEW-541) or stable expression of a truncated, mutated IGF-1R, led to a synergistic decrease in cell proliferation and phosphorylation of extracellular signal regulated kinase (ERK) and increase in cell detachment and apoptosis compared with inhibition of either pathway alone.")
       (:PMID . "18263593") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We investigated whether Src and FAK mediate strain induced ERK phosphorylation and migration in human Caco-2 intestinal epithelial cells on fibronectin.")
       (:PMID . "18400991") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "576") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "577") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "925") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "2a820383-0a1a-4902-a3ef-628e15fd9ceb"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ERK1") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "However, addition of FAK siRNA reduced ERK1 and ERK2 phosphorylation in all conditions (), demonstrating that ECM induced ERK phosphorylation occurred through a FAK signaling pathway.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Membranes were incubated with the following primary antibodies : antiphosphotyrosine FAK (Tyr397, Tyr576/7, Tyr925), phosphorylated Src (pTyr419, (n-p) Tyr530), phosphorylated ERK (p-ERK), FAK, GAPDH, Src, and ERK, which were obtained from Cell Signaling Technology.")
       (:PMID . "24360952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We also found blockage of FAK activation by Y15 reduced the phosphorylation of Src and ERK, and inhibition of Src activation with PP2 reduced both FAK and ERK activation of JEG-3 cells induced by CsA.")
       (:PMID . "22766276") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 activation in PCa cells was regulated by Class IA PI3K isoforms, Src, and FAK in LNCaP cells treated with CXCL13; however, both Class IA and Class IB PI3K isoforms as well as Src and FAK could lead to ERK1/2 phosphorylation in PC3 cells treated with CXCL13.")
       (:PMID . "20412587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results both confirm previous siRNA findings that FAK activation stimulates ERK1/2 phosphorylation and also stimulates expression of osteogenic markers.The signaling mechanisms linking integrin binding with the commitment of hMSC to the osteogenic lineage are essentially unknown.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Transient FAK silencing in Me # 28 cells induced 35% reduction of ERK phosphorylation (XREF_FIG), confirming that FAK expression and/or activation could regulate ERK phosphorylation.")
       (:PMID . "24091658") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, reduction of FAK or ERK1/2 phosphorylation by FAK small interfering RNA (FAK siRNA) potentiated the effect of alpha-mangostin.")
       (:PMID . "20652762") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This model may also explain LCK-SHP2-induced ERK activation in nonattached cells, as FRNK inhibits both 397 Y-FAK phosphorylation and ERK activation in nonattached LCK-SHP2 cells.")
       (:PMID . "11956229") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, dual inhibition of FAK, using either a dominant negative construct (FAK-CD) or small interfering RNA, and IGF-1R, using a specific small molecule tyrosine kinase inhibitor (AEW-541) or stable expression of a truncated, mutated IGF-1R, led to a synergistic decrease in cell proliferation and phosphorylation of extracellular signal regulated kinase (ERK) and increase in cell detachment and apoptosis compared with inhibition of either pathway alone.")
       (:PMID . "18263593") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We investigated whether Src and FAK mediate strain induced ERK phosphorylation and migration in human Caco-2 intestinal epithelial cells on fibronectin.")
       (:PMID . "18400991") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "1690a4d5-5b32-47e5-a15a-4dfa1ee550b5"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ERK1") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "However, addition of FAK siRNA reduced ERK1 and ERK2 phosphorylation in all conditions (), demonstrating that ECM induced ERK phosphorylation occurred through a FAK signaling pathway.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Membranes were incubated with the following primary antibodies : antiphosphotyrosine FAK (Tyr397, Tyr576/7, Tyr925), phosphorylated Src (pTyr419, (n-p) Tyr530), phosphorylated ERK (p-ERK), FAK, GAPDH, Src, and ERK, which were obtained from Cell Signaling Technology.")
       (:PMID . "24360952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We also found blockage of FAK activation by Y15 reduced the phosphorylation of Src and ERK, and inhibition of Src activation with PP2 reduced both FAK and ERK activation of JEG-3 cells induced by CsA.")
       (:PMID . "22766276") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 activation in PCa cells was regulated by Class IA PI3K isoforms, Src, and FAK in LNCaP cells treated with CXCL13; however, both Class IA and Class IB PI3K isoforms as well as Src and FAK could lead to ERK1/2 phosphorylation in PC3 cells treated with CXCL13.")
       (:PMID . "20412587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results both confirm previous siRNA findings that FAK activation stimulates ERK1/2 phosphorylation and also stimulates expression of osteogenic markers.The signaling mechanisms linking integrin binding with the commitment of hMSC to the osteogenic lineage are essentially unknown.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Transient FAK silencing in Me # 28 cells induced 35% reduction of ERK phosphorylation (XREF_FIG), confirming that FAK expression and/or activation could regulate ERK phosphorylation.")
       (:PMID . "24091658") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, reduction of FAK or ERK1/2 phosphorylation by FAK small interfering RNA (FAK siRNA) potentiated the effect of alpha-mangostin.")
       (:PMID . "20652762") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This model may also explain LCK-SHP2-induced ERK activation in nonattached cells, as FRNK inhibits both 397 Y-FAK phosphorylation and ERK activation in nonattached LCK-SHP2 cells.")
       (:PMID . "11956229") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, dual inhibition of FAK, using either a dominant negative construct (FAK-CD) or small interfering RNA, and IGF-1R, using a specific small molecule tyrosine kinase inhibitor (AEW-541) or stable expression of a truncated, mutated IGF-1R, led to a synergistic decrease in cell proliferation and phosphorylation of extracellular signal regulated kinase (ERK) and increase in cell detachment and apoptosis compared with inhibition of either pathway alone.")
       (:PMID . "18263593") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We investigated whether Src and FAK mediate strain induced ERK phosphorylation and migration in human Caco-2 intestinal epithelial cells on fibronectin.")
       (:PMID . "18400991") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "70f40ccb-3c9f-4d36-b6a4-9cf3e404715f"))
    ((:SUB (:DB--REFS (:+TEXT+ . "ERK1") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "However, addition of FAK siRNA reduced ERK1 and ERK2 phosphorylation in all conditions (), demonstrating that ECM induced ERK phosphorylation occurred through a FAK signaling pathway.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, the molecular mechanism by which these synergic effects occur remains elusive.Here, we describe an important role for FAK in IGF-1R activation by showing that FAK enables a-loop independent IGF-1R phosphorylation and Akt and ERK activation upon ligand stimulation.")
       (:PMID . "19545541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Membranes were incubated with the following primary antibodies : antiphosphotyrosine FAK (Tyr397, Tyr576/7, Tyr925), phosphorylated Src (pTyr419, (n-p) Tyr530), phosphorylated ERK (p-ERK), FAK, GAPDH, Src, and ERK, which were obtained from Cell Signaling Technology.")
       (:PMID . "24360952") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We also found blockage of FAK activation by Y15 reduced the phosphorylation of Src and ERK, and inhibition of Src activation with PP2 reduced both FAK and ERK activation of JEG-3 cells induced by CsA.")
       (:PMID . "22766276") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 activation in PCa cells was regulated by Class IA PI3K isoforms, Src, and FAK in LNCaP cells treated with CXCL13; however, both Class IA and Class IB PI3K isoforms as well as Src and FAK could lead to ERK1/2 phosphorylation in PC3 cells treated with CXCL13.")
       (:PMID . "20412587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results both confirm previous siRNA findings that FAK activation stimulates ERK1/2 phosphorylation and also stimulates expression of osteogenic markers.The signaling mechanisms linking integrin binding with the commitment of hMSC to the osteogenic lineage are essentially unknown.")
       (:PMID . "17081517") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Transient FAK silencing in Me # 28 cells induced 35% reduction of ERK phosphorylation (XREF_FIG), confirming that FAK expression and/or activation could regulate ERK phosphorylation.")
       (:PMID . "24091658") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, reduction of FAK or ERK1/2 phosphorylation by FAK small interfering RNA (FAK siRNA) potentiated the effect of alpha-mangostin.")
       (:PMID . "20652762") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This model may also explain LCK-SHP2-induced ERK activation in nonattached cells, as FRNK inhibits both 397 Y-FAK phosphorylation and ERK activation in nonattached LCK-SHP2 cells.")
       (:PMID . "11956229") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, dual inhibition of FAK, using either a dominant negative construct (FAK-CD) or small interfering RNA, and IGF-1R, using a specific small molecule tyrosine kinase inhibitor (AEW-541) or stable expression of a truncated, mutated IGF-1R, led to a synergistic decrease in cell proliferation and phosphorylation of extracellular signal regulated kinase (ERK) and increase in cell detachment and apoptosis compared with inhibition of either pathway alone.")
       (:PMID . "18263593") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_1_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We investigated whether Src and FAK mediate strain induced ERK phosphorylation and migration in human Caco-2 intestinal epithelial cells on fibronectin.")
       (:PMID . "18400991") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "397") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "576") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "577") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "861") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "925") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "Y") (:POSITION . "407") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "cae60fb5-7ea4-497e-b44c-b4a067eccb0f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "ea8cecdd-d655-4053-a4b1-432cb6dce8a5"
      "d045a0e3-0216-45bd-a3f2-1145b7edd546"
      "dc49f894-7682-4e15-b553-7ad5639db91c"
      "89f74e55-e930-4955-9db3-4f43cde944f6"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "e96340ab-1678-44bf-a46e-557e8c9cbdf3"
      "3e649a24-f7d0-48f5-99a9-e1540f5b047f"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "c86885c1-07eb-444e-8f86-bf7898c8e31e"
      "979e4698-6c1a-4fe5-a382-f46277cdd39e"
      "0096c82f-3470-4300-8073-60fee0f749e6"
      "3382a162-2bb5-43bf-a941-5cb5751acd58")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8503013") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "1c01971b-4be3-4c9a-8198-06fdf5ed9f60"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "206eb96b-3ab4-4baa-b709-89b6f10fd7ea"
      "8b34d9a7-3abe-429d-b9cd-a41a78757d39"
      "e77f4908-3923-481b-85d2-fd20283c0894"
      "8cefb99b-90c3-4885-a8d4-ba3c2073634e"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "24a02f5c-2690-44b8-aca4-09fe1904ccd1"
      "8f27c8ea-68d1-4a70-ba74-19d9a361bac3"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "12919d24-e9f7-4a77-bf77-adac3128bbff"
      "83bc77cb-943f-4610-b448-2ccd843eb901"
      "32cf92e3-bcf1-4317-a958-99eac4a16f3f"
      "521fac6b-b821-46c3-9a37-5c0d38e7ea82")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8503013") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "1e5f506d-3880-420a-9135-221c084b5d50"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "69e021cb-ab86-4d89-8808-ff4f2b1ff56d"
      "f1d2becc-7fe8-469c-9869-866ff8e79aef"
      "584ea5ee-134d-4768-88b8-957466212a34"
      "76857b24-03df-4a9f-9001-fc9e415ece2a"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "415c3f2e-abd0-4747-9e7c-08ab845a2555"
      "933544bb-4660-4492-a9a0-92a816d44739"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "79282ec1-555e-4da6-9db2-0a3e406c8e20"
      "73555502-f242-480e-b34c-260c2283cadb"
      "9f71284a-d14a-4506-8faf-b65ab2b16968"
      "13950348-946f-4a55-b334-a4560d92ef1c")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8503013") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "b5bdfe39-d509-4ee4-a269-32fd6dd4c54a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "3f5f25be-94c8-4d18-8e06-509f3a506276"
      "7e7088f2-88f2-47ae-96ef-c6abfa567836"
      "594973a9-150b-4519-95d1-c1e0ece3f7a7"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "c88f9048-fe20-4550-9d88-ec63c13df511"
      "186a6367-f9ef-4792-a7fa-b10ecde06422"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "604f6705-f866-4c33-8c19-a281585bba56"
      "107a34db-b4e2-4d37-8e77-588762cf3eee"
      "eaf6d877-ce6c-4840-b9f9-61957f066c8d"
      "cee0f633-9158-45a5-92ad-afbbf01552d3"
      "b8811162-b12b-4a93-942f-ee2c132633d3")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8503013") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "52da9dba-5a69-4ac1-80fb-afa2e97a531f"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "5d83bbf2-18a7-4ac7-81e6-eaae935423a8"
      "d0381b0b-1d3b-415e-b183-e4c02e20fa91"
      "7d0ba51c-9171-44f0-a73c-466ebec3e089"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "5966142b-5f38-4645-9b6b-8d40d580d4b9"
      "2997bf3a-1bad-4d13-8966-eb130370d4ab"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "170a8969-4a40-4b01-ac26-f5b1561fea17"
      "328d7d42-79ee-4756-8753-63c3daa719d5"
      "b9768f7a-5a1e-4c69-b662-080c78bdde83"
      "5940904e-e963-49e0-8f9e-5c34958cf243"
      "c6adb805-2021-4db4-afc0-428c34e5a27c")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8503013") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "c5515c41-721a-47b2-8bb9-a5d1ea165a39"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "545293dd-4b48-4848-a5a7-1bc734391282"
      "326d67f8-d175-4981-b5c0-c21b27d1627c"
      "150a9ed9-8d2d-44bc-b0b7-bc7b166db59b"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "3a6fb8dd-1929-4058-b249-d4f648254c76"
      "42e08003-362d-47e3-82a2-7eb7e744a041"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "6f6b7417-8f04-4bde-b8c1-4541847c8ffd"
      "ae5021c1-9f5b-40f5-a273-2cb76a2988a3"
      "822ba71d-f5ac-43ac-8a96-1194ad76314c"
      "122a02e9-1262-4e96-83b3-f02f95a100fd"
      "1b24a0f7-6fc0-4a2d-8211-3c599f0024a2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "7992057") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "1330321") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8248196") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_ffcf3fd1d761dd46ec330c7be8a47262")
       (:PMID . "8503013") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4ed7b64b-f1fb-4804-a617-4b443a8424b2"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "55479597-4ba6-48d6-aa65-41770f696b29"
      "5ab92945-5605-470a-92b5-455cf511460f"
      "18f712ae-eb1e-408b-81e2-15533c9b3c9d"
      "69a4c642-6b31-42ed-ac30-4e07aeb0797f"
      "ed09f81a-d8f1-47ea-bc64-bd746a8a282f"
      "c7778d0f-9206-40c1-a65f-867601367871"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "c185222a-cc2a-4bd7-926e-9a5fbca9f14a"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "43181e90-23df-49ad-9725-c0607e158a0f"
      "4ae4bdb1-2b0a-4f04-84f1-8ce73bd6014a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19219045") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "f7d2ce48-ab74-44a5-9c41-2730b48f5335"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "4061a974-1e05-459c-abfd-538b7666a495"
      "910f260e-2322-4471-8557-77d828a63690"
      "8218b9c0-0e0c-4ee4-b559-357cd1ff149b"
      "b5866cbf-9029-4961-8b4f-1746a7739af3"
      "3238afb4-e688-42d4-ad95-f01465a58411"
      "9a3a2801-5b38-4799-91d0-4fc5d6ffa6cb"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "cb8c9f62-24fa-44e8-a937-b0d2da43b482"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "66f2beca-53bc-49aa-91cf-280c03d58df5"
      "8910a53b-048c-4a58-a764-f6d8e87085e6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19219045") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4537f538-2756-4f29-939a-d38911b0fb8a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "861b50bc-aa80-4e9a-8825-f22b61c90793"
      "29cb26b1-8552-435a-af9f-78389da1058d"
      "a1667edc-912d-4f8a-9376-1d92c3c209bf"
      "f99b5dee-aa3a-4d11-9293-dba81165a414"
      "81765c03-290c-41fa-866c-14cdf077ade4"
      "d5bc5c83-e9b5-4e73-b064-b15e70c492c3"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "3196a3e6-eebd-4371-bc4e-28a0247846af"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "d6aee0ed-0524-4b9f-8ad6-0152a7057fdb"
      "5a2f20c6-a0a6-4510-9f4e-71b06666474a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19219045") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "632782b1-0a3c-42e1-8f48-01dbb51a50ab"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "20173488-afe6-44d8-b76e-1b154a212e61"
      "c5d78097-c617-4493-ab97-e76f6870198b"
      "db877509-fcd8-48ae-b23f-553544202dfe"
      "968802b6-d64a-497e-b673-41f6f0f5f841"
      "db8a6fd4-c5f3-4108-a837-61b5490e45db"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "fc340b3a-dee4-4196-8006-031f89329c5c"
      "bfcf8ee7-d5b4-476f-b56c-988cd93b742f"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "b4c4499f-5a2c-4af2-b58e-5b4ecbd04526"
      "859da347-2d27-435c-a8c5-480e4924c264")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19219045") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "007be961-d3c8-46e4-910a-429abfda946b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "9c1c8679-a879-4bd0-98df-f2d1061748e1"
      "f7dccb74-30b8-4f82-b0c8-8ead214dbc48"
      "4c87c4b1-c18a-4716-8ce8-a9090399b4b5"
      "ce02fe81-a8ad-42c2-9e92-e489948c7c47"
      "188ab763-c0aa-436f-bd7d-cf8783a3a913"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "96a78504-a62f-4d8a-acb3-7adb3dabe003"
      "59df918d-8beb-4a58-b594-beaf9cec8c4a"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "cbaaccf0-e7e5-4246-862a-ffcfd4d279fb"
      "088da04d-7071-45d2-b118-efa5b313cb6a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19219045") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a7429820-199c-43c1-bb76-0bf1aa4823b9"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "9e68d415-4198-49de-bd7a-bbdc2c53312a"
      "dba00813-abf9-4acf-82ea-95d66919a1d5"
      "49edc636-a9e0-4514-9b0d-2043b9d91887"
      "4fa135a2-c0c3-42d2-ae35-da955c8346ea"
      "8e14a7e3-5829-46e4-9297-2feba6fa5b0c"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "e64f7085-9c3d-40a2-a634-5f6c8ef07ba3"
      "a4d6d8d5-5bec-4789-aa6a-7e392c174d9d"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "96d14c7d-f99c-41ef-bed3-64259819af74"
      "eec7e689-9dd0-40eb-9ea1-ed724d147891")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19541618") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_65349490d13cab2bc50fe0ea1149c2e4")
       (:PMID . "19219045") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4b3c3ba5-8bb1-4954-a0dc-ced10e570e86"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "d0e9d4e7-f082-4de7-a71c-e0e526fe87b1"
      "3b4a86b2-1b3d-4fba-84be-b65d4bdb18e0"
      "797b6c50-078f-4c2e-a5f5-3db8a1051c30"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "eddbfd4a-5f40-4848-9471-3d2c3102380f"
      "04187a0f-9658-466d-b528-98ed26ed0581"
      "9b783abb-a84d-40a4-aa18-6cc507a696ec"
      "72adef8e-0f27-4a96-b2a5-1b0359231d82")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_114708980b4f72f5bdd5871b21155f7c")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e876bfdbbc720fd3d20ee23530c42b0")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_172c87349e2bab9aeb7f026b269eaa5e")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6a5ccba690460fd4e3798dc21ca9676c")
       (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "0b88b35a-36fd-4549-996f-87ecfd6d807a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "8ec5ad22-cfd7-44c2-8b2a-ec6eec23cddc"
      "e3a3845b-becd-41f6-b093-1f16be4e8938"
      "ab14b8ea-7ff8-4e5a-b656-69d8175f79a7"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "47233dbf-314c-49ed-a92d-e9343c0a00d9"
      "d6eab462-3873-4c50-94cf-cd506fe85bb9"
      "1aef804b-02f7-48ea-92cb-2fce2567a081"
      "deca939c-93c0-4242-b042-686940e6f401")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_114708980b4f72f5bdd5871b21155f7c")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e876bfdbbc720fd3d20ee23530c42b0")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_172c87349e2bab9aeb7f026b269eaa5e")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6a5ccba690460fd4e3798dc21ca9676c")
       (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "d395b5ba-4d9b-41e2-9a56-c111d6d4a9a6"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "0a61bb47-5fa0-4c32-a1a2-efad5bf23232"
      "ec155759-195e-4d2e-b2b5-c99bbc3aa499"
      "01b202a2-4adf-40f6-89ea-84c517968426"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "cde18ffd-a777-4fb5-a2f4-ccd30602083e"
      "57e37332-fdf9-43ec-b2fc-d68833acad2c"
      "ba884e7e-5c0e-409a-92c6-becb86e7ffe2"
      "b84f0fb9-f9fc-46a9-b081-1e146cacb337")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_114708980b4f72f5bdd5871b21155f7c")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e876bfdbbc720fd3d20ee23530c42b0")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_172c87349e2bab9aeb7f026b269eaa5e")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6a5ccba690460fd4e3798dc21ca9676c")
       (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "09e8a3f2-0530-45fb-b354-85e2953c4ba4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "716e8976-55d3-4886-a676-10020192c89e"
      "9a18b2c8-0efe-49be-8bfe-91b5c5516206"
      "b46ef146-f98f-4581-a7c7-f6f8f9a69ff6"
      "b33e5e5a-5273-431f-bf96-911375da44a8"
      "ebdeffcc-5026-4a06-9109-d3cefd68b62d"
      "6127eb02-87b0-4122-8656-4c7df90d2398"
      "376d3eb8-09ca-4003-8627-9b821072b0d6"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_172c87349e2bab9aeb7f026b269eaa5e")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_114708980b4f72f5bdd5871b21155f7c")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e876bfdbbc720fd3d20ee23530c42b0")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6a5ccba690460fd4e3798dc21ca9676c")
       (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4ea3ffbc-8766-495b-b9ed-b79513bc9eae"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "eff408bb-1933-40ab-ba6a-84754042e6dd"
      "0070b89c-0f9b-4d81-921d-8a01bde6f34a"
      "6f24cfab-296c-4eb4-aa3c-22b1469f3a30"
      "a8dc5b6b-d0d0-4308-b55e-6f4707c44045"
      "3b11738b-7703-4901-8730-6f9c11ff4bc6"
      "55a44c68-25cc-41e7-b416-bd0ef5c3e461"
      "5d048e19-491e-4838-b99f-e7d6ca45b4f5"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_172c87349e2bab9aeb7f026b269eaa5e")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_114708980b4f72f5bdd5871b21155f7c")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e876bfdbbc720fd3d20ee23530c42b0")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6a5ccba690460fd4e3798dc21ca9676c")
       (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "84a54b80-52dc-448a-9430-d8ed9709be5a"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "87fabf68-fa92-421b-bbc5-920c30fb2ae1"
      "bf0e838c-b084-4b60-9669-d72acd2fd2c7"
      "07914a5a-b2e0-4d3a-8017-324ddbf75c18"
      "aea2afce-c2d8-4c86-95e7-a08c3969ec18"
      "c470e90a-3c15-43ae-838b-c8615ddf6ce3"
      "086dd677-293e-4caf-803b-6af40bcc297b"
      "0b7cd92c-44a7-4a00-b489-1c645cc4a45d"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_172c87349e2bab9aeb7f026b269eaa5e")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_114708980b4f72f5bdd5871b21155f7c")
       (:PMID . "15466214") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_2e876bfdbbc720fd3d20ee23530c42b0")
       (:PMID . "8394352") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6a5ccba690460fd4e3798dc21ca9676c")
       (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "35cff869-1fd2-4cb9-adf8-e8742e3d98ab"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "5c68a2c0-4fd3-4b06-90c0-c7a27d74ea46"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "6b513cb3-642b-44ab-9ba1-399761a24aac"
      "9927802d-456e-4d36-8a0f-19d1199a8bd1"
      "d1d8e165-2fc0-446a-b14e-310ae9c37d7d"
      "1b2214e5-d08c-4524-b859-98e77de99c6b"
      "aaf2fc22-aac2-453d-a08b-9ec29e16f619"
      "dbc3c8a3-a448-451c-83b5-f7b09701c89f"
      "b5c6537b-c3bf-48b4-b89c-95196ba99278"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "2a5a4e9c-20d2-4878-abf1-908f2583de44"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "eeeb2fd4-8e8c-4819-9568-8f9355b7e106"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "1fdf0fe5-d630-4ffd-bf6f-0cf2b06c263e"
      "6fc2cc60-31b7-4de0-9864-7b5ac7363fb9"
      "7a2339ee-8679-43e4-8c29-e32423ece44e"
      "6afdc186-47cc-4d8a-ab6a-7301b9c8b7e7"
      "fd066b42-3b86-474a-8ceb-7971293d08f1"
      "57076cfd-947b-451a-87f6-3bcdc4a28165"
      "1fe43078-ddde-4e6f-bfcf-79ead73f77a4"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "b8c46a72-3ec9-4080-86c0-85485394647e"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "224b6bdd-d98d-4f9b-ae84-23a5e56ab8e7"
      "430cc5d3-2ab0-40e1-8148-e6ef7b5147b9"
      "faa49b7c-d386-4fcf-b391-c2dd68ea6eef"
      "06921424-7b9d-4c39-b53f-7f38dc47672a"
      "184a65f7-ae0d-4abb-88bc-d5bb7c851f8c"
      "d722037f-dd27-4c75-aa2f-562fc5fc2ee2"
      "7e60f1a6-2fa3-4bc3-b60b-ce05f6fbde94"
      "1c77f5d3-cfb9-4fe3-ab6f-b522a380d6b1"
      "12ccd273-5bcc-4a5a-a3e7-d8db139c1dcd"
      "9b0e31cd-e10b-4396-8d10-fa31e915f499")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "218")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "e2469398-24d7-47b3-ac3e-e9c1b8777321"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "3afa9d7a-0c73-46d0-97c6-32c496f51a4a"
      "a37243df-f321-4135-9ed3-fc13e5544d65"
      "2f00a2a5-1dd2-44d8-896b-72a181a999ce"
      "53424508-ab35-476f-9c69-9ba21511276c"
      "d65163d6-693c-4b14-8166-56106233649a"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "36e776aa-e021-4051-92eb-13b6e1e63844"
      "5a6cb602-8670-46e1-b54f-a7437f3b577b"
      "8b9d6cef-da0d-4766-8855-dbf5264ffd30")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "17f1b85b-6890-40ae-be8b-042dd8882b06"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "6412eb42-b7b8-4d9a-ab27-786533e9bd64"
      "80604f8f-d519-4c92-851b-29f6ac03bd0c"
      "84679366-be0f-4206-b85c-3503fa02e6b7"
      "c66b959e-a494-4019-a3e6-3130f707cd40"
      "f360d45b-8d52-4f3a-9c95-4a1ad2b18929"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "8ec78a91-a608-4b9e-bc8a-6d7eb8694234"
      "ff86e4bf-1e6c-440b-a8aa-f94f8b233c33"
      "444ce5e4-7e6b-4b27-8fec-e1c9751a9d12")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "63990583-291c-460c-8c2d-ee5481e09ec1"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "Q02750") (:+HGNC+ . "6840"))
      (:NAME . "MAP2K1"))
     (:SUPPORTED--BY "9b0e31cd-e10b-4396-8d10-fa31e915f499"
      "da969952-56c3-4e14-866c-43ce50cf32ec"
      "ad5ec119-92bf-4b1a-b433-7e212320de30"
      "6285e6fb-0ac0-4e71-9338-fc23994139f4"
      "e5e77fb2-82ff-4d5b-884a-ae8658ab8780"
      "1536b9ea-cf9c-4633-9c9e-4122e753bcb0"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659"
      "acbed43d-f3fa-423f-804f-8dddf8fb8826"
      "829c4c9b-875a-4835-9fb0-56eae5f5ab69"
      "f6a544f0-37d8-418e-a237-006d74c2363a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "95eca078-3531-4a11-b8c5-1ed52c3c0907"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "4fe51595-2ee3-4f30-be7b-73494f393aac"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "bc8f969c-30db-4947-9164-bbfc00bed495"
      "fc31d4fe-7a01-4182-b69e-cdb5ce52e377"
      "2d7a8fc1-dc42-42da-acd1-c2e1c2738cd2"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "dc35d42c-9046-4a1f-8217-bc0fa644e516"
      "59e2c443-8e10-449e-8659-37e88bef1f94"
      "1f1a7334-7fd8-4d1f-824b-27e61cd74517"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "8ddebe94-33e0-4bbe-b040-2dcc36495d59"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "e0a46381-846a-49f1-88a8-9cec1994a31e"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "b8de2e11-9754-49c9-9d79-eecda72bbbed"
      "83f4f0cd-6bc1-411b-ab2d-dd0cec059a06"
      "a8fb40cd-1ba9-482c-a209-4f771d3de3e2"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "c81b8395-a80d-4ee3-9489-b8ae11c68fda"
      "ec8f2a81-90a3-4ea1-8ee5-b1408cd4ebd9"
      "6cf65400-1cda-4b86-af1c-1ac5e58dd1fd"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4df07fc0-257e-4796-8c7d-76ebadbedfc2"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "3b9c7be8-bebb-4797-9c62-cac34eeba7a1"
      "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "e81a465e-5f3a-42c1-9348-99914642f3ee"
      "dec1bff6-b9ed-4cf3-a80f-3e376a98fdd2"
      "434dd307-f7e2-45af-9fa0-f6310b268e8c"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "e9f8b8db-c265-4362-99b4-beee471413e5"
      "c192f995-85f0-42ae-8fd8-dc788aaa3c36"
      "88e055c9-568d-42e0-9e3c-dc12fc403d84"
      "a7d6433e-bea2-44f2-b3bb-23c043bb2659")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "222")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "da8ecb13-f6c4-4025-8af1-2cc6a84bf9a9"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "61cb0340-f046-47a7-a535-1f707f2531cc"
      "4a09b2a0-89ff-4f7e-ab3e-742bfa9d8918"
      "917a1b41-5417-4abb-8a18-febbaf79a040"
      "041d2266-5c7b-49bb-93d6-4ebc7ca56f02"
      "5f7b6d94-a375-4e7b-adf0-22e4edd27dfd"
      "6b5759f7-d7c0-4db0-9621-3ac82b6ecd8e"
      "dda24568-3959-4b87-87a4-a6203e021a26")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "017a9148-8abb-4ee2-8a3d-1e2ae604f1bf"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "ec4c3c69-d4b1-4472-8736-86e11bcc7116"
      "32ec4a76-1a08-49ba-956c-e85c6b793d01"
      "b1b6fba4-a743-4783-8b90-933f7c97ebcb"
      "10951958-60fd-41de-9f70-13f812cfa2e6"
      "b7cc59da-7067-476c-bcb6-2cf4f103f8a4"
      "75635c0f-9b99-4293-b539-b8a2744535a8"
      "5fa6fb4a-41c0-4116-9732-88fd75c69d30")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "73828f41-abfc-4436-bdbe-8c847a9cd7aa"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P36507") (:+HGNC+ . "6842"))
      (:NAME . "MAP2K2"))
     (:SUPPORTED--BY "25ea06ee-1af0-42b4-9e65-5fbf8d6cb564"
      "9aba78c0-9fb1-4dbf-97b5-25153f50f87a"
      "4c9b4e20-9437-4e37-ab15-56a047ec7d19"
      "1b83106b-e85d-47bb-bbc4-bcf8ebfb9236"
      "de4c65e0-8e7b-4deb-8c8b-f46d48c21c25"
      "e5ea80f4-9ca2-44ee-831f-91aef084520a"
      "956fc7fd-734f-493b-8a8b-5c982ccd3677"
      "d8df86a9-19da-47e6-ab33-5ea568dc8d0b"
      "e66b399a-caa5-4728-891c-75aa5b1221c6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "11136732") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6b7d652a55cd8249bb55e22843821c1d")
       (:PMID . "12750173") (:SOURCE--API . "biopax")))
     (:POSITION . "226")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "02a77410-e25e-4db0-b513-c2aea2c7ced8"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d"
      "8020c196-7442-4323-bbcc-bef7712794ef"
      "51b34f75-34f0-4bad-b2c2-3f3fe3f3c30a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "09912f87-0746-47c7-9b4b-ad39e723809c"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d"
      "8020c196-7442-4323-bbcc-bef7712794ef"
      "7b3f5691-4ccb-455e-805e-c8f36da67195")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4ba36955-5ebb-4489-9a45-69ecdea0f057"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "a6d371cc-8c55-4bdd-ab9b-d3f54dcaae4d"
      "8020c196-7442-4323-bbcc-bef7712794ef"
      "ec4e2197-e3cb-4fbf-b2d1-2088e3886935")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "185")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "72a1074b-aadc-4797-ac2d-953a66bc9f3d"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef"
      "f086c2c6-b7d9-4146-a49c-3a0ba3c47dde"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "f2a06211-d994-42f6-b308-65b73f3e1376"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef"
      "846b0911-2ae4-40c3-b510-111e8641efa0"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "043305d7-b1d7-44f0-bb95-ab73322c7803"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P28482") (:+HGNC+ . "6871")) (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef"
      "3a8187cd-7082-43f8-8708-4ad4103d0159"
      "ee7aca37-7cd0-4675-a4e8-167017d5cdc9")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "187")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "199562a8-c706-4637-85f5-52a4dc69abfc"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0d920125-bd7d-456d-8a90-7673e3c83616"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "f1bb53a0-b956-4993-8383-846d69e846a7")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "6170901d-e435-4255-a70b-948ddc6a4947"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0d920125-bd7d-456d-8a90-7673e3c83616"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "9d232c4d-f0de-43a7-98fb-7e61947038e8")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "b0e931cc-b2c7-4ff7-a33f-bb513301ac32"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "0d920125-bd7d-456d-8a90-7673e3c83616"
      "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "d4bde1ff-1b0c-4ef7-b873-e53d0c9dde4c")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "202")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "644df912-f7ba-49c1-ac21-dc962e00b124"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "9d2aa4b0-21c8-437b-805c-1631337d7a84"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "e96c4895-0a45-4836-a398-d523e0dcb483")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "bb8bcd51-a68e-489b-b396-7fe7206a4cde"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "c3d25dcb-0796-413d-a175-7d3cd6f54670"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "e96c4895-0a45-4836-a398-d523e0dcb483")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "cb6c461d-c089-429b-9c09-66fdf7a23024"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P27361") (:+HGNC+ . "6877")) (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d"
      "00d974fc-0b96-446c-9487-b65b456ed311"
      "55f6d6e5-5020-4e55-984e-96b9acb83c1b"
      "e96c4895-0a45-4836-a398-d523e0dcb483")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "19435802") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_13953a072d6f992f2388d85f9059a475")
       (:PMID . "18319301") (:SOURCE--API . "biopax")))
     (:POSITION . "204")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P04049") (:+HGNC+ . "9829")) (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "717b2768-4d4d-47f2-892c-882b90c7f299"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "RB") (:+HGNC+ . "9884") (:+UP+ . "P06400")
       (:+NCIT+ . "C17394"))
      (:NAME . "RB1"))
     (:SUPPORTED--BY "4c7d247d-9366-43ab-a412-8e4406ebf998")
     (:EVIDENCE
      ((:TEXT
        . "Whereas, CDKs phosphorylate Rb in mid to late G1 phase (XREF_BIBR - XREF_BIBR), our lab has demonstrated that Raf-1 kinase binds and phosphorylates Rb early in the G1 phase (XREF_BIBR).")
       (:PMID . "21139044") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Furthermore, the small molecule, RRD-251, previously shown to prevent Rb inactivation by blocking Raf1 kinase phosphorylation of Rb, also facilitates HLA-DRA induction in the cells studied here.")
       (:PMID . "23041127") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RAF1_DirectlyIncreases_p_HGNC_RB1_pmod_P")
       (:TEXT
        . "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase.")
       (:PMID . "16170185") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RAF1_DirectlyIncreases_p_HGNC_RB1_pmod_P")
       (:TEXT
        . "Disruption of the Rb-Raf-1 interaction by a nine-amino-acid peptide inhibits Rb phosphorylation, cell proliferation, and vascular endothelial growth factor-mediated capillary tubule formation. ")
       (:PMID . "15485920") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RAF1_DirectlyIncreases_p_HGNC_RB1_pmod_P")
       (:TEXT
        . "<E22> Raf1 can bind pRb and p130, which are not thereby dissociated from E2F complexes, although promoter inhibition is reversed (Wang et al., 1998). There was no detectable binding to p107. Binding to pRb is mediated by the Nterminal 28 amino acids of Raf1. The kinase activity of Raf1 was required to reverse the pRb-mediated promoter repression (Wang et al., 1998), but the phosphorylation sites on pRb remain to be described and therefore are not indicated in the diagram.")
       (:PMID . "10436023") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3c2e0e0909a1f68e32b40577da7be5d7")
       (:PMID . "9819434") (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Further, Raf-1 was able to phosphorylate Rb in vitro quite efficiently.")
       (:PMID . "9819434") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "471") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "338") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RAF-1") (:+HGNC+ . "9829") (:+NCIT+ . "C17484")
       (:+UP+ . "P04049"))
      (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "812a451f-c4b1-4c8d-8a76-b2e9c292ebae"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "RB") (:+HGNC+ . "9884") (:+UP+ . "P06400")
       (:+NCIT+ . "C17394"))
      (:NAME . "RB1"))
     (:SUPPORTED--BY "4c7d247d-9366-43ab-a412-8e4406ebf998")
     (:EVIDENCE
      ((:TEXT
        . "Whereas, CDKs phosphorylate Rb in mid to late G1 phase (XREF_BIBR - XREF_BIBR), our lab has demonstrated that Raf-1 kinase binds and phosphorylates Rb early in the G1 phase (XREF_BIBR).")
       (:PMID . "21139044") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Furthermore, the small molecule, RRD-251, previously shown to prevent Rb inactivation by blocking Raf1 kinase phosphorylation of Rb, also facilitates HLA-DRA induction in the cells studied here.")
       (:PMID . "23041127") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RAF1_DirectlyIncreases_p_HGNC_RB1_pmod_P")
       (:TEXT
        . "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase.")
       (:PMID . "16170185") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RAF1_DirectlyIncreases_p_HGNC_RB1_pmod_P")
       (:TEXT
        . "Disruption of the Rb-Raf-1 interaction by a nine-amino-acid peptide inhibits Rb phosphorylation, cell proliferation, and vascular endothelial growth factor-mediated capillary tubule formation. ")
       (:PMID . "15485920") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RAF1_DirectlyIncreases_p_HGNC_RB1_pmod_P")
       (:TEXT
        . "<E22> Raf1 can bind pRb and p130, which are not thereby dissociated from E2F complexes, although promoter inhibition is reversed (Wang et al., 1998). There was no detectable binding to p107. Binding to pRb is mediated by the Nterminal 28 amino acids of Raf1. The kinase activity of Raf1 was required to reverse the pRb-mediated promoter repression (Wang et al., 1998), but the phosphorylation sites on pRb remain to be described and therefore are not indicated in the diagram.")
       (:PMID . "10436023") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3c2e0e0909a1f68e32b40577da7be5d7")
       (:PMID . "9819434") (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Further, Raf-1 was able to phosphorylate Rb in vitro quite efficiently.")
       (:PMID . "9819434") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "621") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RAF-1") (:+HGNC+ . "9829") (:+NCIT+ . "C17484")
       (:+UP+ . "P04049"))
      (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "812a451f-c4b1-4c8d-8a76-b2e9c292ebae"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "RB") (:+HGNC+ . "9884") (:+UP+ . "P06400")
       (:+NCIT+ . "C17394"))
      (:NAME . "RB1"))
     (:SUPPORTED--BY "4c7d247d-9366-43ab-a412-8e4406ebf998")
     (:EVIDENCE
      ((:TEXT
        . "Whereas, CDKs phosphorylate Rb in mid to late G1 phase (XREF_BIBR - XREF_BIBR), our lab has demonstrated that Raf-1 kinase binds and phosphorylates Rb early in the G1 phase (XREF_BIBR).")
       (:PMID . "21139044") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Furthermore, the small molecule, RRD-251, previously shown to prevent Rb inactivation by blocking Raf1 kinase phosphorylation of Rb, also facilitates HLA-DRA induction in the cells studied here.")
       (:PMID . "23041127") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RAF1_DirectlyIncreases_p_HGNC_RB1_pmod_P")
       (:TEXT
        . "157,167 The antiapoptotic effects of C-Raf are also mediated through the ankyrin-repeat protein Tvl-1 and apoptosis signal-regulated kinase-1.166,168,169 In addition, C-Raf phosphorylates Rb, p53, Cdc25, and other cell cycle regulatory proteins in metaphase.")
       (:PMID . "16170185") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RAF1_DirectlyIncreases_p_HGNC_RB1_pmod_P")
       (:TEXT
        . "Disruption of the Rb-Raf-1 interaction by a nine-amino-acid peptide inhibits Rb phosphorylation, cell proliferation, and vascular endothelial growth factor-mediated capillary tubule formation. ")
       (:PMID . "15485920") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RAF1_DirectlyIncreases_p_HGNC_RB1_pmod_P")
       (:TEXT
        . "<E22> Raf1 can bind pRb and p130, which are not thereby dissociated from E2F complexes, although promoter inhibition is reversed (Wang et al., 1998). There was no detectable binding to p107. Binding to pRb is mediated by the Nterminal 28 amino acids of Raf1. The kinase activity of Raf1 was required to reverse the pRb-mediated promoter repression (Wang et al., 1998), but the phosphorylation sites on pRb remain to be described and therefore are not indicated in the diagram.")
       (:PMID . "10436023") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3c2e0e0909a1f68e32b40577da7be5d7")
       (:PMID . "9819434") (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Further, Raf-1 was able to phosphorylate Rb in vitro quite efficiently.")
       (:PMID . "9819434") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "268") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "269") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RAF-1") (:+HGNC+ . "9829") (:+NCIT+ . "C17484")
       (:+UP+ . "P04049"))
      (:NAME . "RAF1"))
     (:TYPE . "Phosphorylation")
     (:ID . "812a451f-c4b1-4c8d-8a76-b2e9c292ebae"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "6cb07b90-245e-4365-bd39-1ba7a7b69271"
      "3b085760-047b-4de6-a358-6f53aa726e61"
      "90cd000a-2a54-42e4-b077-3a6fe82f3523")
     (:EVIDENCE
      ((:TEXT
        . "In turn, activated ROCK directly phosphorylates FAK on Ser732.")
       (:PMID . "16760434") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_57c5e334a5cd17eedbf856ea182ba06b")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Le Boeuef et al (2006) proposed a mechanism whereby ROCK1 phosphorylates FAK at Ser732 and that this phosphorylation is required for subsequent phosphorylation of Tyr407, possibly by Pyk2 XREF_BIBR.")
       (:PMID . "22348083") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In turn, activated ROCK directly phosphorylates FAK on Ser732")
       (:PMID . "16760434") (:SOURCE--API . "sparser"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_ROCK1_DirectlyIncreases_p_HGNC_PTK2_pmod_P_S_732")
       (:TEXT . "PhosphoElm data from PMID 15212693") (:PMID . "16760434")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_cf7551f1624e906d8fe12e8abb768a4b")
       (:PMID . "9182576") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_cf7551f1624e906d8fe12e8abb768a4b")
       (:PMID . "10744763") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_cf7551f1624e906d8fe12e8abb768a4b")
       (:PMID . "16760434") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_cf7551f1624e906d8fe12e8abb768a4b")
       (:PMID . "15247219") (:SOURCE--API . "biopax"))
      ((:TEXT
        . "In turn, activated ROCK directly phosphorylates FAK on Ser732.")
       (:PMID . "16760434") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "732")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "ROCK1") (:+UP+ . "Q13464") (:+HGNC+ . "10251"))
      (:NAME . "ROCK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "5f8c5843-f1a7-4cf7-af58-dafdcd4f2f31"))
    ((:SUB (:DB--REFS (:+TEXT+ . "CFL1") (:+UP+ . "P23528") (:+HGNC+ . "1874"))
      (:NAME . "CFL1"))
     (:SUPPORTED--BY "5e7c48d0-736c-4997-b42b-b7dfdb074ce3")
     (:EVIDENCE
      ((:TEXT
        . "Y-27632, a specific inhibitor of ROCK, inhibited LIM-kinase-induced cofilin phosphorylation but did not affect fibronectin induced or TESK1 induced cofilin phosphorylation in HeLa cells.")
       (:PMID . "11294912") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Knockdown of ROCK2, but not ROCK1, specifically reduced cofilin S3 phosphorylation (XREF_FIG).")
       (:PMID . "26169356") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Y-27632 and ROCK siRNA inhibits the phosphorylation of LIMK2 and Cofilin.")
       (:PMID . "24528629") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition to regulating polarity through myosin activity, ROCK2 phosphorylated the actin-severing protein cofilin on Ser3, resulting in adhesion and PSD maturation.")
       (:PMID . "26169356") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "In an attempt to elucidate the mechanism of SecPH inhibition of cofilin phosphorylation by ROCK activated LIMK2, we postulated that SecPH might prevent LIMK2 from interacting with ROCK.")
       (:PMID . "23082153") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, since both MPYT1 and Cofilin can be phosphorylated by ROCK independent mechanisms, their phosphorylation state may or may not accurately monitor ROCK activity.")
       (:PMID . "22942252") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "While our studies found that Cofilin, rather than MYPT1, provided a more accurate biomarker for pan-ROCK inhibitor treatment, our use of isoform specific siRNA to selectively silence ROCK1 or ROCK2 found that inhibition of either isoform alone inhibited anchorage independent growth, yet inhibition of both ROCK1 and ROCK2 were required to suppress Cofilin phosphorylation.")
       (:PMID . "22942252") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ROCK, which is a downstream effector of Rho, did not phosphorylate cofilin directly but phosphorylated LIM-kinase, which in turn was activated to phosphorylate cofilin.")
       (:PMID . "10436159") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "ROCKII inhibition (H-1152) and siRNA suppression also reduced cofilin phosphorylation in stathmin suppressed cells, indicating that ROCKII mediates stathmin 's regulation of cofilin phosphorylation.")
       (:PMID . "23396365") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Inhibition of ROCK did not significantly decrease leading-edge cofilin phosphorylation in RacQL expressing cells (12% decrease compared to uninhibited RacQL cells, p = 0.544) (A and 1B).")
       (:PMID . "17981134") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "ROCK2") (:+UP+ . "O75116") (:+HGNC+ . "10252"))
      (:NAME . "ROCK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "86f7ee50-e60d-4db4-b744-bdaf482ee447"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "3b085760-047b-4de6-a358-6f53aa726e61"
      "90cd000a-2a54-42e4-b077-3a6fe82f3523"
      "97085d9b-423a-4b41-b7e0-a9c7eb7133a5")
     (:EVIDENCE
      ((:TEXT
        . "In turn, activated ROCK directly phosphorylates FAK on Ser732.")
       (:PMID . "16760434") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In turn, activated ROCK directly phosphorylates FAK on Ser732.")
       (:PMID . "16760434") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In turn, activated ROCK directly phosphorylates FAK on Ser732")
       (:PMID . "16760434") (:SOURCE--API . "sparser")))
     (:POSITION . "732")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "ROCK2") (:+UP+ . "O75116") (:+HGNC+ . "10252"))
      (:NAME . "ROCK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "1de4fed0-787d-4755-8df4-a8241dcde2dd"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "beta-catenin") (:+UP+ . "P35222")
       (:+HGNC+ . "2514"))
      (:NAME . "CTNNB1"))
     (:SUPPORTED--BY "bc96c7d8-d6b6-4dd5-934f-b0b393675faf")
     (:EVIDENCE
      ((:TEXT
        . "ROS scavenger (DPI) mediated rescue of SHP2 expression and downregulation in phosphorylation of beta-catenin.")
       (:PMID . "24965120") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "ROS") (:+UP+ . "P08922") (:+HGNC+ . "10261"))
      (:NAME . "ROS1"))
     (:TYPE . "Phosphorylation")
     (:ID . "af194dc9-4eeb-4f1a-82f7-fecc455b57e2"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "PHAS-I") (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:TEXT
        . "Neither PHAS-I nor PHAS-II was phosphorylated by the insulin stimulated protein kinases, p90rsk or plO ^.")
       (:PMID . "9381973") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "8-CPT-INDUCED INCREASE IN PHOSPHORYLATION OF S6K, 4EBP-1, AND eIF4E, 4EBP1, RSK, AND MNK1 IN 1-LN CELLS STIMULATED WITH 8-CPT.")
       (:PMID . "19725049") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "380") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "359") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "573") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "363") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KA1") (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "455dfb17-5360-49c0-9b21-b190b983cd3d"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERALPHA") (:+NCIT+ . "C38361") (:+UP+ . "P03372")
       (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf")
     (:EVIDENCE
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_594239c5cdbab4d9f48cd854d1f7c4c9")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "380") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "359") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "573") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "363") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KA1") (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "4aacd718-0a3e-4f74-bd47-631186186c13"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "595c27db-1d32-425d-8876-a51951f4500e"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "6bacda08-04c7-417d-a8f0-5dff26ec6898"
      "1b4fe41d-0142-46f6-adeb-ce5473f50dbd"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1b785b5ceab82dfbf4a4787c376f89d3")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "On one hand, Erk phosphorylates and activates p90RSK, and on the other hand, Erk serves as an adaptor and priming kinase through binding to the DEF domain of GSK-3beta and phosphorylating GSK-3beta at the T residue, to facilitate phosphorylation of GSK-3beta by p90RSK on Ser9, which leads to the inactivation of GSK-3beta.")
       (:PMID . "16039586") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "On one hand, Erk phosphorylates and activates p90RSK, and on the other hand, Erk serves as an adaptor and priming kinase through binding to the DEF domain of GSK-3beta and phosphorylating GSK-3beta at the T residue, to facilitate phosphorylation of GSK-3beta by p90RSK on Ser9, which leads to the inactivation of GSK-3beta.")
       (:PMID . "16039586") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "380") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "359") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "573") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "363") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "Q15418") (:+HGNC+ . "10430")) (:NAME . "RPS6KA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "1054b536-d158-421f-b73e-6f7c5b041f1c"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "rpS6") (:+UP+ . "P62753") (:+HGNC+ . "10429"))
      (:NAME . "RPS6"))
     (:SUPPORTED--BY "9f93c547-87c7-4f56-86b3-2d4155413eae"
      "a00b1a9e-7ac6-4940-845d-b6c713ddeb5c"
      "5e762d2f-73f3-4952-9222-6a3e13eb8666")
     (:EVIDENCE
      ((:TEXT
        . "In this work, the use of three different RSK-targets in conditions where the contribution of other AGC-kinases was low or absent, provided the same conclusions regarding RSK inhibition.Originally, RSK dependent phosphorylation of S235 and S236 on rpS6 was identified as an ERK1/2 dependent and rapamycin resistant event.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Originally, RSK dependent phosphorylation of S235 and S236 on rpS6 was identified as an ERK1/2 dependent and rapamycin resistant event.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a693bb6970afb8cb6d8e2dad8d6f3d0d")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "The phosphorylation of rpS6 at S235 and S236 can be mediated by RSK and/or p70S6K.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "235")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "380") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "359") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "573") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "363") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KA1") (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "22e9d49b-c452-4c7c-9147-e6981a4cae9c"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "12992216-69c2-418c-a486-1732896693c6"
      "9669dd29-aa3c-4505-a9ea-340a7e2910c2"
      "b63db8c6-09c2-4044-8482-01ebf2be3da7"
      "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3")
     (:EVIDENCE
      ((:TEXT
        . "Initially, using an in vitro kinase assay, we show that RSK1 and RSK2 are able to directly phosphorylate an YB-1 S102 peptide that mimics the region surrounding the S102 site.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The kinase-dead RSK1 mutant, however, was unable to phosphorylate YB-1 at S102.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:FOUND--BY . "Phosphorylation_syntax_1a_verb") (:TISSUE) (:LOCATION)
        (:CELL--LINE "cellosaurus:CVCL_M359") (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The RSK1 and RSK2 specific inhibitor SL0101 [XREF_BIBR, XREF_BIBR], as well as RSK1 targeted or RSK2 targeted siRNA, were able to reduce the phosphorylation of YB-1 at S102 even following induction by the classic tumour promoter PMA.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This model therefore supports our previous work demonstrating that RSK phosphorylates YB-1 at S102 XREF_BIBR and confirmed that the CPP could mimic this critical site.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We therefore took a bioinformatics approach to identify potential candidates, and determined that p90 ribosomal S6 kinase (RSK) may also phosphorylate YB-1 at S102 [XREF_BIBR].")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "RSK phosphorylates YB-1 at serine residue 102.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "We conclude that RSK1 and RSK2 are able to phosphorylate YB-1 S102, providing a newly described mechanism whereby this transcription factor is activated in breast cancer.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9572a9ddbcaac4766e1b48459a11c12a")
       (:SOURCE--API . "biopax")))
     (:POSITION . "102")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "380") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "732") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "221") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "359") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "573") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "363") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RSK1") (:+UP+ . "Q15418") (:+HGNC+ . "10430"))
      (:NAME . "RPS6KA1"))
     (:TYPE . "Phosphorylation")
     (:ID . "d53fed36-32c0-4ef2-8c5a-ace09284ba52"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "BAD") (:+NCIT+ . "C21191") (:+UP+ . "Q92934")
       (:+HGNC+ . "936"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "Consequently, AT 1 R induced phosphorylation of BAD by RSK provides an example of how an appreciation of the distinct characteristics of beta-arrestin versus G protein signaling can illuminate issues of apparent \" compartmentalization \" of cellular signaling events.")
       (:PMID . "19171933") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Consequently, AT 1 R induced phosphorylation of BAD by RSK provides an example of how an appreciation of the distinct characteristics of beta-arrestin versus G protein signaling can illuminate issues of apparent \" compartmentalization \" of cellular signaling events.")
       (:PMID . "19171933") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Despite this evidence that beta-arrestin-2-mediated ERK activation accounts for only the later (> 5 min) occurring phosphorylation of p90RSK, the data in XREF_FIG, suggest that, as in the VSMCs, almost all of the downstream phosphorylation of BAD by RSK is mediated by the pool of p90RSK, which is activated through beta-arrestin-dependent ERK.")
       (:PMID . "19171933") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Despite this evidence that beta-arrestin-2-mediated ERK activation accounts for only the later (> 5 min) occurring phosphorylation of p90RSK, the data in XREF_FIG, suggest that, as in the VSMCs, almost all of the downstream phosphorylation of BAD by RSK is mediated by the pool of p90RSK, which is activated through beta-arrestin-dependent ERK")
       (:PMID . "19171933") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Silencing of hSPRY2 also inhibited serum induced activation of p90RSK and decreased phosphorylation of pro apoptotic protein BAD (BCL2-antagonist of cell death) by p90RSK.")
       (:PMID . "18070883") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "360") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "377") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "570") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KA2") (:+UP+ . "Q15349") (:+HGNC+ . "10431"))
      (:NAME . "RPS6KA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "062de1d4-67f3-48c7-99cd-74a71fe3bb8b"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "PHAS-I") (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:TEXT
        . "Neither PHAS-I nor PHAS-II was phosphorylated by the insulin stimulated protein kinases, p90rsk or plO ^.")
       (:PMID . "9381973") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "8-CPT-INDUCED INCREASE IN PHOSPHORYLATION OF S6K, 4EBP-1, AND eIF4E, 4EBP1, RSK, AND MNK1 IN 1-LN CELLS STIMULATED WITH 8-CPT.")
       (:PMID . "19725049") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "360") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "377") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "570") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KA2") (:+UP+ . "Q15349") (:+HGNC+ . "10431"))
      (:NAME . "RPS6KA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "0aca0c63-8ccd-413a-a1e7-f9d3a4c2dde1"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "GSK-3beta") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE
      ((:TEXT
        . "Another important finding is identification of a mechanism to elucidate accurately how the Erk and p90RSK pathway phosphorylates and inactivates GSK-3beta.")
       (:PMID . "16039586") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "360") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "377") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "570") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KA2") (:+UP+ . "Q15349") (:+HGNC+ . "10431"))
      (:NAME . "RPS6KA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "fd507459-959e-42c3-b1ab-871eef150fab"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "rpS6") (:+UP+ . "P62753") (:+HGNC+ . "10429"))
      (:NAME . "RPS6"))
     (:SUPPORTED--BY "5e762d2f-73f3-4952-9222-6a3e13eb8666")
     (:EVIDENCE
      ((:TEXT
        . "The off-target effects of the RSK inhibitors on p70S6K made it impossible to determine the true RSK actions on PMA induced rpS6 phosphorylation.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, with the use of rapamycin, PMA induced phosphorylation of rpS6 by RSK could be detected, and this was confirmed by siRNA mediated depletion of RSK1 and RSK2.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These results confirm that 10muM BI-D1870 inhibits the phosphorylation of most RSK targets stronger than 100muM SL0101.The activity of p70S6K was differentially affected by the two inhibitors, which could mask the real RSK dependent phosphorylation of rpS6.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The activity of p70S6K was differentially affected by the two inhibitors, which could mask the real RSK dependent phosphorylation of rpS6.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, to detect the phosphorylation of rpS6 by RSK we used the mTORC1 inhibitor, rapamycin (A).")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "RSK may also induce rpS6 phosphorylation by regulating tuberin (TSC2) and raptor, thereby resulting in activation of mTORC1-p70S6K.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In this manner, we can not rule out the off-target inhibition of Akt phosphorylation at S473 as the cause for the strong inhibitory effect of SL0101 on mTORC1.A greater inhibition of proliferation was observed in the presence of 100muM SL0101 when compared to 1muM BI-D1870, yet these concentrations inhibit RSK dependent phosphorylation of rpS6, eIF4B, and GSK3alpha to a similar extent.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "360") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "377") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "570") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KA2") (:+UP+ . "Q15349") (:+HGNC+ . "10431"))
      (:NAME . "RPS6KA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "666860c3-48db-48f2-8b36-d639209ed6bd"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "d02b64d4-8022-4449-a1e6-f860a9412e4d"
      "4892dc86-e556-4a44-9cbd-03a67923bf30"
      "12992216-69c2-418c-a486-1732896693c6")
     (:EVIDENCE
      ((:TEXT
        . "This model therefore supports our previous work demonstrating that RSK phosphorylates YB-1 at S102 XREF_BIBR and confirmed that the CPP could mimic this critical site.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "We therefore took a bioinformatics approach to identify potential candidates, and determined that p90 ribosomal S6 kinase (RSK) may also phosphorylate YB-1 at S102 [XREF_BIBR].")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "RSK phosphorylates YB-1 at serine residue 102.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "102")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:POSITION . "360") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "377") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "T") (:POSITION . "570") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "218") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KA2") (:+UP+ . "Q15349") (:+HGNC+ . "10431"))
      (:NAME . "RPS6KA2"))
     (:TYPE . "Phosphorylation")
     (:ID . "15611d46-d3ba-47c3-a861-1af59d76dec1"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "O15530") (:+HGNC+ . "8816")) (:NAME . "PDPK1"))
     (:SUPPORTED--BY "8533aaa6-269b-4622-934c-197fe0319e91"
      "4c3ae63d-5421-4db5-ab0a-21f8f808c98b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5f8550a931dd56c0d9302ec5c4684d85")
       (:PMID . "10856237") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5f8550a931dd56c0d9302ec5c4684d85")
       (:PMID . "10480933") (:SOURCE--API . "biopax")))
     (:POSITION . "241")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "529") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "386") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T))
       ((:RESIDUE . "S") (:POSITION . "369") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432")) (:NAME . "RPS6KA3"))
     (:TYPE . "Phosphorylation")
     (:ID . "87d85fe6-cead-4a6d-bc98-525c7663d0cd"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "PHAS-I") (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:TEXT
        . "Neither PHAS-I nor PHAS-II was phosphorylated by the insulin stimulated protein kinases, p90rsk or plO ^.")
       (:PMID . "9381973") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "8-CPT-INDUCED INCREASE IN PHOSPHORYLATION OF S6K, 4EBP-1, AND eIF4E, 4EBP1, RSK, AND MNK1 IN 1-LN CELLS STIMULATED WITH 8-CPT.")
       (:PMID . "19725049") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KA3") (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:TYPE . "Phosphorylation")
     (:ID . "4617bf6c-6251-43c9-9bbb-1766d2ea4c9b"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERALPHA") (:+HGNC+ . "3467") (:+UP+ . "P03372")
       (:+NCIT+ . "C38361"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d")
     (:EVIDENCE
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_f15fce7f11cc619db13e3f3501d48104")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "167")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KA3") (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:TYPE . "Phosphorylation")
     (:ID . "4aacd718-0a3e-4f74-bd47-631186186c13"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49840") (:+HGNC+ . "4616")) (:NAME . "GSK3A"))
     (:SUPPORTED--BY "a950ec98-3882-4735-8a62-508ddba18532"
      "86590d1e-5c17-4ace-b08d-68b21d155a42"
      "ae05b9f3-092a-488d-a510-c58cd5836e8f"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6e988ff897a654ac2a001993c2d72e80")
       (:SOURCE--API . "biopax")))
     (:POSITION . "21")
     (:ENZ (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:TYPE . "Phosphorylation")
     (:ID . "3e498e39-e9da-408c-b66a-4fe71ad0afba"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "9bd25457-7c84-43ef-9af5-65bc3f783aa9"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "On one hand, Erk phosphorylates and activates p90RSK, and on the other hand, Erk serves as an adaptor and priming kinase through binding to the DEF domain of GSK-3beta and phosphorylating GSK-3beta at the T residue, to facilitate phosphorylation of GSK-3beta by p90RSK on Ser9, which leads to the inactivation of GSK-3beta.")
       (:PMID . "16039586") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "On one hand, Erk phosphorylates and activates p90RSK, and on the other hand, Erk serves as an adaptor and priming kinase through binding to the DEF domain of GSK-3beta and phosphorylating GSK-3beta at the T residue, to facilitate phosphorylation of GSK-3beta by p90RSK on Ser9, which leads to the inactivation of GSK-3beta.")
       (:PMID . "16039586") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_58afe8d57dabee901acf788802ec7af4")
       (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:TYPE . "Phosphorylation")
     (:ID . "8ec178a8-1c38-4727-b7fb-3ca0bac7c29c"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "rpS6") (:+UP+ . "P62753") (:+HGNC+ . "10429"))
      (:NAME . "RPS6"))
     (:SUPPORTED--BY "6c983ae7-65ba-4a8e-8b84-f2933c0b1ee2"
      "9f93c547-87c7-4f56-86b3-2d4155413eae"
      "5e762d2f-73f3-4952-9222-6a3e13eb8666")
     (:EVIDENCE
      ((:TEXT
        . "In this work, the use of three different RSK-targets in conditions where the contribution of other AGC-kinases was low or absent, provided the same conclusions regarding RSK inhibition.Originally, RSK dependent phosphorylation of S235 and S236 on rpS6 was identified as an ERK1/2 dependent and rapamycin resistant event.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Originally, RSK dependent phosphorylation of S235 and S236 on rpS6 was identified as an ERK1/2 dependent and rapamycin resistant event.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The phosphorylation of rpS6 at S235 and S236 can be mediated by RSK and/or p70S6K.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_46b8ece91c00c0fa8c1142990ad913d9")
       (:SOURCE--API . "biopax")))
     (:POSITION . "235")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KA3") (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:TYPE . "Phosphorylation")
     (:ID . "cd307328-0b5e-4470-b893-49111de8974b"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "c4de9bbf-3087-4235-82a1-663bdb028b62"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "b687d2b3-5e01-4a52-a955-697bbfd5f3ee"
      "442d41dd-998a-447e-83bb-625c6e2b82eb"
      "2eeeaba3-098c-44b3-866d-94e607e66258")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4e2b274013bf40409e0ba458a2725ef6")
       (:SOURCE--API . "biopax")))
     (:POSITION . "727")
     (:ENZ (:DB--REFS (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:TYPE . "Phosphorylation")
     (:ID . "8a27cfac-f40e-412a-b89d-147dddd57f5e"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "2a1e08d7-d1f1-44c4-a8d9-c40b7f4b3d1c"
      "9a4f4ec5-4ed7-43dd-a7aa-d31ef273493b"
      "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "12992216-69c2-418c-a486-1732896693c6")
     (:EVIDENCE
      ((:TEXT
        . "This model therefore supports our previous work demonstrating that RSK phosphorylates YB-1 at S102 XREF_BIBR and confirmed that the CPP could mimic this critical site.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "RSK phosphorylates YB-1 at serine residue 102.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Initially, using an in vitro kinase assay, we show that RSK1 and RSK2 are able to directly phosphorylate an YB-1 S102 peptide that mimics the region surrounding the S102 site.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "More specifically it is the serine/threonine kinases RSK1 and RSK2 that are able to phosphorylate YB-1 at the key S102 residue in BLBC cells.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The RSK1 and RSK2 specific inhibitor SL0101 [XREF_BIBR, XREF_BIBR], as well as RSK1 targeted or RSK2 targeted siRNA, were able to reduce the phosphorylation of YB-1 at S102 even following induction by the classic tumour promoter PMA.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We conclude that RSK1 and RSK2 are able to phosphorylate YB-1 S102, providing a newly described mechanism whereby this transcription factor is activated in breast cancer.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We therefore took a bioinformatics approach to identify potential candidates, and determined that p90 ribosomal S6 kinase (RSK) may also phosphorylate YB-1 at S102 [XREF_BIBR].")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_81a33fae32e83af4ce70757dd65da7d1")
       (:SOURCE--API . "biopax")))
     (:POSITION . "102")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KA3") (:+UP+ . "P51812") (:+HGNC+ . "10432"))
      (:NAME . "RPS6KA3"))
     (:TYPE . "Phosphorylation")
     (:ID . "65355be2-24f8-4220-84bb-035705758e52"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "BAD") (:+HGNC+ . "936") (:+UP+ . "Q92934")
       (:+NCIT+ . "C21191"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "Consequently, AT 1 R induced phosphorylation of BAD by RSK provides an example of how an appreciation of the distinct characteristics of beta-arrestin versus G protein signaling can illuminate issues of apparent \" compartmentalization \" of cellular signaling events.")
       (:PMID . "19171933") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Consequently, AT 1 R induced phosphorylation of BAD by RSK provides an example of how an appreciation of the distinct characteristics of beta-arrestin versus G protein signaling can illuminate issues of apparent \" compartmentalization \" of cellular signaling events.")
       (:PMID . "19171933") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Despite this evidence that beta-arrestin-2-mediated ERK activation accounts for only the later (> 5 min) occurring phosphorylation of p90RSK, the data in XREF_FIG, suggest that, as in the VSMCs, almost all of the downstream phosphorylation of BAD by RSK is mediated by the pool of p90RSK, which is activated through beta-arrestin-dependent ERK.")
       (:PMID . "19171933") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Despite this evidence that beta-arrestin-2-mediated ERK activation accounts for only the later (> 5 min) occurring phosphorylation of p90RSK, the data in XREF_FIG, suggest that, as in the VSMCs, almost all of the downstream phosphorylation of BAD by RSK is mediated by the pool of p90RSK, which is activated through beta-arrestin-dependent ERK")
       (:PMID . "19171933") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Silencing of hSPRY2 also inhibited serum induced activation of p90RSK and decreased phosphorylation of pro apoptotic protein BAD (BCL2-antagonist of cell death) by p90RSK.")
       (:PMID . "18070883") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KA6") (:+UP+ . "Q9UK32") (:+HGNC+ . "10435"))
      (:NAME . "RPS6KA6"))
     (:TYPE . "Phosphorylation")
     (:ID . "062de1d4-67f3-48c7-99cd-74a71fe3bb8b"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "PHAS-I") (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:TEXT
        . "Neither PHAS-I nor PHAS-II was phosphorylated by the insulin stimulated protein kinases, p90rsk or plO ^.")
       (:PMID . "9381973") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "8-CPT-INDUCED INCREASE IN PHOSPHORYLATION OF S6K, 4EBP-1, AND eIF4E, 4EBP1, RSK, AND MNK1 IN 1-LN CELLS STIMULATED WITH 8-CPT.")
       (:PMID . "19725049") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KA6") (:+UP+ . "Q9UK32") (:+HGNC+ . "10435"))
      (:NAME . "RPS6KA6"))
     (:TYPE . "Phosphorylation")
     (:ID . "0253d41c-76f6-48d8-aca5-226e808fdfaa"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "GSK-3beta") (:+UP+ . "P49841") (:+HGNC+ . "4617"))
      (:NAME . "GSK3B"))
     (:SUPPORTED--BY "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE
      ((:TEXT
        . "Another important finding is identification of a mechanism to elucidate accurately how the Erk and p90RSK pathway phosphorylates and inactivates GSK-3beta.")
       (:PMID . "16039586") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KA6") (:+UP+ . "Q9UK32") (:+HGNC+ . "10435"))
      (:NAME . "RPS6KA6"))
     (:TYPE . "Phosphorylation")
     (:ID . "e9f70204-a57f-4c4b-a02f-b1bb4331962f"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "rpS6") (:+UP+ . "P62753") (:+HGNC+ . "10429"))
      (:NAME . "RPS6"))
     (:SUPPORTED--BY "5e762d2f-73f3-4952-9222-6a3e13eb8666")
     (:EVIDENCE
      ((:TEXT
        . "These results confirm that 10muM BI-D1870 inhibits the phosphorylation of most RSK targets stronger than 100muM SL0101.The activity of p70S6K was differentially affected by the two inhibitors, which could mask the real RSK dependent phosphorylation of rpS6.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The off-target effects of the RSK inhibitors on p70S6K made it impossible to determine the true RSK actions on PMA induced rpS6 phosphorylation.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, with the use of rapamycin, PMA induced phosphorylation of rpS6 by RSK could be detected, and this was confirmed by siRNA mediated depletion of RSK1 and RSK2.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The activity of p70S6K was differentially affected by the two inhibitors, which could mask the real RSK dependent phosphorylation of rpS6.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, to detect the phosphorylation of rpS6 by RSK we used the mTORC1 inhibitor, rapamycin (A).")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In this manner, we can not rule out the off-target inhibition of Akt phosphorylation at S473 as the cause for the strong inhibitory effect of SL0101 on mTORC1.A greater inhibition of proliferation was observed in the presence of 100muM SL0101 when compared to 1muM BI-D1870, yet these concentrations inhibit RSK dependent phosphorylation of rpS6, eIF4B, and GSK3alpha to a similar extent.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "RSK may also induce rpS6 phosphorylation by regulating tuberin (TSC2) and raptor, thereby resulting in activation of mTORC1-p70S6K.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KA6") (:+UP+ . "Q9UK32") (:+HGNC+ . "10435"))
      (:NAME . "RPS6KA6"))
     (:TYPE . "Phosphorylation")
     (:ID . "79b937d1-eeda-48c2-9bad-d322120baa56"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "YB-1") (:+HGNC+ . "8014") (:+NCIT+ . "C93120")
       (:+UP+ . "P67809"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "86fa82a7-42ee-48ad-aceb-93a83c92225c"
      "517131c3-784c-45fa-8bda-b060d2db0c3b"
      "12992216-69c2-418c-a486-1732896693c6")
     (:EVIDENCE
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This model therefore supports our previous work demonstrating that RSK phosphorylates YB-1 at S102 XREF_BIBR and confirmed that the CPP could mimic this critical site.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We therefore took a bioinformatics approach to identify potential candidates, and determined that p90 ribosomal S6 kinase (RSK) may also phosphorylate YB-1 at S102 [XREF_BIBR].")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "RSK phosphorylates YB-1 at serine residue 102.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "102")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KA6") (:+UP+ . "Q9UK32") (:+HGNC+ . "10435"))
      (:NAME . "RPS6KA6"))
     (:TYPE . "Phosphorylation")
     (:ID . "a12a52c9-2b79-4974-8ed4-768a3f95e891"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "S6K1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "10b386e8-afad-4e8c-843d-bfeccb554c2b"
      "257ed663-137d-4113-95cb-02bae596a37e")
     (:EVIDENCE
      ((:TEXT
        . "Inhibition of the 4E-BP1 and S6K1 phosphorylation by ectopic S6K1 overexpression seems to be specific for the mTOR pathway, because a similar inhibition of 4E-BP1 and S6K1 phosphorylation is seen with rapamycin.")
       (:PMID . "11967149") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "S6K1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "7fd04039-21f3-4c65-b00e-d48d3986d2e2"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "S6K1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:SUPPORTED--BY "22075d03-1821-413f-838d-897ace837581"
      "e80f79e2-d3eb-4d11-94b0-5e2230799bd3")
     (:EVIDENCE
      ((:TEXT
        . "Inhibition of the 4E-BP1 and S6K1 phosphorylation by ectopic S6K1 overexpression seems to be specific for the mTOR pathway, because a similar inhibition of 4E-BP1 and S6K1 phosphorylation is seen with rapamycin.")
       (:PMID . "11967149") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "S6K1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "76d40e3b-4804-4d5f-a3dd-da7bf1d798a9"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:SUPPORTED--BY "df56aaff-4c68-43f1-821c-fe3fc6b34783"
      "e1b0afb1-ceb0-4467-b6f1-a5ca42389457"
      "5364107e-5925-43a7-bc75-ea2e23e33359"
      "4c0066b0-5288-40c4-8558-4cf79c14fa55"
      "9c55d32d-8de2-4d09-be08-9220441b11b8"
      "acba7e24-11c0-4cf8-bb6c-9d0d7f042817")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "11287630") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "18952604") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "17709744") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "15306821") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "15249583") (:SOURCE--API . "biopax")))
     (:POSITION . "307")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "874b014d-c8ff-44f2-935b-552c7c4ed04d"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P35568") (:+HGNC+ . "6125")) (:NAME . "IRS1"))
     (:SUPPORTED--BY "df56aaff-4c68-43f1-821c-fe3fc6b34783"
      "c61658ee-ca3a-47ec-9c5f-3cf268c770c3"
      "5364107e-5925-43a7-bc75-ea2e23e33359"
      "4c0066b0-5288-40c4-8558-4cf79c14fa55"
      "9c55d32d-8de2-4d09-be08-9220441b11b8"
      "823d3bf4-0e4b-4e7e-b402-85a75d74e05a")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "11287630") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "18952604") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "17709744") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "15306821") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6259cc481a00a1c72786d295ad5f0828")
       (:PMID . "15249583") (:SOURCE--API . "biopax")))
     (:POSITION . "307")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "e2411e45-091e-4111-a715-4d9cfa8e3978"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Chk1") (:+UP+ . "O14757") (:+HGNC+ . "1925"))
      (:NAME . "CHEK1"))
     (:SUPPORTED--BY "e98af424-48cc-47d8-80fa-652306775da2")
     (:EVIDENCE
      ((:TEXT
        . "The level of Chk1 phosphorylation by p90 RSK increased rapidly until 20 min and reached ~ 1 mol of phosphate and mol of protein (XREF_FIG).")
       (:PMID . "22357623") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KB1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "40ff7de0-a9bb-4567-ba3b-80024d735a4b"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Chk1") (:+UP+ . "O14757") (:+HGNC+ . "1925"))
      (:NAME . "CHEK1"))
     (:SUPPORTED--BY "e98af424-48cc-47d8-80fa-652306775da2")
     (:EVIDENCE
      ((:TEXT
        . "The level of Chk1 phosphorylation by p90 RSK increased rapidly until 20 min and reached ~ 1 mol of phosphate and mol of protein (XREF_FIG).")
       (:PMID . "22357623") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KB1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "f53c9c2f-98ad-4e0f-b7ef-17ad0a5171f6"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "4E-BP1") (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:TEXT
        . "Surprisingly, the long, kinase active S6K1 isoform (Iso-1) inhibited 3D acinus formation and reduced 4E-BP1 phosphorylation, cap dependent translation, and transformation invitro and invivo, demonstrating many properties that characterize a tumor suppressor.")
       (:PMID . "23273915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, S6K1 also phosphorylates the ribosomal protein 4EBP1, releases it from hindering the elongation initiation factor 4E (elF4E) and thus promotes mRNA translation.")
       (:PMID . "21701776") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "mTORC1 phosphorylates the p70S6 kinase (p70S6K), which in turn phosphorylates the S6 ribosomal protein and 4E-BP1, leading to protein translation (XREF_BIBR).")
       (:PMID . "23536724") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Expression of peroxiredoxin 1 (Prx1) had no effect on p70S6K and S6 phosphorylation.Nonphosphorylated 4E-BP1 binds and sequesters eIF-4E, thereby inhibiting formation of the eIF-4F complex involved in initiation of Cap dependent translation of a subset of mRNAs that include cyclin D1 and c-Myc ().")
       (:PMID . "18692468") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "8-CPT-INDUCED INCREASE IN PHOSPHORYLATION OF S6K, 4EBP-1, AND eIF4E, 4EBP1, RSK, AND MNK1 IN 1-LN CELLS STIMULATED WITH 8-CPT.")
       (:PMID . "19725049") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The mTORC1 controls the rate of protein synthesis through phosphorylation and activation of its substrates, p70S6 ribosomal kinase 1 (p70S6K) and eukaryotic translation initiation factor 4E (eIF4E) binding protein-1 (4E-BP1) and once phosphorylated, p70S6K phosphorylates ribosomal protein S6 and 4E-BP1 becomes dissociated from eIF4 and promote mRNA translation and protein synthesis [XREF_BIBR].")
       (:PMID . "23991179") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Insulin stimulated phosphorylation of 4E-BP1, as assessed by retarded band migration on SDS-PAGE immunoblots, is inhibited by overexpression of S6K1.")
       (:PMID . "11967149") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "S6K1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "bcd77668-9daa-48a2-b4e0-3fa91f594ba3"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "4E-BP1") (:+UP+ . "Q13541") (:+HGNC+ . "3288"))
      (:NAME . "EIF4EBP1"))
     (:SUPPORTED--BY "d70fa808-99cf-4d1d-b42e-cb2ebf15430c")
     (:EVIDENCE
      ((:TEXT
        . "Surprisingly, the long, kinase active S6K1 isoform (Iso-1) inhibited 3D acinus formation and reduced 4E-BP1 phosphorylation, cap dependent translation, and transformation invitro and invivo, demonstrating many properties that characterize a tumor suppressor.")
       (:PMID . "23273915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_3_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, S6K1 also phosphorylates the ribosomal protein 4EBP1, releases it from hindering the elongation initiation factor 4E (elF4E) and thus promotes mRNA translation.")
       (:PMID . "21701776") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "mTORC1 phosphorylates the p70S6 kinase (p70S6K), which in turn phosphorylates the S6 ribosomal protein and 4E-BP1, leading to protein translation (XREF_BIBR).")
       (:PMID . "23536724") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Expression of peroxiredoxin 1 (Prx1) had no effect on p70S6K and S6 phosphorylation.Nonphosphorylated 4E-BP1 binds and sequesters eIF-4E, thereby inhibiting formation of the eIF-4F complex involved in initiation of Cap dependent translation of a subset of mRNAs that include cyclin D1 and c-Myc ().")
       (:PMID . "18692468") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "8-CPT-INDUCED INCREASE IN PHOSPHORYLATION OF S6K, 4EBP-1, AND eIF4E, 4EBP1, RSK, AND MNK1 IN 1-LN CELLS STIMULATED WITH 8-CPT.")
       (:PMID . "19725049") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The mTORC1 controls the rate of protein synthesis through phosphorylation and activation of its substrates, p70S6 ribosomal kinase 1 (p70S6K) and eukaryotic translation initiation factor 4E (eIF4E) binding protein-1 (4E-BP1) and once phosphorylated, p70S6K phosphorylates ribosomal protein S6 and 4E-BP1 becomes dissociated from eIF4 and promote mRNA translation and protein synthesis [XREF_BIBR].")
       (:PMID . "23991179") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Insulin stimulated phosphorylation of 4E-BP1, as assessed by retarded band migration on SDS-PAGE immunoblots, is inhibited by overexpression of S6K1.")
       (:PMID . "11967149") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "S6K1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "2ea48937-f5ac-49c2-be48-95ae7d956dcc"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERalpha") (:+NCIT+ . "C38361") (:+UP+ . "P03372")
       (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "c37ba951-622c-499a-99b9-37295c98e8fb"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d")
     (:EVIDENCE
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR])")
       (:PMID . "21531565") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERα on Ser167; this confers estrogen-independent transcriptional activity ( xref , [ xref – xref ]).")
       (:PMID . "21531565") (:SOURCE--API . "sparser"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_aa6ca8e5b8db387a07f615bd4b59146c")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "S6K") (:+NCIT+ . "C84315") (:+HGNC+ . "10436")
       (:+UP+ . "P23443"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "9e25662d-523d-4a81-9423-1e5510c477b3"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "ERalpha") (:+NCIT+ . "C38361") (:+UP+ . "P03372")
       (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:SUPPORTED--BY "e1ed00e7-4267-49c5-aaa3-b742feffb430"
      "e2df7413-ee90-45cb-9264-7f35c860d4cf"
      "d23c7c58-2bf1-477e-87e5-eaf3f7669a0d")
     (:EVIDENCE
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR])")
       (:PMID . "21531565") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERα on Ser167; this confers estrogen-independent transcriptional activity ( xref , [ xref – xref ]).")
       (:PMID . "21531565") (:SOURCE--API . "sparser"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_aa6ca8e5b8db387a07f615bd4b59146c")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "RSK, AKT, and S6K phosphorylate ERalpha on Ser167; this confers estrogen independent transcriptional activity (XREF_FIG, [XREF_BIBR - XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:POSITION . "167")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "S6K") (:+NCIT+ . "C84315") (:+HGNC+ . "10436")
       (:+UP+ . "P23443"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "9e25662d-523d-4a81-9423-1e5510c477b3"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "GSK3alpha") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:SUPPORTED--BY "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:TEXT
        . "In addition, both RSK and Akt can phosphorylate the same residues of GSK3alpha and beta.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Moreover, GSK3alpha and beta can also be phosphorylated by p70S6K following loss of the TSC1 and TSC2 complex.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In this manner, we can not rule out the off-target inhibition of Akt phosphorylation at S473 as the cause for the strong inhibitory effect of SL0101 on mTORC1.A greater inhibition of proliferation was observed in the presence of 100muM SL0101 when compared to 1muM BI-D1870, yet these concentrations inhibit RSK dependent phosphorylation of rpS6, eIF4B, and GSK3alpha to a similar extent.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our data demonstrate that, under conditions in which growth factor stimulation of Akt is attenuated, S6K1 can directly phosphorylate and inhibit GSK3 in vivo (C, bottom).")
       (:PMID . "17052453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our finding that GSK3 is constitutively phosphorylated by S6K1 in TSC deficient MEFs suggests that GSK3 remains inhibited in these cells under serum starvation conditions.")
       (:PMID . "17052453") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KB1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "db440d6b-da35-46a2-a193-16f19d612ec1"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "GSK3alpha") (:+UP+ . "P49840") (:+HGNC+ . "4616"))
      (:NAME . "GSK3A"))
     (:SUPPORTED--BY "ae05b9f3-092a-488d-a510-c58cd5836e8f")
     (:EVIDENCE
      ((:TEXT
        . "In addition, both RSK and Akt can phosphorylate the same residues of GSK3alpha and beta.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Moreover, GSK3alpha and beta can also be phosphorylated by p70S6K following loss of the TSC1 and TSC2 complex.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In this manner, we can not rule out the off-target inhibition of Akt phosphorylation at S473 as the cause for the strong inhibitory effect of SL0101 on mTORC1.A greater inhibition of proliferation was observed in the presence of 100muM SL0101 when compared to 1muM BI-D1870, yet these concentrations inhibit RSK dependent phosphorylation of rpS6, eIF4B, and GSK3alpha to a similar extent.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our data demonstrate that, under conditions in which growth factor stimulation of Akt is attenuated, S6K1 can directly phosphorylate and inhibit GSK3 in vivo (C, bottom).")
       (:PMID . "17052453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Our finding that GSK3 is constitutively phosphorylated by S6K1 in TSC deficient MEFs suggests that GSK3 remains inhibited in these cells under serum starvation conditions.")
       (:PMID . "17052453") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KB1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "bee6e352-4855-4cdd-8e80-3d9821a92899"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "206b5181-93fa-45d6-b08b-776116c25464"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "c39bd3dd-c98a-41f2-97d0-b95853c7b0de")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1c9c60f02187fa3a0e3998e8936b94e9")
       (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "d778b057-b956-4e88-aa0b-f056f4de4d78"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "5e1e9328-f4f0-424e-a750-286d1be923ac"
      "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "6d0f427b-37ec-496b-bfe1-f3b9c1a4aa19")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_1c9c60f02187fa3a0e3998e8936b94e9")
       (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "d778b057-b956-4e88-aa0b-f056f4de4d78"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "mTOR") (:+UP+ . "P42345") (:+HGNC+ . "3942"))
      (:NAME . "MTOR"))
     (:SUPPORTED--BY "c3fd1005-b622-4721-8f84-11a8568461ca"
      "86b77d1b-cad8-48a4-842d-ab3e301c36cf"
      "3f164d35-7b34-4585-bbd6-884b979e4395"
      "d07589a5-1480-4cfb-af33-35e13b6c39de"
      "e20ea4ea-43a4-4fed-b58d-5517f73f2874")
     (:EVIDENCE
      ((:TEXT
        . "Knockdown of p70S6K also reduced mTOR phosphorylation at Ser 2448 (D), consistent with the results of Chiang et al..")
       (:PMID . "21329734") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, S6K1 Iso-1 can phosphorylate mTOR at serine 2448 (F, A, and A), although the consequences of this phosphorylation on mTOR activity are not fully understood (;).")
       (:PMID . "23273915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3a7b0077a17b084765575e348e07aa68")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Phosphorylation of mammalian target of rapamycin (mTOR) at Ser 2448 is mediated by p70S6 kinase.")
       (:PMID . "15899889") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here we show that p70S6 kinase phosphorylates mTOR at Ser 2448 in vitro and that ectopic expression of rapamycin resistant p70S6 kinase restores Ser 2448 phosphorylation in rapamycin treated cells.")
       (:PMID . "15899889") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Visfatin also increased HIF1alpha expression in a rapamycin-inhibitable manner, but it increased Akt phosphorylation at Ser 473 in a rapamycin independent manner (B), suggesting that visfatin increases VEGF expression via the mTOR signaling pathway.To confirm that mTOR signaling is involved in visfatin induced VEGF expression, we examined the effect of knockdown of p70S6K, which reportedly mediates mTOR phosphorylation at Ser 2448.")
       (:PMID . "21329734") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, S6K1 short isoforms can not induce mTOR S2448 phosphorylation, as they lack a functional kinase domain and are catalytically inactive (A and E-S2G).")
       (:PMID . "23273915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "2448")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p70S6K") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "3bd817d3-dddf-486b-a2d6-8bf2a8c5ea58"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "mTOR") (:+UP+ . "P42345") (:+HGNC+ . "3942"))
      (:NAME . "MTOR"))
     (:SUPPORTED--BY "c3fd1005-b622-4721-8f84-11a8568461ca"
      "86b77d1b-cad8-48a4-842d-ab3e301c36cf"
      "3f164d35-7b34-4585-bbd6-884b979e4395"
      "942e02e4-ecde-4e99-97fc-7ec5b199aa8e"
      "e20ea4ea-43a4-4fed-b58d-5517f73f2874")
     (:EVIDENCE
      ((:TEXT
        . "Knockdown of p70S6K also reduced mTOR phosphorylation at Ser 2448 (D), consistent with the results of Chiang et al..")
       (:PMID . "21329734") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, S6K1 Iso-1 can phosphorylate mTOR at serine 2448 (F, A, and A), although the consequences of this phosphorylation on mTOR activity are not fully understood (;).")
       (:PMID . "23273915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3a7b0077a17b084765575e348e07aa68")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Phosphorylation of mammalian target of rapamycin (mTOR) at Ser 2448 is mediated by p70S6 kinase.")
       (:PMID . "15899889") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here we show that p70S6 kinase phosphorylates mTOR at Ser 2448 in vitro and that ectopic expression of rapamycin resistant p70S6 kinase restores Ser 2448 phosphorylation in rapamycin treated cells.")
       (:PMID . "15899889") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "Visfatin also increased HIF1alpha expression in a rapamycin-inhibitable manner, but it increased Akt phosphorylation at Ser 473 in a rapamycin independent manner (B), suggesting that visfatin increases VEGF expression via the mTOR signaling pathway.To confirm that mTOR signaling is involved in visfatin induced VEGF expression, we examined the effect of knockdown of p70S6K, which reportedly mediates mTOR phosphorylation at Ser 2448.")
       (:PMID . "21329734") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, S6K1 short isoforms can not induce mTOR S2448 phosphorylation, as they lack a functional kinase domain and are catalytically inactive (A and E-S2G).")
       (:PMID . "23273915") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "2448")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "p70S6K") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "2e42d7a0-cc75-4dd1-a315-eab8ffc45c48"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P62753") (:+HGNC+ . "10429")) (:NAME . "RPS6"))
     (:SUPPORTED--BY "3ad6f34b-8cb0-4626-a0d6-779474ce33a2"
      "9f93c547-87c7-4f56-86b3-2d4155413eae"
      "5e762d2f-73f3-4952-9222-6a3e13eb8666"
      "8fecb827-1842-4cbb-91d3-f8360bdc8edb")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "In this work, the use of three different RSK-targets in conditions where the contribution of other AGC-kinases was low or absent, provided the same conclusions regarding RSK inhibition.Originally, RSK dependent phosphorylation of S235 and S236 on rpS6 was identified as an ERK1/2 dependent and rapamycin resistant event.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Originally, RSK dependent phosphorylation of S235 and S236 on rpS6 was identified as an ERK1/2 dependent and rapamycin resistant event.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The phosphorylation of rpS6 at S235 and S236 can be mediated by RSK and/or p70S6K.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7d9f75750e481f3c18ce5b154895abc1")
       (:SOURCE--API . "biopax")))
     (:POSITION . "235")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "84ea7ef3-d817-4348-b363-e482193a63c3"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P62753") (:+HGNC+ . "10429")) (:NAME . "RPS6"))
     (:SUPPORTED--BY "7fe0277c-021b-4af2-ace6-9893af486126"
      "9f93c547-87c7-4f56-86b3-2d4155413eae"
      "5e762d2f-73f3-4952-9222-6a3e13eb8666"
      "8fecb827-1842-4cbb-91d3-f8360bdc8edb")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:TEXT
        . "In this work, the use of three different RSK-targets in conditions where the contribution of other AGC-kinases was low or absent, provided the same conclusions regarding RSK inhibition.Originally, RSK dependent phosphorylation of S235 and S236 on rpS6 was identified as an ERK1/2 dependent and rapamycin resistant event.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Originally, RSK dependent phosphorylation of S235 and S236 on rpS6 was identified as an ERK1/2 dependent and rapamycin resistant event.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The phosphorylation of rpS6 at S235 and S236 can be mediated by RSK and/or p70S6K.")
       (:PMID . "25889895") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7d9f75750e481f3c18ce5b154895abc1")
       (:SOURCE--API . "biopax")))
     (:POSITION . "235")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "84ea7ef3-d817-4348-b363-e482193a63c3"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P62753") (:+HGNC+ . "10429")) (:NAME . "RPS6"))
     (:SUPPORTED--BY "65d5d616-57c0-4707-9742-344a3c26ff26"
      "5e762d2f-73f3-4952-9222-6a3e13eb8666"
      "8fecb827-1842-4cbb-91d3-f8360bdc8edb"
      "b8492025-e85e-45e5-a877-347bc53b57d6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RPS6KB1_DirectlyIncreases_p_HGNC_RPS6_pmod_P_S_240")
       (:TEXT
        . "we found that S6K1, but not RSK1 or RSK2, was capable of phosphorylating rpS6 on Ser240/244.")
       (:PMID . "17360704") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RPS6KB1_DirectlyIncreases_p_HGNC_RPS6_pmod_P_S_240")
       (:TEXT
        . "from full text:Phosphorylation of rpS6 is mediated by both S6K1 and p90RSK, whereby S6K1 phosphorylates two sets of sites, S235/236 and S240/244, and p90RSK phosphorylates only S235/236")
       (:PMID . "16543272") (:SOURCE--API . "bel"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7d34e7f352b3c4407b1991393a2eb9c0")
       (:SOURCE--API . "biopax")))
     (:POSITION . "240")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "374212e2-6469-40ba-9ed2-1aacdb29dcec"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P62753") (:+HGNC+ . "10429")) (:NAME . "RPS6"))
     (:SUPPORTED--BY "2c3f3bdd-3791-44bf-b5f1-01b5d2f635fe"
      "5e762d2f-73f3-4952-9222-6a3e13eb8666"
      "8fecb827-1842-4cbb-91d3-f8360bdc8edb"
      "b8492025-e85e-45e5-a877-347bc53b57d6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RPS6KB1_DirectlyIncreases_p_HGNC_RPS6_pmod_P_S_240")
       (:TEXT
        . "we found that S6K1, but not RSK1 or RSK2, was capable of phosphorylating rpS6 on Ser240/244.")
       (:PMID . "17360704") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_RPS6KB1_DirectlyIncreases_p_HGNC_RPS6_pmod_P_S_240")
       (:TEXT
        . "from full text:Phosphorylation of rpS6 is mediated by both S6K1 and p90RSK, whereby S6K1 phosphorylates two sets of sites, S235/236 and S240/244, and p90RSK phosphorylates only S235/236")
       (:PMID . "16543272") (:SOURCE--API . "bel"))
      ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_7d34e7f352b3c4407b1991393a2eb9c0")
       (:SOURCE--API . "biopax")))
     (:POSITION . "240")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P23443") (:+HGNC+ . "10436")) (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "3a065c66-92c3-4a1e-b2e9-6ecb22ced2f3"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "12992216-69c2-418c-a486-1732896693c6"
      "368ce5a9-d02f-41fc-b0de-381a391e3216"
      "37fe4769-0e91-4486-8a03-6751d6473002")
     (:EVIDENCE
      ((:TEXT
        . "This model therefore supports our previous work demonstrating that RSK phosphorylates YB-1 at S102 XREF_BIBR and confirmed that the CPP could mimic this critical site.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We therefore took a bioinformatics approach to identify potential candidates, and determined that p90 ribosomal S6 kinase (RSK) may also phosphorylate YB-1 at S102 [XREF_BIBR].")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "RSK phosphorylates YB-1 at serine residue 102.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "102")
     (:ENZ
      (:MODS
       ((:RESIDUE . "S") (:MOD--TYPE . "phosphorylation") (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KB1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "1eedf8e3-e488-4e00-8aed-86ab6335a715"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "12992216-69c2-418c-a486-1732896693c6"
      "5c3f7015-3139-41a7-bfde-e7e6541dba6e"
      "c2ca092b-a010-4143-be6a-19a89ea8a41c")
     (:EVIDENCE
      ((:TEXT
        . "This model therefore supports our previous work demonstrating that RSK phosphorylates YB-1 at S102 XREF_BIBR and confirmed that the CPP could mimic this critical site.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We therefore took a bioinformatics approach to identify potential candidates, and determined that p90 ribosomal S6 kinase (RSK) may also phosphorylate YB-1 at S102 [XREF_BIBR].")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT . "RSK phosphorylates YB-1 at serine residue 102.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "102")
     (:ENZ
      (:MODS
       ((:RESIDUE . "T") (:POSITION . "412") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "RPS6KB1") (:+UP+ . "P23443") (:+HGNC+ . "10436"))
      (:NAME . "RPS6KB1"))
     (:TYPE . "Phosphorylation")
     (:ID . "5509d5c9-f0ba-47df-bee8-fb6efccbbd86"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "BAD") (:+HGNC+ . "936") (:+UP+ . "Q92934")
       (:+NCIT+ . "C21191"))
      (:NAME . "BAD"))
     (:SUPPORTED--BY "332756f7-fb53-4e69-a4f8-55ba4cfb7e3e")
     (:EVIDENCE
      ((:TEXT
        . "Consequently, AT 1 R induced phosphorylation of BAD by RSK provides an example of how an appreciation of the distinct characteristics of beta-arrestin versus G protein signaling can illuminate issues of apparent \" compartmentalization \" of cellular signaling events.")
       (:PMID . "19171933") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Despite this evidence that beta-arrestin-2-mediated ERK activation accounts for only the later (> 5 min) occurring phosphorylation of p90RSK, the data in XREF_FIG, suggest that, as in the VSMCs, almost all of the downstream phosphorylation of BAD by RSK is mediated by the pool of p90RSK, which is activated through beta-arrestin-dependent ERK.")
       (:PMID . "19171933") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Despite this evidence that beta-arrestin-2-mediated ERK activation accounts for only the later (> 5 min) occurring phosphorylation of p90RSK, the data in XREF_FIG, suggest that, as in the VSMCs, almost all of the downstream phosphorylation of BAD by RSK is mediated by the pool of p90RSK, which is activated through beta-arrestin-dependent ERK")
       (:PMID . "19171933") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Consequently, AT 1 R induced phosphorylation of BAD by RSK provides an example of how an appreciation of the distinct characteristics of beta-arrestin versus G protein signaling can illuminate issues of apparent \" compartmentalization \" of cellular signaling events.")
       (:PMID . "19171933") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KB2") (:+UP+ . "Q9UBS0") (:+HGNC+ . "10437"))
      (:NAME . "RPS6KB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "062de1d4-67f3-48c7-99cd-74a71fe3bb8b"))
    ((:SUB (:DB--REFS (:+TEXT+ . "Chk1") (:+UP+ . "O14757") (:+HGNC+ . "1925"))
      (:NAME . "CHEK1"))
     (:SUPPORTED--BY "e98af424-48cc-47d8-80fa-652306775da2")
     (:EVIDENCE
      ((:TEXT
        . "The level of Chk1 phosphorylation by p90 RSK increased rapidly until 20 min and reached ~ 1 mol of phosphate and mol of protein (XREF_FIG).")
       (:PMID . "22357623") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KB2") (:+UP+ . "Q9UBS0") (:+HGNC+ . "10437"))
      (:NAME . "RPS6KB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "3929231a-e56b-4d76-b653-3506dfc4acb9"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P49841") (:+HGNC+ . "4617")) (:NAME . "GSK3B"))
     (:SUPPORTED--BY "9db105c4-2ccb-4cd3-b001-d0b2ca6971d3"
      "2b785b92-a1af-4262-8a8d-2e132fc6a753"
      "595c27db-1d32-425d-8876-a51951f4500e"
      "0649116a-e8ad-45f3-b527-4a2de2d14b15")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a98d4eb0df26892246d966e49e84a871")
       (:SOURCE--API . "biopax")))
     (:POSITION . "9")
     (:ENZ (:DB--REFS (:+UP+ . "Q9UBS0") (:+HGNC+ . "10437"))
      (:NAME . "RPS6KB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "2356bfe2-d330-48a7-b45e-a86892895f89"))
    ((:RESIDUE . "S")
     (:SUB
      (:DB--REFS (:+TEXT+ . "S6") (:+UP+ . "P62753") (:+HGNC+ . "10429")
       (:+IP+ . "IPR000529"))
      (:NAME . "RPS6"))
     (:SUPPORTED--BY "0e68cd18-3b0f-40a9-b4d1-0931984fbab7"
      "5e762d2f-73f3-4952-9222-6a3e13eb8666")
     (:EVIDENCE
      ((:TEXT
        . "S6 is phosphorylated by both S6K1 and the closely related S6K2 on Ser and Ser as well as Ser and Ser.")
       (:PMID . "21890410") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "S6K2") (:+UP+ . "Q9UBS0") (:+HGNC+ . "10437"))
      (:NAME . "RPS6KB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "4c277bc0-a794-4d47-bf3a-4a68ac4b40d4"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+TEXT+ . "YB-1") (:+UP+ . "P67809") (:+HGNC+ . "8014"))
      (:NAME . "YBX1"))
     (:SUPPORTED--BY "9a4f4ec5-4ed7-43dd-a7aa-d31ef273493b"
      "12992216-69c2-418c-a486-1732896693c6"
      "9a7dfec8-4b42-4f4c-bb3e-8b8ca1c16ce3"
      "ec6f53d8-e5f2-4124-a63c-7b3156c8e286")
     (:EVIDENCE
      ((:TEXT . "RSK phosphorylates YB-1 at serine residue 102.")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This model therefore supports our previous work demonstrating that RSK phosphorylates YB-1 at S102 XREF_BIBR and confirmed that the CPP could mimic this critical site.")
       (:PMID . "20844753") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AKT- and RSK phosphorylate YB1 on Ser102, which upregulates its transcriptional activity, thereby inducing proliferation and anchorage independent growth (XREF_FIG, [XREF_BIBR, XREF_BIBR]).")
       (:PMID . "21531565") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We therefore took a bioinformatics approach to identify potential candidates, and determined that p90 ribosomal S6 kinase (RSK) may also phosphorylate YB-1 at S102 [XREF_BIBR].")
       (:PMID . "19036157") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "102")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "RPS6KB2") (:+UP+ . "Q9UBS0") (:+HGNC+ . "10437"))
      (:NAME . "RPS6KB2"))
     (:TYPE . "Phosphorylation")
     (:ID . "fd460c0d-105d-4025-bf2e-f9c065a1fbfc"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "3f5d58ce-a5bb-499b-816d-bfc417e2ba05"
      "d3c3020b-5e90-4620-a31b-d85ce60b3986"
      "5377520e-d1c5-494f-ad7e-4cdea1263c43"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "3b085760-047b-4de6-a358-6f53aa726e61"
      "caa5977d-23f0-49d5-965b-13f08f286c1a"
      "fa1da671-2db0-4483-8d88-e2e8f20b5eb0")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "12590707") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "11369622") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "15728464") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e870fc97ac6294e31b0e6aae1fa44092")
       (:PMID . "10753828") (:SOURCE--API . "biopax")))
     (:POSITION . "397")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "2c8ba606-46fa-470b-819b-fec4b53b3df7"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "db67ab01-ace3-486f-9c0a-fe0ac876cb9d"
      "ff51b262-1ddb-459c-b88b-b286975d27a3"
      "865c0915-0952-45ed-8c6b-c2fc6fe638e3"
      "1f9e903b-b337-4022-b907-fc559bac1720"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f"
      "e54f9a92-e741-4427-8c47-e05eedbddfb3"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_6278dbc67f82bd0bd390e123ba9c2db8")
       (:PMID . "11940572") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9344858") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "10815799") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "9484840") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d62e9b0649680e622d87dae995a26a67")
       (:PMID . "11404481") (:SOURCE--API . "biopax")))
     (:POSITION . "705")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "7a06d067-b7cd-4cf8-9689-a486573e0727"))
    ((:RESIDUE . "Y")
     (:SUB
      (:DB--REFS (:+TEXT+ . "Cav-1") (:+UP+ . "Q03135") (:+HGNC+ . "1527"))
      (:NAME . "CAV1"))
     (:SUPPORTED--BY "47405939-9d00-4700-8177-c7ad08c18ea7"
      "4902657d-8a63-40a1-a9a8-a0d7a479f8e2"
      "a99e4137-b216-4a42-afc2-df2c1f93e3ff"
      "97b762de-956e-43d1-b600-06c3e60194c1"
      "5bd52550-8edc-47dc-868c-96f84dab42c6")
     (:EVIDENCE
      ((:TEXT
        . "In the same year, Shajahan et al. [XREF_BIBR] showed that the Src phosphorylation of Tyr 14 on Cav-1 regulates paclitaxel mediated apoptosis in MCF-7 breast cancer cells.")
       (:PMID . "21382479") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_CAV1_pmod_P_Y_14")
       (:TEXT
        . "Src phosphorylation of Tyr-14 on CAV1 regulates its cellular localization and function.")
       (:PMID . "17190831") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_CAV1_pmod_P_Y_14")
       (:TEXT
        . "Of interest, activation of PAR1 resulted in the phosphorylation of caveolin-1, a principal component of caveolae, on tyrosine 14 by a Gi-linked Src kinase pathway and p38 mitogen-activated protein kinase.")
       (:PMID . "16678999") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_CAV1_pmod_P_Y_14")
       (:TEXT
        . "It is known that Cav1 is Src-phosphorylated on tyrosine 14 in response to EGF treatment, although the significance of this modification is unknown.")
       (:PMID . "16332692") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_CAV1_pmod_P_Y_14")
       (:TEXT . "12921535;14992595") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_CAV1_pmod_P_Y_14")
       (:TEXT
        . "In this study, we provide evidence that the VEGF-dependent tyrosine phosphorylation of caveolin-1 induces interaction of the protein with the membrane-type 1 matrix metalloproteinase (MT1-MMP). This interaction requires the phosphorylation of caveolin-1 on tyrosine 14 by members of the Src family of protein kinases, such as Src and Fyn, because it is completely abolished by expression of a catalytically inactive Src mutant or by site-directed mutagenesis of tyrosine 14 of caveolin-1. ")
       (:PMID . "15466865") (:SOURCE--API . "bel"))
      ((:TEXT
        . "Src phosphorylation of Tyr 14 on CAV1 regulates its cellular localization and function.")
       (:PMID . "17190831") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Stimulation of epithelial cells with EGF has been shown to result in a profound increase in the number of caveolar structures at the plasma membrane, along with Src phosphorylation of CAV1 on tyrosine 14 [XREF_BIBR], and indeed EGF induced CAV1 mRNA in a study examining the effect of the PPARgamma ligand rosiglitazone on phosphorylation of the EGFR [XREF_BIBR].")
       (:PMID . "19604397") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_380ef57fcc1ebc87f0cddba5dd3e8c59")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Src, Abl, and Fyn phosphorylate caveolin-1 on its Tyr 14 residue in response to various stimuli, including insulin, oxidative stress, and angiotensin II osmotic shock XREF_BIBR.")
       (:PMID . "25672415") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "14")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "99921cc9-eb5b-4aee-b84c-a6881ffafe23"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P22681") (:+HGNC+ . "1541")) (:NAME . "CBL"))
     (:SUPPORTED--BY "b9849644-d09f-4647-8d93-d9b70afcfa43"
      "4b14d4eb-68dc-44c8-b53b-a708f0bd1359"
      "e1acf903-d082-41ea-8403-664c47185015"
      "891e51a2-bf6d-4f15-b913-9bfec50d5a49")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_CBL_pmod_P_Y_774")
       (:TEXT . "12522270;12604776;10829062") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a0248c62f2698533ccc297057ace518f")
       (:SOURCE--API . "biopax")))
     (:POSITION . "774")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "f55e2d1a-f1bc-4205-adca-c0f3fd41487d"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P00533") (:+HGNC+ . "3236")) (:NAME . "EGFR"))
     (:SUPPORTED--BY "a25f2c7b-f2f7-4047-bfc4-8714da031f39"
      "f58436a8-9b1e-4230-89e4-82e1da7e1a96"
      "7b2ca553-3f9b-4078-8eeb-2f23ced50823"
      "211e5a21-549a-4e72-9cd1-a9ace8c1fa70"
      "a8188ef3-2d6b-4c6f-9046-9e16d880162a")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0306be7cb8f045d525fed75bd6e2d205")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_EGFR_pmod_P_Y_992")
       (:TEXT
        . "A subset of peptides corresponding to the eight possible tyrosine phosphorylation sites within the EGFR autophosphorylation domain was demonstrated to bind to the SH2 domain of c-src. Those which bound to the SH2 domain included peptides derived from EGFR sequences flanking Y992, Y1086, Y1101, and Y1148. These data indicate that specific EGF receptor c-src phosphorylation sites are also ligands for the SH2 domain of c-src. ")
       (:PMID . "8845374") (:SOURCE--API . "bel")))
     (:POSITION . "1016")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "b4e4a539-7e98-4477-b5d4-02894282efe3"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK1") (:+UP+ . "P28482") (:+HGNC+ . "6871"))
      (:NAME . "MAPK1"))
     (:SUPPORTED--BY "8020c196-7442-4323-bbcc-bef7712794ef")
     (:EVIDENCE
      ((:TEXT
        . "Src and focal adhesion kinase mediate mechanical strain induced proliferation and ERK1/2 phosphorylation in human H441 pulmonary epithelial cells.")
       (:PMID . "17215324") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, pharmacological inhibition of Src dramatically repressed ERK phosphorylation, while inhibition of PI3K had no effect (XREF_FIG), supporting the conclusion that ERK is regulated by the FAK and Src complex downstream of integrin mediated signaling.")
       (:PMID . "19826415") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, ERK phosphorylation is also blocked by inhibitors of PKC and Src (XREF_FIG).")
       (:PMID . "19879874") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We hypothesized that beta-arrestins may act as the signaling initiators to regulate PAR1 induced, Src dependent phosphorylation of ERK1/2 by forming signaling complexes with PAR1.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These results indicate that elevated PRL1 expression leads to Src activation, which promotes phosphorylation of focal adhesion proteins and ERK1/2 activation.")
       (:PMID . "19199380") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To further determine whether beta-arrestins mediate Src dependent, PAR1 induced phosphorylation of ERK1/2, Src inhibitor, PP1, was used to block Src mediated phosphorylation of ERK1/2 in HEK 293 cells.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This effect requires both SRC and p130Cas, which leads to SHC phosphorylation and MAPK activation.")
       (:PMID . "19948216") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Consistent with this finding, we further uncovers new signaling pathways mediated by TK in promoting keratinocyte migration through activation of membrane bound PAR1, TK stimulated intracellular PKC and Src pathway to further activate EGFR and phosphorylate ERK or Src via MMP mediated release of EGF ligands (as shown in XREF_FIG).")
       (:PMID . "19879874") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Moreover, MAPK phosphorylation could be blocked by a specific Src inhibitor and by a Src specific siRNA.")
       (:PMID . "24440771") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The association of beta-arrestin1 and de-phosphorylated Src (Tyr527) enhances the kinase activity of Src as well as beta2AR mediated phosphorylation of ERK1/2.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, SPR mediated ERK1/2 phosphorylation is significantly reduced by the Src kinase inhibitor PP2.")
       (:PMID . "18095097") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As expected, TH1-WT inhibited ERK phosphorylation driven by c-Src (XREF_FIG).")
       (:PMID . "22238675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here, we show that CLL cells express lymphocyte specific protein tyrosine kinase (LCK) and that inhibition of this Src family tyrosine kinase with the specific inhibitor [4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo [3,2-d] pyrimidin-7-yl-cyclopentane (Lck-i)], or reduction of its expression with siRNA, blocks the induction of CD79a, Syk, inhibitor of IkappaB kinase (IKK), Akt, and extracellular signal regulated kinase (ERK) phosphorylation by BCR cross linking in these cells.")
       (:PMID . "23505068") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_8a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These observations suggest that LYN is the major Src family kinase that is recruited by PSTPIP2 to repress ERK phosphorylation and mediate suppression of megakaryocyte differentiation.")
       (:PMID . "24407241") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Therefore, the two beta-arrestin isoforms have opposing effects in regulating PAR1 induced activation and degradation of Src as well as PAR1 induced, Src dependent phosphorylation of ERK1/2.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These results confirm that PAR1 induced phosphorylation of ERK1/2 is mediated by Src dependent signaling pathway in HEK 293 cells.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To examine whether mGluR1a mediated ERK1/2 phosphorylation was mediated by Src and Pyk2 mediated pathway, we pretreated primary mouse cortical neurons with and without the Src family kinase inhibitor PP2 (10 muM) for 60 min prior to treating the neurons with and without 50 muM DHPG.")
       (:PMID . "20180987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "mGluR1 mediates ERK1/2 phosphorylation by a Src and Pyk2 dependent pathway.")
       (:PMID . "20180987") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Instead, CNK1 mediates the vascular endothelial growth factor (VEGF)-dependent, Src mediated Raf phosphorylation and subsequent ERK activation.")
       (:PMID . "21320536") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 activation in PCa cells was regulated by Class IA PI3K isoforms, Src, and FAK in LNCaP cells treated with CXCL13; however, both Class IA and Class IB PI3K isoforms as well as Src and FAK could lead to ERK1/2 phosphorylation in PC3 cells treated with CXCL13.")
       (:PMID . "20412587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The EGFR inhibitor AG 1478, Src kinase inhibitor 1, and MEK 1/2 inhibitor PD184161 all effectively blocked the ERK1/2 phosphorylation.")
       (:PMID . "26006730") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We investigated whether Src and FAK mediate strain induced ERK phosphorylation and migration in human Caco-2 intestinal epithelial cells on fibronectin.")
       (:PMID . "18400991") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, knockdown of c-Src by siRNAs reduced cell proliferation and phosphorylation of ERK1/2, AKT, and GSK3beta.")
       (:PMID . "23615537") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The Src family kinase inhibitor, PP2 (20 nM-20 microM) attenuated CCh stimulated EGFR and ERK phosphorylation and potentiated chloride secretory responses to CCh.")
       (:PMID . "10777553") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The Src family inhibitor PP2 attenuates fMLP induced ERK1/2 phosphorylation in IL-5-primed human blood eosinophils.")
       (:PMID . "21106848") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, rescue of Src activity is not sufficient to restore Erk1/2 phosphorylation and proliferation.")
       (:PMID . "20453886") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "d817cdb2-b295-4877-a6c7-173e711ebe60"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "MAPK3") (:+UP+ . "P27361") (:+HGNC+ . "6877"))
      (:NAME . "MAPK3"))
     (:SUPPORTED--BY "ab3cc196-b988-48e8-a51b-bad86d52aa6d")
     (:EVIDENCE
      ((:TEXT
        . "Therefore, the two beta-arrestin isoforms have opposing effects in regulating PAR1 induced activation and degradation of Src as well as PAR1 induced, Src dependent phosphorylation of ERK1/2.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Moreover, MAPK phosphorylation could be blocked by a specific Src inhibitor and by a Src specific siRNA.")
       (:PMID . "24440771") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, pharmacological inhibition of Src dramatically repressed ERK phosphorylation, while inhibition of PI3K had no effect (XREF_FIG), supporting the conclusion that ERK is regulated by the FAK and Src complex downstream of integrin mediated signaling.")
       (:PMID . "19826415") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, ERK phosphorylation is also blocked by inhibitors of PKC and Src (XREF_FIG).")
       (:PMID . "19879874") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Consistent with this finding, we further uncovers new signaling pathways mediated by TK in promoting keratinocyte migration through activation of membrane bound PAR1, TK stimulated intracellular PKC and Src pathway to further activate EGFR and phosphorylate ERK or Src via MMP mediated release of EGF ligands (as shown in XREF_FIG).")
       (:PMID . "19879874") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To examine whether mGluR1a mediated ERK1/2 phosphorylation was mediated by Src and Pyk2 mediated pathway, we pretreated primary mouse cortical neurons with and without the Src family kinase inhibitor PP2 (10 muM) for 60 min prior to treating the neurons with and without 50 muM DHPG.")
       (:PMID . "20180987") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "To further determine whether beta-arrestins mediate Src dependent, PAR1 induced phosphorylation of ERK1/2, Src inhibitor, PP1, was used to block Src mediated phosphorylation of ERK1/2 in HEK 293 cells.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This effect requires both SRC and p130Cas, which leads to SHC phosphorylation and MAPK activation.")
       (:PMID . "19948216") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These observations suggest that LYN is the major Src family kinase that is recruited by PSTPIP2 to repress ERK phosphorylation and mediate suppression of megakaryocyte differentiation.")
       (:PMID . "24407241") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The Src family inhibitor PP2 attenuates fMLP induced ERK1/2 phosphorylation in IL-5-primed human blood eosinophils.")
       (:PMID . "21106848") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Src and focal adhesion kinase mediate mechanical strain induced proliferation and ERK1/2 phosphorylation in human H441 pulmonary epithelial cells.")
       (:PMID . "17215324") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The association of beta-arrestin1 and de-phosphorylated Src (Tyr527) enhances the kinase activity of Src as well as beta2AR mediated phosphorylation of ERK1/2.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results confirm that PAR1 induced phosphorylation of ERK1/2 is mediated by Src dependent signaling pathway in HEK 293 cells.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We hypothesized that beta-arrestins may act as the signaling initiators to regulate PAR1 induced, Src dependent phosphorylation of ERK1/2 by forming signaling complexes with PAR1.")
       (:PMID . "16580177") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Instead, CNK1 mediates the vascular endothelial growth factor (VEGF)-dependent, Src mediated Raf phosphorylation and subsequent ERK activation.")
       (:PMID . "21320536") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "mGluR1 mediates ERK1/2 phosphorylation by a Src and Pyk2 dependent pathway.")
       (:PMID . "20180987") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here, we show that CLL cells express lymphocyte specific protein tyrosine kinase (LCK) and that inhibition of this Src family tyrosine kinase with the specific inhibitor [4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo [3,2-d] pyrimidin-7-yl-cyclopentane (Lck-i)], or reduction of its expression with siRNA, blocks the induction of CD79a, Syk, inhibitor of IkappaB kinase (IKK), Akt, and extracellular signal regulated kinase (ERK) phosphorylation by BCR cross linking in these cells.")
       (:PMID . "23505068") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_token_8a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results indicate that elevated PRL1 expression leads to Src activation, which promotes phosphorylation of focal adhesion proteins and ERK1/2 activation.")
       (:PMID . "19199380") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, SPR mediated ERK1/2 phosphorylation is significantly reduced by the Src kinase inhibitor PP2.")
       (:PMID . "18095097") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "ERK1/2 activation in PCa cells was regulated by Class IA PI3K isoforms, Src, and FAK in LNCaP cells treated with CXCL13; however, both Class IA and Class IB PI3K isoforms as well as Src and FAK could lead to ERK1/2 phosphorylation in PC3 cells treated with CXCL13.")
       (:PMID . "20412587") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "As expected, TH1-WT inhibited ERK phosphorylation driven by c-Src (XREF_FIG).")
       (:PMID . "22238675") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The EGFR inhibitor AG 1478, Src kinase inhibitor 1, and MEK 1/2 inhibitor PD184161 all effectively blocked the ERK1/2 phosphorylation.")
       (:PMID . "26006730") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, knockdown of c-Src by siRNAs reduced cell proliferation and phosphorylation of ERK1/2, AKT, and GSK3beta.")
       (:PMID . "23615537") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The Src family kinase inhibitor, PP2 (20 nM-20 microM) attenuated CCh stimulated EGFR and ERK phosphorylation and potentiated chloride secretory responses to CCh.")
       (:PMID . "10777553") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, rescue of Src activity is not sufficient to restore Erk1/2 phosphorylation and proliferation.")
       (:PMID . "20453886") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We investigated whether Src and FAK mediate strain induced ERK phosphorylation and migration in human Caco-2 intestinal epithelial cells on fibronectin.")
       (:PMID . "18400991") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "f5cd97a2-da22-4745-ba95-8955fad3761b"))
    ((:RESIDUE . "Y")
     (:SUB
      (:DB--REFS (:+TEXT+ . "PKCdelta") (:+UP+ . "Q05655") (:+HGNC+ . "9399"))
      (:NAME . "PRKCD"))
     (:SUPPORTED--BY "f04b1c4e-0f5e-485e-9c0e-a79db2cf9c25"
      "476e67d4-a29e-42e1-9e4d-ac585a24498e"
      "9197ad5a-8ef2-4c2f-8904-3c1fcf272ba1")
     (:EVIDENCE
      ((:TEXT
        . "Kinase assays were performed with cTnI as substrate - without and with Src - to determine whether Thr 295 and Thr 141 influence PKCdelta-Thr 505 phosphorylation, PKCdelta tyrosine phosphorylation by Src, and/or PKCdelta phosphorylation of cTnI.")
       (:PMID . "19366211") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, PKCdelta is phosphorylated and its activity down regulated by v-Src in v-Src transformed cells, whereas PKCdelta activity and tyrosine phosphorylation were upregulated by Src in other model systems.")
       (:PMID . "15337529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The tyrosine phosphorylation of PKCdelta and the decrease in GS expression induced by platelet derived growth factor (PDGF) were abolished by the Src kinase inhibitors PP1 and PP2.")
       (:PMID . "10945993") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We demonstrate, however, that, in whole cell cultures of skeletal muscle, insulin induces an increase in Src activity.The relation between Src induced tyrosine phosphorylation of PKCdelta and its activation appears to depend on the cell type involved.")
       (:PMID . "15337529") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "905c6357-8acd-42ce-b2b9-33060932c441"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "ff4549d4-31a7-4f22-b759-db689e6848b0"
      "3b085760-047b-4de6-a358-6f53aa726e61"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "730d49b8-cb6b-4c8e-a72c-c3b2d973c4d3"
      "8ee9b97d-fb64-4405-996b-708e238bc9e9")
     (:EVIDENCE
      ((:TEXT
        . "Src also phosphorylates FAK at Tyr 407 , Tyr 861 or Tyr 925 , creating docking sites for other SH2 domain-bearing molecules, such as Grb2, which links FAK to activation of the mitogen-activated protein kinase (MAPK) cascade ( xref , xref , xref ).")
       (:PMID . "20407018") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "Src also phosphorylates FAK at Tyr 407, Tyr 861 or Tyr 925, creating docking sites for other SH2 domain bearing molecules, such as Grb2, which links FAK to activation of the mitogen activated protein kinase (MAPK) cascade (XREF_BIBR, XREF_BIBR, XREF_BIBR).")
       (:PMID . "20407018") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Cellular Src can also phosphorylate FAK on Y407, Y861, and Y925, creating SH2-domain binding sites for interacting proteins such as Grb2 ().")
       (:PMID . "19055942") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_c1070eada2d0aa3460ec3295923066ad")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Following attachment, Src further phosphorylates FAK on Y407, Y576, Y577, Y861, and Y925, which in turn regulates FAK kinase activity and downstream signalling ().")
       (:PMID . "18562041") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "407")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "e4cf461c-c702-465a-97e3-82db1baf5fc7"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "f0a0f9d9-43e5-4558-a048-5be9f161ae73"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "3dd4cd0c-3882-43f5-bf49-876da353e079"
      "ebcceb7a-89b6-438e-9dab-c1f72a36f8df"
      "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:TEXT
        . "However, Src phosphorylation of FAK at Y576 and Y577 and Y925 is important for enhancing downstream signaling.")
       (:PMID . "26923073") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "When phosphorylated, Y397 becomes a binding site for the tyrosine kinase Src, which phosphorylates FAK at Y576 and Y577 to further activate FAK kinase activity [XREF_BIBR, XREF_BIBR].")
       (:PMID . "19695571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Following attachment, Src further phosphorylates FAK on Y407, Y576, Y577, Y861, and Y925, which in turn regulates FAK kinase activity and downstream signalling ().")
       (:PMID . "18562041") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Phosphorylation of FAK by Src on Y576 and Y577 is an important step in the formation of active signaling complex and is required for maximal enzymatic activity of FAK (XREF_BIBR).")
       (:PMID . "20515733") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "For example, active FAK can facilitate auto-phosphorylation at its tyrosine site Y397, which recruits and activates Src kinase via Src SH2 domain, with active Src further promotes the phosphorylation of FAK at the tyrosine sites Y576 and Y577 and the subsequent maximal activation of FAK kinase XREF_BIBR, XREF_BIBR.")
       (:PMID . "24015220") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Src recruitment results in Src dependent phosphorylation of FAK at FAK Y576 and FAK Y577 leading to maximal adhesion induced FAK activation (XREF_BIBR).")
       (:PMID . "26833789") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_3d9737bcf27fa596efb8397c23de59bd")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Src inhibition also prevented strain induced FAK phosphorylation at Tyr 397 and Tyr 576 but not FAK-Tyr 925 or ERK phosphorylation.")
       (:PMID . "18400991") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:POSITION . "576")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "4867974c-0764-482f-9c72-eec0326029db"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "f23f9510-13ba-42de-8d8e-88554edb73db"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "34721a90-0c05-4de1-a662-3733bf57779d"
      "3b085760-047b-4de6-a358-6f53aa726e61"
      "95de175b-9a5e-4702-9cfb-18170ea89e97")
     (:EVIDENCE
      ((:TEXT
        . "However, Src phosphorylation of FAK at Y576 and Y577 and Y925 is important for enhancing downstream signaling.")
       (:PMID . "26923073") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "When phosphorylated, Y397 becomes a binding site for the tyrosine kinase Src, which phosphorylates FAK at Y576 and Y577 to further activate FAK kinase activity [XREF_BIBR, XREF_BIBR].")
       (:PMID . "19695571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e2967c484c6adaa15552a696cd8f0a00")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Src recruitment results in Src dependent phosphorylation of FAK at FAK Y576 and FAK Y577 leading to maximal adhesion induced FAK activation (XREF_BIBR).")
       (:PMID . "26833789") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_8_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "577")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "1cb7e055-3027-458f-8756-5be6e0a9ed35"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "Q05397") (:+HGNC+ . "9611")) (:NAME . "PTK2"))
     (:SUPPORTED--BY "ded388e8-50b1-4991-b617-63601ea3c0bd"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "3b085760-047b-4de6-a358-6f53aa726e61"
      "835d925f-d497-4cae-9a85-f7d707c159f8"
      "8b39791a-debb-4e59-95ce-b2fd25c7f556")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_PTK2_pmod_P_Y_861")
       (:TEXT
        . "Previously identified Src sites include catalytic domain tyrosines-576 and -577, important for maximal FAK kinase activity, and tyrosine-925, which permits an SH2-mediated association with Grb2. Here we report that tyrosine-861 is the major Src site in the carboxyl-terminal domain of FAK. Phosphotyrosine-861 may function in additional interactions between FAK and SH2-containing proteins.")
       (:PMID . "8941336") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_PTK2_pmod_P_Y_861")
       (:TEXT
        . "Using a constitutively active form for Mer (CDMer) or Gas6 as a ligand to stimulate Mer, we found that Mer activation induced a post-receptor signaling cascade involving Src-mediated tyrosine phosphorylation of FAK on Tyr(861), the recruitment of FAK(Tyr861) to the alphavbeta5 integrin, and increased formation of p130(CAS)/CrkII/Dock180 complex to activate Rac1.")
       (:PMID . "15673687") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_PTK2_pmod_P_Y_861")
       (:TEXT
        . "This study establishes that HER2/HRG signaling selectively upregulates Tyr phosphorylation of c-Src at Tyr-215 located within the SH2 domain, increases c-Src kinase activity and selectively upregulates Tyr phosphorylation of FAK at Tyr-861. HER2-overexpressing tumors showed increased levels of c-Src phosphorylation at Tyr-215. These findings suggest that HER2/HRG influence metastasis of breast cancer cells through a novel signaling pathway involving phosphorylation of FAK tyrosine 861 via activation of c-Src tyrosine 215.")
       (:PMID . "12753909") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_PTK2_pmod_P_Y_861")
       (:TEXT
        . "We propose that FAK/c-Src bipartite enzyme is a sensor of cytoplasmic shrinkage, and that the phosphorylation on FAK Tyr-861 by Src and subsequent reorganization of F-actin can initiate an anti-apoptotic signaling pathway that protects cells from hyperosmotic stress.")
       (:PMID . "17289681") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_PTK2_pmod_P_Y_861")
       (:TEXT . "8941336;11927607") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_PTK2_pmod_P_Y_861")
       (:TEXT
        . "A reduction in tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin occurred in FL cells under these conditions. In contrast, increased FAK and paxillin phosphorylation was documented in dPXXP cells. Differential FAK phosphorylation occurred at the major autophosphorylation site Y(397) and Src phosphorylation site Y(861). Concordant with these findings, there was decreased interaction between FAK and its downstream partners p(130)Cas and Crk observed in FL cells but not in dPXXP cells.")
       (:PMID . "16859681") (:SOURCE--API . "bel"))
      ((:TEXT
        . "Src also phosphorylates FAK at Tyr 407, Tyr 861 or Tyr 925, creating docking sites for other SH2 domain bearing molecules, such as Grb2, which links FAK to activation of the mitogen activated protein kinase (MAPK) cascade (XREF_BIBR, XREF_BIBR, XREF_BIBR).")
       (:PMID . "20407018") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Cellular Src can also phosphorylate FAK on Y407, Y861, and Y925, creating SH2-domain binding sites for interacting proteins such as Grb2 ().")
       (:PMID . "19055942") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_9ad14f99f6ceebb37159cc6559e27500")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Following attachment, Src further phosphorylates FAK on Y407, Y576, Y577, Y861, and Y925, which in turn regulates FAK kinase activity and downstream signalling ().")
       (:PMID . "18562041") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "861")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "36a598cc-da36-4b1e-9c51-ddb62820bfa6"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "86727b24-7e72-4ae7-bc92-d561431eb4fc"
      "d3e9656e-8eef-4a20-ba81-a897869153d3"
      "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "ca123c61-99a0-4c4c-8404-a847c1e6b074"
      "976e64fb-d06a-4267-b3a6-e9f6b9c7fd5d"
      "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:TEXT
        . "As Src is highly activated in these prostate cancer cell lines [XREF_BIBR], it may be that Src phosphorylation of FAK Y925 is sufficiently robust such that Yes can not further increase FAK Y925 phosphorylation; hence increased FAK Y925 phosphorylation was not observed in our selected cells.")
       (:PMID . "25868388") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "However, Src phosphorylation of FAK at Y576 and Y577 and Y925 is important for enhancing downstream signaling.")
       (:PMID . "26923073") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Inhibition of Src signaling impairs tyrosine phosphorylation of tyrosine residue 925 of FAK following adhesion to fibronectin.")
       (:PMID . "11476890") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Following attachment, Src further phosphorylates FAK on Y407, Y576, Y577, Y861, and Y925, which in turn regulates FAK kinase activity and downstream signalling ().")
       (:PMID . "18562041") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b72eb5bd05a6071718fdcfd2b2940ec4")
       (:PMID . "12110680") (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Then src phosphorylates FAK on tyrosine 925, which leads to the recruitment of Grb-2 (an adapter protein) and SOS (a regulator of ras-type GTPases) to the FAK signaling complex.")
       (:PMID . "20621036") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_PTK2_pmod_P_Y_925")
       (:TEXT
        . "In the first case, recruited FAK autophosphorylates at 397Y and associates with c-Src or Fyn, which further phosphorylates it at 925Y. Phosphorylated FAK binds to the Grb2-Sos complex and activates the Ras-ERK cascade [60,61].")
       (:PMID . "14984767") (:SOURCE--API . "bel"))
      ((:TEXT
        . "Src also phosphorylates FAK at Tyr 407, Tyr 861 or Tyr 925, creating docking sites for other SH2 domain bearing molecules, such as Grb2, which links FAK to activation of the mitogen activated protein kinase (MAPK) cascade (XREF_BIBR, XREF_BIBR, XREF_BIBR).")
       (:PMID . "20407018") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Cellular Src can also phosphorylate FAK on Y407, Y861, and Y925, creating SH2-domain binding sites for interacting proteins such as Grb2 ().")
       (:PMID . "19055942") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Then src phosphorylates FAK on tyrosine 925, which leads to the recruitment of Grb-2 (an adapter protein) and SOS (a regulator of ras-type GTPases) to the FAK signaling complex.")
       (:PMID . "20621036") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Moreover, FAK Y925 phosphorylation by Src promotes Grb2-FAK interactions which, along with Shc, link FAK to the Ras pathway (XREF_BIBR; XREF_BIBR).")
       (:PMID . "19826415") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_fc4831733d49fcd2e616973b645dface")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Then src phosphorylates FAK on tyrosine 925, which leads to the recruitment of Grb-2 (an adapter protein) and SOS (a regulator of ras-type GTPases) to the FAK signaling complex")
       (:PMID . "20621036") (:SOURCE--API . "sparser")))
     (:POSITION . "925")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "7f27b4c9-10c1-40ea-a2a3-add603459163"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P29353") (:+HGNC+ . "10840")) (:NAME . "SHC1"))
     (:SUPPORTED--BY "a8ebafe3-178c-4733-85ef-da822f944763"
      "6c52a78c-6f62-43cf-acae-6ad34315efa2"
      "c152fe2a-86a6-4991-a393-51aa22cdd939"
      "5155385d-534b-4c6b-9930-a0bd655d3cea"
      "710fc506-e0f1-40f4-a5e5-397f31264284")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y_349")
       (:TEXT . "11075717;9121430;9710204;10891441;11687594;15592455;9927207")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y_349")
       (:TEXT
        . "These residues are present in the central proline-rich (CH1) region and are conserved in all isoforms of Shc. Y239/240 are co-ordinately phosphorylated by the Src protein-tyrosine kinase in vitro, and in response to epidermal growth factor stimulation or in v-src-transformed cells in vivo.")
       (:PMID . "8939605") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_a7f85edb523be7681f0d5b2a2c63a1f4")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_4e4e11b1202e4bd9b3922cc8f874b375")
       (:SOURCE--API . "biopax")))
     (:POSITION . "349")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "76e20214-7797-4f91-b31d-fe8b31dd5d2d"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P29353") (:+HGNC+ . "10840")) (:NAME . "SHC1"))
     (:SUPPORTED--BY "710fc506-e0f1-40f4-a5e5-397f31264284"
      "5155385d-534b-4c6b-9930-a0bd655d3cea"
      "3c69b225-72cb-49fc-be14-76875aa9740b"
      "c152fe2a-86a6-4991-a393-51aa22cdd939")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_154632acee90e29495499f72707c1a1f")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y_350")
       (:TEXT . "11075717;9121430;9710204;15592455;9927207")
       (:PMID . "15212693") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y_350")
       (:TEXT
        . "These residues are present in the central proline-rich (CH1) region and are conserved in all isoforms of Shc. Y239/240 are co-ordinately phosphorylated by the Src protein-tyrosine kinase in vitro, and in response to epidermal growth factor stimulation or in v-src-transformed cells in vivo.")
       (:PMID . "8939605") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_dcaea048d69800e1de6100c3d72a1927")
       (:SOURCE--API . "biopax")))
     (:POSITION . "350")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "71be94f6-cba0-4772-ab95-8419a701fcf5"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P29353") (:+HGNC+ . "10840")) (:NAME . "SHC1"))
     (:SUPPORTED--BY "caaac4ae-ef68-4fde-b910-70ef6d06227b"
      "c152fe2a-86a6-4991-a393-51aa22cdd939"
      "5155385d-534b-4c6b-9930-a0bd655d3cea"
      "2f39465c-d415-4d7f-8c3d-22ed7e90e822"
      "710fc506-e0f1-40f4-a5e5-397f31264284")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_SHC1_pmod_P_Y_317")
       (:TEXT
        . "In this study, we observed that curcumin inhibited the kinase activity of v-Src, which led to a decrease in tyrosyl substrate phosphorylation of Shc, cortactin, and FAK. Our in vitro kinase experiment revealed that the inhibitory effect of curcumin on Src could be direct. Consistent with the abrogation of Src activity was the reduction of Src-Tyr-416 phosphorylation, Src-mediated Shc-Tyr-317 phosphorylation, decreased ERK activation, and cell proliferation in v-Src transformed cells.")
       (:PMID . "14637190") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_5a20211f9b2e36e0fe65010343cb9c61")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_97758067d942279ce2d40ba130145396")
       (:SOURCE--API . "biopax")))
     (:POSITION . "427")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "844279c3-d6fc-4386-aa57-0b649bb9f2b7"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "8438aecb-18c5-4b9e-8637-c6459ccef94f"
      "90083100-66a7-43e0-bfaf-02db6a90f675"
      "7e2a23f4-b5ba-4462-8d06-ecfee696315a"
      "49c993fa-b398-4b4c-a732-182efc9277a1"
      "3f726eff-048e-440e-a9f6-a8a0ec29d11b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_8e227e3ec04d2e8c013e34d18d6afc2a")
       (:PMID . "15702476") (:SOURCE--API . "biopax"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_STAT5A_pmod_P_Y_694")
       (:TEXT
        . "When Src and STAT5 were co-expressed in COS7 cells, tyrosine phosphorylation of STAT5 was observed, and tyrosine residue 694 (Tyr 694) of STAT5A was identified as the major phosphorylation site by Src. ")
       (:PMID . "11641791") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/kin_p_HGNC_SRC_DirectlyIncreases_p_HGNC_STAT5A_pmod_P_Y_694")
       (:TEXT . "11641791;17081983") (:PMID . "15212693")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_e18cf28ecb0c4b4ca4d112c6f1a8afcd")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "694")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+UP+ . "P12931") (:+HGNC+ . "11283")) (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "e38215d1-3efa-4e33-8a5e-992c7efc2b43"))
    ((:RESIDUE . "Y")
     (:SUB
      (:DB--REFS (:+TEXT+ . "STAT5b") (:+UP+ . "P51692") (:+HGNC+ . "11367"))
      (:NAME . "STAT5B"))
     (:SUPPORTED--BY "b41a4ce4-dd7c-4fb3-b1fb-85d6023340f3"
      "a4384270-79dc-4ac1-93a4-5753ac8b92bf"
      "4a4c0516-ed8b-4714-b322-a74a5b5c36d5"
      "531bd670-c6e5-46c0-9dbe-4f517555ff59"
      "f544f8d2-88de-42a6-a44c-c7488cb1e1b6")
     (:EVIDENCE
      ((:TEXT
        . "Since Brk and c-Src are both able to phosphorylate STAT5b on Y699, the potential cooperation between Brk and c-Src was investigated.")
       (:PMID . "17997837") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "These conformational differences may in part be due to differential effects of Prl and Src on Stat5b tyrosine phosphorylation, since Src induced several additional sites of tyrosine phosphorylation of Stat5b at residues other than Tyr 699, including Tyr 724 and Tyr 679.")
       (:PMID . "12621061") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_48d812c9e192b6a9365781e96dba8b5d")
       (:SOURCE--API . "biopax")))
     (:POSITION . "699")
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "c-Src") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "f6d6766d-46b1-42f0-9ab3-4d6ce6dd3c93"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "YAP1") (:+UP+ . "P46937") (:+HGNC+ . "16262"))
      (:NAME . "YAP1"))
     (:SUPPORTED--BY "9f45cc54-8c1c-4abb-a11c-5f205594be93")
     (:EVIDENCE
      ((:TEXT
        . "YAP1 binds to YES1 and is phosphorylated by SRC family kinases in embryonic stem cells (XREF_BIBR).")
       (:PMID . "23245941") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Although both YES1 and SRC phosphorylated YAP1, suppression of SRC failed to inhibit the proliferation and AI growth of beta-catenin active cell lines (XREF_SUPPLEMENTARY).")
       (:PMID . "23245941") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Hahn and colleagues recently highlighted that, by using a YAP1 mutant for all LATS1 phosphorylation sites (5SA) including the inhibitory S127-YAP1 phosphorylation, while permissive, required additional phosphorylation of Y357-YAP1 by the SRC family kinase (SFK) YES to activate transcription [XREF_BIBR].")
       (:PMID . "26549256") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We find that RASSF1C actually supports tumorigenesis by promoting SRC and YES mediated phosphorylation of E-cadherin, beta-catenin, and YAP1, disrupting cell-cell contacts and initiating an EMT like response.")
       (:PMID . "26549256") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, we concluded that both YES1 and SRC are able to phosphorylate YAP1 but only YES1 is essential for the survival of beta-catenin active cell lines.")
       (:PMID . "23245941") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "To determine whether YES1 or SRC phosphorylates YAP1, we expressed YAP1 in 293T cells and assessed YAP1 tyrosine phosphorylation when co-expressed with YES1 or SRC (XREF_FIG).")
       (:PMID . "23245941") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:ENZ
      (:MODS
       ((:RESIDUE . "Y") (:POSITION . "419") (:MOD--TYPE . "phosphorylation")
        (:IS--MODIFIED . T)))
      (:DB--REFS (:+TEXT+ . "SRC") (:+UP+ . "P12931") (:+HGNC+ . "11283"))
      (:NAME . "SRC"))
     (:TYPE . "Phosphorylation")
     (:ID . "1b67af4c-d75d-4faa-ba2c-6636532b68ce"))
    ((:RESIDUE . "T")
     (:SUB
      (:DB--REFS (:+TEXT+ . "PRKAA2") (:+UP+ . "P54646") (:+HGNC+ . "9377"))
      (:NAME . "PRKAA2"))
     (:SUPPORTED--BY "3bdd2dfa-98b3-40c7-b006-0354a0707431"
      "185acd99-05fa-401d-9391-6873390c7d92"
      "9403942d-669c-40c9-bba4-28132b0d4c15")
     (:EVIDENCE
      ((:TEXT
        . "Under conditions of low cellular energy (high AMP/ATP ratio), LKB1 phosphorylates AMPK on T172, and subsequently, activated AMPK phosphorylates TSC2 at T1227 and S1345, activating the Rheb-GAP activity of TSC, which catalyzes the conversion of Rheb-GTP to Rheb-GDP and thus inhibits mTORC1 activity [ xref - xref ].")
       (:PMID . "20491627") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "The LKB1 protein, in association with the accessory proteins STRAD and MO25, phosphorylates AMPKalpha at Thr172 in its activation loop, leading to AMPK activation when AMPK is in the AMP bound state.")
       (:PMID . "24086281") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The phosphorylation of AMPK at Thr172 by the upstream kinase LKB1 is necessary for its activation and PB reportedly activates AMPK in an LKB1 dependent manner XREF_BIBR.")
       (:PMID . "22815988") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Under conditions of low cellular energy (high AMP and ATP ratio), LKB1 phosphorylates AMPK on T172, and subsequently, activated AMPK phosphorylates TSC2 at T1227 and S1345, activating the Rheb-GAP activity of TSC, which catalyzes the conversion of Rheb-GTP to Rheb-GDP and thus inhibits mTORC1 activity [XREF_BIBR - XREF_BIBR].")
       (:PMID . "20491627") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "AMPK alpha1 can be phosphorylated at Thr172 by two different AMPKK, the tumor suppressor kinase LKB1, and the Ca/calmodulin dependent protein kinase kinase beta (CaMKKbeta).")
       (:PMID . "21232561") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We show that LKB1 directly phosphorylates Thr 172 of AMPKalpha in vitro and activates its kinase activity.")
       (:PMID . "14985505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "During energy stress, LKB1 phosphorylates AMPK at threonine 172 (T172), resulting in AMPK activation ().")
       (:PMID . "26212320") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "LKB1 phosphorylates AMPK at T172 and affects phosphorylation of YAP at S127 in an AMPK independent manner ().")
       (:PMID . "26678338") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "LKB1 phosphorylates AMPK at T172 and affects phosphorylation of YAP at S127 in an AMPK independent manner ().")
       (:PMID . "26678338") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Finally, Berberine significantly increased the phosphorylation of LKB1 at Ser307 and gene silencing of LKB1 attenuated Berberine enhanced AMPK Thr172 phosphorylation in BAEC.")
       (:PMID . "21079763") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "LKB1 is the major kinase for AMPKalpha in response to energy stress and phosphorylates AMPKalpha at Thr172 ().")
       (:PMID . "26876938") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We observe an increase in the AMP and ATP ratio, which promotes the phosphorylation of AMPK on Thr172 by the protein kinase LKB1.")
       (:PMID . "23110147") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "172")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "LKB1") (:+UP+ . "Q15831") (:+HGNC+ . "11389"))
      (:NAME . "STK11"))
     (:TYPE . "Phosphorylation")
     (:ID . "b643a018-5a72-493d-87e4-c0e36d023db7"))
    ((:RESIDUE . "S")
     (:SUB (:DB--REFS (:+UP+ . "P46937") (:+HGNC+ . "16262")) (:NAME . "YAP1"))
     (:SUPPORTED--BY "9f45cc54-8c1c-4abb-a11c-5f205594be93"
      "96b80240-ecab-4ae4-aa18-aa3b42ba17c1"
      "a3313379-b236-4688-9829-1cf7c5cd4769")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_b142d943953edb031412a3473d15abc0")
       (:SOURCE--API . "biopax"))
      ((:SOURCE--API . "phosphosite")))
     (:POSITION . "127")
     (:ENZ (:DB--REFS (:+UP+ . "Q13188") (:+HGNC+ . "11406")) (:NAME . "STK3"))
     (:TYPE . "Phosphorylation")
     (:ID . "0749e214-1b99-48e7-be68-691175bae201"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "FOXO3") (:+UP+ . "O43524") (:+HGNC+ . "3821"))
      (:NAME . "FOXO3"))
     (:SUPPORTED--BY "c72805ce-5398-4ce7-bfc1-560f39139191")
     (:EVIDENCE
      ((:TEXT
        . "The MST1 kinase phosphorylates FoxO transcription factors in the cytosol and histone H2B in the nucleus to promote cellular apoptosis.")
       (:PMID . "18510339") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "MST1 phosphorylates FOXO proteins and promotes their nuclear translocation for inducing cell death in neurons [XREF_BIBR].")
       (:PMID . "19212654") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Recently, MST1 was reported to induce apoptosis in neuronal cells by phosphorylating and activating FOXO3 transcription factors in response to oxidative stress ().")
       (:PMID . "17889669") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In contrast to Akt and PKB, MST1 phosphorylation of FoxO3 promotes its nuclear translocation, thereby inducing cell death XREF_BIBR.")
       (:PMID . "21249150") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Although the lack of an appropriate antibody for the specific immunohistochemical detection of serine 207 residue in FOXO3 phosphorylated by MST1 kinaseprevented the detection of FoxO3 activity modified by MST1, these results, coupled with the results of in vitro assays, suggest that BRAF V600E may alleviate the tumor suppressor function of RASSF1A-MST1 and vice versa.")
       (:PMID . "21249150") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2b_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We find that the MST1 regulatory region enhances FoxO phosphorylation while inhibiting histone H2B phosphorylation, consistent with the cellular properties of MST1.")
       (:PMID . "18510339") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "MST1 phosphorylates FOXO proteins at a conserved site within the forkhead domain that disrupts their interaction with 14-3-3 proteins, promotes FOXO nuclear translocation, and thereby induces cell death in neurons.")
       (:PMID . "16751106") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "MST1") (:+UP+ . "Q13043") (:+HGNC+ . "11408"))
      (:NAME . "STK4"))
     (:TYPE . "Phosphorylation")
     (:ID . "8053ff60-e367-421a-a157-552bc6c51749"))
    ((:RESIDUE . "T")
     (:SUB (:DB--REFS (:+UP+ . "P31749") (:+HGNC+ . "391")) (:NAME . "AKT1"))
     (:SUPPORTED--BY "5bd5b442-5525-40d4-b7b5-32404d83e4fd"
      "b0cbde8b-46e3-4757-819f-18c35f74fbb4"
      "17d2a17b-18d9-48b0-85c4-5722d07bc66d"
      "2d0c1b00-41a3-41a5-b9c5-41366e2ba7ec")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_bd8057d49979f1f32af13627ab8866f1")
       (:SOURCE--API . "biopax")))
     (:POSITION . "308")
     (:ENZ (:DB--REFS (:+UP+ . "Q9UHD2") (:+HGNC+ . "11584")) (:NAME . "TBK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "9b7ba93c-33bf-4544-832f-b0b3ae5a3c60"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:SUPPORTED--BY "3d9aa6b4-7526-4b87-927f-895a951eaaf8")
     (:EVIDENCE
      ((:TEXT
        . "In addition, recent studies have identified that TBK1 directly phosphorylates AKT to inhibit apoptosis and support oncogenic transformation [11,12].")
       (:PMID . "24027431") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Interestingly, shRNA mediated TBK1 silencing promoted the phosphorylation of AKT as well as the AKT-mTORC1 downstream proteins Foxo1 and S6 (XREF_SUPPLEMENTARY).")
       (:PMID . "25606824") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, recent studies have identified that TBK1 directly phosphorylates AKT to inhibit apoptosis and support oncogenic transformation [11,12].")
       (:PMID . "24027431") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "RalB mediated activation of TBK1 promotes TBK1 assembly with the exocyst complex through its interaction with Sec5 leading to inflammatory responses and prosurvival signalling by directly phosphorylating multiple sites on Akt XREF_BIBR.")
       (:PMID . "26656453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "IkappaB kinase epsilon and TANK binding kinase 1 activate AKT by direct phosphorylation.")
       (:PMID . "21464307") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "TBK1 phosphorylates AKT at several residues, including threonine 195 and serine 378, although the functional significance has not been defined XREF_BIBR.")
       (:PMID . "25606824") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Furthermore, TBK1 knockdown had minimal effects on serum stimulated AKT phosphorylation in the five cell lines analyzed.")
       (:PMID . "24962318") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In vitro kinase assays combined with reversed-phase liquid chromatography mass spectrometry analysis showed that TBK1 enhanced phosphorylation of Akt on Ser (473), whereas knockdown of TBK1 expression by short interfering RNA in macrophages decreased poly (I : C) - and LPS induced Akt phosphorylation.")
       (:PMID . "21106850") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "IKK physically interacts with and phosphorylates FOXO3a independently of Akt, which causes nuclear exclusion of FOXO3a and subsequently proteolysis of FOXO3a via the betaTrCP mediated ubiquitin (Ub)-dependent proteasome pathway (XREF_BIBR).")
       (:PMID . "21911455") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Using the Cre-ER-inducible KO system, we found that TBK1 ablation in adult mice also caused aberrant phosphorylation of AKT and S6 in T cells (XREF_SUPPLEMENTARY), further emphasizing a pivotal role for TBK1 in controlling the activation of AKT and its downstream targets, Foxo1 and mTORC1.")
       (:PMID . "25606824") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "TBK1") (:+UP+ . "Q9UHD2") (:+HGNC+ . "11584"))
      (:NAME . "TBK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "035fb493-7232-43ca-90f2-4eb3f9e711a9"))
    ((:SUB (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:SUPPORTED--BY "f34164fc-7fa7-42c7-9c21-eda670618949")
     (:EVIDENCE
      ((:TEXT
        . "TBK1 phosphorylates AKT at several residues, including threonine 195 and serine 378, although the functional significance has not been defined XREF_BIBR.")
       (:PMID . "25606824") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Using the Cre-ER-inducible KO system, we found that TBK1 ablation in adult mice also caused aberrant phosphorylation of AKT and S6 in T cells (XREF_SUPPLEMENTARY), further emphasizing a pivotal role for TBK1 in controlling the activation of AKT and its downstream targets, Foxo1 and mTORC1.")
       (:PMID . "25606824") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Interestingly, shRNA mediated TBK1 silencing promoted the phosphorylation of AKT as well as the AKT-mTORC1 downstream proteins Foxo1 and S6 (XREF_SUPPLEMENTARY).")
       (:PMID . "25606824") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In addition, recent studies have identified that TBK1 directly phosphorylates AKT to inhibit apoptosis and support oncogenic transformation [11,12].")
       (:PMID . "24027431") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, recent studies have identified that TBK1 directly phosphorylates AKT to inhibit apoptosis and support oncogenic transformation [11,12].")
       (:PMID . "24027431") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "RalB mediated activation of TBK1 promotes TBK1 assembly with the exocyst complex through its interaction with Sec5 leading to inflammatory responses and prosurvival signalling by directly phosphorylating multiple sites on Akt XREF_BIBR.")
       (:PMID . "26656453") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_3a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Furthermore, TBK1 knockdown had minimal effects on serum stimulated AKT phosphorylation in the five cell lines analyzed.")
       (:PMID . "24962318") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "IkappaB kinase epsilon and TANK binding kinase 1 activate AKT by direct phosphorylation.")
       (:PMID . "21464307") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "In vitro kinase assays combined with reversed-phase liquid chromatography mass spectrometry analysis showed that TBK1 enhanced phosphorylation of Akt on Ser (473), whereas knockdown of TBK1 expression by short interfering RNA in macrophages decreased poly (I : C) - and LPS induced Akt phosphorylation.")
       (:PMID . "21106850") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "IKK physically interacts with and phosphorylates FOXO3a independently of Akt, which causes nuclear exclusion of FOXO3a and subsequently proteolysis of FOXO3a via the betaTrCP mediated ubiquitin (Ub)-dependent proteasome pathway (XREF_BIBR).")
       (:PMID . "21911455") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "TBK1") (:+UP+ . "Q9UHD2") (:+HGNC+ . "11584"))
      (:NAME . "TBK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "af080a61-b76e-49d5-8588-d9aa4f6402dc"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "FOXO3a") (:+UP+ . "O43524") (:+HGNC+ . "3821"))
      (:NAME . "FOXO3"))
     (:SUPPORTED--BY "c72805ce-5398-4ce7-bfc1-560f39139191")
     (:EVIDENCE
      ((:TEXT
        . "Thus, IKK phosphorylation of FOXO3a also serves as a vital mechanism in promoting cell growth and tumorigenesis.")
       (:PMID . "21238503") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Additionally, the IkappaB kinase phosphorylates FOXO3a transcription factor, blocking its induction of proapoptotic genes.")
       (:PMID . "21242888") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Blocking of AKT and IkappaB kinase (IKK) activity prevents FOXO3a phosphorylation, leading to T CM cell death.")
       (:PMID . "17190839") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "IKK physically interacts with and phosphorylates FOXO3a independently of Akt, which causes nuclear exclusion of FOXO3a and subsequently proteolysis of FOXO3a via the betaTrCP mediated ubiquitin (Ub)-dependent proteasome pathway (XREF_BIBR).")
       (:PMID . "21911455") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This increased expression of activated IKK in T CM could lead to FOXO3a phosphorylation and the inhibition of its transcriptional activity.")
       (:PMID . "17190839") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "It has been shown in Foxo3a deficient mice and in vitro assays using human lymphocytes that the maintenance of CD34 + stem cells (XREF_BIBR - XREF_BIBR), T cell progenitors (XREF_BIBR) and mature central memory CD4 + T cells (T CM) (XREF_BIBR) are mediated by increased AKT, ERK and IKK kinase activities, whose functions are to induce the phosphorylation of Foxo3a (XREF_BIBR, XREF_BIBR, XREF_BIBR).")
       (:PMID . "22748238") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, we could not rule out certain minor target sites matching the putative IKK recognition sequences for phosphorylation in FOXO3a that might be phosphorylated by IKKbeta.To confirm that S644 is the site of IKK catalyzed phosphorylation of the endogenous FOXO3a protein in response to TNFalpha, we raised an Ab against a phosphopeptide corresponding to the phosphorylation site of S644 and used this Ab for IB analysis.")
       (:PMID . "15084260") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "One set of signals activates the IKK complex to phosphorylate FOXO3 and to initially liberate NF-kappaB and drive the immediate cytokine expression.")
       (:PMID . "19636295") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Hu reported that FOXO3 might be phosphorylated by IKK in breast cancer cells.")
       (:PMID . "19636295") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, IKK phosphorylation of FOXO3a also serves as a vital mechanism in promoting cell growth and tumorigenesis.")
       (:PMID . "21238503") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "IKK physically interacts with and phosphorylates FOXO3a independently of Akt, which causes nuclear exclusion of FOXO3a and subsequently proteolysis of FOXO3a via the betaTrCP mediated ubiquitin (Ub)-dependent proteasome pathway (XREF_BIBR).")
       (:PMID . "21911455") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "To address if IKK could phosphorylate FOXO3a in vitro, we produced several overlapping fragments of FOXO3a (FO3a) fused to GST and used these proteins as substrates in an IKKbeta-immunocomplex kinase assay and showed that the C-terminal portion Gst-FO3a (301-673) but not the N-terminal portion Gst-FO3a (1-300) was phosphorylated by IKKbeta and the intensity of phosphorylation was comparable to that of Gst-IkappaBalpha, a known substrate of IKKbeta.")
       (:PMID . "15084260") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "It is thus likely that activated AKT and IKK promote CD4 + cell survival in part by phosphorylating FOXO3a, thereby repressing its transcriptional activity and leading to the down-regulation of the proapoptotic molecule Bim.")
       (:PMID . "17190839") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Some studies reported that IKK can induce phosphorylation, ubiquitination, and degradation of forkhead box, class O (FOXO) factors, and promote cell proliferation and tumorigenesis [XREF_BIBR].")
       (:PMID . "23035900") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The cytoplasmic localization FOXO3a is regulated by IkappaB kinase (IKK) phosphorylation of FOXO3a, which also induces proteasome degradation of FOXO3a [XREF_BIBR].")
       (:PMID . "21238503") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "TBK1") (:+UP+ . "Q9UHD2") (:+HGNC+ . "11584"))
      (:NAME . "TBK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "679f30fa-3091-4310-899b-ff2c20ec9914"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "STAT6") (:+UP+ . "P42226") (:+HGNC+ . "11368"))
      (:NAME . "STAT6"))
     (:SUPPORTED--BY "3bd8cbdf-e4aa-4d6d-8164-41f93270d10e")
     (:EVIDENCE
      ((:TEXT
        . "A similar mechanism may facilitate phosphorylation of STAT6 by TBK1 in the setting of antiviral innate immunity (XREF_BIBR).")
       (:PMID . "23453972") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The importance of this residue was shown by the observation that LA interacted with TBK1 constitutively, in a way that probably affected TBK1 phosphorylation of STAT6 (data not shown).")
       (:PMID . "22000020") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "TBK1") (:+UP+ . "Q9UHD2") (:+HGNC+ . "11584"))
      (:NAME . "TBK1"))
     (:TYPE . "Phosphorylation")
     (:ID . "bbd9bfda-75cc-467b-b677-f827e4ab980a"))
    ((:RESIDUE . "Y")
     (:SUB
      (:DB--REFS (:+TEXT+ . "STAT3") (:+UP+ . "P40763") (:+HGNC+ . "11364"))
      (:NAME . "STAT3"))
     (:SUPPORTED--BY "f4779790-8788-4c65-83e6-91a3085004f7"
      "1f9e903b-b337-4022-b907-fc559bac1720"
      "e5e0ab98-e8ef-4793-a010-f5aeb8b2a8c2"
      "4a20277f-00ce-45f0-a600-1cf3924d94ca"
      "ee53fa87-34c2-4646-a12e-dfe03589fe5f")
     (:EVIDENCE
      ((:TEXT
        . "26 STAT3 is phosphorylated by JAK tyrosine kinases at Tyr705 which transduces the signals of IL6.")
       (:PMID . "24687132") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "17 Latent STAT3 is recruited to the activated receptor via phosphotyrosine-SH2 recognition, and is phosphorylated at Tyr705 by JAK and Src.")
       (:PMID . "24922077") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In response to cytokines binding to their receptors on the cell surface, STAT3 is phosphorylated on Y705 by activated JAKs.")
       (:PMID . "24129709") (:SOURCE--API . "sparser"))
      ((:TEXT
        . "17 Latent STAT3 is recruited to the activated receptor via phosphotyrosine-SH2 recognition, and is phosphorylated at Tyr705 by JAK and Src.")
       (:PMID . "24922077") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "AG490, a JAK specific inhibitor, can significantly suppress STAT3 signaling by inhibiting the phosphorylation of Tyr705 of STAT3 [38].")
       (:PMID . "18592012") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1b_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Members of the JAK and Tyk family of tyrosine kinases mediate phosphorylation of STAT3 at Tyr705 during CNTF signaling; however, the kinase responsible for phosphorylation at STAT3 Tyr727 appears to depend on both the extracellular stimulus and the cellular context.")
       (:PMID . "10660304") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Conditioned medium of ADSC activated the downstream JAK1 and JAK2 and TYK2 that lead to their target STAT3 Tyr 705 phosphorylation in rnCM and HL-1 cardiomyocytes.")
       (:PMID . "23406316") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We found that phosphorylation of STAT3 at Y705, which is mediated by JAK kinases and is critical for its activation, is inhibited at 24h by ibrutinib and AZD2014, but not at earlier timepoints (Fig XREF_FIG).")
       (:PMID . "24970801") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In response to cytokine stimulation, STAT3 is phosphorylated on tyrosine 705 by the JAK2 and TYK2 kinase, resulting in its dissociation from the cytoplasmic tail of cytokine receptors and dimerization.")
       (:PMID . "23084476") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_2a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In response to cytokine stimulation, STAT3 is phosphorylated on tyrosine 705 by the JAK2 and TYK2 kinase, resulting in its dissociation from the cytoplasmic tail of cytokine receptors and dimerization.")
       (:PMID . "23084476") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:POSITION . "705")
     (:ENZ
      (:DB--REFS (:+TEXT+ . "TYK2") (:+UP+ . "P29597") (:+HGNC+ . "12440"))
      (:NAME . "TYK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "7ee73cba-dd58-45cd-93f3-9796b1467429"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "STAT5A") (:+UP+ . "P42229") (:+HGNC+ . "11366"))
      (:NAME . "STAT5A"))
     (:SUPPORTED--BY "90083100-66a7-43e0-bfaf-02db6a90f675")
     (:EVIDENCE
      ((:TEXT
        . "The Jak-1 and Tyk-2 phosphorylate the STAT proteins which either homo-or heterodimerizes and then translocates to the nucleus and then binds to a consensus DNA sequence called the interferon stimulated response element (ISRE).")
       (:PMID . "17877826") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_5_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "SOCS3 is able to block JAK phosphorylation of STAT and thereby inhibit further signaling XREF_BIBR; XREF_BIBR.")
       (:PMID . "24438103") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "STAT5a and STAT5b are subsequently phosphorylated by JAK kinases on tyrosine residues Y694 and Y699, respectively.")
       (:PMID . "15313458") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "The activated JAK molecules then phosphorylate multiple sites on the cytokine receptor that allow for STAT binding and phosphorylation by JAK (XREF_BIBR).")
       (:PMID . "19223541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The tyrosine kinase Tyk2, which mediates the phosphorylation of STAT5, was also responsible for the phosphorylation of VHR at Tyr (138).")
       (:PMID . "17785772") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:ENZ
      (:DB--REFS (:+TEXT+ . "Tyk-2") (:+UP+ . "P29597") (:+HGNC+ . "12440"))
      (:NAME . "TYK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "4d603d7f-7c7e-4815-a8b1-a42331ed2667"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+UP+ . "P42226") (:+HGNC+ . "11368"))
      (:NAME . "STAT6"))
     (:SUPPORTED--BY "9574247a-6bd0-4a4e-b0ca-fc7600bcde82"
      "16d95465-aa9b-4e02-99be-bbebbbbf7a40"
      "3bd8cbdf-e4aa-4d6d-8164-41f93270d10e"
      "32e81d43-dda6-46e6-b40d-b68b05e59267")
     (:EVIDENCE ((:SOURCE--API . "phosphosite"))) (:POSITION . "641")
     (:ENZ (:DB--REFS (:+UP+ . "P29597") (:+HGNC+ . "12440")) (:NAME . "TYK2"))
     (:TYPE . "Phosphorylation")
     (:ID . "e32807c4-d4c9-40db-a694-1ccb53b6e706"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "835d925f-d497-4cae-9a85-f7d707c159f8"
      "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:TEXT
        . "While the above experiments provided strong evidence that Yes kinase preferentially phosphorylates FAK Y861 relative to the other FAK tyrosine sites, these experiments could not exclude potential roles of other SFKs expressed in PCa cells.")
       (:PMID . "25868388") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_d817ff01365fe9e8b0e7a081472f6a50")
       (:SOURCE--API . "biopax")))
     (:POSITION . "861")
     (:ENZ (:DB--REFS (:+TEXT+ . "Yes") (:+UP+ . "P07947") (:+HGNC+ . "12841"))
      (:NAME . "YES1"))
     (:TYPE . "Phosphorylation")
     (:ID . "1b49598c-30df-44e5-80cd-f117d70fb9cc"))
    ((:RESIDUE . "Y")
     (:SUB (:DB--REFS (:+TEXT+ . "FAK") (:+UP+ . "Q05397") (:+HGNC+ . "9611"))
      (:NAME . "PTK2"))
     (:SUPPORTED--BY "240a18e3-2e6d-442b-961c-f20a82e11b49"
      "ca123c61-99a0-4c4c-8404-a847c1e6b074"
      "3b085760-047b-4de6-a358-6f53aa726e61")
     (:EVIDENCE
      ((:TEXT
        . "As Src is highly activated in these prostate cancer cell lines [XREF_BIBR], it may be that Src phosphorylation of FAK Y925 is sufficiently robust such that Yes can not further increase FAK Y925 phosphorylation; hence increased FAK Y925 phosphorylation was not observed in our selected cells.")
       (:PMID . "25868388") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_4_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:SOURCE--ID
        . "http://pathwaycommons.org/pc2/Catalysis_0ebc0e734c3eeaafdbcf8f9ea5bdb37c")
       (:SOURCE--API . "biopax"))
      ((:TEXT
        . "Then src phosphorylates FAK on tyrosine 925, which leads to the recruitment of Grb-2 (an adapter protein) and SOS (a regulator of ras-type GTPases) to the FAK signaling complex.")
       (:PMID . "20621036") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:POSITION . "925")
     (:ENZ (:DB--REFS (:+TEXT+ . "Yes") (:+UP+ . "P07947") (:+HGNC+ . "12841"))
      (:NAME . "YES1"))
     (:TYPE . "Phosphorylation")
     (:ID . "a441f269-02e9-4db7-95c2-c11631ab204f"))
    ((:SUB
      (:DB--REFS (:+TEXT+ . "Y357-YAP1") (:+UP+ . "P46937")
       (:+HGNC+ . "16262"))
      (:NAME . "YAP1"))
     (:SUPPORTED--BY "9f45cc54-8c1c-4abb-a11c-5f205594be93")
     (:EVIDENCE
      ((:TEXT
        . "Hahn and colleagues recently highlighted that, by using a YAP1 mutant for all LATS1 phosphorylation sites (5SA) including the inhibitory S127-YAP1 phosphorylation, while permissive, required additional phosphorylation of Y357-YAP1 by the SRC family kinase (SFK) YES to activate transcription [XREF_BIBR].")
       (:PMID . "26549256") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "We expressed two YAP1 mutants : YAP1 DeltaSH3bm, which disrupts the interaction of YES1 with YAP1 (XREF_BIBR; XREF_BIBR), and YAP Y357F, which prevents YES1 phosphorylation of YAP1 (XREF_BIBR).")
       (:PMID . "24954536") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, we concluded that both YES1 and SRC are able to phosphorylate YAP1 but only YES1 is essential for the survival of beta-catenin active cell lines.")
       (:PMID . "23245941") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Since the Wnt and beta-catenin pathway has been shown to be crucial for gut development in zebrafish (XREF_BIBR), we concluded that phosphorylation of YAP1 by YES1 is essential for developmental and malignant processes that are dependent on the function of beta-catenin.")
       (:PMID . "23245941") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Although both YES1 and SRC phosphorylated YAP1, suppression of SRC failed to inhibit the proliferation and AI growth of beta-catenin active cell lines (XREF_SUPPLEMENTARY).")
       (:PMID . "23245941") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_verb"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Since we recently reported a role for YES1 phosphorylation of YAP1 for beta-catenin signaling (XREF_BIBR), we investigated whether YES1 played a role in KRAS signaling.")
       (:PMID . "24954536") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "Phosphorylation_syntax_1a_noun"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:ENZ (:DB--REFS (:+TEXT+ . "YES") (:+UP+ . "P07947") (:+HGNC+ . "12841"))
      (:NAME . "YES1"))
     (:TYPE . "Phosphorylation")
     (:ID . "13b7f675-78c1-4c11-9fb4-1ba70a5c06a0"))
    ((:RAS (:DB--REFS (:+TEXT+ . "HRAS") (:+UP+ . "P01112") (:+HGNC+ . "5173"))
      (:NAME . "HRAS"))
     (:GAP (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "catalytic"))
      (:DB--REFS (:+UP+ . "Q5VWQ8") (:+HGNC+ . "17294")) (:NAME . "DAB2IP"))
     (:TYPE . "RasGap") (:ID . "2a22ffa2-8d26-49d6-8228-e7e4b2bc8610")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_DAB2IP_DirectlyDecreases_gtp_p_PFH_RAS_Family")
       (:TEXT
        . "After activating Ras using EGF The presence of EGF increased the reporter gene activity at least 5-fold. However, DIP1/2 could inhibit the reporter gene activity in a dose-dependent manner.")
       (:PMID . "10542228") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_DAB2IP_DirectlyDecreases_gtp_p_PFH_RAS_Family")
       (:TEXT
        . "hDAB2IP (human DAB2 (also known as DOC-2) interactive protein) is a novel GTPase-activating protein for modulating the Ras-mediated signal pathway")
       (:PMID . "12446720") (:SOURCE--API . "bel"))))
    ((:RAS (:DB--REFS (:+UP+ . "P01116") (:+HGNC+ . "6407")) (:NAME . "KRAS"))
     (:GAP (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "catalytic"))
      (:DB--REFS (:+UP+ . "Q5VWQ8") (:+HGNC+ . "17294")) (:NAME . "DAB2IP"))
     (:TYPE . "RasGap") (:ID . "261829a7-5aba-44b8-88bb-3c3616df047d")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_DAB2IP_DirectlyDecreases_gtp_p_HGNC_KRAS")
       (:TEXT
        . "hDAB2IP (human DAB2 (also known as DOC-2) interactive protein) is a novel GTPase-activating protein for modulating the Ras-mediated signal pathway")
       (:PMID . "12446720") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_DAB2IP_DirectlyDecreases_gtp_p_HGNC_KRAS")
       (:TEXT
        . "GST-DIP1/2 fusion protein containing the minimal Ras GAP domain (23), and either this fusion protein or GST protein was incubated with human recombinant [gamma -32P]GTP-bound Ha-Ras protein. The increasing amounts of GST-DIP1/2 (ranging from 0.2 to 1 Ã‚Âµg) stimulated Ras GTPase activity in a dose-dependent manner ")
       (:PMID . "11812785") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_DAB2IP_DirectlyDecreases_gtp_p_PFH_RAS_Family")
       (:TEXT
        . "After activating Ras using EGF The presence of EGF increased the reporter gene activity at least 5-fold. However, DIP1/2 could inhibit the reporter gene activity in a dose-dependent manner.")
       (:PMID . "10542228") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_DAB2IP_DirectlyDecreases_gtp_p_PFH_RAS_Family")
       (:TEXT
        . "hDAB2IP (human DAB2 (also known as DOC-2) interactive protein) is a novel GTPase-activating protein for modulating the Ras-mediated signal pathway")
       (:PMID . "12446720") (:SOURCE--API . "bel"))))
    ((:RAS (:DB--REFS (:+TEXT+ . "NRAS") (:+UP+ . "P01111") (:+HGNC+ . "7989"))
      (:NAME . "NRAS"))
     (:GAP (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "catalytic"))
      (:DB--REFS (:+UP+ . "Q5VWQ8") (:+HGNC+ . "17294")) (:NAME . "DAB2IP"))
     (:TYPE . "RasGap") (:ID . "fd2d5382-db1f-4cea-822a-d41bd9b78d18")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_DAB2IP_DirectlyDecreases_gtp_p_PFH_RAS_Family")
       (:TEXT
        . "After activating Ras using EGF The presence of EGF increased the reporter gene activity at least 5-fold. However, DIP1/2 could inhibit the reporter gene activity in a dose-dependent manner.")
       (:PMID . "10542228") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_DAB2IP_DirectlyDecreases_gtp_p_PFH_RAS_Family")
       (:TEXT
        . "hDAB2IP (human DAB2 (also known as DOC-2) interactive protein) is a novel GTPase-activating protein for modulating the Ras-mediated signal pathway")
       (:PMID . "12446720") (:SOURCE--API . "bel"))))
    ((:RAS (:DB--REFS (:+UP+ . "P01112") (:+HGNC+ . "5173")) (:NAME . "HRAS"))
     (:TYPE . "RasGef") (:ID . "08a20252-206d-4437-af03-8e6a85226725")
     (:GEF (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "catalytic"))
      (:DB--REFS (:+UP+ . "P21359") (:+HGNC+ . "7765")) (:NAME . "NF1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_NF1_DirectlyIncreases_gtp_p_HGNC_HRAS")
       (:TEXT
        . "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)")
       (:PMID . "17052212") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_NF1_DirectlyIncreases_gtp_p_PFH_RAS_Family")
       (:TEXT
        . "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)")
       (:PMID . "17052212") (:SOURCE--API . "bel"))))
    ((:RAS (:DB--REFS (:+TEXT+ . "HRAS") (:+UP+ . "P01112") (:+HGNC+ . "5173"))
      (:NAME . "HRAS"))
     (:TYPE . "RasGef") (:ID . "24653f68-b204-42c7-a7e4-2c84d206e1a4")
     (:GEF (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "catalytic"))
      (:DB--REFS (:+UP+ . "P20936") (:+HGNC+ . "9871")) (:NAME . "RASA1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_RASA1_DirectlyIncreases_gtp_p_PFH_RAS_Family")
       (:TEXT
        . "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)")
       (:PMID . "17052212") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_RASA1_DirectlyIncreases_gtp_p_HGNC_HRAS")
       (:TEXT
        . "Thus, while p120 and NF1 (neurofibromatosis-related protein 1) are clearly Ras-specific and do not enhance the catalytic activity of Rap, RASA1 (p120-RASGAP)")
       (:PMID . "17052212") (:SOURCE--API . "bel"))))
    ((:RAS (:DB--REFS (:+UP+ . "P01112") (:+HGNC+ . "5173")) (:NAME . "HRAS"))
     (:TYPE . "RasGef") (:ID . "2a49589d-d045-4266-b0f5-873b03f35398")
     (:GEF (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "catalytic"))
      (:DB--REFS (:+UP+ . "Q07889") (:+HGNC+ . "11187")) (:NAME . "SOS1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_SOS1_DirectlyIncreases_gtp_p_HGNC_HRAS")
       (:TEXT . "Fig.1") (:PMID . "15567848") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_SOS1_DirectlyIncreases_gtp_p_HGNC_HRAS")
       (:TEXT . "Figure 1 | The ErbB signalling network.") (:PMID . "11252954")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_SOS1_DirectlyIncreases_gtp_p_HGNC_HRAS")
       (:TEXT
        . "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways.")
       (:PMID . "17486115") (:SOURCE--API . "bel"))))
    ((:RAS (:DB--REFS (:+UP+ . "P01116") (:+HGNC+ . "6407")) (:NAME . "KRAS"))
     (:TYPE . "RasGef") (:ID . "c7bf675e-bc4b-486e-adba-7e91e0b0c45f")
     (:GEF (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "catalytic"))
      (:DB--REFS (:+UP+ . "Q07889") (:+HGNC+ . "11187")) (:NAME . "SOS1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_SOS1_DirectlyIncreases_gtp_p_HGNC_KRAS")
       (:TEXT . "Figure 1 | The ErbB signalling network.") (:PMID . "11252954")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_SOS1_DirectlyIncreases_gtp_p_HGNC_KRAS")
       (:TEXT . "Fig.1") (:PMID . "15567848") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_SOS1_DirectlyIncreases_gtp_p_HGNC_KRAS")
       (:TEXT
        . "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways.")
       (:PMID . "17486115") (:SOURCE--API . "bel"))))
    ((:SUPPORTED--BY "1fb08603-93d2-4d09-a731-db5bc38d535b")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_SOS1_DirectlyIncreases_gtp_p_HGNC_NRAS")
       (:TEXT . "Figure 1 | The ErbB signalling network.") (:PMID . "11252954")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_SOS1_DirectlyIncreases_gtp_p_HGNC_NRAS")
       (:TEXT . "Fig.1") (:PMID . "15567848") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_SOS1_DirectlyIncreases_gtp_p_HGNC_NRAS")
       (:TEXT
        . "The activation of Ras by the guanine nucleotide-exchange factor Son of sevenless (Sos) constitutes the rate-limiting step in the transduction process that links receptor tyrosine kinases to Ras-triggered intracellular signalling pathways.")
       (:PMID . "17486115") (:SOURCE--API . "bel")))
     (:RAS (:DB--REFS (:+UP+ . "P01111") (:+HGNC+ . "7989")) (:NAME . "NRAS"))
     (:TYPE . "RasGef") (:ID . "e1074457-a4f9-4bb5-bd46-f4f719613dd3")
     (:GEF (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "catalytic"))
      (:DB--REFS (:+UP+ . "Q07889") (:+HGNC+ . "11187")) (:NAME . "SOS1")))
    ((:RAS (:DB--REFS (:+UP+ . "P63000") (:+HGNC+ . "9801")) (:NAME . "RAC1"))
     (:TYPE . "RasGef") (:ID . "fe2da496-707e-4b43-9aef-42e30e5143d5")
     (:GEF (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "catalytic"))
      (:DB--REFS (:+UP+ . "Q13009") (:+HGNC+ . "11805")) (:NAME . "TIAM1"))
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_TIAM1_DirectlyIncreases_gtp_p_HGNC_RAC1")
       (:TEXT
        . "Tiam1 and Ras-GRF1 are guanine nucleotide exchange factors (GEFs) that activate the Rac GTPase.")
       (:PMID . "12024021") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/cat_p_HGNC_TIAM1_DirectlyIncreases_gtp_p_HGNC_RAC1")
       (:TEXT
        . "Tiam1 and Ras-GRF1 are guanine nucleotide exchange factors (GEFs) that activate the Rac GTPase.")
       (:PMID . "12024021") (:SOURCE--API . "bel"))))
    ((:OBJ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "RasGtpActivation") (:OBJ--ACTIVITY . "kinase")
     (:SUPPORTED--BY "a5fc4cdc-ed40-481d-9286-e0dd7ee79eb6")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_HRAS_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT
        . "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.")
       (:PMID . "16803888") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_HRAS_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "Figure 1 | The ErbB signalling network.") (:PMID . "11252954")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_HRAS_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT
        . "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.")
       (:PMID . "16803888") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_HRAS_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT
        . "In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.")
       (:PMID . "16803888") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_HRAS_DirectlyIncreases_kin_p_PFH_RAF_Family")
       (:TEXT
        . "As shown in Figure 3, Raf kinases are activated by Ras, other small GTPase regulatory proteins, and scaffolding proteins, and the magnitude and quality of downstream signaling are dependent on the integration of activating events and protein interactions.")
       (:PMID . "16170185") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_HRAS_DirectlyIncreases_kin_p_PFH_RAF_Family")
       (:TEXT . "Figure 1 | The ErbB signalling network.") (:PMID . "11252954")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_HRAS_DirectlyIncreases_kin_p_PFH_RAF_Family")
       (:TEXT . "Fig.1") (:PMID . "15567848") (:SOURCE--API . "bel")))
     (:SUBJ (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "gtpbound"))
      (:DB--REFS (:+UP+ . "P01112") (:+HGNC+ . "5173")) (:NAME . "HRAS"))
     (:ID . "3fe28607-4c99-4255-8d17-396c0ef6be34"))
    ((:OBJ (:DB--REFS (:+UP+ . "Q13009") (:+HGNC+ . "11805"))
      (:NAME . "TIAM1"))
     (:TYPE . "RasGtpActivation") (:OBJ--ACTIVITY . "catalytic")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_PFH_RAS_Family_DirectlyIncreases_cat_p_HGNC_TIAM1")
       (:TEXT
        . "Here we demonstrate that Tiam1, a Rac-specific GEF, preferentially associates with activated GTP-bound Ras through a Ras-binding domain. Furthermore, activated Ras and Tiam1 cooperate to cause synergistic formation of Rac-GTP in a PI(3)K-independent manner. Thus, Tiam1 can function as an effector that directly mediates Ras activation of Rac.")
       (:PMID . "12134164") (:SOURCE--API . "bel")))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "HRAS") (:+UP+ . "P01112") (:+HGNC+ . "5173"))
      (:NAME . "HRAS"))
     (:ID . "16f57b17-d277-41be-b682-3e12f9190cb7"))
    ((:OBJ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "RasGtpActivation") (:OBJ--ACTIVITY . "kinase")
     (:SUPPORTED--BY "cf89b9f2-81fb-45cc-abb4-af3942261721")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_KRAS_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "Figure 1 | The ErbB signalling network.") (:PMID . "11252954")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_KRAS_DirectlyIncreases_kin_p_PFH_RAF_Family")
       (:TEXT . "Figure 1 | The ErbB signalling network.") (:PMID . "11252954")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_HGNC_KRAS_DirectlyIncreases_kin_p_PFH_RAF_Family")
       (:TEXT
        . "As shown in Figure 3, Raf kinases are activated by Ras, other small GTPase regulatory proteins, and scaffolding proteins, and the magnitude and quality of downstream signaling are dependent on the integration of activating events and protein interactions.")
       (:PMID . "16170185") (:SOURCE--API . "bel")))
     (:SUBJ (:ACTIVATION (:IS--ACTIVE . T) (:ACTIVITY--TYPE . "gtpbound"))
      (:DB--REFS (:+UP+ . "P01116") (:+HGNC+ . "6407")) (:NAME . "KRAS"))
     (:ID . "cd0fe138-4985-4975-b7cd-4137a18d2c32"))
    ((:OBJ (:DB--REFS (:+UP+ . "P15056") (:+HGNC+ . "1097")) (:NAME . "BRAF"))
     (:TYPE . "RasGtpActivation") (:OBJ--ACTIVITY . "kinase")
     (:EVIDENCE
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_PFH_RAS_Family_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT . "Figure 1 | The ErbB signalling network.") (:PMID . "11252954")
       (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_PFH_RAS_Family_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT
        . "Protein kinase A-dependent phosphorylation of serine 43 within the regulatory domain of Raf-1 reciprocally potentiates its interaction with Rheb and decreases its interaction with H-Ras.")
       (:PMID . "9001246") (:SOURCE--API . "bel"))
      ((:SOURCE--ID
        . "http://www.openbel.org/bel/gtp_p_PFH_RAS_Family_DirectlyIncreases_kin_p_HGNC_BRAF")
       (:TEXT
        . "Protein kinase A-dependent phosphorylation of serine 43 within the regulatory domain of Raf-1 reciprocally potentiates its interaction with Rheb and decreases its interaction with H-Ras.")
       (:PMID . "9001246") (:SOURCE--API . "bel")))
     (:SUBJ
      (:DB--REFS (:+TEXT+ . "NRAS") (:+UP+ . "P01111") (:+HGNC+ . "7989"))
      (:NAME . "NRAS"))
     (:ID . "6f5e9d38-dd09-42e1-8fe9-20589a44b682"))
    ((:TO--LOCATION . "membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "AKT1") (:+UP+ . "P31749") (:+HGNC+ . "391"))
      (:NAME . "AKT1"))
     (:EVIDENCE
      ((:TEXT
        . "PI3K activation, mainly by growth factors, results in the accumulation of PIP3 in cellular membranes (Kapeller and Cantley) resulting in the translocation of AKT from cytoplasmic stores to cellular membranes.")
       (:PMID . "11875759") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Following PIP3 production by PI3Kinase activation, PIP3 recruits Akt and PDK to membranes, leading to Akt phosphorylation and activation by PDK.")
       (:PMID . "26470790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Akt is recruited to the membrane via interactions with PIP 3 and is activated by phosphorylation.")
       (:PMID . "21325624") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Upon stimulation with insulin, AKT is recruited to cellular membranes by binding of its amino terminal pleckstrin (PH) domain to membrane bound phosphatidylinositol 3,4,5, trisphosphate (PIP).")
       (:PMID . "15890450") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10469"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activated PI3K phosphorylates phosphoinositide 3,4 bisphosphate (PIP 2) to phosphoinositide 3,4,5 trisphosphate (PIP 3), which recruits the serine/threonine kinase Akt to the membrane where it is phosphorylated and activated.")
       (:PMID . "21372221") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:CELL--LINE "cellosaurus:CVCL_7955") (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PTEN antagonizes the PI3K and AKT pathway by dephosphorylating PIP3, resulting in a decreased translocation of AKT to cellular membranes and subsequent down-regulation of AKT activation.")
       (:PMID . "11875759") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Here, we show that the translocation of GTP-Rac to membranes is independent of effector interactions, but instead requires the polybasic sequence near the carboxyl terminus.")
       (:PMID . "11862216") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause") (:SPECIES))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PTEN antagonizes PI3K function by dephosphorylating phosphatidylinositol 3,4,5-triphosphate [PtdIns (3,5,5) P, PIP3], resulting in decreased translocation of Akt to cellular membranes and subsequent down-regulation of Akt activation, which is involved in a positive manner in signaling pathways that promote cell growth, apoptosis, proliferation, differentiation, motility, and cytoskeletal organization.")
       (:PMID . "19010541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PIP3 is a key regulator of the PI3K and Akt signaling pathway : it recruits Akt to the membrane surface, an event critical for Akt activation.")
       (:PMID . "22479427") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUPPORTED--BY "b8feb497-d14e-4638-afe5-730812d897cf")
     (:TYPE . "Translocation") (:ID . "5dd63794-ab3e-4a8a-963c-886354628db1"))
    ((:TO--LOCATION . "membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "AKT2") (:+UP+ . "P31751") (:+HGNC+ . "392"))
      (:NAME . "AKT2"))
     (:EVIDENCE
      ((:TEXT
        . "PI3K activation, mainly by growth factors, results in the accumulation of PIP3 in cellular membranes (Kapeller and Cantley) resulting in the translocation of AKT from cytoplasmic stores to cellular membranes.")
       (:PMID . "11875759") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PTEN antagonizes the PI3K and AKT pathway by dephosphorylating PIP3, resulting in a decreased translocation of AKT to cellular membranes and subsequent down-regulation of AKT activation.")
       (:PMID . "11875759") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Following PIP3 production by PI3Kinase activation, PIP3 recruits Akt and PDK to membranes, leading to Akt phosphorylation and activation by PDK.")
       (:PMID . "26470790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activated PI3K phosphorylates phosphoinositide 3,4 bisphosphate (PIP 2) to phosphoinositide 3,4,5 trisphosphate (PIP 3), which recruits the serine/threonine kinase Akt to the membrane where it is phosphorylated and activated.")
       (:PMID . "21372221") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:CELL--LINE "cellosaurus:CVCL_7955") (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt is recruited to the membrane via interactions with PIP 3 and is activated by phosphorylation.")
       (:PMID . "21325624") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Upon stimulation with insulin, AKT is recruited to cellular membranes by binding of its amino terminal pleckstrin (PH) domain to membrane bound phosphatidylinositol 3,4,5, trisphosphate (PIP).")
       (:PMID . "15890450") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10469"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PIP3 is a key regulator of the PI3K and Akt signaling pathway : it recruits Akt to the membrane surface, an event critical for Akt activation.")
       (:PMID . "22479427") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "PTEN antagonizes PI3K function by dephosphorylating phosphatidylinositol 3,4,5-triphosphate [PtdIns (3,5,5) P, PIP3], resulting in decreased translocation of Akt to cellular membranes and subsequent down-regulation of Akt activation, which is involved in a positive manner in signaling pathways that promote cell growth, apoptosis, proliferation, differentiation, motility, and cytoskeletal organization.")
       (:PMID . "19010541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUPPORTED--BY "0242abe8-bea5-424f-af62-4569ba8559dd")
     (:TYPE . "Translocation") (:ID . "6429758e-c1b8-46a8-aeb1-03c9d6165b98"))
    ((:TO--LOCATION . "membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "AKT3") (:+UP+ . "Q9Y243") (:+HGNC+ . "393"))
      (:NAME . "AKT3"))
     (:EVIDENCE
      ((:TEXT
        . "PI3K activation, mainly by growth factors, results in the accumulation of PIP3 in cellular membranes (Kapeller and Cantley) resulting in the translocation of AKT from cytoplasmic stores to cellular membranes.")
       (:PMID . "11875759") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PTEN antagonizes the PI3K and AKT pathway by dephosphorylating PIP3, resulting in a decreased translocation of AKT to cellular membranes and subsequent down-regulation of AKT activation.")
       (:PMID . "11875759") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PTEN antagonizes PI3K function by dephosphorylating phosphatidylinositol 3,4,5-triphosphate [PtdIns (3,5,5) P, PIP3], resulting in decreased translocation of Akt to cellular membranes and subsequent down-regulation of Akt activation, which is involved in a positive manner in signaling pathways that promote cell growth, apoptosis, proliferation, differentiation, motility, and cytoskeletal organization.")
       (:PMID . "19010541") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PIP3 is a key regulator of the PI3K and Akt signaling pathway : it recruits Akt to the membrane surface, an event critical for Akt activation.")
       (:PMID . "22479427") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Upon stimulation with insulin, AKT is recruited to cellular membranes by binding of its amino terminal pleckstrin (PH) domain to membrane bound phosphatidylinositol 3,4,5, trisphosphate (PIP).")
       (:PMID . "15890450") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10469"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activated PI3K phosphorylates phosphoinositide 3,4 bisphosphate (PIP 2) to phosphoinositide 3,4,5 trisphosphate (PIP 3), which recruits the serine/threonine kinase Akt to the membrane where it is phosphorylated and activated.")
       (:PMID . "21372221") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:CELL--LINE "cellosaurus:CVCL_7955") (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Akt is recruited to the membrane via interactions with PIP 3 and is activated by phosphorylation.")
       (:PMID . "21325624") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Following PIP3 production by PI3Kinase activation, PIP3 recruits Akt and PDK to membranes, leading to Akt phosphorylation and activation by PDK.")
       (:PMID . "26470790") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUPPORTED--BY "dce038cb-f5ea-454d-bbf8-5ee1893bd667")
     (:TYPE . "Translocation") (:ID . "32e5800b-7cd2-4be6-8e19-576dc6b14cd5"))
    ((:TO--LOCATION . "membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "ARAF") (:+UP+ . "P10398") (:+HGNC+ . "646"))
      (:NAME . "ARAF"))
     (:EVIDENCE
      ((:TEXT
        . "Active RAS recruits RAF to the membrane for activation through a complex process involving changes in phosphorylation and binding to other enzymes and scaffold proteins (XREF_BIBR).")
       (:PMID . "20141835") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "When Raf is recruited to the membrane, it colocalized with the membrane pool of TAP-1 (XREF_FIG).")
       (:PMID . "20230813") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:6239"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "TAP-1 regulated the recruitment of Raf to membrane bound Ras.")
       (:PMID . "20230813") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:6239"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the classical model of Raf activation, Raf translocates to the membrane where it binds RAS and subsequently phosphorylates MEK1/2 starting thus the cellular response to the extracellular ligands.")
       (:PMID . "19298812") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE "uaz:UA-CLine-100047")
        (:TISSUE) (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the classical model of Raf activation, Raf translocates to the membrane where it binds RAS and subsequently phosphorylates MEK1/2 starting thus the cellular response to the extracellular ligands.")
       (:PMID . "19298812") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUPPORTED--BY "2f5bdc12-2a4c-458e-b6c1-1bf2af1f3e2d")
     (:TYPE . "Translocation") (:ID . "bd54ea33-76b4-459f-9c52-8f345a1136c8"))
    ((:TO--LOCATION . "membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:EVIDENCE
      ((:TEXT
        . "Active RAS recruits RAF to the membrane for activation through a complex process involving changes in phosphorylation and binding to other enzymes and scaffold proteins (XREF_BIBR).")
       (:PMID . "20141835") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In the classical model of Raf activation, Raf translocates to the membrane where it binds RAS and subsequently phosphorylates MEK1/2 starting thus the cellular response to the extracellular ligands.")
       (:PMID . "19298812") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE "uaz:UA-CLine-100047")
        (:TISSUE) (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "When Raf is recruited to the membrane, it colocalized with the membrane pool of TAP-1 (XREF_FIG).")
       (:PMID . "20230813") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:6239"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "TAP-1 regulated the recruitment of Raf to membrane bound Ras.")
       (:PMID . "20230813") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:6239"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the classical model of Raf activation, Raf translocates to the membrane where it binds RAS and subsequently phosphorylates MEK1/2 starting thus the cellular response to the extracellular ligands.")
       (:PMID . "19298812") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUPPORTED--BY "9cccd8f9-db3a-4539-b6d9-cbdd8d986609")
     (:TYPE . "Translocation") (:ID . "170e8806-4359-46d1-a141-d7ac09b0a992"))
    ((:TO--LOCATION . "plasma membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "BRAF") (:+UP+ . "P15056") (:+HGNC+ . "1097"))
      (:NAME . "BRAF"))
     (:EVIDENCE
      ((:TEXT
        . "This interaction promotes both Raf translocation to the plasma membrane and activation of Raf kinase activity.")
       (:PMID . "7730360") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:8355"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Activated Ras translocates Raf to the plasma membrane where association with membrane lipids and 14-3-3 proteins mediate Raf phosphorylation and activation ().")
       (:PMID . "17126402") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In its simplest form, RAS recruits cytosolic RAF to the plasma membrane for activation, with one of the essential steps being the phosphorylation of two amino acids (T598 and S601 of B-RAF; see Note at the end of the main text for amino acid numbering used in this review) within the activation segment of the kinase domain.")
       (:PMID . "15488754") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Because B-Raf is recruited to the plasma membrane, we investigated the possibility that GFP-CC-SAM localized to the plasma membrane by binding B-Raf.")
       (:PMID . "23250398") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:CELL--LINE "cellosaurus:CVCL_E012") (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Upon activation, RAS binding to the RAS binding domain (RBD) of RAF recruits RAF to the plasma membrane, where other activating events take place.")
       (:PMID . "24211266") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005829")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Stimulation of this pathway is typically initiated by receptor mediated activation of the small G protein Ras, which binds to and recruits the serine/threonine kinase Raf to the plasma membrane, where Raf becomes fully activated.")
       (:PMID . "15979847") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:4932"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The initiating event in Raf activation is believed to be Ras binding to the Ras binding domain (RBD) of Raf in the N-terminal regulatory region that recruits Raf to the plasma membrane, where other activating events take place.Shoc2/Sur-8 codes for a protein comprised almost entirely of leucine rich repeats.")
       (:PMID . "16630891") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005829")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The recruitment of Raf to the plasma membrane by GTP bound Ras leads to stimulation of Raf kinase activity through an undefined mechanism.")
       (:PMID . "10461188") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:4932"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Recently, we demonstrated that CNK is required for insulin induced Ras mediated activation of Raf, MEK, and ERK in S2 cells and that CNK is at least partly responsible for recruiting Raf to the plasma membrane enriched fraction of these cells.")
       (:PMID . "15028221") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUPPORTED--BY "9cccd8f9-db3a-4539-b6d9-cbdd8d986609")
     (:TYPE . "Translocation") (:ID . "390865d8-358b-4c72-8123-9bd7081a375a"))
    ((:TO--LOCATION . "cytoplasm") (:TYPE . "Translocation")
     (:ID . "a9651740-7fda-4a94-9dda-7392864c17a3")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "Cdc6-wt") (:+UP+ . "Q99741") (:+HGNC+ . "1744"))
      (:NAME . "CDC6"))
     (:EVIDENCE
      ((:TEXT
        . "Cdc6-wt was translocated to the cytoplasm when cyclin A was coexpressed, whereas Cdc6-AAA was not even if cyclin A was coexpressed (XREF_FIG).")
       (:PMID . "16801388") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005737")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, endogenous Cdc6 may undergo the same fate during extraction as Cdc6-YFP and may be exported to the cytoplasm as well in unperturbed S-phase cells.")
       (:PMID . "25875233") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0031965")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Also, non-chromatin-bound Cdc6 is exported to the cytoplasm in S phase.")
       (:PMID . "25498505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005813")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "After Cdc6 participates in pre-RC formation in the nucleus during G1 phase, non-chromatin-bound Cdc6 translocates to the cytoplasm at the G1/S-phase transition.")
       (:PMID . "25498505") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN "uberon:UBERON:0002488")
        (:CELL--LINE) (:TISSUE) (:LOCATION "go:GO:0005737")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "CDC6, a replication licensing protein, is partially exported to the cytoplasm in human cells through phosphorylation by Cdk during S phase, but a significant proportion remains in the nucleus.")
       (:PMID . "20048340") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_3b_verb_passive"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "HsCdc6 is nuclear in G1, but translocates to the cytoplasm at the start of S phase via Crm1 dependent export.")
       (:PMID . "10339564") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005737")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))))
    ((:TO--LOCATION . "cytoplasm") (:FROM--LOCATION . "nucleus")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "p27") (:+UP+ . "P46527") (:+HGNC+ . "1785"))
      (:NAME . "CDKN1B"))
     (:EVIDENCE
      ((:TEXT
        . "In particular, the kinase that phosphorylates p27 on Ser 10 and the additional factor (s) necessary for the translocation of p27 from the nucleus to the cytoplasm have not yet been identified.")
       (:PMID . "12507555") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005737")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "For normal cell cycle progression induced by mitogens, translocation of p27 from the nucleus to the cytoplasm in G0/early G1 is necessary.")
       (:PMID . "23707388") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "p27 interacts with Jab1 and CSN5 and is translocated from the nucleus to the cytoplasm by Jab1 and CSN5, and Siah1 E3 ligase is involved in cytoplasmic p27 degradation.")
       (:PMID . "24949832") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_3a_verb_passive"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Jab1 can accelerate the degradation of p27 by translocating p27 from nucleus to cytoplasm where degradation occur (XREF_BIBR).")
       (:PMID . "20890423") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2a_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Overexpression of p38 in mammalian cells results in the translocation of p27 from the nucleus to the cytoplasm, causing a decrease in the amount of p27 in the cell by accelerating its degradation through the ubiquitin and proteasome pathway.")
       (:PMID . "19493606") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "When cells are stimulated by appropriate signals, p27 becomes phosphorylated on serine 10 (Ser10) and translocates from the nucleus to the cytoplasm.")
       (:PMID . "20837141") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_8a_verb_active_no_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "jab1 plays a role in transporting p27 from the nucleus to the cytoplasm, by which p27 can be degraded.")
       (:PMID . "12860294") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_2a_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Endogenous p27 is rapidly exported from the nucleus to the cytoplasm in response to mitogen stimulation, where it binds GRB2 concomitant with a decrease in GRB2 associated SOS.")
       (:PMID . "12748278") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_3a_verb_passive")
        (:SPECIES "taxonomy:4932"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, p27 (Kip1) is exported from the nucleus to the cytoplasm at G0-G1 (refs 9-11).")
       (:PMID . "15531880") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_3a_verb_passive") (:SPECIES))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUPPORTED--BY "9a9efbb2-49e3-4981-8b6e-1da127d09bf7"
      "c1269efd-e2d0-411e-af5d-34291417c196")
     (:TYPE . "Translocation") (:ID . "7be64222-94e5-4876-aea5-4604cef5caa7"))
    ((:FROM--LOCATION . "cytoplasm")
     (:AGENT (:DB--REFS (:+TEXT+ . "ER") (:+UP+ . "P03372") (:+HGNC+ . "3467"))
      (:NAME . "ESR1"))
     (:EVIDENCE
      ((:TEXT
        . "Palmitoylation promotes the physical interaction of ER with the caveolin-1 protein (XREF_BIBR), and caveolin-1 transports ER from cytoplasm to caveolae rafts in the PM (XREF_BIBR).")
       (:PMID . "22031296") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2a_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUPPORTED--BY "2fe7af93-7179-499f-93ce-01ef550d80f4")
     (:TYPE . "Translocation") (:ID . "dbdf2c24-2bac-44d7-9fab-14629ee37f57"))
    ((:TO--LOCATION . "cytosol")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "FOXO-3") (:+NCIT+ . "C52907") (:+UP+ . "O43524")
       (:+HGNC+ . "3821"))
      (:NAME . "FOXO3"))
     (:EVIDENCE
      ((:TEXT
        . "FOXO3 translocated from the nucleus to the cytosol during the first 30 min of TNFalpha treatment (XREF_FIG).")
       (:PMID . "19636295") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE))))
     (:SUPPORTED--BY "52f7bd88-312c-4b53-b8d5-e9a4c24f1ce8")
     (:TYPE . "Translocation") (:ID . "995b9947-0432-4027-8ea1-5b35c72e451a"))
    ((:TO--LOCATION . "nucleus") (:TYPE . "Translocation")
     (:ID . "5e3fbf89-8f50-41ec-9892-4ef287a35324")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "IRS-1") (:+UP+ . "P35568") (:+HGNC+ . "6125"))
      (:NAME . "IRS1"))
     (:EVIDENCE
      ((:TEXT
        . "In JCV T-antigen positive cells however, IRS-1 translocates to the nucleus, where it has been found in a complex with Rad51 (XREF_BIBR, XREF_BIBR).")
       (:PMID . "19117011") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Here we show that IRS-1 is translocated to the nucleus in the presence of the early viral protein-T-antigen of the human polyomavirus JC.")
       (:PMID . "11877394") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Previously, we demonstrated that a fraction of IRS-1 binds ERalpha, translocates to the nucleus, and modulates ERalpha dependent transcription at estrogen response elements (ERE).")
       (:PMID . "17591841") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "Although the mechanism by which IRS-1 is translocated to the nucleus is not well established, it could utilize its own putative nuclear localization signal (XREF_BIBR).")
       (:PMID . "19117011") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:0000062") (:ORGAN) (:CELL--LINE)
        (:TISSUE) (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10633"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In JCV T-antigen positive cells however, IRS-1 translocates to the nucleus, where it has been found in a complex with Rad51 (XREF_BIBR, XREF_BIBR).")
       (:PMID . "19117011") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The situation is quite different when IRS-1 is translocated to the nucleus by ERbeta.")
       (:PMID . "19117011") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_3b_verb_passive"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "In addition, when IRS-1 is translocated to the nucleus (see below), its action is PI3-K-independent.")
       (:PMID . "18851963") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen.")
       (:PMID . "11877394") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))))
    ((:TO--LOCATION . "nucleus") (:FROM--LOCATION . "cytoplasm")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "NFKB1") (:+UP+ . "P19838") (:+HGNC+ . "7794"))
      (:NAME . "NFKB1"))
     (:EVIDENCE
      ((:TEXT
        . "TGF-beta results in NF-kappaB translocation from cytoplasm to nucleus as demonstrated by p65 Western blot analysis of nuclear extracts of treated FET-1 cells.")
       (:PMID . "16288847") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Moreover, in Prx1 knockdown cells, NF-kappaB translocation from cytoplasm to nucleus was decreased compared with control cells (XREF_FIG, lower panel).")
       (:PMID . "25162226") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:CELL--LINE "cellosaurus:CVCL_1681") (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Time dependent NFkappaB translocation from the cytoplasm to the nucleus was next assessed as a reflection of activation of the canonical NFkappaB pathway.")
       (:PMID . "26272519") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005634")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Upon its activation, NF-kappaB translocates from the cytoplasm to the nucleus where its p65 subunit is acetylated by the histone acetyltransferase CREB binding protein (CBP)/p300 at lysine 310 (K310).")
       (:PMID . "18342601") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:0000084") (:ORGAN) (:CELL--LINE)
        (:TISSUE) (:LOCATION "go:GO:0019015")
        (:FOUND--BY . "translocation_8a_verb_active_no_cause")
        (:SPECIES "taxonomy:12721"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In this condition, we showed that Ebp1 is upregulated, translocated from the cytoplasm to the nucleus and binds to the podoplanin promoter to result in a dramatic increase of podoplanin mRNA and protein.")
       (:PMID . "23975429") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005737")
        (:FOUND--BY . "translocation_3a_verb_passive")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We demonstrated here that LPS induced NF-kappaB translocation from the cytoplasm to the nucleus was significantly reduced in UFH pretreated cells in different concentrations, especially in 1U/ml ().")
       (:PMID . "25023776") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_4a_noun_with_cause"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Under inflammatory stimuli, activated NF-kappaB translocates from the cytoplasm to the nucleus, binds to its consensus sequences in the promoter and initiates the transcription of target genes.")
       (:PMID . "20617556") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:0000359") (:ORGAN) (:CELL--LINE)
        (:TISSUE) (:LOCATION "go:GO:0005737")
        (:FOUND--BY . "translocation_8a_verb_active_no_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In response to specific stimuli, the translocation of NF-kappaB (p65) from the cytoplasm to the nucleus requires dynamic alterations of the actin cytoskeleton.")
       (:PMID . "26450610") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN "uberon:UBERON:0003003")
        (:CELL--LINE) (:TISSUE) (:LOCATION "go:GO:0015629")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:10116"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "We demonstrated that there is increased phosphorylation of IkappaBalpha along with significant translocation of p50 from the cytoplasm to the nucleus that is dependent upon gp120.")
       (:PMID . "21712995") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:0000127") (:ORGAN) (:CELL--LINE)
        (:TISSUE) (:LOCATION "go:GO:0005737")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "gp120 translocated NF-kappaB1 from cytoplasm to nucleus in astrocyte cells.")
       (:PMID . "21712995") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2a_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUPPORTED--BY "27b012fe-f055-451a-a5f4-bb21ff74912b"
      "413a5a06-bedd-4e2a-9da1-b2f16ea4d4ce")
     (:TYPE . "Translocation") (:ID . "9a4e4bc1-7e57-4512-91f3-4320651bb7b8"))
    ((:TO--LOCATION . "membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "PAK1") (:+UP+ . "Q13153") (:+HGNC+ . "8590"))
      (:NAME . "PAK1"))
     (:EVIDENCE
      ((:TEXT
        . "The same region in PAK has been shown to interact with the adapter protein Nck that recruits PAK to the cytoplasmic membrane if both proteins are co-expressed.")
       (:PMID . "17543336") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:4932"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "CK2alpha, CKIP-1, and PAK1 are translocated to membrane ruffles in response to the epidermal growth factor (EGF), where CKIP-1 mediates the interaction between CK2alpha and PAK1 in a PI3K dependent manner.")
       (:PMID . "26160174") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_3b_verb_passive") (:SPECIES))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The adapter protein Nck binds to the first proline rich region (PxxP motif) of PAK through its Src homologue region 3 (SH3 domain) and recruits PAK to membrane located receptor tyrosine kinases.")
       (:PMID . "17543336") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T))))
     (:SUPPORTED--BY "b2736bcb-e28e-4fa0-af72-eddc48b7a29d")
     (:TYPE . "Translocation") (:ID . "68616867-a43f-4e8c-9f6d-12f5620c4710"))
    ((:TYPE . "Translocation") (:ID . "d5f84141-7507-4d86-bc3b-491efb134489")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "PDK1") (:+UP+ . "O15530") (:+HGNC+ . "8816"))
      (:NAME . "PDPK1"))
     (:EVIDENCE
      ((:TEXT
        . "PDK1 is recruited to cell membranes upon PI3K activation, where it phosphorylates and activates Akt, the major mediator of the PI3K signaling pathway (XREF_BIBR).")
       (:PMID . "21708979") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "uniprot:SL-0039")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PIP 3 recruits PDK1 (protein dependent kinase 1) to the cell membrane where it binds and phosphorylates Akt at amino acid residue T308.")
       (:PMID . "22110663") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The Pleckstrin-homology (PH) domain containing kinase PDK1 is also recruited to cell membranes in response to PI3K activation, and is independently required for PI3K mediated transformation in several systems (XREF_BIBR; XREF_BIBR; XREF_BIBR).")
       (:PMID . "19573809") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:CELL--LINE "cellosaurus:CVCL_0105") (:TISSUE)
        (:LOCATION "uniprot:SL-0039")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PIP3 recruits Akt and PDK1 (3-phosphoinositide-dependent kinase 1) to the cell membrane, where Akt is phosphorylated at Thr308 of catalytic domain by PDK1 and subsequently at Ser473 of carboxyl hydrophobic domain by a kinase currently known as mTORC2.")
       (:PMID . "21767636") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))))
    ((:TO--LOCATION . "plasma membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "PKC-theta") (:+UP+ . "Q04759") (:+HGNC+ . "9410"))
      (:NAME . "PRKCQ"))
     (:EVIDENCE
      ((:TEXT
        . "We demonstrate that PKC-theta is recruited to the plasma membrane in the disulfide linked form in naive T cells, and that activation of PKC-theta is redox dependent and requires de novo synthesis of glutathione.")
       (:PMID . "23436678") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:0000084") (:ORGAN) (:CELL--LINE)
        (:TISSUE) (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In T lymphocytes, PDK-1 recruits PKC theta and various adaptor proteins to the plasma membrane that assemble to promote NF-kappaB activation.")
       (:PMID . "17826953") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The importance of the V3 domain in targeting PKC-theta to CD28 and the IS is not inconsistent with the established importance of the C1 domain in recruiting PKC-theta to the plasma membrane or IS.")
       (:PMID . "21964608") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:CELL--LINE "cellosaurus:CVCL_E031") (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "This is the first study that shows that the activity of PKC-theta is regulated by the intracellular redox state, and that PKC-theta is recruited to the plasma membrane in an inactive form in naive T cells.")
       (:PMID . "23436678") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:0000898") (:ORGAN) (:CELL--LINE)
        (:TISSUE) (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PKCtheta is released from the auto-inhibition after recruitment to the plasma membrane, where it binds to diacylglycerol (reviewed in [XREF_BIBR]).")
       (:PMID . "25889880") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0001772")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUPPORTED--BY "7af7e0c0-a062-434d-baee-0aa76fee6ab0")
     (:TYPE . "Translocation") (:ID . "155872d7-b740-4e17-877a-c14e4253981a"))
    ((:TO--LOCATION . "plasma membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "Rac") (:+UP+ . "P63000") (:+HGNC+ . "9801"))
      (:NAME . "RAC1"))
     (:EVIDENCE
      ((:TEXT
        . "In contrast, in the cells attached to an ECM, the guanosine triphosphate bound Rac translocates to the plasma membrane, where it connects with a downstream pathway.Several possible downstream signaling mechanisms of PKC were reported, including ERK1/2 (;), p38 MAPK (;;;), Stat3 (), and myosin light-chain phosphorylation and activation (), In particular, at the time this paper is written, more than 20 publications reported that p38 MAPK plays a critical role in migration control of various cell types.")
       (:PMID . "16543902") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "However, activated Rac1 translocates to the plasma membrane in an integrin dependent fashion (XREF_BIBR).")
       (:PMID . "16492808") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:CELL--LINE "cellosaurus:CVCL_0045") (:TISSUE)
        (:LOCATION "go:GO:0001726")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "These results therefore suggest that ARF1 is required for EGF dependent Rac1 interaction with IRSp53, thereby providing a mechanism by which ARF1 regulates cell migration.It has been shown that Rac1 can form an IRSp53 mediated complex with WAVE2 and translocate to the plasma membrane.")
       (:PMID . "23707487") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "PIPKI-alpha does a job other PIPKI isoforms can not; it recruits Rac1 to the plasma membrane upon integrin activation, spatially regulating the actin organizing GTPase during migration.")
       (:PMID . "20660631") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN "uberon:UBERON:2000106")
        (:CELL--LINE) (:TISSUE) (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_2b_verb_apposition") (:SPECIES))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Rac can recruit WAVE to the plasma membrane and its effects on actin are largely dependent on WAVE (XREF_BIBR; XREF_BIBR).")
       (:PMID . "19917258") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Rac1 is recruited to the plasma membrane and maintained in lipid rafts through signaling involving integrins and phosphorylated caveolin (XREF_BIBR, XREF_BIBR).")
       (:PMID . "22918955") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:0000066")
        (:ORGAN "uberon:UBERON:0000479") (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUPPORTED--BY "8a4937cd-8b1d-4b78-a199-d252710bb226")
     (:TYPE . "Translocation") (:ID . "97c9063a-6b7a-4145-950f-bdb9f6fdf60c"))
    ((:TO--LOCATION . "membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "Raf1") (:+UP+ . "P04049") (:+HGNC+ . "9829"))
      (:NAME . "RAF1"))
     (:EVIDENCE
      ((:TEXT
        . "Growth factor stimulation recruits Raf1 to this membrane domain.")
       (:PMID . "9099670") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_2b_verb_apposition") (:SPECIES))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the classical model of Raf activation, Raf translocates to the membrane where it binds RAS and subsequently phosphorylates MEK1/2 starting thus the cellular response to the extracellular ligands.")
       (:PMID . "19298812") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE "uaz:UA-CLine-100047")
        (:TISSUE) (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_8b_verb_active_no_cause")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "C-RAF is cytosolic under basal conditions and is recruited to the membrane fraction by RAS (D, lanes 1 and 7) but is not recruited by BRAF, BRAF, BRAF, or B-RAF (D, lanes 3-6).")
       (:PMID . "16364920") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_3b_verb_passive"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "When Raf is recruited to the membrane, it colocalized with the membrane pool of TAP-1 (XREF_FIG).")
       (:PMID . "20230813") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:6239"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "In the classical model of Raf activation, Raf translocates to the membrane where it binds RAS and subsequently phosphorylates MEK1/2 starting thus the cellular response to the extracellular ligands.")
       (:PMID . "19298812") (:SOURCE--API . "trips")
       (:EPISTEMICS (:SECTION--TYPE)))
      ((:TEXT
        . "TAP-1 regulated the recruitment of Raf to membrane bound Ras.")
       (:PMID . "20230813") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:6239"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The recruitment of Raf-1 to the membrane and its activation require binding to phosphatidic acid XREF_BIBR, XREF_BIBR.")
       (:PMID . "21738705") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE "uaz:CVCL_9115")
        (:TISSUE) (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "A wide variety of growth factors and mitogens are known to activate the Ras-Raf-1-MEK-1/2-ERK-1/2 signaling cascade, in which Ras, activated by extracellular signals, recruits Raf-1 to the membrane, where it is activated by other protein kinases.")
       (:PMID . "18771726") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Thus, ManLAM binding to DC-SIGN leads to activation of Raf-1 independent of TLR signaling.Raf-1 activation requires recruitment of Raf-1 to the membrane through an interaction with the active form of the small GTPase Ras ().")
       (:PMID . "17462920") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_4a_noun_with_cause"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The binding to active Ras and M-Ras in vivo was confirmed by the findings that DA-Raf1 was translocated to the cellular membranes to colocalize with Ras and M-Ras activated by mitogenic signals.")
       (:PMID . "17535970") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE "cl:CL:0000056") (:ORGAN) (:CELL--LINE)
        (:TISSUE) (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Active RAS recruits RAF to the membrane for activation through a complex process involving changes in phosphorylation and binding to other enzymes and scaffold proteins (XREF_BIBR).")
       (:PMID . "20141835") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Upon mitogenic stimulation, dephosphorylation of S259 residue by protein phosphatase 2A (PP2A) leads to the release of 14-3-3zeta from pS233 and pS259 site [XREF_BIBR], which results in translocation of C-Raf to the membrane and activates the downstream effector MEK kinase (MAP2K) [XREF_BIBR - XREF_BIBR].")
       (:PMID . "26295714") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN)
        (:CELL--LINE "cellosaurus:CVCL_6353") (:TISSUE)
        (:LOCATION "go:GO:0016020")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUPPORTED--BY "a099251b-3fa5-43ed-bc31-8b3837f035ed")
     (:TYPE . "Translocation") (:ID . "99768c36-ee37-44d8-98d5-182df27d3f05"))
    ((:TO--LOCATION . "plasma membrane")
     (:AGENT
      (:DB--REFS (:+TEXT+ . "RAF1") (:+UP+ . "P04049") (:+HGNC+ . "9829"))
      (:NAME . "RAF1"))
     (:EVIDENCE
      ((:TEXT
        . "In its simplest form, RAS recruits cytosolic RAF to the plasma membrane for activation, with one of the essential steps being the phosphorylation of two amino acids (T598 and S601 of B-RAF; see Note at the end of the main text for amino acid numbering used in this review) within the activation segment of the kinase domain.")
       (:PMID . "15488754") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "This interaction promotes both Raf translocation to the plasma membrane and activation of Raf kinase activity.")
       (:PMID . "7730360") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:8355"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Marais R, Light Y, Paterson HF, Marshall CJ : Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.")
       (:PMID . "9069260") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Activated Ras translocates Raf to the plasma membrane where association with membrane lipids and 14-3-3 proteins mediate Raf phosphorylation and activation ().")
       (:PMID . "17126402") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "The initiating event in Raf activation is believed to be Ras binding to the Ras binding domain (RBD) of Raf in the N-terminal regulatory region that recruits Raf to the plasma membrane, where other activating events take place.Shoc2/Sur-8 codes for a protein comprised almost entirely of leucine rich repeats.")
       (:PMID . "16630891") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005829")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The complex of Shoc2 and Ras-GTP provides a platform for recruiting Raf1 to the plasma membrane, thereby triggering the MEK-ERK signaling cascade.")
       (:PMID . "20071468") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "HRas binds with high affinity to Raf-1 XREF_BIBR and recruits Raf-1 to the plasma membrane, where it is activated XREF_BIBR XREF_BIBR.")
       (:PMID . "25757571") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_2b_verb_apposition"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "Recently, we demonstrated that CNK is required for insulin induced Ras mediated activation of Raf, MEK, and ERK in S2 cells and that CNK is at least partly responsible for recruiting Raf to the plasma membrane enriched fraction of these cells.")
       (:PMID . "15028221") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "One in vivo consequence of the Ras and Raf -1 interaction is the recruitment of Raf-1 to the plasma membrane.")
       (:PMID . "15664191") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Upon activation, RAS binding to the RAS binding domain (RBD) of RAF recruits RAF to the plasma membrane, where other activating events take place.")
       (:PMID . "24211266") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005829")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:9606"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Stimulation of this pathway is typically initiated by receptor mediated activation of the small G protein Ras, which binds to and recruits the serine/threonine kinase Raf to the plasma membrane, where Raf becomes fully activated.")
       (:PMID . "15979847") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_2b_verb_apposition")
        (:SPECIES "taxonomy:4932"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "The recruitment of Raf to the plasma membrane by GTP bound Ras leads to stimulation of Raf kinase activity through an undefined mechanism.")
       (:PMID . "10461188") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005886")
        (:FOUND--BY . "translocation_4a_noun_with_cause")
        (:SPECIES "taxonomy:4932"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT)))
      ((:TEXT
        . "Thus, there is some evidence that Raf-1 may be recruited to the plasma membrane by phosphatidic acid rather than by its interaction with Ras, but its activation still requires activated Ras.")
       (:PMID . "12384139") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:FOUND--BY . "translocation_3b_verb_passive"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT . T)))
      ((:TEXT
        . "A-Raf is specifically located to mitochondria (XREF_BIBR), whereas DA-Raf1 was diffusely present throughout the cytoplasm and translocated to the plasma membrane and vesicle membranes by the mitogenic signals.")
       (:PMID . "17535970") (:SOURCE--API . "reach")
       (:ANNOTATIONS (:CELL--TYPE) (:ORGAN) (:CELL--LINE) (:TISSUE)
        (:LOCATION "go:GO:0005737")
        (:FOUND--BY . "translocation_3b_verb_passive")
        (:SPECIES "taxonomy:10090"))
       (:EPISTEMICS (:SECTION--TYPE) (:DIRECT))))
     (:SUPPORTED--BY "a099251b-3fa5-43ed-bc31-8b3837f035ed")
     (:TYPE . "Translocation") (:ID . "33356570-84eb-4dff-8c41-db7d37a58198"))))
